<SEC-DOCUMENT>0001570562-20-000061.txt : 20200225
<SEC-HEADER>0001570562-20-000061.hdr.sgml : 20200225
<ACCEPTANCE-DATETIME>20200225160751
ACCESSION NUMBER:		0001570562-20-000061
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200225
DATE AS OF CHANGE:		20200225

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Evolus, Inc.
		CENTRAL INDEX KEY:			0001570562
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				461385614
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38381
		FILM NUMBER:		20650662

	BUSINESS ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		(949) 284-4555

	MAIL ADDRESS:	
		STREET 1:		520 NEWPORT CENTER DRIVE
		STREET 2:		SUITE 1200
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>evolus12311910-k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1FBBF3DAE0735EC7AC52B28C2D904926"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:15pt;"><font style="font-family:Times New Roman;font-size:15pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:15pt;"><font style="font-family:Times New Roman;font-size:15pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;color:#000000;">_____________________________</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:16pt;"><font style="font-family:Times New Roman;font-size:16pt;color:#000000;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;color:#000000;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;">&#9746;</font><font style="font-family:Times New Roman;font-size:6pt;">&#32;&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">For the fiscal year ended&#160;</font><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">December&#160;31, 2019</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">or</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:11pt;font-weight:bold;">&#9744;&#160;&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 O</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">R 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to      </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:12pt;"><font style="font-family:Times New Roman;font-size:12pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Commission File Number:&#160;001-38381</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:20pt;"><font style="font-family:Times New Roman;font-size:20pt;font-weight:bold;">EVOLUS, INC.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Delaware</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">46-1385614</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(State or other jurisdiction of </font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Identification Number)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">520 Newport Center Dr., Suite 1200</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Newport Beach, California 92660</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(949) 284-4555</font></div><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:6pt;"><font style="font-family:Times New Roman;font-size:6pt;font-weight:bold;">_____________________________</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;text-decoration:underline;">Title of each class</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;text-decoration:underline;">Trading Symbol(s)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;text-decoration:underline;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Common Stock, $0.00001 par value per share</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">EOLS</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">The Nasdaq Stock Market LLC</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">None</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#9744; No&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;color:#000000;font-style:normal;font-weight:normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be&#160;submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#9744;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:7pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:22%;"></td><td style="width:52%;"></td><td style="width:21%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Large&#160;accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Accelerated filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Non-accelerated&#160;filer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Smaller&#160;reporting&#160;company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">&#9746;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. &#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160;&#160;&#160;&#160;Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $238.7 million, based on the closing price of the registrant&#8217;s common stock on the Nasdaq Global Market of $14.62&#160;per share for such date.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">As of </font><font style="font-family:Times New Roman;font-size:7pt;">February&#160;21, 2020</font><font style="font-family:Times New Roman;font-size:7pt;">, </font><font style="font-family:Times New Roman;font-size:7pt;">33,728,035</font><font style="font-family:Times New Roman;font-size:7pt;">&#32;shares of the registrant&#8217;s sole class of common stock were outstanding.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:7pt;"><font style="font-family:Times New Roman;font-size:7pt;">Portions of the registrant's Proxy Statement for the 2020 Annual Meeting of Stockholders are incorporated herein by reference in Part III of this Annual Report on Form 10-K to the extent stated herein. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the registrant's fiscal year ended December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><a name="s91756416F4AD50AAA7E6A87462CA6FF0"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:86%;"></td><td style="width:6%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EVOLUS, INC.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART I</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3B252B9E505F5F8E8D301F8DB5A937A6"><font style="font-family:Times New Roman;font-size:10pt;">Business</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3B252B9E505F5F8E8D301F8DB5A937A6">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCBF3CE2E7723525D8A2C2BAB92C9E962"><font style="font-family:Times New Roman;font-size:10pt;">Risk Factors</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sCBF3CE2E7723525D8A2C2BAB92C9E962">14</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 1B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s9D18256262CB5A869C7BBA194F05784F"><font style="font-family:Times New Roman;font-size:10pt;">Unresolved Staff Comments</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s9D18256262CB5A869C7BBA194F05784F">52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 2</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s9C513115FAA1528A80E26CC9E14BD333"><font style="font-family:Times New Roman;font-size:10pt;">Properties</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s9C513115FAA1528A80E26CC9E14BD333">52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 3</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s369704392783536AA0B99EBCF034B551"><font style="font-family:Times New Roman;font-size:10pt;">Legal Proceedings</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s369704392783536AA0B99EBCF034B551">52</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 4</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s01C112F7D9F858F58766B9EFFF8842C4"><font style="font-family:Times New Roman;font-size:10pt;">Mine Safety Disclosures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s01C112F7D9F858F58766B9EFFF8842C4">53</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART II</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s17A268D5792C5A28AC50F46EE34DE0BD"><font style="font-family:Times New Roman;font-size:10pt;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s17A268D5792C5A28AC50F46EE34DE0BD">53</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 6</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3D00B65D91A95A7A9F6345B4A3F3E4FF"><font style="font-family:Times New Roman;font-size:10pt;">Selected Financial Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3D00B65D91A95A7A9F6345B4A3F3E4FF">55</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 7</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD098724857265CBC99375F6F496C842F"><font style="font-family:Times New Roman;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sD098724857265CBC99375F6F496C842F">56</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 7A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3760B3F60EA35ED587FF1AD8CD6DC5C9"><font style="font-family:Times New Roman;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s3760B3F60EA35ED587FF1AD8CD6DC5C9">66</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 8</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF33C898598B351E395F5E85B8FE85108"><font style="font-family:Times New Roman;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF33C898598B351E395F5E85B8FE85108">67</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s363C3FDF8E825D4891BCAABCAA61A7A6"><font style="font-family:Times New Roman;font-size:10pt;">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s363C3FDF8E825D4891BCAABCAA61A7A6">101</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9A</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6CF2BE3C82DE5D7B9294D61F8E8EE30B"><font style="font-family:Times New Roman;font-size:10pt;">Controls and Procedures</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6CF2BE3C82DE5D7B9294D61F8E8EE30B">101</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 9B</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAB269C72196F5ED7A1A280BE36B77F86"><font style="font-family:Times New Roman;font-size:10pt;">Other Information</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sAB269C72196F5ED7A1A280BE36B77F86">101</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART III</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 10</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s75DE065D73EB5D6FA88DA440D44A4667"><font style="font-family:Times New Roman;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s75DE065D73EB5D6FA88DA440D44A4667">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 11</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2F78747C4C695E59930A179FFB28E78C"><font style="font-family:Times New Roman;font-size:10pt;">Executive Compensation </font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s2F78747C4C695E59930A179FFB28E78C">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA42DFE57D8465CBABDEF8475CA902D20"><font style="font-family:Times New Roman;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA42DFE57D8465CBABDEF8475CA902D20">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 13</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA27DD64C88455B19AEB72C54A5DBDD2C"><font style="font-family:Times New Roman;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA27DD64C88455B19AEB72C54A5DBDD2C">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 14</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s32699A63EDD953CF9099F7E48100E3D7"><font style="font-family:Times New Roman;font-size:10pt;">Principal Accounting Fees and Services</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s32699A63EDD953CF9099F7E48100E3D7">103</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">PART IV</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 15</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5A894A9CF1025878800CA15D1F7FD634"><font style="font-family:Times New Roman;font-size:10pt;">Exhibits, Financial Statement Schedules</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s5A894A9CF1025878800CA15D1F7FD634">103</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Item 16</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0DF9E4C047AE52B18363986339B44757"><font style="font-family:Times New Roman;font-size:10pt;">Form 10-K Summary</font></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0DF9E4C047AE52B18363986339B44757">105</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:22px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;color:#3216ff;text-decoration:underline;" href="#sBEFAA117E5885200B7CED176AE1DDBB6"><font style="font-family:Times New Roman;font-size:10pt;color:#3216ff;text-decoration:underline;">Signatures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">i</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sE841E6190F1651A7AA9083D3E3501B16"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Special Note Regarding Forward-Looking Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, that involve risks and uncertainties, including statements based on our current expectations, assumptions, estimates and projections about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms, or other comparable terms intended to identify statements about the future. Forward-looking statements include, but are not limited to, statements about:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize our sole product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;including our ability to successfully market and sell Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to our customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;">and comply with any related restrictions, limitations and warnings in the label of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any relevant regulatory requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the potential market size, opportunity and growth potential for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the attractiveness of the product characteristics of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;(including the benefits of a 900 kilodalton, or kDa, botulinum toxin type A complex) and the rate and degree of physician and patient acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the pricing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, and the flexibility of our pricing and marketing strategy compared to our competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the performance of our third-party licensors, suppliers, manufacturers and distributors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our expectations regarding our future development of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;for other indications and approval in other jurisdictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the accuracy of our estimates regarding the amount and timing of expenses, revenue, capital requirements and needs for additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory and legislative developments in the United States, European Union, or EU, Canada and other countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">developments and projections relating to our competitors and our industry, including competing products and procedures;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the loss of key management personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our future financial performance and our ability to continue as a going concern; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the results and impact of current and any future legal proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The forward-looking statements included herein are not guarantees of future performance or events and are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control.&#160; As such, our actual results may differ materially from those expressed in any forward-looking statements.&#160; Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1. &#8220;Business&#8221; and Item 1A. &#8220;Risk Factors&#8221; of Part&#160;I and Item 7. &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part&#160;II of this Annual Report on Form&#160;10-K.&#160;Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission, or SEC.&#160;In light of the significant risks and uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking statements.&#160;Except as required by law, we undertake no obligation to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should read this Annual Report on Form 10-K and the documents we file with the SEC, with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.</font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unless the context indicates otherwise, as used in this Annual Report on Form 10-K, the terms &#8220;Evolus,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Evolus, Inc., a Delaware corporation, and our subsidiaries taken as a whole, unless otherwise noted. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">EVOLUS</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#8482;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Evolux&#8482; are three of our trademarks that are used in this Annual Report on Form 10-K. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the trade name in the United States for our approved product with non-proprietary name, prabotulinumtoxinA-xvfs.  The product has different trade names outside of the United States, but is referred to throughout this Annual Report on Form 10-K as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  This Annual Report on Form 10-K also includes trademarks, trade names and service marks that are the property of other organizations, such as BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Cosmetic, which we refer to throughout this Annual Report on Form 10-K as BOTOX. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174; and &#8482; symbols, but those references are not intended to indicate that we will not assert, to the fullest extent under applicable law, our rights, or that the applicable owner will not assert its rights, to these trademarks and trade names. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s6F73B78F2E3A587498B833521BCD39AF"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Part I</font></div><div><a name="s3B252B9E505F5F8E8D301F8DB5A937A6"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 1.  &#160;&#160;&#160;&#160;Business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our first product, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physician and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer customers and consumers a compelling value proposition with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">United States</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2019, we received the approval of our first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As part of our commercial launch in the United States, we introduced the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Experience Treatment, or J.E.T., an exclusive program for aesthetic providers and consumers to be the first to experience Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. J.E.T. offered aesthetic providers the opportunity to receive multiple shipments of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through August 2019. The program was made available through our technology platform, &#8220;Evolus Practice&#8221;, which allows providers to open a new account, order Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, pay invoices and engage with our customer experience team and medical affairs representatives. We enrolled over 5,000 customer accounts in JET.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the J.E.T program, in 2019, we launched marketing programs designed to increase the adoption of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;by customer accounts and to drive consumer demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  The next phase of our U.S. launch will be the release of our customer loyalty program, branded Evolux&#8482;, and our consumer loyalty program in 2020. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">International </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Canada in October 2019 through our distribution partner, Clarion Medical Technologies, Inc., or Clarion. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In September 2019, we received approval from the European Commission, to market the product in all 28 EU member states, Iceland, Norway and Liechtenstein. We plan to launch Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Europe in 2020.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our Market </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our primary market is self-pay aesthetic healthcare, which includes medical products purchased by physicians that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. By focusing on the self-pay medical aesthetics market, we believe we are not exposed to reimbursement risk associated with a reliance on payments from such third-party payors, and we are subject to fewer regulations that place limits on the types of marketing and other interactions we have with physicians.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Within the self-pay aesthetic market, the global aesthetic neurotoxin market was estimated to generate approximately $2.7 billion of revenue in 2019 and is estimated to grow to approximately $3.9 billion in 2022. The U.S. aesthetic neurotoxin market was estimated to generate $1.4 billion in sales in 2019 and is expected to grow to approximately $2.0 billion in 2022.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the growth in the medical aesthetics market is driven by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increased use by millennials who are increasingly seeking medical aesthetic treatments and utilizing neurotoxins as an entry point for aesthetic procedures due to their minimally invasive nature;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">an aging population together with an increasing life expectancy, which is resulting in more consumers with a desire for improved appearance and well-being over a longer period of time; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">rising disposable income, with the U.S. Bureau of Economic Analysis reporting that real disposable income in the United States increased approximately 19% from December 2012 to December 2019;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">growing awareness, utilization and acceptance of elective or minimally invasive aesthetic procedures;&#160;and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">continued innovation and improved accessibility to these treatments due to an increase in the number of physicians who perform these procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Within the multiple age groups that receive aesthetic neurotoxin treatments, we strategically focus our marketing efforts on the millennial segment which is the largest cohort in the U.S. population. In 2019 there are estimated to be approximately 73 million millennials, defined as individuals born between 1981 and 1996. We believe that approximately 1.7 million females between the age of 30 and 39, which includes many individuals we define as millennials, are considering neurotoxins in the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our Competitive Strengths </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We offer physicians and consumers a compelling value proposition because:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;offers the U.S. market the first known 900 kDa neurotoxin alternative to BOTOX</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The manufacture of both Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and BOTOX starts with a 900 kDa complex, includes adding the excipients human serum albumin, or HSA, and sodium chloride, and finishes by vacuum drying. We believe Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only known neurotoxin product in the United States with a 900 kDa neurotoxin complex other than BOTOX. We also believe an important component of competitiveness in the neurotoxin market relates to the characteristics associated with the 900 kDa complex and the potential of the accessory proteins to increase the effectiveness of the active toxin portion of the complex.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Results from our TRANSPARENCY global clinical program in more than 2,100 patients provides robust data to physicians evaluating the purchase of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe the comprehensive TRANSPARENCY clinical data set, including a head-to-head Phase III study comparing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and BOTOX,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provides physicians with confidence in recommending Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to their patients.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">We offer a unique technology platform.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;We provide a simple, personal and connected experience for physicians utilizing our proprietary technology platform. We have built and continue to improve our platform with the goal of limiting friction and enhancing the overall experience for physicians and ultimately consumers. We are modernizing the customer engagement with our proprietary &#8220;Evolus Practice&#8221; app. We not only leverage technology for operational efficiency, but more importantly, to enhance a customer&#8217;s experience. The combination of a highly specialized sales force and our technology platform is an effective and competitive model. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Enhanced level of physician-customer interaction through a self-pay, aesthetic-only marketing strategy. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have elected to specifically target the self-pay aesthetic market. With a reduced regulatory burden compared to third-party payor reimbursed therapeutic products, there is a number of benefits that market participants in reimbursed markets are unable to achieve, such as an enhanced level of interaction with our physician-customers. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only U.S. neurotoxin without a therapeutic indication. We believe pursuing an aesthetic-only non-reimbursed product strategy creates meaningful strategic advantages in the United States, including pricing and marketing flexibility. We utilize this flexibility to drive market adoption through programs such as promotional events, experience product programs and pricing strategies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">We have strong relationships with aesthetic key opinion leaders, or KOLs</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We have established relationships with aesthetic KOLs as a result of our management team&#8217;s industry experience and engagement of our clinical trial investigators. KOLs are important information resources to the general physician-customer market due to their clinical expertise, academic reputations, active clinical practices and their status as medical innovators. The broader physician community often looks to KOLs for their experience with products and procedures as part of their new product and procedure adoption process.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Our management team has significant experience and expertise in medical aesthetics</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our management team has extensive experience in self-pay healthcare markets, in the development, market launch and commercialization of major medical products, execution and integration of business development transactions, identification of and </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-left:48px;padding-bottom:12px;text-align:left;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">partnerships with KOLs, and understanding of the regulatory environment of the healthcare markets. Key members of our leadership team have also served in relevant senior leadership positions with leading aesthetic companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2019, we launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States with our own specialty sales organization now consisting of over 150 positions between representatives, management and other sales employees and in Canada through our distribution partner, Clarion.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt"> </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We plan to expand our product offerings over time through in-licensing, partnerships and acquisitions. The key components of our strategy are:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Partner outside of the United States to reach and serve physicians and consumers in those territories. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursue an aesthetic-only strategy to enhance marketing and pricing flexibility along with improving transparency for our customers.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Leverage our strong KOL relationships to assist in scientific presentations, publications, and other methods to drive success of our commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Leverage our differentiated digital platform to efficiently open new accounts, personalize the purchasing process and efficiently deploy marketing programs at scale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Establish a leading medical aesthetics company by in-licensing technology, developing partnerships and potentially acquiring products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an injectable formulation of a 900 kDa botulinum toxin type A complex designed to address the needs of the large and growing facial aesthetics market. We completed the TRANSPARENCY global clinical program which enrolled over 2,100 adult subjects</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;">. The results of the TRANSPARENCY global clinical program </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">were used to support our applications for regulatory approvals in the United States, EU and Canada.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As demonstrated in the figure below, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;contains a 900 kDa botulinum toxin type A complex produced by the bacterium </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clostridium botulinum.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The active part of the neurotoxin is the 150 kDa component, and the remaining 750 kDA of the complex is made up of accessory proteins that we believe help with the function of the active portion of the toxin. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;has the same mechanism of action as other type A botulinum toxins. When injected intramuscularly at therapeutic doses, botulinum toxin causes a chemical denervation of the muscle resulting in localized reduction of muscle activity. Botulinum toxin type A specifically blocks peripheral acetylcholine release at presynaptic cholinergic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of acetylcholine from vesicles situated within the nerve endings leading to denervation and relaxation of the muscle.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#000000;font-style:italic;">Diagram of Botulinum Toxin Type A</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;"><img src="a900kda.jpg" alt="a900kda.jpg" style="height:249px;width:205px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">TRANSPARENCY: Evolus Clinical Development for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">TRANSPARENCY was a comprehensive five-study clinical development program for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and  was used to meet the regulatory requirements for a Biologics License Application, or BLA, in the United States, a Marketing Authorisation Application, or MAA, in the EU, and a New Drug Submission, or NDS, in Canada, for the treatment of moderate to severe glabellar lines. The TRANSPARENCY program, which was developed in consultation with the FDA, Canadian, and European regulatory bodies, included three multicenter, randomized, double-blinded, controlled, single dose Phase III studies titled EV-001, EV-002 and EVB-003. Each Phase III study lasted 150 days. The TRANSPARENCY program also included two open label, multiple dose, long-term Phase II studies titled EV-004 and EV-006, each lasting one year. Between September 2014 and August 2016, over 2,100 adult male and female subjects with moderate to severe glabellar lines at maximum frown participated in this program.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In our clinical trials, subjects received intramuscular injections in five target sites in muscles that contribute to the formation of glabellar lines: the midline of the procerus, the inferomedial aspect of each corrugator, and the superior middle aspect of each corrugator. Each of the five target sites was injected with 0.1 milliliters, or mL, for a total of 0.5mL. Subjects assigned (in the open label studies) or randomized (in the controlled studies) to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;received a total of 20&#160;units per treatment, administered as 4 units per 0.1mL and those subjects who were randomized to the placebo group received 0.5mL saline. In our EVB-003 Phase III trial, the only study of the five with both a placebo and active control arm, subjects randomized to the active control received a total of 20 units of BOTOX administered as 4&#160;units per 0.1mL.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">All five studies contributed data to the evaluation of efficacy and safety of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Phase III U.S. Based Clinical Trials. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The two identical U.S. Phase III studies, EV-001 and EV-002, enrolled subjects who were selected from a population of healthy adults, at least 18 years of age, who had moderate to severe glabellar lines at maximum frown, as independently assessed by the investigator and subject using the 4-point photonumeric Glabellar Line Scale, or GLS, where 0=no lines, 1=mild lines, 2=moderate lines and 3=severe lines. On Day 0, eligible subjects were randomly assigned in a 3:1 ratio to receive a single treatment of either Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or placebo. Subjects were followed for 150 days after treatment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. This was a composite endpoint in which a responder was a subject with a 2 point improvement or greater on the GLS from Day 0 to Day 30 at maximum frown, only if independently agreed by both investigator and subject assessment. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Both studies met the primary endpoint of superiority over placebo. The percentages of responders in the intent to treat population for the composite primary endpoint, a two point or greater score composite improvement, in each of the two controlled single dose studies were:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">EV-001: 1.2% placebo, 67.5% Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, with an absolute difference between the groups of 66.3%, 95% CI (59.0, 72.4)</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">EV-002: 1.3% placebo, 70.4% Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, with an absolute difference between the groups of 69.1%, 95% CI (61.5, 75.1)</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the EV-002 study, the adverse event, or AE, rate was 26.9% in the placebo group and 28.5% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;group. Placebo and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;groups were similar in the overall incidence of subjects who experienced one or more AEs. Four Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;subjects (4/246, 1.6%) experienced a serious adverse event, or SAE, but none were assessed as study drug related. Placebo and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;groups were also similar in the percentages of subjects who experienced an AE assessed by the investigator as study drug related: 7.7% of placebo subjects and 9.8% of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;subjects. The drug related eyelid and eyebrow ptosis rates in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;arm were 1.2% and 0.4% respectively. Overall, AEs with an incidence of 1% or greater were headache at 9.3% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;groups and 7.6% in the placebo groups and eyelid ptosis at 1% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;groups and 0% in the placebo groups.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Phase III European and Canadian Clinical Trial for Glabellar Lines</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The EVB-003 study was the third Phase III safety and efficacy study in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;clinical development program, and was conducted in Europe and Canada. 540 subjects with moderate to severe glabellar lines, or a GLS score of 2 or 3, as assessed by the investigator, were eligible to be enrolled provided that subjects also felt their glabellar lines had an important psychological impact, such as on their mood, anxiety or depressive symptoms. On Day 0, eligible subjects were randomly assigned in a 5:5:1 ratio to receive a single treatment of 20 units of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, 20 units of BOTOX or placebo. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The primary efficacy endpoint was defined as the proportion of subjects classified as responders on Day 30. A responder was a subject with a GLS score of 0 or 1, as assessed by the investigator at maximum frown. The primary analysis of the primary efficacy endpoint in the EVB-003 study showed the superiority of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;over placebo, and established non-inferiority of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to BOTOX. The percentages of responders for the primary efficacy endpoint were:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.2% in the placebo group, 95% CI (0.0, 9.8);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">82.8% in the BOTOX group, 95% CI (78.1, 87.5); and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">87.2% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;group, 95% CI (83.0, 91.5).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A confidence interval, or CI, is a range of values in which, statistically, there is a specified level of confidence where the result lies. As an example, in the results above for this Phase III study, the results indicate that there is a 95% level of confidence that the responder rate for placebo was between 0.0% and 9.8%, which we express as: 95% CI (0.0, 9.8). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The absolute differences between the treatment groups were:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">83.1% between Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and placebo groups, 95% CI (70.3, 89.4), (p&lt;0.001), indicating Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;was superior to placebo; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.4% between Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and BOTOX groups, 95% CI (-1.9, 10.8), with non&#8209;inferiority of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;versus BOTOX concluded based on the lower bound of the 95% CI for the absolute difference exceeding -10.0%.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">EU Phase III Primary Endpoint - Responder Rates at Maximum Frown on Day 30 (GLS = 0 or 1) by Investigator Assessment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">EU Phase III Primary Endpoint - Non-Inferiority, at Maximum Frown on Day 30 by Investigator Assessment</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="favors1.jpg" alt="favors1.jpg" style="height:180px;width:268px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:188px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="favors.jpg" alt="favors.jpg" style="height:129px;width:325px;"></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As presented in the table below, within each group, 32.7% of placebo subjects, 41.9% of BOTOX subjects and 37.6% of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;subjects experienced AEs. One placebo subject (1/49, 2.0%), one BOTOX subject (1/246, 0.4%) and three Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;subjects (3/245, 1.2%) experienced a total of 11 SAEs and none were assessed as study drug related. The drug related eyelid ptosis rates were 1.6% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;arm and 0% in the BOTOX arm and the eyebrow ptosis rates were 0% in the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;arm and 0.4% in the BOTOX arm.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">EU and Canadian Phase III Trial - Adverse Event Rate Summary</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;"><img src="adverseeventtable1.jpg" alt="adverseeventtable1.jpg" style="height:166px;width:348px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As presented in the table below, in EVB-003, we also assessed as a secondary endpoint &#8805; 1 point improvement GLS at maximum frown for both investigator and patient satisfaction. The investigator assessment at Day 2, the beginning of the study, and at Day 150, at the end of the study, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is statistically superior to placebo as measured by a one-point improvement on the GLS scale by investigator assessment. We also looked at subject satisfaction on Day 30, and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was superior to placebo at 91% versus 6%&#160;in the placebo arm.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">EU and Canadian Phase III Trial - Select Secondary Endpoints</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.47619047619048%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="secondary.jpg" alt="secondary.jpg" style="height:169px;width:522px;"></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*P-Value Placebo vs Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#160;&lt;0.001</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong Pharmaceuticals Co. Ltd., or Daewoong, manufactures and supplies Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to us. Daewoong has over 70 years of experience manufacturing pharmaceutical products and is one of the largest pharmaceutical companies in South Korea. Daewoong constructed a facility in South Korea where Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is produced. We believe this facility will be sufficient to meet demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the foreseeable future. The FDA conducted a </font><font style="font-family:Times New Roman;font-size:10pt;">current Good Manufacturing Practice, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">cGMP, and pre-approval inspection of the facility in November 2017 in connection with our BLA for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The UK Medicines and Healthcare Products Regulatory Agency, or MHRA, also completed an inspection of the manufacturing facility in February 2018 in connection with our MAA. The U.S. FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019 included approval to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at Daewoong&#8217;s facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On September 30, 2013, we entered into the Daewoong Agreement with Daewoong, pursuant to which Daewoong agreed to manufacture and supply Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and grant us an exclusive license to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for aesthetic indications in the United States, EU, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, or CIS, and South Africa, each, a covered territory. Daewoong also granted us a non-exclusive license to do the same in Japan. In connection with our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million and agreed to make milestone payments upon certain confidential development and commercial milestones, including payment to Daewoong upon each of FDA and EMA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Under the Daewoong Agreement, the maximum aggregate amount of milestone payments that could be owed to Daewoong upon the satisfaction of all milestones is $13.5 million. Upon the FDA approval in February 2019 and EMA approval in September 2019, we paid $2.0 million and $1.0 million milestone payment, respectively. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive remaining contingent milestone payments of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Daewoong Agreement, Daewoong has agreed to supply us with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;at an agreed-upon, transfer price, and we have agreed to make milestone payments upon completion of certain confidential development and commercial milestones. Our exclusivity is subject to certain minimum annual purchases upon commercialization and if we fail to meet these targets, Daewoong may, at its option, convert the exclusive license to a non-exclusive license. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions.  During the term of the Daewoong Agreement, we cannot purchase, sell or distribute any competing products in a covered territory or Japan or sell Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;outside a covered territory or Japan. We also have the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a covered territory or Japan. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The initial term of the Daewoong Agreement is from September 30, 2013 to the later of (i) the fifth anniversary of approval from the relevant governmental authority necessary to market and sell Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or (ii) September 30, 2023, and automatically renews for unlimited additional three-year terms if we meet certain performance requirements. The Daewoong Agreement will terminate (A) upon written notice by either us or Daewoong upon a continuing default that remains uncured within 90 days (or 30 days for a payment default) by the other party, or (B) without notice upon the bankruptcy or insolvency of our company. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are the sole owner of any marketing authorization and clinical trial results we pursue in a covered territory. However, if we do not renew the Daewoong Agreement or upon termination of the Daewoong Agreement due to a breach by us, we are obligated to transfer our rights to Daewoong.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also provides that Daewoong will indemnify us for any losses arising out of (i) Daewoong&#8217;s willful misconduct or gross negligence in performing its obligations under the agreement, (ii) Daewoong&#8217;s breach of the agreement, or (iii) any allegation that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or Daewoong&#8217;s trademark infringes or misappropriates the rights of a third party, except, in each case, as a result of our willful misconduct or gross negligence. We have agreed to indemnify Daewoong for any losses arising out of (A) our willful misconduct or gross negligence in performing our obligations under the agreement, or (B) our breach of the agreement, except, in each case, as a result of Daewoong&#8217;s willful misconduct or gross negligence. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our primary competitors in the pharmaceutical market are companies offering injectable dose forms of botulinum toxin. There are only four approved injectable botulinum toxin type A neurotoxins in the United States, including Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. There are also other injectable botulinum toxin type A products being developed for the U.S. market. We believe the primary competing products in this market include BOTOX, Dysport and Xeomin:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">BOTOX, marketed by Allergan plc, or Allergan, received FDA approval in 2002 for glabellar lines. Allergan was the first company to market neurotoxins for aesthetic purposes.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Dysport, marketed by Galderma S.A., or Galderma, received FDA approval in 2009 for glabellar lines.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Xeomin, marketed by Merz Pharma GmbH &amp; Co., or Merz, received FDA approval in 2011 for glabellar lines.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also aware that Revance Therapeutics, Inc. has submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin and received a target date action date of November 25, 2020 under the Prescription Drug User Fee Act.  If the BLA is approved, we expect the competition in the U.S. injectable botulinum toxin market to further increase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the companies commercializing and developing neurotoxins, there are other products and treatments that may indirectly compete with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, such as dermal fillers, laser treatments, brow lifts, chemical peels, fat injections and cold therapy. We compete with various companies that have products in these medical aesthetic categories. Among these companies are Allergan, Sanofi, Sun Pharma, Valeant Pharmaceuticals International, Inc., or Valeant, Mentor Worldwide LLC, a division of Johnson &amp; Johnson, Merz, Galderma, and Skinceuticals, a division of L&#8217;Oreal SA. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, including competing injectable botulinum toxin type A formulations that are in various phases of development in North America for the treatment of glabellar lines. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Seasonality</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">into the U.S. aesthetic neurotoxin market in May 2019.  Given the early stage of our launch of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we have not experienced seasonality in our net revenue to date. However, we are aware that historically the aesthetic neurotoxin market experiences higher revenue in the second and fourth calendar quarters as compared to the first and third calendar quarters. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Government Regulation in the United States</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our business has been, and will continue to be, subject to a variety of laws including the Federal Food Drug and Cosmetic Act, or FFDCA, and the Public Health Service Act, or the PHS Act, among others. Biologics and medical devices are subject to regulation under the FFDCA and PHS Act.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the United States, cosmetics, dietary supplements, biopharmaceutical products and medical devices are subject to extensive regulation by the FDA. The FFDCA, PHS Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, regulatory approval, license or clearance, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of these products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending license or marketing applications, warning letters and other enforcement actions, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">FDA Marketing Approval</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">completion of nonclinical laboratory tests and animal studies according to good laboratory practices, or GLPs, and applicable requirements for the humane use of laboratory animals or other applicable regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">submission to the FDA of an investigative new drug application, or IND, which must become effective before human clinical trials may begin;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed biological product for its intended use, according to the FDA&#8217;s regulations, commonly referred to as good clinical practices, or GCPs, and any additional requirements including those for the protection of human research subjects and their health and other personal information;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">submission to the FDA of a BLA for marketing approval that includes substantive evidence of safety;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">purity and potency from results of nonclinical testing and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#8217;s identity, strength, quality and purity and, if applicable, the FDA&#8217;s current good tissue practices for the use of human cellular and tissue products;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">potential FDA audits of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">FDA review and approval of the BLA</font><font style="font-family:Times New Roman;font-size:9pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Post-Approval Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Once a BLA is approved, a product is subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologics, including standards and regulations, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase IV testing, Risk Evaluation and Mitigation Strategies, or REMS, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging and labeling procedures must continue to conform to cGMP after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with applicable regulations such as cGMP and the Quality System Regulation. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other Regulation of the Healthcare Industry</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we do not currently have plans for our neurotoxin product to be covered by insurance or government reimbursement programs, if we were to offer reimbursable products, we could be subject to federal laws and regulations covering reimbursable products, such as the Anti-Kickback Statute, Stark Law and Physician Payment Sunshine Act. These laws that may affect our ability to operate include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Anti-Kickback Statute, which prohibit persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce either the referral of an individual, or furnishing or arranging for a good or service, for which payment may be made under a federal healthcare program;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Federal False Claims Act which imposes civil and criminal liability on individuals and entities who submit, or cause to be submitted, false or fraudulent claims for payment to the government;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Civil Monetary Penalties Law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;), which prohibits certain payments made to foreign government officials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services relating to healthcare matters; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Federal Physician Payments Sunshine Act, and its implementing regulations, which require that certain manufacturers of drugs, medical devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program (with certain exceptions) to report to the CMS information related to certain payments or other transfers of value made or distributed to physicians, which is defined broadly to include other healthcare providers, teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">State and foreign law equivalents of the foregoing and state laws regarding pharmaceutical company marketing compliance, reporting and disclosure obligations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our operations are found to be in violation of any of these laws, regulations, rules or policies or any other law or governmental regulation, or if interpretations of the foregoing change, we may be subject to civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Government Regulation in Europe</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the European Economic Area, or EEA (which is composed of the 28 Member States of the EU plus Norway, Iceland and Liechtenstein), medicinal products can only be commercialized after obtaining a Marketing Authorization, or MA.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There are two types of MAs:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use, or CHMP, of the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Because we are a biotechnology medicinal products company, we are eligible for a Community MA under the Centralized Procedure.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Product Approval Process Outside the United States and Europe</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the United States and EU, we may be subject to a variety of regulations in other jurisdictions governing manufacturing, clinical trials, commercial sales and distribution of our future products.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Whether or not we obtain FDA approval or MA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval or MA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Data Privacy and Security Laws and Regulations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are also subject to data privacy and security regulation by the federal government, states and non-U.S. jurisdictions in which we conduct our business. For example, HIPAA, as amended by the Health Information Technology and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#8217;s privacy and security standards directly applicable to &#8220;business associates,&#8221; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state and non-U.S. laws, including the General Data Protection Regulation adopted by the EU, govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Environmental Regulation</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:normal;">We are subject to numerous foreign, federal, state, and local environmental, health and safety laws and regulations relating to, among other matters, safe working conditions, manufacturing practices, fire hazard control, product stewardship and end-of-life handling or disposition of products, and environmental protection, including those governing the generation, storage, handling, use, transportation and disposal of hazardous or potentially hazardous substances and biological materials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our History</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We were incorporated in November 2012 and are headquartered in Newport Beach, California. In a series of related transactions in 2013, Strathspey Crown Holdings Group, LLC (formerly known as Strathspey Crown Holdings, LLC), or SCH, acquired all of our outstanding equity in exchange for membership interests in SCH. In 2014, SCH contributed our equity that it had acquired in 2013 to its subsidiary operating entity, ALPHAEON Corporation, or Alphaeon. As a result of these transactions, prior to our initial public offering we were a wholly-owned subsidiary of Alphaeon. In 2019 Alphaeon changed its name to AEON Biopharma, Inc. We continue to refer to the renamed AEON Biopharma, Inc. as Alphaeon.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon owned 25.8% of our outstanding shares of common stock. Subsequent to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon contributed all of the shares it held in us to Alphaeon 1, LLC. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">235</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;employees, all of whom constituted full-time employees. None of our employees are represented by a collective bargaining agreement, and we have never experienced any work stoppage. We believe we have good relations with our employees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Corporate Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We were incorporated in the State of Delaware in November 2012. Our principal executive offices are located at&#160;520 Newport Center Drive, Suite 1200, Newport Beach, California 92660,&#160;and our telephone number is (949) 284-4555. Our website address is www.evolus.com. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, our website a part of this Annual Report on Form 10-K or any other filing we make with the SEC. We are an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and also a smaller reporting company, and therefore we are subject to reduced public company reporting requirements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Available Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We make available, free of charge, on our website at www.evolus.com our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports, as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC.  All such reports are also available free of charge via EDGAR through the SEC website at www.sec.gov.&#160; We do not incorporate the information on or accessible through these websites into this Annual Report on Form 10-K, and you should not consider any information on, or that can be accessed through, these websites a part of this Annual Report on Form 10-K or any other filing we make with the SEC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13</font></div></div><hr style="page-break-after:always"><div><a name="sCBF3CE2E7723525D8A2C2BAB92C9E962"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 1A.&#160;&#160;&#160;&#160;Risk Factors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">You should carefully consider the risks and uncertainties described below, together with all the other information in this Annual Report on Form 10-K, including Item 7&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the financial statements and the related notes included in Item 8 &#8220;Financial Statements and Supplementary Data.&#8221; If any of the following risks actually occurs, our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. Unless otherwise indicated, references to our business being seriously harmed in these risk factors will include harm to our business, reputation, financial condition, results of operations, revenue, and future prospects. In that event, the market price of our common stock could decline, and you could lose part or all of your investment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to Our Business and Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have a limited operating history and have incurred significant losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We have only one product and limited commercial sales, which, together with our limited operating history, make it difficult to assess our future viability. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a limited operating history. To date, we have invested substantially all of our efforts and financial resources in the clinical development, regulatory approval, and commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is currently our only product. We began selling Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States in May 2019 and through a distribution partner in Canada in October 2019 and have a limited history of generating revenue. We are not profitable and have incurred losses in each year since our inception in 2012. We have a limited operating history upon which you can evaluate our business and prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or greater experience commercializing a product. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the medical aesthetics field. We continue to incur significant expenses related to the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We have recorded net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and had an accumulated deficit as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$213.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will continue as we commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our ability to achieve revenue and profitability is dependent on our ability to successfully market and commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently depend entirely on the successful commercialization of our only product, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. If we are unable to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, we may never generate sufficient revenue to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have only one product, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and our business presently depends entirely on our ability to successfully commercialize it in a timely manner. While the product was commercially launched in the United States in May 2019 and through a distribution partner in Canada in October 2019, we have a limited history of generating revenue for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our near-term prospects, including our ability to generate revenue, as well as our future growth, depend entirely on the successful commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will depend on a number of factors, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our success in educating physicians and consumers about the benefits, administration and use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the prevalence, duration and severity of potential side effects experienced with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">achieving and maintaining compliance with all regulatory requirements applicable to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability to raise additional capital on acceptable terms, or at all, if needed, to support our operations and further commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the acceptance by physicians and consumers of the safety and efficacy of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">, whether alone or in collaboration with others, including our ability to hire, retain and train sales representatives in the United States;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability of our current manufacturer and any third parties with whom we may contract to remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with current Good Manufacturing Practice, or cGMP, requirements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to accurately forecast demand for our products, the ability of our third-party manufacturers to scale production to meet that demand and our ability to effectively manage our working capital requirements including the purchase of inventory and collection of receivables;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to resolve ongoing legal proceedings in a timely and cost-effective manner;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the availability, perceived advantages, relative cost, relative safety and relative efficacy of competing products, the timing of new product introductions by our competitors, and the sales and marketing tactics of our competitors, including bundling of multiple products, in response to our launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant issues commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Further, we may never be able to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. In addition, our experience as a commercial company is limited. Accordingly, we may not be able to generate sufficient revenue through the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates to continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;faces, and any of our future product candidates will face, significant competition and our failure to effectively compete may prevent us from achieving significant market penetration and expansion. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">In May 2019, we commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#32;into the highly competitive U.S. aesthetic neurotoxin market. In the long term, we expect to expand our focus to the broader self-pay healthcare market. Many of our potential competitors, including Allergan in particular who first launched BOTOX for cosmetic uses in 2002 and has since maintained the highest market share position in the aesthetic neurotoxin market with its BOTOX product, are large, experienced companies that enjoy significant competitive advantages, such as: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">substantially greater financial resources enabling them to, among other things, market and discount aggressively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">large and established research and development, manufacturing, personnel and marketing resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">greater brand recognition for their products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">larger sales forces;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">larger aesthetic product portfolios allowing the companies to bundle products to provide customers more choices and to further discount their products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">greater existing market share in the aesthetic neurotoxin product market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">long standing customer loyalty programs and sales contracts with large customers;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">established business and financial relationships with customers, aesthetic societies and universities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These competitors may also try to compete with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on price both directly, through rebates and promotional programs to high volume physicians and coupons to consumers, and indirectly, through attractive product bundling with complimentary products, such as dermal fillers that offer convenience and an effectively lower price compared to the total price of purchasing each product separately. These companies may also seek to compete based on their longer operating history. Larger companies may be better capitalized than us and, accordingly, are able to offer greater customer loyalty benefits to encourage repeat use of their products and finance a sustained global advertising campaign to compete with our commercialization efforts at launch. A number of our larger competitors also have access to a significant amount of studies and publications that they could use to compete with us.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors and other parties may also seek to impact regulatory approval of our future product applications through the filing of citizen petitions or other similar documents, which could require costly and time-consuming responses to the regulatory agencies. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Larger competitors could seek to prevent or delay our commercialization efforts via costly litigation which can be lengthy and expensive and serve to distract our management team&#8217;s attention. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We could face competition from other sources as well, including academic institutions, governmental agencies and public and private research institutions. In addition, we are aware of other companies also developing and/or marketing products in one or more of our target markets, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">including competing injectable botulinum toxin type A formulations that are currently in Phase III clinical development in North America for the treatment of glabellar lines. For example, Revance Therapeutics, Inc. has submitted a BLA to the FDA for an injectable botulinum toxin type A neurotoxin and received a target date action date of November 25, 2020 under the Prescription Drug User Fee Act.  If the BLA is approved, we expect the competition in the U.S. injectable botulinum toxin market to further increase.  We would face similar risks with respect to any future product candidates that we may seek to develop or commercialize in the broader self-pay healthcare market. Successful competitors in that market have the ability to effectively discover, obtain patents, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our strategy of competing in the aesthetic neurotoxin market is dependent on the marketing and pricing flexibility that we believe is afforded to a company with a portfolio limited to self-pay healthcare, comprised of products and procedures that are not reimbursed by third-party payors. In the event that regulations applicable to reimbursed products are changed to apply to self-pay healthcare products, we would no longer have this flexibility and we may not be able to compete as effectively with our competitors which may have a material effect on our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The first use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is in aesthetic medicine. The aesthetic product market, and the facial aesthetic market in particular, is highly competitive and dynamic and is characterized by rapid and substantial technological development and product innovations. We have received regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines and launched commercially in the United States and through a distribution partner in Canada. We anticipate that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will face significant competition from other facial aesthetic products, such as other injectable and topical botulinum toxins and dermal fillers. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may also compete with unapproved and off-label treatments. In addition, competitors may develop new technologies within the aesthetic market that may be superior in safety and efficacy to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or offer alternatives to the use of toxins, including surgical and radio frequency techniques. To compete successfully in the aesthetic market, we will have to demonstrate that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is at least as safe and effective as current products sold by our competitors. Competition in the aesthetic market could result in price-cutting and reduced profit margins, any of which would harm our business, financial condition and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to less stringent regulatory requirements, there are many more aesthetic products and procedures available for use in international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial opportunity could also be reduced or eliminated if our competitors develop and commercialize products that are safer, are more effective, have fewer or less severe side effects, are more convenient or are less expensive than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product that we may develop. Our competitors also may obtain FDA or other regulatory approval for these products more rapidly than we may obtain approval for our products, which could result in our competitors establishing a strong market position before we are able to enter the market, which may create additional barriers to successfully commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates and attracting physician and consumer demand.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We rely on the license and supply agreement, the Daewoong Agreement, with Daewoong to provide us exclusive rights to distribute Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;in certain territories. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our development or commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement, we have secured an exclusive license from Daewoong, a South Korean pharmaceutical manufacturer, to import, distribute, promote, market, develop, offer for sale and otherwise commercialize and exploit Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for aesthetic indications in the United States, EU, Canada, Australia, Russia, C.I.S. and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Daewoong Agreement imposes on us obligations relating to exclusivity, territorial rights, development, commercialization, funding, payment, diligence, sublicensing, intellectual property protection and other matters. We are obligated to conduct development activities, obtain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, obtain from Daewoong all of our product supply requirements for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and pay to Daewoong regulatory milestone payments and other cash payments in connection with the net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In addition, under the Daewoong Agreement, we are required to submit our commercialization plan to a joint steering committee, or JSC, comprised of an equal number of development and commercial representatives from Daewoong and us, for review and input. Although the Daewoong Agreement provides us with final decision-making power regarding the marketing, promotion, sale and/or distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, any disagreement among the JSC would be referred to Daewoong&#8217;s and our respective senior management for resolution </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">if the JSC is unable to reach a decision within thirty days, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">which may result in a delay in our ability to implement our commercialization plan or harm our working relationship with Daewoong. If we fail to achieve minimum annual purchase targets of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;under the Daewoong Agreement, Daewoong may, at its sole option, elect to convert the exclusive license to a non-exclusive license. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The initial term of the Daewoong Agreement will expire on the later of September 30, 2023 or the fifth anniversary of our receipt of marketing approval in any of the aforementioned territories. The Daewoong Agreement will renew for unlimited additional three-year terms after the expiration of the initial term, only if we meet certain performance requirements during the initial term or preceding renewal term, as applicable. We or Daewoong may terminate the Daewoong Agreement if the other party breaches any of its duties or obligations and such breach continues without cure for ninety days, or thirty days in the case of a payment breach, or if we declare bankruptcy or assign our business for the benefit of creditors. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages to Daewoong and Daewoong may have the right to terminate our license. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Daewoong Agreement, we may not have sufficient funds available to meet our obligations, which would allow Daewoong to terminate the Daewoong Agreement. Any termination or loss of rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect our ability to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which in turn would have a material adverse effect on our business, operating results and prospects. If we were to lose our rights under the Daewoong Agreement, we believe it would be difficult for us to find an alternative supplier of a botulinum toxin type A complex. In addition, to the extent the alternative supplier has not secured regulatory approvals in a jurisdiction, we would have to expend significant resources to obtain regulatory approvals that may never be obtained or require several years to obtain, which could significantly delay commercialization. We may be unable to raise additional capital to fund our operations during this extended time on terms acceptable to us or at all. Additionally, if we experience delays as a result of a dispute with Daewoong, the demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;could be materially and adversely affected.  Additionally, if the Daewoong Agreement is terminated, breached or has certain other adverse actions, it may constitute an event of default under our loan and security agreement, or credit facility, with Oxford Finance, LLC, or Oxford. Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We currently rely solely on Daewoong to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, and as such, any production or other problems with Daewoong could adversely affect us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We depend solely upon Daewoong for the manufacturing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Although alternative sources of supply may exist, the number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for and qualify alternative suppliers, which could have a material adverse effect on our business. Suppliers of any new product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">17</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our reliance on Daewoong entails additional risks, including reliance on Daewoong for regulatory compliance and quality assurance, the possible breach of the Daewoong Agreement by Daewoong, and the possible termination or nonrenewal of the Daewoong Agreement at a time that is costly or inconvenient for us. Our failure, or the failure of Daewoong, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our dependence on Daewoong also subjects us to all of the risks related to Daewoong&#8217;s business, which are all generally beyond our control. Daewoong&#8217;s ability to perform its obligations under the Daewoong Agreement is dependent on Daewoong&#8217;s operational and financial health, which could be negatively impacted by several factors, including changes in the economic, political and legislative conditions in South Korea and the broader region in general and the ability of Daewoong to continue to successfully attract customers and compete in its market. Furthermore, Daewoong&#8217;s recently constructed manufacturing facility is Daewoong&#8217;s only facility meeting FDA and European Medicines Agency, or EMA, cGMP requirements. Daewoong&#8217;s lack of familiarity with, or inability to effectively operate, the facility and produce products of consistent quality, may harm our ability to compete in our market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on Daewoong for day-to-day compliance with cGMP for production of drug substance and finished products. Facilities used by Daewoong to produce the drug substance and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. If the safety of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize our product and we may be held liable for injuries sustained as a result. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product into the United States or other countries as a result of, among other things, regulatory agency approval requirements, taxes, tariffs, local import requirements such as import duties or inspections, incomplete or inaccurate import documentation or defective packaging. Any of these factors could adversely impact our ability to effectively commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any failure or refusal by Daewoong or any other third party to supply Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product candidates or products that we may develop could delay, prevent or impair our clinical development or commercialization efforts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">may prevent or delay our commercialization efforts and interrupt our supply of products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our commercial success depends in part on our avoiding infringement of the proprietary rights of third parties. Competitors in the field of dermatology, aesthetic medicine and neurotoxins have developed large portfolios of patents and patent applications in fields relating to our business. In particular, there are patents held by third parties that relate to the treatment with neurotoxin-based products for the indication we are currently developing. There may also be patent applications that have been filed but not published that, when issued as patents, could be asserted against us. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the technology, medical device and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter-party reexamination proceedings before the U.S. Patent and Trademark Office, or USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As the technology, medical device and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third parties may assert that we or any of our current or future licensors, including Daewoong, are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, methods of manufacture or methods for treatment related to the use or manufacture of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents or until such patents expire. Similarly, if any third-party patent were held by a court of competent jurisdiction to cover aspects of our methods of use, the holders of any such patent may be able </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">18</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to claims of patent infringement, third parties may bring claims against us asserting misappropriation of proprietary technology or other information in the development, manufacture and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates. Defense of such a claim would require dedicated time and resources, which time and resources could otherwise be used by us toward the maintenance of our own intellectual property and the development and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates or by any of our current or future licensors for operational upkeep and manufacturing of our products. Presently, we are a defendant in a lawsuit brought by Medytox, Inc., or Medytox, on June 7, 2017 in the Superior Court of the State of California, alleging, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us, or the Medytox Litigation. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong filed a motion to dismiss or stay for forum non conveniens, claiming that the place where the complaint has been filed, in the Superior Court of the State of California, is not the proper place for the trial of the claims in the complaint because, among other reasons, the underlying facts that gave rise to the complaint occurred in South Korea. Daewoong&#8217;s motion to dismiss was granted by the Superior Court of the State of California on October 12, 2017. As a result, the action filed with the Superior Court of the State of California is stayed pending resolution of the proceedings in South Korea. In October 2017, Medytox initiated a civil lawsuit against Daewoong and its parent company, Daewoong Co. Ltd., in the Seoul Central District Court in Seoul, South Korea, related to the same subject matter in the Medytox Litigation and is seeking, among other things, money damages, injunctive relief and destruction of related documents and products. None of us, Alphaeon or SCH are parties to the litigation in the Seoul Central District Court.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 27, 2018, pursuant to a motion to dismiss brought by Daewoong, the Superior Court of the State of California dismissed Medytox&#8217;s suit against Daewoong, without prejudice, on the basis that Medytox had brought a substantially similar proceeding against Daewoong in South Korea. The proceedings against us, Alphaeon and SCH remain stayed in the Superior Court of the State of California pending resolution of the proceedings between Medytox and Daewoong in South Korea. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While the proceedings between Medytox and Daewoong in South Korea are progressing, legal proceedings are inherently uncertain and we cannot predict what actions may be taken by the Seoul Central District Court in connection with such proceedings. Due to these factors and because we are not a direct party to the proceedings, we are unable to provide any assurances about when such proceedings may be resolved or whether&#160;such resolution may occur sooner or later than we otherwise anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code Section 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code Section 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us, Alphaeon, SCH or Daewoong or to quantify any risk of loss. The Medytox Litigation and any other similar claims, suits, government investigations and proceedings are inherently uncertain and their results may not be favorable for us. For example, if the Medytox Litigation has a negative outcome for us, Alphaeon or Daewoong, it could result in us losing access to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and the manufacturing process and require us to negotiate a new license with Medytox for continued access to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We may not be able to successfully negotiate such license on terms acceptable to us or at all. If we are unable to license Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we may not be able to find a replacement product, if at all, without expending significant resources and being required to seek additional regulatory approvals, which would be uncertain, time consuming and costly. Regardless of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">19</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the outcome, such proceedings can have an adverse impact on us because of legal costs, diversion of management resources and other factors. An adverse ruling against either us or one of the other defendants of any such proceedings could adversely affect our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission, or the ITC, containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the ITC Complaint.  The ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The ITC complaint calls for an investigation by the ITC under Section 337 of the Tariff Act of 1930.  The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen BTX Strain, and (vii) exclusion and cease and desist orders. We intend to defend ourselves vigorously in the proceedings. The ITC has set a target date for the final determination of the matter for October 2020. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States and a cease and desist order which would bar sales and marketing of our sole product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United Sates either of which would adversely affect our ability to carry our out our business and which would have an adverse effect on our business, financial position, results of operations, or cash flows and could also result in reputational harm. Any of these consequences could adversely affect our business and results of operations.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, in certain cases if there is preliminary or permanent relief granted under the Medytox Litigation or the ITC matter, it may constitute an event of default under our credit facility.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including cash.  Any such action could materially and adversely affect our business and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us or any of our current or future licensors may request and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement, we or any of our current or future licensors may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties which may not be commercially or more available, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible or require substantial time and monetary expenditure. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research, manufacture clinical trial supplies or allow commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. Similarly, third-party patents could exist that might be enforced against our products, resulting in either an injunction prohibiting our sales, or with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Borrowings under our credit facility could adversely affect our financial condition and restrict our operating flexibility. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into a credit facility with Oxford, or the lender, pursuant to which the lender will make term loans available to us of up to $100.0 million, or the credit facility. The credit facility provides that the term loans will be funded in two advances. The first tranche of $75.0 million was funded on the closing date, and the second tranche of $25.0 million may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones with no event of default occurring. The credit facility bears an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR (London Inter-Bank Offered Rate) rate plus 7.0%. We have agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which will be followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility contains customary affirmative and restrictive covenants and representations and warranties. We are bound by certain affirmative covenants setting forth actions that are required during the term of the credit facility including, without limitation, certain requirements to deliver financial and other required information to Oxford, obligations to maintain certain insurance, and certain notice requirements. Additionally, we are bound by certain restrictive covenants setting forth actions that are not permitted to be taken during the term of the credit facility without Oxford&#8217;s prior written consent, including, without limitation, incurring certain additional indebtedness, consummating certain mergers, acquisitions or other business combination transactions, or incurring any non-permitted lien or other encumbrance on our assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Interest payments, fees, covenants and restrictions under the credit facility could have important consequences, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to obtain additional financing on satisfactory terms to fund our working capital requirements, capital expenditures, potential acquisitions, debt obligations and other general corporate requirements, and making it more difficult for us to satisfy our obligations with respect to any such additional financing; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">increasing our vulnerability to general economic downturns, competition and industry conditions, which could place us at a competitive disadvantage compared to our competitors with no debt obligations or with debt obligations on more favorable terms; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">limiting our ability to pursue acquisition opportunities and to license intellectual property outside specified exceptions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The occurrence of any one of these events could have an adverse effect on our business, financial condition, operating results or cash flows and ability to satisfy our obligations under the credit facility and any other indebtedness. If new debt is incurred in addition to debt incurred under the credit facility, the related risks that we face would be increased. The terms of the credit facility may restrict our current and future operations, particularly our ability to respond to changes in our business or to take certain actions. The credit facility contains, and the terms of any future indebtedness of ours would likely contain, a number of restrictive covenants that impose significant operating restrictions, including restrictions on our ability to engage in acts that may be in our best long-term interests. The credit facility includes covenants that, among other things and subject to certain exceptions and limits, restrict or otherwise limit our ability to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">dispose of assets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">undergo certain business, management, ownership, business and other fundamental changes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain merger, acquisition and consolidation transactions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">incur additional indebtedness and create liens and other encumbrances;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">make restricted payments, including dividends and other distributions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">engage in certain transactions with affiliates.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default including, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.  Under the credit facility, in the event of default, a default interest rate equal to the applicable rate plus 5.0% would apply and Oxford, as collateral agent, could exercise remedies against including the ability to declare any outstanding debt immediately due and payable. In addition, the credit facility is secured by certain of our existing and hereafter created or acquired assets, including our intellectual property, cash, accounts receivable, equipment, general intangibles, inventory and all of the proceeds and products of the foregoing. If we are unable to pay any amounts due and payable under the credit facility because we do not have sufficient cash on hand or are unable to obtain alternative financing on acceptable terms, the lenders could initiate a bankruptcy proceeding or proceed against any assets that serve as collateral to secure the credit facility. These restrictions could limit our ability to obtain future financings, make needed capital expenditures, withstand future downturns in the economy or otherwise conduct necessary corporate activities. We may also be prevented from taking advantage of business opportunities that arise because of limitations imposed on us by the restrictive covenants under the credit facility.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">21</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may require additional financing to fund our future operations, and a failure to obtain additional capital when so needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have utilized substantial amounts of cash since our inception in order to conduct clinical development to support regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, EU and Canada and in connection with the launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States and Canada. We expect that we will continue to expend substantial resources for the foreseeable future in order to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and for the clinical development of any additional product candidates we may choose to pursue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the near term, these expenditures will include costs associated with the development and continuation of our marketing programs and commercialization infrastructure in connection with commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">within and outside of the United States. In the long term, these expenditures will include costs associated with the continued commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates, such as research and development, conducting preclinical studies and clinical trials and manufacturing and supplying as well as marketing and selling any products approved for sale. In addition, other unanticipated costs may arise. Because the regulatory approval process and commercialization expenditures needed to meet our sales objectives are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. We expect to incur additional costs as we continue to operate as a public company, hire additional personnel and expand our operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We anticipate that our existing cash, cash equivalents and investments will be sufficient to fund our current operating plan for the next twelve months. However, we may require additional funds earlier than we currently expect in the event that market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is slower than expected. Our currently anticipated expenditures for the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may exceed existing cash, cash equivalents and investments, and we may need to seek additional debt or equity financing.  Additionally, under our credit facility, in order to draw the final $25.0 million of the facility, we must meet a number of conditions including maintaining compliance with covenants under the credit facility and the achievement of specified net sales targets based on a trailing six-month basis. In the event we are unable to reach this net sales milestone, we will not be able to draw the additional $25.0 million. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had not yet met the net sales milestone to draw the second tranche.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may need to raise additional capital to fund our operations and continue to support both our near and long-term expenditures. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our future capital requirements depend on many factors, including:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or if any other future product candidates are approved for sale, including marketing, sales and distribution costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the scope, progress, results and costs of researching and developing any future product candidates, and conducting preclinical and clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to accurately forecast demand for our products, the ability of our third-party manufacturers to scale production to meet that demand and our ability to effectively manage our working capital requirements including the purchase of inventory and collection of receivables;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs under our third-party manufacturing and supply arrangements for our current and any future product candidates and any products we commercialize;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the terms of and timing of such arrangements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of, and the costs involved in, obtaining and maintaining regulatory approvals for any future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the degree and rate of market acceptance of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of alternative and competing products, the timing of new product introductions by competitors and other actions by competitors in the marketplace;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs of operating as a public company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">costs associated with any acquisition or in-license of products and product candidates, technologies or businesses.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">22</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, technologies, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings or offerings of securities convertible into our equity, the ownership interest of our existing stockholders will be diluted and the terms of any such securities may have a preference over our common stock. Debt financing, receivables financing and royalty financing may also be coupled with an equity component, such as warrants to purchase our capital stock, which could also result in dilution of our existing stockholders&#8217; ownership, and such dilution may be material. Additionally, if we raise additional capital through debt financing, we will have increased fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt or making capital expenditures to meet specified financial ratios, and other operational restrictions, any of which could restrict our ability to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates or operate as a business and may result in liens being placed on our assets. If we were to default on any of our indebtedness, we could lose such assets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the event we are unable to raise sufficient capital to fund our commercialization efforts to achieve specified minimum sales targets under the Daewoong Agreement, we will lose exclusivity of the license that we have been granted under the Daewoong Agreement.  In addition, if we are unable to raise additional capital when required or on acceptable terms, we may be required to significantly reduce operating expenses and delay, reduce the scope of or discontinue some of our development programs, commercialization efforts or other aspects of our business plan, out-license intellectual property rights to our product candidates and sell unsecured assets, or a combination of the above. As a result, our ability to achieve profitability or to respond to competitive pressures would be significantly limited and may have a material adverse effect on our business, results of operations, financial condition and/or our ability to fund our scheduled obligations on a timely basis or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;may fail to achieve the broad degree of physician adoption and use necessary for commercial success. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may fail to gain sufficient market acceptance by physicians, consumers and others in the medical aesthetics community. The commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates will depend significantly on the broad adoption and use of the resulting product by physicians for approved indications, including, in the case of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the treatment of glabellar lines and other aesthetic indications that we may seek to pursue. We are aware that other companies are seeking to develop alternative products and treatments, any of which could impact the demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The degree and rate of physician adoption of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates depend on a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness, ease of use and safety of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates as compared to existing products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">physician and consumer willingness to adopt Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to treat glabellar lines or other aesthetic indications we may pursue over products and brands with which consumers and physicians may have more familiarity or recognition </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or additional approved uses</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">overcoming any biases physicians or consumers may have toward the use, safety and efficacy of existing products or treatments </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and successful marketing of the benefits of a 900 kDa botulinum toxin type A complex</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates in relation to alternative products or treatments and willingness to pay for the product or treatment on the part of consumers&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">proper training and administration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates by physicians and medical staff&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer satisfaction with the results and administration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates and overall treatment experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">negative selling efforts by our competitors against </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">our competitors&#8217; long standing relationships with customers, including Allergan in particular, given their longstanding dominance of the market, which we may not be able to overcome in order to get customers to adopt Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">changes in pricing, </font><font style="font-family:Times New Roman;font-size:10pt;">promotional, negative sales tactics, promotion of longer-term purchase agreements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and bundling efforts by competitors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the filing of various lawsuits by competitors with the intent of preventing or delaying our product launches, to distract management&#8217;s attention from operating our business and to devote significant financial resources to defend such litigation attempts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer demand for the treatment of glabellar lines or other aesthetic indications that may be approved in the future;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the willingness of consumers to pay for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates relative to other discretionary items, especially during economically challenging times&#894;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the revenue and profitability that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;and any future product candidates may offer a physician as compared to alternative products or treatments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the effectiveness of our sales, marketing and distribution efforts and our ability to develop our brand awareness;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any adverse impact on our brand resulting from key opinion leader relationships with Alphaeon or SCH, whether or not related to us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a perception that </font><font style="font-family:Times New Roman;font-size:10pt;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">are unproven or experimental, or perceived differences in product performance, reliability, features and ease of use characteristics versus our competitors&#8217; products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to compete with our competitors&#8217; product bundling offerings as we initially launch Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;as a stand-alone product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">adverse </font><font style="font-family:Times New Roman;font-size:10pt;">publicity </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">about our product candidates, competitive products, or the industry as a whole, or favorable publicity about competitive products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, in its clinical trials, Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was clinically tested with one Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;unit compared to one BOTOX unit. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only known neurotoxin product in the United States with a 900 kDa complex other than BOTOX. We believe that aesthetic physicians&#8217; familiarity with the 900 kDa complex&#8217;s handling, preparation and dosing will more easily facilitate incorporation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into their practices. However, the ease of integration of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into a physician&#8217;s practice may not be as seamless as we anticipate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates fail to achieve the broad degree of physician adoption necessary for commercial success, our operating results and financial condition will be adversely affected, which may delay, prevent or limit our ability to generate revenue and continue our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If there is not sufficient consumer demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, our financial results and future prospects will be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Treatment of glabellar lines with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an elective procedure, the cost of which must be borne by the consumer, and we do not expect costs related to the treatment to be reimbursable through any third-party payor, such as Medicaid, Medicare or commercial insurance. The decision by a consumer to undergo treatment with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines or other aesthetic indications that we may pursue may be influenced by a number of factors, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any sales and marketing programs that we, or any third parties we engage, undertake, and as to which we have limited experience;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which physicians recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;to their patients;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the extent to which Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;satisfies consumer expectations </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and overcoming consumer loyalty with existing products and brands</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our ability to properly train physicians in the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;such that their consumers do not experience excessive discomfort during treatment or adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the cost, safety and effectiveness of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;versus other aesthetic treatments;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">24</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the development </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;availability of alternative products and treatments that seek to address similar goals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">consumer sentiment about the benefits and risks of aesthetic procedures generally and Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;in particular;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the success of any direct-to-consumer marketing efforts that we may initiate; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the ability and ease with which physicians are able to incorporate Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;into their practices; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in demographic and social trends; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">general consumer </font><font style="font-family:Times New Roman;font-size:10pt;">confidence</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which may be impacted by economic and political conditions.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is the only U.S. neurotoxin without a therapeutic indication, although other companies may seek to develop a similar product in the future. We believe pursuing an aesthetic-only non-reimbursed product strategy will allow for meaningful strategic advantages in the United States, including pricing and marketing flexibility. However, physicians may choose to not pass any cost benefits received by them due to such pricing flexibility to their patients. In addition, companies offering aesthetic products competitive to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, whether they pursue an aesthetic-only non-reimbursed product strategy or not, may nonetheless try to compete with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on price both directly through rebates, promotional programs and coupons and indirectly through attractive product bundling and customer loyalty programs. Our business, financial results and future prospects will be materially harmed if we cannot generate sufficient consumer demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we have not pursued regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for indications other than for the treatment of glabellar lines, which may limit adoption of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin product and may be able to market such product for use in a way we cannot. For example, we are aware that one of our competitors, </font><font style="font-family:Times New Roman;font-size:10pt;font-style:normal;font-weight:normal;">Allergan plc</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and therefore is able to market its product across a greater number of indications than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are unable to obtain approval for indications in addition to glabellar lines, our marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any other product candidate for which we seek approval as a biologic may face competition sooner than anticipated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With the enactment of the Biologics Price Competition and Innovation Act of 2009, or the BPCI Act, as part of the Patient Protection and Affordable Care Act, an abbreviated pathway for the approval of biosimilar or interchangeable biological products was created. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until twelve years after the original branded product was approved under a Biologics License Application, or BLA. The law is complex and is still being interpreted and implemented by the FDA. For example, one company has filed a Citizen Petition requesting that the FDA not apply the BPCI Act to pre-enactment BLAs. As a result, its ultimate impact, implementation and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider any of our product candidates to be a reference product for competing products, potentially creating the opportunity for competition sooner than anticipated. Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;is manufactured exclusively in one facility located in South Korea, and we plan to utilize this facility to support commercial production of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">. If this facility were damaged or destroyed, or if there occurs a significant disruption in operations at this facility for any reason, our ability to continue to operate our business would be materially harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong developed the manufacturing process for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in a recently constructed facility located in South Korea. If this facility were to be damaged, destroyed or otherwise unable to operate or comply with regulatory requirements, whether due to earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if operations at the facility is disrupted for any other </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reason, such an event could jeopardize Daewoong&#8217;s ability to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as promptly as we or our customers expect or possibly at all. If we experience delays in achieving our development objectives, or if Daewoong is unable to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within a timeframe that meets our and our customers&#8217; expectations, our business, prospects, financial results and reputation could be materially harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If these disruptions exceed coverage provided by Daewoong&#8217;s insurance policies, Daewoong may be unable to satisfy its obligations to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We or the third parties upon whom we depend may be adversely affected by earthquakes or other natural disasters, public health crises, or political unrest and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or political unrest. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong, the sole manufacturer of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in a facility located in South Korea. In addition, the underlying drug substance for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is also manufactured in a separate facility on the same campus. As a result of the concentration of the manufacturing and storage facilities for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on this single campus, we are subject to risks that manmade or natural events will impact our supply of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;.</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. For example, extreme weather events at or near Daewoong&#8217;s facilities may impact the accessibility or viability of such facilities. As well, the earthquakes in the Pacific Rim region is high and the Daewoong facility is in close proximity to major earthquake fault lines. Additionally, public health crises may affect South Korea. For example, beginning in December 2019, a strain of coronavirus was reported to have surfaced in Wuhan, China which spread to other areas within Asia. If this or any other public health crisis effects operations at Daewoong, it would have an adverse effect on the ability for Daewoong to manufacture our product. There is also a level of political unrest and potential military conflict or uncertainty in South Korea and the broader region. For example, the operations of the South Korean manufacturing plant may experience unrest or security issues due to the threats posed by&#160;North&#160;Korea.  Natural disasters or political unrest could severely disrupt Daewoong&#8217;s operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If a natural disaster, public health crisis or political unrest, power outage or other event occurred that prevented Daewoong from using all or a significant portion of its manufacturing facility, or prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. In particular, because Daewoong manufactures Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in its facility, in the event of a natural disaster, public health crisis, political unrest, power outage or other event affecting this facility, we would be required to seek additional manufacturing facilities and capabilities that have obtained the necessary approvals required by state, federal or other applicable authorities in order to continue or resume manufacturing activities, which we may not be able to do on commercially reasonable terms if at all. Any disaster recovery and business continuity plans that we and Daewoong have in place or put in place may not be adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of our or Daewoong&#8217;s lack of disaster recovery and business continuity plans, or the adequacy thereof, which could have a material adverse effect on our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;is limited to use for the treatment of glabellar lines, and if we want to expand the indications for which we market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, we will need to obtain additional regulatory approvals, which will be expensive and may not be granted. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have received regulatory approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States for the treatment of moderate to severe glabellar lines. The terms of that approval restrict our ability to market or advertise Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for other indications, which could limit physician and consumer adoption. Under the U.S. Federal Food Drug and Cosmetic Act, we may generally only market Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for approved indications. Many of our competitors have received approval of multiple aesthetic and therapeutic indications for their neurotoxin products and may be able to market such products for use in a way we cannot. For example, we are aware that one of our competitors, Allergan, has obtained and plans to obtain additional indications for its neurotoxin product within medical aesthetics and, therefore, is able to market its product across a greater number of indications than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are unable to obtain approval for indications in addition to our approval for glabellar lines, our marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will be severely limited. As a result, we may not generate physician and consumer demand or approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We have entered into an agreement with Alphaeon relating to certain rights to the therapeutic indications of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;under the Daewoong Agreement and, as a result, we will not be able to pursue therapeutic indications for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On December 18, 2017, we entered into the therapeutic agreement with Alphaeon, or the therapeutic agreement, relating to certain rights to the therapeutic indications of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;under the Daewoong Agreement. Pursuant to the Daewoong Agreement, we received an option to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to cover all </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">26</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">therapeutic uses in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">United States, EU, Canada, Australia, Russia, C.I.S. and South Africa, or the covered</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;territories, and Japan, or the therapeutic option. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">However, pursuant to the therapeutic agreement, we agreed not to sell, sub-license or otherwise dispose in whole or in part the therapeutic option or the rights underlying the therapeutic option and hold the therapeutic option and the underlying rights in trust for Alphaeon. In September 2018, Alphaeon exercised the right to obtain the therapeutic option to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and remitted the option exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2019, Alphaeon and Daewoong entered into a direct distribution agreement for botulinum toxin products for therapeutic uses that is separate and distinct from the Daewoong Agreement.  Our entry into the therapeutic agreement and the entry by Alphaeon into an agreement directly with Daewoong eliminates our ability to expand the permitted uses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">botulinum toxin products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for therapeutic indications.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or </font><font style="font-family:Times New Roman;font-size:10pt;">other similar regulatory authorities</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as reflected in the product&#8217;s approved labeling. Physicians could use Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;on their patients in a manner that is inconsistent with the approved label of the treatment of moderate to severe glabellar lines, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters from and be subject to other enforcement actions by the FDA, the EMA and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&#8217;s attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of our products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry. In addition, regulatory authorities outside the United States may impose similar fines, penalties or sanctions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Physicians may also misuse Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management&#8217;s attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our products. Furthermore, the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any of our future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling or result in post-approval regulatory action.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Unforeseen side effects from Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or our future product candidates could arise either during clinical development or after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, the EMA or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, the EMA or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">27</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or any of our future product candidates, after obtaining regulatory approval in the United States or other jurisdictions, a number of potentially negative consequences could result, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may withdraw their approval of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require a recall of the product or we may voluntarily recall a product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require us to create a medication guide outlining the risks of such side effects for distribution to patients or institute a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Risk Evaluation and Mitigation Strategies, or </font><font style="font-family:Times New Roman;font-size:10pt;">REMS;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be subject to limitations as to how we market or promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we may be required to change the way the product is administered or modify the product in some other way;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory authorities may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our brand </font><font style="font-family:Times New Roman;font-size:10pt;">and</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product, negatively impact our revenues and could substantially increase the costs of commercializing our products. The demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;could also be negatively impacted by any adverse effects of a competitor&#8217;s product or treatment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our failure to successfully in-license, acquire, develop and market additional product candidates or approved products would impair our ability to grow our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Although most of our effort is focused on the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a key element of our long-term strategy is to in-license, acquire, develop, market and commercialize a portfolio of products to serve the self-pay aesthetic market. Because our internal research and development capabilities are limited, we may be dependent upon pharmaceutical and other companies, academic scientists and other researchers to sell or license products or technology to us. The success of this strategy depends partly upon our ability to identify and select promising pharmaceutical product candidates and products, negotiate licensing or acquisition agreements with their current owners and finance these arrangements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The process of proposing, negotiating and implementing a license or acquisition of a product candidate or approved product is lengthy and complex. Other companies, including some with substantially greater financial, marketing, sales and other resources, may compete with us for the license or acquisition of product candidates and approved products. We have limited resources to identify and execute the acquisition or in-licensing of third-party products, businesses and technologies and integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or licensing opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. We may not be able to acquire the rights to additional product candidates on terms that we find acceptable, or at all.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Further, any product candidates that we acquire may require additional development efforts prior to commercial sale, including preclinical or clinical testing and approval by the FDA, the EMA and other similar regulatory authorities. All product candidates are prone to risks of failure during pharmaceutical product development, including the possibility that a product candidate will not be shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, any approved products that we acquire may not be manufactured or sold profitably or achieve market acceptance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">28</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to establish sufficient sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any other future product candidates or generate significant product revenue. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, we built sales and marketing capabilities. We have no prior experience in the marketing, sale and distribution of aesthetic medicine products, and there are significant risks involved in building and managing a sales organization, including our ability to retain and incentivize qualified individuals, provide adequate training to sales and marketing personnel, generate sufficient sales leads, effectively manage a geographically dispersed sales and marketing team, adequately provide complementary products to be offered by sales personnel, which may otherwise put us at a competitive disadvantage relative to companies with more extensive product lines, and handle any unforeseen costs and expenses. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. To the extent we commercialize our product candidates by entering into agreements with third-party collaborators, we may have limited or no control over the sales, marketing and distribution activities of these third parties, in which case our future revenues would depend heavily on the success of the efforts of these third parties. If we are not successful in commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we would incur significant additional losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To successfully commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;outside the United States or any other future product candidates in the United States, EU, Canada and other jurisdictions we may seek to enter, we will need to build our marketing, sales, distribution, managerial and other capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may need to increase the size of our organization, and we may experience difficulties in managing this growth. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">235</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;employees, all of whom constituted full-time employees. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management and personnel, systems and facilities currently in place may not be adequate to support future growth. Our need to effectively execute our growth strategy requires that we:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage any of our future clinical trials effectively;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">identify, recruit, retain, incentivize and integrate any additional employees;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">continue</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to improve our operational, financial and management controls, reporting systems and procedures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, vendors and other agents may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates applicable regulations, including those laws requiring the reporting of true, complete and accurate information to regulatory agencies, manufacturing standards and federal and state healthcare laws and regulations. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. Although our strategy to focus only on the self-pay market will reduce our risk under the Anti-Kickback Statute, we could face liability under similar state laws that are not limited to products </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">29</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reimbursed by the government or if we obtain regulatory approval for products reimbursed by federal healthcare programs in the future. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, referrals, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment and the curtailment or restructuring of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">In the future, we may rely on third-parties and consultants to conduct all of our preclinical studies and clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the future, we may rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties, such as contract research organizations, or CROs, to conduct clinical trials on our product candidates. The third parties with whom we may contract for execution of any of our future clinical trials may play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, any of these third parties may not be our employees, and except for contractual duties and obligations, we would have limited ability to control the amount or timing of resources that they devote to any of our future programs. Although we may rely on these third parties to conduct our preclinical studies and clinical trials, we would remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable investigational plan and protocol. Moreover, the FDA and other similar regulatory authorities require us to comply with, among other requirements, good clinical practices, or GCPs, for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We may also rely on consultants to assist in the execution, including data collection and analysis, of any of our future clinical trials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the execution of preclinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, requires coordination among various parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. If the third parties or consultants conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for and will not be able to, or may be delayed in our efforts to, successfully commercialize any future product candidates being tested in such trials. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We plan to rely on third-party distribution partners for the distribution of our products, product candidates and services outside of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">United States</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, which could delay or limit our ability to generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With respect to certain markets for our products, product candidates and services outside of the United States, we plan to retain third-party service providers to perform functions related to the marketing, distribution and sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates. Key aspects of those functions may be out of our direct control, including regulatory compliance, warehousing and inventory management, distribution, contract administration, accounts receivable management and call center management. Any future distribution partners may hold significant control over important aspects of the commercialization of our products, including market identification, regulatory compliance, marketing methods, pricing, composition of sales force and promotional activities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to control the amount and timing of resources that any current or future third-party distribution partners may devote to our products, or prevent any third-party distribution partners from pursuing the development of alternative technologies or products that compete with our products, except to the extent our contractual arrangements protect us against </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">such activities. Also, we may not be able to prevent any other third-party distribution partners from withdrawing its support of our products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities or otherwise fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver product to meet commercial demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample accountability and regulatory monitoring, including adverse event reporting, safety database management and other product maintenance services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market our products could be jeopardized or we could be subject to regulatory sanctions, and any indemnity we may receive from such third-party service providers could be limited by such provider&#8217;s ability to pay and otherwise might not be sufficient to cover all losses we may experience.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We forecast the demand for commercial quantities of our products, and if our forecasts are inaccurate, we may experience delays in shipments, increased inventory costs or inventory levels, and reduced cash flow.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong. Pursuant to the Daewoong Agreement, we submit forecasts of anticipated product orders to Daewoong and may, from time to time, submit purchase orders on the basis of these forecasting requirements. Our limited historical experience may not provide us with enough data to accurately predict future demand. In addition, we expect Daewoong to manufacture its own product, Nabota, a botulinum toxin formulation, from this facility for sale in the South Korean market and other markets in which we do not have exclusive rights. If our business significantly expands, our demand for commercial products would increase and Daewoong may be unable to meet our increased demand. In addition, our product will have fixed future expiration dates. If we overestimate our component and material requirements, we will have excess inventory, which may have to be disposed of if such inventory exceeds approved expiration dates, which would result in lost revenues and increase our expenses. If we underestimate our component and material requirements, we may have inadequate inventory, which could interrupt, delay or prevent delivery of our products to our customers. Any of these occurrences would negatively affect our financial performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our international operations will expose us to risks, and failure to manage these risks may adversely affect our operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently have operations in the United States and may have operations in EU in the future. International operations are subject to a number of inherent risks, and our future results could be adversely affected by a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">requirements or preferences for domestic products or solutions, which could reduce demand for our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">differing existing or future regulatory and certification requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management communication and integration problems resulting from cultural and geographic dispersion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater difficulty in collecting accounts receivable and longer collection periods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties in enforcing contracts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">difficulties and costs of staffing and managing non-U.S. operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the uncertainty of protection for intellectual property rights in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">tariffs and trade barriers, export regulations and other regulatory and contractual limitations on our ability to sell our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">multiple, conflicting and changing laws and regulations such as privacy regulations, including General Data Protection Regulation, or GDPR, tax laws, export and import restrictions, employment laws, immigration laws, labor laws, regulatory requirements and other governmental approvals, permits and licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">more stringent data protection standards in some countries;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">greater risk of a failure of foreign employees to comply with both U.S. and foreign laws, including export and antitrust regulations, the U.S. Foreign Corrupt Practices Act, or FCPA, quality assurance and other healthcare regulatory requirements and any trade regulations ensuring fair trade practices;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">31</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">heightened risk of unfair or corrupt business practices in certain geographies and of improper or fraudulent sales arrangements that may impact financial results and result in restatements of, or irregularities in, financial statements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">foreign currency exchange rates and the generally lower average sales prices available in most international markets compared to those in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">United States</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">potentially adverse tax consequences, including multiple and possibly overlapping tax structures and difficulties relating to repatriation of cash; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">economic, legal and regulatory uncertainty associated with the United Kingdom leaving the EU, or Brexit; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">political and </font><font style="font-family:Times New Roman;font-size:10pt;">economic</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;instability, political unrest and terrorism.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These and other factors could harm our ability to gain future revenue and, consequently, materially impact our business, operating results and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">A perception of a conflict of interest of our indirect physician investors by other physicians or consumers could negatively impact our future product sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to our initial public offering, we were indirectly funded through investments in our controlling stockholder, Alphaeon, and its majority stockholder, SCH, in part, by leading physicians in the self-pay healthcare market, or the indirect physician investors.  As a result, through Alphaeon (and, subsequent to its transfer of shares, Alphaeon 1, LLC) and SCH, these indirect physician investors may have an indirect financial interest in our success (as our successes, if any, will in part be imputed to Alphaeon 1, LLC and ultimately SCH) and may be more inclined to use, promote or recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to their patients and other physicians.  Other physicians may become aware of the indirect and potential financial interest and investments of these indirect physician investors, who realize additional incentives by recommending Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. If other physicians perceive this to be a significant conflict, they may be unwilling to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates without obtaining additional third-party evidence of their benefits and efficacy. If consumers perceive these indirect physician investors have a conflict of interest in recommending Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates, they may be unwilling to purchase Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates and may have a negative view of our brand, which could harm our reputation in the market. If physicians do not recommend Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates or consumers choose not to purchase any of our products as a result of these conflicts of interest, it could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We face an inherent risk of product liability as a result of the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any of our future product candidates. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted against us under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">decreased demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;or any future product candidates or products we develop;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">injury to our reputation and significant negative media attention;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">withdrawal of clinical trial participants or cancellation of clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant costs to defend the related litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a diversion of management&#8217;s time and our resources;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">substantial monetary awards to trial participants or patients;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">32</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">loss of revenue; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the inability to commercialize any products we develop; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a decline in our share price.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future products that we develop. We currently carry product liability insurance covering our clinical trials. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to attract and keep senior management and key scientific personnel, we may be unable to commercialize Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;successfully, or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management. We believe that our future success is highly dependent upon the contributions of our senior management, particularly David Moatazedi, our President, Chief Executive Officer and member of our board of directors, Lauren Silvernail, our Chief Financial Officer and Executive Vice President, Corporate Development, Rui Avelar, our Chief Medical Officer and Head of R&amp;D, and Michael Jafar, our Chief Marketing Officer, as well as other members of our senior management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future products we develop. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we could experience difficulties attracting and retaining qualified employees in the future. For example, competition for qualified personnel in the pharmaceuticals and aesthetic medicine field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information or that their former employers own their research output. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the market for aesthetic medical procedures may be particularly vulnerable to unfavorable economic conditions. We do not expect Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines to be reimbursed by any government or third-party payor and, as a result, our product will be ultimately paid for by the consumer. Demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is tied to discretionary spending levels of our targeted consumer population. A severe or prolonged economic downturn could result in a variety of risks to our business, including a decline in the discretionary spending of our target consumer population, which could lead to a weakened demand for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates. A severe or prolonged economic down turn may also affect our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our business strategy was developed based on a number of important assumptions about the self-pay healthcare market. For example, we believe that the number of self-pay healthcare procedures will increase in the future. However, these trends are uncertain and limited sources exist to obtain reliable market data. Therefore, sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any of our future product candidates could differ materially from our projections if our assumptions are incorrect.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our near-term strategy of focusing exclusively on the self-pay healthcare market may limit our ability to increase sales or achieve profitability. For example, to maintain our business model, we cannot offer products or services available in the broader healthcare market that are reimbursed by third-party payors such as Medicare, Medicaid or commercial insurance. This eliminates our ability to offer a substantial number of products and indications for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, which could result in sanctions or other penalties that would harm our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We incur and expect to incur significant legal, accounting, information technology and other expenses as a public company, including costs resulting from public company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq Global Market, or Nasdaq, and the rules of the SEC require that we satisfy certain corporate governance requirements. Our management and other personnel devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to Section 404 of the Sarbanes-Oxley Act, or Section 404, and the related rules of the SEC, which generally require our management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. In order to maintain effective internal controls, we will need additional financial personnel, systems and resources. However, for so long as we remain an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we intend to take advantage of certain exemptions from various reporting requirements that are applicable to public companies that are not emerging growth companies, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b). Once we are no longer an emerging growth company or, if prior to such date, we opt to no longer take advantage of the applicable exemption, we will be required to include an opinion from our independent registered public accounting firm on the effectiveness of our internal control over financial reporting. We will remain an emerging growth company until the earliest of: (i) December 31, 2023; (ii) the first fiscal year after our gross annual revenues are $1.07 billion or more; (iii) the date on which we have, during the immediately preceding three-year period, issued more than $1.0 billion in non-convertible debt securities; or (iv) the end of any fiscal year in which the market value of our common stock held by non-affiliates is $700 million or more as of the end of the second quarter of that fiscal year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we have conducted a review of our internal controls for the purpose of providing the reports required by these rules, during the course of our review and testing, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from the Nasdaq Global Market or other adverse consequences that would materially harm our business and reputation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business involves the use of hazardous materials, and we and our third-party manufacturer and supplier must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our research and development and manufacturing activities in the future may, and Daewoong&#8217;s manufacturing and supplying activities presently do, involve the controlled storage, use and disposal of hazardous materials, including botulinum toxin type A, a key component of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and other hazardous compounds. We and Daewoong are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at Daewoong&#8217;s facilities pending their use and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">disposal. We and Daewoong cannot eliminate the risk of contamination, which could cause an interruption of Daewoong&#8217;s manufacturing processes, our commercialization efforts, business operations and environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, manufacture, storage, handling and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by Daewoong for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, this may not eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may use third-party collaborators to help us develop, validate or commercialize any new products, and our ability to commercialize such products could be impaired or delayed if these collaborations are unsuccessful. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may license or selectively pursue strategic collaborations for the development, validation and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any future product candidates. In any third-party collaboration, we would be dependent upon the success of the collaborators in performing their responsibilities and their continued cooperation. Our collaborators may not cooperate with us or perform their obligations under our agreements with them. Our collaborators may choose to pursue alternative technologies in preference to those being developed in collaboration with us. The development, validation and commercialization of our product candidates will be delayed if collaborators fail to conduct their responsibilities in a timely manner or in accordance with applicable regulatory requirements or if they breach or terminate their collaboration agreements with us. Disputes with our collaborators could also impair our reputation or result in development delays, decreased revenues and litigation expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, we may face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to consumers, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of such product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">candidates or bring them to market and generate revenue.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. Under Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards, or NOLs, and other pre-change tax attributes, such as research tax credits, to offset its post-change income may be limited. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$179.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of federal NOLs and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$94.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of state NOLs available to offset our future taxable income, if any. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had federal research and development credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. These federal and state NOLs and federal research and development tax credit carryforwards expire at various dates beginning in 2034. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOLs to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">35</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">tax liability to us. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increased regulatory oversight and uncertainty relating to the&#160;LIBOR&#160;calculation process and potential phasing out of&#160;LIBOR&#160;after 2021 may adversely affect the results of our operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2019, we had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of outstanding indebtedness that bears interest at a floating rate using LIBOR as the applicable reference rate and that have maturities beyond 2021. On July 27, 2017, the United Kingdom&#8217;s Financial Conduct Authority, which regulates LIBOR, announced that it intends to stop persuading or compelling banks to submit rates for the calculation of&#160;LIBOR&#160;after 2021. The announcement indicates that the continuation of&#160;LIBOR&#160;on the current basis cannot and will not be guaranteed after 2021. It is impossible to predict whether and to what extent banks will continue to provide&#160;LIBOR&#160;submissions to the administrator of&#160;LIBOR, whether&#160;LIBOR&#160;rates will cease to be published or supported before or after 2021 or whether any additional reforms to&#160;LIBOR&#160;may be enacted in the United Kingdom or elsewhere. Efforts in the United States to identify a set of alternative U.S. dollar reference interest rates include proposals by the Alternative Reference Rates Committee of the Federal Reserve Board and the Federal Reserve Bank of New York. Uncertainty as to the nature of alternative reference rates and as to potential changes in other reforms to&#160;LIBOR&#160;may adversely affect&#160;LIBOR&#160;rates and may impact the availability and cost of borrowings, including the rates we pay on our credit facility with Oxford. If&#160;LIBOR&#160;rates are no longer available or do not remain an acceptable market benchmark, any successor or replacement interest rates may perform differently, which may adversely affect our interest expenses. We may incur significant costs to&#160;transition&#160;our borrowing arrangement with Oxford from&#160;LIBOR, which may have an adverse effect on our results of operations. The effect of a&#160;transition&#160;away from&#160;LIBOR&#160;on our company cannot yet be determined, and management continues to evaluate the LIBOR exposure risks.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures or breach by hackers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyberattacks or cyber intrusions over the internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyberattacks or cyber intrusions, including by computer hackers, foreign governments and cyberterrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our current or future product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service, government files or penalties and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, or PII, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various international, federal and state privacy and security laws, if applicable, including the GDPR, the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Clinical Health Act of 2009, and its implementing rules and regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. Additionally, the regulatory environment governing information, security and privacy laws is increasingly demanding and continues to evolve and a number of states have adopted laws and regulations that may affect our privacy and data security practices regarding the use, disclosure and protection of PII. For example, the California Consumer Privacy Act, among other things, has created new individual privacy rights and imposes increased obligations on companies handling PII.  We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">O</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ur liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyberattacks and other related breaches.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to Intellectual Property </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we or any of our current </font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">or</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;future licensors</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">, including Daewoong, are unable to maintain, obtain or protect intellectual property rights related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any of our future product candidates, we may not be able to compete effectively in our market.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We and our current licensor, Daewoong, currently rely upon a combination of trademarks, trade secret protection, confidentiality agreements and proprietary know-how. Botulinum toxin cannot be patented, as it is produced by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Clostridium</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">botulinum</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a gram-positive, rod-shaped, anaerobic, spore-forming, motile bacterium with the ability to produce the neurotoxin botulinum. Only the manufacturing process for botulinum toxin can be patented, for which Daewoong has obtained a U.S. patent. Our trade secrets and other confidential proprietary information and those of our licensors could be disclosed or competitors could otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we or any of our current or future licensors may encounter significant problems in protecting and defending our or their intellectual property both in the United States and internationally. If we or any of our current or future licensors are unable to prevent material disclosure of the non-patented intellectual property related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to third parties, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the protection afforded by trademarks, confidentiality agreements and proprietary know-how, we may in the future rely upon in-licensed patents for any future product offerings. The strength of patents we may in-license in the technology and healthcare fields involves complex legal and scientific questions and can be uncertain. The patent applications that we may in-license may fail to result in issued patents with claims that cover any of our future product candidates in the United States or in other foreign countries, and the issued patents that we may in-license may be declared invalid or unenforceable. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are reliant on the ability of Daewoong, as the licensor of our only product, and will be reliant on future licensors of any future product candidates, to maintain their intellectual property and protect their intellectual property against misappropriation, infringement or other violation. We may not have primary control over our future licensors&#8217; patent prosecution activities. Furthermore, we may not be allowed to comment on prosecution strategies, and patent applications may be abandoned by the patent owner without our knowledge or consent. With respect to patents that are issued to our licensors, or patents that may be issued on patent applications, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. As a licensee, we are reliant on Daewoong and our future licensors to defend any third-party claims, including Daewoong&#8217;s defense in connection with the Medytox Litigation, which is defined below. Our licensors may not defend or prosecute such actions as vigorously or in the manner that we would have if entitled to do so, and we will be subject to any judgment or settlement resulting from such actions. Also, a third-party may challenge the validity of our in-licensing transactions. Furthermore, even if they are unchallenged, any of our future in-licensed patents and patent applications may not adequately protect the licensors or our intellectual property or prevent others from designing around their or our claims.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our intellectual property or the patents and other intellectual property of our licensors, which could be expensive and time-consuming. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Competitors may infringe our intellectual property, including any future patents we may acquire, or the patents and other intellectual property of our licensors, including Daewoong. As a result, we or any of our current or future licensors may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse determination of any litigation or other proceedings could put one or more of such patents at risk of being invalidated or interpreted narrowly. Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to any of our future patent applications or those of our licensors or collaborators. Litigation or USPTO proceedings brought by us or any of our current or future licensors may fail or may be invoked against us or our licensors by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management or the management of any of our current or future licensors, including Daewoong. We may not be able, alone or with any of our </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">37</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">current or future licensors or collaborators, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Most of our competitors are larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating our intellectual property. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal research programs, or in-license needed technology or other product candidates. There could also be public announcements of the results of the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative, it could cause the price of shares of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States and in some cases may even force us to grant a compulsory license to competitors or other third parties. Consequently, we may not be able to prevent third parties from using our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in domestic and foreign intellectual property laws. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to seeking patents for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We seek to protect our trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, collaborators, consultants, advisors and other third parties. We expect to enter into confidentiality and invention assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts within and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">38</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We employ individuals who were previously employed at other pharmaceutical or medical aesthetic companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. Any litigation or the threat thereof may adversely affect our ability to hire employees. A loss of key personnel or their work product could diminish or prevent our ability to commercialize product candidates, which could have an adverse effect on our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A third party may hold intellectual property, including patent rights that are important or necessary to the development of our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Third parties may assert that we are using trademarks or trade names that are confusingly similar to their marks. If any third party were able to establish that our trademarks or trade names were infringing their marks, that third party may be able to block our ability to use the infringing trademark or trade name. In addition, if a third party were to bring such a claim, we would be required to dedicate time and resources to fight the claim, which time and resources could otherwise be used toward the maintenance of our own intellectual property.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Parties making claims against us may request and obtain injunctive or other equitable relief, which could prevent our ability to use the subject trademarks or trade names. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement. We may be required to re-brand one or more of our products, product candidates, or services offered under the infringing trademark or trade name, which may require substantial time and monetary expenditure. Third parties could claim senior rights in marks which might be enforced against our use of trademarks or trade names, resulting in either an injunction prohibiting our sales under those trademarks or trade names.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to Government Regulation </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our business and products are subject to extensive government regulation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, the EU, Canada and other countries, principally by the FDA, the U.S. Drug Enforcement Administration, the Centers for Disease Control and Prevention, the EMA and other similar regulatory authorities. Daewoong is also subject to extensive regulation by the FDA and the South Korean regulatory authorities as well as other regulatory authorities. Our failure to comply with all applicable regulatory requirements, or Daewoong&#8217;s failure to comply with applicable regulatory requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act, the Public Health Service Act, and the Controlled Substances Act, may subject us to operating restrictions and criminal prosecution, monetary penalties and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">39</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other enforcement or administrative actions, including, sanctions, warnings, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, or exclusion from future participation in the Medicare and Medicaid programs. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Following regulatory approval, we, and our direct and indirect suppliers, including Daewoong, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections may result in requirements that we implement REMS programs, requirements that we complete government mandated clinical trials, and government enforcement actions including those relating to labeling, advertising, marketing and promotion, as well as regulations governing manufacturing controls. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenue will be materially impaired.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may not obtain regulatory approval for the commercialization of any future product candidates. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug and biologic products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, with regulations differing from country to country. If we, our products or the manufacturing facilities for our products fail to comply with applicable regulatory requirements, a regulatory agency may:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">commence criminal investigations and prosecutions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">impose other civil or criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend any ongoing clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">delay or refuse to approve pending applications or supplements to approved applications filed by us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refuse to permit drugs or active ingredients to be imported or exported;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">seize or detain products or require us to initiate a product recall.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we or our collaborators must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA, the EMA or other similar foreign regulatory authorities, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we and our collaborators believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA, the EMA and other similar regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt clinical trials and result in the FDA, the EMA or other similar regulatory authorities delaying or denying approval of a product candidate for any or all targeted indications. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Regulatory approval of a BLA or BLA supplement, MAA, or other product approval is not guaranteed, and the approval process is expensive and may take several years. The FDA, the EMA and other regulatory authorities have substantial discretion in the approval process. Despite the time and expense expended, failure can occur at any stage, and we could </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">40</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">encounter problems that cause us to abandon, modify or repeat clinical trials, or perform additional preclinical studies and clinical trials. The number of preclinical studies and clinical trials that will be required for the FDA, the EMA or other regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations applicable to any particular product candidate. The FDA, the EMA and other regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">a product candidate may not be deemed safe, effective, pure or potent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the data from preclinical studies and clinical trials may not be deemed sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the FDA or other regulatory authorities might not approve our third-party manufacturers&#8217; processes or facilities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">deficiencies in the formulation, quality control, labeling, or specifications of a product candidate </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">or in response to citizen petitions or similar documents filed in connection with the product candidate</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general requirements intended to address risks associated with a class of drugs, such as a new REMS requirement for neurotoxins;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the enactment of new laws or promulgation of new regulations that change the approval requirements; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the FDA or other regulatory authorities may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If any future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain approval, our business and results of operations will be materially and adversely harmed. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense, limit or delay regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any other approved products are subject to continual regulatory review by the FDA, the EMA and other similar regulatory authorities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Any regulatory approvals that we or our collaborators receive for any future product candidates may also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase IV clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and any other future product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and compliance with GCP requirements, for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">fines, warning letters or holds on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">refusal by the FDA, the EMA or other similar regulatory authorities to approve pending applications or supplements to approved applications filed by us or our strategic collaborators or suspension or revocation of product license approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">product seizure or detention or refusal to permit the import or export of products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">injunctions or the imposition of civil or criminal penalties.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">41</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to obtain regulatory approvals in foreign jurisdictions for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any future product candidates, we will be unable to market our products outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to regulations in the United States, we are and will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future products. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in markets outside of the United States. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;or any future products may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so, we could be subject to sanctions that would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Some participants in our clinical trials have reported adverse events after being treated with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. If we are successful in commercializing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any other product candidate, the FDA and other regulatory agency regulations require that we report certain information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events that we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA, the EMA or other similar regulatory authorities could take action including criminal prosecution, the imposition of civil monetary penalties, seizure of our products, or delay in approval or clearance of future products. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We may in the future be subject to various U.S. federal and state laws pertaining to health care fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While we do not expect that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;will subject us to the various U.S. federal and most state laws intended to prevent health care fraud and abuse, we may in the future become subject to such laws. The Anti-Kickback Statute prohibits the offer, receipt, or payment of remuneration in exchange for or to induce the referral of patients or the use of products or services that would be paid for in whole or part by Medicare, Medicaid or other federal health care programs. Remuneration has been broadly defined to include anything of value, including cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state health care programs as well as private payors. Violations of anti-kickback and other applicable laws can result in exclusion from federal health care programs and substantial civil and criminal penalties. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The federal False Claims Act, or FCA, imposes liability on persons who, among other things, present or cause to be presented false or fraudulent claims for payment by a federal health care program. The FCA has been used to prosecute persons submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the federal government and share a portion of the recovery of successful claims. Some state law equivalents of the above federal laws, such as the Anti-Kickback Statute and FCA, apply to items or services regardless of whether the good or service was reimbursed by a government program, so called all-payor laws. These all-payor laws could apply to our sales and marketing activities even if the Anti-Kickback Statute and FCA laws are inapplicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">If our marketing or other arrangements were determined to violate anti-kickback or related laws, including the FCA or an all-payor law, then we could be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">42</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">curtailment or restructuring of our operations, any of which could materially and adversely affect our ability to operate our business and our financial results. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">State and federal authorities have aggressively targeted pharmaceutical companies for alleged violations of these anti-fraud statutes, based on improper research or consulting contracts with doctors, certain marketing arrangements with pharmacies and other healthcare providers that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. Companies targeted in such prosecutions have paid substantial fines, have been ordered to implement extensive corrective action plans, and have in many cases become subject to consent decrees severely restricting the manner in which they conduct their business, among other consequences. Additionally, federal and state regulators have brought criminal actions against individual employees responsible for alleged violations. If we become the target of such an investigation or prosecution based on our contractual relationships with providers or institutions, or our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Also, the FCPA and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. Our internal control policies and procedures may not protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legislative or regulatory healthcare reforms in the United States and other countries may make it more difficult and costly for us to obtain regulatory clearance or approval of any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From time to time, legislation is drafted and introduced in the U.S. Congress or other countries that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, regulations and guidance are often revised or reinterpreted by the FDA and other regulatory authorities in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future product candidates. Such changes could, among other things, require: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to manufacturing or marketing methods;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes to product labeling or promotional materials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">recall, replacement, or discontinuance of one or more of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">additional recordkeeping.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to Our Relationship with Alphaeon and Alphaeon 1, LLC</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Alphaeon 1, LLC may exert significant influence over our business, and the concentrated ownership of our common stock and certain contractual rights of Alphaeon 1, LLC may prevent you and other stockholders from influencing significant decisions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of our outstanding shares of common stock.  Subsequent to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon contributed all of those shares to Alphaeon 1, LLC. This concentrated ownership position may provide Alphaeon 1, LLC with significant influence in determining the outcome of corporate actions requiring stockholder approval, including the election and removal of directors. This significant stock ownership may also discourage transactions involving a change-of-control of our company, including transactions in which you as a holder of our common stock might otherwise receive a premium for your shares.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our directors may have actual or potential conflicts of interest because of their ownership of debt and equity securities in Alphaeon and Alphaeon 1, LLC and their positions with Alphaeon and Alphaeon 1, LLC. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Vikram Malik, Simone Blank, Kristine Romine, M.D., and Robert Hayman serve on our board of directors.  Such directors or entities they are affiliated with currently own and may in the future own equity, debt or convertible debt of Alphaeon and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">43</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Alphaeon 1, LLC, which we refer to collectively as the Alphaeon entities. These individuals&#8217; or entities&#8217; holdings of debt or equity securities, options to purchase shares of Alphaeon entities or other equity awards in the Alphaeon entities may be significant for some of these persons or entities compared to these persons&#8217; or entities&#8217; total assets. Additionally, each of Mr. Malik, and Ms. Blank serve on the board of directors of Alphaeon and board of managers of Alphaeon 1, LLC. Their positions at the Alphaeon entities and the ownership of any Alphaeon entities equity, debt or equity awards may create, or may create the appearance of, conflicts of interest when these directors are faced with decisions that could have different implications for the Alphaeon entities than the decisions have for us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These decisions include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">corporate opportunities; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating decisions for our business may have on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Alphaeon entities </font><font style="font-family:Times New Roman;font-size:10pt;">consolidated financial statements; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the impact that operating or capital decisions (including the incurrence of indebtedness) for our business may have on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Alphaeon entities&#8217;</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;current or future indebtedness or the covenants under that indebtedness; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing and amount of financing efforts, whether they are debt or equity, and the amount of resulting dilution to existing shareholders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">business combinations involving us; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our dividend policy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">management stock ownership; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the related party services and agreements between Alphaeon and us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Potential conflicts of interest could also arise if we decide to enter into any new commercial arrangements with the Alphaeon entities or SCH in the future or in connection with the Alphaeon entities desire to enter into new commercial arrangements with third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Furthermore, disputes may arise between the Alphaeon entities and us relating to our past and ongoing relationship, and these potential conflicts of interest may make it more difficult for us to favorably resolve such disputes, including those related to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">indemnification and other matters arising from our initial public offering;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the nature, quality and pricing of services Alphaeon agrees to provide to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales or other disposal by Alphaeon 1, LLC of all or a portion of its ownership interest in us; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">business combinations involving us.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We may not be able to resolve any potential conflicts, and even if we do, the resolution may be less favorable to us than if we were dealing with an unaffiliated party. While we are not controlled by the Alphaeon entities, we may not have the leverage to negotiate amendments to these agreements, if required, on terms as favorable to us as those we would negotiate with an unaffiliated third party.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Alphaeon and its directors and officers will have limited liability to us or you for breach of fiduciary duty. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides that, subject to any contractual provision to the contrary, Alphaeon has no obligation to refrain from: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">engaging in the same or similar business activities or lines of business as we do;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">doing business with any of our clients or consumers; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">employing or otherwise engaging any of our officers or employees.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">44</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides for the allocation of certain corporate opportunities between us and Alphaeon. Under these provisions, neither Alphaeon nor its other affiliates, nor any of their officers, directors, agents, stockholders, members, partners and subsidiaries, will have any obligation to present to us certain corporate opportunities. For example, a director or officer of our company who also serves as a director, officer or employee of Alphaeon or any of its other affiliates may present to Alphaeon certain acquisitions, in-licenses, potential development programs or other opportunities that may be complementary to our business, if he or she was not offered such corporate opportunity in his or her capacity as our director or officer, and, as a result, such opportunities may not be available to us. To the extent attractive corporate opportunities are allocated to Alphaeon or its other affiliates instead of to us, we may not be able to benefit from these opportunities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, under our certificate of incorporation, neither Alphaeon nor any officer or director of Alphaeon, except as provided in our certificate of incorporation, will be liable to us or to our stockholders for breach of any fiduciary or other duty by reason of any of these activities. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Risks Related to Our Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">The trading price of our common stock may be volatile, and purchasers of our common stock could incur substantial losses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our stock price is volatile. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For example, the closing price of our common stock during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;has ranged from a low of $11.58 to a high of $28.91. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The stock market in general and the market for earlier-stage pharmaceutical and medical aesthetic companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, some of which are beyond our control, including: </font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements of regulatory approval or disapproval of product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse results from or delays in clinical trials of any of our future product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">unanticipated safety concerns related to the use of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;">&#32;or any of our future products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">any termination or loss of rights under the Daewoong Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the FDA or other U.S. or foreign regulatory or legal actions or changes affecting us or our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse developments concerning our manufacturer or any future strategic partnerships;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">adverse developments concerning litigation pending against us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">introductions and announcements of new technologies and products by us, any commercialization partners or our competitors, and the timing of these introductions and announcements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">variations in our financial results or those of companies that are perceived to be similar to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">success or failure of competitive products or medical aesthetic products generally;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in the structure of healthcare payment systems;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, new product approvals and introductions, joint ventures or capital commitments;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">overall financial market conditions for the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts&#8217; reports or recommendations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">quarterly variations in our results of operations or those of our competitors</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">the public&#8217;s reaction to our earnings releases, other public announcements and filings with the SEC;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">rumors and market speculation involving us or other companies in our industry;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">45</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#000000;">short selling of our common stock or the publication of opinions regarding our business prospects in a manner that is designed to create negative market momentum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">sales of substantial amounts of our stock by Alphaeon or other significant stockholders or our insiders, or the expectation that such sales might occur;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">general economic, industry and market conditions, including the size and growth, if any, of the medical aesthetics market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">news reports relating to trends, concerns and other issues in medical aesthetics market or the pharmaceutical or biopharmaceutical industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">operating and stock performance of other companies that investors deem comparable to us and overall performance of the equity markets;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">additions or departures of key personnel, including our Chief Executive Officer, Chief Financial Officer, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Chief Medical Officer and Chief Marketing Officer; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">intellectual property, product liability or other litigation against us, our manufacturer or other parties on which we rely or litigation against our general industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">announcements or actions taken by Alphaeon as our controlling stockholder, including sales of substantial amounts of our common stock by Alphaeon; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">changes in accounting standards, policies, guidelines, interpretations or principles; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">other factors </font><font style="font-family:Times New Roman;font-size:10pt;">described</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in this &#8220;Risk Factors&#8221; section.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, the stock market in general, and the market for pharmaceutical, biotechnology and medical aesthetics companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors may affect the market price of our common stock, regardless of our actual operating performance. In the past, following periods of volatility in the overall market and the market prices of a particular company&#8217;s securities, securities class action litigation has often been instituted against that company. We may become the target of this type of litigation in the future. Securities litigation, if instituted against us, could result in substantial costs and divert our management&#8217;s attention and resources from our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are no longer a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">controlled company</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#160;within the meaning of the Nasdaq Marketplace Rules. Prior to May 2019, we qualified for, and relied on, exemptions from certain corporate governance requirements and our stockholders were not afforded the same protections as the stockholders of companies that are subject to such requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of a sale of shares by Alphaeon in May 2019, we are no longer a &#8220;controlled company&#8221; within the meaning of the corporate governance standards of the Nasdaq Marketplace Rules. Under these rules, a listed company of which more than 50% of the voting power is held by an individual, group or another company is a &#8220;controlled company&#8221; and may elect not to comply with certain corporate governance requirements, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that a majority of our board of directors consist of independent directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that our nominating and corporate governance committee be comprised entirely of independent directors with a written charter addressing the committee's purpose and responsibilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement that our compensation committee be comprised entirely of independent directors with a written charter addressing the committee's purpose and responsibilities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the requirement for an annual performance evaluation of our nominating and corporate governance and compensation committees;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Since we utilized certain of these exemptions, our nominating and corporate governance and compensation committees do not consist entirely of independent directors. As a result, we will be required to comply with the above-referenced </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">46</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">requirements within one year. We may have difficulty complying with the requirements listed above and while we intend to do so, we cannot assure you that we will be able to comply with such requirements before the end of the phase-in period for compliance. Accordingly, unless and until we comply with these requirements, you will not have the same protections afforded to stockholders of companies that are subject to and in compliance with all of the corporate governance requirements of Nasdaq.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our business could be negatively affected as a result of actions of activist stockholders, and such activism could impact the trading value of our securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Stockholders may, from time to time, engage in proxy solicitations or advance stockholder proposals, or otherwise attempt to effect changes and assert influence on our board of directors and management. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our board of directors</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">could have an adverse effect on our </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating results and financial condition. A proxy contest would require us to incur significant legal and advisory fees, proxy solicitation expenses and administrative and associated costs and require significant time and attention by our board of directors and management, diverting their attention from the pursuit of our business strategy. Any perceived uncertainties as to our future direction and control, our ability to execute on our strategy, or changes to the composition of our board of directors or senior management team arising from a proxy contest could lead to the perception of a change in the direction of our business or instability which may result in the loss of potential business opportunities, make it more difficult to pursue our strategic initiatives, or limit our ability to attract and retain qualified personnel and business partners, any of which could adversely affect our business and operating results. If individuals are ultimately elected to our board of directors with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create additional value for our stockholders. We may choose to initiate, or may become subject to, litigation as a result of the proxy contest or matters arising from the proxy contest, which would serve as a further distraction to our board of directors and management and would require us to incur significant additional costs. In addition, actions such as those described above could cause significant fluctuations in our stock price based upon temporary or speculative market perceptions or other factors that do not necessarily reflect the underlying fundamentals and prospects of our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to securities litigation, which is expensive and could divert management attention.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The market price of our common stock may be volatile, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could have a material and adverse effect on our business, financial condition, and results of operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">If securities or industry analysts publish unfavorable research about our business or decrease the frequency or cease to provide coverage of our company, our stock price and trading volume could decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The trading market for our common stock depends in part on the research and reports that equity research analysts publish about us and our business. If one or more of the equity research analysts who cover us downgrades our common stock or issues other unfavorable commentary or research the price of our common stock may decline. If one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause the trading price or trading volume of our common stock to decline.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Certain of our historical financial data is not necessarily representative of the results that we would have achieved as a stand-alone company and may not be a reliable indicator of our future results.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our historical financial data included in this Annual Report on Form 10-K does not reflect the financial condition, results of operations or cash flows that we would have achieved as a stand-alone company during the periods presented or those we will achieve in the future. This is primarily the result of the following factors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">our historical financial data reflects expense allocations for certain support functions that are provided on a centralized basis within Alphaeon, such as expenses for business technology, facilities, legal, finance, human resources and business development, that may be higher or lower than the comparable expenses that we would have actually incurred, or will incur in the future, as a stand-alone company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">significant</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;increases have and will continue to occur in our cost structure as a result of our being a public company, including costs related to public company reporting, investor relations and compliance with the Sarbanes-Oxley Act; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our becoming a commercial company in 2019.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, it may be difficult for investors to compare our future results to historical results or to evaluate our relative performance or trends in our business. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of our common stock by us, Alphaeon 1, LLC or others, or the perception that such sales may occur, could depress the market price of our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33,728,035</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock iss</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ued and outstanding </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;21, 2020</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales by us of</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;a substantial number of shares of our common stock in the public market, or the perception that these sales might occur, could significantly reduce the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of our outstanding shares of common stock. Subsequent to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon contributed all of those shares to Alphaeon 1, LLC.  Subject to the restrictions described in the paragraph below, future sales of these shares in the public market will be subject to the volume and other restrictions of Rule 144 under the Securities Act for so long as Alphaeon 1, LLC is deemed to be our affiliate, unless the shares to be sold are registered with the SEC. The sale by Alphaeon 1, LLC of a substantial number of shares of our common stock, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have filed a registration statement with the SEC covering shares of our common stock available for future issuance under our&#160;2017 Omnibus Incentive Plan and may file future registration statements covering shares of our common stock for future issuance under any future plans. Upon effectiveness of such registration statements, any shares subsequently issued under such plans will be eligible for sale in the public market, except to the extent that they are restricted by the lock-up agreements referred to above and subject to compliance with Rule 144 in the case of our affiliates. Sales of a large number of the shares issued under these plans in the public market, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our certificate of incorporation and bylaws, as well as Delaware law, could discourage a takeover.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation, bylaws and Delaware law contain provisions that might enable our management to resist a takeover and might make it more difficult for an investor to acquire a substantial block of our common stock. These include the following provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">permit our board of directors to issue shares of preferred stock, with any rights, preferences and privileges as they may designate, without stockholder approval, which could be used to dilute the ownership of a hostile bidder significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that the authorized number of directors may be changed only by resolution of our board of directors </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and that</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">a director may only be removed for cause by the affirmative vote of the holders of at least 66 2/3% of our voting stock</font><font style="font-family:Times New Roman;font-size:10pt;">;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that all vacancies, including newly created directorships, may, except as otherwise required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">divide our board of directors into three classes, with each class serving staggered three-year terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#8217;s notice, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#8217;s own slate of directors or otherwise attempting to obtain control of our company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">prohibit cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; and</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">provide that special meetings of our stockholders may be called only by the chairman of the board, our Chief Executive Officer or by</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;our</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors, which may delay the ability of our stockholders to force consideration by our company of a take-over proposal or to take certain corporate actions, including the removal of directors.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, we are subject to Section 203 of the General Corporation Law of the State of Delaware, or the DGCL, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. This provision could have the effect of delaying or preventing a change-of-control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, our certificate of incorporation specifies that the Court of Chancery of the State of Delaware is the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Our certificate of incorporation designates the Court of Chancery of the State of Delaware as the&#160;sole and exclusive forum&#160;for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation provides that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the&#160;sole and exclusive forum&#160;for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims that are based upon a violation of a duty by a current or former director, officer or stockholder in such capacity, or as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery of the State of Delaware, or the Court of Chancery, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants and the claim not being one which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. For example, this choice of forum provision would not apply to claims brought pursuant to the Exchange Act or the Securities Act of 1933, as amended, or any other claim for which the federal courts have exclusive jurisdiction. Any person purchasing or otherwise acquiring any interest in any shares of our capital stock shall be deemed to have notice of and to have consented to this provision of our certificate of incorporation. The choice of forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This choice of forum provision may limit our stockholders&#8217; ability to bring a claim in a judicial forum that they find favorable for disputes with us or our directors, officers, employees or agents, which may discourage such lawsuits against us and our directors, officers, employees and agents even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near Delaware. The Court of Chancery may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our certificate of incorporation inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could have a material adverse effect on our business, financial condition or results of operations.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">49</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our certificate of incorporation and bylaws provide that we can indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. Separate indemnity agreements have been issued with each director and executive officer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, as permitted by Section 145 of the DGCL, our bylaws and our indemnification agreements that we have entered into with our directors and officers, among other things provide that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have indemnified our directors and officers for serving us in those capacities, or for serving as a director, officer, employee or agent of other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that we may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to our best interest and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">We will be required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The rights conferred in our bylaws will not be exclusive. W</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">e may not retroactively amend our bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result, claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We have not paid dividends in the past and do not expect to pay dividends in the future, and any return on investment may be limited to the value of our stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never paid cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future, and the payment of dividends is also restricted under our credit facility. The payment of dividends on our common stock will depend on our earnings, financial condition and other business and economic factors affecting us at such time as our board of directors may consider relevant. If we do not pay dividends, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company,&#8221; and the reduced reporting requirements available to emerging growth companies could make our common stock less attractive to investors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we remain an emerging growth company, we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies. These provisions include, but are not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">being permitted to have only two years of audited financial statements and only two years of related selected financial data and management&#8217;s discussion and analysis of financial condition and results of operations disclosure;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">an exemption from compliance with the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">reduced disclosure about executive compensation arrangements in our periodic reports, registration statements and proxy statements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">exemptions from the requirements to seek non-binding advisory votes on executive compensation or golden parachute arrangements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the extent we take advantage of any of these exemptions, the information that we provide stockholders may be different than what is available with respect to other public companies. Investors may find our common stock less attractive because </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50</font></div></div><hr style="page-break-after:always"><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including exemption from compliance with the auditor attestation requirements of Section 404(b) and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. Investors could find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our trading price may be more volatile.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The requirements of being a public company may strain our resources, divert management&#8217;s attention and affect our ability to attract and retain executive management and qualified board members.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the Nasdaq Marketplace Rules and other applicable securities rules and regulations. Complying with these rules and regulations will increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and increase demand on our systems and resources, particularly after we are no longer an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may need to hire more employees in the future or engage outside consultants to assist us in complying with these requirements, which will increase our costs and expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased selling, general and administrative expenses and a diversion of our management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">51</font></div></div><hr style="page-break-after:always"><div><a name="s9D18256262CB5A869C7BBA194F05784F"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable. </font></div><div><a name="s9C513115FAA1528A80E26CC9E14BD333"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 2.&#160;&#160;&#160;&#160;Properties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our corporate headquarters is located at 520 Newport Center Drive, Suite 1200, Newport Beach, CA 92660, in a facility that we lease, encompassing approximately 17,758 square feet of space. The lease for this facility expires on January 31, 2025. We believe our facilities are sufficient for our current needs. When our lease expires, we may exercise our renewal option or look for additional or alternate space for our operations, and we believe that suitable additional or alternative space will be available in the future on commercially reasonable terms.</font></div><div><a name="s369704392783536AA0B99EBCF034B551"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 3.  &#160;&#160;&#160;&#160;Legal Proceedings.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On June 7, 2017, Medytox Inc., or Medytox, filed an initial complaint in the Superior Court of the State of California, or the Medytox Litigation, against, us, Alphaeon, SCH, Daewoong, Byung Kook Lee, Jae Chun Yoon, Jae Seung Yoon and Chang Woo Suh, among others, or collectively, the defendants. On August 14, 2017, Medytox filed an amended complaint against the defendants, or the amended complaint. The amended complaint alleges, among other things, that Daewoong stole Medytox&#8217;s botulinum toxin bacterial strain, or the BTX strain, that Daewoong misappropriated certain trade secrets of Medytox, including the process used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(which Medytox claims is similar to its biopharmaceutical drug, Meditoxin) using the BTX strain, and that Daewoong thereby interfered with Medytox&#8217;s plan to license Meditoxin to us. Medytox claims that as a result of Daewoong&#8217;s conduct, we entered into the Daewoong Agreement instead of an agreement with Medytox to license Meditoxin.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Daewoong filed a motion to dismiss or stay for forum non conveniens, claiming that the place where the complaint has been filed, in the Superior Court of the State of California, is not the proper place for the trial of the claims in the complaint because, among other reasons, the underlying facts that gave rise to the complaint occurred in South Korea. Daewoong&#8217;s motion to dismiss was granted by the Superior Court of the State of California on October 12, 2017. As a result, the action filed with the Superior Court of the State of California is stayed pending resolution of the proceedings in South Korea. In October 2017, Medytox initiated a civil lawsuit against Daewoong and its parent company, Daewoong Co. Ltd., in the Seoul Central District Court in Seoul, South Korea, related to the same subject matter in the Medytox Litigation and is seeking, among other things, money damages, injunctive relief and destruction of related documents and products. We are not a party to the litigation in the Seoul Central District Court.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On April 27, 2018, pursuant to a motion to dismiss brought by Daewoong, the Superior Court of the State of California dismissed Medytox&#8217;s suit against Daewoong, without prejudice, on the basis that Medytox had brought a substantially similar proceeding against Daewoong in South Korea. The proceedings against us remain stayed in the Superior Court of the State of California pending resolution of the proceedings between Medytox and Daewoong in South Korea.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">With specific regard to us, Medytox alleges that (i) we have violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to us as a result of our relationship with Daewoong, (ii) we have stolen the BTX strain through our possession of and refusal to return the BTX strain, (iii) we have engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the BTX strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting us from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are vigorously defending Medytox&#8217;s claims against us. Given the early stage in the Medytox Litigation, we are unable to predict the likelihood of success of Medytox&#8217;s claims against us or Daewoong or to quantify any risk of loss. The litigation could go on for an extended period of time and require us to dedicate significant financial and management resources to those efforts. While we are entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. An adverse ruling against either us or one of the other defendants could materially and adversely affect our business, consolidated </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">financial position, results of operations, or cash flows and could also result in reputational harm. Even if we are successful, the litigation may result in delays in our product development, reputational damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">ITC Complaint</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission, or the ITC, containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or the ITC Complaint.  On March 6, 2019, the ITC instituted an investigation </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as ITC Inv. No. 337-TA-1145, or the ITC Action. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The ITC complaint calls for an investigation by the ITC Office of Unfair Import Investigations, or OUII, under Section 337 of the Tariff Act of 1930.  The ITC complaint seeks (i) an investigation pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen BTX Strain, and (vii) exclusion and cease and desist orders.  In January 2020, the three sets of parties to the ITC action, (i) the Complainants - Allergan and Medytox, (ii) the Respondents - us and Daewoong and (iii) the OUII, each submitted pre-hearing briefs to the Administrative Law Judge assigned to the ITC Action setting forth each parties positions on the substantive issues and preliminary conclusions prior to the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">evidentiary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;hearing.  From February 4-7, 2020, the Administrative Law Judge held an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">evidentiary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;hearing on the ITC Action.  An initial determination by the Administrative Law Judge is due by June 5, 2020 and the target date for the final determination by the ITC is October 6, 2020. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We intend to defend the claims contained in the ITC complaint and the related </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ITC Action</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;vigorously.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Given the current stage of the ITC Action, we are unable to predict the likelihood of success of Medytox&#8217;s and Allergan&#8217;s claims against us or Daewoong or to quantify the risk of the imposition of an exclusion order or cease and desist order. The ITC Action could require us to dedicate significant financial and management resources to those efforts. While we are entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. An adverse ruling by the ITC against either us or Daewoong could result in the imposition of an exclusion order which would bar imports of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;  </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">within the United States and a cease and desist order which would bar sales and marketing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, either of which would materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Even if we are successful, the ITC Action may result in reputational damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Other Matters</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, Medytox initiated a criminal investigation into the foregoing matter in South Korea, which appears to target one or more of the above defendants, but does not appear to target us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition to the Medytox Litigation and the ITC Complaint, from time to time, we may be subject to other legal proceedings and claims in the ordinary course of business.</font></div><div><a name="s01C112F7D9F858F58766B9EFFF8842C4"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 4.&#160;&#160;&#160;&#160;Mine Safety Disclosures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div><a name="s350153FD870858B78B11AA94C1ADCB92"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Part II</font></div><div><a name="s17A268D5792C5A28AC50F46EE34DE0BD"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 5. &#160;&#160;&#160;&#160;Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our common stock has been listed and traded on the Nasdaq under the symbol &#8220;EOLS&#8221; since February 12, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Holders of Record</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;">February&#160;21, 2020</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had approximately 38&#160;holders of record of our common stock. This number does not include beneficial owners whose shares were held in street name. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Dividend Policy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have never declared or paid any cash dividends on our capital stock and we do not currently intend to pay any cash dividends on our capital stock for the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. Any future determination related to our dividend policy will be made at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements, tax considerations, legal or contractual restrictions, business prospects, the requirements of current or then-existing debt instruments, general economic conditions and other factors our board of directors may deem relevant.  The payment of dividends is also restricted under our credit facility.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Recent Sales of Unregistered Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">From January 1, 2018 to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the period covered by this Annual Report on Form 10-K, we did not issue any unregistered securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Purchases of Equity Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We made no purchases of our equity securities during the fourth quarter of the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">54</font></div></div><hr style="page-break-after:always"><div><a name="s3D00B65D91A95A7A9F6345B4A3F3E4FF"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 6.&#160;&#160;&#160;&#160;Selected Financial Data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">55</font></div></div><hr style="page-break-after:always"><div><a name="sD098724857265CBC99375F6F496C842F"></a></div><div style="font-family:Times New Roman;"><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 7.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">The following discussion contains management&#8217;s discussion and analysis of our financial condition and results of operations and should be read together with the historical financial statements, the notes thereto included in Item 8 &#8220;Financial Statements and Supplementary Data&#8221; and included elsewhere in this Annual Report on Form 10-K.  This discussion contains forward-looking statements that reflect our plans, estimates and beliefs and involve numerous risks and uncertainties, including but not limited to those described in the Item 1A &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. Actual results may differ materially from those contained in any forward-looking statements. You should carefully read &#8220;Special Note Regarding Forward-Looking Statements&#8221; and Item 1A &#8220;Risk Factors.&#8221;</font></div><div><a name="s75B44A3953BF5DCC98CBBBB7DF7667A9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are a performance beauty company with a customer-centric approach focused on delivering breakthrough products in the self-pay aesthetic market. In February 2019, we received the approval of our first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration, or FDA. In May 2019, we commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States and through a distribution partner in Canada in October 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. Our primary market is the self-pay aesthetic market, which includes medical products purchased by physician and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. We believe we offer customers and consumers a compelling value proposition with Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Currently, onabotulinumtoxinA (BOTOX) is the neurotoxin market leader, and prior to the approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, was the only known 900 kDa botulinum toxin type A complex approved in the United States. We believe aesthetic physicians generally prefer the performance characteristics of the complete 900 kDa neurotoxin complex and are accustomed to injecting this formulation. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2019, as part of our commercial launch, we introduced the Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;Experience Treatment, or J.E.T., an exclusive program for aesthetic providers and consumers to be the first to experience Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  J.E.T. offered aesthetic providers the opportunity to receive multiple shipments of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and ended in August 2019.  The program was made available through our technology platform, &#8220;Evolus Practice,&#8221; which allows providers to open a new account, order Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, pay invoices and engage with our customer experience team and medical affairs representatives.  We did not recognize net revenues from shipments made through the J.E.T. program. We have generated revenue from aesthetic practices that purchased products directly from us after completion or outside of the J.E.T. program. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As a result of our J.E.T. program and customer and consumer marketing initiatives throughout 2019, we have established a broad base of over 3,500 customer accounts ordering Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Customer accounts that participated in J.E.T. drove greater than 80% of our U.S. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">net revenue for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, we received approval from Health Canada&#160;for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients under 65 years of age.&#160;We began marketing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Canada in October 2019 through our distribution partner Clarion Medical Technologies, Inc., or Clarion. In September 2019, we also received approval from the European Commission, to market the product in all 28 EU member states, Iceland, Norway and Liechtenstein. We plan to launch Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in Europe in 2020. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have a limited history of generating revenue from Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and have never been profitable. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$213.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We incurred net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We expect to continue to incur significant expenses for the foreseeable future as we increase marketing efforts for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and maintain our regulatory approvals. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Daewoong License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, we </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and Daewoong Pharmaceuticals Co. Ltd., or Daewoong, entered </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">into the Daewoong Agreement&#160;pursuant to which we have an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong for aesthetic indications in the United States, EU, Great Britain, Canada, Australia, Russia, C.I.S., and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan.&#160;Under the Daewoong Agreement, we are required to make certain minimum annual purchases in order to maintain the exclusivity of the license. These minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and our future market share in various jurisdictions. In connection with </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our entry into the Daewoong Agreement, we made an upfront payment to Daewoong of $2.5 million. We further agreed to make milestone payments upon achievement of certain confidential development and commercial milestones, including a confidential payment to Daewoong upon each of the U.S. Food and Drug Administration, or FDA, and the European Medicines Agency, or the EMA, approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Under the Daewoong Agreement, the maximum aggregate amount of milestone payments that could be owed to Daewoong upon the satisfaction of all milestones is $13.5 million. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval in February 2019 and EMA approval in September 2019, the Company paid $2.0 million and $1.0 million milestone payments, respectively. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive remaining contingent milestone payments of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Daewoong Agreement, Daewoong is responsible for all costs related to the manufacturing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including costs related to the operation and upkeep of its manufacturing facility, and we are responsible for all costs related to obtaining regulatory approval, including clinical expenses, and commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We had the option to expand the permitted use of the product beyond aesthetic indications and into therapeutic indications. This option was assigned to ALPHAEON Corporation, or Alphaeon who exercised the option by remitting payment directly to Daewoong in November 2018. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For additional information about the Daewoong Agreement, see Item 1 &#8220;Business&#8212;Daewoong License and Supply Agreement.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Royalties and Notes Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We are obligated to make the following future payments to the founders of Evolus (i) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and (ii) a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;promissory note that matures in November 2021. The obligations set forth in (i) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States. The fair value of the obligations set forth in items (i) and (ii) are valued quarterly and are referred to in our financial statements as the &#8220;contingent royalty obligation.&#8221; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Our Relationship with Alphaeon </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For periods prior to the completion of our initial public offering on February 12, 2018, we funded our operations primarily through contributions and related party borrowings from Alphaeon.  Accordingly, we derived our financial statements by allocating expenses associated with our operations from Alphaeon&#8217;s consolidated financial statements in accordance with applicable accounting standards and SEC regulations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, we entered into a services agreement with Alphaeon, or the services agreement, which became effective in connection with our initial public offering. The services agreement sets forth certain terms between Alphaeon and us that govern the respective responsibilities and obligations between Alphaeon and us, as it relates to the services to be performed between us. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The services agreement has a one-year term and thereafter renews for successive one-year terms unless terminated by either party. We or Alphaeon may terminate the services agreement upon sixty days&#8217; notice to the other party. In accordance with the services agreement, we paid Alphaeon $5.0 million to settle our historical related party borrowings from Alphaeon upon our initial public offering. There were no significant services provided under the services agreement since our initial public offering.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon owned&#160;approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of our outstanding shares of common stock and had changed its name to AEON Biopharma, Inc. We continue to refer to the renamed AEON Biopharma, Inc. as Alphaeon.  Subsequent to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon contributed all of the shares it held in us to Alphaeon 1, LLC. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">57</font></div></div><hr style="page-break-after:always"><div><a name="s947F2DFF48265FE491B801C6376A0812"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Results of Operations </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Comparison of the Years Ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">2018</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our results of operations for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Product revenue, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Service revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">0.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">34.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Product cost of sales (excludes amortization of intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-style:italic;">As a percentage of net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">113.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">29.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">84.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">6.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">4.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">10.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(6.3</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">4.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">0.0</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">4.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">125.9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">46.1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">79.8</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #231f20;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(99.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(52.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Non operating expense, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(6.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(0.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(5.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(105.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(58.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #231f20;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Income tax (benefit) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(15.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">0.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(15.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(90.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(46.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(43.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Revenues</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently operate in one reportable segment and all of our net revenues are derived from sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Net revenues consist of revenues, net of customer rebates and coupons. Revenues are recognized when the control of the promised goods is transferred to the customer in an amount that reflects the consideration to which we expect to be entitled in exchange for those products or services. During the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded net revenues of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;consisting of product revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the United States and service revenue of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">through a distribution partner in Canada.  We commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and began shipping to customers in the United States in May 2019 and launched through a distribution partner in Canada in October 2019.  We recorded the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada as service revenue on a net basis. We did not record any net revenue during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cost of Sales</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our cost of sales was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for&#160;the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which primarily&#160;consisted of the cost of inventory that was purchased from Daewoong for product sales in the United States. We did not record any cost of sales during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Our gross profit as a percentage of net revenues was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">77.1%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and benefited from one-time reduced, launch pricing from our manufacturing partner. Our gross profit may fluctuate in the future as we deplete inventory purchased at the one-time launch pricing and implement various marketing programs that may affect the average selling price of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We anticipate that our cost of sales will increase as Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sales increase.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Selling, General and Administrative</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Selling, general and administrative expenses&#160;increased by&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$84.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$113.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;from&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$29.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;The&#160;increase&#160;was primarily attributable to&#160;the U.S. launch of&#160;Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This included&#160;higher personnel-related expenses as a result of hiring a U.S. sales force, building out our corporate and commercial infrastructure and incurring marketing expenses&#160;including the J.E.T. program. Shipments under the J.E.T. program ended in August 2019. Personnel-related expenses, including stock-based compensation, increased by $39.4 </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">million and marketing and selling expenses, including expenses related to the J.E.T. program, increased by $26.0 million from the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Selling, general and administrative expenses may fluctuate in the future primarily due to potential changes in marketing strategies, and performance-based personnel-related expenses, such as commissions and bonuses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development expenses&#160;decreased by&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;from&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The&#160;decrease&#160;was primarily attributable to&#160;the completion of the U.S. clinical trial activities related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in 2018, partially offset by&#160;one-time bonuses of&#160;$1.6 million&#160;to certain current and former employees upon FDA approval of&#160;Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019. We expect our overall research and development expense to increase if and when we seek to develop further product candidates and pursue regulatory approvals in other jurisdictions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revaluation of Contingent Royalty Obligation Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the revaluation charges of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, were primarily driven by changes in management assumptions related to revenue forecasts based on management&#8217;s assessment of current and future markets of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and marketing and distribution strategies, discount rate and timing of cash flows. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Depreciation and Amortization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Depreciation and amortization&#160;increased&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;from a de minimis amount for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;This was primarily attributable to amortization of the distribution right asset related to&#160;Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;over 20 years as well as amortization of the internal-use software costs over two years.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Non-Operating Expense, Net</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Non-operating expenses, net, increased by&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;from&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Interest income increased by&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which was primarily attributable to interest earned from short-term investments. Interest expense&#160;increased by&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$7.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;from&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which&#160;was primarily attributable to interest incurred on our long-term debt to Oxford Finance, LLC and the contingent promissory note payable to the Evolus Founders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Income Taxes (Benefit) Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Income tax benefit&#160;was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;as compared to a de minimis provision for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This was primarily attributable to&#160;a partial release of the deferred tax assets valuation allowance. Upon the reclassification of the indefinite-lived IPR&amp;D intangible asset to a definite-lived distribution right intangible asset in the first quarter of 2019 upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the related deferred tax liability became a source of future taxable income in the assessment of the realization of deferred tax assets, and as a result, a portion of the previously existing valuation allowance was released.</font></div><div><a name="sB48BA5D25DFF514FA8328D450C7153B9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had cash and cash equivalents of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$109.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, short-term investments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and stockholders&#8217; equity of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$79.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have a limited history of generating revenues and only began shipping Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we had an accumulated deficit of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$213.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and working capital of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$127.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We had net losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$90.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and we used net cash in operating activities of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the&#160;years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Initial Public Offering</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2018, we closed our initial public offering and sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, inclusive of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock issued upon the exercise by the underwriters of their option to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">purchase additional shares. The net proceeds were approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Follow-On Public Offerings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, we closed a follow-on public offering and sold&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of our common stock at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, inclusive of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds were approximately&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2019, we closed a follow-on public offering and sold </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,999,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of our common stock at a price of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share, inclusive of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">782,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock issued upon the exercise by the underwriters of their option to purchase additional shares. The net proceeds were approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">after deducting underwriting discounts and commissions, excluding other offering expenses. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Loan and Security Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, or the closing date, we entered into a loan and security agreement, or the credit facility, with Oxford Finance, LLC, as collateral agent, or Oxford, pursuant to which the lender made term loans available to us of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the credit facility. The credit facility provides that the term loans will be funded in two advances. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date, and the second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at our request, no later than September 30, 2020, upon achieving specified minimum net sales milestones and no event of default is occurring. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of 9.5%, or the 30-day U.S. Dollar LIBOR rate plus 7.0%. We have agreed to pay interest only on each tranche funded pursuant to the credit facility for the first 36 months until May 2022, which will be followed by a 23-month amortization period. Notwithstanding the foregoing, if we maintain compliance with the specified minimum net sales covenant and meet other conditions during the initial interest-only period, upon our request, the interest only period may be extended by an additional 12 months to a total of 48 months followed by an 11-month amortization period.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, we will be required to pay to Oxford a final payment of 5.5% of the full principal amount of the term loans funded, or the final payment. We may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to 3.0% of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, 2.0% of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or 1.0% of the amount prepaid if the prepayment occurs thereafter, or the Prepayment Fee.  If the term loans are accelerated following the occurrence of an event of default, we will be required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the final payment, the Prepayment Fee, and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of our assets. The credit facility includes affirmative and negative covenants applicable to us, our current subsidiary and any subsidiaries we may create in the future. The affirmative covenants include, among others, covenants requiring us to maintain our legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus 5.0% and Oxford, as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including our cash. These events of default include, among other things, any failure by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, our insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against us, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also provides us with the ability, under certain conditions, to obtain up to a $25.0 million revolving line of credit secured by our inventory, accounts receivable and cash proceeds of both. Oxford has the right of first refusal, but not the obligation, to provide such a revolving line of credit. There is no guarantee that such a line would be available to us on terms favorable to us or at all. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had met the conditions to enter into a $25.0 million revolving line of credit.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We lease office facilities under various operating lease agreements. Our corporate headquarters is located in Newport Beach, California, in a facility that we subleased until January 2020 under a non-cancelable operating lease for a fixed amount each month. On May 15, 2019, we entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease commenced on February 1, 2020 and expires on January 31, 2025 with an option to extend the term for an additional&#160;60 months. Lease payments increase based on an annual rent escalation clause that occurs on each February 1 anniversary. We&#160;may, under certain circumstances, terminate the lease on the&#160;36 months&#160;anniversary of the lease commencement date by providing a written notice&#160;12 months&#160;prior to such anniversary and paying a termination fee&#160;equal to six months basic rent plus certain other expenses. We have an option to extend the term of the lease for an additional&#160;60 months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Current and Future Capital Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We believe that our current capital resources, which consist of cash, cash equivalents and short-term investments, will be sufficient to fund operations through at least the next twelve&#160;months based on our expected cash burn rate from the date of the issuance of this Annual Report on Form 10-K. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Until such time, if ever, as we can generate substantial product revenue to cover our costs of operations, we expect to finance our cash needs through additional draws against the Oxford term loan and revolving line of credit, entering into licensing or collaboration agreements with partners, other debt or equity financings, or other sources of financing. Sufficient funds may not be available to us at all or on attractive terms when needed from these sources. To the extent that we raise additional capital through the future sale of equity, the ownership interests of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our existing common stockholders. If we raise additional funds through the issuance of debt securities, these securities could contain covenants that would restrict our operations. We may require additional capital beyond our currently anticipated amounts.&#160;If we are unable to obtain additional funding from these or other sources when needed, we may need to significantly reduce our controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspend certain research and development, sales and marketing programs and other operational goals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources, which consist of cash, cash equivalents and short-term investments, sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of our products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the number and characteristics of any future product candidates we develop or acquire;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing of any cash milestone payments to Daewoong if we successfully achieve certain predetermined milestones; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to forecast demand for our products, scale our supply to meet that demand and manage working capital effectively</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of manufacturing our product or any future product candidates and any products we successfully commercialize, including costs associated with building our supply chain; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of commercialization activities for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;or any future product candidates are approved or cleared for sale, including marketing, sales and distribution costs;  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the cost of maintaining a sales force, the productivity of that sales force, and the market acceptance of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of any such agreements that we may enter into; </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any product liability or other lawsuits related to our products; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the expenses needed to attract and retain skilled personnel; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs associated with being a public company; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including ongoing litigation costs related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and the outcome of this and any other future patent litigation we may be involved in; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the timing, receipt and amount of sales of any future approved or cleared products, if any.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes our cash flows for the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.69047619047619%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #231f20;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(in millions)</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #231f20;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Net cash (used in) provided by:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Operating activities </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(93.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(25.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(67.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Investing activities </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(23.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">(23.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">Financing activities </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">133.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">118.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">16.7</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93.2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">109.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">93.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Operating Activities </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used in operating activities increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The increase in cash used in operating activities was primarily attributable to an increase in net loss of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$43.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, as adjusted for certain non-cash items. In 2019, there was an increase in non-cash income tax benefit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;resulting from partial release of the deferred tax assets valuation allowance. There were also increases in non-cash stock-based compensation expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions related to the rebate and coupon programs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and depreciation and amortization of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which were partially offset by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$6.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;decrease in revaluation of our contingent royalty obligation. Cash used in working capital increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.6 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which was primarily driven by inventory purchases, timing of accounts receivable collections, timing of vendor billing and invoice payments, and increased expenditures associated with the hiring of our sales force and expansion of our commercialization infrastructure in connection with launching </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Investing Activities </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash used in investing activities increased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$23.4 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from a de minimis amount&#160;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The increase in cash used in investing activities was primarily attributable to purchases of short-term investments net of maturities of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$18.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and additions to capitalized software of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash provided by financing activities increased by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$14.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$133.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$118.8 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We received proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$71.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in March 2019 from the credit facility net of discounts and issuance costs and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in November 2019 from the public offering of common stock after deducting underwriting discounts and commissions, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from issuance of common stock related to the incentive equity plan. This was offset by </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of milestone and contingent royalty payments to the Evolus Founders and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in payments to Daewoong ($2.0 million in February 2019 and $1.0 million in December 2019 subsequent to the FDA&#8217;s approval and EMA&#8217;s approval, respectively, of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) during 2019. We received proceeds of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56.3 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the initial public offering in February 2018 and the follow-on public offering in July 2018, respectively. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Indebtedness</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Currently, we have no indebtedness to Alphaeon. For periods prior to the completion of our initial public offering on February 12, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Alphaeon provided us certain services that were not covered under a services agreement, including, without limitation, general and administrative support services and research and development support services. Alphaeon had allocated a certain percentage of personnel to perform the services that it provided to us based on its good faith estimate of the required services. These allocated costs have historically increased related-party borrowings. The costs reflect Alphaeon full-time equivalent, or FTE, rate for the applicable personnel, plus out-of-pocket expenses such as occupancy costs associated with the FTEs allocated to providing us these services. We historically have not recorded a mark-up on the external or internal expenses Alphaeon allocates to us. All Alphaeon-provided operating expenses shown in our financial statements were treated as related party borrowings from Alphaeon to us for the period between January 1, 2018 and February 11, 2018. Since the initial public offering, we have not relied on Alphaeon for funding and in connection with the closing of our initial public offering the related party borrowings were settled in full. As of the completion of our initial public offering on February 12, 2018, we assumed from Alphaeon the revised payment obligations under the Amended Purchase Agreement of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39.7 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.0 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon our initial public offering on February 12, 2018, we were released of the $140.7 million note obligation for all guaranty and security obligations, and the related party receivable from Alphaeon of $73.7 million was settled, resulting in a capital contribution of $67.0 million. Alphaeon&#8217;s security interest in Evolus&#8217; assets also was terminated. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Payment Obligations Related to the Acquisition by Alphaeon</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, the revised payment obligations consist of (i) an approximately $9.2 million up-front payment upon obtaining FDA approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the treatment of glabellar lines, which was paid in full in 2018, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (iii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;outside of the United States, and (iv) a $20.0 million promissory note that matures in November 2021. The revised payment obligations set forth in (ii) and (iii) above will terminate in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States in the second quarter of 2029. Neither Evolus nor Alphaeon has the right to terminate any future payments for a one-time lump sum payment. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, we recorded an aggregate balance of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$59.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67.1 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, on our balance sheet for the revised payment obligations and the promissory note owed to the Evolus Founders (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$41.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.2 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, for the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16.9 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, for the contingent promissory note). We paid the Evolus Founders $9.2 million in February 2019 subsequent to the FDA&#8217;s approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Purchase Agreement, in February 2019, Evolus paid one-time bonuses of $1.6 million to certain former and current employees upon FDA approval of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">License and Supply Agreement with Daewoong</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement,&#160;$13.5 million&#160;in additional cash consideration was due to Daewoong based upon the Company&#8217;s successful completion of certain technical and sales milestones. We </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">paid Daewoong $2.0 million in February 2019 and $1.0 million in December 2019 subsequent to the FDA&#8217;s approval and EMA&#8217;s approval, respectively, of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive remaining contingent milestone payments of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10.5 million</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div><a name="sFA11CF6B95805B7F99BDC8FCCEBB1FC9"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We do not have any off-balance sheet arrangements as defined in the rules and regulations of the SEC. We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose. </font></div><div><a name="s8311C7B27F1E58D8AC4EA8CC1E1950C6"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Contractual Obligations and Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">63</font></div></div><hr style="page-break-after:always"><div><a name="sB11C55A0A5D750BFBE719608E156612D"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Critical Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management&#8217;s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements as well as the expenses incurred during the reporting period. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions and such differences could be material to the financial position and results of operations. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts and experience. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">While our significant accounting policies are more fully described in the notes to our financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be most critical for fully understanding and evaluating our financial condition and results of operations, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We recognize revenue when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration to which we expect to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We currently operate in one reportable segment and all of our net revenue is derived from sales of&#160;Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. We</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;generate product revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States and service revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through a distribution partner in Canada. For product revenue, w</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">e&#160;recognize revenue when control of&#160;Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;is transferred to a customer upon receipt. We do not accept product returns except under limited circumstances such as damages in transit or ineffective product. Any amounts related to taxes assessed by governmental authorities are excluded from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general, and marketing expenses on the condensed statements of operations and comprehensive loss. Payment terms are short-term and customer contracts do not include significant financing components. For service revenue, we are determined to be the agent in the distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada and record the sale as service revenue on a net basis.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We provide customers with trade and volume discounts and prompt pay discounts that are directly reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for the volume rebates and coupon programs. Volume rebates are contractually offered to certain customers. Generally, the rebates payable to each customer are determined based on the contract and quarterly purchase volumes. Through the coupon program, customers receive coupons redeemable into gift cards funded by us for the benefit of consumers. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and expectations of future redemptions prior to the coupon expiration date. The coupons are accrued based on estimated redemption rates and the volume of products purchased and recorded as a reduction to revenues on product delivery.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. We assess the probability that we will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, we estimate the amounts of receivables considered uncollectible to reflect an allowance for doubtful accounts.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Contingent Royalty Obligation and Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We determine the fair value of the contingent royalty obligation payable to the Evolus Founders under the Amended Purchase Agreement based on significant unobservable inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined each period end and recorded in operating expenses in the statements of operations and comprehensive loss and in the current and non-current liabilities in the balance sheets. The significant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">unobservable input assumptions that can significantly change the fair value includes (i) projected net revenues during the payment period, (ii) the discount rate and (iii) the timing of payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We also determined the fair value of the contingent promissory note payable at present value using a discount rate for similar rated debt securities and is based on an estimated date that we believe the contingent promissory note will mature.  Accretion related to the contingent promissory note is recorded in interest expense of the statements of operations and comprehensive loss with a corresponding increase to the non-current liabilities section of the balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. We review goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. We perform an annual qualitative assessment of goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, we perform a two-step process. The first step involves comparing the fair value of our reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, we have determined that there is one reporting unit. There has been no impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;20&#160;years.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying condensed balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;two years&#160;upon being placed in service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was&#160;no&#160;material impairment of long-lived assets for any periods presented.</font></div><div><a name="s8BD42336AE805929BB32D840C1E333B3"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Recently Issued and Adopted Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We describe the recently issued accounting pronouncements that apply to us in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">-Recent Accounting Pronouncements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">65</font></div></div><hr style="page-break-after:always"><div><a name="s3760B3F60EA35ED587FF1AD8CD6DC5C9"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 7A.  &#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosure About Market Risk.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Not applicable.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">66</font></div></div><hr style="page-break-after:always"><div><a name="sF33C898598B351E395F5E85B8FE85108"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 8.&#160; &#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Index to Financial Statements</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:89%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Page</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s58A90F88353650EC921CF54C7544A90C"><font style="font-family:Times New Roman;font-size:10pt;">Report of Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s58A90F88353650EC921CF54C7544A90C">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sF33C898598B351E395F5E85B8FE85108"><font style="font-family:Times New Roman;font-size:10pt;">Financial Statements:</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sED3C836DCDED53539F92A8AFB8860E96"><font style="font-family:Times New Roman;font-size:10pt;">Balance Sheets</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sED3C836DCDED53539F92A8AFB8860E96">69</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s15421ECD1F4D5D279000706CF7C6E044"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Operations and Comprehensive Loss</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s15421ECD1F4D5D279000706CF7C6E044">70</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0A1A50ACC35E581E80A870EE481340CC"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Stockholders&#8217; Equity (Deficit)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s0A1A50ACC35E581E80A870EE481340CC">71</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA1EBE2BBE2A052E6A4E93A83B4CF9BD4"><font style="font-family:Times New Roman;font-size:10pt;">Statements of Cash Flows</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sA1EBE2BBE2A052E6A4E93A83B4CF9BD4">72</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6E97244133035F8CAA9C9B7B4E611A0A"><font style="font-family:Times New Roman;font-size:10pt;">Notes to Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s6E97244133035F8CAA9C9B7B4E611A0A">74</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">67</font></div></div><hr style="page-break-after:always"><div><a name="s58A90F88353650EC921CF54C7544A90C"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">To the Stockholders and the Board of Directors of Evolus, Inc. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have audited the accompanying balance sheets of Evolus, Inc. (the Company) as of December 31, 2019 and 2018, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:67%;"></td><td style="width:19%;"></td><td style="width:14%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have served as the Company's auditor since 2017.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Irvine, California</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:Times New Roman;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">68</font></div></div><hr style="page-break-after:always"><div><a name="sED3C836DCDED53539F92A8AFB8860E96"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Balance Sheets</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except par value and share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">ASSETS</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">109,892</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accounts receivable, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">10,661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">6,407</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,177</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">152,197</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">94,339</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">902</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">4,068</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Intangible assets, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">59,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Goodwill</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">2,429</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">221</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">240,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Current Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,796</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,558</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">13,960</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,718</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,483</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">24,439</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">5,276</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">3,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">41,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">50,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Contingent promissory note payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">17,945</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">16,904</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Long-term debt, net of discounts and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">73,508</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred tax liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">160,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">87,460</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Commitments and contingencies (Note 7)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Stockholders&#8217; equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Common Stock, $0.00001 par value; 100,000,000 shares authorized; </font><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">33,562,665 and 27,274,991 shares issued and outstanding at December 31, 2019 and December 31, 2018, re</font><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">spectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">292,509</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">207,408</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accumulated other comprehensive gain</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(213,059</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">(123,025</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total stockholders&#8217; equity</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">79,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;">84,384</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;color:#333333;font-weight:bold;">Total liabilities and stockholders&#8217; equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">240,442</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;">171,844</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">69</font></div></div><hr style="page-break-after:always"><div><a name="s15421ECD1F4D5D279000706CF7C6E044"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Operations and Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4126984126984%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Product revenue, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">34,237</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Service revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total net revenues</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">34,925</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Product cost of sales (excludes amortization of intangible assets)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">8,014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Gross profit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">26,911</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Selling, general and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">113,593</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">29,146</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,973</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,487</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">10,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">4,132</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">125,858</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">46,142</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(98,947</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,142</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,839</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Interest expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(7,953</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(863</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Loss before income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(105,061</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,802</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Income tax (benefit) expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(15,027</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(90,034</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Other comprehensive gain:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Unrealized gain on available-for-sale securities, net of tax</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(90,028</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(3.19</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average shares outstanding used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">28,237,816</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24,402,368</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">70</font></div></div><hr style="page-break-after:always"><div><a name="s0A1A50ACC35E581E80A870EE481340CC"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Stockholders&#8217; Equity (Deficit)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.84567901234568%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"></td></tr><tr><td style="width:39%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Series A Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Additional Paid In Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Other Comprehensive Gain</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Accumulated Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,250,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,527,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(75,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(75,543</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed contribution from Parent, increase of related-party receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,051</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deemed distribution to Parent, increase of convertible note obligation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,385</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(615</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Preferred stock conversion upon initial public offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,250,000</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,065,875</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon initial public offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,047,514</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,445</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">53,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon follow-on offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">3,600,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,379</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">34,602</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(46,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2018</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">27,274,991</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">207,408</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(123,025</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">84,384</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock upon follow-on offering, net of issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,999,550</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,022</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with the incentive equity plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">288,124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">9,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">9,624</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(90,034</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(90,034</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other comprehensive gain</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Balance at December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">33,562,665</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">292,509</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">(213,059</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">79,457</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">71</font></div></div><hr style="page-break-after:always"><div><a name="sA1EBE2BBE2A052E6A4E93A83B4CF9BD4"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Cash Flows </font></div><div style="line-height:120%;padding-bottom:1px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:85.31746031746032%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(90,034</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(46,867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">4,132</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Stock-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">9,518</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Provisions for rebate and coupon programs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">12,325</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Provision for bad debts</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Amortization of discount on short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,038</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Amortization of operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">873</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Amortization of debt discount and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred income taxes</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">65</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Revaluation of contingent royalty obligation to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">4,160</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;">10,500</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Changes in assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Inventories</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(4,482</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(11,048</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,874</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(992</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,742</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,733</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(13</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(190</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(211</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(93,383</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(25,667</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(345</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Additions to capitalized software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(4,222</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Purchases of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(113,867</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Maturities of short-term investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">95,000</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash used in investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(23,434</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payment of contingent royalty obligation to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(9,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Milestone payment for intangible assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from issuance of long-term debt, net of discounts</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,906</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments for debt issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,205</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payment for debt obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,044</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from initial public offering, net of underwriting fees</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">56,330</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Proceeds from follow-on offering, net of underwriting fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,315</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">67,680</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments for offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(203</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(1,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,127</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Payments on related party borrowings</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(5,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Issuance of common stock in connection with incentive equity plan</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">2,455</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(239</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">133,547</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">118,838</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,730</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash and cash equivalents, beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash and cash equivalents, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">109,892</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">93,162</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">72</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Statements of Cash Flows (Continued)</font></div><div style="line-height:120%;padding-bottom:1px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.88888888888889%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#231f20;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;font-weight:bold;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash paid for interest</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Cash paid for operating leases</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">923</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;background-color:#cceeff;color:#333333;font-weight:bold;">Non-cash investing and financing information:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party receivable</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">73,690</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Related party borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(68,767</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Note obligation</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(140,688</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">39,700</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Contingent promissory note payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">16,042</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, convertible note write-off</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">66,998</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capital contribution from Parent, forgiveness of related party borrowings</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">13,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Deferred offering costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(2,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accounts payable, paid by Parent</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(163</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">5,566</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Landlord paid tenant improvements</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Financed D &amp; O insurance payment</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">1,561</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Capitalized software recorded in accounts payable and accrued expenses</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">87</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">Accrued offering costs, unpaid</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">(90</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#333333;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">See accompanying notes to financial statements.</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">73</font></div></div><hr style="page-break-after:always"><div><a name="s6E97244133035F8CAA9C9B7B4E611A0A"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:1pt;"><font style="font-family:Times New Roman;font-size:1pt;color:#000000;font-weight:bold;">&#160;</font></div><div><a name="sC7304F16DBE6587B88984A4DB46C9448"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 1</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Organization</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. The product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States in May 2019 and in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company&#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&#8217;s common stock on a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.6527</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-for-1 basis (the &#8220;Stock Split&#8221;). The Company&#8217;s then-outstanding shares of convertible Series A preferred stock (&#8220;Series A preferred stock&#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts in the accompanying financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;additional shares of common stock, at an offering price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,330</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&#8217;s then-outstanding shares of Series A preferred stock were automatically converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock. In connection with the completion of its IPO, the Company&#8217;s amended and restated certificate of incorporation was further amended and restated to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share.   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed a follow-on public offering and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67,680</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2019, the Company completed a follow-on public offering and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,999,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">782,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,315</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON Corporation (&#8220;Alphaeon&#8221;), which is majority-owned by Strathspey Crown Holdings Group, LLC, formerly known as SCH-AEON, LLC, (&#8220;SCH&#8221;), owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the Company&#8217;s outstanding shares of common stock, respectively. See Note 11.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#32;Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information.</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2019 Alphaeon changed its name to AEON Biopharma, Inc. and contributed all of the shares it held in the Company to Alphaeon 1, LLC. The Company continues to refer to the renamed AEON Biopharma, Inc. as &#8220;Alphaeon&#8221; and Alphaeon 1, LLC as &#8220;Alphaeon 1, LLC.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Liquidity and Financial Condition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Since inception, the Company has incurred </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">74</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">recurring net operating losses, which include operating losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$90,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46,867</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93,383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,667</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash for operations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$109,892</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in cash and cash equivalents plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19,911</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in short-term investments and an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$213,059</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain and expand market acceptance of its product and achieve a level of revenues adequate to support its cost structure and operate its business and sell products without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources, which consist of cash, ca</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sh equivalents and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the incurrence of additional debt allowed under existing debt arrangements, the entry into licensing or collaboration agreements with partners, sale of its equity securities, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</font></div><div><a name="s461695AE61B158129D80434AC73ABD1B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 2</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Reclassification&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (&#8220;Daewoong&#8221;) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">76</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method with prioritization of the items with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for any periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">77</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reporting unit. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau&#174;&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;upon being placed in service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">78</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon, the Company recognized a contingent royalty obligation payable to the Evolus Founders. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information. The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined at each reporting period end and recorded in operating expenses in the statements of operations and comprehensive loss and as a liability in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon (See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information), the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the statement of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term debt represents the debt balance with Oxford Finance (&#8220;Oxford&#8221;), net of debt issuance costs. See Note 6, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Oxford Term Loans</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">79</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates product revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States and service revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through a distribution partner in Canada.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada as it does not control the product before control is transferred to a customer. &#160;The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. For the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of revenue related to Canada sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and purchase volumes. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and future expectations. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,709</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for rebate and coupon programs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12,325</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,616</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">80</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the&#160;year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.  The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, allowance for doubtful accounts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provision for bad debts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and there were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;write-offs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is within one year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Advertising Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Advertising costs are expensed as incurred and primarily include costs related to social media ads. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company incurred advertising costs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,407</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Prior to the IPO, the Company calculated its income tax amounts using a separate return methodology and presented these amounts as if it were a separate taxpayer from Alphaeon in each jurisdiction. Subsequent to the IPO, the Company has prepared its stand-alone tax return. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">81</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. For the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, excluded from the dilutive net loss per share computation were stock options of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,977,401</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,257,801</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and non-vested RSUs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">179,758</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">221,292</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recently Adopted Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">82</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740,&#160;Compensation - Stock Compensation - Income Taxes. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarified that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that superseded the lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard required lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allowed companies to continue to use the legacy guidance in ASC 840, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allowed for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying balance sheet, but did not have an impact on the statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recent Pronouncements&#160;Not&#160;Yet Adopted&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">(Topic 326)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">: Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">83</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 for public business entities, excluding entities eligible to be smaller reporting companies, and early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of determining the effects adoption will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2019, the FASB issued&#160;ASU No. 2019-12,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2019-12&#160;eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This ASU also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements.</font></div><div><a name="sF418D1D4345F5FD6B5163DD6ADEF3D2A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any short-term investments for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">84</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;investments had been in a continuous unrealized loss position for more than 12 months, and the Company did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t record any other-than-temporary impairments on these securities. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flow method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in the United States, (iii) the discount rate and (iv) the timing of payments. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates between </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of regulatory approval and expected sales. &#160;Significant increases (decreases) in discount rate would result in a significantly lower (higher) fair value measurement, which could impact materially the fair value reported on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Assumption of the royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Financial Assets and Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">85</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">(Level 2). As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note and long-term debt was estimated to be </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,696</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$76,203</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The fair value of operating lease liabilities&#160;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;approximated their carrying value. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17,181</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><a name="s300713C4F0D559138A473E7186D830D2"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:30%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,397</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">63,491</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">84,699</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80,846</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:30%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;&#32;&#32;&#32;________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">&#32;&#32;&#32;&#32;&#32;*   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:41%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,729</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">41,621</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,208</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and IPR&amp;D of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,076</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The IPR&amp;D recognized represents the license and associated distribution right to develop Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in additional cash consideration was due to Daewoong based upon the Company&#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on February 1, 2019, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment which increased the cost basis of the IPR&amp;D, and the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In connection with EU approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company paid a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which also increased the cost basis of the distribution right. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">86</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,415</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, related to costs of computer software developed for internal use. The software is amortized over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period using the straight-line method. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, total intangible assets amortization expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,853</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss, respectively.</font></div><div><a name="sD41AA8F38D985F0DB106CF7FDD3EBDD7"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accrued Expenses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,229</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,228</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">87</font></div></div><hr style="page-break-after:always"><div><a name="s9d1745d04c29466daca57be923245f67"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 6</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">. Oxford Term Loans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;with Oxford. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Term Loans&#8221;), available in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;advances, to the Company. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month basis and no event of default. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company agreed to pay interest-only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;until May 2022, which is followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest-only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the full principal amount of the term loans funded (&#8220;Final Payment&#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the amount prepaid if the prepayment occurs thereafter (&#8220;Prepayment Fee&#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of the Company&#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At the closing date, the Company incurred </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,094</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,205</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in debt discounts and issuance costs related to the Term Loans, respectively. Debt&#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs allocated to the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The Final Payment on the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,125</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and amortized into interest expense over the life of the term loan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">88</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:28%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total principal payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unamortized debt discounts and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,492</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long term debt, net of discounts and issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73,508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><a name="s60B03429FA7558FE9ABC5A06C1B759D1"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company leases office facilities under various operating lease agreements. The Company&#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expired on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease commenced on February 1, 2020 and expires on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company may, under certain circumstances, terminate the lease on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month anniversary of the lease commencement date by providing a written notice </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;prior to such anniversary and paying a termination fee&#160;equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;percent</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;annual rent escalation clause that occurs on each June 1 anniversary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sublease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;income was not significant. Upon signing the sublease, the Company recorded an impairment charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to the right-of-use asset related to the original lease.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">110</font></div></td><td style="vertical-align:bottom;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.0</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">89</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease&#160;expenses were included in the selling, general and administration expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.27777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:78%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,205</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,366</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total rental expense for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$334</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.48412698412699%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:21%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Certain minimum purchase commitments related to the purchase of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are described below.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product is manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company held an option to obtain the therapeutic rights to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in its licensed territories which was held in trust for Alphaeon during the fourth quarter of 2017 for a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;reduction in related party borrowings. In September&#160;2018, Alphaeon exercised the right to obtain the therapeutic option to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and remitted the option exercise price directly to Daewoong.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">90</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, the Company was obligated to make milestone payments to Daewoong for certain confidential development and commercial milestones associated with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive remaining contingent milestone payments of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) originally instituted </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;Medytox Litigation&#8221;). </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. The Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">ITC Case</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145 (the &#8220;ITC Action&#8221;). The ITC Complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">91</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Company intends to defend itself vigorously in the proceedings. In January 2020, the three sets of parties to the ITC Action, (i) the Complainants - Allergan and Medytox, (ii) the Respondents - the Company and Daewoong and (iii) the OUII, each submitted pre-hearing briefs to the Administrative Law Judge assigned to the ITC Action setting forth each party&#8217;s positions on the substantive issues prior to the evidentiary hearing.  From February 4-7, 2020, the Administrative Law Judge held an evidentiary hearing on the ITC Action.  An initial determination by the Administrative Law Judge is due by June 5, 2020 and the target date for the final determination by the ITC is October 6, 2020. An adverse ruling by the ITC against either the Company or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;into the United States and a cease and desist order which would bar sales and marketing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;within the United Sates either of which would materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm. Even if the Company is successful, the ITC Action may result in reputation damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</font></div><div><a name="s05F0303A16E25EAD8BD2CC8DA0EC5D4D"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 8</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Convertible Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to IPO, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,500,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,250,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were issued and outstanding to Alphaeon. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. In connection with the IPO, all shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized, issued or outstanding as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;were issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33,562,665</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares were issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Equity Related Transactions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company assumed from Alphaeon the revised payment obligations under the Amended Purchase Agreement of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related to the contingent promissory note at that date). See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for more information. Pursuant to the Amended Purchase Agreement, Alphaeon agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the services agreement (see Note 11, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). Additionally, the Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to Alphaeon in satisfaction of a portion of the outstanding related party borrowings (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The remaining balance of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">92</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,188</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was recharacterized as a capital contribution from Alphaeon pursuant to the services agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 21, 2017, t</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he board of directors and the then-sole stockholder of the Company approved the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, plus an annual increase on each anniversary of November 21, 2017 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018 and 2019, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,337,821</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares, respectively, were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has available an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,249,380</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock for future issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Options are granted at exercise prices based on the Company&#8217;s grant date common share price. The restricted stock units (&#8220;RSUs&#8221;) and options generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;awards granted with performance conditions or market conditions for the period presented. The options generally have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Black&#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The significant assumptions used in the Black-Scholes option-pricing are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determining Fair Value of the Underlying Common Stock.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;For options awards granted after the completion of the Company&#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&#8217;s common stock was not traded in a public stock market exchange prior to the Company&#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&#8217;s initial public offering, the Board of Directors determined the Company&#8217;s common stock fair market value on as needed basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Volatility.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Term.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">93</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Risk&#8209;Free Rate.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Dividends.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:59%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.32%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:41%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,321,451</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.63</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(273,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(328,117</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">800,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">12.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested and expected to vest, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The total intrinsic value of options exercised in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,311</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded expenses related to stock options of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8,302</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,099</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,529</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.6 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">94</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSUs activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:59%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(25,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24.81</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">229,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15.89</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded expenses related to restricted stock units of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,216</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,304</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Total fair value of RSUs vested during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$357</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$771</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,377</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.7 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">106</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;for capitalized  software information. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Separation of Service with the Former President and Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2018, the Company entered into a separation agreement (the &#8220;Separation Agreement&#8221;) with its then President and Chief Executive Officer. Pursuant to the Separation Agreement, the Company modified previously </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">granted stock options resulting in an incremental vesting of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,424</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;stock options and related stock-based compensation expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$451</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As part of the Separation Agreement, the Company issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock net of tax withholding for vested restricted stock units. An additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50,112</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$980</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and reflected in selling, general and administrative on the statements of operations and comprehensive loss for the year ended December 31, 2018. </font></div><div><a name="s086ffc3bf22a4d51b3bce3a73ddefb52"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 9. Employee Benefit Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees.  On July 1, 2019, the Company began providing matching contributions, which totaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$479</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">95</font></div></div><hr style="page-break-after:always"><div><a name="sF2E23E14C4A35FEEA071E19541391011"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current provision</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred (benefit) provision </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total (benefit) provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">179,589</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years do not expire. </font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;">&#32;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Company has state NOL carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$94,118</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2038. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,377</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which has an indefinite carryforward period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The NOL and the R&amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon. After the Company left the Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may result in the expiration of NOL and R&amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;D credits generated through  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;are likely to be limited by Section&#160;382 and 383. The Company anticipates that an ownership change as defined under Section&#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s NOL and R&amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s balance sheet, statement of operations, or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">96</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">42,756</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,929</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other deferred assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,176</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent obligation - imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(36,972</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(32,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12,970</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fixed asset depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;in February 2019, the Company&#8217;s IPR&amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset. Accordingly, the Company released </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15,055</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of its valuation allowance for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The total valuation allowance balance did not significantly change in 2019 due to the increase related to the current year operating loss as offset by the release as discussed above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,905</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">California NOL write-off</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,938</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in state tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">97</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;accrued interest and penalties associated with uncertain tax positions as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company&#8217;s tax returns for all years since inception are open for audit. </font></div><div><a name="s55A407F5118E5247A777D0AA884A586B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">.&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Services with Alphaeon</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from Alphaeon. For 2018, selling, general and administrative expenses included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;of expenses allocated by Alphaeon. After completion of the Company&#8217;s IPO, Alphaeon did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t incur any administrative or research and development expenses on the Company&#8217;s behalf. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company entered into a services agreement with Alphaeon, or the services agreement, which became effective upon the Company&#8217;s IPO. The services agreement sets forth certain agreements between Alphaeon and the Company that governs the respective responsibilities and obligations between Alphaeon and the Company </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as it relates to the services to be performed between them</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The services agreement has a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year term and thereafter will renew for successive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;year terms unless sooner terminated by either party. The Company or Alphaeon may terminate the services agreement upon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sixty days</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8217; notice to the other party. In accordance with the services agreement, the Company paid Alphaeon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;during the first quarter of 2018, subsequent to the IPO. There were no significant services provided under the services agreement after the IPO. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Evolus had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;related party accounts receivable or payable with Alphaeon. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Note Obligation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to certain debt transactions entered into by Alphaeon in 2016 and 2017 and guaranty provided by the Company, as a co-obligor to these debt obligations, the Company applied the accounting guidance provided in ASC 405-40, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Obligations Resulting from Joint and Several Liability Arrangements </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and recorded a note obligation. During the first quarter of 2018, Alphaeon issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$800</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;additional convertible promissory notes, including&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;convertible promissory notes to the Company&#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the notes increased to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140,688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;times the total outstanding principal amount of  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,275</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) immediately prior to the IPO. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$615</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in excess of the then balance of additional paid-in capital was recorded in accumulated deficit. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018 immediately prior to its IPO, the Company recorded&#160;an increase of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,051</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the receivable from Alphaeon with a corresponding increase in additional paid-in capital. The related party receivable balance increased to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,690</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;immediately prior to the IPO. As of February 12, 2018, the Company was released of the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140,688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;note obligation </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">98</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">for all guaranty and security obligations under the guaranty agreements, and its related party receivable from Alphaeon of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,690</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was settled, resulting in a capital contribution of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$66,998</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Alphaeon&#8217;s security interest in Evolus&#8217; assets was also terminated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH purchased its equity interests included individuals who were previously employed by the Company in operational roles, including the Company&#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Payment Obligations Related to the Acquisition by Alphaeon</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company was acquired by SCH in 2013 and subsequently by its subsidiary, Alphaeon Corporation, by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,200</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;up-front payment upon obtaining FDA approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the treatment of glabellar lines which was paid in full in 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iii) a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(comprised of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;related to the contingent royalty obligation payable and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;related to the contingent promissory note) as of February 12, 2018. See&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for more information about the Company&#8217;s accounting thereof.&#160;In addition, the outstanding related party borrowings from Alphaeon as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from Alphaeon, the fair value of which, as of February 12, 2018, was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,575</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to certain current and former employees upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, including a one-time bonus of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;paid to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development.&#160;The payment is included in research and development expenses in the accompanying statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30 days</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the exclusive license of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;or the business related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by Alphaeon or any of its subsidiaries or affiliates constitutes a change-of-control.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&#8217;s assumption of the revised payment </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">99</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">obligations under the Amended Stock Purchase Agreement from Alphaeon. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (&#8220;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of Alphaeon. However, pursuant to previous agreements among Alphaeon, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind Alphaeon&#8217;s acquisition of Clarion. As a result, Alphaeon owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,600</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;(&#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee Alphaeon owes. In addition, Alphaeon and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The service revenue related to the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;through Clarion in 2019 was recorded based on terms that were not in the scope of the Distribution Agreement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100</font></div></div><hr style="page-break-after:always"><div><a name="s363C3FDF8E825D4891BCAABCAA61A7A6"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9. &#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s6CF2BE3C82DE5D7B9294D61F8E8EE30B"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9A. &#160;&#160;&#160;&#160;Controls and Procedures.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, under the supervision and with the participation of our Chief Executive Officer and our Chief Financial Officer, our principal executive and principal financial officers, respectively, conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act of 1934, as amended, as of the end of the period covered by this Annual Report on Form 10-K. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective (a)&#160;to ensure that information that we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms and (b)&#160;to include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Management&#8217;s Annual Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-15(f) under the Exchange Act. Under the supervision and with the participation of senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our internal control over financial reporting based on the framework in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Internal Control-Integrated Framework</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on the evaluation under that framework and applicable SEC rules, our management concluded that our internal control over financial reporting was effective as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm on our internal control over financial reporting due to an exemption established pursuant to the JOBS Act for &#8220;emerging growth companies.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Changes in Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Inherent Limitations of Internal Controls</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls over financial reporting will prevent or detect all errors and all fraud. A control system, no matter how well&#160;designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management overriding of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</font></div><div><a name="sAB269C72196F5ED7A1A280BE36B77F86"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 9B.  &#160;&#160;&#160;&#160;Other Information.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><a name="s14ED74F9CF7358A6ABBC15DD143DDFA0"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Part III</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">101</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Evolus, Inc.</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Notes to Financial Statements</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(in thousands, except share and per share data)</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain information required by Part&#160;III is omitted from this annual report on Form&#160;10&#8209;K and is incorporated herein by reference to our definitive Proxy Statement for our 2020 Annual Meeting of Stockholders (&#8220;Proxy Statement&#8221;), which we intend to file pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended, within 120&#160;days after December&#160;31, 2019.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">102</font></div></div><hr style="page-break-after:always"><div><a name="s75DE065D73EB5D6FA88DA440D44A4667"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 10.  &#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Except as disclosed below with respect to our Code of Conduct, the information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">We have a Code of Conduct applicable to all directors, officers and employees of the Company.  We have posted the Code of Business Conduct on our website at www.evolus.com.  We will post any amendments to the Code of Conduct on our website.  In accordance with the requirements of the SEC and Nasdaq, we will also post waivers applicable to any of our officers or directors from provisions of the Code of Conduct on our website.</font></div><div><a name="s2F78747C4C695E59930A179FFB28E78C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 11.  &#160;&#160;&#160;&#160;Executive Compensation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders.</font></div><div><a name="sA42DFE57D8465CBABDEF8475CA902D20"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 12. &#160;&#160;&#160;&#160;Security Ownership of Certain of Beneficial Owners and Management and Related Stockholder Matters.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders.</font></div><div><a name="sA27DD64C88455B19AEB72C54A5DBDD2C"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 13.  &#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders.</font></div><div><a name="s32699A63EDD953CF9099F7E48100E3D7"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 14.  &#160;&#160;&#160;&#160;Principal Accounting Fees and Services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The information required by this item is incorporated herein by reference to information contained in the Proxy Statement for our 2020 Annual Meeting of Stockholders.</font></div><div><a name="s73BCB0000F7756CBA4D3B9FC40F5BAB1"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Part IV</font></div><div><a name="s5A894A9CF1025878800CA15D1F7FD634"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 15. &#160;&#160;&#160;&#160; Exhibits, Financial Statement Schedules. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(a)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The following documents are filed as part of this Annual Report on Form 10-K:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(1) Financial Statements.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;See Item 8  &#8220;Financial Statements and Supplemental Information&#8221; elsewhere in this Annual Report on Form 10-K.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(2) Financial Statement Schedules.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;None. Financial statement schedules have been omitted because they are not applicable.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">(3) Exhibits.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#32;The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form&#160;10-K:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Incorporated by Reference</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Form</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">File No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Exhibit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filing Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">Filed Herewith</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:Times New Roman;font-size:9pt;font-weight:bold;">(x)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit21s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">2.1&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit21s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Contribution Agreement, dated as of October 3, 2013, by and among Strathspey Crown Holdings, LLC, the Registrant, the Shareholders of the Registrant, and J. Christopher Marmo,  as the Shareholders&#8217; Representative, as amended on September 22, 2014, November 3, 2015, February 15, 2016 and April 14, 2016.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">3.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit318-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amended and Restated Certificate of Incorporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2/12/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">3.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018001474/exhibit328-k21218.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amended and Restated Bylaws.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2/12/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">103</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">4.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit41s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Specimen certificate evidencing shares of common stock of the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">4.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit42s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Stockholders&#8217; Agreement, dated as of December 14, 2017, by and among ALPHAEON Corporation, Dental Innovations BVBA, Longitude Venture Partners II, L.P. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit4312311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">4.3</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit4312311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Description of Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.1&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit101s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.2&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit102s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Amendment to Stock Purchase Agreement, dated as of September 30, 2014, by and between Strathspey Crown Holdings, LLC and ALPHAEON Corporation.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.3&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit103s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">License and Supply Agreement, dated as of September 30, 2013, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.4&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit104s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">First Amendment to License and Supply Agreement, dated as of February 26, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.5&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit105s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Second Amendment to License and Supply Agreement, dated as of July 15, 2014, by and between Daewoong Pharmaceutical Co., Ltd. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.5</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.6+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit106s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.7+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit107s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Option Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.8+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit108s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Dueling Option Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.9+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit109s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Restricted Shares Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.10+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1010s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit101112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.11+</font></a></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit101112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of RSU Award Agreement under 2017 Omnibus Incentive Plan (Updated 2020)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.12+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1011s-1a.htm"><font style="font-family:Times New Roman;font-size:10pt;">Form of Indemnification Agreement by and between the Registrant and its directors and officers.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1012s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.13</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000162828018000572/exhibit1012s-1a1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Services Agreement, dated as of January 23, 2018, by and between ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1/A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/25/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.14&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1020s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Second Amendment to Stock Purchase Agreement, dated as of December 14, 2017, by and among SCH-AEON, LLC (f/k/a Strathspey Crown Holdings, LLC), ALPHAEON Corporation, the Registrant and J. Christopher Marmo, as Contributors&#8217; Representative, and acknowledged by the parties listed as Contributors on the signature pages thereto.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1021s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.15</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1021s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Tax Indemnity Agreement, dated as of December 14, 2017, by and among the Registrant, J. Christopher Marmo, as the Contributors&#8217; Representative and each of the individuals listed on the signature pages thereto.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.21</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1022s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.16&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1022s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Exclusive Distribution and Supply Agreement, dated as of November 30, 2017, by and between Clarion Medical Technologies Inc. and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.22</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1023s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.17&#8224;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit1023s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Therapeutic Option Letter Agreement, dated December 18, 2017, by and between ALPHAEON Corporation and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.23</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.18+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1029s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of May 6, 2018, by and between David Moatazedi and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.29</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.19+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1030s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of May 29, 2018, by and between Lauren Silvernail and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.30</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">104</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:8%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1031s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.20+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000078/exhibit1031s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated as of June 18, 2018, by and between Michael Jafar and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-226186</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">7/16/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000038/exhibit1031.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.21+</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000038/exhibit1031.htm"><font style="font-family:Times New Roman;font-size:10pt;">Employment Agreement, dated August 15, 2018, by and between Rui Avelar and the Registrant.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.31</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3/20/19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000070/evolus10103311910-q.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.22&#8225;</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000070/evolus10103311910-q.htm"><font style="font-family:Times New Roman;font-size:10pt;">Loan and Security Agreement, dated as of March 15, 2019, by and between the Company and Oxford Finance, LLC</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5/1/19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000131/evolus10106301910-q.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.23</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000131/evolus10106301910-q.htm"><font style="font-family:Times New Roman;font-size:10pt;">First Amendment to Loan and Security Agreement, dated as of July 18, 2019, by and between the Registrant and Oxford Finance, LLC</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10-Q</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8/12/19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000085/ticlease.htm"><font style="font-family:Times New Roman;font-size:10pt;">10.24</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056219000085/ticlease.htm"><font style="font-family:Times New Roman;font-size:10pt;">Lease, dated as of May 15, 2019, between the Registrant and 520 Newport Center Drive LLC</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8-K</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">001-38381</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5/21/19</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit211s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">21.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1570562/000157056218000008/exhibit211s-1.htm"><font style="font-family:Times New Roman;font-size:10pt;">List of Subsidiaries.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">S-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">333-222478</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1/9/18</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit23112311910-k.htm"><font style="font-family:Times New Roman;font-size:10pt;">23.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit23112311910-k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Consent of Ernst &amp; Young LLP, independent registered public accounting firm.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBEFAA117E5885200B7CED176AE1DDBB6"><font style="font-family:Times New Roman;font-size:10pt;">24.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#sBEFAA117E5885200B7CED176AE1DDBB6"><font style="font-family:Times New Roman;font-size:10pt;">Power of Attorney (included on signature page).</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31212311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">31.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31212311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">32.1#</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32112311910k.htm"><font style="font-family:Times New Roman;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.INS*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Instance Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.SCH*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Schema Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.CAL*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.DEF*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.LAB*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101.PRE*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">X</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">_____________</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90167158308752%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:3%;"></td><td style="width:97%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">+</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The Registrant has omitted and filed separately with the Securities and Exchange Commission portions of the exhibit pursuant to a confidential treatment request under Rule 406 promulgated under the Securities Act of 1933, as amended, or the Securities Act.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8225;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Portions of this exhibit have been omitted pursuant to Rule 601(b)(10) of Regulation S-K. The omitted information is not material and would likely cause competitive harm to the registrant if publicly disclosed.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">#</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">The information in Exhibit 32.1 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act (including this Annual Report on Form 10-K), unless the Registrant specifically incorporates the foregoing information into those documents by reference.</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;"><br></font></div><div><a name="s0DF9E4C047AE52B18363986339B44757"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Item 16. &#160;&#160;&#160;&#160;Form 10-K Summary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">None.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">105</font></div></div><hr style="page-break-after:always"><div><a name="sBEFAA117E5885200B7CED176AE1DDBB6"></a></div><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">February&#160;25, 2020</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:right;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.05555555555556%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:10%;"></td><td style="width:90%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">EVOLUS, INC.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">POWER OF ATTORNEY</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The undersigned directors and officers of Evolus, Inc. constitute and appoint David Moatazedi and Lauren P. Silvernail, and each of them, as their true and lawful attorneys and agents with power of substitution, to do any and all acts and things in our name and behalf in our capacities as directors and officers and to execute any and all instruments for us and in our names in the capacities indicated below, which said attorneys and agents may deem necessary or advisable to enable said corporation to comply with the Securities Exchange Act of 1934, as amended, and any rules, regulations and requirements of the Securities and Exchange Commission, in connection with this Annual Report on Form&#160;10-K, including specifically but without limitation, power and authority to sign for us or any of us in our names in the capacities indicated below, any and all amendments hereto; and we do hereby ratify and confirm all that said attorneys and agents shall do or cause to be done by virtue hereof.&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">President, Chief Executive Officer and</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Member of the Board of Directors</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Moatazedi</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Lauren P. Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chief Financial Officer and<br>Executive Vice President of Corporate Development<br>(Principal Financial and Accounting Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Lauren P. Silvernail</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Vikram Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Chairman of the Board of Directors</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Vikram Malik</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Simone Blank</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Bosun Hau</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Bosun Hau</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Kristine Romine, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Robert Hayman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Robert Hayman</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><a style="font-family:Times New Roman;font-size:10pt;" href="#s91756416F4AD50AAA7E6A87462CA6FF0"><font style="font-family:Times New Roman;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Signature</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Title</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;text-decoration:underline;">Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">David Gill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Peter C. Farrell, Ph.D., AM.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Peter C. Farrell, Ph.D., AM.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">/s/ Karah Parschauer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td rowspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">February 25, 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Karah Parschauer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>exhibit4312311910k.htm
<DESCRIPTION>EXHIBIT 4.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sabb52784aa844479b854c12f30794259"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 4.3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following is a summary of the rights of our common stock and preferred stock, certain provisions of our certificate of incorporation and our bylaws, and applicable law. This summary does not purport to be complete and is qualified in its entirety by the provisions of our certificate of incorporation and bylaws, copies of which are filed as exhibits to our Annual Report on Form 10-K for the year ended December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our authorized capital stock consists of:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,000,000 shares of common stock, par value $0.00001 per share; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,000,000 shares of preferred stock, par value $0.00001 per share.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of December 31, 2019, there were </font><font style="font-family:inherit;font-size:10pt;">33,562,665</font><font style="font-family:inherit;font-size:10pt;">&#32;outstanding shares of our common stock. As of that date, there were outstanding options to purchase </font><font style="font-family:inherit;font-size:10pt;">3,977,401</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock and </font><font style="font-family:inherit;font-size:10pt;">229,870</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock issuable upon the vesting and settlement of restricted stock units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following summarizes the rights of holders of our common stock:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Voting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of our common stock are entitled to one vote per share. The number of authorized shares of common stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the voting power of our capital stock entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law, or DGCL.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Dividends</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to preferences that may be applicable to the holders of outstanding shares of preferred stock, the holders of common stock are entitled to share equally, on a per share basis, in any dividends when, as and if declared by our board of directors out of assets legally available for dividends (except that in the event a dividend or distribution is paid in the form of common stock (or rights to acquire such stock), then holders of common stock shall receive common stock (or rights to acquire such stock, as the case may be).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a Delaware corporation, we are subject to certain restrictions on dividends under the DGCL. Generally, a Delaware corporation may only pay dividends either out of &#8220;surplus&#8221; or out of the current or the immediately preceding year's net profits. Surplus is defined as the excess, if any, at any given time, of the total assets of a corporation over its total liabilities and statutory capital. The value of a corporation&#8217;s assets can be measured in a number of ways and may not necessarily equal their book value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidation Rights</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon our liquidation, dissolution or winding up, after satisfaction of all our liabilities and the payment of any liquidation preference of any outstanding preferred stock, the holders of shares of common stock will be entitled to share equally, on a per share basis, in all of our assets legally remaining for distribution after payment of all debt and other liabilities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Redemption Rights</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no redemption or sinking fund provisions applicable to our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Preemptive Rights and Conversion Rights</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no preemptive or conversion rights applicable to our common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no shares of our preferred stock outstanding, but our board of directors is authorized, without further action by our stockholders, to create and issue one or more series of preferred stock and to fix the rights, powers, preferences and privileges thereof. Among other rights, our board of directors may determine, without further vote or action by our stockholders:</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number of shares constituting the series and the distinctive designation of the series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the dividend rate on the shares of the series, whether dividends will be cumulative, and if so, from which date or dates, and the relative rights of priority, if any, of payment of dividends on shares of the series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the series will have voting rights in addition to the voting rights provided by law and, if so, the terms of the voting rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the series will have conversion privileges and, if so, the terms and conditions of conversion;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether or not the shares of the series will be redeemable or exchangeable, and, if so, the dates, terms and conditions of redemption or exchange, as the case may be;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the series will have a sinking fund for the redemption or purchase of shares of that series, and, if so, the terms and amount of the sinking fund; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rights of the shares of the series in the event of our voluntary or involuntary liquidation, dissolution or winding up and the relative rights or priority, if any, of payment of shares of the series.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any future issuance of shares of preferred stock, or the issuance of rights to purchase shares of preferred stock, could, among other things, decrease the amount of earnings and assets available for distribution to the holders of common stock or could adversely affect the rights and powers, including voting rights, of the holders of the common stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Registration Rights</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 14, 2017, we entered into a stockholders&#8217; agreement with ALPHAEON Corporation, or Alphaeon, Dental Innovations BVBA, or DI, as collateral agent, and Longitude Venture Partners II, L.P., or Longitude, as a secured party, that provided Alphaeon (and upon an event of default by Alphaeon under certain convertible bridge note and convertible promissory notes then-outstanding, DI and Longitude) with registration rights relating to shares of our common stock held by Alphaeon (and then-pledged to DI and Longitude). Subsequent to December&#160;31, 2019, Alphaeon changed its name to AEON-Biopharma, Inc. but we continue to refer to the renamed AEON-Biopharma, Inc. as Alphaeon.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the stockholders&#8217; agreement, certain stockholders party thereto may request that we register for resale all or a portion of their shares of common stock. Certain stockholders party thereto may also request that we file an automatic shelf registration statement on Form S-3 that covers the registrable securities requested to be registered, to the extent we are eligible to do so. Depending on certain conditions, and in addition to other exclusions, we may defer a demand registration for up to 90 days in any twelve-month period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the event that we propose to register any of our securities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), either for our account or for the account of our other security holders, the stockholders party to the stockholders&#8217; agreement are entitled to certain piggyback registration rights allowing them to include their shares in the registration, subject to certain marketing and other limitations. As a result, whenever we propose to file a registration statement under the Securities Act,  the stockholders party to the stockholders&#8217; agreement are entitled to notice of the registration and the right to include their shares in such registration.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The stockholders&#8217; agreement provides that we must pay all registration expenses (other than the underwriting discounts and commissions) in connection with effecting any demand registration or shelf registration. The stockholders&#8217; agreement contains customary indemnification and contribution provisions by us for the benefit of  the stockholders party thereto and their affiliates and, in limited situations, by the stockholders party thereto for the benefit of us and any underwriters with respect to written information furnished to us by such stockholders and stated by such stockholders to be specifically included in any registration statement, prospectus or related document.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registration rights remain in effect with respect to any shares covered by the stockholders&#8217; agreement until (i) all such shares have been sold pursuant to an effective registration statement under the Securities Act, or (ii) such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of the shares without limitation during a three-month period without registration. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2018, Alphaeon distributed a certain number of shares of our common stock that it held to certain of its noteholders in exchange for the extinguishment of outstanding debt obligations. As part of that distribution, such noteholders, including DI and Alpha International Investment Ltd., became parties to the stockholders&#8217; agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2019, Alphaeon transferred a certain number of shares of our common stock that it held to its majority stockholder, Strathspey Crown Holdings Group, LLC, or SCH. As part of that transaction, SCH became a party to the stockholders&#8217; agreement. </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to December&#160;31, 2019, Alphaeon contributed all of the remaining shares of our common stock that it held in us to Alphaeon 1, LLC. As part of that contribution, Alphaeon 1, LLC became a party to the stockholders&#8217; agreement and succeeded to all of Alphaeon&#8217;s rights thereunder.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Anti-Takeover Effects of Provisions of our Certificate of Incorporation, Bylaws and Delaware Law</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Delaware Anti-Takeover Law</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to Section 203 of the DGCL, or Section 203. Section 203 generally prohibits a public Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that such stockholder became an interested stockholder, unless:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prior to such time the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (i) by persons who are directors and also officers and (ii) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">at or subsequent to such time the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, Section 203 defines a business combination to include:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any merger or consolidation involving the corporation and the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any sale, transfer, pledge or other disposition involving the interested stockholder of 10% or more of the assets of the corporation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#9642;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, Section 203 defines an interested stockholder as any entity (other than the corporation and any direct or indirect majority-owned subsidiary of the corporation) or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with, associated with or controlling or controlled by such entity or person.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certificate of Incorporation and Bylaws</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following provisions of our certificate of incorporation and bylaws may make a change-of-control of our company more difficult and could delay, defer or prevent a tender offer or other takeover attempt that a stockholder might consider to be in its best interest, including takeover attempts that might result in the payment of a premium to stockholders over the market price for their shares. These provisions also may promote the continuity of our management by making it more difficult for a person to remove or change the incumbent members of our board of directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Authorized but Unissued Shares; Undesignated Preferred Stock</font><font style="font-family:inherit;font-size:10pt;">. The authorized but unissued shares of our common stock will be available for future issuance without stockholder approval, subject to applicable law and the Nasdaq Marketplace Rules. These additional shares may be used for a variety of corporate purposes, including future public offerings to raise additional capital, acquisitions and employee benefit plans. In addition, our board of directors may authorize, without stockholder approval, the issuance of undesignated preferred stock with voting rights or other rights or preferences designated from time to time by our board of directors (including the right to approve an acquisition or other change in our control). The existence of authorized but unissued shares of common stock or preferred stock may enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Election and Removal of Directors</font><font style="font-family:inherit;font-size:10pt;">. Our board of directors will consist of not less than five nor more than nine directors. The exact number of directors will be fixed from time to time only by resolution of our board of directors. Our board of directors currently has seven members.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our certificate of incorporation provides that directors may be removed only for cause and only by the affirmative vote of holders of at least 66 2/3% of our then outstanding voting stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Classified Board of Directors</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation provides that our board of directors is classified with approximately one-third of the directors elected each year. The authorized number of directors may be changed only by resolution of the board of directors. The directors are divided into three classes, designated class I, class II and class III. Each class consists, as nearly as may be possible, of one-third of the total number of directors constituting the entire board of directors. At each annual meeting of stockholders, successors to the class of directors whose term expires at that annual meeting will be elected until the third annual meeting of stockholders next succeeding the elections or until their successors are duly elected and qualified or until their earlier death, resignation or removal. In addition, if the number of directors is changed, any increase or decrease will be apportioned by our board of directors among the classes so as to maintain the number of directors in each class as nearly equal as possible, and any additional director of any class elected to fill a vacancy resulting from an increase in such class or from the removal from office, death, disability, resignation or disqualification of a director or other cause will hold office for a term that will coincide with the remaining term of that class, but in no case will a decrease in the number of directors have the effect of removing or shortening the term of any incumbent director.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Director Vacancies</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation authorizes only our board of directors to fill vacant directorships.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">No Cumulative Voting</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation provides that stockholders do not have the right to cumulate votes in the election of directors (therefore allowing the holders of a majority of the shares of common stock entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Special Meetings of Stockholders</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation and bylaws provide that special meetings of our stockholders may only be called by the chairman of the board, our Chief Executive Officer or by our board of directors pursuant to a resolution adopted by a majority of the total number of authorized directors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Advance Notice Procedures for Director Nominations</font><font style="font-family:inherit;font-size:10pt;">. Our bylaws establish advance notice procedures for stockholders seeking to nominate candidates for election as directors at an annual or special meeting of stockholders. Although our bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Action by Written Consent</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation provides that any action required or permitted to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing in lieu of a meeting of such stockholders, subject to the rights of the holders of any series of preferred stock.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Amending Our Certificate of Incorporation and Bylaws</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation and bylaws may be amended by the affirmative vote of the holders of at least 66 2/3% of the voting power of our then-outstanding common stock. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Jurisdiction</font><font style="font-family:inherit;font-size:10pt;">. Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery shall be the sole and exclusive forum for all &#8220;internal corporate claims.&#8221; &#8220;Internal corporate claims&#8221; are claims, (i)&#160;that are based upon a violation of a duty by a current or former director or officer or stockholder in such capacity, or (ii)&#160;as to which Title 8 of the DGCL confers jurisdiction upon the Court of Chancery, except for, as to each of (i)&#160;and (ii) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. This exclusive forum provision is intended to apply to claims arising under Delaware state law and would not apply to claims brought pursuant to the Securities Exchange Act of 1934, as amended, or the Securities Act, or any other claim for which the federal courts have exclusive jurisdiction. The exclusive forum provision in our certificate of incorporation will not relieve us of our duties to comply with the federal securities laws and the rules and regulations thereunder, and our stockholders will not be deemed to have waived our compliance with these laws, rules and regulations.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Conflicts of Interest</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware law permits corporations to adopt provisions renouncing any interest or expectancy in certain opportunities that are presented to the corporation or its officers, directors or stockholders. Our certificate of incorporation, to the maximum extent permitted from time to time by Delaware law, renounces any interest or expectancy that we have in, or right to be offered an opportunity to participate in, specified business opportunities that are from time to time presented to Alphaeon or any of its officers, directors, stockholders, agents, members, partners, subsidiaries (other than our company) and affiliates, other than those directors and officers of our company who are offered business opportunities in their capacity as directors and officers of our company, or the specified parties. Our certificate of incorporation provides that, to the fullest extent permitted by law, none of the specified parties will have any duty to refrain from engaging in a corporate opportunity that we might reasonably be deemed to have pursued or had the ability or desire to pursue if granted the opportunity to do so. In addition, to the fullest extent permitted by law, in the event that any of the specified parties acquire knowledge of a potential transaction or other business opportunity which may be a corporate opportunity for itself or himself or its or his affiliates or for us, such person will have no duty to communicate or offer such transaction or business opportunity to us and they may take any such opportunity for themselves or offer it to another person or entity. Our certificate of incorporation does not renounce our interest in any business opportunity that is offered to a director or officer of our company in his or her capacity as a director or officer of our company. To the fullest extent permitted by law, no business opportunity will be deemed to be a potential corporate opportunity for us unless we would be permitted to undertake the opportunity under our certificate of incorporation, we have sufficient financial resources to undertake the opportunity and the opportunity would be in line with our business.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nasdaq Global Market Listing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock is listed on the Nasdaq Global Market under the symbol &#8220;EOLS.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Transfer Agent and Registrar</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 250 Royall Street, Canton, Massachusetts 02021.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>exhibit101112311910k.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEFB04B5CC412CC171BDD79C9B83C0538"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RSU AWARD AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EVOLUS, INC. 2017 OMNIBUS INCENTIVE PLAN</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Evolus, Inc. (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Company</font><font style="font-family:inherit;font-size:11pt;">&#8221;) grants to the Grantee named below (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">you</font><font style="font-family:inherit;font-size:11pt;">&#8221;) the number of restricted stock units (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RSUs</font><font style="font-family:inherit;font-size:11pt;">&#8221;) set forth below (the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Award</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:33%;"></td><td style="width:67%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Plan:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Evolus, Inc. 2017 Omnibus Incentive Plan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Defined Terms:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As set forth in the Plan, unless otherwise defined in this Agreement</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grantee:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[________]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Grant Date:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[________]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Number of RSUs Granted:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">[________]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Definition of RSU:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Each RSU will entitle you to receive one Share at such future date or dates and subject to such terms as set forth in this Agreement.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting Schedule:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The RSUs will become vested and payable on the following schedule, as long as you do not have a Separation from Service before the applicable vesting date:</font></div><div style="padding-bottom:8px;padding-top:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:8px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Acceleration of Vesting:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">All of the RSUs that are then outstanding and unvested will become vested and payable immediately if you incur a Separation from Service by the Company without Cause on, immediately prior to, or  within two years after a Change in Control.  </font></div><div style="padding-bottom:8px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By signing below, you agree that the Award is granted under and governed by the terms of the Plan and this RSU Award Agreement (including the attached RSU Terms) (this RSU Award Agreement, include the attached RSU Terms, is referred to as this &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), as of the Grant Date.  [The &#8220;Detrimental Conduct&#8221; provisions of Section 3.3.3 of the Plan shall not apply to the Award.  Section 3.3.2 of the Plan shall apply to the Award to the extent of a clawback policy adopted to comply with the Sarbanes-Oxley Act, the Dodd Frank Act, or applicable rules of the Securities and Exchange Commission (or applicable listing agency) adopted thereunder.]</font></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">GRANTEE</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sign Name:  </font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name:  </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">EVOLUS, INC.</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Sign Name:  </font><font style="font-family:inherit;font-size:11pt;font-style:italic;text-decoration:underline;">/s/</font><font style="font-family:inherit;font-size:11pt;font-style:italic;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Print Name: </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-bottom:16px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:            </font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">RSU TERMS</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:justify;text-indent:0px;"><font style="padding-bottom:16px;text-align:justify;font-family:inherit;font-size:11pt;padding-right:48px;">1.</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Grant of RSUs</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Award is subject to the terms of the Plan.  The terms of the Plan are incorporated into this Agreement by this reference.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">You must accept the terms of this Agreement by returning a signed copy to the Company within 60 days after the Agreement is presented to you for review (or timely completing such other procedures for accepting the terms of this Agreement as the Committee may establish from time to time).  The  Award is subject to cancellation in its entirety if you do not timely accept the terms of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Restrictions</font><font style="font-family:inherit;font-size:11pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">You will have no rights or privileges of a Stockholder as to the RSUs before settlement under Section 5 below (&#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Settlement</font><font style="font-family:inherit;font-size:11pt;">&#8221;), including no right to vote or receive dividends or other distributions; in addition, the following terms will apply:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">you will not be entitled to delivery of any Shares with respect to the RSUs until Settlement (if at all), and upon the satisfaction of all other terms;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">you may not sell, transfer (other than by will or the laws of descent and distribution), assign, pledge, or otherwise encumber or dispose of the RSUs before Settlement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">you will forfeit all of the RSUs and all of your rights under the RSUs will terminate in their entirety upon the occurrence of an event described in Section 4 below.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Any attempt to dispose of the RSUs or any interest in the RSUs in a manner contrary to the terms of this Agreement will be void and of no effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Vesting Period</font><font style="font-family:inherit;font-size:11pt;">.  The &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Vesting Period</font><font style="font-family:inherit;font-size:11pt;">&#8221; is the period beginning on the Grant Date and ending on the date the RSUs, or such applicable portion of the RSUs, are deemed vested and payable under the terms set forth in table at the beginning of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Forfeiture</font><font style="font-family:inherit;font-size:11pt;">.  If, during the Vesting Period, (i) you incur a Separation from Service (for the avoidance of doubt, which does not otherwise result in the immediate vesting and payment of the RSUs in accordance with the terms hereof), or (ii) you materially breach this Agreement, all of your rights to the RSUs (to the extent not theretofore vested) will terminate immediately and be forfeited in their entirety.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Settlement of RSUs</font><font style="font-family:inherit;font-size:11pt;">.  Delivery of Shares or other amounts under this Agreement will be subject to the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">The Company will deliver to you one Share for each RSU that has become vested hereunder within 74 days after the vesting date of the RSU, subject to the tax withholding provisions of Section 6.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Any issuance of Shares under the Award may be effected on a non-certificated basis, to the extent not prohibited by applicable law or the applicable rules of any securities exchange or similar entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In addition, any Shares issued hereunder will be subject to any stop-transfer orders and other restrictions as the Company may deem advisable under the rules, regulations, and other requirements of the SEC, any </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">securities exchange or similar entity upon which the Shares are then listed, and any applicable federal or state securities law, and the Company may cause a legend or legends to be placed on any certificates to make appropriate reference to these restrictions.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Tax Withholding</font><font style="font-family:inherit;font-size:11pt;">.  You will be required to meet any applicable tax withholding obligation related to the Award in accordance with the tax withholding provisions of Section 17.3 of the Plan (or any successor provision).  By signing this Agreement, you agree that any tax withholding obligation arising in connection with the vesting and payment of the RSUs subject to your Award will be satisfied as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company will determine the amount of any federal, state, local or other income, employment, or other taxes which the Company or any of its subsidiaries may be obligated to withhold with respect to the delivery of Shares in payment of your RSUs that become vested (such withholding obligations, the &#8220;</font><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Withholding Obligation</font><font style="font-family:inherit;font-size:11pt;">&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You hereby irrevocably instruct the Company (and any third-party broker designated by the Company) to sell in one or more transactions on the open market, for and on your behalf, from the Shares otherwise deliverable to you in payment of your vested RSUs, a number of such Shares (valued at the applicable sale prices applying the applicable broker&#8217;s customary methodology) to satisfy the Withholding Obligation and any brokerage fees and commissions arising in connection with such sale (rounded up to the nearest whole share).  Such sale shall occur in connection with the delivery of the Shares in payment of the vested RSUs subject to your Award.  The proceeds of such sale, in an amount equal to the Withholding Obligation, shall be promptly remitted to the Company to satisfy the Withholding Obligation.  Any brokerage fees and commissions arising in connection with such sale shall also be satisfied from the proceeds of such sale.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Any such sale of Shares for and on your behalf will be conducted through a broker designated by the Company.  You agree to execute any and all such other documents as may be requested by the Company or such broker, as applicable, in order to implement and consummate the transactions contemplated by this letter agreement.  You agree to comply with any administrative rules and procedures established by the Company with respect to such transactions.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:48px;"><font style="font-family:inherit;font-size:11pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">For clarity, should any tax withholding event arise in connection with the Award other than in connection with the delivery of Shares in payment of vested RSUs subject to the Award, you remain obligated to satisfy such tax withholding obligations in accordance with the Plan.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Adjustment</font><font style="font-family:inherit;font-size:11pt;">.  Upon any event described in Section 15 of the Plan (or any successor provision) occurring after the Grant Date, the adjustment provisions of that section will apply to the Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Bound by Plan and Committee Decisions</font><font style="font-family:inherit;font-size:11pt;">.  By accepting the Award, you acknowledge that you have received a copy of the Plan, have had an opportunity to review the Plan, and agree to be bound by all of the terms of the Plan.  If there is any conflict between this Agreement and the Plan, the Plan will control.  The authority to manage and control the operation and administration of this Agreement and the Plan is vested in the Committee.  The Committee has all powers under this Agreement that it has under the Plan.  Any interpretation of this Agreement or the Plan by the Committee and any decision made by the Committee related to the Agreement or the Plan will be final and binding on all Persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Your Representations</font><font style="font-family:inherit;font-size:11pt;">.  You represent to the Company that you have read and fully understand this Agreement and the Plan and that your decision to participate in the Plan is completely voluntary.  You also acknowledge that you are relying solely on your own advisors regarding the tax consequences of the Award.  </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">You acknowledge and agree  the Company (i) makes no representations or undertakings regarding the tax consequences of the Award and (ii) does not commit to structure the terms of the Award to reduce or eliminate your liability for taxes in respect of the Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Regulatory and Other Limitations</font><font style="font-family:inherit;font-size:11pt;">.  Notwithstanding anything else in this Agreement, the Committee may impose conditions, restrictions, and limitations on the issuance of Shares under the Award unless and until the Committee determines that the issuance complies with (a) all registration requirements under the Securities Act, (b) all listing requirements of any securities exchange or similar entity on which the Shares are listed, (c) all Company policies and administrative rules, and (d) all applicable laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11.</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:inherit;font-size:11pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:11pt;">.  Any notice that may be required or permitted under this Agreement must be in writing and may be delivered personally, by intraoffice mail, or by electronic mail or via a postal service (postage prepaid) to the electronic mail or postal address and directed to the person as the receiving party may designate in writing from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Waiver</font><font style="font-family:inherit;font-size:11pt;">.  The waiver by any party to this Agreement of a breach of any provision of the Agreement will not operate or be construed as a waiver of any other or subsequent breach.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Entire Agreement</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement and the Plan constitute the entire agreement between you and the Company related to the Award.  Any prior agreements, commitments, or negotiations concerning the Award are superseded.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Binding Effect; Successors</font><font style="font-family:inherit;font-size:11pt;">.  The obligations and rights of the Company under this Agreement will be binding upon and inure to the benefit of the Company and any successor corporation or organization resulting from the merger, consolidation, sale, or other reorganization of the Company, or upon any successor corporation or organization succeeding to substantially all of the assets and business of the Company.  Your obligations and rights under this Agreement will be binding upon and inure to your benefit and the benefit of your beneficiaries, executors, administrators, heirs, and successors.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Governing Law; Consent to Jurisdiction; Consent to Venue; Service of Process</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement will be construed and interpreted in accordance with the internal laws of the State of California without regard to principles of conflicts of law thereof, or principles of conflicts of laws of any other jurisdiction that could cause the application of the laws of any jurisdiction other than the State of California.  For purposes of resolving any dispute that arises directly or indirectly from the relationship of the parties evidenced by this Agreement, you hereby submit to and consent to the exclusive jurisdiction of the State of California and agree that any related litigation must be conducted solely in the courts of Orange County, California or the federal courts for the United States for the Central District of California, where this Agreement is made and/or to be performed, and no other courts.  You may be served with process in any manner permitted under State of California law, or by United States registered or certified mail, return receipt requested.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement may be amended at any time by the Committee, except that no amendment may, without your consent, materially impair your rights under the Award.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:11pt;">.  The invalidity or unenforceability of any provision of this Agreement will not affect the validity or enforceability of any other provision of the Agreement, and each other provision will be severable and enforceable to the extent permitted by law.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">No Rights to Service</font><font style="font-family:inherit;font-size:11pt;">.  Nothing in this Agreement will be construed as giving you any right to be retained in any position with the Company or its Affiliates.  Nothing in this Agreement will interfere with or restrict the rights of the Company or its Affiliates&#8212;which are expressly reserved&#8212;to remove, terminate, or discharge you at any time for any reason whatsoever or for no reason, subject to the Company&#8217;s certificate of incorporation, bylaws, and other similar governing documents and applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Section 409A</font><font style="font-family:inherit;font-size:11pt;">.  The RSUs are intended to be exempt from (or, to the extent not exempt, to comply with) Section 409A, and this Agreement will be administered and interpreted consistently with that intent.  For purposes of Section 409A, each installment payment under this Agreement or the Plan, or otherwise payable to you, will be treated as a separate payment.  This paragraph will not be construed as a guarantee of any particular tax effect for your benefits under this Agreement and the Company does not guarantee that any such benefits will satisfy the provisions of Section 409A or any other provision of the Code.  Notwithstanding anything else in this Agreement, to the extent required to avoid accelerated taxation or tax penalties under Section 409A, amounts that would otherwise be payable and benefits that would otherwise be provided under this Agreement during the six-month period immediately following your Separation from Service will instead be paid on the first payroll date after the six-month anniversary of your Separation from Service (or your death, if earlier).  Notwithstanding the foregoing, neither the Company nor the Committee will have any obligation to take any action to prevent the assessment of any additional tax or penalty on you under Section 409A and neither the Company nor the Committee will have any liability to you for such tax or penalty.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Further Assurances</font><font style="font-family:inherit;font-size:11pt;">.  You must, upon request of the Company or the Committee, do all acts and execute, deliver, and perform all additional documents, instruments, and agreements that may be reasonably required by the Company or the Committee to implement the provisions and purposes of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Clawback</font><font style="font-family:inherit;font-size:11pt;">.  All awards, amounts, or benefits received or outstanding under the Plan will be subject to clawback, cancellation, recoupment, rescission, payback, reduction, or other similar action in accordance with the terms of any Company clawback or similar policy or any applicable law related to such actions, as may be in effect from time to time.  You acknowledge and consent to the Company&#8217;s application, implementation, and enforcement of any applicable Company clawback or similar policy that may apply to you, whether adopted before or after the Grant Date (including the forfeiture, clawback, and detrimental conduct provisions contained in Section 3.3 of the Plan as of the Grant Date), and any provision of applicable law relating to clawback, cancellation, recoupment, rescission, payback, or reduction of compensation, and the Company may take such actions as may be necessary to effectuate any such policy or applicable law, without further consideration or action.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(l)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Electronic Delivery and Acceptance</font><font style="font-family:inherit;font-size:11pt;">.  The Company may deliver any documents related to current or future participation in the Plan by electronic means.  You consent to receive those documents by electronic delivery and to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(m)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:11pt;">.  This Agreement may be executed in any number of counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">* * *</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>exhibit23112311910-k.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDF12B488589E532D9E09FF7092EE5519"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit&#160;23.1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#333333;">We consent to the incorporation by reference in the Registration Statement (Forms S-8 No. 333-223068 and 333-229184), pertaining to the Evolus, Inc. 2017 Omnibus Incentive Plan of Evolus, Inc. of our report dated </font><font style="font-family:inherit;font-size:10pt;color:#333333;">February&#160;25, 2020</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#333333;">with respect to the financial statements of Evolus, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.3076923076923%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:46%;"></td><td style="width:31%;"></td><td style="width:23%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Irvine, California&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;25, 2020</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exhibit31112311910k.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE1EE932BFE7D524F93962186E87ED2DB"></a></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, David Moatazedi, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:53px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:29px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February&#160;25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President, Chief Executive Officer and Director</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exhibit31212311910k.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s85DC0906533450428FF1EA8B7DBA7DF2"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Lauren Silvernail, certify that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K of Evolus, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such&#160;internal control over financial reporting, or caused such&#160;internal control over financial reporting&#160;to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:66px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:36px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:33px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:65px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:32px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February&#160;25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exhibit32112311910k.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8500AA8BE4755E4C8962C2404983793D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:24px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER AND</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C.</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#167; 1350 AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:16px;text-align:justify;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the undersigned hereby certifies, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, in his or her capacity as an officer of Evolus, Inc., that, to his or her knowledge:</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1) the Annual Report on Form&#160;10-K of Evolus, Inc. for the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2019</font><font style="font-family:inherit;font-size:10pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934; and </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:16px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Evolus, Inc.</font></div><div style="line-height:138%;text-align:left;padding-left:33px;text-indent:-34px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:44%;"></td><td style="width:5%;"></td><td style="width:5%;"></td><td style="width:46%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February&#160;25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Moatazedi</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: February&#160;25, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:1px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="padding-top:1px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lauren Silvernail</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer and Executive Vice President, Corporate Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:1px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>eols-20191231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:F6BA0DADB8555352B78D65A68A3D95F4,x:81903e9b60cd448b9fb13634f4558501-->
<xbrli:xbrl xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:eols="http://www.evolus.com/20191231" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="eols-20191231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2020Q1Feb21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul01-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Nov01-Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-11-01</xbrli:startDate>
			<xbrli:endDate>2019-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Jan31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q3Jul01-Jul31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-01</xbrli:startDate>
			<xbrli:endDate>2018-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q4Nov01-Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">eols:FollowOnOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-11-01</xbrli:startDate>
			<xbrli:endDate>2019-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q3Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_SoftwareDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_srt_StatementGeographicalAxis_country_CA_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_eols_OxfordTermLoansMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:OxfordTermLoansMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">eols:ContingentRoyaltyObligationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2013Q4YTD_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-10-01</xbrli:startDate>
			<xbrli:endDate>2013-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-01</xbrli:startDate>
			<xbrli:endDate>2019-02-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2013Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-03-15</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">eols:ApplicableRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">eols:TermLoanFacilityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-15</xbrli:startDate>
			<xbrli:endDate>2019-03-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_dei_LegalEntityAxis_eols_DaewoongMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:DaewoongMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-21</xbrli:startDate>
			<xbrli:endDate>2017-11-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb11_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q2_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-05-01</xbrli:startDate>
			<xbrli:endDate>2018-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsMarketConditionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsPerformanceConditionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsMarketConditionsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">eols:RestrictedStockUnitsRSUsMarketConditionsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb11_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Nov30_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-30</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:SCHAEONLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-12</xbrli:startDate>
			<xbrli:endDate>2018-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2019Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Feb11_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-02-11</xbrli:startDate>
			<xbrli:endDate>2018-02-11</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Feb28_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">eols:ChiefMedicalOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2018Q1QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb11_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-11</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2019Q1Feb28_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">eols:EvolusIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec14_dei_LegalEntityAxis_eols_ALPHAEONMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-14</xbrli:startDate>
			<xbrli:endDate>2017-12-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2018Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001570562</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">eols:ALPHAEONMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:MajorityShareholderMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="advance">
		<xbrli:measure>eols:advance</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="unit">
		<xbrli:measure>eols:unit</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="year">
		<xbrli:measure>eols:year</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2019Q4YTD" id="Fact-2069826B26D3D3E1285BD189FA7D7729">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2019Q4YTD" id="Fact-A31BB16DD4F4E70DE0FED189FA7AB3BA">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2019Q4YTD" id="Fact-33F8B99B44208F1A6A4DD189FA7E5187">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2019Q4YTD" id="Fact-73F836B081920B37C45DD189FA77759E">2019</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2019Q4YTD" id="Fact-F7629B119B41C0553881D189FA7D42DA">2019-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2019Q4YTD" id="Fact-A16D09A258A0B171F72ED189FA76E25B">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2019Q4YTD" id="Fact-6FA09C2015C92BC72033D189FA7BF2E4">0001570562</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2020Q1Feb21" decimals="INF" id="Fact-86F250A02D4B4C06D1C5D189FA786D3F" unitRef="shares">33728035</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2019Q4YTD" id="Fact-32F3C98258B7FB0D4E38D189FA789F3D">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityEmergingGrowthCompany contextRef="FD2019Q4YTD" id="Fact-F9D9364CFC45A3B5F627D189FA7BB61E">true</dei:EntityEmergingGrowthCompany>
	<dei:EntityExTransitionPeriod contextRef="FD2019Q4YTD" id="Fact-1C5C965FB833D8869087D189FA7DF551">true</dei:EntityExTransitionPeriod>
	<dei:EntityFilerCategory contextRef="FD2019Q4YTD" id="Fact-B86DD34664A62D8957F7D189FA78FF68">Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityInteractiveDataCurrent contextRef="FD2019Q4YTD" id="Fact-7CBEDFBCF5ABF5289ABC457EDAEBED91">Yes</dei:EntityInteractiveDataCurrent>
	<dei:EntityPublicFloat contextRef="FI2019Q2" decimals="-5" id="Fact-9CD3B35D7AC9D108E932D189FA7DD2E9" unitRef="usd">238700000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2019Q4YTD" id="Fact-F153902BBE8D92A209C2D189FA79DC41">EVOLUS, INC.</dei:EntityRegistrantName>
	<dei:EntityShellCompany contextRef="FD2019Q4YTD" id="Fact-0E2B807A8472B350DEEED189FA76C1C0">false</dei:EntityShellCompany>
	<dei:EntitySmallBusiness contextRef="FD2019Q4YTD" id="Fact-7FAE520966055260C455D189FA7BF1FD">true</dei:EntitySmallBusiness>
	<dei:EntityVoluntaryFilers contextRef="FD2019Q4YTD" id="Fact-EAF2BF2443AA4EFBF7DFD189FA76C2C5">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2019Q4YTD" id="Fact-8C024CF9B6CE06121EE3D189FA7D7C5D">No</dei:EntityWellKnownSeasonedIssuer>
	<eols:AccountsPayablePaidbyParent contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A9A8E03688DE3B3A3D7F37D08C45E83B" unitRef="usd">163000</eols:AccountsPayablePaidbyParent>
	<eols:AccountsPayablePaidbyParent contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8E5D03215282B017667537D05D24656D" unitRef="usd">0</eols:AccountsPayablePaidbyParent>
	<eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements contextRef="D2013Q4Oct_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-34407AD3BC6302CDD5403CC87A855A92">P3Y</eols:AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements>
	<eols:AllocatedShareBasedCompensationExpenseCapitalized contextRef="FD2018Q4YTD" decimals="INF" id="Fact-F25F9163DEF946ECC46940038BEBD0E3" unitRef="usd">0</eols:AllocatedShareBasedCompensationExpenseCapitalized>
	<eols:AllocatedShareBasedCompensationExpenseCapitalized contextRef="FD2019Q4YTD" decimals="-3" id="Fact-02FFE68702F2A709C35940036AA33D1C" unitRef="usd">106000</eols:AllocatedShareBasedCompensationExpenseCapitalized>
	<eols:BusinessAcquisitionUnwindingFee contextRef="D2017Q4Nov30_dei_LegalEntityAxis_eols_ALPHAEONMember" decimals="-3" id="Fact-79A7C3A0FC9AB97EC5E7D189FAAFDF26" unitRef="usd">9600000</eols:BusinessAcquisitionUnwindingFee>
	<eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="INF" id="Fact-7AD4E1C209F30C1C9C173CE572FAA0DC" unitRef="usd">9200000</eols:BusinessCombinationUpfrontPaymentUponObtainingFDAApproval>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2018Q4YTD" decimals="-3" id="Fact-50B8711E5521FC9D7932D189FAB2C90B" unitRef="usd">66998000</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionConvertibleNoteWriteOff contextRef="FD2019Q4YTD" decimals="-3" id="Fact-5440AA1A26A9836FB7F3D189FAAE920B" unitRef="usd">0</eols:CapitalContributionConvertibleNoteWriteOff>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="D2018Q1Feb12" decimals="-3" id="Fact-82C21A21131365455951D189FA84A160" unitRef="usd">13188000</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-16CE0F5483EE519AC6A5D189FAA6524B" unitRef="usd">13188000</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionForgivenessofRelatedPartyBorrowings contextRef="FD2019Q4YTD" decimals="-3" id="Fact-CABDFA227AB955FB2FCCD189FAB0B1E2" unitRef="usd">0</eols:CapitalContributionForgivenessofRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EB692E9369498060CD3ED189FAA4009B" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-AE8F802A8652930875C037A6A80CEF87" unitRef="usd">13188000</eols:CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings>
	<eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance contextRef="I2018Q4Nov21" decimals="INF" id="Fact-E73CFF99C8850878DA03D189FA6FEBF4" unitRef="shares">1091000</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
	<eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance contextRef="I2019Q4Nov21" decimals="INF" id="Fact-522AD123B4FAC6AAED9B3FA605DA8689" unitRef="shares">1337821</eols:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
	<eols:ContingentPromissoryNote contextRef="FD2018Q4YTD" decimals="-3" id="Fact-82E26423C3887FC76337D189FA7A69D1" unitRef="usd">16042000</eols:ContingentPromissoryNote>
	<eols:ContingentPromissoryNote contextRef="FD2019Q4YTD" decimals="-3" id="Fact-126A0B1217972A789A5FD189FAA6F6A5" unitRef="usd">0</eols:ContingentPromissoryNote>
	<eols:ContingentRoyaltyObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7A242F7E105E6CC5E11BD189FA723C6D" unitRef="usd">39700000</eols:ContingentRoyaltyObligation>
	<eols:ContingentRoyaltyObligation contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3289E3254B938C36BDE9D189FA964446" unitRef="usd">0</eols:ContingentRoyaltyObligation>
	<eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8A39676F54D604B61C86D189FAA80AE1" unitRef="usd">0</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
	<eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-CB525867B850F26F3DC1D189FAAA183B" unitRef="usd">3483000</eols:ContingentRoyaltyObligationPayabletoRelatedPartyCurrent>
	<eols:DebtInstrumentAdditionalAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-197019AAB7D7384B79483CA8B93802C4">P11M</eols:DebtInstrumentAdditionalAmortizationPeriod>
	<eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-52EFB9AEAA3BAE0A42D73CA7AFD2A9A6">P12M</eols:DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment>
	<eols:DebtInstrumentAmortizationPeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-98550B19A0ED8147BD673CA7746C0E29">P23M</eols:DebtInstrumentAmortizationPeriod>
	<eols:DebtInstrumentDefaultInterestRate contextRef="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember_us-gaap_VariableRateAxis_eols_ApplicableRateMember" decimals="INF" id="Fact-1C2475E74143103E2A873CA9D2F45CCD" unitRef="number">0.05</eols:DebtInstrumentDefaultInterestRate>
	<eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-0E410BDA5CC685B93F5D3CA92D6BFD62" unitRef="number">0.055</eols:DebtInstrumentPercentageOfPrincipalAmountBalloonPayment>
	<eols:DebtInstrumentPeriodOfInterestOnlyPayments contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-95D1CCD6A6C5BB38DF333CA7063222F8">P36M</eols:DebtInstrumentPeriodOfInterestOnlyPayments>
	<eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-5FDB8DDED07E0E89C8F33CA94FAEB9D0" unitRef="number">0.03</eols:DebtInstrumentPrepaymentFeePercentageNextTwelveMonths>
	<eols:DebtInstrumentPrepaymentFeePercentageThereafter contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-58D5135FAC04BB85BDAC3CA98A8E9594" unitRef="number">0.01</eols:DebtInstrumentPrepaymentFeePercentageThereafter>
	<eols:DebtInstrumentPrepaymentFeePercentageYearTwo contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-4082480ACE663592F87F3CA96E9EAD24" unitRef="number">0.02</eols:DebtInstrumentPrepaymentFeePercentageYearTwo>
	<eols:DebtInstrumentTermAggregatePeriod contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-7A79698066A59157FAEB3CA85E4ACB9E">P48M</eols:DebtInstrumentTermAggregatePeriod>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7F303D40759CE9BD6F4DD189FA9773E4" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5B8BAA3C63B055FC47BA37A6A808E88A" unitRef="usd">1051000</eols:DeemedContributionFromParentIncreaseOfRelatedPartyReceivable>
	<eols:DeferredTaxAssets.OperatingLeaseLiabilities contextRef="FI2019Q4" decimals="-3" id="Fact-1C4642BF5C3E771C2BED37F66BB2AF70" unitRef="usd">1274000</eols:DeferredTaxAssets.OperatingLeaseLiabilities>
	<eols:DeferredTaxAssetsPromissoryNoteDebtDiscount contextRef="FI2018Q4" decimals="-3" id="Fact-368DF9C2856F98CC5CE1D189FA80A6F9" unitRef="usd">101000</eols:DeferredTaxAssetsPromissoryNoteDebtDiscount>
	<eols:DeferredTaxAssetsPromissoryNoteDebtDiscount contextRef="FI2019Q4" decimals="-3" id="Fact-C0EB499AE22C25770578D189FA8AC525" unitRef="usd">199000</eols:DeferredTaxAssetsPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5FC89129E420EE7D676B3F17CDA23A6C" unitRef="usd">0</eols:EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount>
	<eols:EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount contextRef="FD2019Q4YTD" decimals="-3" id="Fact-9023F242FE62515496883F17CD9D0637" unitRef="usd">5174000</eols:EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount>
	<eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B757D5DAF8256BA84EF5D189FA709F60" unitRef="usd">105000</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount contextRef="FD2019Q4YTD" decimals="-3" id="Fact-AB3DC41D31D6EAE2588CD189FA697804" unitRef="usd">128000</eols:EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount>
	<eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2B18F9C32E7F119A0618D189FA71F115" unitRef="usd">2938000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
	<eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F07387CC37EEB93759EDD189FAAFF6A5" unitRef="usd">1040000</eols:EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation>
	<eols:IncreaseDecreaseInOperatingLeaseLiabilities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-39CDDA55929D21EAFA2537BD03B19614" unitRef="usd">-654000</eols:IncreaseDecreaseInOperatingLeaseLiabilities>
	<eols:IntangibleAssetsGrossIncludingGoodwill contextRef="FI2019Q4" decimals="-3" id="Fact-221377007DD55B39C69B3CD56AB00F3B" unitRef="usd">84699000</eols:IntangibleAssetsGrossIncludingGoodwill>
	<eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate contextRef="FD2019Q4YTD" id="Fact-CC203003250EC4B351444023FC30E597">P12M</eols:LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate>
	<eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent contextRef="FD2019Q4YTD" id="Fact-306A2DCAB1F61018DF9F40241CF11BC2">P6M</eols:LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent>
	<eols:LesseeOperatingLeaseTerminationPeriod contextRef="FD2019Q4YTD" id="Fact-F4208DA4D03493B2DDDB4023D7E3C34F">P36M</eols:LesseeOperatingLeaseTerminationPeriod>
	<eols:LineofCreditFacilityNumberofAdvances contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-72C2EAEDD0A7699219866E143009EA02" unitRef="advance">2</eols:LineofCreditFacilityNumberofAdvances>
	<eols:LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn contextRef="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" id="Fact-220F71D0927F2A8E2D516E182CDA9E17">P6M</eols:LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn>
	<eols:MilestonePaymentCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7454AA7B5A744B64CF0737DB13364752" unitRef="usd">0</eols:MilestonePaymentCurrent>
	<eols:MilestonePaymentCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-189EA33A39333BFCA85A37DB2C77D4EE" unitRef="usd">1709000</eols:MilestonePaymentCurrent>
	<eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement contextRef="FD2019Q4YTD_dei_LegalEntityAxis_eols_DaewoongMember" decimals="-3" id="Fact-CEEC6F1D5805CF8955D7403624E3D04A" unitRef="usd">10500000</eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement>
	<eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-72D4996EE513925A11D03CC6343F9D51" unitRef="usd">1000000</eols:MilestonePaymentInConnectionWithLicenseAndSupplyAgreement>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="D2019Q1Feb01_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-0F01DA44578FBDF485C13CC8BE9EEC8C" unitRef="usd">2000000</eols:MilestonePaymentsForIntangibleAssets>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-AD5E9F3CDB62763A6F2D37C1ED19EEA3" unitRef="usd">0</eols:MilestonePaymentsForIntangibleAssets>
	<eols:MilestonePaymentsForIntangibleAssets contextRef="FD2019Q4YTD" decimals="-3" id="Fact-82B16584FD7BC1D9B8DD37C0E2C4D441" unitRef="usd">3000000</eols:MilestonePaymentsForIntangibleAssets>
	<eols:NonCashAccruedandUnpaidOfferingCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E628FFA7B9C6A9C15266D189FAADE568" unitRef="usd">0</eols:NonCashAccruedandUnpaidOfferingCosts>
	<eols:NonCashAccruedandUnpaidOfferingCosts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-980F674DA0D65020C6E4D189FAAF86D5" unitRef="usd">90000</eols:NonCashAccruedandUnpaidOfferingCosts>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-63C4ED61F5DC8AE90459D189FA7C629A" unitRef="usd">2885000</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashDeferredOfferingCosts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-67EB33F884FB4CB0EA70D189FA80DC3E" unitRef="usd">0</eols:NonCashDeferredOfferingCosts>
	<eols:NonCashFinanceAndInsurancePayment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5A8F3E9330DE8185F8BD37D08E39E970" unitRef="usd">0</eols:NonCashFinanceAndInsurancePayment>
	<eols:NonCashFinanceAndInsurancePayment contextRef="FD2019Q4YTD" decimals="-3" id="Fact-EEBA6124CD0FC6E91A9337D05FE51D22" unitRef="usd">1561000</eols:NonCashFinanceAndInsurancePayment>
	<eols:NonCashLandlordPaidTenantImprovement contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B36AAFF388ECB4EFD9DE37D08D9D5B6D" unitRef="usd">0</eols:NonCashLandlordPaidTenantImprovement>
	<eols:NonCashLandlordPaidTenantImprovement contextRef="FD2019Q4YTD" decimals="-3" id="Fact-1E71D0DF9A4A3BB1BCDA37D05F13391D" unitRef="usd">781000</eols:NonCashLandlordPaidTenantImprovement>
	<eols:NonCashNoteObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D5B04BC6A6B9A22D776BD189FAAF348F" unitRef="usd">140688000</eols:NonCashNoteObligation>
	<eols:NonCashNoteObligation contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E3C00929299D228E4DBDD189FA9B35BA" unitRef="usd">0</eols:NonCashNoteObligation>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2017Q4QTD_dei_LegalEntityAxis_eols_ALPHAEONMember" decimals="-3" id="Fact-8EEB9FB234CA76681E4AD189FA67A1AE" unitRef="usd">2500000</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FD7DA507F17D76EE63C9D189FA9CC6F1" unitRef="usd">68767000</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyBorrowings contextRef="FD2019Q4YTD" decimals="-3" id="Fact-4CFD07F023287C767C28D189FA94A93F" unitRef="usd">0</eols:NonCashRelatedPartyBorrowings>
	<eols:NonCashRelatedPartyReceivable contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-41B13E35353A1221AF9A450921D7E09E" unitRef="usd">1051000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-329A1C12335C077C45A7D189FA92D496" unitRef="usd">73690000</eols:NonCashRelatedPartyReceivable>
	<eols:NonCashRelatedPartyReceivable contextRef="FD2019Q4YTD" decimals="-3" id="Fact-FD6AD9DC23128368AB62D189FA8DD51E" unitRef="usd">0</eols:NonCashRelatedPartyReceivable>
	<eols:OperatingLeasePercentageOfAnnualRentEscalation contextRef="FD2019Q4YTD" decimals="2" id="Fact-E0344C46B86E6A488EB8402523DB82C7" unitRef="number">0.03</eols:OperatingLeasePercentageOfAnnualRentEscalation>
	<eols:OperatingLeaseRightofUseAssetAmortization contextRef="FD2019Q4YTD" decimals="-3" id="Fact-5CEFFBDD5C8F30FD6B3737B900A69564" unitRef="usd">873000</eols:OperatingLeaseRightofUseAssetAmortization>
	<eols:PaymentsOfContingentRoyaltyObligation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9157DBF5DF81C532A41D37C1EC72912B" unitRef="usd">0</eols:PaymentsOfContingentRoyaltyObligation>
	<eols:PaymentsOfContingentRoyaltyObligation contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F1458315FAF7B926722237C0E21EBE01" unitRef="usd">9677000</eols:PaymentsOfContingentRoyaltyObligation>
	<eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan contextRef="FD2018Q4YTD" decimals="-3" id="Fact-74FBAF0C20620865DD29D189FAA0CDD7" unitRef="usd">-239000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
	<eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan contextRef="FD2019Q4YTD" decimals="-3" id="Fact-DB4AE660545CE9A66FF6D189FA73CB68" unitRef="usd">2455000</eols:ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan>
	<eols:ProvisionsForRebateAndCouponPrograms contextRef="FD2018Q4YTD" decimals="-3" id="Fact-72EBB2A1D1C5FDF18F1037B7569DA141" unitRef="usd">0</eols:ProvisionsForRebateAndCouponPrograms>
	<eols:ProvisionsForRebateAndCouponPrograms contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3E83710CA5E82DF32C7B37B754A8FDC2" unitRef="usd">12325000</eols:ProvisionsForRebateAndCouponPrograms>
	<eols:RebatesAndCouponsCreditsAndPayments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-091AD2EEAAF89F9A9570447AD1150FCD" unitRef="usd">10616000</eols:RebatesAndCouponsCreditsAndPayments>
	<eols:RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier contextRef="D2018Q1_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-740EEA86A42A70FF913F4502DCA283E3" unitRef="number">2.5</eols:RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier>
	<eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" id="Fact-EFE206C8727D410484853CE5B16C14B5">P10Y</eols:RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale>
	<eols:RelatedPartyTransactionPeriodToNotifyTermination contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-EDD71CAC9B702CD1D4A144DFB0485E80">P60D</eols:RelatedPartyTransactionPeriodToNotifyTermination>
	<eols:RelatedPartyTransactionRenewalPeriodOption contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-99F898E43CF2D2E47747D189FA7933B3">P1Y</eols:RelatedPartyTransactionRenewalPeriodOption>
	<eols:RelatedPartyTransactionTermOfAgreement contextRef="D2018Q1Jan1-Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" id="Fact-2A9120D7867A2480B60FD189FAA86A64">P1Y</eols:RelatedPartyTransactionTermOfAgreement>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-2A7AAEFDF0A5FD458779D189FA803A04" unitRef="usd">10500000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-8BF9CF905640734C23C0456DCF9072C7" unitRef="usd">10500000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2019Q4YTD" decimals="-3" id="Fact-5966C96624573AC3E4C1D189FA7B38DF" unitRef="usd">4160000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:RevaluationofContingentRoyaltyObligationPayable contextRef="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-86514B09169EF1CE8797456DCFBC4589" unitRef="usd">4160000</eols:RevaluationofContingentRoyaltyObligationPayable>
	<eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-197C94D52F976FB70AA9D189FA88A157">P6Y</eols:SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm>
	<eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-2432E199C76EA0FEF6F337A6A803A408" unitRef="shares">34602</eols:StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD" decimals="-3" id="Fact-AD5885370054E2CF868BD189FA7C1A75" unitRef="usd">-239000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-1A494FF32A931EDA4D8337A6A7FDEDA0" unitRef="usd">-239000</eols:StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan>
	<eols:StockPurchaseAgreementPeriodAvailabletoCureBreach contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_ALPHAEONMember" id="Fact-C520BF3FDB9FA2A9A6F73CE2E7E511F1">P30D</eols:StockPurchaseAgreementPeriodAvailabletoCureBreach>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-103C58608A146BF8BF67D189FA8A2899" unitRef="usd">3718000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-60517CBF9CCEF853B60ED189FA707485" unitRef="usd">13960000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C2BFE37B3D8480642AECD189FA9A435F" unitRef="usd">1558000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-BFCA42B723472A67E41ED189FA9A44D8" unitRef="usd">5796000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-E67D66BF9DF64BEC4E388059D3F0462B" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-D18B8205A9F83DD7D3B38059E3BC83C4" unitRef="usd">10661000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-68DA278A95393215F8BA37B91FD9A397" unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3D0A2D3C75CD05824A4E37B8FFE4273A" unitRef="usd">1038000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-4E5241CF577EFCE6476AD189FAA7EB28" unitRef="usd">3718000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-4F3D4613BD4AD30B57A5D189FA987365" unitRef="usd">13960000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-AA9AA3547D8671C1526737DB10E0CA04" unitRef="usd">931000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-36475F3924D2C90C700437DB2A83D186" unitRef="usd">5794000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2018Q4" decimals="-3" id="Fact-A3B0075D8B6287CDDCA580737C892131" unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="FI2019Q4" decimals="-3" id="Fact-E653CBD420067BD1433780737B1FF8B7" unitRef="usd">6000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2018Q4" decimals="-3" id="Fact-4A74FC72797AF9452C1AD189FAA1F99E" unitRef="usd">207408000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2019Q4" decimals="-3" id="Fact-D726EB240F5284E38F7FD189FAA5EB9D" unitRef="usd">292509000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EED9D6EA33FC23E25202D189FA88DA2D" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-0BE8D0180780C79FBC1637A6A7FFCDC7" unitRef="usd">66998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-23A6849412F72E0E9EB5D189FA97BC7D" unitRef="usd">6971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8B1915923F830BF4DADC37A6A810EE15" unitRef="usd">6971000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q4YTD" decimals="-3" id="Fact-04A9E5824B3F00ED0B9A37AC9D2D0619" unitRef="usd">9624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-842E1B8576014989F42D37AC9A1FBCF3" unitRef="usd">9624000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdvertisingExpense contextRef="FD2018Q4YTD" decimals="INF" id="Fact-CA75E0BA263ABA7207974484ECE0CB16" unitRef="usd">0</us-gaap:AdvertisingExpense>
	<us-gaap:AdvertisingExpense contextRef="FD2019Q4YTD" decimals="-3" id="Fact-DA880F7992DFD5732A864484A40D81CF" unitRef="usd">1407000</us-gaap:AdvertisingExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="D2018Q2_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="-3" id="Fact-EB8EEA73FE72A33105AFD189FA6F1424" unitRef="usd">451000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-5FB640CD379D81A23653D189FA92F7EC" unitRef="usd">6971000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-10E5F33B5AA624B993ECD189FA8EE917" unitRef="usd">4099000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-CA5AE7FA66F3C5F78D4FD189FA860AEA" unitRef="usd">1304000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-584D2E2EC25906F86F533F256C12ED12" unitRef="usd">5570000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="-3" id="Fact-195F31D48DA55FEE499FD189FA873812" unitRef="usd">980000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-F635E576DFC07ED04F503F256C3192F3" unitRef="usd">1401000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD" decimals="-3" id="Fact-443EA945BF199BC67476D189FA95E535" unitRef="usd">9518000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-5C90B38AB30ED0CC03C13FAEBBF578B8" unitRef="usd">8302000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-99F5647B86DA84D4F8FB4000F6B70A4B" unitRef="usd">1216000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-8A5BF5D8E41815E7EEF93F256C808420" unitRef="usd">8862000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-D34B7AAE1753DAE837833F256C60A5B2" unitRef="usd">656000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2019Q4" decimals="-3" id="Fact-842247896A72645839BC447C8E5007E3" unitRef="usd">387000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AllowanceForLoanAndLeaseLossesWriteOffs contextRef="FD2019Q4YTD" decimals="INF" id="Fact-5A5814A92346F11AF19A44821BD8C34C" unitRef="usd">0</us-gaap:AllowanceForLoanAndLeaseLossesWriteOffs>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2018Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-A5BA565C73D8BB5D25D94052AB7BC7EA" unitRef="number">0.250</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputDiscountRateMember" decimals="3" id="Fact-EC3F308F1671B06FF4AB40527419F7B8" unitRef="number">0.160</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AlternativeInvestmentMeasurementInput contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember_us-gaap_MeasurementInputTypeAxis_us-gaap_MeasurementInputExpectedTermMember" decimals="INF" id="Fact-4DF685B283EC4A17066640523A0396F2" unitRef="year">10</us-gaap:AlternativeInvestmentMeasurementInput>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-47B83770384FBAFB3EB237B9213266B8" unitRef="usd">863000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-365649FC78DDB3BDC42337B901DB5D1A" unitRef="usd">2156000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2018Q4YTD" decimals="INF" id="Fact-A262743BDE71CFE1A9843CC98B4C0C3A" unitRef="usd">0</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AmortizationOfIntangibleAssets contextRef="FD2019Q4YTD" decimals="-3" id="Fact-DE3BD62CE77E30A45D343CC96ACFD046" unitRef="usd">3853000</us-gaap:AmortizationOfIntangibleAssets>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-F46915F9D9B7773F2E474486B78E36E3" unitRef="shares">3257801</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-67D218E4920E69C50B2E4486F2949CF9" unitRef="shares">221292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-9004A53C9281F7239EAA4486AB009FC3" unitRef="shares">3977401</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="0" id="Fact-33DE707EE5351DBA44424486E636205E" unitRef="shares">179758</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2018Q4" decimals="-3" id="Fact-E3DBFDB1CDDA4712EA7FD189FAA9002E" unitRef="usd">171844000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2019Q4" decimals="-3" id="Fact-34960E945361656092AAD189FAA312ED" unitRef="usd">240442000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-6784C224D244AABB9E72D189FA9F1714" unitRef="usd">94339000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-261E6E25F0A47991A889D189FA9D21AF" unitRef="usd">152197000</us-gaap:AssetsCurrent>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3C55A5B1D343D90F26314049687E838A" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-43817CE0FAC47671A07B40496B02E1F5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-34D2C4969253378347364049657FBAD1" unitRef="usd">19905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-46BECBF0B96D3C0627E940496D47067A" unitRef="usd">19911000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-3557BFF5BF521B92FC49D189FAA458C0" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-296CB20AB51C0F819EE3D189FAA8D6C5" unitRef="usd">19911000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2017Q4Dec14_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="INF" id="Fact-1D2A4F40B897C3892F353CE23B25DF9C" unitRef="number">0.5</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DF0D4F0A3F8E8EDC76D8D189FA6C729E" unitRef="usd">10500000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="FD2019Q4YTD" decimals="-3" id="Fact-5DAE8B55A98241D7B974D189FA6813F4" unitRef="usd">4160000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
	<us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="I2013Q4Oct2013_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-125E460B91E52DA4BF973CC89FE4E4B5" unitRef="usd">13500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets contextRef="FI2013Q4_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-66E3422CB1CD4914A20F3CC5AE5C7295" unitRef="usd">56076000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2018Q4YTD" decimals="-3" id="Fact-021C278A4DB5804D3D5C37D08EE0311F" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E2CBC277FFA4E2E216F437D060C2C29B" unitRef="usd">87000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
	<us-gaap:CapitalizedComputerSoftwareAdditions contextRef="FD2018Q4YTD" decimals="INF" id="Fact-97603BDD0A68CEDB79CD3CC9215E3BC6" unitRef="usd">0</us-gaap:CapitalizedComputerSoftwareAdditions>
	<us-gaap:CapitalizedComputerSoftwareAdditions contextRef="FD2019Q4YTD" decimals="-3" id="Fact-84F30B0C6F08138459CC3CC903A93C25" unitRef="usd">4415000</us-gaap:CapitalizedComputerSoftwareAdditions>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2018Q4" decimals="-3" id="Fact-CF724DB5596DA5F8D1C6D189FAA05568" unitRef="usd">93162000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2019Q4" decimals="-3" id="Fact-9AB030C2D31220068FAED189FA9951DA" unitRef="usd">109892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2017Q4" decimals="-3" id="Fact-C30B8FCAE9713CC347D9D189FA6E70AC" unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2018Q4" decimals="-3" id="Fact-2D3197EC5BEA57F13C06D189FA90EF9B" unitRef="usd">93162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="FI2019Q4" decimals="-3" id="Fact-8611B32CA00DE840D8E9D189FAB2102A" unitRef="usd">109892000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2018Q4YTD" decimals="-3" id="Fact-1810707C834980991FFBD189FA6E7FF2" unitRef="usd">93162000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="FD2019Q4YTD" decimals="-3" id="Fact-37E8B62A34D725CE5923D189FA7F1470" unitRef="usd">16730000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2018Q4" id="Fact-06AEFA7A53AC3446D620D189FAAD33CE" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2019Q4" id="Fact-0C8CD164C9E6B70E7639D189FA9FC832" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2019Q4" decimals="INF" id="Fact-9D4C1C5AE1ABDAB802FFD189FA82CF04" unitRef="shares">2249380</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-0D6A2A9527D5040CD1C9D189FA700A5D" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-20074CCAEB1860FB8AADD189FA693788" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-2E2642F648B9047D9E34D189FA6E0E74" unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-692FB5CB6629901CEC55D189FA6C7F2B" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-A46A38DF34635B81E4D1D189FA68AB29" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="I2018Q1Feb12" decimals="INF" id="Fact-E3A582F2937A23A1EA1FD189FA722FC4" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-35D23F600582CE428A90D189FA6FE8FF" unitRef="shares">27274991</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-A69561BFF1FFC79092D3D189FAB2F0AF" unitRef="shares">33562665</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-3267639CBE29DA6F4E345AC10C4266D6" unitRef="shares">33562665</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-99088F579532164406ACD189FA6B1C13" unitRef="shares">27274991</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-F1E2E9AD7D90741756BDD189FA6C300E" unitRef="shares">33562665</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-E98CC77A91C83C36A015D189FAA35186" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2019Q4" decimals="-3" id="Fact-46D081E7F80CF098BB2DD189FAA8333D" unitRef="usd">1000</us-gaap:CommonStockValue>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-E25CF1340DCD86FA0F6BAB1718A044A3" unitRef="usd">-46867000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ComprehensiveIncomeNetOfTax contextRef="FD2019Q4YTD" decimals="-3" id="Fact-26D09551F8B94EC4D321AB16F57A35B6" unitRef="usd">-90028000</us-gaap:ComprehensiveIncomeNetOfTax>
	<us-gaap:ContractualObligation contextRef="FI2018Q4" decimals="-3" id="Fact-10A24B4C8FE57245532DD189FA973569" unitRef="usd">50200000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="FI2019Q4" decimals="-3" id="Fact-B1508E39DB2FD0922A57D189FA9D7F1F" unitRef="usd">41200000</us-gaap:ContractualObligation>
	<us-gaap:ContractualObligation contextRef="I2018Q1Feb12" decimals="-3" id="Fact-7E11F93501E74D32F7D43CE4F84B945F" unitRef="usd">39700000</us-gaap:ContractualObligation>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="I2018Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-82C83D2C3FC0CA348B8DD189FA78B9BD" unitRef="shares">2065875</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7A32207EEDECF64AF8B2AB141D4CA385" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CostOfGoodsAndServicesSold contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E5772CE9D69616408020AB1430ABBB9C" unitRef="usd">8014000</us-gaap:CostOfGoodsAndServicesSold>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-077B0A11CAC3DED12DF9D189FA782318" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-2AA2CCD2C8C62B2E04CDD189FAB09B97" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9CD2DA7FB146085FF2F8D189FA6DC26D" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D5AB5DC727830D9EF547D189FA765CCE" unitRef="usd">28000</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-214E8BD1D0468F246D23D189FA74F8F5" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-014F559722D6ABB87EAED189FA771451" unitRef="usd">28000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2019Q1Mar15_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember_us-gaap_VariableRateAxis_us-gaap_LondonInterbankOfferedRateLIBORMember" decimals="INF" id="Fact-685705B1E9EC38FD90273CA64FF3DD26" unitRef="number">0.07</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2019Q4" decimals="-3" id="Fact-8A3A0727582582A7C3DF3CB0FBB814A7" unitRef="usd">75000000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="INF" id="Fact-97A1F6A5A9BFFC322F943CAADF47A4E1" unitRef="number">0.116</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-5EFB67A9A0BBD174BECB3CA6337D812A" unitRef="number">0.095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="-3" id="Fact-AF909B98FAC6EBA963BC3CA9F9FA7A6D" unitRef="usd">1094000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet contextRef="FI2019Q4" decimals="-3" id="Fact-96B97D610A7E0065C98D3CB394E090BF" unitRef="usd">1492000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
	<us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger contextRef="FI2019Q4" decimals="INF" id="Fact-195DABD0C58E6768940F40549579BDA7" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-16C15E0617549A58B0EED189FA75186F" unitRef="usd">44000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F8DD95AAB08EE2C382CED189FA75C888" unitRef="usd">-10299000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredFinanceCostsGross contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityMember" decimals="-3" id="Fact-EFFB453499620BB3D0E53CAA157871E8" unitRef="usd">2205000</us-gaap:DeferredFinanceCostsGross>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3BD8B9572C94AE5FD2BDD189FA690B08" unitRef="usd">65000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-9AE92478853365567CEFD189FAAD54FB" unitRef="usd">-15055000</us-gaap:DeferredIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-3FF3ABB03C49B99F8166D189FA7C6617" unitRef="usd">15055000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2019Q4" decimals="-3" id="Fact-A4DD6A89F2565B6BB576D189FA850766" unitRef="usd">14131000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2018Q4" decimals="-3" id="Fact-F1C7BA914272B5A221C1D189FA9DCBD7" unitRef="usd">15055000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="FI2019Q4" decimals="-3" id="Fact-99BBD352B4C8050B7D4BD189FAA72A07" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0619E448A022DC42BC1F80630D21BEF1" unitRef="usd">25000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2019Q4" decimals="-3" id="Fact-12CF62E42471244F84C580631A20FD62" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-F8F863E2099253306F8A458BDC099924" unitRef="usd">0</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-8B6EE5E1A7645DCCD536458BDBDE89D1" unitRef="usd">-25000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-021968F93DFD5FD9442BD189FA7BF9C2" unitRef="usd">21000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C90C486485E4A3C160BCD189FA771AE9" unitRef="usd">-4756000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2018Q4" decimals="-3" id="Fact-22A6673A5B1A3423DF6FD189FA7E0C53" unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2019Q4" decimals="-3" id="Fact-6CA2AFF719A23AC54B85D189FA787E1F" unitRef="usd">14131000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2018Q4" decimals="-3" id="Fact-9E7E895EFEBEF39082A7D189FA866483" unitRef="usd">27929000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="FI2019Q4" decimals="-3" id="Fact-303090F2F434C2103CD0D189FA978DB2" unitRef="usd">42756000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2018Q4" decimals="-3" id="Fact-DC27BFB29F503C46D671D189FA8D1AF7" unitRef="usd">11000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2019Q4" decimals="-3" id="Fact-1490DAB1C85421A1C265D189FA93DBD4" unitRef="usd">12000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="FI2018Q4" decimals="-3" id="Fact-F302F3A2EFE4168960A7D189FA74853E" unitRef="usd">608000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation contextRef="FI2019Q4" decimals="-3" id="Fact-A41F2D579BE7E12C62A1D189FA8475F9" unitRef="usd">1962000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2018Q4" decimals="-3" id="Fact-43DAF9CE1AE14A16BD95D189FA7B92CA" unitRef="usd">1455000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="FI2019Q4" decimals="-3" id="Fact-29728CE33B3B7D54934FD189FA7614F1" unitRef="usd">2430000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="FI2018Q4" decimals="-3" id="Fact-E8C04F809CA21319E0D4D189FA86110C" unitRef="usd">2176000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther contextRef="FI2019Q4" decimals="-3" id="Fact-BBC1EAB98140D50CAC99D189FA969C49" unitRef="usd">2470000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2018Q4" decimals="-3" id="Fact-81F4D0CC5F7DE1AEE6A4D189FA93347C" unitRef="usd">32280000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2019Q4" decimals="-3" id="Fact-69820D3706A4F9D7A3CDD189FA7D6C65" unitRef="usd">36972000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2018Q4" decimals="-3" id="Fact-314C8BA6D3B70E27A7B8D189FA7D1796" unitRef="usd">15055000</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilities contextRef="FI2019Q4" decimals="-3" id="Fact-2CCAC4FB5ED19A668654D189FA96FB10" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2018Q4" decimals="-3" id="Fact-6673E2907D9854918788D189FA7AD90C" unitRef="usd">15055000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="FI2019Q4" decimals="-3" id="Fact-002055A5CFB93E072A21D189FA879AC9" unitRef="usd">12970000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
	<us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="FI2019Q4" decimals="-3" id="Fact-D8BBCF1C52F6FD6AD17C37F4162148B9" unitRef="usd">1017000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2018Q4" decimals="-3" id="Fact-90DDDA2289E40A729DB737F4973A4C77" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="FI2019Q4" decimals="-3" id="Fact-A735E88D7E3FD37B701B37F49736AE8A" unitRef="usd">144000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
	<us-gaap:DefinedContributionPlanCostRecognized contextRef="FD2019Q4YTD" decimals="-3" id="Fact-4CBF7755C6C96804242437F25000999F" unitRef="usd">479000</us-gaap:DefinedContributionPlanCostRecognized>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2018Q4YTD" decimals="-3" id="Fact-805666B01284BCF42096D189FA7EE0AB" unitRef="usd">9000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2019Q4YTD" decimals="-3" id="Fact-24611FE2D54A7260EBFAD189FA7C0B19" unitRef="usd">4132000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:Dividends contextRef="D2018Q1_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-1E7E3D6FAB14A2C6E48744FDDE366604" unitRef="usd">66998000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FD99092CB6A277DE4C1ED189FA8BAA48" unitRef="usd">2000000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-E26315D1392FDA6F9D8837A6A7D87590" unitRef="usd">1385000</us-gaap:Dividends>
	<us-gaap:Dividends contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-25ADCE2E08E2A18C952237A6A85031F0" unitRef="usd">615000</us-gaap:Dividends>
	<us-gaap:DueFromRelatedParties contextRef="I2018Q1Jan31_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-91F6DA8160C691E0AB184509B073A55D" unitRef="usd">73690000</us-gaap:DueFromRelatedParties>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2018Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-8E9412B87AB2E10D70BE44E396077591" unitRef="usd">0</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueFromRelatedPartiesCurrent contextRef="FI2019Q4_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="INF" id="Fact-2FC7EDBA2DB5BA6FBEC5D189FA9E76D0" unitRef="usd">0</us-gaap:DueFromRelatedPartiesCurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2019Q1Feb28_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-19BB35B8B217C416CA5E3CE44C32D7DD" unitRef="usd">1575000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:DueToRelatedPartiesCurrentAndNoncurrent contextRef="I2019Q1Feb28_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_eols_ChiefMedicalOfficerMember" decimals="-3" id="Fact-3E41E6BBE50EC1A5F41D3CE464115AB6" unitRef="usd">700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2018Q4YTD" decimals="2" id="Fact-47E71749CE70D124E3BCD189FA79C88C" unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2019Q4YTD" decimals="2" id="Fact-04219F47D7685E6739F4D189FA774888" unitRef="usdPerShare">-3.19</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-523EDFC608592B7B2C37D189FA8934C7" unitRef="usd">2577000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-422E1204CB006675B6B3D189FA6D13D8" unitRef="usd">5229000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-F4B7C4EA4EF0108E1D29D189FA8588A6">P2Y6M29D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-6BE4776DBFA2BAD36F52D189FA74871A">P8M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-6BA607BFEA1AF74AAE5FD189FA6C1A1A" unitRef="usd">1377000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-7C3BA010B82A40DD48E0D189FA85FC78" unitRef="usd">21529000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-56B7979F6680B321B9A5404ABE32BC99" unitRef="usd">19911000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-E9E9B5FE8AB574F0E84D404AC1D82ADA" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-70B40C5E3EE8FE5325BC404AC5D6250E" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-7B144FB631093948FA004202EFA20D21" unitRef="usd">19911000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-71A57A726BBC66864A01404E468388D7" unitRef="usd">39700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-07C6FB52A94731BE129A404E4683A570" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2018Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-6F0CB360ACF9BE447F8C404F0F394BD3" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements contextRef="FD2019Q4YTD_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-F4DBD36A973A6B8F79894523E7B65C0C" unitRef="usd">9677000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-C6B161E0AD3411BFCE22404EEC83FE95" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-8D6C635B8F20C4B6DA75404B989D14E6" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-5C0AAF487F1EFC30BE39404B9C638170" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-78955F1276B492B6FC8B404BA1105232" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-FA62D576D0F28461C0034057E6DA61B1" unitRef="usd">17181000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-AC4EDA3AE363208E5BAA404EEC831EA6" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-EC7A93731FE7C77BA4FF404B95886EE8" unitRef="usd">50200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-3F44DA1D0CAE3748D55A404B11AF0044" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-7A56AA6D2A2363B9ABAA404B15637AB9" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-9A241CB01BB7F293E7BE404B18B8E24E" unitRef="usd">44683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_eols_ContingentRoyaltyObligationMember" decimals="-3" id="Fact-83C61016E8F54681260D404EEC934275" unitRef="usd">44683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_NotesPayableOtherPayablesMember" decimals="-3" id="Fact-0FB966420E4F39F18A17404B0DE3A373" unitRef="usd">44683000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="D2019Q1Feb01_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" id="Fact-93FA93A83408259DA6D83CC69B96A7B1">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" id="Fact-412624582AC21D1F38C53CD5AB68D6A9">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" id="Fact-3C205B56845F1B2591284462FE3949A8">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_SoftwareDevelopmentMember" id="Fact-E3C8FADB27405B42873044632A3D412A">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4" decimals="-3" id="Fact-E95EDC5EE9BA2609D96E3CD56C185011" unitRef="usd">3853000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-7098CDA192AEC2FCF6873CD5017BCBC9" unitRef="usd">1174000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-AF1A4E4F14F8F32497253CD4F9C9DA1E" unitRef="usd">2679000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="FI2019Q4" decimals="-3" id="Fact-527763A0BE97CEF8F81A3CDC17EB22A2" unitRef="usd">41621000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="FI2019Q4" decimals="-3" id="Fact-E230FEF2A12195B2A71A3CDC6FD91B0C" unitRef="usd">5423000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="FI2019Q4" decimals="-3" id="Fact-13698381C87330B2FD773CDC1734332E" unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="FI2019Q4" decimals="-3" id="Fact-3C1B961FD56C3E914C7C3CDC167CBD2C" unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="FI2019Q4" decimals="-3" id="Fact-144462E859AEE2FE0BD93CDC158F8AC3" unitRef="usd">2955000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
	<us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="FI2019Q4" decimals="-3" id="Fact-1021F8C91125530F12003CDC140F476C" unitRef="usd">3729000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4" decimals="-3" id="Fact-BA9AF7816E87181F2AF23CD5060FD73C" unitRef="usd">63491000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-1BA4FC10514D0C4113D53CD4FE5C88A5" unitRef="usd">4415000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsGross contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-0603725784BD3484B5ED3CD4F61C907B" unitRef="usd">59076000</us-gaap:FiniteLivedIntangibleAssetsGross>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4" decimals="-3" id="Fact-B500A8ACD26E624631A93CDC18B4CBF4" unitRef="usd">59638000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" decimals="-3" id="Fact-ED95B412FC1F4DACB8E03CD504D7B2E2" unitRef="usd">3241000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsNet contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" decimals="-3" id="Fact-2A07FF13FB4234E8347D3CD4FC948D0E" unitRef="usd">56397000</us-gaap:FiniteLivedIntangibleAssetsNet>
	<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_ComputerSoftwareIntangibleAssetMember" id="Fact-E34616FA7580AD73AE263CCABC5423F7">P2Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
	<us-gaap:Goodwill contextRef="FI2018Q4" decimals="-3" id="Fact-0F2393FE003B0ADA4198D189FAA0757D" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:Goodwill contextRef="FI2019Q4" decimals="-3" id="Fact-77E67C586CCA7338B8F9D189FA99BA7B" unitRef="usd">21208000</us-gaap:Goodwill>
	<us-gaap:GoodwillAcquiredDuringPeriod contextRef="FD2013Q4YTD_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-EC939BC5A3B277125FE73CC58A094256" unitRef="usd">21208000</us-gaap:GoodwillAcquiredDuringPeriod>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-114F2BA14FD3B099F1AF445ED5D07B62" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-8F6D97E6A4467A418115445ED5C1A504" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GoodwillImpairmentLoss contextRef="FD2019Q4YTD" decimals="INF" id="Fact-5B8A42BFFFBF40851304D189FA6735E8" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
	<us-gaap:GrossProfit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-EDA74553ABFFBA1F0FC2AB141DEABE05" unitRef="usd">0</us-gaap:GrossProfit>
	<us-gaap:GrossProfit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-F3051E4BCD6688C373C9AB143152ED6B" unitRef="usd">26911000</us-gaap:GrossProfit>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2017Q4YTD" decimals="INF" id="Fact-4687A7A0EBA40F8FEC55D189FA966DFF" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2018Q4YTD" decimals="INF" id="Fact-AB66143F2907DC6B8F6FD189FA95F65E" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="FD2019Q4YTD" decimals="INF" id="Fact-BE70C48F32E4F93B5102D189FAA21F01" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2018Q4YTD" decimals="-3" id="Fact-92C774CDF4E1E882ECB0D189FA7C7623" unitRef="usd">-46802000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D982775CA3410EBDCDF6D189FA7D1AD8" unitRef="usd">-105061000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2018Q4" decimals="INF" id="Fact-07D914EF2510CB1FABD83F14A7A5B43F" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="FI2019Q4" decimals="INF" id="Fact-8452B1AB47085405F0553F145DB0EDD4" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3825BB56102DB1FC980CD189FA790ACB" unitRef="usd">65000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2019Q4YTD" decimals="-3" id="Fact-9C36264168E7B66F3A82D189FA75F7CF" unitRef="usd">-15027000</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2018Q4YTD" decimals="-3" id="Fact-32C18248222E72D1191AD189FA6BDAB2" unitRef="usd">9801000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A738E2F3AEEB33B5350AD189FA6CE12A" unitRef="usd">4691000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-38F77244476FB2483ABCD189FA68E98A" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8B93B4985A9A8DB6B9C1D189FA71F5F7" unitRef="usd">-1371000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2018Q4YTD" decimals="-3" id="Fact-743BE67BA272B978E9CDD189FA72D810" unitRef="usd">-9828000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2019Q4YTD" decimals="-3" id="Fact-EB2C76786982CF28F6C3D189FA6BA6E7" unitRef="usd">-22063000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-758488751F57D5E018F1D189FA6FF5D7" unitRef="usd">17000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D0B87B344BAD5F64EAC6D189FA72F333" unitRef="usd">1002000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2018Q4YTD" decimals="-3" id="Fact-AFE35636F30A54D8AA9BD189FA70A9A4" unitRef="usd">474000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-3E812A538B46D55AB0B1D189FA9AFC38" unitRef="usd">521000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2018Q4YTD" decimals="-3" id="Fact-CEB748F58FEDAFE0C0DBD189FA6CC04F" unitRef="usd">-3148000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C225BF96DC977BF9F092D189FA9CB3F0" unitRef="usd">-3905000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxContingenciesOther contextRef="FD2018Q4YTD" decimals="-3" id="Fact-75D59699D4D5B82EBD8D3F17168DEB4A" unitRef="usd">0</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
	<us-gaap:IncomeTaxReconciliationTaxContingenciesOther contextRef="FD2019Q4YTD" decimals="-3" id="Fact-ACC579B2C0D24904C53F3F1716785648" unitRef="usd">50000</us-gaap:IncomeTaxReconciliationTaxContingenciesOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2018Q4YTD" decimals="-3" id="Fact-669746CE8558D0B283E4D189FA79E9EC" unitRef="usd">294000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E013398AA6AF20CFC646D189FA74BBAD" unitRef="usd">294000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4B192944EE636292CE09D189FAB15FF6" unitRef="usd">1275000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A71868E18C610BFAEE34D189FA9EA56D" unitRef="usd">183000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2018Q4YTD" decimals="-3" id="Fact-06781DBF441891BFD8D037BCDEC4CE53" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2019Q4YTD" decimals="-3" id="Fact-AD931FB87EF5122E2C4B37BCCD842FCF" unitRef="usd">11048000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A28D6D079AF092DB49BED189FA7F321E" unitRef="usd">2733000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-49C3609A7E6F092B6982D189FAADC5D6" unitRef="usd">-2742000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-994D6436817CB4E82425D189FA95B7E9" unitRef="usd">-13000</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredLiabilities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-518CC70C99330B06FD91D189FAB129D7" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredLiabilities>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2018Q4YTD" decimals="-3" id="Fact-98C8628732ABFCD913B137BCDD75F415" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInInventories contextRef="FD2019Q4YTD" decimals="-3" id="Fact-0582C6F2B7880027EE9637BCCC7F2B00" unitRef="usd">4482000</us-gaap:IncreaseDecreaseInInventories>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-800FF416176BFD3986C7D189FA9A0061" unitRef="usd">211000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2019Q4YTD" decimals="-3" id="Fact-AE3DDD66AEE15C06FD20D189FA6C6336" unitRef="usd">190000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0D0D1381A9262662F843D189FA6A7581" unitRef="usd">992000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C4C9E7306EE9F1C37AC3D189FA8755A4" unitRef="usd">1874000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" decimals="-3" id="Fact-96A6617B63606B17850C4574C81AC95B" unitRef="usd">56076000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-45D22992463EBEAA5709D189FA9C4CE8" unitRef="usd">56076000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="FI2019Q4" decimals="-3" id="Fact-8EAE378E8C3A17E6A7C4D189FAA3612E" unitRef="usd">59638000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2018Q4" decimals="-3" id="Fact-1B78D5B7BD3D4955EFAF3CD79F406B15" unitRef="usd">77284000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:IntangibleAssetsNetIncludingGoodwill contextRef="FI2019Q4" decimals="-3" id="Fact-A0C5574A75B84867D2C73CD56D32FA00" unitRef="usd">80846000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
	<us-gaap:InterestCostsCapitalized contextRef="D2019Q1Mar15_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="-3" id="Fact-DEE477981B06178052773CAB6E3FBD24" unitRef="usd">4125000</us-gaap:InterestCostsCapitalized>
	<us-gaap:InterestPaidNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-9B2A9BE5D5BF9C12ED5237CE3A885A8A" unitRef="usd">0</us-gaap:InterestPaidNet>
	<us-gaap:InterestPaidNet contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C3DBCBB0BF51D9C6A9DD37CE2755B2BD" unitRef="usd">5166000</us-gaap:InterestPaidNet>
	<us-gaap:InventoryNet contextRef="FI2018Q4" decimals="-3" id="Fact-F529E75B520AE33D785F8059D49077A9" unitRef="usd">0</us-gaap:InventoryNet>
	<us-gaap:InventoryNet contextRef="FI2019Q4" decimals="-3" id="Fact-305C0522F4D5E97438488059E462AAA2" unitRef="usd">6407000</us-gaap:InventoryNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BD9372FEF53DB542A1E2D189FA78DC32" unitRef="usd">203000</us-gaap:InvestmentIncomeNet>
	<us-gaap:InvestmentIncomeNet contextRef="FD2019Q4YTD" decimals="-3" id="Fact-033012F35A170647465DD189FA7B9967" unitRef="usd">1839000</us-gaap:InvestmentIncomeNet>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7110CF5D3639BE911AE64038B28EC1EC" unitRef="usd">334000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-E86792ADD464ECB43130402B9D1C366D" unitRef="usd">1275000</us-gaap:LeaseCost>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="FI2019Q4" decimals="-3" id="Fact-EB127A695334E56EE43C402FD3020CE6" unitRef="usd">6459000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="FI2019Q4" decimals="-3" id="Fact-6591EA142F9E9F46DE00402FD21342B1" unitRef="usd">114000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="FI2019Q4" decimals="-3" id="Fact-6D1B1BE2FEE5154F4AB3403024A7B69A" unitRef="usd">1201000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="FI2019Q4" decimals="-3" id="Fact-8FF0DF1A14E38DA38A3B402FD11E8551" unitRef="usd">1369000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="FI2019Q4" decimals="-3" id="Fact-E75FA23E19D5550D9E6A402FD042AA0E" unitRef="usd">1312000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="FI2019Q4" decimals="-3" id="Fact-7525DB9F12A0A8E4D6A1402FCF64DAB8" unitRef="usd">1258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
	<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="FI2019Q4" decimals="-3" id="Fact-5626E807F57018045AA1402FCE7C969F" unitRef="usd">1205000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
	<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="FI2019Q4" decimals="-3" id="Fact-FCCF85BB3033C39FD418402FD40A86CC" unitRef="usd">1366000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
	<us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="FI2019Q4" id="Fact-C2D3324AFCE9B633EC754024433B8EE4">P60M</us-gaap:LesseeOperatingLeaseRenewalTerm>
	<us-gaap:Liabilities contextRef="FI2018Q4" decimals="-3" id="Fact-A1CDEA3846BF755FF023D189FAA05F8C" unitRef="usd">87460000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2019Q4" decimals="-3" id="Fact-E0EA1D14AF031FFE1B75D189FAA9B576" unitRef="usd">160985000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-5A9026C8064DADE7CB3FD189FAAB7EF6" unitRef="usd">171844000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2019Q4" decimals="-3" id="Fact-5F481B1117D6F3475794D189FAAC13D0" unitRef="usd">240442000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-A057B35E27F6A2A2D0B5D189FA97441C" unitRef="usd">5276000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-BAE8CAF2D4783CC0EEFCD189FA9F4901" unitRef="usd">24439000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-4A09F08632665B2E18723CA5B799BFA9" unitRef="usd">75000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_DebtInstrumentAxis_eols_TermLoanFacilityTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-A81754EAB13311A8D9443CA5D8D2FE24" unitRef="usd">25000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="I2019Q1_us-gaap_LongtermDebtTypeAxis_us-gaap_SecuredDebtMember" decimals="INF" id="Fact-9E15DAB925BE6366A16137E137959D51" unitRef="usd">100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
	<us-gaap:LongTermDebt contextRef="FI2019Q4" decimals="-3" id="Fact-6438DD9209BFCF95D0D76E3656AC1E4E" unitRef="usd">73508000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="FI2019Q4" decimals="-3" id="Fact-80F35052C604C4FA7D7E3CB0FB1A3C6E" unitRef="usd">9783000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="FI2019Q4" decimals="-3" id="Fact-9D3E0CE14689E0B611663CB0FA92D2C3" unitRef="usd">39130000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2019Q4" decimals="-3" id="Fact-FFEEE206137C6EF0F9623CB0F9E66344" unitRef="usd">26087000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-C49A1218CD91C6DC740980652E8E437C" unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermDebtNoncurrent contextRef="FI2019Q4" decimals="-3" id="Fact-97D46CAED2278584C2F1806520325F86" unitRef="usd">73508000</us-gaap:LongTermDebtNoncurrent>
	<us-gaap:LongTermNotesPayable contextRef="FI2018Q4" decimals="-3" id="Fact-6B05483D850CF5AA6E2FD189FAA43281" unitRef="usd">16904000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2019Q4" decimals="-3" id="Fact-72FF9751F1F3EC4EFA72D189FAA94F5C" unitRef="usd">17945000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="I2018Q1Feb12" decimals="-3" id="Fact-7E9C83BCCBCAE08243BA3CE4DA97527B" unitRef="usd">16042000</us-gaap:LongTermNotesPayable>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2018Q4" decimals="INF" id="Fact-CE6E997BF2FA31B50FBFD189FA972334" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:LossContingencyAccrualAtCarryingValue contextRef="FI2019Q4" decimals="INF" id="Fact-A6BE367DD14CAA773827D189FA6C75FB" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
	<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="FI2018Q4_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-F5E8ADE82A9E9FF4B2F6D189FA7F2738" unitRef="number">0.560</us-gaap:MinorityInterestOwnershipPercentageByParent>
	<us-gaap:MinorityInterestOwnershipPercentageByParent contextRef="FI2019Q4_srt_OwnershipAxis_eols_EvolusIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="3" id="Fact-75548F693B5408D1DEF74075B6C4C178" unitRef="number">0.258</us-gaap:MinorityInterestOwnershipPercentageByParent>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-023D01DA37D6B6ADB774D189FA691E73" unitRef="usd">118838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-9EB1D67D6FABE256F882D189FAAECF94" unitRef="usd">133547000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0273B037D6DBC3C47459D189FAAE2EFD" unitRef="usd">-9000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A17E068CCFBB32B2148FD189FAA55896" unitRef="usd">-23434000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0185B6A3C80E66988B4FD189FA938F52" unitRef="usd">-25667000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2018Q4YTD" decimals="-5" id="Fact-671DC30D240E6734A65AD189FA73842C" unitRef="usd">-25700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q4YTD" decimals="-3" id="Fact-563C15388B5BB4FC9AE7D189FA8C70FB" unitRef="usd">-93383000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2019Q4YTD" decimals="-5" id="Fact-83E92B17C18621B1BA84D189FA7F8E22" unitRef="usd">-93400000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-0C154CA9B4C7E4AFED7AD189FA735175" unitRef="usd">-46867000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-DE9C0A285835F0582F2637A6A8321A4E" unitRef="usd">-46867000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q4YTD" decimals="-3" id="Fact-836C88197113F740945AD189FA804279" unitRef="usd">-90034000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-73A1287D77B3A75DD99537ACFC07A454" unitRef="usd">-90034000</us-gaap:NetIncomeLoss>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_eols_OxfordTermLoansMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-6B6F85CFBBC06712560D4057C370C436" unitRef="usd">76203000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NotesPayableFairValueDisclosure contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" decimals="-3" id="Fact-11C95B21BC5EB922EF3940579B9E4A12" unitRef="usd">16696000</us-gaap:NotesPayableFairValueDisclosure>
	<us-gaap:NumberOfReportingUnits contextRef="FD2019Q4YTD" decimals="INF" id="Fact-FEA40C88973FBCCF532ED189FAAA799F" unitRef="unit">1</us-gaap:NumberOfReportingUnits>
	<us-gaap:OperatingExpenses contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C25CD5292FC9D9108DF9D189FA7A28B1" unitRef="usd">46142000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A7FE183E6D5C4825FD5CD189FA728B5B" unitRef="usd">125858000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2018Q4YTD" decimals="-3" id="Fact-41B9437D78B3BEA5449DD189FA7F0408" unitRef="usd">-46142000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A00F78D65320A5CEB0DFD189FA770A98" unitRef="usd">-98947000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeaseCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-1ACD3F8835A75952F826402B93BD1C13" unitRef="usd">1080000</us-gaap:OperatingLeaseCost>
	<us-gaap:OperatingLeaseImpairmentLoss contextRef="FD2019Q4YTD" decimals="-3" id="Fact-5AB35ADD5A6DC3D0B33640249DABDB69" unitRef="usd">80000</us-gaap:OperatingLeaseImpairmentLoss>
	<us-gaap:OperatingLeaseLiability contextRef="FI2019Q4" decimals="-3" id="Fact-DBAD4C0BA9AE6EA3637D402FD5597C54" unitRef="usd">5093000</us-gaap:OperatingLeaseLiability>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-7B0AB5A8A5544A5B5211458BDC7CD084" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-18DBE16579204D052D4CD189FAA929B6" unitRef="usd">1200000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-3C13FC73962FD5CF55FE449D1A63EBCA" unitRef="usd">916000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityCurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-295733785EF9E74D736B458BDC486ED9" unitRef="usd">916000</us-gaap:OperatingLeaseLiabilityCurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-0224908A32FDF61157C8458BDBBF0D8B" unitRef="usd">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="FI2019Q4" decimals="-3" id="Fact-B61866A866CB9460C7C4D189FAA1D802" unitRef="usd">3893000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan01" decimals="-3" id="Fact-6EC207D0CA03547F15F3449D1E4BF547" unitRef="usd">138000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-1E7909ADC818B7518B28458BDC9CAEF5" unitRef="usd">138000</us-gaap:OperatingLeaseLiabilityNoncurrent>
	<us-gaap:OperatingLeasePayments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-36DD33A963F1B87D9CDD37CE28881F02" unitRef="usd">923000</us-gaap:OperatingLeasePayments>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2018Q4" decimals="-3" id="Fact-755863C38BB78121295C458BDC38BD2E" unitRef="usd">0</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="FI2019Q4" decimals="-3" id="Fact-270AC8745D7EC36D45D7805DE2EF4715" unitRef="usd">4068000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan01" decimals="-3" id="Fact-4A9D8837BA9A64A0CF18449D1680CEC5" unitRef="usd">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseRightOfUseAsset contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" decimals="-3" id="Fact-AB54C6B4FF6D39842CB1458BDC6B0443" unitRef="usd">1029000</us-gaap:OperatingLeaseRightOfUseAsset>
	<us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="FI2019Q4" decimals="3" id="Fact-36C3E2310E881D2E9A96402BDCCAEBA6" unitRef="number">0.094</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
	<us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="FI2019Q4" id="Fact-5AAF48AD78DBFFBE4AB1402BDA46D6B7">P5Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2018Q4" decimals="-3" id="Fact-2AC0A25C347AF0715BBD402055713F06" unitRef="usd">1029000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-5382A965B7FDD67045E740201C7F1850" unitRef="usd">890000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2018Q4" decimals="-3" id="Fact-82B8C6DAA7AC8C25877A402042C7FF2B" unitRef="usd">0</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2018Q4" decimals="-3" id="Fact-0E61A4B1493DE5142CC840202E899E0D" unitRef="usd">139000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-3" id="Fact-C42F68BE8D14F0767CCCD189FA8C3BB8" unitRef="usd">179589000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OperatingLossCarryforwards contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember" decimals="-3" id="Fact-0DF0160F74F5D94833173F1090F172A7" unitRef="usd">94118000</us-gaap:OperatingLossCarryforwards>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-8A151E020D1C1D6DCA7BD189FA91FB0C" unitRef="usd">210000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-CEF6CB17D5D2E0071C39D189FA6A27A7" unitRef="usd">1228000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2018Q4" decimals="-3" id="Fact-405AE985B6DD1510896DD189FAABE643" unitRef="usd">221000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2019Q4" decimals="-3" id="Fact-78DE438D93C6708C9CCCD189FAA1C3EB" unitRef="usd">2429000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8EB6A63A40E7D910B79D37AFAD5F2BCE" unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1AF10B3FCDA0FD3EEBAB37AFAD5B4B01" unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-376EE583EC71EB790D67AB1C0D7CBAFC" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="FD2019Q4YTD" decimals="-3" id="Fact-7F2D3547C352F5B6A211AB1C1AC80EB9" unitRef="usd">6000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-3B0C8096ABFDBE8026A7D189FA74B8F9" unitRef="usd">-863000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2019Q4YTD" decimals="-3" id="Fact-7F906F4BA4DD6C0AA5B9D189FA7EE006" unitRef="usd">-7953000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale contextRef="FD2019Q4YTD" decimals="INF" id="Fact-A46A5D42B1A7B8094C8240556AC87705" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
	<us-gaap:PaymentsForSoftware contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B8124BC4349CE0B7AFFF37BF47E54E74" unitRef="usd">0</us-gaap:PaymentsForSoftware>
	<us-gaap:PaymentsForSoftware contextRef="FD2019Q4YTD" decimals="-3" id="Fact-C322B8124BADCDFB64A937BF37CCE24D" unitRef="usd">4222000</us-gaap:PaymentsForSoftware>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D9E161D7379063AFC3A837C1EE69FA20" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-0C9673252A372C35AC6037C10B01470E" unitRef="usd">2205000</us-gaap:PaymentsOfDebtIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-BEAF12CCC245320FE193D189FA9CA81E" unitRef="usd">1060000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-52C8C48C298FBBE1A7ACD189FA7646BD" unitRef="usd">203000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A9A8CD83D1EC9F050D5637BF9FB8F5E0" unitRef="usd">0</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquireInvestments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-83B1050D4AD0922216E037BF82C91D67" unitRef="usd">113867000</us-gaap:PaymentsToAcquireInvestments>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2018Q4YTD" decimals="-3" id="Fact-54830FE4F4959171F4A1D189FA97954C" unitRef="usd">9000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2019Q4YTD" decimals="-3" id="Fact-BD0CF5F54C33A3D75CCED189FA95ED76" unitRef="usd">345000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2018Q4" decimals="INF" id="Fact-18CDBFFBC628F88EF340D189FA6972A9" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2019Q4" decimals="INF" id="Fact-FD23709B8C48FB00E6CDD189FA71CA92" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-F1157ED2AA99E44DDF29D189FA81EC47" unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2018Q4" decimals="INF" id="Fact-6C248C9DAB06B846BA9FD189FA6FDC10" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q4" decimals="INF" id="Fact-C5F72174D8662D89BB43D189FA6A0CAB" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-8F5FD20A7E3E1B9A2EF93F31933E544A" unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2018Q1Feb11_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-ABEDB95317ADABDD142AD189FA732623" unitRef="shares">2500000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesAuthorized contextRef="I2018Q1Feb12" decimals="INF" id="Fact-107909AA3CD8C86B746FD189FA70E84C" unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2018Q4" decimals="INF" id="Fact-A98126AB3242CE3A9058D189FA682885" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q4" decimals="INF" id="Fact-A75655B8B92AC1ACC3E7D189FA6D5518" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-15DE72EFA23D50D7CF4AD189FA8F81C8" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="I2018Q1Feb11_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="0" id="Fact-A2624078FAFA995FF6CA7795F5E06061" unitRef="shares">1250000</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2018Q4" decimals="INF" id="Fact-7373FB1F28D2EABD70B9D189FA6AAA7F" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q4" decimals="INF" id="Fact-816CFEE564C1FCB68839D189FA6B3F44" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-679C2B6083DDCC504759D189FA7E8C87" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="I2018Q1Feb11_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="INF" id="Fact-73B6931A8044E3E503F63F9A476EF554" unitRef="shares">1250000</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockValue contextRef="FI2018Q4" decimals="-3" id="Fact-8A4AFAA990DCD38E5C80D189FAABBF61" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PreferredStockValue contextRef="FI2019Q4" decimals="-3" id="Fact-56F07C86927012CEFCC2D189FAA1703D" unitRef="usd">0</us-gaap:PreferredStockValue>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2018Q4" decimals="-3" id="Fact-D0AACE759A2F33B0D638D189FAA31459" unitRef="usd">1177000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2019Q4" decimals="-3" id="Fact-E079481BED8CCC835DB3D189FAA54031" unitRef="usd">5326000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="D2018Q1Feb12" decimals="-3" id="Fact-C90E512964C4B2225275D189FA7030C0" unitRef="usd">56330000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2018Q4YTD" decimals="-3" id="Fact-D57E19E41FB63F09E0DCD189FA6800A6" unitRef="usd">56330000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="FD2019Q4YTD" decimals="-3" id="Fact-2F1D56E8C50B6D1570B9D189FAAF7F37" unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2018Q3Jul01-Jul31" decimals="-3" id="Fact-FD5005C4F4A9139629FDD189FA7BF9BF" unitRef="usd">67680000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2019Q4Nov01-Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-CD67AA74F336707F2E0B407470FE8FA5" unitRef="usd">73315000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2018Q4YTD" decimals="-3" id="Fact-C48B2B26C603EFCF4E6FD189FA95236C" unitRef="usd">67680000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2019Q4YTD" decimals="-3" id="Fact-4897290FC05E24DAC4DDD189FA6AF77F" unitRef="usd">73315000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4E7CD9CEE6264A990C9537C1EDBE6816" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="FD2019Q4YTD" decimals="-3" id="Fact-4ABB96984B5AC8320B4D37C0E3674191" unitRef="usd">73906000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F65238FEDE8AE46836A637BFA0651F80" unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D195D3B458AC2B69E92337BF84108A90" unitRef="usd">95000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-DD98852C4F25BDBC35C3D189FAADC0BC" unitRef="usd">1127000</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:ProceedsFromRelatedPartyDebt contextRef="FD2019Q4YTD" decimals="-3" id="Fact-535E58480D4A811E622AD189FA6BE8F4" unitRef="usd">0</us-gaap:ProceedsFromRelatedPartyDebt>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2018Q4" decimals="-3" id="Fact-B82A72753CE0BB915338D189FAA5B9A8" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2019Q4" decimals="-3" id="Fact-EF1B0D64BE32293A0823D189FAA2B981" unitRef="usd">902000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2018Q4YTD" decimals="-3" id="Fact-47DDEBB0AED09885BC3937BB5604DDC0" unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:ProvisionForDoubtfulAccounts contextRef="FD2019Q4YTD" decimals="-3" id="Fact-49EE36B4336CB111006437BB560016AB" unitRef="usd">387000</us-gaap:ProvisionForDoubtfulAccounts>
	<us-gaap:PurchaseObligation contextRef="FI2019Q4" decimals="-3" id="Fact-82E1F74C08D60A36CA2F403533935EBA" unitRef="usd">4602000</us-gaap:PurchaseObligation>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2017Q4Dec14_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-10635AD2919FB81EA0133CE55206943F" unitRef="usd">20000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2018Q1Feb11_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-CF8FCACAA30B3662672744FBFF669184" unitRef="usd">56275000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2018Q1Feb12_dei_LegalEntityAxis_eols_SCHAEONLLCMember_us-gaap_BusinessAcquisitionAxis_eols_EvolusIncMember" decimals="-3" id="Fact-6E60F71C4F9B620483223CE4B5C5E97F" unitRef="usd">55742000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="D2018Q1_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-824550225D0A30D9E68944FBECCAE63D" unitRef="usd">140688000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q1QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember" decimals="-3" id="Fact-148DFD08CEF56409BAE044EB902CA2CE" unitRef="usd">24000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q1QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-BAB60C46151C9C36264044E9BA57F462" unitRef="usd">800000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="INF" id="Fact-3A4797AF58FBECEFBE433CEC2E984E16" unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="FD2018Q4YTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" decimals="-3" id="Fact-E93E41AF191D43C40CBA3CE68EE2E414" unitRef="usd">383000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-B08DE404C97093EB911F37C1EF0C6967" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfLongTermDebt contextRef="FD2019Q4YTD" decimals="-3" id="Fact-319426627285E6667C9E37C1388657CD" unitRef="usd">1044000</us-gaap:RepaymentsOfLongTermDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2018Q1QTD_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-A5F58599CF3463B34D2D3FA27F1B5FBF" unitRef="usd">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2018Q4YTD" decimals="-3" id="Fact-A90B0DF2C409C05D0349D189FA6E708B" unitRef="usd">5000000</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:RepaymentsOfRelatedPartyDebt contextRef="FD2019Q4YTD" decimals="-3" id="Fact-FA3E1E57D6CEE8A0D4B1D189FAB2D5E9" unitRef="usd">0</us-gaap:RepaymentsOfRelatedPartyDebt>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-7C6EC15C002AA548ADB7D189FA79659D" unitRef="usd">6487000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2019Q4YTD" decimals="-3" id="Fact-B169BEA06C8F0911F77FD189FA74E2BA" unitRef="usd">3973000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2018Q4" decimals="-3" id="Fact-0EBB21BE019138FBB536D189FA990279" unitRef="usd">-123025000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2019Q4" decimals="-3" id="Fact-E54FCC3F6DBBB4415E02D189FA9A171A" unitRef="usd">-213059000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="I2018Q1Feb11_dei_LegalEntityAxis_eols_ALPHAEONMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_us-gaap_MajorityShareholderMember" decimals="-3" id="Fact-89BF637CA57AB7B5BA8445019092C615" unitRef="usd">-615000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD" decimals="-3" id="Fact-FF651111B44C8EA310B1AB141CAF1E5C" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-209044FB320927DEF5AF379D451D971C" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" decimals="-3" id="Fact-09514A61FB708EB65BA8379D47BDA9F2" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD" decimals="-3" id="Fact-43CBEA85D2577601A30FAB143005F5A6" unitRef="usd">34925000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" decimals="-3" id="Fact-F80EBB15D6E6AC357E22379D43A5B560" unitRef="usd">34237000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember" decimals="-3" id="Fact-BE451911730AADC02C46379D461CA7E3" unitRef="usd">688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ServiceMember_srt_StatementGeographicalAxis_country_CA_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" decimals="-3" id="Fact-8DBA95F959A797282B5C456BEF68010F" unitRef="usd">688000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
	<us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="FD2019Q4YTD" decimals="-3" id="Fact-62F9A28B4373B03CCC7A37D05DF148F7" unitRef="usd">5566000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-F3DF45101C0D3B3E1389D189FA74E71D" unitRef="shares">5047514</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2018Q1Feb12_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-DD0403497E16CCB9C5F7D189FA74C011" unitRef="shares">47514</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2019Q4Nov01-Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="INF" id="Fact-59E8357093287467205340715A9519A3" unitRef="shares">5999550</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2019Q4Nov01-Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-E27DDD942A1CCF1EA6B5407425C23FC4" unitRef="shares">782550</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q1Feb12" decimals="INF" id="Fact-1190F9ED087252FD784AD189FA751E6E" unitRef="usdPerShare">12.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2018Q3Jul31" decimals="2" id="Fact-C011B78F2D4A00A561E9D189FA7292A8" unitRef="usdPerShare">20.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2019Q4Nov30_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="2" id="Fact-9B29AB23C3A348399D2840734FC85B5B" unitRef="usdPerShare">13.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2018Q4YTD" decimals="-3" id="Fact-4A63431B2F8508ED9BD9D189FA7516A3" unitRef="usd">29146000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="FD2019Q4YTD" decimals="-3" id="Fact-95183C90BF5A1FA8C30CD189FA774939" unitRef="usd">113593000</us-gaap:SellingGeneralAndAdministrativeExpense>
	<us-gaap:ShareBasedCompensation contextRef="FD2018Q4YTD" decimals="-3" id="Fact-F6D00BE2CAF957EA55CED189FA9CEA22" unitRef="usd">6971000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2019Q4YTD" decimals="-3" id="Fact-922FDAB0F9A72801B0B1D189FAA2E15D" unitRef="usd">9518000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-35EA157E95B780E9F200D189FA7CE46B">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" id="Fact-AFF3EEFD28DD6E599B8C3FA872888B68">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-1235BFEE1141B0C936494006DCD9441E" unitRef="shares">19409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-6843F2E91546DF4F928B400701E44D4D" unitRef="usdPerShare">13.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsMarketConditionsMember" decimals="INF" id="Fact-053DDAA514C116337B514064E589C11A" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" decimals="INF" id="Fact-31F8A894B9B68D75530C40649C29E8DD" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsMarketConditionsMember" decimals="INF" id="Fact-9627410538C3618053444064E49728A1" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" decimals="INF" id="Fact-50AFFC8297965D4B3A554062863B76F5" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-6AB86543610C01D9A6494006C89646D7" unitRef="shares">3000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-A892D406AF3E6211CF1D4006E9D8B026" unitRef="usdPerShare">18.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-771897D2D2F6E74325F0D189FA698A65" unitRef="shares">271404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-DB38E6B6806C0A9227823F255772A7EF" unitRef="shares">229870</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-E3DA0A2FE9101D870EE3D189FA8E50A5" unitRef="usdPerShare">16.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-859C8BAD4EC6CD2A8A783F255772348E" unitRef="usdPerShare">15.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="INF" id="Fact-F8AAFC740F18489EA5D64006D2D4F5DA" unitRef="shares">25125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-78205FE5801276F117A940023D6EE640" unitRef="usd">771000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="-3" id="Fact-6AE8A93AC9FB7659BE66400216D64C83" unitRef="usd">357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" decimals="2" id="Fact-90E61AF6BB576D681BF84006F63E6E26" unitRef="usdPerShare">24.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-737310743A4CCD067DD5D189FA920DF6" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="INF" id="Fact-1C42B943C40B874C35EDD189FA8114A9" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-3287AB51BD54E66C095BD189FA91691C" unitRef="number">0.5776</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-A6B9A9468D873BDE4DC3D189FA903A8C" unitRef="number">0.5932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-47F46B487691FD8CE69ED189FA901ED6" unitRef="number">0.0265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="4" id="Fact-7CA74F5AACBDEDDC1032D189FA91C1A2" unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q4Nov21" decimals="INF" id="Fact-A95C85B0982354D9488AD189FA841BE6" unitRef="shares">4361291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2019Q4" decimals="INF" id="Fact-588C365CCBA5EE71CA15D189FA8672D9" unitRef="shares">800595</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2019Q4" decimals="2" id="Fact-679BD72172ABB1916398D189FA895DCB" unitRef="usdPerShare">12.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2018Q4YTD" decimals="-3" id="Fact-ED5E713E84F84E185A0E3FF484DEA147" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2019Q4YTD" decimals="-3" id="Fact-D69488B4653C775040143FF463CB1292" unitRef="usd">2311000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2019Q4YTD" decimals="INF" id="Fact-0774B1119E9AAE78E3353F263B45C8B5" unitRef="shares">328117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-61AF1D1114DDF7CA650FD189FA845687" unitRef="shares">34602</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2019Q4YTD" decimals="INF" id="Fact-7EAB6E82CAF3B6A6EF6A3F261F75305C" unitRef="shares">1321451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2018Q4" decimals="-3" id="Fact-3F9C5FAB05535C964E8ED189FA8CDE90" unitRef="usd">7119000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2019Q4" decimals="-3" id="Fact-152BAB4D099ACFF01C9E3F25C4AE7826" unitRef="usd">7198000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2018Q4" decimals="INF" id="Fact-F2D8342A98FCFC6F33E3D189FA894316" unitRef="shares">3257801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2019Q4" decimals="INF" id="Fact-CE840199FE25D2CB526D3F25BAA7ECA0" unitRef="shares">3977401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2018Q4" decimals="2" id="Fact-0E53A4B859C427210D2BD189FA8BB586" unitRef="usdPerShare">11.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2019Q4" decimals="2" id="Fact-EB4FFB2A2BBEFFE3B9723F25BE9ABD7F" unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2019Q4" decimals="-3" id="Fact-C3D7FC300D5A3EAAEAFA3FFB9155A950" unitRef="usd">7198000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2019Q4" decimals="INF" id="Fact-992A4132609820773DFD3FF90A25FBD6" unitRef="shares">3977401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2019Q4" decimals="2" id="Fact-A7FF85B9307E7D424D5A3FF9616ADB30" unitRef="usdPerShare">14.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="D2017Q4Nov21" decimals="INF" id="Fact-5CD71FEEBCFB464DF89DD189FA77FC25" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-7FD23A87E261ABF809BF3F2655F88B84" unitRef="usdPerShare">9.98</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-48594A4FE76A3730E9E13F26624F03A1" unitRef="usdPerShare">15.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2019Q4YTD" decimals="2" id="Fact-07017204F212DA86C5B43F26496A12D9" unitRef="usdPerShare">18.63</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-C3096DBA028CB8BF4A82D189FA83CA8A">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B72CE7CDB053964310623CF5163BB0C3">P6Y2M27D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-00E3115C4314AF387BEAD189FA91FAA7">P6Y2M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2019Q4" decimals="-3" id="Fact-25D78D558EB2372D4F30D189FA837795" unitRef="usd">1880000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q4YTD" id="Fact-FD73529B5D3126DB99E93F2707B104E7">P8Y3M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2018Q4YTD" id="Fact-79715A8D63EE89740B1BD189FA8F0663">P9Y3M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2019Q4YTD" id="Fact-390362DC099EC7A903CE3F25C199404E">P8Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2019Q4YTD" id="Fact-0A04EB1F0C040D6AC7603FF9B80E5835">P8Y6M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-80842305367D9CDDC0C5D189FA8296EE" unitRef="shares">100424</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="D2018Q2_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_srt_ChiefExecutiveOfficerMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" id="Fact-1C2E2D08F7B4ADB39735D189FA827F35" unitRef="shares">50112</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-291B1644BF1C7DC02DE0D189FA7143DE" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-33586B694D855515D30AD189FA6E4DF0" unitRef="shares">27274991</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-C00A854AC8535BBB35A537AA69D45DFE" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-B3D34AFBB69E1776363F37AA7297F187" unitRef="shares">33562665</us-gaap:SharesIssued>
	<us-gaap:ShortTermLeaseCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8D0BA6775B9115BBB961402B9A2F93C6" unitRef="usd">85000</us-gaap:ShortTermLeaseCost>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-6BFE31F778E0387A697D37A6A7F4DEE7" unitRef="shares">-1250000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-7C15F6A7C21C99FB708937A6A7F933CA" unitRef="shares">2065875</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q3Jul01-Jul31" decimals="INF" id="Fact-ED480BD422AD908EA64BD189FA823EAD" unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2018Q3Jul01-Jul31_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember" decimals="INF" id="Fact-FE72512A17C024FC8E30D189FA740D21" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="INF" id="Fact-8A3A5E003F08EB7FB93637A6A7E6CDD6" unitRef="shares">3600000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-F58529D190617A27592637A6A7E1ACE1" unitRef="shares">5047514</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="INF" id="Fact-A87517D396D07D3178ED37ABFC7B5138" unitRef="shares">288124</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="INF" id="Fact-E370D7AFE138F323262237ABEA3E7F20" unitRef="shares">5999550</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2019Q4YTD" decimals="INF" id="Fact-9255CB623E1868E6BE7C3F262EE79362" unitRef="shares">273734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="FD2018Q4YTD" decimals="-3" id="Fact-36C82EF9DCAE6D37970237AD7C4BE248" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-528730A5BD3B0935A65237A6A7EBBD27" unitRef="usd">67379000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-6806CCEF40D54CF9F9C237A6A840A362" unitRef="usd">53445000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-A77899972BA5B28E9D9D37A6A7EF1D41" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-299B1A2A4A5E0D6EDF8BD189FAA6A9CB" unitRef="usd">67379000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2018Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-73FAB38C9EA49072F5F0D189FA70D01E" unitRef="usd">53446000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-2A96E5DB09361B1E36D537AC0526607D" unitRef="usd">2455000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-FBA3E028E9F1722F7DB437ABF2C4625B" unitRef="usd">73022000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_eols_FollowOnOfferingMember" decimals="-3" id="Fact-AB92F317912692F7301737AC0D126BE6" unitRef="usd">2455000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2019Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember" decimals="-3" id="Fact-9D2EFB2B154B068E342637ABFAB54D21" unitRef="usd">73022000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4" decimals="-3" id="Fact-9DA1F2E62C5592B1EE89D189FAA78E70" unitRef="usd">84384000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-1E017755CC8FB6CDA433D189FA8E98E4" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-D1F2C2F3FFCEA111BFD937A6FEE6ECA6" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-411DE8E013C1B48689C0D189FAA5D1DD" unitRef="usd">207408000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-774EDF93EB47AD8410A6D189FAA32F72" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-71C3EC59DCFA49A8D321D189FA8DFCC0" unitRef="usd">-123025000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4" decimals="-3" id="Fact-B1DA59E16F2FA4BFF4E7D189FA9DFD23" unitRef="usd">79457000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementClassOfStockAxis_us-gaap_ConvertiblePreferredStockMember_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" decimals="-3" id="Fact-D879EE1E4FA0F846B05237AA6F0EC80D" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-B51C95DAF65FAA48531037AA79FD6116" unitRef="usd">6000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F01DED77ABD5AC5EDFF937AA77C931BB" unitRef="usd">292509000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-E2960BBF5D2275EDE2B437AA7591C385" unitRef="usd">1000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-9C853176AD21EDA3F08537AA7BE08564" unitRef="usd">-213059000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="D2018Q1Jan1-Jan31" decimals="4" id="Fact-CE1F42E3E3405843F37CD189FA7AF647" unitRef="number">1.6527</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-CB36DFBCC599D34CC06AD189FA8BAF4B" unitRef="usd">1377000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2019Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_StateAndLocalJurisdictionMember_us-gaap_TaxCreditCarryforwardAxis_us-gaap_ResearchMember" decimals="-3" id="Fact-0533DB3A88D05375BF4AD189FA8D5491" unitRef="usd">1383000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-17B77D33863E29A8231DD189FA84A50B" unitRef="usd">2109000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2018Q4" decimals="-3" id="Fact-DDA921EB07BAB1642882D189FA99EF35" unitRef="usd">2435000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2019Q4" decimals="-3" id="Fact-A14DBC83533B3963A691D189FA7F89A3" unitRef="usd">2761000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2018Q4YTD" decimals="-3" id="Fact-185424E7D5E416B730E3D189FA735769" unitRef="usd">326000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2019Q4YTD" decimals="-3" id="Fact-8A69E32B72DB0D3C6CC9D189FA71CF0C" unitRef="usd">326000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="FD2019Q4YTD" decimals="-3" id="Fact-A2CA4FB6D79CB44ECEBD3F1326C13500" unitRef="usd">-15055000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
	<us-gaap:VariableLeaseCost contextRef="FD2019Q4YTD" decimals="-3" id="Fact-18491CF51A46F0AC7A0D402B969CB9F8" unitRef="usd">110000</us-gaap:VariableLeaseCost>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2018Q4YTD" decimals="0" id="Fact-5C6E2CE492973B2377E2D189FA73CA96" unitRef="shares">24402368</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2019Q4YTD" decimals="0" id="Fact-F6F74D6D336EF0AED64FD189FA7C7227" unitRef="shares">28237816</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-3DB8496B274508992A1FD189FA69F4E1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Accrued Expenses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued volume-based rebate and coupon liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;13,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
	<us-gaap:AdvertisingCostsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-5499BC7AB2FA30521A1C59E32B0A2593">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Advertising Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Advertising costs are expensed as incurred and primarily include costs related to social media ads.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-9CD0149D923774FB2E27D189FAAA8DF1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-FEE7E4F4F013B19FB8BF444D24713512">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-086FD3BF0842DF8C3D21D189FAAC2EEE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company leases office facilities under various operating lease agreements. The Company&amp;#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expired on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease commenced on February 1, 2020 and expires on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company may, under certain circumstances, terminate the lease on the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;36&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month anniversary of the lease commencement date by providing a written notice &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; prior to such anniversary and paying a termination fee&amp;#160;equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;60 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; percent&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; annual rent escalation clause that occurs on each June 1 anniversary&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;60 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;sublease&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; income was not significant. Upon signing the sublease, the Company recorded an impairment charge of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$80&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to the right-of-use asset related to the original lease.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&amp;#160;in&amp;#160;determining&amp;#160;if the renewal option is reasonably certain to be exercised.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the components of operating lease expense and other quantitative information were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Fixed operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Variable operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Short-term operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease&amp;#160;expenses were included in the selling, general and administration expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table presents the maturity of the Company&amp;#8217;s operating lease liabilities as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, future minimum payments under the operating lease agreements with non-cancelable terms as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.27777777777779%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total operating lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Less: imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Total rental expense for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$334&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.48412698412699%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Purchase Commitments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,602&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Certain minimum purchase commitments related to the purchase of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; are described below.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License and Supply Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product is manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) in a territory covered by the Daewoong Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company held an option to obtain the therapeutic rights to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in its licensed territories which was held in trust for Alphaeon during the fourth quarter of 2017 for a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reduction in related party borrowings. In September&amp;#160;2018, Alphaeon exercised the right to obtain the therapeutic option to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and remitted the option exercise price directly to Daewoong.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Daewoong Agreement, the Company was obligated to make milestone payments to Daewoong for certain confidential development and commercial milestones associated with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, Daewoong is eligible to receive remaining contingent milestone payments of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&amp;#8217;s future market share in various jurisdictions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Legal Proceedings&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&amp;#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;No&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; amounts were accrued as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Medytox Litigation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&amp;#8220;Medytox&amp;#8221;) originally instituted &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &amp;#167; 3426 because Daewoong&amp;#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&amp;#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp;amp; Prof. Code &amp;#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&amp;#8217;s rights&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;Medytox Litigation&amp;#8221;). &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (v) attorneys&amp;#8217; fees and costs.  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company believes it has meritorious defenses and intends to vigorously defend Medytox&amp;#8217;s claims. The Company is unable to determine the likelihood of success of Medytox&amp;#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&amp;#8217;s ability to carry out its business and which would have a material adverse effect on the Company&amp;#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;ITC Case&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &amp;#8220;Allergan&amp;#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &amp;#8220;ITC&amp;#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is an unfair act. The ITC matter is entitled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;In the Matter of Certain Botulinum Toxin Products&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (the &amp;#8220;ITC Complaint&amp;#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145 (the &amp;#8220;ITC Action&amp;#8221;). The ITC Complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&amp;#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. In January 2020, the three sets of parties to the ITC Action, (i) the Complainants - Allergan and Medytox, (ii) the Respondents - the Company and Daewoong and (iii) the OUII, each submitted pre-hearing briefs to the Administrative Law Judge assigned to the ITC Action setting forth each party&amp;#8217;s positions on the substantive issues prior to the evidentiary hearing.  From February 4-7, 2020, the Administrative Law Judge held an evidentiary hearing on the ITC Action.  An initial determination by the Administrative Law Judge is due by June 5, 2020 and the target date for the final determination by the ITC is October 6, 2020. An adverse ruling by the ITC against either the Company or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; into the United States and a cease and desist order which would bar sales and marketing of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; within the United Sates either of which would materially adversely affect the Company&amp;#8217;s ability to carry out its business and which would have a material adverse effect on the Company&amp;#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm. Even if the Company is successful, the ITC Action may result in reputation damage or other collateral consequences.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Legal Matters&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&amp;#8217;s financial results for that period.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-43250671B1CADD81BFD3D189FAADC16E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Contingent Payment Obligation Payable to the Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon, the Company recognized a contingent royalty obligation payable to the Evolus Founders. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined at each reporting period end and recorded in operating expenses in the statements of operations and comprehensive loss and as a liability in the balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon (See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information), the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the statement of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
	<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="FD2019Q4YTD" id="Fact-83D3312B7A3ACEF30CF537F0A94D7195">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Employee Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company maintains a defined contribution&amp;#160;401(k) plan covering substantially all employees.  On July 1, 2019, the Company began providing matching contributions, which totaled &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$479&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2019Q4YTD" id="Fact-45B5B7CA2CD28D87974E44475B72DD48">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (&amp;#8220;Daewoong&amp;#8221;) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Daewoong Agreement, and Daewoong&amp;#8217;s rights relating to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are subject to litigation. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;for additional information regarding such litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&amp;#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&amp;#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&amp;#8217; ability to pay.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-E0967116211F6FBF876837E33BC84C76">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Oxford Term Loans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On March 15, 2019, the Company entered into a credit facility of up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$100,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; with Oxford. Pursuant to the terms of the credit facility, the lender extended term loans (the &amp;#8220;Term Loans&amp;#8221;), available in &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; advances, to the Company. The first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was funded on the closing date. The second tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month basis and no event of default. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;9.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, or the 30-day U.S. Dollar LIBOR rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;7.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Company agreed to pay interest-only on each tranche funded for the first &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;36 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; until May 2022, which is followed by a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;23&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&amp;#8217;s request, the interest-only period may be extended by an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;12 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to a total of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;48 months&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; followed by an &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-month amortization period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.5%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the full principal amount of the term loans funded (&amp;#8220;Final Payment&amp;#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the amount prepaid if the prepayment occurs thereafter (&amp;#8220;Prepayment Fee&amp;#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&amp;#8217;s expenses and interest at the default rate with respect to any past due amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The credit facility is secured by substantially all of the Company&amp;#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&amp;#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&amp;#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company was in compliance with its debt covenants.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;At the closing date, the Company incurred &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,094&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,205&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in debt discounts and issuance costs related to the Term Loans, respectively. Debt&amp;#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&amp;#160;discounts and issuance costs allocated to the first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The Final Payment on the first tranche of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$75,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,125&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and amortized into interest expense over the life of the term loan. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;11.6%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the principal amounts of long-term debt maturities during each of the next five fiscal years are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total principal payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Unamortized debt discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Long term debt, net of discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;73,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DebtPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-478B84CE454EA0E542314454D4F8B907">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term debt represents the debt balance with Oxford Finance (&amp;#8220;Oxford&amp;#8221;), net of debt issuance costs. See Note 6, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Oxford Term Loans&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&amp;#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
	<us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="FD2019Q4YTD" id="Fact-1BCB144D5BA09A0301DD4046826F62B0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any short-term investments for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all of the Company&amp;#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&amp;#8217;s short-term investments, considered available-for-sale, as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-C85C72693E8FF262100BD189FAA98784">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. For the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueDisclosuresTextBlock contextRef="FD2019Q4YTD" id="Fact-961E72ACCD948A65FD54404574B54D2D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Fair Value Measurements and Short-Term Investments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any short-term investments for the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all of the Company&amp;#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&amp;#8217;s short-term investments, considered available-for-sale, as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gross Unrealized&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Estimated&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; investments had been in a continuous unrealized loss position for more than 12 months, and the Company did &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairments on these securities. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flow method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year anniversary of the first commercial sale of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States, (iii) the discount rate and (iv) the timing of payments. During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company utilized discount rates between &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;16.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;25.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, reflecting changes in the Company&amp;#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of regulatory approval and expected sales. &amp;#160;Significant increases (decreases) in discount rate would result in a significantly lower (higher) fair value measurement, which could impact materially the fair value reported on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Assumption of the royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Other Financial Assets and Liabilities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the fair value of contingent promissory note and long-term debt was estimated to be &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,696&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$76,203&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. The fair value of operating lease liabilities&amp;#160;at &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; approximated their carrying value. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the fair value of contingent promissory note was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$17,181&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2019Q4YTD" id="Fact-484C4DD961E700B7DB2D404789833E3B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, beginning of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,677&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Assumption of the royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,700&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in fair value recorded in operating expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,160&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;10,500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fair value, end of period&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2019Q4YTD" id="Fact-1B80291A6F0B75E6B0E9D189FAA7BC55">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-2DA7FC69E3E273FA2EAC3CD334D9CD14">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Definite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Distribution right&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Capitalized software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;63,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;84,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;80,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;IPR&amp;amp;D**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;    ________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;     *   Intangible assets with indefinite lives have an indeterminable average life.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;** IPR&amp;amp;D is presented as &amp;#8220;intangible assets, net&amp;#8221; in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; that are subject to amortization:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;41,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21,208&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and IPR&amp;amp;D of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56,076&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The IPR&amp;amp;D recognized represents the license and associated distribution right to develop Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the initial term of which expires in September 2023 and is automatically extended for unlimited additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;three&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, up to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13,500&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in additional cash consideration was due to Daewoong based upon the Company&amp;#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;on February 1, 2019, the Company paid Daewoong a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment which increased the cost basis of the IPR&amp;amp;D, and the IPR&amp;amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. In connection with EU approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company paid a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which also increased the cost basis of the distribution right. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company capitalized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,415&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, related to costs of computer software developed for internal use. The software is amortized over a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year period using the straight-line method. For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, total intangible assets amortization expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$3,853&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
	<us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="FD2019Q4YTD" id="Fact-8664D1A08C9F9DE45A19D189FAAB849F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of goodwill for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
	<us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="FD2019Q4YTD" id="Fact-86EA8F6057E1F55A302BD189FAA608A3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in February 2019, the in process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) related to Jeuveau&amp;#174;&amp;#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&amp;#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;upon being placed in service.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of long-lived assets for any periods presented&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-EB0E50FC34911D99E5E3D189FA8EEB73">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total current provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred (benefit) provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(10,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(4,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred (benefit) provision &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total (benefit) provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has federal net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards of $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;179,589&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years do not expire. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:11pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:11pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;the Company has state NOL carryforwards of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$94,118&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which will begin to expire in 2038. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has federal research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) credit carryforwards of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,377&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which will begin to expire in 2034. The Company also has California R&amp;amp;D credit carryforwards of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,383&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which has an indefinite carryforward period. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The NOL and the R&amp;amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon. After the Company left the Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&amp;#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may result in the expiration of NOL and R&amp;amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;amp;D credits generated through  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; are likely to be limited by Section&amp;#160;382 and 383. The Company anticipates that an ownership change as defined under Section&amp;#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&amp;#8217;s ability to utilize its NOL and R&amp;amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&amp;#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&amp;#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&amp;#8217;s NOL and R&amp;amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&amp;#8217;s balance sheet, statement of operations, or cash flows.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net operating losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;42,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other deferred assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent obligation - imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(36,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(32,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;14,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(12,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fixed asset depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in February 2019, the Company&amp;#8217;s IPR&amp;amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset. Accordingly, the Company released &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$15,055&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of its valuation allowance for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The total valuation allowance balance did not significantly change in 2019 due to the increase related to the current year operating loss as offset by the release as discussed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(22,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State income taxes, net of Federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;California NOL write-off&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Revaluation of contingent royalty obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Meals and entertainment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in state tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development tax credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Increases to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&amp;#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&amp;#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&amp;#160;months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; accrued interest and penalties associated with uncertain tax positions as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Company&amp;#8217;s tax returns for all years since inception are open for audit.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-B22FBA8339CFE1618B1ED189FAA8E764">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Prior to the IPO, the Company calculated its income tax amounts using a separate return methodology and presented these amounts as if it were a separate taxpayer from Alphaeon in each jurisdiction. Subsequent to the IPO, the Company has prepared its stand-alone tax return. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&amp;#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&amp;#160;50%&amp;#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InventoryPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-FB7DDAF57C911091D5AB44502BD556F1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&amp;#8209;in, first&amp;#8209;out method with prioritization of the items with the earliest expiration dates.&amp;#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for any periods presented. Adverse changes in assumptions utilized in the Company&amp;#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
	<us-gaap:InvestmentPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-99B9D83FADF98DAFE14B444E2423BE50">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&amp;#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
	<us-gaap:LeaseCostTableTextBlock contextRef="FD2019Q4YTD" id="Fact-DAC8E333560E20D336394029A97DFB2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the components of operating lease expense and other quantitative information were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:17%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Fixed operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Variable operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;110&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Short-term operating lease expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;85&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:17px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average remaining lease term (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Weighted-average discount rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
	<us-gaap:LesseeLeasesPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-C4AED04E26955606A3474452E49C652B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&amp;#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&amp;#8220;ROU&amp;#8221;) asset which represents the Company&amp;#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&amp;#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&amp;#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
	<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-4629FD4695BD0D4188F8402D4B6AC051">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table presents the maturity of the Company&amp;#8217;s operating lease liabilities as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, future minimum payments under the operating lease agreements with non-cancelable terms as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.27777777777779%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:78%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,201&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,205&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,312&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,369&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;114&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total operating lease payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6,459&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Less: imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,366&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Present value of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,093&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-073A9A38C666D90EE6C5D189FAA2E902">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recently Adopted Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&amp;#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&amp;#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&amp;#8217;s financial statements upon adoption on January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740,&amp;#160;Compensation - Stock Compensation - Income Taxes. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09,&amp;#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarified that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8220;ASC 842&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that superseded the lease guidance under&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard required lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allowed companies to continue to use the legacy guidance in ASC 840, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allowed for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying balance sheet, but did not have an impact on the statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recent Pronouncements&amp;#160;Not&amp;#160;Yet Adopted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;(Topic 326)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;: Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&amp;#160;The FASB also subsequently issued ASU No. 2019-04, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&amp;#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 for public business entities, excluding entities eligible to be smaller reporting companies, and early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of determining the effects adoption will have on its financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Intangibles&amp;#8212;Goodwill and Other (Topic 350):&amp;#160;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&amp;#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The update&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In December 2019, the FASB issued&amp;#160;ASU No. 2019-12,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2019-12&amp;#160;eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This ASU also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-EEA4166C2DE082D21361D189FA8065A8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Organization&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Organization and Description of Business&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Evolus, Inc., (&amp;#8220;Evolus&amp;#8221; or the &amp;#8220;Company&amp;#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &amp;#8220;FDA&amp;#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&amp;#8220;EC&amp;#8221;) in September 2019. The product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &amp;#8220;frown lines,&amp;#8221; in adults. The Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States in May 2019 and in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2018, the Company&amp;#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&amp;#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&amp;#8217;s common stock on a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1.6527&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-for-1 basis (the &amp;#8220;Stock Split&amp;#8221;). The Company&amp;#8217;s then-outstanding shares of convertible Series A preferred stock (&amp;#8220;Series A preferred stock&amp;#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts in the accompanying financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, the Company completed its initial public offering (&amp;#8220;IPO&amp;#8221;) and issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5,047,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;shares of common stock, which included the exercise by the underwriters of their option to purchase &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;47,514&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; additional shares of common stock, at an offering price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$12.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56,330&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&amp;#8217;s then-outstanding shares of Series A preferred stock were automatically converted into &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,065,875&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock. In connection with the completion of its IPO, the Company&amp;#8217;s amended and restated certificate of incorporation was further amended and restated to provide for &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;authorized shares of common stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share.   &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Company completed a follow-on public offering and issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3,600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;600,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock, at a price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$67,680&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In November 2019, the Company completed a follow-on public offering and issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;5,999,550&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;782,550&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock, at a price to the public of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13.00&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. The Company received net proceeds of approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$73,315&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, ALPHAEON Corporation (&amp;#8220;Alphaeon&amp;#8221;), which is majority-owned by Strathspey Crown Holdings Group, LLC, formerly known as SCH-AEON, LLC, (&amp;#8220;SCH&amp;#8221;), owned&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;25.8%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;56.0%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;of the Company&amp;#8217;s outstanding shares of common stock, respectively. See Note 11.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt; Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, for more information.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2019 Alphaeon changed its name to AEON Biopharma, Inc. and contributed all of the shares it held in the Company to Alphaeon 1, LLC. The Company continues to refer to the renamed AEON Biopharma, Inc. as &amp;#8220;Alphaeon&amp;#8221; and Alphaeon 1, LLC as &amp;#8220;Alphaeon 1, LLC.&amp;#8221;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Liquidity and Financial Condition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements&amp;#160;have been prepared&amp;#160;on a basis that&amp;#160;assumes that&amp;#160;the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&amp;#8217;s assets and the satisfaction of the Company&amp;#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Since inception, the Company has incurred recurring net operating losses, which include operating losses of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$90,034&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$46,867&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Additionally, the Company used &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$93,383&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$25,667&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in cash for operations in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$109,892&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in cash and cash equivalents plus &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$19,911&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in short-term investments and an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$213,059&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain and expand market acceptance of its product and achieve a level of revenues adequate to support its cost structure and operate its business and sell products without infringing third party intellectual property rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company believes that its current capital resources, which consist of cash, ca&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;sh equivalents and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the incurrence of additional debt allowed under existing debt arrangements, the entry into licensing or collaboration agreements with partners, sale of its equity securities, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="FD2019Q4YTD" id="Fact-825883F41D32E74A9952443D37F2072C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Reclassification&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
	<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-77F29DF55C43BCCDDD23D189FAA64AB1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Services with Alphaeon&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to the Company&amp;#8217;s IPO in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from Alphaeon. For 2018, selling, general and administrative expenses included &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$383&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of expenses allocated by Alphaeon. After completion of the Company&amp;#8217;s IPO, Alphaeon did &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;t incur any administrative or research and development expenses on the Company&amp;#8217;s behalf. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2018, the Company entered into a services agreement with Alphaeon, or the services agreement, which became effective upon the Company&amp;#8217;s IPO. The services agreement sets forth certain agreements between Alphaeon and the Company that governs the respective responsibilities and obligations between Alphaeon and the Company &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;as it relates to the services to be performed between them&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; The services agreement has a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year term and thereafter will renew for successive &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; year terms unless sooner terminated by either party. The Company or Alphaeon may terminate the services agreement upon &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;sixty days&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8217; notice to the other party. In accordance with the services agreement, the Company paid Alphaeon &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; during the first quarter of 2018, subsequent to the IPO. There were no significant services provided under the services agreement after the IPO. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, Evolus had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related party accounts receivable or payable with Alphaeon. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Note Obligation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Pursuant to certain debt transactions entered into by Alphaeon in 2016 and 2017 and guaranty provided by the Company, as a co-obligor to these debt obligations, the Company applied the accounting guidance provided in ASC 405-40, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Obligations Resulting from Joint and Several Liability Arrangements &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;and recorded a note obligation. During the first quarter of 2018, Alphaeon issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$800&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;additional convertible promissory notes, including&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$24&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;convertible promissory notes to the Company&amp;#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the notes increased to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$140,688&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;(&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.5&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; times the total outstanding principal amount of  &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$56,275&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) immediately prior to the IPO. Approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$615&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in excess of the then balance of additional paid-in capital was recorded in accumulated deficit. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2018 immediately prior to its IPO, the Company recorded&amp;#160;an increase of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,051&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in the receivable from Alphaeon with a corresponding increase in additional paid-in capital. The related party receivable balance increased to&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$73,690&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;immediately prior to the IPO. As of February 12, 2018, the Company was released of the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$140,688&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;note obligation for all guaranty and security obligations under the guaranty agreements, and its related party receivable from Alphaeon of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$73,690&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;was settled, resulting in a capital contribution of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$66,998&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Alphaeon&amp;#8217;s security interest in Evolus&amp;#8217; assets was also terminated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain of the Evolus Founders from whom SCH purchased its equity interests included individuals who were previously employed by the Company in operational roles, including the Company&amp;#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Payment Obligations Related to the Acquisition by Alphaeon&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company was acquired by SCH in 2013 and subsequently by its subsidiary, Alphaeon Corporation, by means of a stock purchase agreement (&amp;#8220;Stock Purchase Agreement&amp;#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&amp;#8220;Amended Stock Purchase Agreement&amp;#8221;), and, as a result, effective upon the closing of the Company&amp;#8217;s IPO, the Company assumed all of Alphaeon&amp;#8217;s payment obligations under the Amended Stock Purchase Agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9,200&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;up-front payment upon obtaining FDA approval for Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;for the treatment of glabellar lines which was paid in full in 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, and (iii) a&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$20,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year anniversary of the first commercial sale of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$55,742&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;(comprised of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$39,700&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;related to the contingent royalty obligation payable and&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,042&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;related to the contingent promissory note) as of February 12, 2018. See&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Fair Value Measurements and Short-Term Investments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;for more information about the Company&amp;#8217;s accounting thereof.&amp;#160;In addition, the outstanding related party borrowings from Alphaeon as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from Alphaeon, the fair value of which, as of February 12, 2018, was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$55,742&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,575&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;to certain current and former employees upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in February 2019, including a one-time bonus of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$700&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;paid to the Company&amp;#8217;s Chief Medical Officer and Head of Research &amp;amp; Development.&amp;#160;The payment is included in research and development expenses in the accompanying statements of operations and comprehensive loss for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;30 days&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&amp;#8217; assets, (ii) the exclusive license of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;or the business related to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by Alphaeon or any of its subsidiaries or affiliates constitutes a change-of-control.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&amp;#8220;Tax Indemnity Agreement&amp;#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&amp;#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement from Alphaeon. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&amp;#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (&amp;#8220;Distribution Agreement&amp;#8221;), with Clarion Medical Technologies Inc. (&amp;#8220;Clarion&amp;#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to Clarion in Canada.&amp;#160; Clarion was previously a wholly-owned subsidiary of Alphaeon. However, pursuant to previous agreements among Alphaeon, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind Alphaeon&amp;#8217;s acquisition of Clarion. As a result, Alphaeon owes the equity holders of Clarion an unwinding fee of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$9,600&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;Unwinding Fee&amp;#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee Alphaeon owes. In addition, Alphaeon and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The service revenue related to the sale of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; through Clarion in 2019 was recorded based on terms that were not in the scope of the Distribution Agreement.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2019Q4YTD" id="Fact-A51D185639C73CE9C550D189FAA30191">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&amp;#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-6A60DE5A6804B6AA14EF44598F384C7C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies Accounting Standards Codification 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASC 606&amp;#8221;), to account for revenue generated since the commercial launch of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in May 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;General&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company currently generates product revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States and service revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; through a distribution partner in Canada.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&amp;#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in Canada as it does not control the product before control is transferred to a customer. &amp;#160;The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. For the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company recognized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$688&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of revenue related to Canada sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disaggregation of Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Gross-to-Net Revenue Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company provides customers with trade and volume discounts and prompt pay discounts that are reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Volume-based Rebates - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and purchase volumes. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Coupons - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and future expectations. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the accrued volume-based rebate and coupon liability was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,709&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provisions for rebate and coupon programs were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$12,325&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which were offset by related payments of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,616&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Contract balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any contract assets nor unbilled receivables as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&amp;#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the&amp;#160;year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Collectability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&amp;#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&amp;#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.  The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, allowance for doubtful accounts was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$387&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provision for bad debts was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$387&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and there were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; write-offs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Practical Expedients&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is within one year.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-8FDC69AAB0FAD705DD3FD189FA927ADB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accrued expenses consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued professional services&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,794&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;931&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued payroll and related benefits&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,229&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,577&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued volume-based rebate and coupon liability&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,709&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other accrued expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,228&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;210&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;13,960&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="FD2019Q4YTD" id="Fact-3A03EFAA630E132FF587D189FA90D076">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The current and deferred expense is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total current provision&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred (benefit) provision:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Federal &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(10,299&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(4,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred (benefit) provision &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total (benefit) provision for income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-01BB1A3E6E82005801ABD189FA8C7F15">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The components of deferred tax assets and liabilities were as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net operating losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;42,756&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;27,929&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,430&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other deferred assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,470&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Accrued compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,962&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;608&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent obligation - imputed interest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;199&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;101&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;11&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(36,972&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(32,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;14,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(12,970&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Fixed asset depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(144&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(14,131&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Net deferred income taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2019Q4YTD" id="Fact-7EAD31386C505A317602D189FA890783">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(22,063&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(9,828&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;State income taxes, net of Federal benefit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,905&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,148&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;California NOL write-off&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Revaluation of contingent royalty obligation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,040&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,938&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Meals and entertainment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,002&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Change in state tax rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,371&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Stock compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;521&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;474&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Research and development tax credit&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(294&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Promissory note - debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;128&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;105&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Other, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,691&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Income tax provision (benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(15,027&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2019Q4YTD" id="Fact-7E90F43F5B49953274FDD189FA71ECDA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2019Q4YTD" id="Fact-9CCB0E67BEE72105E2D9404715F2FB42">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Available-for-sale debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;U.S treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;19,911&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;44,683&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December&amp;#160;31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Contingent royalty obligation payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;50,200&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2019Q4YTD" id="Fact-5400D36B93BA14693698D189FAB21CE3">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.48412698412699%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;890&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;139&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:2px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="FD2019Q4YTD" id="Fact-5BEF1B592CF197B2DDD13CD37A230279">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Definite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Distribution right&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;20&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(2,679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,397&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Capitalized software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;4,415&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(1,174&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,241&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Intangible assets, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;63,491&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;59,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible asset&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;84,699&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(3,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;80,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:21%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted-Average Life (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Original Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Accumulated Amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Net Book Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;"&gt;Indefinite-lived intangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;IPR&amp;amp;D**&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;56,076&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;21,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total as of December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;77,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;    ________________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;     *   Intangible assets with indefinite lives have an indeterminable average life.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:8pt;color:#000000;"&gt;** IPR&amp;amp;D is presented as &amp;#8220;intangible assets, net&amp;#8221; in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2019Q4YTD" id="Fact-5FA7826BC742EEC59BD837E3B704030F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the principal amounts of long-term debt maturities during each of the next five fiscal years are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:28%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;26,087&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;39,130&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total principal payments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;75,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Unamortized debt discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(1,492&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Long term debt, net of discounts and issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;73,508&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="FD2019Q4YTD" id="Fact-1F0EB08CAD58A3CE6844448918CD16DE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-D28250C7AD4FDE2B15E3D189FA8ED7F7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of RSUs activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(25,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(19,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;229,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;15.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2019Q4YTD" id="Fact-8F8492343F4D989EB659D189FA7A808B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,321,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(273,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(328,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,977,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;800,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;12.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested and expected to vest, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,977,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2019Q4YTD" id="Fact-A06218E0D076D5899D57D189FA7F6569">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.32%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.76%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.65%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2019Q4YTD" id="Fact-7BBB9DB4FB226BF52D34D189FA8B6272">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;As of December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,109&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Increases to current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;326&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,761&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,435&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="FD2019Q4YTD" id="Fact-667B7421CE9B7C464DBB3CD39EC1B905">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table outlines the estimated future amortization expense related to intangible assets held as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; that are subject to amortization:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:57%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Fiscal year&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,423&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;3,729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2023&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2024&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2,955&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;41,621&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59,638&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2019Q4YTD" id="Fact-8AC563862FBB2CDE1A58D189FAA731C1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2019Q4YTD" id="Fact-116631E6BD7A8A03AEB1D189FAAC81A5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate, and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units (&amp;#8220;RSUs&amp;#8221;) is based on the fair value of the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2019Q4YTD" id="Fact-77D171AC7520DDCA2771D189FAA13D7D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;). &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Reclassification&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&amp;#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&amp;#8217;s actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Risks and Uncertainties&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (&amp;#8220;Daewoong&amp;#8221;) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&amp;#8217;s commercialization of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Daewoong Agreement, and Daewoong&amp;#8217;s rights relating to Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, are subject to litigation. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 7&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;for additional information regarding such litigation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company commercially launched Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&amp;#8217;s business and its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Segment Reporting&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has determined that it operates in a single &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;operating and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;reportable segment. The Company&amp;#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&amp;#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&amp;#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&amp;#8217; ability to pay.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Short-Term Investments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&amp;#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Inventories&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&amp;#8209;in, first&amp;#8209;out method with prioritization of the items with the earliest expiration dates.&amp;#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for any periods presented. Adverse changes in assumptions utilized in the Company&amp;#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 1&amp;#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 2&amp;#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Level 3&amp;#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Goodwill&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;"&gt;Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&amp;#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; reporting unit. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of goodwill for any of the periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Intangible Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Upon FDA approval of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;in February 2019, the in process research and development (&amp;#8220;IPR&amp;amp;D&amp;#8221;) related to Jeuveau&amp;#174;&amp;#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&amp;#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;20 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;two years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;upon being placed in service.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; impairment of long-lived assets for any periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In accordance with Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&amp;#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&amp;#8220;ROU&amp;#8221;) asset which represents the Company&amp;#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&amp;#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&amp;#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Research and Development Expenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&amp;#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Contingent Payment Obligation Payable to the Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon, the Company recognized a contingent royalty obligation payable to the Evolus Founders. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined at each reporting period end and recorded in operating expenses in the statements of operations and comprehensive loss and as a liability in the balance sheets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Contingent Promissory Note Payable to Evolus Founders&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon (See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information), the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the statement of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Long-term Debt&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Long-term debt represents the debt balance with Oxford Finance (&amp;#8220;Oxford&amp;#8221;), net of debt issuance costs. See Note 6, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Oxford Term Loans&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&amp;#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company applies Accounting Standards Codification 606, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (&amp;#8220;ASC 606&amp;#8221;), to account for revenue generated since the commercial launch of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in May 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;General&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company currently generates product revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; in the United States and service revenue from the sale of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174;&lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; through a distribution partner in Canada.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&amp;#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#174; &lt;/sup&gt;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;in Canada as it does not control the product before control is transferred to a customer. &amp;#160;The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. For the year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company recognized &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$688&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of revenue related to Canada sales. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disaggregation of Revenue&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Gross-to-Net Revenue Adjustments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company provides customers with trade and volume discounts and prompt pay discounts that are reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Volume-based Rebates - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and purchase volumes. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Coupons - &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and future expectations. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the accrued volume-based rebate and coupon liability was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,709&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provisions for rebate and coupon programs were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$12,325&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which were offset by related payments of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$10,616&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Contract balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&amp;#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company did not have any contract assets nor unbilled receivables as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. Sales commissions are included in selling, general and administrative expenses when incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&amp;#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the&amp;#160;year ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Collectability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&amp;#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&amp;#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.  The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, allowance for doubtful accounts was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$387&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.  For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, provision for bad debts was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$387&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and there were &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; write-offs.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Practical Expedients&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is within one year.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Stock-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&amp;#8217;s common stock, expected risk-free interest rate, and the option&amp;#8217;s expected life. The fair value of the Company&amp;#8217;s restricted stock units (&amp;#8220;RSUs&amp;#8221;) is based on the fair value of the grant date of the Company&amp;#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Advertising Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Advertising costs are expensed as incurred and primarily include costs related to social media ads. For the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company incurred advertising costs of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,407&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Prior to the IPO, the Company calculated its income tax amounts using a separate return methodology and presented these amounts as if it were a separate taxpayer from Alphaeon in each jurisdiction. Subsequent to the IPO, the Company has prepared its stand-alone tax return. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company&amp;#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&amp;#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&amp;#160;50%&amp;#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. For the years ended &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, excluded from the dilutive net loss per share computation were stock options of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3,977,401&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;3,257,801&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, and non-vested RSUs of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;179,758&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;221,292&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recently Adopted Pronouncements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Disclosure Update and Simplification&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&amp;#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&amp;#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&amp;#8217;s financial statements upon adoption on January 1, 2019.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In July 2018, the Financial Accounting Standards Board (the &amp;#8220;FASB&amp;#8221;) issued&amp;#160;ASU No. 2018-09,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740,&amp;#160;Compensation - Stock Compensation - Income Taxes. The guidance in paragraph 718-740-35-2, as amended by the amendments in&amp;#160;ASU 2016-09,&amp;#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&amp;#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarified that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 842, or &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8220;ASC 842&amp;#8221;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, a new comprehensive lease accounting model that superseded the lease guidance under&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases (Topic 840)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The new accounting standard required lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allowed companies to continue to use the legacy guidance in ASC 840, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allowed for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying balance sheet, but did not have an impact on the statements of operations and comprehensive loss. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:16%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Adjustments Due to the Adoption of ASC 842&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;January 1, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Operating lease right-of-use assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;1,029&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Current portion of operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;916&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Operating lease liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Recent Pronouncements&amp;#160;Not&amp;#160;Yet Adopted&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No. 2016-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;(Topic 326)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;: Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Codification Improvements to Topic 326, Financial Instruments - Credit Losses&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&amp;#160;The FASB also subsequently issued ASU No. 2019-04, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Codification Improvements to Topic 326, Financial Instruments&amp;#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 for public business entities, excluding entities eligible to be smaller reporting companies, and early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of determining the effects adoption will have on its financial statements. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No. 2017-04,&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;&amp;#160;Intangibles&amp;#8212;Goodwill and Other (Topic 350):&amp;#160;Simplifying the Test for Goodwill Impairment&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&amp;#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&amp;#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU 2018-13, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurement (Topic 820): Disclosure Framework &amp;#8212; Changes to the Disclosure Requirements for Fair Value Measurement.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The update&amp;#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&amp;#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In August 2018, the FASB issued&amp;#160;ASU No. 2018-15,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Intangibles-Goodwill and Other-Internal-Use Software: Customer&amp;#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2018-15&amp;#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In December 2019, the FASB issued&amp;#160;ASU No. 2019-12,&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&amp;#160;ASU 2019-12&amp;#160;eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This ASU also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2019Q4YTD" id="Fact-3DA3A1B9C6737023CECCD189FA6D87F0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt;Stockholders&amp;#8217; Equity (Deficit)&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"&gt; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Convertible Series A Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Prior to IPO, the Company had &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,500,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Series A preferred stock&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized, of which &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,250,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were issued and outstanding to Alphaeon. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. In connection with the IPO, all shares of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Series A preferred stock&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were converted into &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,065,875&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized, issued or outstanding as of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Preferred Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;10,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;none&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; were issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The Company has &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; authorized shares of common stock with a par value of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0.00001&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; per share. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;33,562,665&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares were issued and outstanding.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Equity Related Transactions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;As of February 12, 2018, the Company assumed from Alphaeon the revised payment obligations under the Amended Purchase Agreement of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$55,742&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; (comprised of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$39,700&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent royalty obligation and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$16,042&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; related to the contingent promissory note at that date). See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 3&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Fair Value Measurements and Short-Term Investments&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for more information. Pursuant to the Amended Purchase Agreement, Alphaeon agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the services agreement (see Note 11, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;). Additionally, the Company paid &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$5,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; to Alphaeon in satisfaction of a portion of the outstanding related party borrowings (see &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 11&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Related Party Transactions&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;). The remaining balance of related party borrowings of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$13,188&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was recharacterized as a capital contribution from Alphaeon pursuant to the services agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;2017 Omnibus Incentive Plan and Stock-based Compensation Allocation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;On November 21, 2017, t&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;he board of directors and the then-sole stockholder of the Company approved the Company&amp;#8217;s 2017 Omnibus Incentive Plan (the &amp;#8220;Plan&amp;#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&amp;#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4,361,291&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares, plus an annual increase on each anniversary of November 21, 2017 equal to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;4%&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of the total issued and outstanding shares of the Company&amp;#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&amp;#8217;s board of directors). On November 21, 2018 and 2019, an additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,091,000&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;1,337,821&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares, respectively, were reserved under the evergreen provision of the Plan. As of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company has available an aggregate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2,249,380&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock for future issuance under the Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Stock-Based Award Activity and Balances&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Options are granted at exercise prices based on the Company&amp;#8217;s grant date common share price. The restricted stock units (&amp;#8220;RSUs&amp;#8221;) and options generally vest over a &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;one&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-to &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;four&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;-year period. There have been &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;no&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; awards granted with performance conditions or market conditions for the period presented. The options generally have a contractual term of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The Black&amp;#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&amp;#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&amp;#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The significant assumptions used in the Black-Scholes option-pricing are as follows:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Determining Fair Value of the Underlying Common Stock.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;For options awards granted after the completion of the Company&amp;#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&amp;#8217;s common stock was not traded in a public stock market exchange prior to the Company&amp;#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&amp;#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&amp;#8217;s initial public offering, the Board of Directors determined the Company&amp;#8217;s common stock fair market value on as needed basis.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Expected Volatility.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The Company has limited data regarding company&amp;#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Expected Term.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &amp;#8220;plain vanilla&amp;#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&amp;#8209;average expected term of the Company&amp;#8217;s options is approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;six years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Risk&amp;#8209;Free Rate.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The risk&amp;#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&amp;#8209;coupon issues with a term approximately equal to the expected life of the option being valued.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:24px;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"&gt;Dividends.&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;zero&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:20%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;59.32%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;57.76%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.42%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;2.65%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Expected life (years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;6.24&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Dividend yield rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;&amp;#8212;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of stock option activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Aggregate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Exercise&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Contractual&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Intrinsic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Per Share&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Terms (Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,257,801&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;11.99&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;9.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,119&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,321,451&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(273,734&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9.98&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Cancelled/forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(328,117&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;15.15&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,977,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Exercisable, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;800,595&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;12.50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested and expected to vest, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,977,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;14.07&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8.51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;7,198&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. The total intrinsic value of options exercised in the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;was&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$2,311&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;&amp;#160;and&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company recorded expenses related to stock options of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$8,302&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$4,099&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$21,529&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2.6 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;A summary of RSUs activity under the Plan for the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;year ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, is presented below:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Weighted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Restricted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Average&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Grant Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;271,404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;16.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;3,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;18.33&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(25,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;24.81&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;(19,409&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;13.71&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Outstanding, December 31, 2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;229,870&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;15.89&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;During the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company recorded expenses related to restricted stock units of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,216&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,304&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. Total fair value of RSUs vested during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$357&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$771&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;December&amp;#160;31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, there was &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$1,377&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&amp;#160;&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;0.7 years&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;The following table summarizes stock-based compensation expense arising from the above Plan:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:18%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Selling, general and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;8,862&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;5,570&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;1,401&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;9,518&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#333333;"&gt;6,971&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In addition, during the &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;years ended December 31, 2019&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;2018&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, the Company capitalized $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;106&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and $&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;0&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;"&gt;Note 4&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;, &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;"&gt;Goodwill and Intangible Assets&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; for capitalized  software information. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Separation of Service with the Former President and Chief Executive Officer&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;In May 2018, the Company entered into a separation agreement (the &amp;#8220;Separation Agreement&amp;#8221;) with its then President and Chief Executive Officer. Pursuant to the Separation Agreement, the Company modified previously &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;granted stock options resulting in an incremental vesting of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;100,424&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; stock options and related stock-based compensation expense of &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$451&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;. As part of the Separation Agreement, the Company issued &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;34,602&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock net of tax withholding for vested restricted stock units. An additional &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;50,112&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately &lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;$980&lt;/font&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt; and reflected in selling, general and administrative on the statements of operations and comprehensive loss for the year ended December 31, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2019Q4YTD" id="Fact-F9420315EBBA0B4876E0D189FAA16712">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;font style="font-family:Times New Roman;font-size:10pt;color:#000000;"&gt;Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&amp;#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&amp;#8217;s actual results could differ materially from those estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>eols-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.evolus.com/20191231" xmlns:eols="http://www.evolus.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="eols-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedExpenses" roleURI="http://www.evolus.com/role/AccruedExpenses">
        <link:definition>2105100 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.evolus.com/role/AccruedExpensesDetails">
        <link:definition>2405402 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.evolus.com/role/AccruedExpensesTables">
        <link:definition>2305301 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.evolus.com/role/BalanceSheets">
        <link:definition>1001000 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.evolus.com/role/CommitmentsAndContingencies">
        <link:definition>2107100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails">
        <link:definition>2407403 - Disclosure - Commitments and Contingencies - Components of Lease Expense and Other Quantitative Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails">
        <link:definition>2407405 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Non-cancelable Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails">
        <link:definition>2407404 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2">
        <link:definition>2407404 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2407402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2307301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.evolus.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.evolus.com/role/EmployeeBenefitPlan">
        <link:definition>2109100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2409401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestments" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments">
        <link:definition>2103100 - Disclosure - Fair Value Measurements and Short-Term Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>2403403 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails">
        <link:definition>2403404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails">
        <link:definition>2403405 - Disclosure - Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails">
        <link:definition>2403402 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAndShortTermInvestmentsTables" roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables">
        <link:definition>2303301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssets" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets">
        <link:definition>2104100 - Disclosure - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails">
        <link:definition>2404403 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsNarrativeDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails">
        <link:definition>2404404 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>2404402 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillAndIntangibleAssetsTables" roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables">
        <link:definition>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.evolus.com/role/IncomeTaxes">
        <link:definition>2110100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails">
        <link:definition>2410402 - Disclosure - Income Taxes - Components of Current and Deferred Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>2410404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>2410403 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfEffectiveTaxDetails" roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails">
        <link:definition>2410405 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.evolus.com/role/IncomeTaxesTables">
        <link:definition>2310301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>2410406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.evolus.com/role/Organization">
        <link:definition>2101100 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.evolus.com/role/OrganizationDetails">
        <link:definition>2401401 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoans" roleURI="http://www.evolus.com/role/OxfordTermLoans">
        <link:definition>2106100 - Disclosure - Oxford Term Loans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansMaturitiesOfDebtDetails" roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails">
        <link:definition>2406403 - Disclosure - Oxford Term Loans - Maturities of Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansNarrativeDetails" roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails">
        <link:definition>2406402 - Disclosure - Oxford Term Loans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OxfordTermLoansTables" roleURI="http://www.evolus.com/role/OxfordTermLoansTables">
        <link:definition>2306301 - Disclosure - Oxford Term Loans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.evolus.com/role/RelatedPartyTransactions">
        <link:definition>2111100 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsDetails" roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails">
        <link:definition>2411401 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfCashFlows" roleURI="http://www.evolus.com/role/StatementsOfCashFlows">
        <link:definition>1004000 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsOfStockholdersEquityDeficit" roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.evolus.com/role/StockholdersEquityDeficit">
        <link:definition>2108100 - Disclosure - Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitKeyValuationAssumptionsDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails">
        <link:definition>2408403 - Disclosure - Stockholders' Equity (Deficit) - Key Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitNarrativeDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails">
        <link:definition>2408402 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails">
        <link:definition>2408405 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails">
        <link:definition>2408404 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitStockBasedCompensationExpenseDetails" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails">
        <link:definition>2408406 - Disclosure - Stockholders' Equity (Deficit) - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables">
        <link:definition>2308301 - Disclosure - Stockholders' Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of ASC 842 on Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="eols_ALPHAEONMember" name="ALPHAEONMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_AccountsPayablePaidbyParent" name="AccountsPayablePaidbyParent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" name="AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_AllocatedShareBasedCompensationExpenseCapitalized" name="AllocatedShareBasedCompensationExpenseCapitalized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ApplicableRateMember" name="ApplicableRateMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessAcquisitionUnwindingFee" name="BusinessAcquisitionUnwindingFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" name="BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionConvertibleNoteWriteOff" name="CapitalContributionConvertibleNoteWriteOff" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionForgivenessofRelatedPartyBorrowings" name="CapitalContributionForgivenessofRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" name="CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ChiefMedicalOfficerMember" name="ChiefMedicalOfficerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_ContingentPromissoryNote" name="ContingentPromissoryNote" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentRoyaltyObligation" name="ContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_ContingentRoyaltyObligationMember" name="ContingentRoyaltyObligationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" name="ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="eols_DaewoongMember" name="DaewoongMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalAmortizationPeriod" name="DebtInstrumentAdditionalAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" name="DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentAmortizationPeriod" name="DebtInstrumentAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentDefaultInterestRate" name="DebtInstrumentDefaultInterestRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" name="DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPeriodOfInterestOnlyPayments" name="DebtInstrumentPeriodOfInterestOnlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" name="DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageThereafter" name="DebtInstrumentPrepaymentFeePercentageThereafter" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentPrepaymentFeePercentageYearTwo" name="DebtInstrumentPrepaymentFeePercentageYearTwo" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_DebtInstrumentTermAggregatePeriod" name="DebtInstrumentTermAggregatePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" name="DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_DeferredTaxAssets.OperatingLeaseLiabilities" name="DeferredTaxAssets.OperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" name="DeferredTaxAssetsPromissoryNoteDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="eols_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount" name="EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" name="EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" name="EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_EvolusIncMember" name="EvolusIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_FollowOnOfferingMember" name="FollowOnOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_IntangibleAssetsGrossIncludingGoodwill" name="IntangibleAssetsGrossIncludingGoodwill" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" name="LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" name="LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LesseeOperatingLeaseTerminationPeriod" name="LesseeOperatingLeaseTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_LineofCreditFacilityNumberofAdvances" name="LineofCreditFacilityNumberofAdvances" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn" name="LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_MilestonePaymentCurrent" name="MilestonePaymentCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" name="MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_MilestonePaymentsForIntangibleAssets" name="MilestonePaymentsForIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashAccruedandUnpaidOfferingCosts" name="NonCashAccruedandUnpaidOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashDeferredOfferingCosts" name="NonCashDeferredOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashFinanceAndInsurancePayment" name="NonCashFinanceAndInsurancePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashLandlordPaidTenantImprovement" name="NonCashLandlordPaidTenantImprovement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashNoteObligation" name="NonCashNoteObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyBorrowings" name="NonCashRelatedPartyBorrowings" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_NonCashRelatedPartyReceivable" name="NonCashRelatedPartyReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_OperatingLeasePercentageOfAnnualRentEscalation" name="OperatingLeasePercentageOfAnnualRentEscalation" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_OperatingLeaseRightofUseAssetAmortization" name="OperatingLeaseRightofUseAssetAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_OxfordTermLoansMember" name="OxfordTermLoansMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_PaymentsOfContingentRoyaltyObligation" name="PaymentsOfContingentRoyaltyObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" name="ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_ProvisionsForRebateAndCouponPrograms" name="ProvisionsForRebateAndCouponPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="eols_RebatesAndCouponsCreditsAndPayments" name="RebatesAndCouponsCreditsAndPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier" name="RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" name="RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionPeriodToNotifyTermination" name="RelatedPartyTransactionPeriodToNotifyTermination" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionRenewalPeriodOption" name="RelatedPartyTransactionRenewalPeriodOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RelatedPartyTransactionTermOfAgreement" name="RelatedPartyTransactionTermOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_RestrictedStockUnitsRSUsMarketConditionsMember" name="RestrictedStockUnitsRSUsMarketConditionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" name="RestrictedStockUnitsRSUsPerformanceConditionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_RevaluationofContingentRoyaltyObligationPayable" name="RevaluationofContingentRoyaltyObligationPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SCHAEONLLCMember" name="SCHAEONLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" name="SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" name="StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" name="StockPurchaseAgreementPeriodAvailabletoCureBreach" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityMember" name="TermLoanFacilityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheOneMember" name="TermLoanFacilityTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="eols_TermLoanFacilityTrancheTwoMember" name="TermLoanFacilityTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>eols-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20191231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20191231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20191231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20191231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:href="eols-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:href="eols-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:href="eols-20191231.xsd#IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20191231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20191231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20191231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20191231.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20191231.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20191231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_3aae0f17-e5b2-b861-7c74-9a4f42f6d1c8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_E754E14F28AC8608998C0F0534F87B76" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_eols_MilestonePaymentCurrent_E754E14F28AC8608998C0F0534F87B76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_9a34fc5e-00bc-420c-8698-6e19b92b8e39" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c90cf113-b51b-4312-22d0-4adb9883d309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_102cf023-53db-cf58-02b1-453717351e05" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_102cf023-53db-cf58-02b1-453717351e05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_6006a94d-54bf-b592-67ad-cc2e5783ac49" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractualObligation_6006a94d-54bf-b592-67ad-cc2e5783ac49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermNotesPayable_622e5770-f948-044b-c6fe-ee319e65b163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_5d3f3f8e-8f06-ee35-6076-a0312a3c4f12" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_4efa230c-b1e9-e41e-ae56-b6a8565f3216" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_ShortTermLeaseCost_4efa230c-b1e9-e41e-ae56-b6a8565f3216" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_4cf71329-74d6-54f3-cadb-acb7f1063f36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_f2a573e7-27e5-db11-63c6-c460733b5ea3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_acfb1bbb-4a5b-18c4-ab71-d62ae0aecfa0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_398384fb-b756-b11a-1ea4-5a5cd4372c82" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_5ad4ca01-bc52-b198-b1fd-3cded668d167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9D5B65A12CC7D3B1F19A40305C4D6F55_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9D5B65A12CC7D3B1F19A40305C4D6F55_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9D5B65A12CC7D3B1F19A40305C4D6F55_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_9D5B65A12CC7D3B1F19A40305C4D6F55_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_9D5B65A12CC7D3B1F19A40305C4D6F55_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9D5B65A12CC7D3B1F19A40305C4D6F55_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_9D5B65A12CC7D3B1F19A40305C4D6F55_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_cddb4eb0-3110-27ee-28d5-5d7adef4fa0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_52d5fc42-d7bd-e657-728c-68a54a8a27d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_28209536-91f9-47af-f5bd-6accbeed43b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_716ff456-95a9-c7d8-efd5-2047c2ac3646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_db859267-14f1-73e3-47c3-03bfc9627628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa802f8f-3c6f-18ed-005d-e578d38097d8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_0572c4a5-7251-883f-b3a9-f968acd71b9b" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_93d4f69b-bb72-4f0f-9406-4537174ecb08" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ad87dc87-7206-5d76-a1ae-6cecdf90521c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e577292a-42b5-1be6-5996-8a37e2ebd0b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_e577292a-42b5-1be6-5996-8a37e2ebd0b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_bc5d002e-802f-bf1e-7d7d-9f1d1a7551a7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_de5e795f-0165-d088-d22e-d01ff8d44317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_1770a893-e2f5-e155-b9aa-1c85cb05acb7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_1770a893-e2f5-e155-b9aa-1c85cb05acb7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_0457699b-36d5-f4cb-6bc8-bda776d56433" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_0457699b-36d5-f4cb-6bc8-bda776d56433" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssets.OperatingLeaseLiabilities" xlink:label="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8321FAC05F7242F2896B37F66350D360" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8321FAC05F7242F2896B37F66350D360" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_2ecf77b9-2735-2d5a-c306-d18a0bd7794e" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_2ecf77b9-2735-2d5a-c306-d18a0bd7794e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_7c7e16b8-0aa9-c1c4-f1b1-272374ca83dc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f57a32ed-0dd0-7e89-043f-8fdc81833b87" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_63B098D854BB4D81624E59F9E467C316" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_63B098D854BB4D81624E59F9E467C316" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_e944ee89-4dbe-bfef-c5af-d18a0bde65b1" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_e944ee89-4dbe-bfef-c5af-d18a0bde65b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_28149ac0-ff6d-6d38-8b4d-ae09bb2e6aba" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_28149ac0-ff6d-6d38-8b4d-ae09bb2e6aba" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_05cc23a1-95bf-5dfd-ffdf-58b097230187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2998d3ea-3247-4459-9f66-28bd5dfb1499" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3c49146a-876e-0398-a795-05386dec675e" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_3c49146a-876e-0398-a795-05386dec675e" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_d6444208-2394-1b12-7711-d18a0c0c1d89" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_d6444208-2394-1b12-7711-d18a0c0c1d89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_8d25b0ea-f9f8-14f7-abf9-3dfa730bde24" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_8d25b0ea-f9f8-14f7-abf9-3dfa730bde24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_a0223de0-196e-53c5-0690-f9f0d2ab9105" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_d39bb101-f79f-a162-9929-01083e9d64b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_73238937-86a2-9126-69f0-c70629155ebe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_a170264f-50ba-a4bb-6d22-ec86b5249633" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_a2f199ce-3001-c200-d488-633bc54206dc" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_1324f141-ce07-0f4a-07d6-453716b79def" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_1324f141-ce07-0f4a-07d6-453716b79def" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_f1e7c55e-b4d6-3af1-4bcc-453716ee9972" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_f1e7c55e-b4d6-3af1-4bcc-453716ee9972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_d03b640f-8d2c-4108-a1c4-1354103a7ee2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_505a1499-71a2-e5de-2af8-1565f94fa52c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0f0975d6-8500-76a0-c74f-5d2f0ed8b620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_5df585f7-cbd5-fdda-5710-23eacb1392b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_88656187-4ecc-4d4b-14df-6b01b08b0a04" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_88656187-4ecc-4d4b-14df-6b01b08b0a04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e79de075-60b8-fab9-9c8a-37a71e0e62c4" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_e79de075-60b8-fab9-9c8a-37a71e0e62c4" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_a482a123-1352-4128-24cb-453716c9e689" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_a482a123-1352-4128-24cb-453716c9e689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_7E8077638A4E4DB0052BFF155B36F5EF" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_7E8077638A4E4DB0052BFF155B36F5EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_5ae19a9f-6de6-075a-2c5a-a587d82ebad5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_5ae19a9f-6de6-075a-2c5a-a587d82ebad5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_94f5ae99-7bd8-4f8c-5311-9522abc2f1bd" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_f368600e-2db9-0e21-7449-4537170a9edc" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_f368600e-2db9-0e21-7449-4537170a9edc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c839a0d8-dfea-e1a5-fc91-ef95e7aed9cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64118bb2-1b72-460a-8e47-0026dedd2749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="13" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c8705fc2-a98a-ac1d-2832-812bd5cae0da" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_3a69f7b9-9eab-d9e6-5159-4537173f08bb" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_3a69f7b9-9eab-d9e6-5159-4537173f08bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_63533ece-96f1-cea4-48da-7ccc623599bb" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_63533ece-96f1-cea4-48da-7ccc623599bb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="locator" />
    <link:calculationArc order="18" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_834a7bf3-d1ec-a251-04d2-cec093e0f492" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_762299f1-2b7a-2409-b4a1-e33b683b691b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForSoftware_762299f1-2b7a-2409-b4a1-e33b683b691b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d3769ff7-3f7d-8a64-ea69-f16e64d6f178" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_36fa2e8f-8278-9ee7-fcfb-31ef0fe41d05" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_98c25af7-47ba-69a3-12c4-e52bd51b359e" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8db01d6d-ae17-523f-94b9-8ab4add4a22e" xlink:to="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef2ac9e8-006f-b467-3389-9a8ceec4bee5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_37156f95-f408-4ced-ed0b-4537172001d7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_37156f95-f408-4ced-ed0b-4537172001d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_56807cce-1c23-b2ed-01fd-e029fa0d6e79" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_b6bcc6f9-d6bd-b7ec-6d33-5c8babf7b60a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_InvestmentIncomeNet_b6bcc6f9-d6bd-b7ec-6d33-5c8babf7b60a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_e88bd855-1cc4-7d92-7586-c29e344f0391" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>eols-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20191231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20191231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20191231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20191231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:href="eols-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:href="eols-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:href="eols-20191231.xsd#IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20191231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20191231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20191231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20191231.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20191231.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20191231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:to="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:to="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:to="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_CCEB575D6E2ECF84D44F4FE7F1F3B86A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:to="loc_eols_ALPHAEONMember_CCEB575D6E2ECF84D44F4FE7F1F3B86A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:to="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_991893C445B952775E914202FBF9252C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_991893C445B952775E914202FBF9252C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6B107CBC491C8A0E0B854202FBFD1665" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6B107CBC491C8A0E0B854202FBFD1665" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:to="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:to="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DD38549E9375EC729C434061A7B84C43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:to="loc_srt_MinimumMember_DD38549E9375EC729C434061A7B84C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E9C04F5C030AEB671BF34061A7B85572" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:to="loc_srt_MaximumMember_E9C04F5C030AEB671BF34061A7B85572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:to="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_FA164A233A76A29AF0A54061A7B7930C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:to="loc_eols_ContingentRoyaltyObligationMember_FA164A233A76A29AF0A54061A7B7930C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:to="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_FF8D711C2AC701938E074FE7F29944FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:to="loc_us-gaap_DistributionRightsMember_FF8D711C2AC701938E074FE7F29944FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_71DC9238896B324CB5204FE7F299ABA4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_71DC9238896B324CB5204FE7F299ABA4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:to="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:to="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_A09DB7308CAE5C03E8774FE7F29901B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:to="loc_eols_SCHAEONLLCMember_A09DB7308CAE5C03E8774FE7F29901B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_77277D586B423145C4FE4FE7F29A792B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:to="loc_eols_EvolusIncMember_77277D586B423145C4FE4FE7F29A792B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_114B17F343722B87696B4FE7F2A12CE1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_114B17F343722B87696B4FE7F2A12CE1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_93C9958B3628AFA5F816456D3F97F1F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:to="loc_us-gaap_DistributionRightsMember_93C9958B3628AFA5F816456D3F97F1F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C1FFA267D2257C4D4D95456D3F99C448" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C1FFA267D2257C4D4D95456D3F99C448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:to="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:to="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:to="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:to="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:to="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A7D109EF0CC157C7A1756E09AFD76CD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:to="loc_us-gaap_CommonStockMember_A7D109EF0CC157C7A1756E09AFD76CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:to="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:to="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_2C1D11FC774BB160FF276E09AFD71A0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_2C1D11FC774BB160FF276E09AFD71A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_CC4E2BD447F9D4007EC16E09AFD81221" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:to="loc_us-gaap_CommonStockMember_CC4E2BD447F9D4007EC16E09AFD81221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F5763E841A11745967DF6E09AFD833B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_us-gaap_IPOMember_F5763E841A11745967DF6E09AFD833B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_479C70B485B027858E526E09AFD92CF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_eols_FollowOnOfferingMember_479C70B485B027858E526E09AFD92CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:to="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:to="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_E69FCFF26FA727628C926E09AFD9612D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:to="loc_us-gaap_MajorityShareholderMember_E69FCFF26FA727628C926E09AFD9612D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:to="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:to="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_6FB1FB484B63509A39186E09AFDABEAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:to="loc_eols_EvolusIncMember_6FB1FB484B63509A39186E09AFDABEAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ECC0271B996522CE6276E09AFDB1F2C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ECC0271B996522CE6276E09AFDB1F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_30E61DD087A80987D5106E09AFDB3EBE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_30E61DD087A80987D5106E09AFDB3EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16E24C1233B73D53FC356E09AFDBD21D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16E24C1233B73D53FC356E09AFDBD21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2B6CCCFBA0FC9885D60D6E09AFDC89B4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2B6CCCFBA0FC9885D60D6E09AFDC89B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4192852621EE02B9773D6E09AFDC0B98" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4192852621EE02B9773D6E09AFDC0B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E18AD2EE401E40C79F856E09AFDC9A16" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E18AD2EE401E40C79F856E09AFDC9A16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:to="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:to="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:to="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:to="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityNumberofAdvances" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn" xlink:label="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C31F4BE997D98BC763EA59C60538FA9C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C31F4BE997D98BC763EA59C60538FA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_21848454996622A6BEE059C60538CF0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:to="loc_eols_EvolusIncMember_21848454996622A6BEE059C60538CF0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:to="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:to="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_D3874B239256FEF4E01F59C605398033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:to="loc_eols_ALPHAEONMember_D3874B239256FEF4E01F59C605398033" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_901B1590EFA47E008D9B59C605391572" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:to="loc_eols_SCHAEONLLCMember_901B1590EFA47E008D9B59C605391572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_41FB8BA5146529B97E5159C6053A99CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:to="loc_eols_ALPHAEONMember_41FB8BA5146529B97E5159C6053A99CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:to="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:to="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_5855FE3A101F43F0507359C6053BBE82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_us-gaap_MajorityShareholderMember_5855FE3A101F43F0507359C6053BBE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7B5A54BC2DD27F56BC1959C6053BB80D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7B5A54BC2DD27F56BC1959C6053BB80D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_BC3075E960618E41F87959C6053B9503" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_BC3075E960618E41F87959C6053B9503" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodToNotifyTermination" xlink:label="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_E610E3606E8749797A7B59C6053CA531" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_E610E3606E8749797A7B59C6053CA531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier" xlink:label="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82FA3CF52F03072A636559C6053D100C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82FA3CF52F03072A636559C6053D100C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_D3A9FC05EEB3783724F859C6053D7837" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_ContractualObligation_D3A9FC05EEB3783724F859C6053D7837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2A8B2C5AB2AEF41C551059C6053E4992" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_LongTermNotesPayable_2A8B2C5AB2AEF41C551059C6053E4992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:to="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:to="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:to="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:to="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:to="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:to="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:to="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:to="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:to="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9C36EBA3F1EE43A4768677A0A62E5BF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_CommonStockMember_9C36EBA3F1EE43A4768677A0A62E5BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:to="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:to="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F9092F5AE0263C4EC77F77A0A62FEE38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:to="loc_us-gaap_IPOMember_F9092F5AE0263C4EC77F77A0A62FEE38" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:to="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6CD082C6AB600E5428C277A0A632F0D8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_NetIncomeLoss_6CD082C6AB600E5428C277A0A632F0D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:to="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61C2923B2A69C6E951EC6E18936029FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61C2923B2A69C6E951EC6E18936029FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:to="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:to="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:to="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:to="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:to="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:to="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:to="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:to="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:to="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:to="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:to="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:to="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:to="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:to="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:to="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:to="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:to="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:to="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:to="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:to="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:to="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:to="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_016CAB1479A0E97E362A3FF439DD4BB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_016CAB1479A0E97E362A3FF439DD4BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04121FB646376B2BEAB23FF4380DBEA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04121FB646376B2BEAB23FF4380DBEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:to="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:to="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_31903B0AA2200DB6D5A36E1894646FA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:to="loc_us-gaap_ServiceMember_31903B0AA2200DB6D5A36E1894646FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C42204A21801ADE553496E189465CFE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C42204A21801ADE553496E189465CFE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_442598D319412C089EA56E1894655F17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_442598D319412C089EA56E1894655F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:to="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:to="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:to="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:to="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_15837CED174F1583224B6E189468395D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_15837CED174F1583224B6E189468395D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RebatesAndCouponsCreditsAndPayments" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_E92CA6DED8516F550B456E1894694CC7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_E92CA6DED8516F550B456E1894694CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs" xlink:label="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>eols-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Estimated Future Amortization Expense of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:to="lab_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:to="lab_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assumption of the royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="arc" />
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399_verboseLabel_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value recorded in operating expenses</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399_label_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable</link:label>
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399_documentation_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revaluation of Contingent Royalty Obligation Payable</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:to="lab_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain (Loss), before Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Investments Available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="lab_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled/forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153_terseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average remaining contractual term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:to="lab_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:to="lab_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:to="lab_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:to="lab_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3_verboseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134_label_en-US" xlink:label="lab_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:to="lab_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_88059676A71BC67A61757796C8B8B223_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_88059676A71BC67A61757796C8B8B223_label_en-US" xlink:label="lab_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:to="lab_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_925F2865C17D991E914C7796C8B87385_terseLabel_en-US" xlink:label="lab_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_925F2865C17D991E914C7796C8B87385_label_en-US" xlink:label="lab_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:to="lab_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3_label_en-US" xlink:label="lab_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:to="lab_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829_label_en-US" xlink:label="lab_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:to="lab_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E_label_en-US" xlink:label="lab_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:to="lab_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83_label_en-US" xlink:label="lab_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:to="lab_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="arc" />
    <link:label id="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1_terseLabel_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SCH</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1_label_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:label id="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1_documentation_en-US" xlink:label="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SCH-AEON, LLC [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:to="lab_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="arc" />
    <link:label id="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83_terseLabel_en-US" xlink:label="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ALPHAEON</link:label>
    <link:label id="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83_label_en-US" xlink:label="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:label id="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83_documentation_en-US" xlink:label="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ALPHAEON [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:to="lab_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="arc" />
    <link:label id="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B_terseLabel_en-US" xlink:label="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Evolus, Inc.</link:label>
    <link:label id="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B_label_en-US" xlink:label="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:label id="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B_documentation_en-US" xlink:label="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Evolus, Inc [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:to="lab_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987_label_en-US" xlink:label="lab_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:to="lab_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4_label_en-US" xlink:label="lab_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:to="lab_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:to="lab_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98_terseLabel_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Majority Shareholder</link:label>
    <link:label id="lab_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98_label_en-US" xlink:label="lab_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Majority Shareholder [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:to="lab_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="arc" />
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:to="lab_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:to="lab_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:to="lab_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="arc" />
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs Performance Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Performance Conditions</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:to="lab_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="arc" />
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA_terseLabel_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs Market Conditions</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA_label_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions [Member]</link:label>
    <link:label id="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA_documentation_en-US" xlink:label="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs), Market Conditions</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:to="lab_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="lab_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:to="lab_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares of convertible preferred stock converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:to="lab_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction amount in period</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:to="lab_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2_label_en-US" xlink:label="lab_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:to="lab_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:to="lab_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments on related party borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6_label_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6_documentation_en-US" xlink:label="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Forgiveness of Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:to="lab_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares authorized under the plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase percentage of maximum shares outstanding (equal to)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="arc" />
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C_terseLabel_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C_label_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C_documentation_en-US" xlink:label="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:to="lab_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contractual term of options</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="arc" />
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C_verboseLabel_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average expected term of options</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C_label_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:label id="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C_documentation_en-US" xlink:label="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:to="lab_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield rate of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of options exercised in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock option costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period for unrecognized costs to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of awards vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized costs other than options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="arc" />
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59_terseLabel_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation expense</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59_label_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:label id="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59_documentation_en-US" xlink:label="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allocated Share-Based Compensation Expense Capitalized</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:to="lab_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares vested (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:to="lab_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:to="lab_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:type="arc" />
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E_terseLabel_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisions for rebate and coupon programs</link:label>
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E_label_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provisions For Rebate And Coupon Programs</link:label>
    <link:label id="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E_documentation_en-US" xlink:label="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provisions For Rebate And Coupon Programs</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:to="lab_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for bad debts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of discount on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:type="arc" />
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49_terseLabel_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49_label_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label id="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49_documentation_en-US" xlink:label="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:to="lab_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:type="arc" />
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D_terseLabel_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D_label_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D_documentation_en-US" xlink:label="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Operating Lease Liabilities</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:to="lab_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Additions to capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83_label_en-US" xlink:label="lab_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Software</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:to="lab_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:type="arc" />
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4_negatedTerseLabel_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of contingent royalty obligation to Evolus Founders</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4_label_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4_documentation_en-US" xlink:label="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:to="lab_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E_negatedTerseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for intangible assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E_label_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E_documentation_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payments For Intangible Assets</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt, net of discounts</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment for debt obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from follow-on offering, net of underwriting fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Related Party Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments on related party borrowings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:to="lab_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:type="arc" />
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E_terseLabel_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with incentive equity plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E_label_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:label id="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E_documentation_en-US" xlink:label="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:to="lab_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:to="lab_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:to="lab_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash investing and financing information:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875_terseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non Cash Related Party Receivable</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:to="lab_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E_label_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E_documentation_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Related Party Borrowings</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:to="lab_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:type="arc" />
    <link:label id="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Note obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E_label_en-US" xlink:label="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:label id="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E_documentation_en-US" xlink:label="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Note Obligation</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:to="lab_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:to="lab_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:type="arc" />
    <link:label id="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1_terseLabel_en-US" xlink:label="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1_label_en-US" xlink:label="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:label id="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1_documentation_en-US" xlink:label="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Promissory Note</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:to="lab_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A_label_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:label id="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A_documentation_en-US" xlink:label="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution, Convertible Note Write-Off</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:to="lab_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:type="arc" />
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0_negatedTerseLabel_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0_label_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:label id="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0_documentation_en-US" xlink:label="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Deferred Offering Costs</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:to="lab_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:type="arc" />
    <link:label id="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4_negatedTerseLabel_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable, paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4_label_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:label id="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4_documentation_en-US" xlink:label="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Paid by Parent</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:to="lab_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:type="arc" />
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268_terseLabel_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Landlord paid tenant improvements</link:label>
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268_label_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Landlord Paid Tenant Improvement</link:label>
    <link:label id="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268_documentation_en-US" xlink:label="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Landlord Paid Tenant Improvement</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashLandlordPaidTenantImprovement" xlink:label="loc_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:to="lab_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:type="arc" />
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3_terseLabel_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financed D &amp; O insurance payment</link:label>
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3_label_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Finance And Insurance Payment</link:label>
    <link:label id="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3_documentation_en-US" xlink:label="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Finance And Insurance Payment</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashFinanceAndInsurancePayment" xlink:label="loc_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:to="lab_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized software recorded in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:type="arc" />
    <link:label id="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB_negatedLabel_en-US" xlink:label="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accrued offering costs, unpaid</link:label>
    <link:label id="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB_label_en-US" xlink:label="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Accrued and Unpaid Offering Costs</link:label>
    <link:label id="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB_documentation_en-US" xlink:label="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Accrued and Unpaid Offering Costs</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashAccruedandUnpaidOfferingCosts" xlink:label="loc_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:to="lab_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Options Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of RSUs Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements and Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="lab_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:to="lab_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:to="lab_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5_label_en-US" xlink:label="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:to="lab_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931_terseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First tranche</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche One [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:to="lab_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="arc" />
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278_verboseLabel_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Second tranche</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278_label_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278_documentation_en-US" xlink:label="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan Facility, Tranche Two [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:to="lab_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:to="lab_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:to="lab_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="arc" />
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIBOR</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="arc" />
    <link:label id="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F_terseLabel_en-US" xlink:label="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Applicable Rate</link:label>
    <link:label id="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F_label_en-US" xlink:label="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:label id="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F_documentation_en-US" xlink:label="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Applicable Rate [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:to="lab_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="lab_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="arc" />
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05_terseLabel_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05_label_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:label id="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05_documentation_en-US" xlink:label="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Number of Advances</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityNumberofAdvances" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:to="lab_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="arc" />
    <link:label id="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889_terseLabel_en-US" xlink:label="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to achieve net sales milestone before second drawn</link:label>
    <link:label id="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889_label_en-US" xlink:label="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Period to Achieve Minimum Net Sales Milestone Before Second Drawn</link:label>
    <link:label id="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889_documentation_en-US" xlink:label="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Period to Achieve Minimum Net Sales Milestone Before Second Drawn</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn" xlink:label="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:to="lab_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate on debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of interest only payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50_label_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:label id="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Period Of Interest Only Payments</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:to="lab_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B_label_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Amortization Period</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:to="lab_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional period of agreement of interest payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Period Of Agreement Of Interest Payment</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:to="lab_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate period</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4_label_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:label id="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4_documentation_en-US" xlink:label="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Aggregate Period</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:to="lab_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional amortization period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9_label_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:label id="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9_documentation_en-US" xlink:label="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Additional Amortization Period</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:to="lab_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of final payment of full principal amount</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472_label_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:label id="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Percentage Of Principal Amount, Balloon Payment</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:to="lab_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, next twelve months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, year two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Year Two</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment fee percentage, thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3_label_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:label id="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3_documentation_en-US" xlink:label="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Prepayment Fee Percentage, Thereafter</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:to="lab_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="arc" />
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E_terseLabel_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Default interest rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E_label_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:label id="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E_documentation_en-US" xlink:label="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Interest Rate</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:to="lab_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:to="lab_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment amortized into interest expense over the life of the term loan</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:to="lab_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating leases, future minimum payments due</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Impact of Adoption of ASC 842 on the Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:to="lab_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments Due to the Adoption of ASC 842</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A_label_en-US" xlink:label="lab_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="lab_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:to="lab_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Gain</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:to="lab_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="arc" />
    <link:label id="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A_terseLabel_en-US" xlink:label="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Follow-on Offering</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A_label_en-US" xlink:label="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:label id="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A_documentation_en-US" xlink:label="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Follow-On Offering [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:to="lab_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:to="lab_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A_label_en-US" xlink:label="lab_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:to="lab_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:to="lab_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="arc" />
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043_terseLabel_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed contribution from Parent, increase of related-party receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043_label_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:label id="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043_documentation_en-US" xlink:label="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deemed Contribution From Parent, Increase Of Related-Party Receivable</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:to="lab_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deemed distribution to Parent, increase of convertible note obligation</link:label>
    <link:label id="lab_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0_label_en-US" xlink:label="lab_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:to="lab_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, convertible note write-off</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="arc" />
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE_terseLabel_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital contribution from Parent, forgiveness of related party borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE_label_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:label id="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE_documentation_en-US" xlink:label="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:to="lab_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversion upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversion upon initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan (in shares)</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:to="lab_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="arc" />
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67_terseLabel_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock in connection with the incentive equity plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67_label_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:label id="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67_documentation_en-US" xlink:label="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:to="lab_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:to="lab_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:to="lab_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:to="lab_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriters Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:to="lab_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A_label_en-US" xlink:label="lab_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:to="lab_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19_label_en-US" xlink:label="lab_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:to="lab_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from initial public offering, net of underwriters fees</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares sold upon completion of follow-on public offering (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:to="lab_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529_negatedLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash used in operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total principal payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:to="lab_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:to="lab_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:to="lab_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:to="lab_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712_label_en-US" xlink:label="lab_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:to="lab_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="arc" />
    <link:label id="lab_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E_label_en-US" xlink:label="lab_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:to="lab_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:to="lab_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total net revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product cost of sales (excludes amortization of intangible assets)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="arc" />
    <link:label id="lab_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666_label_en-US" xlink:label="lab_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:to="lab_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="lab_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="arc" />
    <link:label id="lab_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1_terseLabel_en-US" xlink:label="lab_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation to Evolus Founders</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:to="lab_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:to="lab_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:to="lab_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:to="lab_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:to="lab_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive gain:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current provision:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred (benefit) provision:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred (benefit) provision</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total (benefit) provision for income taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Period</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:to="lab_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, period to provide written notice to terminate contract</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F_label_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:label id="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:to="lab_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:type="arc" />
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7_terseLabel_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, equivalent rent termination period</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7_label_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:label id="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7_documentation_en-US" xlink:label="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:to="lab_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:type="arc" />
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E_terseLabel_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, rent escalation percentage</link:label>
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E_label_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Percentage Of Annual Rent Escalation</link:label>
    <link:label id="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E_documentation_en-US" xlink:label="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Percentage Of Annual Rent Escalation</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_OperatingLeasePercentageOfAnnualRentEscalation" xlink:label="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:to="lab_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment recorded to right-of-use assets related to original lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:type="arc" />
    <link:label id="lab_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A_terseLabel_en-US" xlink:label="lab_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A_label_en-US" xlink:label="lab_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:to="lab_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:to="lab_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:to="lab_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="arc" />
    <link:label id="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6_terseLabel_en-US" xlink:label="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Daewoong</link:label>
    <link:label id="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6_label_en-US" xlink:label="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:label id="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6_documentation_en-US" xlink:label="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Daewoong [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:to="lab_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="lab_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE_terseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party borrowings</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:to="lab_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent milestone payment (up to)</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20_label_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20_documentation_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment In Connection With License And Supply Agreement</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:to="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrual</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="lab_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50_label_en-US" xlink:label="lab_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:to="lab_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:to="lab_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53_label_en-US" xlink:label="lab_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:to="lab_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59_label_en-US" xlink:label="lab_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:to="lab_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:to="lab_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:type="arc" />
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D_terseLabel_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D_label_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:label id="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D_documentation_en-US" xlink:label="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Royalty Obligation Payable to Related Party, Current</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:to="lab_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:to="lab_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of discounts and issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F_label_en-US" xlink:label="lab_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:to="lab_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:to="lab_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:to="lab_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 33,562,665 and 27,274,991 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:to="lab_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:to="lab_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive gain</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:to="lab_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Current and Deferred Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue From Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:to="lab_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:to="lab_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="arc" />
    <link:label id="lab_country_CA_9017C0534B9953F815446E1894663682_terseLabel_en-US" xlink:label="lab_country_CA_9017C0534B9953F815446E1894663682" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:label id="lab_country_CA_9017C0534B9953F815446E1894663682_label_en-US" xlink:label="lab_country_CA_9017C0534B9953F815446E1894663682" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:to="lab_country_CA_9017C0534B9953F815446E1894663682" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution right</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:to="lab_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:to="lab_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:to="lab_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:to="lab_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Useful lives of intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB_terseLabel_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued volume-based rebate and coupon liability</link:label>
    <link:label id="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB_label_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Current</link:label>
    <link:label id="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB_documentation_en-US" xlink:label="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Current</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:to="lab_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued volume-based rebate and coupon liability, current</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="arc" />
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762_terseLabel_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for accrued rebates and coupon liabilities</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762_label_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:label id="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762_documentation_en-US" xlink:label="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rebates And Coupons, Credits And Payments</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RebatesAndCouponsCreditsAndPayments" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:to="lab_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-offs of allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777_label_en-US" xlink:label="lab_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Loan and Lease Losses, Write-offs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs" xlink:label="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:to="lab_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:to="lab_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Securities excluded from the computation of diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:to="lab_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="arc" />
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">R&amp;D</link:label>
    <link:label id="lab_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570_label_en-US" xlink:label="lab_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:to="lab_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NOL carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:to="lab_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Released valuation allowance for deferred tax assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest and penalties related to income tax matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State income taxes, net of Federal benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:type="arc" />
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California NOL write-off</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Net Operating Loss Write-off, Amount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Net Operating Loss Write-off, Amount</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:type="arc" />
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revaluation of contingent royalty obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Meals and entertainment</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Meals and Entertainment, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in state tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:type="arc" />
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF_terseLabel_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note - debt discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF_label_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:label id="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF_documentation_en-US" xlink:label="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:to="lab_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Other, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Book Value</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and related benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="arc" />
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0_label_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0_documentation_en-US" xlink:label="lab_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and Entity Information [Abstract]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="lab_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_38A0F216929C64623F1D456D400CA36C_terseLabel_en-US" xlink:label="lab_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_38A0F216929C64623F1D456D400CA36C_label_en-US" xlink:label="lab_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:to="lab_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A_label_en-US" xlink:label="lab_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:to="lab_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:to="lab_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:to="lab_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:to="lab_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645_label_en-US" xlink:label="lab_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:to="lab_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:to="lab_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:to="lab_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB_label_en-US" xlink:label="lab_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:to="lab_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE_label_en-US" xlink:label="lab_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:to="lab_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:to="lab_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Smaller Reporting Company</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:to="lab_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:type="arc" />
    <link:label id="lab_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:to="lab_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494_label_en-US" xlink:label="lab_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:to="lab_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:to="lab_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:to="lab_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:to="lab_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:to="lab_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="arc" />
    <link:label id="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399_terseLabel_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chief Medical Officer</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399_label_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:label id="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399_documentation_en-US" xlink:label="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chief Medical Officer [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:to="lab_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="arc" />
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of service agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Term Of Agreement</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:to="lab_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of successive renewal of services agreement</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Renewal Period Option</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Renewal Period Option</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:to="lab_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to notify termination to the other party</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period To Notify Termination</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period To Notify Termination</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodToNotifyTermination" xlink:label="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:to="lab_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:to="lab_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party transaction, debt balance multiplier</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction, Debt Balance Multiplier</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Amounts of Transaction, Debt Balance Multiplier</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier" xlink:label="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:to="lab_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="arc" />
    <link:label id="lab_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C_verboseLabel_en-US" xlink:label="lab_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in related party receivable</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:to="lab_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related party receivable</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:to="lab_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="arc" />
    <link:label id="lab_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deemed distribution to parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:to="lab_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="arc" />
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493_terseLabel_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Up-front payment upon obtaining FDA approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493_label_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:label id="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493_documentation_en-US" xlink:label="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Up-front Payment Upon Obtaining FDA Approval</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:to="lab_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="arc" />
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F_terseLabel_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period of termination of first commercial sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F_label_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:label id="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F_documentation_en-US" xlink:label="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transaction, Period Of Termination Of First Commercial Sale</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:to="lab_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="arc" />
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212_terseLabel_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period available to cure breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212_label_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:label id="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212_documentation_en-US" xlink:label="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement, Period Available to Cure Breach</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:to="lab_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of voting interests acquired (at least)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="arc" />
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE_terseLabel_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unwinding fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE_label_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:label id="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE_documentation_en-US" xlink:label="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Acquisition, Unwinding Fee</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:to="lab_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in a continuous loss position for more than 12 months</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairments recorded on investments</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB_verboseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="arc" />
    <link:label id="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13_terseLabel_en-US" xlink:label="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oxford Term Loans</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13_label_en-US" xlink:label="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:label id="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13_documentation_en-US" xlink:label="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oxford Term Loans [Member]</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:to="lab_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50_terseLabel_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50_label_en-US" xlink:label="lab_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alternative Investment, Measurement Input</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:to="lab_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent promissory note payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Definite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Life (Years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:to="lab_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="arc" />
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E_totalLabel_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross (including goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E_label_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:label id="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E_documentation_en-US" xlink:label="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Including Goodwill)</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:to="lab_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net book value</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Composition of Lease Expense and Other Quantitative Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturity of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent royalty obligation payable to Evolus Founders</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill acquired</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="arc" />
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E_terseLabel_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E_label_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:label id="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E_documentation_en-US" xlink:label="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:to="lab_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration upon successful completion of certain technical and sales milestones</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment for intangible assets</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:to="lab_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="arc" />
    <link:label id="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D_verboseLabel_en-US" xlink:label="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:to="lab_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized computer software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Computer Software, Additions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:to="lab_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risks and Uncertainties and Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-Term Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Payment Obligation Payable and Contingent Promissory Note Payable to the Evolus Founders, a Related Party</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D_terseLabel_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D_label_en-US" xlink:label="lab_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:to="lab_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Costs</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:to="lab_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable operating lease expense</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:to="lab_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term operating lease expense</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:to="lab_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease expense</link:label>
    <link:label id="lab_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC_label_en-US" xlink:label="lab_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:to="lab_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="lab_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other deferred assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:type="arc" />
    <link:label id="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319_label_en-US" xlink:label="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets. Operating Lease Liabilities</link:label>
    <link:label id="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets. Operating Lease Liabilities</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssets.OperatingLeaseLiabilities" xlink:label="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:to="lab_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:type="arc" />
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E_terseLabel_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent obligation - imputed interest</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E_label_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Promissory Note, Debt Discount</link:label>
    <link:label id="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E_documentation_en-US" xlink:label="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Promissory Note, Debt Discount</link:label>
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:to="lab_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Intangible amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Fixed asset depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:to="lab_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contributions to 401(k) plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>eols-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpenses" xlink:href="eols-20191231.xsd#AccruedExpenses" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesDetails" xlink:href="eols-20191231.xsd#AccruedExpensesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/AccruedExpensesTables" xlink:href="eols-20191231.xsd#AccruedExpensesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheets" xlink:href="eols-20191231.xsd#BalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:href="eols-20191231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:href="eols-20191231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:href="eols-20191231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:href="eols-20191231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:href="eols-20191231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:href="eols-20191231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:href="eols-20191231.xsd#FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:href="eols-20191231.xsd#GoodwillAndIntangibleAssetsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxes" xlink:href="eols-20191231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:href="eols-20191231.xsd#IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="eols-20191231.xsd#IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:href="eols-20191231.xsd#IncomeTaxesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:href="eols-20191231.xsd#IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesTables" xlink:href="eols-20191231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:href="eols-20191231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/Organization" xlink:href="eols-20191231.xsd#Organization" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OrganizationDetails" xlink:href="eols-20191231.xsd#OrganizationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoans" xlink:href="eols-20191231.xsd#OxfordTermLoans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:href="eols-20191231.xsd#OxfordTermLoansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/OxfordTermLoansTables" xlink:href="eols-20191231.xsd#OxfordTermLoansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactions" xlink:href="eols-20191231.xsd#RelatedPartyTransactions" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:href="eols-20191231.xsd#RelatedPartyTransactionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfCashFlows" xlink:href="eols-20191231.xsd#StatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="eols-20191231.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StatementsOfStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:href="eols-20191231.xsd#StockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:href="eols-20191231.xsd#StockholdersEquityDeficitTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="eols-20191231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_4F7745078A1FDEBD00A059C605287A10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_4F7745078A1FDEBD00A059C605287A10" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_F271CD9629DAE1757F6259C6052886FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5A19FC4C949DBD020A214FE7F2DB07CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_FAC5F49EA54FDCF305CD4FE7F2DC297B" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_9E52EE7B8DFF1F5C9FAD4FE7F2DCEE46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:to="loc_eols_MilestonePaymentCurrent_9E52EE7B8DFF1F5C9FAD4FE7F2DCEE46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_FC50712F61FDF3A2537F4FE7F2DC19D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_28F3BA6A4E1B92884F2D4FE7F2D6D1AA" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4C079616EB70292968994FE7F2DC0BF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A38E52CB3EB13031BD5E378A0E8A3DBF" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4115A566D055232865EE37DC975302C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_669EA198C2AC86ABF11959C605B754F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_669EA198C2AC86ABF11959C605B754F8" xlink:to="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3BAE6A3F4C177148ADA659C605B8DB5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3BAE6A3F4C177148ADA659C605B8DB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D2A16A8694FDC6408E2859C605B8C620" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_D2A16A8694FDC6408E2859C605B8C620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_41DE0F4C4681A57D832E59C605B95337" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_InventoryNet_E25913CDE879411733C359C605B94C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6E44CAE7E2C1C832D0CC59C605B9FDD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C3EC61D4FBB0CF95EB8459C605B8E728" xlink:to="loc_us-gaap_AssetsCurrent_6ADDD9EBB4C68ABB08E359C605B9D94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4EF9C6E5F420E78380AE59C605B90F4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5C48FC34FB1AD7FB773959C605B940D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5C48FC34FB1AD7FB773959C605B940D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_FAD166DA2916D545431A59C605BA3BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_Goodwill_5E7B77930E36D98E9B4259C605BA7B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_B54EE099663252C95E1D59C605BAB0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_BA0292CB1C949B89D83A59C605B7F7C6" xlink:to="loc_us-gaap_Assets_E1B1C476443EF9EC695059C605BA7A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_669EA198C2AC86ABF11959C605B754F8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="loc_us-gaap_AccountsPayableCurrent_658541A31E9C33D455A659C605BBC65F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_671294130E3CED288CEF59C605BBE443" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14617595F22BFB71306F59C605BB35D8" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent" xlink:label="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="loc_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent_DC5757654CD617BB82D459C605BBAF2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87CC99961F09A385151459C605BAF940" xlink:to="loc_us-gaap_LiabilitiesCurrent_9C57D9ED3EB3C054580759C605BBAB8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43E5B3FBB331E638D9D259C605BB0DE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_43E5B3FBB331E638D9D259C605BB0DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_52374C34A8C9E4ADFF9959C605BCDB60" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_ContractualObligation_52374C34A8C9E4ADFF9959C605BCDB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_1558626CCE3972C958BC59C605BCF110" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_LongTermNotesPayable_1558626CCE3972C958BC59C605BCF110" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_74D6AFACB27FA738AD7759C605BCB4D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_659BA2DD34028903654159C605BC933F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_2FEE118B6068DE70A6B859C605BC722B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_2FEE118B6068DE70A6B859C605BC722B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_Liabilities_39D0BB1FF8A034D9631459C605BC085F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_CommitmentsAndContingencies_CBE7ECD69F0F376B5DFD59C605BD7A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_PreferredStockValue_4518AF2C087407A75A5859C605BDC0CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_CommonStockValue_40B96BDAE298718521FC59C605BD86BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_AdditionalPaidInCapital_AF6618B7B75530CB9FE559C605BDD6FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_52AA3F66ED5EE3DFAB2F59C605BD92B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_BF26D0BFE73E092EBA7559C605BE62B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0FED8337CD8F4B1213CF59C605BDAE36" xlink:to="loc_us-gaap_StockholdersEquity_BAB446F35588EC3A1FAE59C605BEDCE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8466AEC7D8C356682A7F59C605BA7C94" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1E350A6FD8389D72D63859C605BE684E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81B5E20F16105F2BADE3378A0F7BA4F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_81B5E20F16105F2BADE3378A0F7BA4F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_54A5B6703909A4F5F595378A0F7BBCE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_54A5B6703909A4F5F595378A0F7BBCE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6D2E67B4975C51F2FA13378A0F7B6141" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6D2E67B4975C51F2FA13378A0F7B6141" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_79E178D72850AA18366E378A0F7BF3BE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_79E178D72850AA18366E378A0F7BF3BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7AF1219D76E8530F430F378A0F7C2C5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7AF1219D76E8530F430F378A0F7C2C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5722DDB33872A9B3AA84378A0F7CB024" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5722DDB33872A9B3AA84378A0F7CB024" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_1F2B3450473D9C38C324378A0F7CB1B8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_CommonStockSharesIssued_1F2B3450473D9C38C324378A0F7CB1B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_A03C637BE3D8A589DD0D378A0F7C3294" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_3A7A3AC0488A64778796378A0F798991" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_A03C637BE3D8A589DD0D378A0F7C3294" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A853F3D00B45558E72DF59C604C8B26B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A853F3D00B45558E72DF59C604C8B26B" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0CA3F7C48F2806E7514659C604C86FB3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_OperatingLeaseCost_5E3624E2976D48EE45A4402B939DDC59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_VariableLeaseCost_F6BEA4DF45DFEA407290402B968B4F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="loc_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_ShortTermLeaseCost_A312D092BBCD108694EC402B9A1D5305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_LeaseCost_53F546F1D77719380A2C402B9D0C36BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_A6223248DCE59ADB402A402BDA1FD133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_FB3647576A030C833F28402B5012ED86" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_BEEEEE389483EE86D97D402BDCA8D1D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_983675C4BED78F276D484032D125F2CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_59F052F3B03819CD8925403156BA77D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_92667D90C3C39935028E403156E681B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B2E760C091EA7AFB2912401FE1C9C641" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_C5C7D40B872B37822989403157363D38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_36BA5B7AFDF8635A678E4030247CABF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_218F23D783BF83F8970D402FCE5B8A68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9532715A6A00596F6C7F402FCF481F15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5E831F40ED08CE05A9AB402FD02BD84F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_980346E3AE4A58368CBF402FD10116E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_F05C160687A29967EBE6402FD1F7A042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_16A04EC9A258960D631C402FD2E8E52F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_43B7E10348D28491672E402FD3E838A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_C0511AE7322A32FE8F80402F4440ED43" xlink:to="loc_us-gaap_OperatingLeaseLiability_843CC5804D0C34743979402FD53D5AD0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:type="locator" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeaseTerminationPeriod" xlink:label="loc_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_eols_LesseeOperatingLeaseTerminationPeriod_8CA7E3C5231CBF680C264FE7F1F09A81" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate" xlink:label="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate_590372A575D02FF93C144FE7F1F1049F" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent" xlink:label="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent_CF540F42A082D94B3A1B4FE7F1F1EFF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_E9F0D92D6145164125CA4FE7F1F134CD" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_OperatingLeasePercentageOfAnnualRentEscalation" xlink:label="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_eols_OperatingLeasePercentageOfAnnualRentEscalation_A10F2D20B2DA09591C634FE7F1F1559E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseImpairmentLoss" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_0A73026A6523FB2AEC1B4FE7F1F19789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PurchaseObligation" xlink:label="loc_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_us-gaap_PurchaseObligation_54DF4FE907BBA67C827A4FE7F1F1D69A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_us-gaap_LeaseAndRentalExpense_8ABB43A9443C2192D9704FE7F1F1F0AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F94B53E3AFAD0B8029DC4FE7F1F05623" xlink:to="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:to="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5469C307DFB0A1CF55A94FE7F1F2E95C" xlink:to="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_CCEB575D6E2ECF84D44F4FE7F1F3B86A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:to="loc_eols_ALPHAEONMember_CCEB575D6E2ECF84D44F4FE7F1F3B86A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DaewoongMember" xlink:label="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_DAE3F61C70E55CB82A9A4FE7F1F34FD5" xlink:to="loc_eols_DaewoongMember_7B958265F560DC0AF4D44FE7F1F3BFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7F21BB225CAB7F16AAA24FE7F1F2B9DE" xlink:to="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_2AFA2F5EF13ACA68953D4FE7F1F47CFE" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_52CFEA5B2AB68B4A54A44FE7F1F4DD20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyAccrualAtCarryingValue" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E839B4EE86C702C753BC4FE7F1F3B6D1" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_B169D7EE0BB5F7420E214FE7F1F41EC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AEBF32786D19E38F0EB3FF5019016C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AEBF32786D19E38F0EB3FF5019016C9" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_F949364FCFDA221373514029A8A6A8FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AEBF32786D19E38F0EB3FF5019016C9" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1B87B17F43DF51BD5EC23FF50190157D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6AEBF32786D19E38F0EB3FF5019016C9" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_9F1D59BF45E2121CEFFA402E0AD9F991" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="eols-20191231.xsd#eols_DocumentAndEntityInformationAbstract" xlink:label="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_DocumentType_38A0F216929C64623F1D456D400CA36C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_AmendmentFlag_BF0314D7B33CF97BB226456D400DD41A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_DocumentPeriodEndDate_97FAC3D83E064F592E98456D400D8E43" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_DocumentFiscalYearFocus_AC589646B3A9BA72EF63456D400D186E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_A7E4AD2E345F2ECD5101456D400D3AEA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityRegistrantName_6AB022B957D48BEB01DD456D400DE645" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityCentralIndexKey_6999A3D218CDE8C6C382456D400DC501" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4D78974BE648972CF284456D400E3425" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityFilerCategory_D1B0D0FD8CDA9B1E4701456D400ECADB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_7C7AC226B96E628743CC456D400E5559" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityPublicFloat_2A33F524E37C84B6D984456D400E2DCE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityEmergingGrowthCompany_F3DFD27F6D1D2D3A93B2456D400E16CE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntitySmallBusiness_71ECA40308BF526D2F98456D400E1B46" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityExTransitionPeriod_DD76ED6D37AA3E4FB5B0456D400F4830" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityShellCompany_865B27D805D58FC76ADF456D400FD494" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityVoluntaryFilers_0F4045814066D410988F456D400F9AB2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityCurrentReportingStatus_C09333D781B0D3D9CEBE456D400F21B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_F1D31C9333ED62CC80BD456D400F856E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_DocumentAndEntityInformationAbstract_B4FD143DDADF832AE13D456D400C32B0" xlink:to="loc_dei_EntityInteractiveDataCurrent_64D11E42BA7161B4566A457EDDCC8CB6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_C74CDAB2E637E321A39159C60467AF9B" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_E358F63BC90F54396CB159C60467F8C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7047363599D25B77F0C337F09478E59A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7047363599D25B77F0C337F09478E59A" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_87B8D4F7A6D5F0742A3637F24FF92390" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8AECFEC54BEA9526FB8759C604EAFBCD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8AECFEC54BEA9526FB8759C604EAFBCD" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2F1CB362EC09DFCF37E759C604EA0D51" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26E7AD5FE0F6413306D74202FBF5E5F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26E7AD5FE0F6413306D74202FBF5E5F2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_77F238B7661113F98D014202FBF9D6BA" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_991893C445B952775E914202FBF9252C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_991893C445B952775E914202FBF9252C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableOtherPayablesMember" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_61F5B3388463569CB5F24202FBF9E3DC" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_951FC0B0503D63F2F8394202FBFA13C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_DBBC22610990A894E4074202FBFA63EE" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0824562493F378CEF7334202FBFAC257" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6D2267A006ED58ED3DCA4202FBFCEA83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8E02EB3688383AC2278F4202FBFAE56F" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_EC56605A45A47424C4814202FBFCF542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67DF0D3EF1FDEBD132CD4202FBF8DED3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue_50364562C665929510B94202FBFDABF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6B107CBC491C8A0E0B854202FBFD1665" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_38F6131DC75BB3E6965C4202FBFC3E66" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6B107CBC491C8A0E0B854202FBFD1665" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_C35C45A55E6E1D25F7804061A7B407F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C35C45A55E6E1D25F7804061A7B407F4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_578429F442BF58AD9C6A4061A7B46F9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C35C45A55E6E1D25F7804061A7B407F4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_CBE003D1D77C8DCB90CB4061A7B4F9E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_C35C45A55E6E1D25F7804061A7B407F4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_F170022C317E704B2E6A4061A7B7B591" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_6BC2FE623740614FEBED4061A7B7CD1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_581DB5B8F2F492B30DAA4061A7B7F912" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_314D00825CB480482B624061A7B7148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_F45CA9908A4720685CF14061A7B86FB2" xlink:to="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_DD38549E9375EC729C434061A7B84C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:to="loc_srt_MinimumMember_DD38549E9375EC729C434061A7B84C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_E9C04F5C030AEB671BF34061A7B85572" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BFBB31123C516F3063F34061A7B854C1" xlink:to="loc_srt_MaximumMember_E9C04F5C030AEB671BF34061A7B85572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A7B7B3EB09D2F60C87B44061A7B58801" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_1694224522883798AC194061A7B6E09B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_4AB5FB85D4C18B6207A44061A7B5450E" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_993BF58F870B0E7A87AF4061A7B633CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_1D4C540BD275F4E3BB644061A7B44873" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_OxfordTermLoansMember" xlink:label="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_040AE68DCAF7554AD8A14061A7B5EAD3" xlink:to="loc_eols_OxfordTermLoansMember_EDE9B96A5D9FB285D3B14061A7B54C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_16FCE0E57234C79CD63B4061A7B640A0" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_FA164A233A76A29AF0A54061A7B7930C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_153E9E75634B1590886D4061A7B6F41D" xlink:to="loc_eols_ContingentRoyaltyObligationMember_FA164A233A76A29AF0A54061A7B7930C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5771BCE0287A0FB726284061A7B4D1FB" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AlternativeInvestmentMeasurementInput" xlink:label="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_AlternativeInvestmentMeasurementInput_89CC9BD8AD08FD75EF4E4061A7B93B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_7E0CCFB3DEAF4D2DD3FD4061A7B96FCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_69AE45E9E3953207A46A4061A7B96BDD" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_E9120B076ABA8ED053F54061A7B9BA5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_E66EC665788421943A4759C604CB779E" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5B9DAE8544FB2206E68259C604CB666E" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligationMember" xlink:label="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_565130234403328F4F4C59C604CC6C24" xlink:to="loc_eols_ContingentRoyaltyObligationMember_B6F9CAAD1B644635EF1159C604CCE4D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable_9CD2876EE9EE4360768859C604CB7093" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_569DE09DF2488662FF4659C604CCE3AA" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_18A101046F12DCF7B2D659C604CD816E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_C51F9E63E186F6D4826359EF5058BFCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_8DD18F722DB026198BCE59C604CD7937" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_7076632DB04F920D745C59C604CDF399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_ED724FA4ED8ACB504B5A59C604CCCC4A" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_EBEDFA4A48E1CBE9215E59C604CDDE5A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8B755A0CE5393E5822C7404318115A53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8B755A0CE5393E5822C7404318115A53" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_71B4860883E3A1FB73C4404318EBAFD4" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5A6B94147252A7AB36DD404318ECC102" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_C28A9E6B00FD2DA5DA98404318ECEE8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0521849AC3A37BC3C150404318EBCCA0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FDBE2B051C8377742E7C404318ED777C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_829176B0C31DD761A1DC404318ED2D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract_C428C586F888C237C72D404318ED15A8" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_F7C3BBE0F4F882C9F0D5404318EE8ACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D4E6501D9E441A694D75404318EC6097" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_C2F9B01F55452203153E404318EE205D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5407AB0B48DC928FC61D404317BD8B89" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5407AB0B48DC928FC61D404317BD8B89" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_2C5A18A9A1AD06551CC5404317BD1CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5407AB0B48DC928FC61D404317BD8B89" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_EAE37D50859FF8EBE1EA404317BDB3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5407AB0B48DC928FC61D404317BD8B89" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_B938D5939A9509F7D5AA404317BD1A65" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41783FE2A9B84A50E42759C6051F7C51" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41783FE2A9B84A50E42759C6051F7C51" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_F690606EA1F20A353AD759C60520CCAC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_C221B0907555B35BBED43CDC6F9AF44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_F0E32B77A2189FB6BC733CD32A476E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_58A2D00C0DD032247F093CD32A47C089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_D26FCB69E3875B0669033CD32A470AA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_C7B479417EAFD48F60E03CD32A470C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_31A5F059C4B1A7FECEF93CD32A487D31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EB9306BD521E1FE847393CD32A40842C" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7D5B4BE8F9C0EAD5E8CB3CD32A481004" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75579D365877DCBE71FD4FE7F298E618" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_75579D365877DCBE71FD4FE7F298E618" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_61AEAC58EF476DAA737C4FE7F298CD52" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_FF8D711C2AC701938E074FE7F29944FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:to="loc_us-gaap_DistributionRightsMember_FF8D711C2AC701938E074FE7F29944FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_71DC9238896B324CB5204FE7F299ABA4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_68FC5C2D1FB6B97FA18D4FE7F2984E5F" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_71DC9238896B324CB5204FE7F299ABA4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5ADEEC481F1BC8CB80524FE7F2991530" xlink:to="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_A09DB7308CAE5C03E8774FE7F29901B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4012271CF03B18472F854FE7F299296F" xlink:to="loc_eols_SCHAEONLLCMember_A09DB7308CAE5C03E8774FE7F29901B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_55526D841982D19B05F04FE7F29A2429" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_77277D586B423145C4FE4FE7F29A792B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_01C851398DDC7DA4C03E4FE7F29AF955" xlink:to="loc_eols_EvolusIncMember_77277D586B423145C4FE4FE7F29A792B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_363B9BE640AE914294CF4FE7F2984C72" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_8E0BCCFABB52AF321F754FE7F2A09888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets_F78BE5EF7BCCF9D1B90A4FE7F2A05830" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements" xlink:label="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements_0BBE61E575F2B5F2DB1A4FE7F2A0D81E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8AA2B85725E53CE68A674FE7F2A0C8E5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_AC6AC682D670CFA1C4AA4FE7F2A14D7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_114B17F343722B87696B4FE7F2A12CE1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_114B17F343722B87696B4FE7F2A12CE1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement" xlink:label="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement_EA9174193183791FFF574FE7F2A1698D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalizedComputerSoftwareAdditions" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAdditions_15696EB151D5F19A9BD64FE7F2A1CCA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_98E2ED612F9D7AEDECE04FE7F2A1783B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_D05A4B8318E2CFC7FB594FE7F29A4455" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_F8A6FD03FB7ED7E62FCB4FE7F2A23C6D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1A111BDDBC09B0DFAC0F456D3F96332E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1A111BDDBC09B0DFAC0F456D3F96332E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_13B40E36F271E993D881456D3F97AB31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_93C9958B3628AFA5F816456D3F97F1F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:to="loc_us-gaap_DistributionRightsMember_93C9958B3628AFA5F816456D3F97F1F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_098C504FAF6F303B983F456D3F97DAA2" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_78AAC9F45FE81AFDB8D2456D3F970FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C64667F259B35EBEC352456D3F980F34" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_AD5CD2C14EE4FDC52802456D3F98B6FF" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_32E2CCC501ED6166B6F8456D3F987789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_E55383B88ACC8186EE7F456D3F961D9A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_62D227861BBF4F3AAF6C456D3F993F43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_F7D0EB55F1D1BE4AC53D456D3F999C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0C377BF4E87AEFCCE432456D3F999E8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C1FFA267D2257C4D4D95456D3F99C448" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_E40C6149A396212ADFBD456D3F9856A3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_C1FFA267D2257C4D4D95456D3F99C448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:to="loc_us-gaap_Goodwill_4E36C30A9C6DD1544DB7456D3F9AEDD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_F1FBD9C59A435BC1F056456D3F995E63" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33AC67D874D5B6C9A0C6456D3F9A45B5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_IntangibleAssetsGrossIncludingGoodwill" xlink:label="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_eols_IntangibleAssetsGrossIncludingGoodwill_64CA15D6A1089A2E999A456D3F9A2B5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_13C98A570BFCE36292CF456D3F98DBB3" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_B3884230CF58F353D98F456D3F9AB609" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_D362DD34E3D6DDF72CCE3CD32BAF5C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5EC9241DA9821B58DD2B3CD32BAF4829" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_CD189B0102C135C1C1BB3CD32BB0CBA1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3EE3982E58EF1041E2AD59C60463B234" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_FF62D6FDD16313D09A2059C6046375A0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_75DBA3C92A7825FFCF8C456D3ED4B3F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75DBA3C92A7825FFCF8C456D3ED4B3F1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_CE40B4E4548573EF1205456D3ED4AE88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_89BDB0DDD821D1427351456D3ED58D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_D9CE5D61191537854284456D3ED4BFFB" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_A079C675B3E689AEA5B0456D3ED51C88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75DBA3C92A7825FFCF8C456D3ED4B3F1" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_3DBF779EA47840CC422F456D3ED55285" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0BCF40575E5556D68B26456D3ED6F136" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_3BF6C5827BDD407356C8456D3ED508EE" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_E262324FBCCC9201B3F9456D3ED612E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_75DBA3C92A7825FFCF8C456D3ED4B3F1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7CCBCFE4558D833C1B71456D3ED66D8F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_19967858D3BBBCE6A133378A0E548B0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract" xlink:label="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19967858D3BBBCE6A133378A0E548B0C" xlink:to="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_EB935E321659DB5C220E378A0E540A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_C1EC64E3311EAF8DD30A378A0E559041" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther_8217B051A888A4EC81E337FB78ED913E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation_2693B5687E82DA53EA7F378A0E55546D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssets.OperatingLeaseLiabilities" xlink:label="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_eols_DeferredTaxAssets.OperatingLeaseLiabilities_8060F02E283F7A45B53337F66B76A319" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeferredTaxAssetsPromissoryNoteDebtDiscount" xlink:label="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount_EE493535684EB0572181378A0E54E08E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_C38E006C5498145F8CA837FAF11E34C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5BADB66ABCE7179711D6378A0E5506CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract_387618873B1E696A50D6378A0E54F9DA" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_CC4B5A4DC111169383CA378A0E56EE4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19967858D3BBBCE6A133378A0E548B0C" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_D7A036A290EDAB841E94378A0E5B51F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_99A29AA4822EA1B3204337F4186C4A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_A76D364F87E9A2F7974C37F49788C50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_98E59E4CE8BC164E0ED3378A0E562E2B" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_152D6E4FD3DDA1AF3EAE378A0E5BBA16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_19967858D3BBBCE6A133378A0E548B0C" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5A2C1013718A8F363793378A0E5CCC9F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_39251F48887B9EE83FE46E1892FF7DB2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_39251F48887B9EE83FE46E1892FF7DB2" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_F14454BD2E6B5B8A9D116E1892FFF054" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:to="loc_us-gaap_DomesticCountryMember_56F3C1893B02343AE1ED6E189300AB75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_DF02458CE647252FD7B36E1892FF99B2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_27A1F045EDA492567A116E18930039C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_75E6AAA44F8377ECD6EF6E1893004081" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_42445DCAE307DBAE11166E189300BE75" xlink:to="loc_us-gaap_ResearchMember_19DE0C92D26BA89925106E1893012570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_249C1C17282D5CEE48A76E1892FF7E16" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_OperatingLossCarryforwards_690CE9A924333E086F9C6E1893013CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_20D05CCACE9B59D366D36E189301B32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_208584AF6F05F074DFEC6E189302A255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_A1E4451DD5A0AB46A3216E189301ACB4" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_DDC916C152342DBD77216E1893021968" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_8A433EDA81E56B5E8C7259C60442969D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_D430BBDB32A3F310B1C959C6044208EC" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount_CA81FC7D639B20595A3A59F9F2100F64" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation_AFB0827DA8C92DD58B0759C6044397A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment_6FB77D224DFBE69D62A559C604436A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_DA165863652BFABFFD1D59C604434557" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_2CB815EA9599C5296E2159C6044335BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_0FF18A76CB9DE684C76559C60444A788" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount" xlink:label="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount_6D2F556BB403B2C3F36159C6044423BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxContingenciesOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingenciesOther_9A47FBDCF4FBE9C61BB559C604445F36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_D5406159B82FC2F020C859C60444C242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_0EA720B24F78EDB31B1359C604449638" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F534DC20AD6E436F529D59C60442BE16" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_0EA720B24F78EDB31B1359C604449638" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7045A59EE2343E02AEC03F0DBDFD685F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7045A59EE2343E02AEC03F0DBDFD685F" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_E87F26BD80EE5BCE31113F0DBDFDD1EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7045A59EE2343E02AEC03F0DBDFD685F" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A8BC573CB95D36611E443F0DBDFE24DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7045A59EE2343E02AEC03F0DBDFD685F" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_890F07BF451CF99A56F83F0DBDFE525A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7045A59EE2343E02AEC03F0DBDFD685F" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_157562B5193A14FBBE7A3F0DBDFEB13F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_021CF76177E26413C813D18A3195C4A2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_021CF76177E26413C813D18A3195C4A2" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_50E5CE5A7862C2EAC92BD18A31954172" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ECC456FF1EAE4FFA1ADFD18A31953395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_A8E582B793742795CDD3D18A3195C8DC" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_B17F12D40BF0CB0BDAD7D18A31960387" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/Organization" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E404E047841355DD9D7378A0F423FCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E404E047841355DD9D7378A0F423FCF" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_B3BFC6CD678DF083B990378A0F421765" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_24F46CD3E0286095E1D76E09AFD549C4" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_303A2BA0BEEEF7F65D256E09AFD6E9DF" xlink:to="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A7D109EF0CC157C7A1756E09AFD76CD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_558E79FC5C09C0060E496E09AFD60CF5" xlink:to="loc_us-gaap_CommonStockMember_A7D109EF0CC157C7A1756E09AFD76CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2E6B0DA415756923DB056E09AFD71F04" xlink:to="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_2C1D11FC774BB160FF276E09AFD71A0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_2C1D11FC774BB160FF276E09AFD71A0D" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_122C45F06FEF6E19D4C96E09AFD76CE8" xlink:to="loc_us-gaap_CommonStockMember_A7D109EF0CC157C7A1756E09AFD76CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_18368322C164C63C579C6E09AFD86D8E" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F5763E841A11745967DF6E09AFD833B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_us-gaap_IPOMember_F5763E841A11745967DF6E09AFD833B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_us-gaap_OverAllotmentOptionMember_C3EEDCF6510C1FD29EBE6E09AFD82A7D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_479C70B485B027858E526E09AFD92CF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_FC4EC390E9AB9B4D8AC36E09AFD88273" xlink:to="loc_eols_FollowOnOfferingMember_479C70B485B027858E526E09AFD92CF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_DC8B178FE1119C816BE86E09AFD936DF" xlink:to="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_E69FCFF26FA727628C926E09AFD9612D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_25CE60A4BAC7884BCF216E09AFD98E2E" xlink:to="loc_us-gaap_MajorityShareholderMember_E69FCFF26FA727628C926E09AFD9612D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_945632737850F7F7EEF16E09AFDA170A" xlink:to="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_6FB1FB484B63509A39186E09AFDABEAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_EE48A4C3B97A20D420836E09AFDA0E19" xlink:to="loc_eols_EvolusIncMember_6FB1FB484B63509A39186E09AFDABEAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_CDF3A9579A5180DD3AEF6E09AFD673CD" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_502288FD2152EF583F236E09AFDBEFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_967F22478F932EF243CD6E09AFDB7293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_81ABE955589F0F1506546E09AFDBA6AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_793DFE68226534AD0D936E09AFDBED3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ECC0271B996522CE6276E09AFDB1F2C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2ECC0271B996522CE6276E09AFDB1F2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_30E61DD087A80987D5106E09AFDB3EBE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_30E61DD087A80987D5106E09AFDB3EBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_16E24C1233B73D53FC356E09AFDBD21D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_16E24C1233B73D53FC356E09AFDBD21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2B6CCCFBA0FC9885D60D6E09AFDC89B4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2B6CCCFBA0FC9885D60D6E09AFDC89B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4192852621EE02B9773D6E09AFDC0B98" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_4192852621EE02B9773D6E09AFDC0B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_78FDA4CB13D001F297286E09AFDC379F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E18AD2EE401E40C79F856E09AFDC9A16" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E18AD2EE401E40C79F856E09AFDC9A16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_F5B248BD52FCC3517F706E09AFDCB3BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_NetIncomeLoss_29DC733A574CE3C294226E09AFDDA449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_63635444E01EF13D750D6E09AFDDD529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BA044F5CD205955908EE6E09AFDD0572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_74BC9EFBD6C09B8117596E09AFDDA9FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_51940C7FBC274E513ACC6E09AFDA59CF" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3C352F7F213D8A8C1DBE6E09AFDD43DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4DB8B69A3A1089C07D0B37E28AFD7A54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4DB8B69A3A1089C07D0B37E28AFD7A54" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_F27F10F0E003327C653037E28AFE2C5C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_FA261DF6EBE4DE0B6B4D3CA8D75BA054" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4CDF42D72571BC5D3E2C3CA8D75C6FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_5EA57E1DC237633ED0C83CA8D75C3498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_5603F02746974C7E25873CB40154798C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_9680A347EEB39D798EC53CB394AD1956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_45BD17614E30BE0706A43CA8D756307F" xlink:to="loc_us-gaap_LongTermDebt_0E31A971735310697B583CA8D75CB1AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0942D2623DABB3D97ED06E139B13D5DB" xlink:to="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_E6B03937A052AB8392A66E139B13811C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuredDebtMember" xlink:label="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1FBA0609E3AF13B651A86E139B144484" xlink:to="loc_us-gaap_SecuredDebtMember_E1844AB22A49A3D9DF9B6E139B14217A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3A737281D5A30FADE1DB6E139B140BE5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityMember" xlink:label="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityMember_61F76D8BC263B05D46156E139B15A3E5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheOneMember" xlink:label="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityTrancheOneMember_8DCD38261685467E96B26E139B157931" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_TermLoanFacilityTrancheTwoMember" xlink:label="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_18EA1A092A06B9DC22776E139B1421AA" xlink:to="loc_eols_TermLoanFacilityTrancheTwoMember_15E9E43CFCB08AA08D606E139B167278" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_40CD05D534DB79655FB76E139B16065D" xlink:to="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_65C879D5E8F7164964D36E139B16A9C6" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ApplicableRateMember" xlink:label="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_459ED85DF5AB7E6DB3076E139B16A259" xlink:to="loc_eols_ApplicableRateMember_47D73871EE9AECB317246E139B16392F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_313A040E8907AF4111EE6E139B130ED4" xlink:to="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_118093DED828663142C16E139B179414" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityNumberofAdvances" xlink:label="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_LineofCreditFacilityNumberofAdvances_232C04707E67D4B07C6A6E142FD67F05" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn" xlink:label="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn_5157BAE08E41C2E04FA76E182C4A0889" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_7A127700C9F9D1C3A6226E139B1760D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_723300C8A7C532B7346F6E139B17C6B3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPeriodOfInterestOnlyPayments" xlink:label="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPeriodOfInterestOnlyPayments_8839626D6DC5E1333E646E139B172A50" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAmortizationPeriod_1635B1AF3936BD4AB2496E139B186D4B" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment" xlink:label="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment_522900F8FF6698C553066E139B18611A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentTermAggregatePeriod" xlink:label="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentTermAggregatePeriod_54B314641690F9FA02B06E139B184AC4" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentAdditionalAmortizationPeriod" xlink:label="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentAdditionalAmortizationPeriod_3BB29351D880BCC34B836E139B18C6D9" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment" xlink:label="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment_160F29D7B5EBDCFB62B16E139B18E472" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths_ACF294D615B455A29E456E139B18C95C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageYearTwo" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageYearTwo_524910D104D2E87DD8FD6E139B19DFF3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentPrepaymentFeePercentageThereafter" xlink:label="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentPrepaymentFeePercentageThereafter_F12216F6D12F7A5907446E139B19A9A3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DebtInstrumentDefaultInterestRate" xlink:label="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_eols_DebtInstrumentDefaultInterestRate_7200EFD0ECE6A389FCFD6E139B19C61E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_1FB019DAA3A05DF064776E139B190B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_DeferredFinanceCostsGross_4B83CB79948F333B6EB66E139B1910F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_1E64BF57BD013AFFF3E96E139B1771F0" xlink:to="loc_us-gaap_InterestCostsCapitalized_02159A2869A51F60F4926E139B1995F3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/OxfordTermLoansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2B680A7198B758818E2F37E28B4E5655" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2B680A7198B758818E2F37E28B4E5655" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_65B7C1AD1D83472CABB937E28B4EF90F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_506744120A47FE0B6EE059C60543D299" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_DCD11AE4A2E39F74A39B59C605439DD1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/RelatedPartyTransactionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_B1854779DA580D80401A59C60537015C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_B1854779DA580D80401A59C60537015C" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_E1E61BC6DFCDF7BA8B2559C60537D1BB" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_9243ED06C8575AC9406159C60537C850" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C31F4BE997D98BC763EA59C60538FA9C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_B567517D6D654EBF430359C60537126D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_C31F4BE997D98BC763EA59C60538FA9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_902EB387BCC7CF72847959C60538B1A7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_21848454996622A6BEE059C60538CF0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_93E1617712F56EF419ED59C605387C1A" xlink:to="loc_eols_EvolusIncMember_21848454996622A6BEE059C60538CF0A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_BDCEB6AE8EA32539B20059C605395661" xlink:to="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_D3874B239256FEF4E01F59C605398033" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:to="loc_eols_ALPHAEONMember_D3874B239256FEF4E01F59C605398033" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_901B1590EFA47E008D9B59C605391572" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1839D74B354FE3B9BCDD59C60539405C" xlink:to="loc_eols_SCHAEONLLCMember_901B1590EFA47E008D9B59C605391572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5FE1625D81298519448959C605394DF7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_C25A11FEB1E046DE447F59C6053AEE80" xlink:to="loc_eols_ALPHAEONMember_D3874B239256FEF4E01F59C605398033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2F75497A435E3E2C46A359C6053A9E91" xlink:to="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_5855FE3A101F43F0507359C6053BBE82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_us-gaap_MajorityShareholderMember_5855FE3A101F43F0507359C6053BBE82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_7B5A54BC2DD27F56BC1959C6053BB80D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_srt_ChiefExecutiveOfficerMember_7B5A54BC2DD27F56BC1959C6053BB80D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ChiefMedicalOfficerMember" xlink:label="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_283EE9EF168D257CDC1559C6053AB78C" xlink:to="loc_eols_ChiefMedicalOfficerMember_6873FB97F2C9AFF276F859C6053B7399" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_68D3ED5AD6FD042570C359C60537DF29" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_BC3075E960618E41F87959C6053B9503" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_BC3075E960618E41F87959C6053B9503" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionTermOfAgreement" xlink:label="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionTermOfAgreement_EF7A9E7AF33F2F7180AF59C6053CF268" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionRenewalPeriodOption" xlink:label="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionRenewalPeriodOption_E2827760BEE9A930002059C6053C50A7" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodToNotifyTermination" xlink:label="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionPeriodToNotifyTermination_A55036C28F9E282C625F59C6053C2745" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_E610E3606E8749797A7B59C6053CA531" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_E610E3606E8749797A7B59C6053CA531" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueFromRelatedPartiesCurrent_6FAE6E254C88BE46C45B59C6053C5385" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier" xlink:label="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier_B4FAE9352225EAC025F659C6053C8BDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82FA3CF52F03072A636559C6053D100C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_82FA3CF52F03072A636559C6053D100C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_NonCashRelatedPartyReceivable_55762BCA04D3F8FAA7BA59C6053D572C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueFromRelatedParties_8A752E7C123F326C016459C6053DD77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_Dividends_643CFFC0BA375E5E2DB259C6053D4F1C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval" xlink:label="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval_69FB6872C42F7D61A16659C6053DD493" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale" xlink:label="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale_DE8A5F82453EDD8551FC59C6053DF72F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_D3A9FC05EEB3783724F859C6053D7837" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_ContractualObligation_D3A9FC05EEB3783724F859C6053D7837" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_2A8B2C5AB2AEF41C551059C6053E4992" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_LongTermNotesPayable_2A8B2C5AB2AEF41C551059C6053E4992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_43B3BBCF13CA4DCBB29E59C6053EBD91" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockPurchaseAgreementPeriodAvailabletoCureBreach" xlink:label="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach_DDB0181DBE0C3ACEC5C159C6053EC212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_195B7820154B442E58EF59C6053E3DCE" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_BusinessAcquisitionUnwindingFee" xlink:label="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_9F3D7C9813B7A5E1600559C6053BB325" xlink:to="loc_eols_BusinessAcquisitionUnwindingFee_E221A0BC3F2410853D5359C6053EA3AE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:to="loc_us-gaap_NetIncomeLoss_40B2500676ACB4D818D677A0A6134F2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_C5B3287BBA11D3905D9F77A0A6139666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_ShareBasedCompensation_FF20E782223EBA85C97377A0A614CEA3" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_2C78C6D3090B968B9BF877A0A614B88E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_08570A1B6EAB98DBBE7D77A0A6148537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_D587223DFBE233FE7D1877A0A614EA91" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_OperatingLeaseRightofUseAssetAmortization" xlink:label="loc_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_eols_OperatingLeaseRightofUseAssetAmortization_EEA4B24139AF5857005F77A0A6148A49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34373C2207A4055D4A8977A0A614B251" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9EDEB90E27C55062E1E077A0A6151CE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_76A4EF8132456B79451B77A0A615A12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_445AFD4E4FA5205435C177A0A6135C92" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_74DF30D395122F2C664A77A0A616ED99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_7DC1F1A48C9AFDA749A777A0A616AFB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_57F92AC3523409B67EBE77A0A6160137" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_FB26696613AB2158F8FE77A0A616E371" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4B05911CC9A5DE52D94E77A0A6165F76" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_eols_IncreaseDecreaseInOperatingLeaseLiabilities_19053688C6116A08955277A0A616873D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredLiabilities_92AFD728BA28EC544C6E77A0A617227C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_337EFF5CC65BF2F74C5D77A0A615E437" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_632F04543E574AEF241C77A0A617D8F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_7DAE7369535F8FF38E8D77A0A61229B3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_D16671B37757DA4DB64677A0A617380F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_B2018215EB9759E5673877A0A6184026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForSoftware" xlink:label="loc_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="loc_us-gaap_PaymentsForSoftware_B7B8466820732F2514A277A0A6182A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_5761D6A9F4ACEF5BA2DE77A0A618385F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_AD6D188C8A00DEB66F1477A0A619AB9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_AA7CE0C67895A23D42ED77A0A617FFD2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44082B817B428B193F5E77A0A619336B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_PaymentsOfContingentRoyaltyObligation" xlink:label="loc_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_eols_PaymentsOfContingentRoyaltyObligation_AE06A119D7C5F264DFB477A0A6196AD4" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentsForIntangibleAssets" xlink:label="loc_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_eols_MilestonePaymentsForIntangibleAssets_F723FC17F11E6A0BFD5777A0A619C16E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_B2C3169675E99CD8F57977A0A619192D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_CEF2C5F5894CCA24C68277A0A61AD452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_40EAEA111A52DCD074D477A0A61AAAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_EAC0CE2CFC56FDE2D61177A0A61A6163" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_AF0D614DDD84D528D9BA77A0A61AF867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_424C26F768B1B9A920FE77A0A61BCA52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_348A91B9A152435BDCD277A0A61B016B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_73C91017197C3E087B4077A0A61B73DD" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan" xlink:label="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan_7F3459B499632CDA2D4077A0A61B939E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_24BFE9A216D2F131E8D777A0A619CDC2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_EA7DE53E8E9F8077CAF677A0A61B3DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_BDD912BB4A6A880E6E8F77A0A61C00CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_F9FA9D5B7DBA73008B9077A0A61C4A75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_60CA41D756C417C2FF9777A0A61CC789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_DF88D8360EF045DAC0B877A0A61275B8" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:to="loc_us-gaap_InterestPaidNet_21911AF8508D218C22B877A0A61CE021" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:to="loc_us-gaap_OperatingLeasePayments_846FF3923EFBE63CED7C77A0A61D104F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_49584EDFF5788369691077A0A61CED10" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyReceivable" xlink:label="loc_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashRelatedPartyReceivable_E1D8D041CDEA6816174F77A0A61D3875" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashRelatedPartyBorrowings" xlink:label="loc_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashRelatedPartyBorrowings_7CE5764A7C9F3C102F2D77A0A61EC45E" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashNoteObligation" xlink:label="loc_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashNoteObligation_7FEBD88E8ED3BBA3D17077A0A61E490E" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentRoyaltyObligation" xlink:label="loc_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_ContingentRoyaltyObligation_8FB9E8F5DCCD42292AD177A0A61EF4AC" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ContingentPromissoryNote" xlink:label="loc_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_ContingentPromissoryNote_F2A729E1D8464151F4EE77A0A61EA0F1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionConvertibleNoteWriteOff" xlink:label="loc_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_CapitalContributionConvertibleNoteWriteOff_F17541C654136D7460AF77A0A61E774A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_4FA2DC17FA08334446A277A0A61EE542" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_4FA2DC17FA08334446A277A0A61EE542" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashDeferredOfferingCosts" xlink:label="loc_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashDeferredOfferingCosts_DD31BE5C885AE772A42477A0A61F50C0" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_AccountsPayablePaidbyParent" xlink:label="loc_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_AccountsPayablePaidbyParent_A840E843D62F765DE03F77A0A61F4BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9BC744836963E04DF46B77A0A61F80D7" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashLandlordPaidTenantImprovement" xlink:label="loc_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashLandlordPaidTenantImprovement_12B0D03F1C4D8CA017EB77A0A61F0268" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashFinanceAndInsurancePayment" xlink:label="loc_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashFinanceAndInsurancePayment_974CA961AB4EBD28CCE177A0A620F8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_D40CD39EA7327EE9FB0377A0A620D63C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_NonCashAccruedandUnpaidOfferingCosts" xlink:label="loc_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5688CB91DD0D391607CC77A0A61D3A67" xlink:to="loc_eols_NonCashAccruedandUnpaidOfferingCosts_38082F66EC0B9F1C8E2877A0A6205ADB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_D3E21CC4A18FD9AC9C2E44E10EE966A0" xlink:to="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:to="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9981569F732BEE49AA7544E10EE9E455" xlink:to="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:to="loc_us-gaap_ProductMember_5D6B3AC15DA0920F455844E10EE9B712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_24CB48450D7C5F0BA99B44E10EE97C2A" xlink:to="loc_us-gaap_ServiceMember_5ADBF003BD78D40EE51044E10EF96E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_730D572574BDA19ABD1344E10EE945EE" xlink:to="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8CA31A6576B68F38CF134531BEF220D2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FF83F15E64393AC5A65C44E10EF9F865" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_00480ACC9B7B2D2BE43444E10EF9BA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_GrossProfit_B89CC355E235C340DFA444E10EF96666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_CB690160DF328100845F44E10EF951FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_E26C97FC9FEF6E8E403F44E10EF986E1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RevaluationofContingentRoyaltyObligationPayable" xlink:label="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_eols_RevaluationofContingentRoyaltyObligationPayable_91ABACCEC3A4975E1D2744E10EF991C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_20FF7EE175CA280D7B4344E10EF99C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_CE0D7A61A5567A0B35CA44E10EF95D98" xlink:to="loc_us-gaap_OperatingExpenses_9BC7845CF62BA7C8B61D44E10EF98DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OperatingIncomeLoss_DC67C5AD1AB3B8B6752C44E10EF9EE8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:to="loc_us-gaap_InvestmentIncomeNet_8DFA4371E2EAC480BFA044E10EF9F5F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_B9FC24B93B219098DA3B44E10EF922D5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_A4DE453C9407C5CBFFA244E10EF9AB0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_15001911A9A2D6BCFD3644E10EF92E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D7165FFB1F718352438B44E10EF933F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_NetIncomeLoss_E4BDC7F3E7F15BDB4C8644E10EF97960" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_8EBB1E47F1288EAF5DDD44E10EF97397" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_B9FA39E2E3240FE9ADAC44E10EF94B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2CB478C65C4D17F863D244E10EF96425" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_CD7FDE7979C4CF171E7A44E10EF99C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E31713CE31B185C5A87644E10EF91D32" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3F696343F61123C14A0B44E10EF97995" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_E5EFDE98D22118B9002B77A0A62C1069" xlink:to="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_E1D57876780BD3C104B077A0A62DB505" xlink:to="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_PreferredStockMember_B7649EDC9004A858E3DE77A0A62D61A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9C36EBA3F1EE43A4768677A0A62E5BF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_CommonStockMember_9C36EBA3F1EE43A4768677A0A62E5BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_312BB1F029368D34670377A0A62E16F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_14810D41711EBC123E0577A0A62E9847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_172DCB3ADD0E99A6E2BD77A0A62D3388" xlink:to="loc_us-gaap_RetainedEarningsMember_C234C18A4CA5BC82629F77A0A62EC6F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7EA49D16BCB35AD188CC77A0A62E428A" xlink:to="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_72744F25335FA70D30FD77A0A62E4B35" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_24FC44F2B44CBC64D29977A0A62F44EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_967194A9EC897DC7674077A0A62FD516" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_F9092F5AE0263C4EC77F77A0A62FEE38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:to="loc_us-gaap_IPOMember_F9092F5AE0263C4EC77F77A0A62FEE38" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_FollowOnOfferingMember" xlink:label="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_AC6093A211476B0C1A7E77A0A62F3706" xlink:to="loc_eols_FollowOnOfferingMember_3FB6DA8BA10E7E305DC777A0A6306D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_366B6405CB22F9B6AE2377A0A62CE63A" xlink:to="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_B8E3F43E0931E9C65DF977A0A63033AC" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_SharesIssued_CA12F1861317F56880C777A0A630E88A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockholdersEquity_26A5423349B201D7ABF177A0A63092A1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable" xlink:label="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable_2174A099E53A4899B3D477A0A631F043" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_Dividends_E62872772F3AC9E8E32977A0A631B6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt_2BCFC6D3AAA8E0E184D377A0A6311AE9" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings_E06783EEE4D4514E6A2977A0A63141CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3D1071693C3DAB4B3FD377A0A6318486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_B43567BA2FE84780AAAA77A0A632999D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_8664A8AEF4159F723E0F77A0A6322646" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7C035C0A89115AD0B62377A0A632C7B7" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_7EDC8D9CB0455788238C77A0A63214F0" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan" xlink:label="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan_330934DF62A2E0EF027E77A0A632BC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_47830FCCC50FDB4986D777A0A6324A45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_6CD082C6AB600E5428C277A0A632F0D8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_NetIncomeLoss_6CD082C6AB600E5428C277A0A632F0D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_43B98D8CB1561310BDCF77A0A63370C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_SharesIssued_6B03710F6284C1520C1077A0A6331980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6939ADF5D8758570673577A0A630EEF2" xlink:to="loc_us-gaap_StockholdersEquity_DDA8F31F96973BA5741E77A0A633D535" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_0889C502EB4358BEC35959C604AC63BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0889C502EB4358BEC35959C604AC63BD" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_BBB5604A82435FCB9A5659C604AC3E87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_635C69D7B6593AF073A26E18935F8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_635C69D7B6593AF073A26E18935F8806" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:to="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5C2857369AD31F0FE2716E18935F18BE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_61C2923B2A69C6E951EC6E18936029FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33535132B873569D9DAD6E18935F1C2D" xlink:to="loc_us-gaap_EmployeeStockOptionMember_61C2923B2A69C6E951EC6E18936029FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6B3F6AAE67590A7D1756E18935F9BA0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_27E5A3F0D4E5A92A978C6E18936019D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_BF6E95C344AD2CEB02716E1893607520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_AE5EBA8E728638DFB49C6E189361A95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CE7ABAB6D266FE74D76B6E18936063FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_24E48C9B90932E6545706E1893616997" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_1EC2DD7E421B1329F9207796C8B58267" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1EC2DD7E421B1329F9207796C8B58267" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D53A861D1D5C7545EB8A7796C8B5AF3C" xlink:to="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_E5AF6B1E76D8A529F61C7796C8B62F60" xlink:to="loc_us-gaap_CommonStockMember_4D0076364CC60CBFD3427796C8B6CA19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_356BE55DEEAFC4F764097796C8B67A86" xlink:to="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_DE8FBE1BE92CD11EEA6D7796C8B6A5B6" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_DDB6B34709F80BEACF707796C8B6E5B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_D66C1C6DBB67B01866AE7796C8B7F66D" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_73704E24A62B5042573D7796C8B739BD" xlink:to="loc_us-gaap_IPOMember_E9EF5F1E535B82599A4D7796C8B7B134" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_88059676A71BC67A61757796C8B8B223" xlink:to="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:to="loc_srt_MinimumMember_2B181F0938B5AADADCB17796C8B842B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_925F2865C17D991E914C7796C8B87385" xlink:to="loc_srt_MaximumMember_2E9D9909EF52E14E98E17796C8B86829" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5B4D1BBE34E745605CD77796C8B82A0E" xlink:to="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SCHAEONLLCMember" xlink:label="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:to="loc_eols_SCHAEONLLCMember_4A13533B74EEF605B4237796C8B9FAA1" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ALPHAEONMember" xlink:label="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_879F2073AE08513BAD657796C8B9CB83" xlink:to="loc_eols_ALPHAEONMember_B4355B0AED2F7BCFB7BA7796C8B99E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_200FF71649AC53C752B27796C8B9202F" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_EvolusIncMember" xlink:label="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B0709BD35BD89FFD5B367796C8B96EA5" xlink:to="loc_eols_EvolusIncMember_FB0AEEF3EBD6949455AD7796C8BAA85B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_3D03295C1E4D0458E1C47796C8BA24DA" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_ECA8C454B5DA31BEC2307796C8BA30B7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_75BE0C47C7E0395A25087796C8BADD1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_624148D10E75A07857597796C8BBC987" xlink:to="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_00877D94FC920FB8E8187796C8BB3FCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_06D3E168376C1B0B332D7796C8BBE0F4" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_D63CCD0B697EB28925217796C8BB4547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9E0E75F3AE076BD29F327796C8BB2445" xlink:to="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MajorityShareholderMember" xlink:label="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:to="loc_us-gaap_MajorityShareholderMember_A5F2B32F56B0C26B57AB7796C8BCBB98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ChiefExecutiveOfficerMember" xlink:label="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_FF6221705D99FB937B607796C8BCD688" xlink:to="loc_srt_ChiefExecutiveOfficerMember_E2EB3C2CC447205E19157796C8BCD8B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_009F715B447B63182F027796C8BC229D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:to="loc_us-gaap_EmployeeStockOptionMember_89D4940AAC9DB2883F2A7796C8BD713F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_88B69BE501702039EE597796C8BCB864" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsPerformanceConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:to="loc_eols_RestrictedStockUnitsRSUsPerformanceConditionsMember_81F30DE27CE3447343AC7796C8BD7E7B" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RestrictedStockUnitsRSUsMarketConditionsMember" xlink:label="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E83DBEE4DB0EDE875EFD7796C8BDE77E" xlink:to="loc_eols_RestrictedStockUnitsRSUsMarketConditionsMember_26FD390078DEFF92A5D67796C8BD1FEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0885583389F9F52CAADA7796C8B57EC6" xlink:to="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_AA8DBB58F193759E96027796C8BE5A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesIssued_D44876E3FDF21919ED5C7796C8BEB014" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_D4ECA447D36B06CEDD777796C8C22AB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_245CA2AD1A58C51795E37796C8C252DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2F8F1075B12B78E87AB87796C8C28C5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_BB1BD76E9BF2B7E24CCD7796C8C2CAD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_469599B1AFBFB0361C617796C8C2AB56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesIssued_43E6C7D168C93669FE687796C8C20DCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_FD5A86C09F0E9E8F42237796C8C20841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_RelatedPartyTransactionAmountsOfTransaction_D27B89556D57803DF5B87796C8C22455" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractualObligation" xlink:label="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ContractualObligation_B2D7496DEEC7756CAE9A7796C8C201D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_LongTermNotesPayable_7FC5F2C17B5D2E8FF4FB7796C8C212CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfRelatedPartyDebt" xlink:label="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_RepaymentsOfRelatedPartyDebt_FDF81425BA28ECAE4BA57796C8C22FC6" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CapitalContributionForgivenessofRelatedPartyBorrowings" xlink:label="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_CapitalContributionForgivenessofRelatedPartyBorrowings_375443450B41FE5A88F57796C8C27ED6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_44CB9B19993FD816E25A7796C8C201A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7A6FD2C11887477DEDC57796C8C24243" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:label="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_21F80D4519E466BD6A077796C8C2FD8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_114FFA11922DB8B9B1B67796C8C2AE1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_FD69FB50DDCC49039F517796C8C29925" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_70E21E315F5474FF5C547796C8C2E864" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_1D6C03E90118221390957796C8C2B44C" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm_731CB6B6284A1B8079D67796C8C21E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_C1476272A6B2C1925E727796C8C2BBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8F3A8A8B33F70EF0FC767796C8C263D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9A39473B794129B859277796C8C2FA1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_469DFB92DF9F339230517796C8C2252D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_B53E8BD7CED0458543D77796C8C281A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_562D3824A4172F7AFC3E7796C8C21200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_4139697E56D0E25163DD7796C8C2AB01" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_AllocatedShareBasedCompensationExpenseCapitalized" xlink:label="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_eols_AllocatedShareBasedCompensationExpenseCapitalized_1FF63D07D22BFCEE3C097796C8C21F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_C9F76CA9E6CAED0D6B3A7796C8C2ADE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_E87AD4D1720650A294BC7796C8BE4117" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1717D6079393BFC096B47796C8C2FC89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_7AF7F8402371DFE92C143FF439DC7295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7AF7F8402371DFE92C143FF439DC7295" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:to="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_81B7E19F7A1C939DCDFE3FF439DD0B35" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_016CAB1479A0E97E362A3FF439DD4BB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_923FB3F6AA5EE76B472D3FF439DD5C03" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_016CAB1479A0E97E362A3FF439DD4BB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_19A8A07242FE43F39D7B3FF439DCD21E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_64C6DDDAB0AEF06D5D8A3FF439DEEA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_427CB076CAFE01F425853FF439DE01C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_858675B21714BFAB31603FF439DFC3D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_286B741D61F47EB388C93FF439DF70E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1AC7A706D88860CFD8373FF439DE7FA9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A7D06D481B72245859663FF439DF809B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_12D2B8A67F9E2D23D4A83FF439DDE726" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_81501640732B60D32FE23FF439DFAAB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A74ADDD08BFF864C53903FF439E0C81D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_29B1541F155F4A2451723FF439E0D3E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_FF5F41680792C45635733FF439E09777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_8ACE462D967E3B9BB18B3FF439DFDC43" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C3CC9A21332E7771097E3FF439E0FA6F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0AED8882707C2104F15A63146110AA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ECF75351F8163C981DAC631461101B40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7A5E9A9EE5ACF0EA08CD63146110CF90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_433AE3F9BE4D6B4A875C63146111DB8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5E6845A440ACC4D41EF463146110B6F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5D0BC8C934CF4E7831EF63146111E6FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_49EAF39299E8F4C84EC563146111B529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7B76CB9D2265ADE4B1D563146111FCCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_256089DF679D96682C63631461129CB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_B5C8054DFDF957BD1FC063146112B8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_ACF64BF618D6799C7C87631461122C95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_8254A43507D0B71D9A90631461115562" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_427F92348DE47A2A97966314611268C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_CB83DD517FBF71C091C56314611268AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_CAC50DAD56728339172A631461125790" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_886A06EFADC250A72AD1631461130565" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_7324C6C27A1CA570CBAF631461134620" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_F11B282BC31866FCF48A6314611352EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract_ADF3E95B81E8ED2088C3631461136153" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_FA4B629D46F8235FD030631461135524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7DDCD676221AA902FCF66314611499AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69A0BA55E524255010CF6314610FDAD6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_69DAE12DDE79CD42AC5863146114F99A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_7BC764EBBE3663C31A61631461145FF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_E5C255F3F45DCACD3CB063146114AC18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract_5734AE2C4B1FC6AB23DA63146114ADF5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_F03FFF66E49319AFA14F6314611445B1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_85640B9D591D2156FC283FF438049536" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_85640B9D591D2156FC283FF438049536" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DE9A900E2B19BD3BBD233FF4380C91C2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04121FB646376B2BEAB23FF4380DBEA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_04121FB646376B2BEAB23FF4380DBEA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2252506DDCE017271A7F3FF4380D0BBF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_870B6D58F54BF80752183FF4380F63C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_79CAECB53F963CEAD5653FF4380C4C35" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7042F75439943CFEF5383FF43810448F" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D67C9A780724BF853B633FF43810196D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E5B69F5DD93831DBCD9E3F0DF7DF9B92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5B69F5DD93831DBCD9E3F0DF7DF9B92" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_FF2C381E8AF779FD46383F0DF7DFF463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5B69F5DD93831DBCD9E3F0DF7DF9B92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3AC393F862CDA51F99E83F0DF7DFFEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5B69F5DD93831DBCD9E3F0DF7DF9B92" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_3D96CE40503FE421631B3F0DF7E020B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E5B69F5DD93831DBCD9E3F0DF7DF9B92" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_09F29BE8F034BA14FE5E3F0DF7E0F5D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E9AC1A0F3D117EAA77E54FE7F373EE1E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E9AC1A0F3D117EAA77E54FE7F373EE1E" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_2CFDA4D2B6300F6B38B04FE7F3748297" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_CD591EB98CAE12321F0E456C02EBA1D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_CD591EB98CAE12321F0E456C02EBA1D6" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_B1CAF20B93CBF6B9DD54456C02EC1205" xlink:to="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_7B8511DF4F0C415C2FA2456C02EC1708" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B98EF584F1FC305D45C9456C02ECD1B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_C96AF48FC071109D46F9456C02EB6987" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_19D410FC63BE0E80E9B0456C02ED36C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_F9595C264E9550064B1A456C02ED5833" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A96BE3B88DA0BAD8FEB8456C02ED4381" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_6DC61C405332B9FC8A2E456C02EDB8B9" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_97DE2A585CCFB5F6324E456C02EEC7FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0091F7DAEEB73918EDB16E18945DB946" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0091F7DAEEB73918EDB16E18945DB946" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_4287F183FF2FAF334F036E18945DCDA6" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F11B849EDA1D79D1BA3F6E18945DD3A3" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_B19DF6AEE6F67D4E80856E18945DE479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_CC2690C34C77F3EC6BD56E18945E6BB1" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7213C7E1DEEF9E7A43626E18945ED369" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_08F61CAF49D8FED820D16E18945E942A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_EF7F9D7E55F76B8FCD0D6E18945F121F" xlink:to="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ServiceMember" xlink:label="loc_us-gaap_ServiceMember_31903B0AA2200DB6D5A36E1894646FA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_EBE3EBC96831D53099DF6E18945F4FF8" xlink:to="loc_us-gaap_ServiceMember_31903B0AA2200DB6D5A36E1894646FA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9BC29E1FBE9117074E996E1894648036" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_C42204A21801ADE553496E189465CFE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_C42204A21801ADE553496E189465CFE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_442598D319412C089EA56E1894655F17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_DB4018DD5BDC78DB09A96E1894648DF3" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_442598D319412C089EA56E1894655F17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_BA439400A5C74F17DF4B6E1894654687" xlink:to="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CA" xlink:label="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A03E81FF049C982520886E1894658452" xlink:to="loc_country_CA_9017C0534B9953F815446E1894663682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C02D19678C327C7B32946E1894668228" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:to="loc_us-gaap_DistributionRightsMember_BD04C8AA859EBD1623BD6E1894663155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SoftwareDevelopmentMember" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_C790A6B3F923DA081D706E1894664424" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_F2E478453CE2A11EB2546E1894677AF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_E9E960330E1AD1DC8C166E18945DED85" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfReportingUnits" xlink:label="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_NumberOfReportingUnits_B95A615D2B3057F5646B6E1894673CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_C69855B4BA81F8FED0F86E1894675BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_D69865E5C9A20A63F7D76E1894673BF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_AE631C7AE11DD38ECBB56E1894676FFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_345F3BCC9F8C49829FA96E189468728A" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_MilestonePaymentCurrent" xlink:label="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_MilestonePaymentCurrent_2F413088399B5A1EB27E6E189468E5AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_035B597A26F86EDBCBFC6E1894685CF5" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_ProvisionsForRebateAndCouponPrograms" xlink:label="loc_eols_ProvisionsForRebateAndCouponPrograms_15837CED174F1583224B6E189468395D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_ProvisionsForRebateAndCouponPrograms_15837CED174F1583224B6E189468395D" xlink:type="arc" />
    <link:loc xlink:href="eols-20191231.xsd#eols_RebatesAndCouponsCreditsAndPayments" xlink:label="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_eols_RebatesAndCouponsCreditsAndPayments_C892C61830E26152E8036E189468F762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_C0F1843CF09B8616D2EF6E189468DD57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_E92CA6DED8516F550B456E1894694CC7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_E92CA6DED8516F550B456E1894694CC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs" xlink:label="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs_680C11F3DC3729E7DF066E1894698777" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AdvertisingExpense_9CC564E6FFC02DF680156E189469659F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_7D687EDF447D85A35C0A6E1894676295" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_C2CA526C1C26CE64C4B26E189469EFF3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_6A11E3E34F9228CB1CD559C6055CF0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_A8B7CDE6F3FE2BB5D87859C6055C0841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_UseOfEstimates_223D4ACFDF58B6CDC91A59C6055C85CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_6166CC6593DCB8A56E6759C6055C2C49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_98D83CFE23B79CDEE39B59C6055C24E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_A70B1D9456ED97CD45AA59C6055D91C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_6F9DB1866E12F969655C59C6055D0513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_6D19D9ABF24CAC99F58459C6055D12ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_85AAFBAD3727D97051FA59C6055D1620" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_C5EA6DF866D252F37B1859C6055D83E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_0DB5937240C1EA9B32C059C6055D07F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_AC8C631DD6F74B88DCC059C6055ED313" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_4708B3C3DF2F4FBD471959C6055ECB8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4E767C3AAFBD878D277C59C6055EBEE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_DebtPolicyTextBlock_598BD57B58868A68870A59C6055E768D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_E88443190AE099D58C9059C6055E6B54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_B4DE4CD89C3752F3E00659C6055E55AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_3966C71C8EF36D3EED5B59E32AD360B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_2EA140DD87CEDA6080A159C6055F1DDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_297B30D13652FC9EAC9C59C6055F5CBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C3097308BB9B0E9A43E259C6055C3342" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_849242E652E1BC4502E159C6055F5FC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_E2D5B3A1123A7C893A5B4488EB02248B" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6141E8612028AB1F0656448918B9832B" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>a900kda.jpg
<TEXT>
begin 644 a900kda.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   2=%$2
M  0    !   2=        8:@  "QC__; $,  @$! @$! @(" @(" @(#!0,#
M P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,# P'"0X/#0P."PP,
M#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( =0!@0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M2!@:HS%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP: '44T-@\XH5L]: '4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\$^!_^4\>M_P#8GR?^A"OO:O@GP/\ \IX];_[$^3_T(5][4 (_W:0#
M(IW6@'F@"AXB^;0[H^D9KYHNUS>W'^^:^F/$?_(#NL?\\C7S/>\74WS#F0\U
MY>9:H^VX1LU-2& 4N!2<>7QR?7VI?OCY?F4=2*\E25MS[56VN&*!0![[MO:F
MXS\OXBAV:M<7E<]$_9Q;'B2^_P"N(KV:O&/V=#O\1WS8V_N0!Z5[*,E>O-?0
M8/\ AI'YCQ$K8Z5AV,TC4N>::5Q74>&8OQ%Y\&7W_7.OG/8%Z>IKZ*^)#@>"
M[[/>.OG5V"MMZ =/K[UY.9;H^\X0_ASOW \T;<4'AE52&9ORH!;'W=K9Z'O]
M*\M-K8^M3MH)MH/"T!L#^]CEO:DSO/\ >#?=Q1=O0?-KHSU']FEOWVK?\ KU
MFO)?V9SFXU;L?E!%>LJV>U?08/\ A(_+^('?'U&O+\CQ3_@I;_RCC_: _P"R
M;^(O_39<U\X?'3_@HO\  OXU_P#!-'XD>"?"?Q2\'Z]XNOOA#KD<&D6E\'NY
M&AT&YDE41]<HD;L1V"'TK[Z9@BEF(55&23VKAO '[47PS^*_C34/#?A;XB>!
M?$OB+26=+W2]*UZUO+VS9&*N)(8Y&="K @A@,$$&NH\4^/?V@SX%7XY_"_\
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MBB@#X)\#_P#*>/6_^Q/D_P#0A7WM7P3X'_Y3QZW_ -B?)_Z$*^]J "BBC/-
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MQ(;X8V_AE?%#M93ZBNL?V8\OV[['O$*[9)B?LQ(2,\=2/JROS'U7P[X$\0_
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MR?[QKRLRW1]MPE\-1^:(U^0[@,-2*&1?O?-TR:6BO+Y4?; >M!4%_8=J**3
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MN0LIX8BOSXUW]G>X_:QN[C0?V<_BA\?IM#99(;SXKZE\6-=O?#FGR*=K1:=
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MZVW/O7CYGJT?<\)R2A-=6Q:*3.?ZTN:\\^SEIN%!Z4'I0WW:AR1+/4/V:?\
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M+@>9*\K;KBZDDF?YW;&]SM&%&%  Z2BB@ HHHH **** "BBB@ HHHH ****
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MQ?$'P/X#TWPK(?\ 3)[+4Q)/%_NKGFN)^'3'_A^UXD&[_F4WX_X$*^]NM "
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M/WGP?_@5_5?D#=:*#UHKY4_9PHHHH ^K/^"7QS?>+O\ ME7UY7R'_P $OO\
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M &E/^2*^(/\ KV-?FG_RU;_>-?I9^TI_R17Q!_U[&OS3_P"6K?[QKXWB?^)
M_>?!_P#@5_5?D!ZT4'K17RI^SA1110!]6?\ !+[_ (_?%W_;*OKROD/_ ()?
M?\?OBW_ME7UY7Z-DG^Y0_KJ?RGXA?\C_ !'JOR04445ZQ\6%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'P1\
M.?\ E.UXD_[%-_\ T(5][U\$?#G_ )3M>)/^Q3?_ -"%?>] !1110!A_$O\
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MY0_KJ?RGXA?\C_$>J_)!1117K'Q84444 %%%% !1110 4444 %%%% !1110
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M%)^TTMU/J^$>(<5E6-4L/'G4M'%=?^"?F$#YBG;U[ ]J P=@I'S=\5T'QO\
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MR/Y+Q6)J5ZLJU5WDVV[]QPHIO5:=6B5C$**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /@CX<_\IVO$G_8IO\
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M[7W_ ! MQ^-.I ,&EKW#\_"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFU6[AT-[55AB7<[-)(H"H,L2P R:\U_X)N_#7QC^Q=\7]4\$?$#PKKWBR_\
MB=$NOZ;\5;?3KFZDO5CB4G1=9^^--DLPQ2V"^59R1DB-(I_,1P#4\!_M(?M2
M_%*Q^)'B[PGH_P %_$_A[P5XT\1>'=.\)/;ZAI>M:W!IE_/:HHU%KF6VBN)!
M$""UMY9;@F,-N3Z$^%/[7W@7XH_LP:+\7)-:L?#/@[5K 7L]SKMW#9+I#!C'
M-;W3L_EQ30S*\4BEOEDC9<\5\K_LZ?M0^*/V;O#WQ<\'Z?\  [XT^+/'EU\3
M?&&IZ#:)X6N=/T76$NM6NKBUE.KW"+9Q6[HRL96<_+]Q9&*JT=W^R1XE_9D\
M"_LS:AXL\.WWQ4T7X;:CK^M^.-,T*T;46L];U;SKH:K:V2H'O(;2YN+R".)8
MVE6.\64*SQ4 ?:OP^^,_@_XM&3_A%?%GAKQ-Y5I;:@_]DZG!>[+:Y\S[/.?+
M9L1R^5+L?[K^6^TG:<=+7R%^PAX?6\_;L_:&\9:7\+?$OPX\,>,-&\)2V5SJ
MVBMI7_"27$8U;S[H1$ QR 20H\<@69<(TB(9!GJ?VR_VI_C%\"OB+I^F_#WX
M/-\0M%N=.CN9]0&H"W\B<RRJT.WV1(VS_P!-/:@#QSX<_P#*=KQ)_P!BF_\
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M(?\ KB_\J_3(=*_,W_@E5_R<(?\ KB_\J_3(=*_5.%?]PCZL_C/QD_Y*.?\
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MLK;W/5O^"*7[0MS\6/VHY;$>#-<T:*&U=Y+JY_U:\<#\:_79&XYKY3_X)?\
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M@'RR6O-MRI=;_D>._M+_ +._@7X1ZO-_8OC'[<JMA;>)1)Y?L37COV33V?\
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M^S^\/Q&\5VVNZR=+LQJ=S%=6NC0+.D-PZ7$7^D78!MRI"1_.I(SY-I]]XX^
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MP2 ^)D]Q)X@\*R,S0VRB\C+'^\<5]S'YCS7YU_\ !($8^-'B3_L'I_.OT6.
M>E?L'#LN; P;/XA\5*,*?$=>RWL_FT&?EH+;6VBD9#BDE&!Q][%>SK<_.MBI
MXAU :/H%]=-Q]G@>3/T!-?C!\6/&]U\0OB3KFL7V);B\NW#'.> Q K]D/B2I
M_P"%>ZM_UZ2?^@FOQ7U3C6]0_P"OJ7_T(U\-QI*7[J*>FMS^B_ '"PG5Q.(M
M[R45?LB'&/3\****^!T6B/Z7>X-\Z;L8/I0079?NY[9[44 ?,*4DVK(<;IWC
MN?8O_!(?XBSZ9XQUSP]+*[07RB2&//RQD=<?6OT%C.Y:_,__ ()5#/[0;?\
M7%J_3 ';CTK]9X;DW@(W>Q_%?B]0ITN)*O(K<R3?K8,9.*=03BBOH#\Q"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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G HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>adverseeventtable1.jpg
<TEXT>
begin 644 adverseeventtable1.jpg
M_]C_X  02D9)1@ ! @$ S #,  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]4HHHH ***3- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "
MT4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0
M M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,
MT +129HS0 M%)FC- "T4F:,T +129HS0 M%)FC- "T4F:,T +129HS0 M%)F
MC- "T4F:,T +129HS0 444F: %HHHH 6BDS1F@!:*3-&: %HI,T9H 6BDS1F
M@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T
M9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %I#1FB@ HHHH 6BDS1F@!:*3
M-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6B
MDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %
MHI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@
M!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H **** "BBB@!:*3-&: %HI
M,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:
M*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H 6BDS1F@!:*3-&: %HI,T9H
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M?_/9/SH_X3*S_P">R?G7FG]@Q>E']@Q>E'UB'</[&JGI?_"96?\ SV3\Z/\
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M?_/9/SH_X3*S_P">R?G7FG]@Q>E']@Q>E'UB'</[&JGI?_"96?\ SV3\Z/\
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MS3^P(?[M']@0_P!VCZQ$/[&JGI?_  F5G_SV7]:/^$RL_P#GLOZUYI_8$/\
M=H_L"'^[1]80?V-5/2_^$RL_^>R_K1_PF5G_ ,]E_6O-/[ A_NT?V!#_ ':/
MK"#^QJIZ7_PF5G_SV7]:7_A,K/\ Y[)^=>9_V!#_ ':/[!B]*/K"#^QJIZ9_
MPF5G_P ]D_.C_A,K/_GLGYUYI_8,7I1_8,7I1]8B']C53TO_ (3*S_Y[)^='
M_"96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K/_GLGYT?\)E9_P#/9/SK
MS3^P8O2C^P8O2CZQ#N']C53TO_A,K/\ Y[)^='_"96?_ #V3\Z\T_L&+TH_L
M&+TH^L0[A_8U4]+_ .$RL_\ GLGYT?\ "96?_/9/SKS3^P8O2C^P8O2CZQ#N
M']C53TO_ (3*S_Y[)^='_"96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K
M/_GLGYT?\)E9_P#/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K/\ Y[)^='_"
M96?_ #V3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_ .$RL_\ GLGYT?\ "96?_/9/
MSKS3^P8O2C^P8O2CZQ#N']C53TO_ (3*S_Y[)^='_"96?_/9/SKS3^P8O2C^
MP8O2CZQ#N']C53TO_A,K/_GLGYT?\)E9_P#/9/SKS3^P8O2C^P8O2CZQ#N']
MC53TO_A,K/\ Y[)^='_"96?_ #V3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_ .$R
ML_\ GLGYT?\ "96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_ (3*S_Y[)^='
M_"96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K/_GLGYT?\)E9_P#/9/SK
MS3^P8O2C^P8O2CZQ#N']C53TO_A,K/\ Y[)^='_"96?_ #V3\Z\T_L&+TH_L
M&+TH^L0[A_8U4]+_ .$RL_\ GLGYT?\ "96?_/9/SKS3^P8O2C^P8O2CZQ#N
M']C53TO_ (3*S_Y[)^='_"96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K
M/_GLGYT?\)E9_P#/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K/\ Y[)^='_"
M96?_ #V3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_ .$RL_\ GLGYT?\ "96?_/9/
MSKS3^P8O2C^P8O2CZQ#N']C53TO_ (3*S_Y[)^='_"96?_/9/SKS3^P8O2C^
MP8O2CZQ#N']C53TO_A,K/_GLGYT?\)E9_P#/9/SKS3^P8O2C^P8O2CZQ#N']
MC53TO_A,K/\ Y[)^='_"96?_ #V3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_ .$R
ML_\ GLGYT?\ "96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_ (3*S_Y[)^='
M_"96?_/9/SKS3^P8O2C^P8O2CZQ#N']C53TO_A,K/_GLGYT?\)E9_P#/9/SK
MS3^P8O2C^P8O2CZQ#N+^QZQZ7_PF-G_SV7\ZBB\<V4O F7@^_P#A7G2:##UV
M]*R=&TQ+K>'&0K<52K)JYG++*L9*)[!_PF-G_P ]D_.C_A,K/_GLGYUYI_8,
M7I1_8,7I4_6(FO\ 8U4]+_X3*S_Y[)^='_"96?\ SV3\Z\T_L&+TH_L&+TH^
ML0[A_8U4]+_X3*S_ .>R?G1_PF5G_P ]D_.O-/[!B]*/[!B]*/K$.X?V-5/2
M_P#A,K/_ )[)^='_  F5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_P"$RL_^
M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M>R?G1_PF5G_SV3\Z\T_L&+TH_L&+TH^L0[A_8U4]+_X3*S_Y[)^='_"96?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4A.!10::6I,MC&TG_CZE_P!W
M^E;-8VD_\?,O^[_2MFKJG)@/A8M)2BD-9G8A:***!A1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%%- "]_I6)X;ZR_P"_6VO]*Q/#G67_ 'ZTI_ SAKK]
M_ VZ*#161W!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53UC
M_4O]*N53UC_4O]*NE\1CBOX4O0[SX='_ $"'_=/\S725S?PZ_P"/"'_=/\S7
M25Z*/CWN%%%% A*44E**D#AOBS_Q[I_UT%8%M]T?05O_ !9_X]T_ZZ"L"V^Z
M/H*Y\5T/9R/>8\4M(*6N4]X**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** $%8FJ?\ 'Q']:VQ6)JG_ !\1_6M*?Q,X\=\,?5&\WWC3!3V^\:8*
MA[G7'86BBBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2@T4&FMR
M9;?(QM)_X^9?]W^E;-8VD_\ 'S+_ +O]*V:TJG)@-F**0THI#61V+J+1110,
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHIKJ +_ $K$\.=9?]^MM?Z5
MB>'.LO\ OUI3^!G%7_CP_KJ;9HH-%9':@HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *IZQ_J7^E7*IZQ_J7^E72^(QQ7\*7H=Y\.O^/"'_=/
M\S725S?PZ_X\(?\ =/\ ,UTE>@CX][A1113$)2BDI14@<-\6?^/=/^N@K MO
MNCZ"M_XL_P#'NG_705@6WW1]!7/BNA[.1[S'BEI!2URGO!1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 @K$U3_CXC^M;8K$U3_CXC^M:4_B9Q
MX[X8^J-YOO&F"GM]XTP5#W.N.PM%%%(84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 E!HH--;DRV^1C:3_ ,?,O^[_ $K9K&TG_CYE_P!W^E;-:53D
MP&S%%(:44AK([%U%HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
MUU %_I6)X<ZR_P"_6VO]*Q/#G67_ 'ZTI_ SBK_QX?UU-LT4&BLCM04444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %4]8_U+_2KE4]8_U+_2KI
M?$8XK^%+T.\^'7_'A#_NG^9KI*YOX=?\>$/^Z?YFNDKT$?'O<****8A*44E*
M*D#AOBS_ ,>Z?]=!6!;?='T%;_Q9_P"/=/\ KH*P+;[H^@KGQ70]G(]YCQ2T
M@I:Y3W@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 05B:I_Q\
M1_6ML5B:I_Q\1_6M*?Q,X\=\,?5&\WWC3!3V^\:8*A[G7'86BBBD,**** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH 2@T4&FMR9;?(QM)_P"/F7_=_I6S
M6-I/_'S+_N_TK9K2J<F V8HI#2BD-9'8NHM%%% PHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 4444 %%%% !1113!"4M(.:,'_)H"Z#-+1BB@-PHHHI %%%% !1110 4444
M%%%% !1110 4444 %%)1UH"PN:2@T9IM!N+1112 **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** $H-%!IK<F6WR,;2?^/F7_=_I6S6
M-I/_ !\R_P"[_2MFM*IR8#9BBD-**0UD=BZBT444#"BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?7K1G%>B7=A%J:<X([$=:X74M-.GN8V_ ^HK.M1Y5='5@LQCB+QDK,JYSQ0
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M*HFO,='"R3UT6]D[W:V>RM_PPE%%%9':%%%% !1110 4444 %%%% !5/6/\
M4O\ 2KE4]8_U+_2KI?$8XK^%+T.\^'7_ !X0_P"Z?YFNDKF_AU_QX0_[I_F:
MZ2O01\>]PHHHIB$I124HJ0.&^+/_ ![I_P!=!6!;?='T%;_Q9_X]T_ZZ"L"V
M^Z/H*Y\5T/9R/>8\4M(*6N4]X**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWVIR7QRY^@'04G5C232&\-B<9-.II%="*[NC>.9O4]_2M'PM*$N%)]"/SK)
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M\127WR_=7T[U2G&FM#.5#%XR45-62*>I7'VB1I/4\5K>$M4%LWDL<!^1GI6
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M4M% ";: *6B@ I,4M% !28I:* "@T44 %%%%%P"BBB@ HHHH **** "BBB@
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MZQ_J7^E7*IZQ_J7^E72^(QQ7\*7H=Y\.O^/"'_=/\S725S?PZ_X\(?\ =/\
M,UTE>@CX][A1113$)2BDHJ0.'^+/_'NG_705@6WW1]!6_P#%G_CW3_KH*P+;
M[H^@K#$[(]G(]YD@HI,TN:Y#W@HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,
MT9HN 449HS1< HHS1FBX!11FC-%P"BC-&:+@%%&:,T7 **,T9HN 449HS1<
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MS44>QB']I5^_Y'C/VJ[_ .>!_*C[5=_\\#^5>S44>QB']I5^_P"1XS]JN_\
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M_P CQG[5=_\ / _E1]JN_P#G@?RKV:BCV,0_M*OW_(\9^U7?_/ _E1]JN_\
MG@?RKV:BCV,0_M*OW_(\9^U7?_/ _E1]JN_^>!_*O9J*/8Q#^TJ_?\CQG[5=
M_P#/ _E1]JN_^>!_*O9J*/8Q#^TJ_?\ (\9^U7?_ #P/Y4?:KO\ YX'\J]FH
MH]C$/[2K]_R/&?M5W_SP/Y4?:KO_ )X'\J]FHH]C$/[2K]_R/&?M5W_SP/Y4
M?:KO_G@?RKV:BCV,0_M*OW_(\9^U7?\ SP/Y4?:KO_G@?RKV:BCV,0_M*OW_
M "/&?M5W_P \#^5'VJ[_ .>!_*O9J*/8Q#^TJ_?\CQG[5=_\\#^5'VJ[_P">
M!_*O9J*/8Q#^TJ_?\CQG[5=_\\#^5'VJ[_YX'\J]FHH]C$/[2K]_R/&?M5W_
M ,\#^5'VJ[_YX'\J]FHH]C$/[2K]_P CQG[5=_\ / _E1]JN_P#G@?RKV:BC
MV,0_M*OW_(\9^U7?_/ _E1]JN_\ G@?RKV:BCV,0_M*OW_(\9^U7?_/ _E1]
MJN_^>!_*O9J*/8Q#^TJ_?\CQG[5=_P#/ _E1]JN_^>!_*O9J*/8Q#^TJ_?\
M(\9^U7?_ #P/Y4?:KO\ YX'\J]FHH]C$/[2K]_R/&?M5W_SP/Y4?:KO_ )X'
M\J]FHH]C$/[2K]_R/&?M5W_SP/Y4?:KO_G@?RKV:BCV,0_M*OW_(\9^U7?\
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M=_\ / _E7LU%'L8A_:5?O^1XS]JN_P#G@?RH^U7?_/ _E7LU%'L8A_:5?O\
MD>,_:KO_ )X'\J/M5W_SP/Y5[-11[&(?VE7[_D>,BZN_^>)_*J^HW%P\966,
MHK<9([XKVZN.^*/_ ![)_P!=E_\ 0'H5&"=["EF%>2M?\B[\/#_H42_W=P^N
M"1FNDKG?A\<V4?U?_P!#:NBK0Y HHHH **** .%^+'_'O'_UU'_H+5TOA7_C
MT@_ZY)_Z"*YKXL?\>\?_ %U'_H+5TOA7_CT@_P"N2?\ H(H U:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\N^)G_'RO\ UR7_ -":
MO4:\N^)G_'RO_7)?_0FH ]17H*6D7H*6@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /*] _P"0L?\ KM/_ ">O5*\KT#_D+'_KM/\
MR>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$
M7_'K/_UQD_\ 0#7&?";_ );_ /;+_P!GKL_$7_'K/_UQD_\ 0#7&?";_ );_
M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 E>7?$S_CY7_KDO\ Z$U>HUY=\3/^
M/E?^N2_^A-0!ZBO04M(O04M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 >5Z!_R%C_ -=I_P"3UZI7E>@?\A8_]=I_Y/7JE !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9_B+_CUG_ZXR?\
MH!KC/A-_RW_[9?\ L]=GXB_X]9_^N,G_ * :XSX3?\M_^V7_ +/0!Z'1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\4?^/9/^NR_^
M@/78UQWQ1_X]D_Z[+_Z ] %[X??\>4?U?_T,UT=<Y\/O^/*/ZO\ ^AFNCH *
M*** "BBB@#A?BQ_Q[Q_]=1_Z"U=+X5_X](/^N2?^@BN:^+'_ ![Q_P#74?\
MH+5TOA7_ (](/^N2?^@B@#5HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $KR[XF?\?*_]<E_]":O4:\N^)G_ !\K_P!<E_\ 0FH ]17H
M*6D7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
M*] _Y"Q_Z[3_ ,GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH S_$7_'K/_P!<9/\ T UQGPF_Y;_]LO\
MV>NS\1?\>L__ %QD_P#0#7&?";_EO_VR_P#9Z /0Z*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ KCOBC_P >R?\ 79?_ $!Z[&N.^*/_
M ![)_P!=E_\ 0'H O?#[_CRC^K_^AFNCKG/A]_QY1_5__0S71T %%%% !111
M0!POQ8_X]X_^NH_]!:NE\*_\>D'_ %R3_P!!%<U\6/\ CWC_ .NH_P#06KI?
M"O\ QZ0?]<D_]!% &K1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 )7EWQ,_X^5_ZY+_Z$U>HUY=\3/\ CY7_ *Y+_P"A-0!ZBO04M(O0
M4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_R
M%C_UVG_D]>J5Y7H'_(6/_7:?^3UZI0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &?XB_X]9_\ KC)_Z :XSX3?\M_^V7_L]=GXB_X]
M9_\ KC)_Z :XSX3?\M_^V7_L] 'H=%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 5QWQ1_P"/9/\ KLO_ * ]=C7'?%'_ (]D_P"NR_\
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M9_Q\K_UR7_T)J]1KR[XF?\?*_P#7)?\ T)J /45Z"EI%Z"EH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*]
M _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH S_$7_ !ZS_P#7&3_T UQGPF_Y;_\ ;+_V>NS\1?\ 'K/_ -<9/_0#
M7&?";_EO_P!LO_9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KCOBC_ ,>R?]=E_P#0'KL:X[XH_P#'LG_79?\ T!Z +WP^_P"/
M*/ZO_P"AFNCKG/A]_P >4?U?_P!#-='0 4444 %%%% '"_%C_CWC_P"NH_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH 2O+OB9_Q\K_UR7_T)J]1KR[XF?\?*_P#7)?\ T)J /45Z"EI%
MZ"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/
M^0L?^NT_\GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH S_$7_ !ZS_P#7&3_T UQGPF_Y;_\ ;+_V>NS\
M1?\ 'K/_ -<9/_0#7&?";_EO_P!LO_9Z /0Z*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFWP?T0W$[7K#Y(5*J3D?.W''8X7.0>FX''< &)X7U)_"5Z//!3!V2@]E;'/
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M@"]FC-8/CK4I-+LY;B$[9$V8. >KJ#P01T-<;X;^*H@MY#>,7G5LH H4,"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M>@?\A8_]=I_Y/7JE>5Z!_P A8_\ 7:?^3UZI0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_ +9?
M^SUV?B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/0!Z'1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<=\4?^/9/^NR_P#H#UV-<=\4?^/9
M/^NR_P#H#T 7OA]_QY1_5_\ T,UT=<Y\/O\ CRC^K_\ H9KHZ "BBB@ HHHH
M X7XL?\ 'O'_ -=1_P"@M72^%?\ CT@_ZY)_Z"*YKXL?\>\?_74?^@M72^%?
M^/2#_KDG_H(H U:*** "BBB@ HHHH **** "BBB@ HHJKJFI)ID3W,APD:DG
MIDXZ 9(&2> ,\D@4 >6_&'7!<3)8J3B$;GY.-S@8&,8R%Y!Y^\1QS7=^ =,&
MGV4*C&70.2!C)D^;GU(!"Y] .G2O&M'T:?Q5<,B$&1]TCLQVCD\G@=R0, =^
MF.G1?\*;O/[\/_?3_P#Q% 'J'BC3EU&UF@<@!HVY<E5!7YE8D= " 3[#G(KR
M/X7ZX--NQ&Q.RX&SJ<;B1L. #DY^4>FXG.,U<_X4W>?WX?\ OI__ (BN=\3^
M%)O#CK%-@[UR&3<5ZX(R0.1W'8$>M 'T-7E_QL_Y=O\ MM_[3KM_"&N#6K6.
MXSE]H5^F=Z\-D+P,GD#C@@X&:\^^-%[OFAM\?<C9\YZ[VQC'ML_'/MR >C>%
MO^/.W_ZX1?\ H K@_C9_R[?]MO\ VG7>>%O^/.W_ .N$7_H KSGXT7V^:&WQ
M]R-GSGKO;&,>VS\<^W(!Z-X6_P"/.W_ZX1?^@"M2LOPM_P >=O\ ]<(O_0!6
MI0 5Q?Q6UP:?:_9P2'N#M&"1\JX+G('(/"D9&0W< BNTS7@_C;4CXBOV6$[A
MN6*/[N#@XX(.""Y)!)Z$=!P #L/@QI@6.6\X+,X0<<@* QY]&W#(_P!D=>WI
M%>-_\*;O/[\/_?3_ /Q%'_"F[S^_#_WT_P#\10!B7[#PUJ#-$05@GR CG[N<
M[-W)SM.ULYYR#FO>;6Y6[19D.5=0RGD9##(.#STKPWQ'\.[G08OM,A1DW 'R
MRQ(SG!.5  SQG/4@=Z[;X0:T+B!K)C\\+$J#@?(W/'<X;.2>FX#/8 &%\7];
M,\ZV2GY(5!8<CYVYY['"XP1TW$9[#OO!'AH:!;K&0!*X#2'OD\[<Y/"YP,''
M4CJ:\M^*5JT-_(S# D5&7D<@(%S^:D<^GI7M\4HF =2"K $$'((/(((Z@T /
M/->6_%?PBD"_VE"""S@2!1\OS9^?V.>#V)(/!SN]2KD_BC=+#82*QP9&C5>#
MR0X;'Y*3SZ>M &;\'_\ CT;_ *^'_P#0$K1^)NBC4K-I ,R0?.IX!P/OC)[;
M<G (R0.N,5G?!_\ X]&_Z^'_ /0$KOA0!Y)\'M<%O,]BQ.)AN3DXW(#D8QC)
M7DGC[H'/%>K75TMHC3.<(BEF."<!1DG YZ5X3XDT\^%K\^6/ECD62/<#C&0P
M')R0#\I.><'H:] ^(/BE)-.62$_\?>T## ,%^\_ )SC&QAG +8)[$ \Y_>>,
M+[T:XD]CM4#_ (#G8@]BV/4U[1KNH+X;LVEC7Y8(PJ+R1V1 <D$@$C/.<9[U
MQ?P=T%D$FHMD!AY:=LC(+'D<C( !!ZA@176^/[,WEC.BXR$#<^D;!S^.%./>
M@#ROP'J5K;7+7=^QR 64LK/ER0=Q(R=PZC((SSD$#/IO_"S-/_Y[?^0Y/_B*
M\\^'GA2V\1"6.9F$B%"H0@';R#C.[(R1GY>,+@_,177?\*<L_P"_-_WTG_Q%
M $VM^,=*UJ(VT\N5/0B.3(/9@=G!'_UCD$BN7^#-TRW,L(/R-#N(P.JLH4YZ
M\!C^?TKH_P#A3EG_ 'YO^^D_^(K7\,^ 8/#TAN(6D+,A7YRI&"0>RCGB@!GQ
M-_Y!\W_;/_T8E<-\(M#2^F>ZD /V<+M!&?F8G#=>J[3C@\G/! KN?B;_ ,@^
M;_MG_P"C$KE_@G_R\_\ ;'_VI0!Z?FO,/C1I['R;H$E!N0@D;03\P(7KE@#D
M^BCIQGT_%17-HEVICD4,AZJP# X.1P>.M '&>"_B#:2016LKB*2- F'R%.Q<
M;M^-H! Z$@YXYX)ZNXTZ#5 KNB2KC*EE5QAL'()!X/'3K7$ZY\'H9\O:N8S@
M_(V73.!@ YW 9ZD[NO XQ7%SP7O@.=><;L'Y23%(!U!'&<9(((!&<C&0: /;
M[^]%C&]PV2L:,QQUPH).,XYXKPO1-5AOK[[9J)^1F9F&UG7./E4C).T<8'S<
M *1M)(]D,O\ PD5B6CP#<P,!\V0&="""0/X2<'C/!XSQ7D/P_P! M]=F>VN&
M()CRFT@'(8$X)/7&>-IR"QX*B@#T_P#X69I__/;_ ,AR?_$56OO'FEWZ-!+(
M&1Q@@QR__$\$=01R#R.:J?\ "F[/^_-_WTG_ ,11_P *;L_[\W_?2?\ Q% '
M(?#V9;;4Q' Q,3F502.60!F7.0,'Y5/0?TKVD&N4T/X:6VBS+=QM(73. S*1
M\RE3T0'H?6NKH =1110 4444 %%%% !1110 4444 )7EWQ,_X^5_ZY+_ .A-
M7J->7?$S_CY7_KDO_H34 >H#H*<*:.@IPH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@#RO0/\ D+'_ *[3_P GKU2O*] _Y"Q_Z[3_
M ,GKU2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_
MQ%_QZS_]<9/_ $ UQGPF_P"6_P#VR_\ 9Z[/Q%_QZS_]<9/_ $ UQGPF_P"6
M_P#VR_\ 9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MP%& ,GGI6=K7A2UULJ]Q&&91@'+*<=<94C(],].<=30 [PM_QYV__7"+_P!
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MR7_T)J]1KR[XF?\ 'RO_ %R7_P!":@#U =!3A2+T%+0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\A8_]=I_Y/7JE>5Z!_P A
M8_\ 7:?^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_ +9?^SUV?B+_ (]9_P#KC)_Z :XS
MX3?\M_\ ME_[/0!Z'1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %<=\4?^/9/^NR_P#H#UV-<=\4?^/9/^NR_P#H#T 7OA]_QY1_5_\
MT,UT=<Y\/O\ CRC^K_\ H9KHZ "BBB@ HHHH X7XL?\ 'O'_ -=1_P"@M72^
M%?\ CT@_ZY)_Z"*YKXL?\>\?_74?^@M72^%?^/2#_KDG_H(H U:*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\N^)G_ !\K_P!<E_\
M0FKU&O+OB9_Q\K_UR7_T)J /45Z"EI%Z"EH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*] _P"0L?\ KM/_
M ">O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_
M !%_QZS_ /7&3_T UQGPF_Y;_P#;+_V>NS\1?\>L_P#UQD_] -<9\)O^6_\
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M:,U4U344TV)[F0X2-23TR<= ,D#)/ &>20*\AU_X@W>OR>1:;T3<2BQ;O-;
M[E3GIDX' [YP#0![31FO&9= UN(%RTV%!/%QN/'H!(23[ 9/:KOA+XESVDJV
M=]RF[86?Y9$/"C<3@$ CYMWS<DDG&" >LYHHHH **YKQ]975Y J6)82"4$['
M\L[=K9Y++QG'&:X'_A'-<_O3?^!(_P#CE 'L=%>.?\(YKG]Z;_P)'_QRL;6;
MW4M%<0W$TRN5# >>6X)(SE6(Z@T >^49Q7(?"Z::XM#-<,SEY6*L[%CM "]R
M2!N#<?CWKE_%'Q.GGF-M88"J^T,%$C.<D<?>7:3]W ). <\XH ]7HKQF70=;
MB!<M-A03Q<;CQZ 2$D^P&3VKI?A[\0VU5OL5US,<E'  #8!)! & 0.AX! P>
M?O 'H.:,TVN3^(/C'_A'X@D1'VB3[H/)5><OCIUX&>">>0I% '749KSGX76U
MU?9O[B:1HQE45WD()XR_)P0.0.O.>A45Z(* '4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\A8_]=I_Y/7JE>5Z!_R%
MC_UVG_D]>J4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_H#UV-<=\4?^/9/^NR_^@/0!>^'W_'E']7_]#-='7.?#[_CRC^K_ /H9KHZ
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M1W%8/Q,_Y!\W_;/_ -&)7E'@Z_NE=K&S8*UT I)P,;<G<&Z@A=W3G!.!NVX
M/<+KQ!;6C&.2:-7'56D52,C(X)STJS;7:7:B2-@R'HRD,#@X/(XZUYK#\%<I
M\\^)#M^['E1P=PY8$\XP>. <CGCG+J.\^']P0C?*_0XS'(JG/(/0CH<'<N3@
MX() /<991""[$!5!)).  .223T K@_B5XKMI;-K:.19'E*@"-@^-K*Q)(/ X
MP.Y/08!(ZV.6/Q#;94GR[B(C@C< X(([@,.0>N",5YIXS^&,>C0/>0R,5C"_
M(X!)+.%SN&W YZ;3TZ\\ &C\)M>M[*VDAFE1'\XMAV"\%5 (+8!Y4].G?J*]
M#M-0CO5WPNKJ#C*,&&>N,@GGFO'O '@!/$2/<3.5C5M@"8#%@ 222",8/U)]
M,<^B>&O $'AZ0W$+2%F0K\Y4C!(/91SQ0!T@:LS_ (2FS_Y^(?\ OZG^->7^
M.]=FUR].F1/B(2+$!\RJ6)4,6]</QT( &5'))V1\%D*8\\^9N^]Y8V[<=-N[
M.<]]V,<8[T >D13"4!U(*L 00<@@\@@CJ#3LUYKX.\&WOAV]];8[@S!EVL-I
M*$H3N!#8[<<@$J23Z50 9K)\67XL+2>;<5(B8*PSD,PVIC'(.XCGMUK6KCOB
MQ>_9K%DQGSI$3.<8P=^??[F.W7/:@"K\']+^SVK7!&#-(<'.<JG XSQAMWH?
MPQ6YX_O#9V$[KC)0+SZ2,$/XX8X]ZK_#/_D'P_\ ;3_T8];>LZ:NJ0R6K8Q(
MA7)&[!(X;'J#@CW'6@#AO@UIJ+#+=X_>-)LR<<*JJW'&>2W/.#@>E>B#FO%?
M"OB$^"+B:VN$)4D*^W[V4SM9=VW*G/?&001Z'K9?C):@$K'*6P< A ">P)#G
M ]\'Z&@#D_B!:#0-1%S%@EBDX!!P&W'(/.2"RD]NN!C%>QW]\FGQM/*P5$&2
M3_GDGH .2>!S7CF@Z9/XYN_M-SDQ Y8X8)M4@^4I'0G/KG!+<GK?^*WBXW3_
M -G1$[(S^\((PS<$+QV3N"?O=1E0: ,:R@F\=WV7)VD[FRP^2(-]T<=1G XY
M8Y/4FO;[6U6T184&$10JCDX"C &3STKF/!/AU/"EL9;@A)),&5F<;1R0BY.
M,9YZY8GDC%/?XGZ>I $I.3@D1R<<$Y.5''&.,G)'&,D '4XHQ69HWB>VUK/V
M>0.1G(Y5N,<[6 ..1SC&>,YK4H \O^+_ /H4UK>1\2C=ANO^K963@Y'!8]N<
M\YKTBPO!?1I<+D+(BL >N& (SC//-<7\9/\ CS3_ *[K_P"@/6O\-Y3+I\!8
MDG#CDYX61@!]   /0<4 =+1110 4444 %%%% !1110 4444 %%%% "5Y=\3/
M^/E?^N2_^A-7J->7?$S_ (^5_P"N2_\ H34 >HKT%+31T%.% !1110 4444
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M%=>3BES0 9KRCXS6"1/#.J@/('#$=]FS;GW&2,]<8'0#'J<LHA!=B J@DDG
M ')))Z 5XQXNUL^,[N.VM@=BG8F1U+'YI#@;@N .N<*N< DB@#U#P3J9U*SA
MG;.XIM))W$E"4+$GNVW/X]^M;=0:?9"QC2W7)6-%49ZX4 #.,<\5/0 4444
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MB<8(.#5WP_X[M-=(BB8B1@3L<;6X]^5)QS@$G'/8X .AHHHH **** "BBB@
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M_77A']V-6S_P)QC/^YR1]#UKJ/B9_P @^;_MG_Z-2LOX-_\ 'F__ %W;_P!
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M1110 E>7?$S_ (^5_P"N2_\ H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %+25B>-M-.I6
M<T"YW%-P &XDH0X4 =VVX_'H>E &U17B_P ,?%BZ/*UO,VV&;&"<X5QP"><
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M-P6.,^I^]M4#(KT;P7X*3PXF3AIW'SO_ .RK_LC\V/)[ ;]A8)8(L$2A408
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M,8&Y25;')XR#CG.,9YK4%<S\.(FBL(0P(.'.",<,[$'Z$$$>HYKIQ0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_P A8_\
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M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2]6%U(#LWP2#&"2J!0<#/7*D<X_+FO8XI1, ZD%6 ((.00>001U!H \F\?>
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MNL2@<.^W'3?)RY'S9PJMC!!!W=<BO4C0 44"B@ HHHH **** "BBB@ HHHH
M**** $KR[XF?\?*_]<E_]":O4:\N^)G_ !\K_P!<E_\ 0FH ]17H*6D7H*6@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \Y\6?"
MDZC*UU:N%,C99),XR<EF##)Y/;'K@@8%<G/INKZ;B'_20 HP(W=U ' &8R0,
M8Z=AVQBO<A10!XO:_#[4=<=7N25!4?/,^]@N<X"Y+9Y)VG:,Y!(->L:)HD6B
MQ"VA&%'4GJ3W8GN3_P#6&  *OT4 <=\4]+EU&T584+LDRL0HR<;67.!R>2.G
MUZ UYQHMOJ>B%GMXID+C!_<L0<=.&4C(['&1D^IKW@4M 'CG_"1ZY_=F_P#
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M /;+_P!GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *3%+10!YUXM^%)U&5KJU<*TC99),XR<EF##)Y/;'K@@8%<E/INKZ=B'
M_2  HP(W=U ' &8R0,8Z=AVQBO<J* /%[7X>ZCKCJ]R2JE1\\S[V"YS@+DMG
MDG:=HSD$@UZSHFB1:+$+: 84=2>I/=B>Y/\ ]88  J_10!R/Q%OKB&#[-;1/
M(9U969%+;1\N00%/W@2.HQU%5OAAX3;1HFN)UVS38P#C*H.0#QD$GDC/9<@$
M$5V](: %%9/BO13K=K):*0K.!@GIE6# ''8XQGMUP>E:HI: /%_!G@.Z>[5Y
M4,26\BLQ<<$HV0J]FR1U!P!SGH#[/2TAH \S\7?"@W$AN+':H8$F-CM^;T3C
M&#Z' !Z'!PO.7,6LVI,+?:3R"2I=^@.,.I/'/(!QGKR!CV\4M 'DVB_"6>\?
MSKY]JMN+!6W2EB>[8*\]2<L>V,G(]4M;9;5%A081%"J,DX"C &3STJ6DH 6N
M7^(TUPEH8[5"[2ML8*A<A&5MQP,XSC&>V>.<$=32&@#S;X6^#GLBU]<(5;&V
M-7&&']YBI&0>PY!QNXP03Z.#BEQ1B@#F_&OA!?$D07.V6/)C8YQSC((]#@<]
M1U&>0?/H[+6/# \F(2%"2!Y:B9.">0,-L!SGD*3W&1Q[+BEH \>TSP'>^)9!
M=7Q9$)Y,A_>$98E50CY1GH"  #E01Q7K&GV26"+!$H5$& !_GDGJ2>2>3S5F
MDQB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N
M.^*/_'LG_79?_0'KL:X[XH_\>R?]=E_] >@"]\/O^/*/ZO\ ^AFNCKG/A]_Q
MY1_5_P#T,UT= !1110 4444 <+\6/^/>/_KJ/_06KI?"O_'I!_UR3_T$5S7Q
M8_X]X_\ KJ/_ $%JZ7PK_P >D'_7)/\ T$4 :M%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!7OK".^&R9%=0<X=0PSTS@@\\U)%$(0$4 *H
M  P !P  .@%248H !1110 4444 %%%%  :BN;5+M3%(H=#C*L P.#D<'CK4M
M% $%A8)IZ+!$H5$& !_GDGJ2>2>3S4]%% !1110 4444 %%%% !1110 4444
M %%%% "5Y=\3/^/E?^N2_P#H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H'_(6/\
MUVG_ )/7JE>5Z!_R%C_UVG_D]>J4 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!G^(O^/6?_KC)_P"@&N,^$W_+?_ME_P"SUV?B+_CU
MG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2O+OB9_Q\K_U
MR7_T)J]1KR[XF?\ 'RO_ %R7_P!":@#U%>@I:1>@I: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH \KT#_D+'_KM/\ R>O5*\KT#_D+
M'_KM/_)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#/\1?\>L__ %QD_P#0#7&?";_EO_VR_P#9Z[/Q%_QZS_\ 7&3_ - -<9\)
MO^6__;+_ -GH ]#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "N.^*/_ ![)_P!=E_\ 0'KL:X[XH_\ 'LG_ %V7_P! >@"]\/O^/*/Z
MO_Z&:Z.N<^'W_'E']7_]#-='0 4444 %%%% '"_%C_CWC_ZZC_T%JZ7PK_QZ
M0?\ 7)/_ $$5S7Q8_P"/>/\ ZZC_ -!:NE\*_P#'I!_UR3_T$4 :M%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E>7?$S_CY7_KDO_H3
M5ZC7EWQ,_P"/E?\ KDO_ *$U 'J*]!2TB]!2T %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110!Y7H'_(6/_7:?^3UZI7E>@?\A8_]=I_Y
M/7JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9_B+
M_CUG_P"N,G_H!KC/A-_RW_[9?^SUV?B+_CUG_P"N,G_H!KC/A-_RW_[9?^ST
M >AT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7'?%'_
M (]D_P"NR_\ H#UV-<=\4?\ CV3_ *[+_P"@/0!>^'W_ !Y1_5__ $,UT=<Y
M\/O^/*/ZO_Z&:Z.@ HHHH **** .%^+'_'O'_P!=1_Z"U=+X5_X](/\ KDG_
M *"*YKXL?\>\?_74?^@M72^%?^/2#_KDG_H(H U:*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*\N^)G_'RO_7)?_0FKU&O+OB9_Q\K_
M -<E_P#0FH ]17H*6D7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 E>7?$S_CY7_KDO_H35ZC7EWQ,_X^5_ZY+_ .A-
M0!ZBO04M(O04M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 >5Z!_R%C_UVG_D]>J5Y7H'_ "%C_P!=I_Y/7JE !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 9_B+_ (]9_P#KC)_Z :XSX3?\
MM_\ ME_[/79^(O\ CUG_ .N,G_H!KC/A-_RW_P"V7_L] 'H=%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MD7H*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5Z!_P A8_\
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M_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\
M%T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N
M1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;
MG^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >
MHT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\
M?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%
M_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y
M=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__
M !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\
MO_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM
M&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='
M_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\
M%T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N
M1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;
MG^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >
MHT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\
M?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%
M_P!\O_\ %T >HT5Y=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >HT5Y
M=_PM&Y_N1?\ ?+__ !='_"T;G^Y%_P!\O_\ %T >H5Y=\3/^/E?^N2_^A-2_
M\+1N?[D7_?+_ /Q=8.NZ])K3B:0*"%"_*"!@$GN3ZT >V@\"G"O+1\3[D?P1
M?]\O_P#%TO\ PM&Y_N1?]\O_ /%T >HT5Y=_PM&Y_N1?]\O_ /%T?\+1N?[D
M7_?+_P#Q= 'J-%>7?\+1N?[D7_?+_P#Q='_"T;G^Y%_WR_\ \70!ZC17EW_"
MT;G^Y%_WR_\ \71_PM&Y_N1?]\O_ /%T >HT5Y=_PM&Y_N1?]\O_ /%T?\+1
MN?[D7_?+_P#Q= 'J-%>7?\+1N?[D7_?+_P#Q='_"T;G^Y%_WR_\ \70!ZC17
MEW_"T;G^Y%_WR_\ \71_PM&Y_N1?]\O_ /%T >HT5Y=_PM&Y_N1?]\O_ /%T
M?\+1N?[D7_?+_P#Q= 'J-%>7?\+1N?[D7_?+_P#Q='_"T;G^Y%_WR_\ \70!
MZC17EW_"T;G^Y%_WR_\ \71_PM&Y_N1?]\O_ /%T >HT5Y=_PM&Y_N1?]\O_
M /%T?\+1N?[D7_?+_P#Q= 'J-%>7?\+1N?[D7_?+_P#Q='_"T;G^Y%_WR_\
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M'_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T
M>HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_
M /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\
M_%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7
M_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]
M\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N
M?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_
MN1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?
M\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_P
MM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-
M%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\
M71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q=
M 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR
M_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_
M /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y
M%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7
M_?+_ /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T
M;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N
M?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17E
MW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?
M\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!Z
MC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >@^(O^/6?_KC)_Z :XSX
M3?\ +?\ [9?^SUEWOQ'N+R-X66/;(K*<*V<,,''S5F>'O$\N@[_*"GS-N=X)
M^[G&,$>M 'M5%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T
M;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?\+1N
M?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!ZC17E
MW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\ _%T?
M\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_ /Q='_"T;G^Y%_WR_P#\70!Z
MC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T >HT5Y=_PM&Y_N1?]\O\
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M'_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\ _%T
M>HT5Y=_PM&Y_N1?]\O\ _%T?\+1N?[D7_?+_ /Q= 'J-%>7?\+1N?[D7_?+_
M /Q='_"T;G^Y%_WR_P#\70!ZC17EW_"T;G^Y%_WR_P#\71_PM&Y_N1?]\O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 E>7_$S_CY7_KDO_H35ZA7EWQ,_P"/E?\ KDO_ *$U 'J
MZ"G"FCH*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH \KT#_D+'_KM/\ R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 E>7?$S_CY7_KDO_H35ZC7EWQ,_P"/E?\ KDO_ *$U 'J*]!2T
MB]!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H
M'_(6/_7:?^3UZI7E>@?\A8_]=I_Y/7JE !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 9_B+_CUG_P"N,G_H!KC/A-_RW_[9?^SUV?B+
M_CUG_P"N,G_H!KC/A-_RW_[9?^ST >AT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7'?%'_ (]D_P"NR_\ H#UV-<=\4?\ CV3_ *[+
M_P"@/0!>^'W_ !Y1_5__ $,UT=<Y\/O^/*/ZO_Z&:Z.@ HHHH **** .%^+'
M_'O'_P!=1_Z"U=+X5_X](/\ KDG_ *"*YKXL?\>\?_74?^@M72^%?^/2#_KD
MG_H(H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*\
MN^)G_'RO_7)?_0FKU&O+OB9_Q\K_ -<E_P#0FH ]17H*6D7H*6@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*
M\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!=I_Y/7JE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 9_B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/79^(O\ CUG_ .N,G_H!KC/A
M-_RW_P"V7_L] 'H=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_ )"Q_P"NT_\
M)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G^(O^/6?_KC)
M_P"@&N,^$W_+?_ME_P"SUV?B+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'N_2N-^(_C"7P\L0@ W2L22W( 0J2N/]K."<\#..2".RKS#XV?\ +M_VV_\
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MX^5_ZY+_ .A-0!Z@.@IPIHZ"G"@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** /*] _Y"Q_Z[3_R>O5*\KT#_D+'_KM/_)Z]4H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\1?\ 'K/_ -<9
M/_0#7&?";_EO_P!LO_9Z[/Q%_P >L_\ UQD_] -<9\)O^6__ &R_]GH ]#HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQX(=QO?((.YP.""3@J,+VZ9P"3708I:*  4444 %%%% !1110 4444 %%%%
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M$(-=C2WD!58C\OE[5(&,;1E3A>G ]!Z5JVMLMJBPH,(BA5&2<!1@#)YZ5-2
M8H *Y#4OA997IWJK1G))\IL Y]F#  =@H _3'848H Y32?AG9:<=Q0R,"2#*
M=W48QM "D?4$Y[],6/$W@2W\1.LTI=75=N48#(SD A@PX)/3'7G/&.CQ10 R
M.(0@(H 50  !@ #@  = *4G%.Q534]233(GN9#A(U)/3)QT R0,D\ 9Y) H
M\P^,FI)/+#;*<O$K%NF!OVX'7.<+G![$'O75?"_0SIMH)& WSG?T&=I V#()
MR,?,/3<1C.:\X\.V#^,+_=-R&8R2<G&T$?*,MG'1!@DJ"#VKW?% ""EHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 2O+OB9_Q\K_UR7_T)J]1KR[XF?\?*
M_P#7)?\ T)J /45Z"EI%Z"EH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*] _Y"Q_Z[3_R>O5* "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S_$7_ !ZS_P#7&3_T
M UQGPF_Y;_\ ;+_V>NS\1?\ 'K/_ -<9/_0#7&?";_EO_P!LO_9Z /0Z***
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MF<$'GFBRL([$;(45%)SA%"C/3. !SQ5FC%  ***6@!,T9I** %HHHH ****
M"BBB@ HHHH **IWFM06)V32QHQ&<.ZJ<=,X)''%6S0 M%%% !1110 4444 %
M0W5HEVICD4,IQE6 8'!R.#QUJ:B@"G9:5%89\F-$W8SL55SCIG &<9JYFBC%
M !1110 4444 %%%% !15.SUJ"^.R&6-V SA'5CCIG )XYJY0 4444 %%%% !
M1110 E>7?$S_ (^5_P"N2_\ H35ZC7EWQ,_X^5_ZY+_Z$U 'J*]!2TB]!2T
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MU'_H+5TOA7_CT@_ZY)_Z"*YKXL?\>\?_ %U'_H+5TOA7_CT@_P"N2?\ H(H
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MJQ!EL3G! D7@8&,*_/7)RN.W!Z=_42<4 +124=* %HI,TM 'CGQD_P"/Q/\
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M. [;$X *QJ2V2,\D#+'GDY XP*]NTS3DTR)+:,82-0!TR<=2< #)/)..22:
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M]AUY.%]2^&?_ "#X?^VG_HQZ .H%%%% !129ILLPA!=B J@DDG  ')))Z 4
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MP00A(((Z$5Q?P9U)YHIK9CE(F4KUR-^[(ZXQE<X ZDGO78^*?^/.X_ZX2_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\A8_P#7:?\
MD]>J5Y7H'_(6/_7:?^3UZI0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'C?P<_X^W_ .N#?^AI7L8KQSX-_P#'X_\ UP;_
M -#2O6-8U9-(A>ZESLC&3@9)R<  >I) ]/4@<T 9_B[Q.GAZ$RL1YC B->NY
ML<<9'RCC<<CCW(!X3P%X3/B-VU:^)<%SA6'WV&.3QC8.@ XR,' 7!QM+N(_%
ME\T]_($B + .X4;0PVQ!CMP.>2!DX)X)R/6HO$EE" BSPA5   EC  '   /
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M 4444 %%%% !1110 4444 %%%% "&C%+10 E>*Z+_P A3_MH?YU[77BFB_\
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M=#@Y7')SQQD^+_ TGAH1NS!UD&"54@*PY*Y/4'^$\$X/RC% 'LOA;_CSM_\
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M_KDO_H34 >H#H*<*:.@IPH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "D-+0: .3\:^!CXG,;>:8Q&&&-@8?-CGJISQSDD<# '.
M>:_X4E_T\_\ D'_[97J&*6@#R[_A2/\ T\_^0?\ [97+^-_!'_"+^5^\\SS=
M_P#!LQLV_P"TV<[J]YKS'XVQ$BW?!V@R@G' )V$#/J<''T/I0!2TKX/_ &^&
M.Y^T8\V-'QY6<;E!QG>,XS7JTTHA!=B J@DDG  ')))Z 50\*_\ 'G;_ /7O
M%_Z *A\8Z?+J-I+;P'$CJ,<[<X(++G_: (YX.<'C- "Z;XLM=3<P0RJSJ<8R
M1G&<[<XW#@G*Y&.>F*UQ7A'@+1+BXO4,8*_9Y 9"<KM .&4]\L 5V]^<\ D>
M\&@#QOPW_P AQO\ KXN?Y25[+7COAB(OKCD D+/<DX'0?.,GT&2!]2!7L5 !
MBBBN#^+FOOI\"VJ<?:=P9LD$*FW(&/[V<'MC(P<\ '#^,=9?Q?>"*V!=!\D2
MX(SW9L$X&3WX^4#=C!KU_P -: F@0+:ISMR6; !9CU)Q^0ZD  9.*XWX3>%/
MLR'49E^=^(MPY"XY<<_Q9P. <#@X:O1NM 'C.D2BQUPF7*YN9@,@_P#+3>$X
MQT;<,'I@YZ<U[,U<!\1OA^^L$7EL 90 K)\J[@.C9./F'0Y/*@8(Q@\O%\1]
M1T0"WG0%L C[1&P?;T'0KD<'DY).<DT =7\8IT6T2-OOM,"HW 'A6R<8)( .
M.,8)!SV.I\,O^0?#_P!M/_1CUP&D>$KWQE,MW>%A$0,NP"DJ " BX'!SD'&W
MJ>3P?8K2T6T184&$10JCDX"C &3STH FHHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/^0L?^NT_\GKU2O*] _Y"
MQ_Z[3_R>O5* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+6+.R,8&3DG)R23ZDDGT] !Q5R@ HHHH **** "BBB@ HHHH **** "BBB@
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M$7&K3"_OLA0<A6Y+?_6KU8+MX[4 +1110 4444 %%%% !1110 4444 %%%%
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MBBB@!#24ZB@ HI* * %HHQ10 AI,T[%&V@!!1FEQ1B@ S2&@T"@!,TM+BC%
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M9IV*,4 -S2BEQ1B@ -)2XHH 3-&:7%% !2&EHH 2BEQ1B@!**7%&* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_
MQ%_QZS_]<9/_ $ UQGPF_P"6_P#VR_\ 9Z[/Q%_QZS_]<9/_ $ UQGPF_P"6
M_P#VR_\ 9Z /0Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@!M*:7%% !0:** $I.E.Q1B@ I,4N*,4 )BEHHH 3%(!GK3J*
M"BBC% #:,4[%&* $QWH%+BC% !24M%  .**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KCOBC_Q[)_UV7_T!Z[&N.^*/_'LG
M_79?_0'H O?#[_CRC^K_ /H9KHZYSX??\>4?U?\ ]#-='0 4444 %%%% '"_
M%C_CWC_ZZC_T%JZ7PK_QZ0?]<D_]!%<U\6/^/>/_ *ZC_P!!:NE\*_\ 'I!_
MUR3_ -!% &K1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4&BD- !FC-9VM>(8-%"O<.$#G X))QUX4$X'<XP,CU%6;&^34(UGB8,C
MC((_SP1T(/(/!YH LYHIH%.S0 45G:UXBM]$"O<.$#G X))QUX4$X'<XP,CU
M%9'_  LS3_\ GM_Y#D_^(H ZFBN6_P"%F:?_ ,]O_(<G_P 15S2?&EIJS^1!
M*&<@D JRYQUQN R>^!SC)Z T ;E%%% !0:*\HT*YN/&6H"\5RD-JX([84DX7
M:#]YP"'.<8SV"K0!ZOB@49JAJ6O6^FY\Z5$(7=AF 8CGD+U/0XP#D\#F@#0I
M*QM.\8V>HX\J9"2VT!CL8DXP KX)SGC Y/'6MB@!U%-JEJVLQ:0GGSL$3(&3
MD\GH !DD_0=,GH#0!>HK/T;78=90S6[;D#;2<,O( .,, >A%:&: "BO/OBU9
M/$D6HPDK)$Q0L@(;:XX)<<@ \>F7]^>P\.:L-7MXKKC,B M@$#<.& !YP&!'
M]3UH T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $
MKR[XF?\ 'RO_ %R7_P!":O4:\N^)G_'RO_7)?_0FH ]17H*6D7H*6@ HHHH
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MS<Q@,#@IP6Z\,&/!XXVD9Y(KD)$/@_4< DK!*#D89C&P!(Y &XHV#TYZ'H:
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M<NBD[' 8MCG V@$'&<#!R<#CK5KX2^*&NU.G298Q+N1B00$!5=GKP3QUX..
M!GT*200@NQ 50223@ #DDD] *\;\%!;C5_,@'[H23L-JD (5<*<8&T<@#..H
M% 'LDLHA!=B J@DDG  ')))Z 5XCXFU>3QG>K##]S=LB'S8QGF0C&1D<MQPH
M .=N:Z_XK>+1:I_9T1&^0?O""<JO!"\=W[@G[O488&I?A1X7%E#]OD!$DP(7
M.1B/(QQ@<L1G//R[<8R<@'8Z/I":1$EK%G9&,#)R3DY))]223Z>@ XJY2T4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y7H'_(
M6/\ UVG_ )/7JE>5Z!_R%C_UVG_D]>J4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!G^(O^/6?_KC)_P"@&N,^$W_+?_ME_P"SUV?B
M+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] 'H=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5QWQ1_X]D_Z[+_Z ]=C7'?%'_CV3_KLO_H#T
M 7OA]_QY1_5__0S71USGP^_X\H_J_P#Z&:Z.@ HHHH **** .%^+'_'O'_UU
M'_H+5TOA7_CT@_ZY)_Z"*YKXL?\ 'O'_ -=1_P"@M72^%?\ CT@_ZY)_Z"*
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M[/P[X3M] 7;"OS'.7;!D.2#C< ..!P,#C.,Y- &U7E'A0G5]9EN=X(B,K*0
M0RC]TH!'&-K YYSCWS7H?B;6?[%MI+O&2B\#&1N8A5SR.,D9YSC..:Y#X-:8
M889;HYQ*ZJ 1CB,'Y@>X)8CV*G\ #T.BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!*\N^)G_'RO\ UR7_ -":O4:\N^)G_'RO_7)?
M_0FH ]17H*6FCH*<* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH \KT#_D+'_KM/_)Z]4KRO0/^0L?^NT_\GKU2@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHKT%+2+T%+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'E>@?\A8_]=I_Y/7JE>5Z!_P A8_\ 7:?^3UZI0 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &?XB_P"/6?\ ZXR?^@&N,^$W_+?_
M +9?^SUV?B+_ (]9_P#KC)_Z :XSX3?\M_\ ME_[/0!Z'1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %<=\4?^/9/^NR_P#H#UV-<=\4
M?^/9/^NR_P#H#T 7OA]_QY1_5_\ T,UT=<Y\/O\ CRC^K_\ H9KHZ "BBB@
MHHHH X7XL?\ 'O'_ -=1_P"@M72^%?\ CT@_ZY)_Z"*YKXL?\>\?_74?^@M7
M2^%?^/2#_KDG_H(H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@!*\N^)G_ !\K_P!<E_\ 0FKU&O+OB9_Q\K_UR7_T)J /45Z"EI%Z
M"EH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RO0/^
M0L?^NT_\GKU2O*] _P"0L?\ KM/_ ">O5* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH S_ !%_QZS_ /7&3_T UQGPF_Y;_P#;+_V>
MNS\1?\>L_P#UQD_] -<9\)O^6_\ VR_]GH ]#HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "N.^*/_'LG_79?_0'KL:X[XH_\>R?]=E_
M] >@"]\/O^/*/ZO_ .AFNCKG/A]_QY1_5_\ T,UT= !1110 4444 <+\6/\
MCWC_ .NH_P#06KI?"O\ QZ0?]<D_]!%<U\6/^/>/_KJ/_06KI?"O_'I!_P!<
MD_\ 010!JT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M5Y=\3/\ CY7_ *Y+_P"A-7J->7?$S_CY7_KDO_H34 >HKT%+2+T%+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E>@?\ (6/_ %VG
M_D]>J5Y7H'_(6/\ UVG_ )/7JE !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 9_B+_CUG_ZXR?^@&N,^$W_ "W_ .V7_L]=GXB_X]9_
M^N,G_H!KC/A-_P M_P#ME_[/0!Z'1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<=\4?^/9/^NR_^@/78UQWQ1_X]D_Z[+_Z ] %[X??
M\>4?U?\ ]#-='7.?#[_CRC^K_P#H9KHZ "BBB@ HHHH X7XL?\>\?_74?^@M
M72^%?^/2#_KDG_H(KFOBQ_Q[Q_\ 74?^@M72^%?^/2#_ *Y)_P"@B@#5HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $KR[XF?\?*_P#7
M)?\ T)J]1KR[XF?\?*_]<E_]":@#U%>@I:1>@I: "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH \KT#_ )"Q_P"NT_\ )Z]4KRO0/^0L
M?^NT_P#)Z]4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#/\1?\>L__7&3_P! -<9\)O\ EO\ ]LO_ &>NS\1?\>L__7&3_P! -<9\
M)O\ EO\ ]LO_ &>@#T.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Y7H'_(6/\ UVG_ )/7JE>5Z!_R%C_UVG_D]>J4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!G^(O^/6?
M_KC)_P"@&N,^$W_+?_ME_P"SUV?B+_CUG_ZXR?\ H!KC/A-_RW_[9?\ L] '
MH=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 2O+OB9_Q\K_UR7_T)J]1KR[XF?\ 'RO_ %R7_P!"
M:@#U%>@I:1>@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH \KT#_D+'_KM/\ R>O5*\KT#_D+'_KM/_)Z]4H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@#/\1?\>L__ %QD_P#0#7&?";_E
MO_VR_P#9Z[/Q%_QZS_\ 7&3_ - -<9\)O^6__;+_ -GH ]#HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
MQ= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?
M*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"WK7^Y+_WR
MG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W
M;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MV
MU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_
M  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q=
M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
MQ= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?
M*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WR
MG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W
M;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MV
MU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_
M  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\ Q= '<T5PW_"W;7^Y+_WRG_Q=
M'_"W;7^Y+_WRG_Q= '<T5PW_  MVU_N2_P#?*?\ Q='_  MVU_N2_P#?*?\
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MO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PMVU_N2_\
M?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_"W;7^Y+
M_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_PMVU_N2_
M]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =S17#?\+=
MM?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PMVU_N
M2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW_"W;
M7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_PMVU
M_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =S17#
M?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 71_PM
MVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<T5PW
M_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_\71_
MPMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\ %T =
MS17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG_P 7
M1_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q= '<
MT5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_]\I_
M\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\
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M\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\I_\
M%T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_ 'RG
M_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_WRG_Q
M= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU_N2_
M]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+_P!\
MI_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?[DO_
M 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^Y+_W
MRG_Q= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_PMVU
M_N2_]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;7^Y+
M_P!\I_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\+=M?
M[DO_ 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"W;7^
MY+_WRG_Q= '<T5PW_"W;7^Y+_P!\I_\ %T?\+=M?[DO_ 'RG_P 70!W-%<-_
MPMVU_N2_]\I_\71_PMVU_N2_]\I_\70!W-%<-_PMVU_N2_\ ?*?_ !='_"W;
M7^Y+_P!\I_\ %T =S17#?\+=M?[DO_?*?_%T?\+=M?[DO_?*?_%T =S17#?\
M+=M?[DO_ 'RG_P 71_PMVU_N2_\ ?*?_ != '<T5PW_"W;7^Y+_WRG_Q='_"
MW;7^Y+_WRG_Q= '<UQWQ1_X]D_Z[+_Z ]5_^%NVO]R7_ +Y3_P"+K!\9>/H-
M;A6&-7!$@;Y@H& K#LQ]: .T^'W_ !Y1_5__ $,UT=<S\.G#V49'J_\ Z&:Z
M:@ HHHH *0\<TM% %&^TF+4!B90P!SA@",^O-4QX/L_^>*?]\+_A6SBEH Q?
M^$0L_P#GBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9
M_P#/%/\ OA?\*VJ* ,7_ (1"S_YXI_WPO^%'_"(6?_/%/^^%_P *VJ* ,7_A
M$+/_ )XI_P!\+_A1_P (A9_\\4_[X7_"MJB@#%_X1"S_ .>*?]\+_A1_PB%G
M_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH Q?\
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MBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9_P#/%/\
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M\(A9_P#/%/\ OA?\*VJ* ,7_ (1"S_YXI_WPO^%'_"(6?_/%/^^%_P *VJ*
M,7_A$+/_ )XI_P!\+_A1_P (A9_\\4_[X7_"MJB@#%_X1"S_ .>*?]\+_A1_
MPB%G_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH
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M_P \4_[X7_"MJB@#%_X1"S_YXI_WPO\ A1_PB%G_ ,\4_P"^%_PK:HH Q?\
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MBG_?"_X4?\(A9_\ /%/^^%_PK:HH Q?^$0L_^>*?]\+_ (4?\(A9_P#/%/\
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M_P"%'_"(6?\ SQ3_ +X7_"MJB@#%_P"$0L_^>*?]\+_A1_PB%G_SQ3_OA?\
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M+/\ YXI_WPO^%'_"(6?_ #Q3_OA?\*VJ* ,7_A$+/_GBG_?"_P"%'_"(6?\
MSQ3_ +X7_"MJB@#%_P"$0L_^>*?]\+_A1_PB%G_SQ3_OA?\ "MJB@#%_X1"S
M_P">*?\ ?"_X4?\ "(6?_/%/^^%_PK:HH Q?^$0L_P#GBG_?"_X4?\(A9_\
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<4 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>favors1.jpg
<TEXT>
begin 644 favors1.jpg
M_]C_X  02D9)1@ ! @$ S #,  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @;"ALB$1<D*B0<&R D*R@H("0I)24Q+R4I+BHK*SDK*BXO
M-#4U-30O.SL[.SL[.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]4HHHH **** "BDS2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHI,T +1
M0** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUYYLRQ Y$:\C'1FY/Z;?;]:Z[P[8"R@1 ,$J"V1@[F&3G@=.G/. !7">,?\
MC[D_X!_Z M>FF@ KS"Y3^Q+SCA8Y ?E)SM.#CG'\)P<_G7IXKS+QC_Q]R?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0C 8X*DC."#^F>F?0]^E<1X:UXZ.[12 A&/S=<J1QG'Z'OP/3! /2*XGXBS
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M<]8SCH,8QRH_ 5MT4 <[;^!+:(Y;<W'1FX^ORA370)&(P%48 & !P !VIU%
M"8K.U+P]!J/S2+\V#\PX;IC/'7&.,YK2HH YI/ %NI!)<X/0L,'VX4'\JW;#
M3X[!?*B7:N2<>Y[Y/)JQ10 C"LW6O#\>K[?,+#9G&T@=<>H/I6G10!%;6JVJ
MB)!A5& !_G_]=2T44 17%JER-LBAAG.& (SZ\U%#I<,!#I&BL.A5%!_,"K5%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MY&)Z<X!V@9[]"?QH KS?#V$@A'<-V+;6'Y #^=<_I]_+X;G,4A)53\RJ<@Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBD- "T4E% "T4@I: "BDH% "T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M44 &*,444 %%%% !1110 4@%+10 4444 %%%% !1110 4444 %%%% !1110
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M MD-K&?WCC#<9PI'(]B?Y<\<&NGVUEW/AF"ZE^TNN6('!/RY&,''T&,=,=J
M,_P9X?-@IGD&)'& ">B\'!'J3U]..AR*WKZV^U1O%G&]67/7&1C-3XHQ0!PG
M@N_32Y)8)SL8D#)(VY3=D$YQWX[>_3,WC?55O!';0D/ELG9\QST4 CCG)XZ]
M/QZ;4=#AU$AI4W%1@')!QZ<$9I+#P_!8'?&@#>IRQ'7H6)QU[=: )=)L?L$2
M0?W5&<$D9ZL>?4YJW110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444F: %HHS10 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !11FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***0T *:\\\5>&I;.5M1@^Z&#D#EE/4M
M@Y!&>3Z9Z8&:]!-><ZOXEFUR0V5K_JWR!@!68 9.2QX'!QTR#@CM0!H:=\2U
M*XN$(8=X\$'KV8C';N<^U92VUQXRE,IPD2' SG:H.,@?WFQR>G;) VBMNT^&
MD00>:[E\?-L("Y]LJ3_CUP.E8MU:7'@R3S(R'C<8R0=I..A&>".HYZ=#]X4
M>CVT*VZK&HPJ@ #V P.M2XJAH>KKJT2W"<9X(R"01U''YCID$' S6A0 TUP'
MQ*U0.R6BG[OS,..IX7W! SQZ$'GMTGBCQ0FBI@8:5A\J_P#LQ]OY]!W(Y+PC
MX=?5Y?MTX!CW$G</OL<]A@8!Y/;^'!YP =;X-TDZ9;JK9W.=[ ]BP&!@@$8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !32V*=3&H JZAJ2V*&1^@Q63_P )G%Z']/\ &IO%G^H;\/YBN& K
M"K6<78];+L!1Q%)R;UNSM!XTB'8_I_C2_P#":Q>A_3_&N+ _SFC'^<UD\1([
M?['P_F=I_P )K%Z']/\ &C_A-8O0_I_C7%X_SFC'^<TOK,@_LC#^9VG_  FL
M7H?T_P :/^$UB]#^G^-<7C_.:,?YS1]9D']D8?S.T_X36+T/Z?XT?\)K%Z']
M/\:XO'^<T8_SFCZS(/[(P_F=I_PFL7H?T_QH_P"$UB]#^G^-<7C_ #FC'^<T
M?69!_9&'\SM/^$UB]#^G^-'_  FL7H?T_P :XO'^<T8_SFCZS(/[(P_F=I_P
MFL7H?T_QH_X36+T/Z?XUQ>/\YHQ_G-'UF0?V1A_,[3_A-8O0_I_C1_PFL7H?
MT_QKB\?YS1C_ #FCZS(/[(P_F=I_PFL7H?T_QH_X36+T/Z?XUQ>/\YHQ_G-'
MUF0?V1A_,[3_ (36+T/Z?XT?\)K%Z']/\:XO'^<T8_SFCZS(/[(P_F=I_P )
MK%Z']/\ &C_A-8O0_I_C7%X_SFC'^<T?69!_9&'\SM/^$UB]#^G^-'_":Q>A
M_3_&N+Q_G-&/\YH^LR#^R,/YG:?\)K%Z']/\:/\ A-8O0_I_C7%X_P YHQ_G
M-'UF0?V1A_,[3_A-8O0_I_C1_P )K%Z']/\ &N+Q_G-&/\YH^LR#^R,/YG:?
M\)K%Z-^G^-'_  FD7HWZ?XUQ?^>M'^>M'UF0O[(P_=G<6OBN.Z<1KG)]:W-U
M><Z'GSTQCK7H@KHH3<U=GDYCAX4*BC'8?FBDI:T1QA1113 **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH I:W$9
M()54$DQ.  ,DDJ<#%>?_  XE"7+ D9:)@,GJ=RG _ $_A7IM<5KWPZ^T.9;9
ME7<>4;(4=<D$9Q],>N#C H [/=7,^/[N);9HF*^82I53RWWNH'4< C/X9YKF
MX] U2,!5,@ & !,  !T&-]6;+X?SWS>;=OC/7G?(<'&,].G0Y...* +?PP@8
M+-)CY6* 'W4$G_T(5T/B77AHT1DX+GA%/<]SQV'4]/3()%:%A9+8QK GW4
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MEK9;'FA1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I*6B@ %%%% !24M% "4"EHH ****
M$-%+10 E%+10 @I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&I:1J
M1A^+_P#4'ZC^8KAA7<^+_P#4'ZC^8KAA7%7^(^CR7_=_F_R0ZBBBL&>H@HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH ****!%W0_^/A/K7HHKSK0_^/A/K7HHKMPWPGS><_QUZ"TM)2ULMCS0
MHHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "BBB@ HHHH 1AD&O1?#O\ Q[Q?[@KSINE>B^'?^/>+_<% &C1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GU
MYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT
M7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ?[@H T:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *0TM% #<4ZBB@ HHHH *#110 F*7%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X!_Z&M<'7>>+O^/63_@'_
M *&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%%# *!10*.@NYH>&_^/F/\
M?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GU
MYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT
M7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#'\7?\>LG_ /_ $-:X.N\\7?\>LG_
M  #_ -#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBA@% HH%'07<T/#?_
M !\Q_C_*O1*\[\-_\?,?X_RKT2N[#_"?-YS_ +Q\D%%%%;'FA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YA?\ ^MD_ZZ-_
M.O3Z\PO_ /6R?]=&_G0!#1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% "-TKT7P[_P >\7^X*\Z;
MI7HOAW_CWB_W!0!HT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X!_P"AK7!UWGB[_CUD
M_P" ?^AK7!UQ8GX_D?1Y)_N[_P 3_)!1116!Z@4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444, H%% HZ"[FAX;
M_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>/D@HHHK8\T**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,+_ /ULG_71
MOYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?\ CWB_W!7G
M3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH ***,T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% &/XN_X]9/^ ?^AK7!UWGB[_CU
MD_X!_P"AK7!UQ8GX_D?1Y)_N[_Q/\D%%%%8'J!1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110P"@44"CH+N:'AO
M_CYC_'^5>B5YWX;_ ./F/\?Y5Z)7=A_A/F\Y_P!X^2"BBBMCS0HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\PO_ /6R?]=&
M_G7I]>87_P#K9/\ KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?^/>+_ '!7
MG3=*]%\._P#'O%_N"@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9I13781@LQ  &23P !WKA=7\72WLGDVF0N"/E7+MZD<9'MC![GT !WE%>?\
MV34K/][F0[?]L2=>/NY;/Y<=:TO#/C)KEEMI^68G#\#GL".![ CV&.] '745
M%=7 MD:5NB*6..N ,UP>D6!\42/-.Y&S;PH['=@#.< 8]#GZ\T >@T5P-Y&_
MA*97B):*0<AB.<=1QW&<@XXSCGG/=0SB91(O*L 0?8C(ZT 24E9VNZTNE1ER
M?G((0=<GZ<<#O_B17/\ @N:>^D>>1V* $8).TLW. ,8&/;!''8XH [$4M HH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH Q_%W_'K)_P#_P!#6N#KO/%W_'K)_P  _P#0UK@Z
MXL3\?R/H\D_W=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_P ?,?X_RKT2
MO._#?_'S'^/\J]$KNP_PGS><_P"\?)!1116QYH4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>87_ /K9/^NC?SKT^O,+_P#U
MLG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.FZ5Z+X=_X]XO
M]P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH Q_%W_'K)_P  _P#0UK@Z[SQ=_P >LG_ /_0UK@ZXL3\?
MR/H\D_W=_P")_D@HHHK ]0**** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH ****& 4"B@4=!=S0\-_P#'S'^/\J]$KSOP
MW_Q\Q_C_ "KT2N[#_"?-YS_O'R04445L>:%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7F%__K9/^NC?SKT^O,+_ /ULG_71
MOYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 C=*]%\._P#'O%_N"O.FZ5Z+X=_X]XO]P4 :
M-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5B^+-6_LZ$[3AY/E7GGGJ>H/ [CH<5M5YQXPOSJ%QY29(
MC^0 9.6SS@8ZYX]\"@"YX!TWS9&N6Z1C"\'&6Z\^P[>^?2NZ(JEHFF#38EA'
M4#+$=V/4]!]!GG %7J ./^(D!*Q2?P@L"?=@"/Y&M+P1<"6V51_ S _7.[^3
M5:\1Z5_:<+1C[P^9?J.W4#D9'/3.:Y#PMXA_L=F@FR$)Y^7E6R 2>AQ@<CD\
M<#K0!Z'7%?$5P3$N>0')'?!VX/XX/Y5T=QXCMK<;FE4C./E.X_DN37#ZW=GQ
M!=!8N0<(IP1P,DL>IQDD].G4=: .R\((4M8P1CACSZ%B0?Q'-:^:CM8!;(L2
M]$4 9ZX Q4>H7RV$;3O]U1VY/H!^)H R_%7B'^RTVH1YK] >P_O8_09[^N"*
MRO!'A\I_ID@QQ^[Y[$$%L>XZ?B<=#6;I%H_B6X,TW*+C=@XXYVJ!UQG],G.3
MSZ$B! %48 & !P !VH \^L(O^$INF:4E5VDX4YP!@  GIUR>.3G@9XM^(?#P
MT0+>6Q8%7^H .<<XZ=N<YS@^\'@)#'<.K#!$; @\$$,O%=%XUF$=JZGJY4#Z
M[@W\@: -#1M0_M&%)\8+#GZ@X/<\9''M5VN=\"6YBMMQ_C=B/IPO\UKHJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** ,?Q=_QZR?\ _\ 0UK@Z[SQ=_QZR?\  /\ T-:X.N+$
M_'\CZ/)/]W?^)_D@HHHK ]0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ****& 4"B@4=!=S0\-_\ 'S'^/\J]$KSO
MPW_Q\Q_C_*O1*[L/\)\WG/\ O'R04445L>:%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7F%_P#ZV3_KHW\Z]/KS"_\ ];)_
MUT;^= $-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 (W2O1?#O_ ![Q?[@KSINE>B^'?^/>+_<%
M &C1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4  >P&!3Z** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_P >LG_ /_0UK@Z[SQ=_QZR?
M\ _]#6N#KBQ/Q_(^CR3_ '=_XG^2"BBBL#U HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_Q
M\Q_C_*O1*\[\-_\ 'S'^/\J]$KNP_P )\WG/^\?)!1116QYH4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>87_\ K9/^NC?S
MKT^O,+__ %LG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*]%\._\>\7^X*\Z;I7
MHOAW_CWB_P!P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#/$N3^0;)_"K.A>.)-XCN"&5CC=@*1G '3 P._?OGC%=U7F/C+_C[D_X!_Z
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M !_E7HE=V'^$^;SG_>/D@HHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O,+_\ ULG_ %T;^=>GUYA?_P"MD_ZZ-_.@
M"&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ KS"__P!;)_UT;^=>GUYA?_ZV3_KHW\Z
M(:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH 1NE>B^'?^/>+_<%>=-TKT7P[_Q[Q?[@H T:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,?Q=_P >LG_ /_0UK@Z[SQ=_QZR?\ _]#6N#KBQ/Q_(^CR3_
M '=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_Q\Q_C_*O1*\[\-_\ 'S'^
M/\J]$KNP_P )\WG/^\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %>87_\ K9/^NC?SKT^O,+__ %LG_71OYT 0
MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 C=*]%\._\>\7^X*\Z;I7HOAW_CWB_P!P4 :-%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% &/XN_P"/63_@'_H:UP==YXN_X]9/^ ?^AK7!UQ8GX_D?1Y)_
MN[_Q/\D%%%%8'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110P"@44"CH+N:'AO_CYC_'^5>B5YWX;_P"/F/\
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M!#1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% "-TKT7P[_Q[Q?[@KSINE>B^'?\ CWB_W!0!HT44
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 8_B[_CUD_X!_Z&M<'7>>+O^/63_@'_ *&M<'7%B?C^1]'D
MG^[O_$_R04445@>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%# *!10*.@NYH>&_^/F/\?Y5Z)7G?AO\ X^8_
MQ_E7HE=V'^$^;SG_ 'CY(****V/-"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KS"_\ ];)_UT;^=>GUYA?_ .MD_P"NC?SH
M AHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO\ <%>=-TKT7P[_ ,>\7^X* -&B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH HZQK":2@ED!(+!?E )R03W(]*QO^%@P?W9/R7_XJCX@_P#'
MNO\ UU'_ *"U5_#'ABWO+=9I%W,Q;^)AT8C'!'I0!8_X6#!_=D_)?_BJW=.U
M./45,D1W*#C.".>#W ]:S_\ A#;7_GG_ .//_P#%5?L--CTY?+B&%)SC)/.
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MN[#_  GS><_[Q\D%%%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5YA?_P"MD_ZZ-_.O3Z\PO_\ 6R?]=&_G0!#1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% "-TKT7P[_Q[Q?[@KSINE>B^'?^/>+_ '!0!HT444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ',_$'_CW7_KJ/_06K&T/QH-.C2W:/(4G+!N<%B>F.V?6NZN;5+D;9%##
M.<, 1GUYJG-X?MY@5,28/]U0I_-<&@"G8>-+>[.W)0]O,  /7N"0/QQ[5N-7
M)Z[X(CV&2W!5E&=N2P.,D]<G)[=NV.<U1\#:T4?[&V2K9*^BD D_@?Y]N2:
M+7Q$F(6*/^$EB1[J !_,UI>"+<16RL/XV9C]<[?Y**ROB+_RQ_[:?^RUM>#?
M^/2/_@?_ *&U &P:XKXB0@-%)_$0P)]E((_F:[>N+^(W_+'_ +:?^RT 7$1]
M3TT*H^;9@ 9Y$;=._)"_GZ52\$:W%:HT$C;6+E@6X4@J._0=.^.V,UM^#?\
MCTC_ .!_^AM5B^\.V]^WFR)EL 9RPZ?0C- ''ZQ??\)+<I!%]P' ) ^K/@X[
M#IGMV)Q70>,M>_L^/R4.))!U!&5'<^O/0?B<Y%79A!X>B:1%"@#@=V/)"YY)
M_7 ]A7(:#I3>(9FN)L[,DL1G!/9 2<XQZ9P !QD&@#5\#:%Y0^V2#!880$#H
M<?-Z\]!TXSU!KK17*W7C"2XD-O:1[R&QN)W @<$X&,#/<G&.O7AVF^,65Q#>
M)Y9;HV"H]!D-SC.><X]NIH ZK%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/XN_X]9/^
M ?\ H:UP==YXN_X]9/\ @'_H:UP=<6)^/Y'T>2?[N_\ $_R04445@>H%%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/!3EO7#*.O3GC:>/I0!Z!FN#^(-YYDJ0C&$7/'7+'D'\ #^-07?C:Y/R?*C
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M_P >LG_ /_0UK@Z[SQ=_QZR?\ _]#6N#KBQ/Q_(^CR3_ '=_XG^2"BBBL#U
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH8!0**!1T%W-#PW_Q\Q_C_*O1*\[\-_\ 'S'^/\J]$KNP_P )\WG/
M^\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>87_\ K9/^NC?SKT^O,+__ %LG_71OYT 0T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 C=*]%\._\>\7^X*\Z;I7HOAW_CWB_P!P4 :-%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2&EHH 2ES11
M0 4E+10 E+110 4444 %5'TF)Y/M!0&3 Y(].AQTR/7KVSBK=% "&@4M% $-
MS91W6/,16QTW*#C/7K26UE':Y\M%7/7:H&<=.E3T4 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% &/XN_X]9/^ ?^AK7!UWGB[_CUD_X!_P"AK7!UQ8GX_D?1Y)_N[_Q/
M\D%%%%8'J!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110P"@44"CH+N:'AO_CYC_'^5>B5YWX;_ ./F/\?Y5Z)7
M=A_A/F\Y_P!X^2"BBBMCS0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\PO_ /6R?]=&_G7I]>87_P#K9/\ KHW\Z (:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH 1NE>B^'?^/>+_ '!7G3=*]%\._P#'O%_N"@#1HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH Q_%W_'K)_P#_P!#6N#KO/%W_'K)_P  _P#0UK@ZXL3\?R/H\D_W
M=_XG^2"BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH8!0**!1T%W-#PW_P ?,?X_RKT2O._#?_'S'^/\
MJ]$KNP_PGS><_P"\?)!1116QYH4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>87_ /K9/^NC?SKT^O,+_P#ULG_71OYT 0T4
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.FZ5Z+X=_X]XO]P4 :-%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** $;I7HOAW_ (]XO]P5YTW2O1?#O_'O%_N"@#1HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M 4444 %%%% !1110 4444 %%%% !7F%__K9/^NC?SKT^O,+_ /ULG_71OYT
M0T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 C=*]%\._P#'O%_N"O.FZ5Z+X=_X]XO]P4 :-%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444, H%%
MHZ"[FAX;_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>/D@HHHK8\T**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O,+_
M /ULG_71OYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1NE>B^'?\
MCWB_W!7G3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNWGOZ=<\^G(!VU<7\1_^6/\ VT_]EKLS7G?C:\^VW B3+; %P.1N)YP!GGD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "O,+__ %LG_71OYUZ?7F%__K9/^NC?SH A
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@!&Z5Z+X=_X]XO]P5YTW2O1?#O_'O%_N"@#1HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "O,+__ %LG_71OYUZ?7F%__K9/^NC?SH AHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!&Z5Z+X=_X]XO]P5YTW2O1?#O_'O%_N"@#1HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B[_
M (]9/^ ?^AK7!UWGB[_CUD_X!_Z&M<'7%B?C^1]'DG^[O_$_R0E+116!Z@44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444, H%% HZ"[FAX;_P"/F/\ '^5>B5YWX;_X^8_Q_E7HE=V'^$^;SG_>
M/D@HHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "O,+_ /ULG_71OYUZ?7F%_P#ZV3_KHW\Z (:*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH 1NE>B^'?\ CWB_W!7G3=*]%\._\>\7^X* -&BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% "-TKT7P[_ ,>\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P ?,?X_RKT2O._#?_'S'^/\J]$KNP_PGS><_P"\?)!1116QYH4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>87_ /K9/^NC
M?SKT^O,+_P#ULG_71OYT 0T444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C=*]%\._\ 'O%_N"O.
MFZ5Z+X=_X]XO]P4 :-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% &'XGUY]'",B!@S'<3G&!VXZ$]C['@TR
MU\;6TJAG;8Q'*E6.#]0,'_/3I6U<VRW2F)QE6&"#_G_]5<^_@"W8D@N,GH&&
M![<J3^9H ??^-[>)"8FWO@X&UL9P<$YV\9ZX.:Y;P?I)OIA)_!$0Q.><]5'X
MD<^V><XKIX? 5O&=Q+L!V9A@_P#?(!_6M^.%8 $0!5'0*,#\A0!'J%H+V-X3
M_&I&2,X)Z''L>:\\TG47\.3LCC(!VN!D9&>&&<9]1GJ#VSFO2P*I:AHT.HX\
MU Q'?D'OQD8..>G2@"B_C.U4$A\D#H%;)]N0!^9KE=4OI/%,RQ1+@*#@'L">
M7) XXQQS[9)YW_\ A7UO_>D_-?\ XFMS3M)BTX%85V[CD\DD_B230 NF6 T^
M)8%Z(.OJ>I/4]3S3-8U1=+B,[<XX R 23T'^/MDXJ[69K7AZ/6-OF%ALSC:0
M.N,]0?2@#EO"6F-JTIOICN"MG.>2XP1P.P'T'0#C(KO*BMK9;51$@PJC  _S
M_P#KJ3- ' ZB/[!OOM+*3&S%ATYW##8^A)X^F>N:T_$7BZ&:!XX7R[C;]TC@
M_>^\!VR/7G\1T]Q;)<C;(H89SA@",^O-10Z7# 0Z1HK#H510?S H S/!VDG3
MX<N,/(=Q!&"!T /\_;)&,UNT44 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B[_ (]9/^ ?
M^AK7!UWGB[_CUD_X!_Z&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%# *
M!10*.@NYH>&_^/F/\?Y5Z)7G?AO_ (^8_P ?Y5Z)7=A_A/F\Y_WCY(****V/
M-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MS"__ -;)_P!=&_G7I]>87_\ K9/^NC?SH AHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z5Z+
MX=_X]XO]P5YTW2O1?#O_ ![Q?[@H T:*** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,444 %+24
M4 %%%% !1110 4M)10 M%)10 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B[_CUD_X
M!_Z&M<'7>>+O^/63_@'_ *&M<'7%B?C^1]'DG^[O_$_R04445@>H%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M# *!10*.@NYH>&_^/F/\?Y5Z)7G?AO\ X^8_Q_E7HE=V'^$^;SG_ 'CY(***
M*V/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KS"_\ ];)_UT;^=>GUYA?_ .MD_P"NC?SH AHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!&Z
M5Z+X=_X]XO\ <%>=-TKT7P[_ ,>\7^X* -&BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\7?\>LG
M_ /_ $-:X.N\\7?\>LG_  #_ -#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBBA@% HH%'07<T/#?_ !\Q_C_*O1*\[\-_\?,?X_RKT2N[#_"?-YS_ +Q\
MD%%%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5YA?\ ^MD_ZZ-_.O3Z\PO_ /6R?]=&_G0!#1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M"-TKT7P[_P >\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%% "-TKT7P[_ ,>\7^X*\Z;I7HOAW_CWB_W!0!HT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"/>+_<%>=-TKT7P[_Q[Q?[@H T:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4445@>H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%%# *!10*.@NYH>&_\ CYC_ !_E7HE>=^&_^/F/\?Y5Z)7=
MA_A/F\Y_WCY(****V/-"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ KS"_P#];)_UT;^=>GUYA?\ ^MD_ZZ-_.@"&BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $;I7HOAW_ (]XO]P5YTW2O1?#O_'O%_N"@#1HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M****& 4"B@4=!=S0\-_\?,?X_P J]$KSOPW_ ,?,?X_RKT2N[#_"?-YS_O'R
M04445L>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7F%_\ ZV3_ *Z-_.O3Z\PO_P#6R?\ 71OYT 0T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 C=*]%\._\>\7^X*\Z;I7HOAW_ (]XO]P4 :-%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M% %#5]&CU
M90D@Z'((X8>N#SU[_P"(%8__  KZW_O2?FO_ ,373T4 <Q_PKZ#^])^:_P#Q
M-2V?@F"T=907)0Y 8C&1TZ '@UT5!H 9574-%AU#'FH&([\@]^,C!QSTZ5<Q
M2T <Q_PKZW_O2?FO_P 36YIVDQ:<"L*[=QR>22?Q))JW10 5F:WX>CU?;YA8
M;,XVD#KC/4'TK3H- $5K;+:J(HQA5& !_G_]=2T"B@"*XM4N1MD4,,YPP!&?
M7FHH=+A@(=(T5AT*HH/Y@5:HH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_QZR?
M\ _]#6N#KO/%W_'K)_P#_P!#6N#KBQ/Q_(^CR3_=W_B?Y(****P/4"BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MBA@% HH%'07<T/#?_'S'^/\ *O1*\[\-_P#'S'^/\J]$KNP_PGS><_[Q\D%%
M%%;'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5YA?_ .MD_P"NC?SKT^O,+_\ ULG_ %T;^= $-%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M(W2O1?#O_'O%_N"O.FZ5Z+X=_P"/>+_<% &C1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!C^+O^/6
M3_@'_H:UP==YXN_X]9/^ ?\ H:UP=<6)^/Y'T>2?[N_\3_)!1116!Z@4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444, H%% HZ"[FAX;_X^8_Q_E7HE>=^&_P#CYC_'^5>B5W8?X3YO.?\ >/D@
MHHHK8\T**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O,+_P#ULG_71OYUZ?7F%_\ ZV3_ *Z-_.@"&BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M$;I7HOAW_CWB_P!P5YTW2O1?#O\ Q[Q?[@H T:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,?Q=_Q
MZR?\ _\ 0UK@Z[SQ=_QZR?\  /\ T-:X.N+$_'\CZ/)/]W?^)_D@HHHK ]0*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ****& 4"B@4=!=S0\-_\ 'S'^/\J]$KSOPW_Q\Q_C_*O1*[L/\)\WG/\
MO'R04445L>:%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7F%_P#ZV3_KHW\Z]/KS"_\ ];)_UT;^= $-%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 (W2O1?#O_ ![Q?[@KSINE>B^'?^/>+_<% &C1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *,T&H
MYIU@!=R%4=2Q 'YF@!^: :HZ=K<.HDK$^XJ,D8(./7D#-7L4 +FBDJG?ZS#I
MV/-<*3VY)[\X&3CCKTH NYHS6-_PF5I_ST_\<?\ ^)K0L-3BU ;XF##OCJ.O
M4'D=.] %FBFNXC!9C@ 9)/  '>N1?Q'<ZQ(8K,!54\N>>,D G<, $<XP6X.,
M\T =A17'0>)9])E$%[@J>=R@9 )P#\O4<'C ;^5=C0 4E5M2U)-.0S2' 'YD
M]@!Z_P#ZSQ7.^%M<N-6E9G(\M5Y 48!/3!SN[$\Y'4=Q@ ZP44@I: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *"<44C4 S&\7-_HSC_<_P#0UKA:[;Q:3]G9/4K^C UQ&:XL1\=_
M(^CR56P[_P 3?X(6BBBL#U HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH>P!0**3.*.@K&CX;_ ./F/\?Y5Z$*
M\[\//MN(S]?Y5Z&#FN[#OW3YK.E?$7\D.-+29I:V/.L%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% " YKS&__ -;)_P!=&_G7
MIN<<UYA=N))'8=W8_F<T 1T44M "44M% "44M% "44M% "44M% "44M% "44
MM% "44M% "44M% "44M% "44M% "44M% "44M% "44M% "44M!&* &MTKT3P
M\<6\7^X*\[?@$^U>C:&GEP1H>R#- &A1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@7G'). "2>I_P]L#-9'@_P ._8$\^0$2N.AXVC/3'J< G/3I@<YZ.@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *1J6D:@$8?B__ %!^H_F*X85W/B__ %!^H_F*X85QU_B/
MH\E_W?YO\D.HHHKG9ZB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH$7=#_X^$^M>BBO.M#_X^$^M>BBN
MW"_"SYO.?XZ]!:6DI:V6QYH4444P"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** &M7ETWWC]37J+5Y=-]X_4T -%+2"EH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@!LG2O2M(_U2?2O-9.E>E:1_JD^E %RBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110!Y]\/O]>W_ %R/_H2UZ#7GWP^_U[?]<C_Z$M>@T <7\1O^6/\
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M$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110(NZ'_ ,?"?6O117G6A_\ 'PGUKT45VX7X6?-YS_'7H+2T
ME+6RV/-"BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 UJ\NF^\?J:]1:O+IOO'ZF@!HI:04M !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 -DZ5Z5I'^J
M3Z5YK)TKTK2/]4GTH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=H4G&.5+ @_0\\9/83:%X.FEF%]>,-X;=MSDDC.,D$ 8(! &1CCCI7:FN/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH !T_/C')ZGWJ:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H!&'XO_P!0?J/YBN&%=SXO
M_P!0?J/YBN&%<=?XCZ/)?]W^;_)#J***YV>H@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!%W0_^/A/K
M7HHKSK0_^/A/K7HHKMPOPL^;SG^.O06EI*6MEL>:%%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K5Y=-]X_4UZBU>73?>/U-
M#12T@I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ;)TKTK2/]4GTKS63I7I6D?ZI/I0!<HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!LD8D!5@"",$'D$'J,52_L"V_YXQ_]^U_PJ_10!CW/@^T
MN3N:)0<8^7*#\E('X]:\^\;Z/'I4XCA!"M&&P23@Y(XSSVSSGFO6:Y;Q#X);
M6I3.9=HP %\O. /?<,\DG\<4 :5CX4MK!Q-$F'7.#N<]00>"Q'0T[Q)KPT2+
MSRI8E@H ..3D\GG' /8\_G6K535M,74XFMW)"OC)7 /!![@^E &1X8\8+KK-
M%LV,H! W;LC.#_",8X^N?:M'7-672(FN'YQP!D DGH.?S/7 !.#BJ/A?PHNA
M;FW;W? SM"X [#DGD]>><#CBM#6M%CUB/R9<XR""IP01^8Z$CD'KZT >71W(
MUZX#W<@16/)YP!GA5Z@=>IX')))Z^EVFJ6EF@BCEB5%& !(O^/YGJ3R:P;GX
M8Q,/W<CJ<]6 88^@"_S_  JM_P *M_Z;?^0__LZ .NCUNWD(598R2< !U))/
M08S5X5P1^%W_ $V_\A__ &==V#0!G>(M:71X6F/WNB#&<L0<9Z<<9/(X''.*
MXSPCH+ZW*;^Z!9,Y&[^)A[8Y4>G S@<@$5I^)O"=SK-P&WJ(0!MR3\H^7=\N
M.23DCGD#!(XKK;2U2S011@*BC  _S^9ZD\F@"#6XS);RJH))B<  9))4X&*Y
M#X6_\M_^V?\ [/7=DUQUUX,EM)OM-C($+;LAN ,G.  I!7T!'& <GL +\39U
M6".,GYFDR![*I!_]"%:WA"U-M:Q*>Z[N/1R6'Z'FLE?!T^IR+)?RAU3HJ<9'
M<=%QVR0"2.,C KL,4 +1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !2-2TC4 C#\7_Z@_4?S%<,*[GQ?_J#]1_,5PPKCK_$
M?1Y+_N_S?Y(=1117.SU$%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110(NZ'_Q\)]:]%%>=:'_ ,?"?6O1
M17;A?A9\WG/\=>@M+24M;+8\T****8!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% #6KRZ;[Q^IKU%J\NF^\?J: &BEI!2T %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 V3I7I6D?ZI/I7FLG2O2M(_U2?2@"Y1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% "8I:** "BBB@! *7%%% #:7%+10 F*,4M% "8I:** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D
M:EI&H!&'XO\ ]0?J/YBN&%=SXO\ ]0?J/YBN&%<=?XCZ/)?]W^;_ "0ZBBBN
M=GJ(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@1=T/\ X^$^M>BBO.M#_P"/A/K7HHKMPOPL^;SG^.O0
M6EI*6MEL>:%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@!K5Y=-]X_4UZBU>73?>/U- #12T@I: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ;)TKTK2
M/]4GTKS63I7I6D?ZI/I0!<HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%%% !1110 4444 %%%% !1110 V3I7I6D?ZI/I7FLG2O2M(_U2?2@"Y1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *YN[^^:Z.N=O!AV'H: (<4M)10 M%)10 M%)10 M%)10
M M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 M%)10 N:2BB@ HHHH ****
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M=L\A5'4D#N?YD#.,5W]E:+9HL*?=0 #I^?&.3U/O0!.*6D%+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !36I310!@>,O^/<_[RUQ5=MXS/\ HY_WEKB<YKBQ/\3Y'TF2W^KOU?Z
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M ****  UO:3_ *L?C_.L&M[2O]6/Q_G0!;HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ Q1BBB@ H(HHH
M 3;2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \R\'?\?4?_ __0&KTVO,O!W_ !]1_P# _P#T!J]-H JWVHQZ>-\K!0>F
M>I^@')Z]JP_^%@0?W9/R7_XJL"&(^*;IB3A,9]PBD  #D G//;))]CU?_"'6
MO_//_P ??_XJ@!VD^)H=3.Q"0_.%88)QZ8)'X9SP>,5L"O/_ !9X?&DE;B#*
MJ3CK]UAR,'.><$^Q'7D"NUTF^^WQ)-_>49QD#/1ASZ'- &9K?BP:5((60G(!
M)R!P>X'.>_!V]/0YK>KS?QO<&6Y93_ J@?3&[^;5Z10!7O;G[-&\N,[%9L=,
MX&<5D^'O%0U=VBV;2%S][<,9 /8>HK1UK_42_P#7)_\ T$UQGP__ ->W_7(_
M^A+0!T7B'Q6-(=8MFXE<_>VC&2!V/H:V;6X%RBRKT=01GK@C-<I\0-.+!+I1
M]WY6//0\K[8SGGU(K4\'WWVNV4'K&2AZ#ITZ?[) H VZYQ?&L;SBV525+;=^
M1U)P" ,Y'3G(X[>NUJDQ@ADD7AEC8@^X4D5P'@[33>7"L1E8OF/7J/N\COGG
M'< T >CBL2_\9V]H=N2Y[^7@@=.Y(!_#/O5?QSJ1M8A"O64D$_[*XR.O?('H
M1FJ_A_P=$\2RS#>T@##!( !&0.",GU_(>I +">/K=B 0XR>I48'OPQ-=!;7*
MW2B5#E6&01_G_P#56-<^"K:52J+M8CA@S'!^A.#_ )Z=:Q/!%VUG,]F_&<\<
MGYTZXQQTSD]\#F@#K=3U2/34\V0X&<# R2<$X_3O@>]<[<?$-%/[N,D8_B8*
M<_0!OYUT&L:.FJH(I"0 P/RD Y ([@^M16GAJWM5V"-6]W 8GCU/\A@>U &1
M:?$"*3B1&4D]L,,>I/!_(&NH1PX#*<@C((Y!![UROC#0(DA-Q&H1D*_=& 03
MC&!@=\YQGC%)\/KMI$DA/W4*D=?XLY'TXS]2: .K=MH) S@=!C)]N<#]:Q-!
M\4KJ\C1!"NT9!)!R <<^AY'KWY]=74;@VT3RKU1&(STR 37#_#__ %[?]<C_
M .A+0!Z!6-XC\1_V-L^3=OW?Q;<;<>Q]:V:XSXB_\L?^VG_LM %B\UD3/9WS
M'9"6E#;CP&92JY_$-@XX'7&:JWEM-//=I$& F$8^:-QO")AU60C8F1D L""2
M,>M:WAJS2\LDAD 9&#@@_P"^W^0>H/(IZZ!-;E4@N&2%?X"B.0,] [#( ' S
MNQ[]* *,;+=W-H(%8+;QR;U8$-&&0*BMN[G' R21\W(YKJJHZ5HT>F B,'+G
M+,Q+.Q]23^?IDG YJ]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 4M;_P!1+_UR?_T$UQGP^_U[?]<C
M_P"A+79ZW_J)?^N3_P#H)KS31]8?27,L8!)4K\P)&"0>Q'I0!ZN>*\Y\;VJP
M7&5X\Q0QZ8R20?SQD^^:F/Q G/\ #'^3?_%56TE%UVY+W+ ;N<<+N/ "#G_$
MD#UYH [[2)"\$3$Y)C0DGDDE1S5EI1&"S'  R2>  .]/Q7#>/-7+,+1#@* 7
MQW)Y Z=ASUQSZB@#7O\ QQ!;$JN7(!Y7&W//&2?U (QTS5>T^(,4G$B,I)[8
M88]2>#^0-'A[P;'&BRSKN=L-@Y 7N 1QD^N>.V.YTM2\*P7J[0@1L'#( ,'W
M P#^/X8ZT :5I>I>+YD;!E/<'VS@^AYZ'FJ'B'7?['19-N[<V,9('0GK@C\.
M_;H:Y'PA=OI]S]F; #DJP./O+G&#ZYX]#GZ5Z!- LX*. RGJ& (_(T >5V>K
M&&X%V>"9"S;1V8_, #[$@?SKJ;/Q[]JD2+RL;V5<[\XR<9^[6-IUDDU^864%
M!+)\N./EW$#'IQTZ=NE=[#I<,!WI&BL.A5%!_,"@"RM9&I^*X-/.QCN;/(3!
M(Z]3D 8QTSGVJ#QCK!TZ+:AP\AP".H ^\>GX=CSD=*Y_PEX674 ;B;_5Y("\
MC)[G/' ]N_TP0#2B^(<98AHV"\X(()//&1P!Q[FM[3-;BU(9B;)QRIX8=.WX
M]1D9[TQ_#ELZ^68EQ@#@8;C_ &A\WZ\]ZX34+9_#=R#&<[?F4M@Y4Y&#C\0>
MA[C'% 'HFH7@LHVF8$A1DA1DX]>W3J?:LG0?%J:JWE%=CX)'(((&._!S[8Z#
M.:W!MG7LRL/8@@C\B"*\XU2R;P_<B10=@;<F"1D=USST^Z<\XY(P: /2:PX?
M%D4TXM4RV21N RN1Z8Y(ZY/08STY%+Q#XJ00 P/\\H'0C<H(R<XS@]NH.3D=
M*@\#:$8LW<@QD83/7!ZMC'&>@/IGL10!V-%(*6@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/\@#T$M0&S6=HVLIJR>8G!'WE[@_X>A[_7(%NZO$LU\R1@JCN3[9P/4^PYH
MX'Q K-?D1G#EXMI/0':N#T/?VKT6O.-%A?6KO[1S@2;V)YP <JN3CTP/;G&!
M7H] 'G^D?\A(_P#76;^3UZ!7FL]T=)OFE8?=E8D=?E?/OUVMD>_6O2$<2 ,I
MR",@CD$'O0!QGQ%;F(8[/SQC^'CUX^G?COC;\''_ $6/_@?_ *&U4?']CYT2
MS#_EFW/3&&XS^8'Y_DWP1K221BS/#IG&?X@26X]QGIZ<^N #J<UQOQ&_Y8_]
MM/\ V6NP=Q&"S'  R2>  .]>>^)[PZU<B*'Y@HVK@Y!/5B.P]">F!G.* .T\
M.*RVT0<Y.P=/0_='0=%P/\:I^,K:.6W9I" R_<)Z[O[H_P![&/U/2M:RM_LL
M:19SL55STS@8S7!ZGJ3^)+A;9#B/=A<>@ZN0<9.,G'8<#G.0#"LMGF)YGW-R
M[NOW<\].>GIS7KR1B,!5& !@ <  =JXOQAX=2WC6>%0H3 ;'H> 3SR0>.Y.>
M3Q6AX)UG[9'Y#GYH@ .@RO0?7'0\>G<T =*#2T 44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!Y]\0?\ 7K_UR'_H359LO 0NHDE\S!=0WW,C# $#[PZ<
M\]_0=ZWQ!_UZ_P#7(?\ H35VFB?ZB+_KDG_H(H Q8/A_ F"S.Q&,\@ ^O&,@
M'ZY]ZZ"VM5M5$2#"J, #_/\ ^NIZ* *.L_\ 'O+_ -<G_P#037,_#G_EM_VS
M_P#9JZ?6_P#42_\ 7)__ $$US'PY_P"6W_;/_P!FH W/$OB#^QT! W.Y( .0
M.!R>G8D<9&<]:P-.O=1U7]Y&P5&)P2J!1CTR"Q';///4]:K_ !"0B=&QP8P,
M]LAFR/PR/SKK_#TPFMXF7D"-1^*C:?U% ')^(=+O%C::>4,B@ JI(!^88^4*
M >3WJQ\.?^6W_;/_ -FK1\<:DD,!MR?GDVX ] P.3Z#C'N?H<9WPY_Y;?]L_
M_9J #XC?\L?^VG_LM;/@X_Z+'_P/_P!#:L[X@V9DC28=$8@\=FQSGMR,?C2>
M"=91T%H>'7.,_P 0))X]QGIZ<^N #K!2U!=7J6:^9(P5?4GVS@>IXZ#FH=-U
MF+4L^2V[;C/!'7..H'I0!Y=IGF^:OD9\S/RXZ_X8QUSQC.>*ZK_B:_Y\FL1&
M_L"[SC(C<]<$E6'7C SM.?KU]*]*M;I;I1*ARK#((_S_ /JH XB^L-2OE\J0
M97(.,QCI]",UN^$=$DTI&$I^^0=H.0..?;)Z''H.3VVKFZ2V&Z1@HSC+$ 9]
M.:6&99P'0AE/0J<C\Q0!Q_Q&_P"6/_;3_P!EK:\'?\>D?_ __0VK%^(W_+'_
M +:?^RU/X+UZ,QK:,=KJ3C)X;<V>/?)QC\1WP =9FO-_$*,E\PA&'WQE<8^\
M0ISSQR?7\:[[4=133D,TAP!^9/8 >O\ ^L\5P>A*=8O1,<XW&0\Y("G*C)Z@
M' ^GIV .L\:-BU<8SDKZ<?,.?Z<9Z^F36/\ #G_EM_VS_P#9JZ37;'[?!)".
MK+Q@@<CD#GU(%<5X*UI-.=HY.!+M^;L",XS['/7MWXY !Z&36-XR_P"/23_@
M'_H:UL5Q_CS65=1:HV3NR^T]-O&TX]^<=L#CI0!-\/0PC<D_)OX'?./F/XC'
MY?GUE87A#36L( 'X9V+8(P1D  ?D,^V<=JW: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH I:SIW]I1-;YV[L<XST(/3(]*X_\
MX0:YV^7O3;G.-SXSC&<;<9QWKO:* ,3PUX:&C@LQW.X&3C@#T'?KU/&<#@8K
M;HHH PM?\*)JQ$@.Q^Y SD>XR.1Z^G'IC!M_!-U;'='(JG&,J[@X].%KNZ*
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M!P,=,CGIWQQTSS7044 <9_PKG_IK_P"0_P#[*K6L^"1,D:6^U2F<ENK9QR6
M)R"/3'/&,8KJ:* *6C:?_9\*09R5'/U)R>PXR>/:KM%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5]1MS<Q/$O5T8#/3)!%</_PK^?\ O1_FW_Q->@44 >?_ /"OY_[T?YM_
M\35[3_A]M*M,^<'E5!P?0;L@_7CV'K7944 -2,1@*!@ 8 '  ':J^I::FH(8
M9!D'\P>Q!]?_ -1XJU10!QG_  KG_IK_ .0__LJ/^%<_]-?_ "'_ /95V=%
M%+2]'BTQ=D0QG&2>2<#N?Z=.N!5PBEHH Y_7/!R:H_G!BCG&>-P.!CID<].^
M..F>:H:3X$-LZ322<HP.U1QD'(^8_AGCV]ZZ^B@!KQB0%6&01@@\@@]JY.Z^
M'BNQ9)-JD\*5W8]L[AG_ #UZUUU% '&?\*Y_Z:_^0_\ [*MG0_"L>E?/]Z3G
MYCQU]!D@<=^O7G!Q6U10!1URQ>]A>&,X9@!DD@8R,CC/49%97A;PJVDLTLC
ML1M 7.,9!SD@'.1_^O/'1T4 ,G@$ZF-N58$$>Q&#7(6W@N:PG$T+KM5N"V2V
M#P00!@\$CJ,^W;LJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .?
M\0>$_P"V)!+OVX4+C;GH2<YW#UK:LK;[+&D6<[%5<],X&,XJ:B@ HHHH KZC
M;FYB>)>KHRC/3)!%97A7P\VD*^\@LY'W22, <=0#G)/Z5NT4 9^M:(FK)Y;\
M$?=8=0?\/4=_K@CF_P#A7/\ TU_\A_\ V5=I10!R<'P]C56#N2Y'! P!TP<9
M.?SZ'L>:O^%/#[:.K[R"SD?=)(P!QU .<D_I6[10!%=6JW2F)QE6&"#_ )__
M %5Q]]\/#U@?N.)/3'/S#KS[#_'M:* .(?P5<W9 GE!49Y+.Y&?0,!UX[BND
MT#0ET=#&#N9CDM@#/H._ ^IY)]:TZ* ,C7O#2:N!D[77HP&>/0CC(_D?QSS2
M>!+BW;='(HP3A@S*V.G8<<>]=Y10!PO_  @D]P^Z:13GJV6=N!QU S^?2NOT
MG3AIT2P YV@\GN223^IJW10!B^(_#G]L[/GV[-W\.[.['N/2JVJ>"8[P+M8J
MR*JYP#D*, D#'/3G/08Q71T4 <7_ ,*Y_P"FO_D/_P"RKIM(T2/2EV1CJ<DG
MECZ9/'3M_B35ZB@ Q7.:UX*34'\Y&\LG[V%R"?7&1@^OKUZYST=% '%_\*Y_
MZ:_^0_\ [*KNE^!(K5M\I\SI@$;0.>I&3GZ=.N0>W3T4 )BEHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HH%% !1110 4444 %%%% !1156_U.+3QOE8*#TSU/
M3H!R>O;I0!:HKFYO'UO&2H#L!W51@_\ ?1!_2M;3]:AU'/E.&([<@]N<'!QS
MUZ4 7J*3-+0 45AW_C*VM.-V\@](QGJ,YSPI_ _UJ>P\46]\0BOAB!PP*G)Q
MQD\$\] 3[4 :M%%07EZEFOF2,%4=R?;.!ZGCH.: )Z*Q?^$RM/\ GI_XX_\
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M@>^* -ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BC-% !1110 4444 %%%!H ***S=7\0PZ3_K#\Q&0JC+$9QGT'XD9P<4 :
M5%9^CZ[%JP+19RN,AA@C.<>W..Q-:% !14%Y>I9KYDC!5'<GVS@>IXZ#FL*;
MQ];QDJ [ =U48/\ WT0?TH Z2BLW3/$4&I?+&_S8'RMPW3.,'KC'.,UI4 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% "4M<7\1_^6/\ VT_]EK-T^ZN]<1;*,X2-<%N5&,8
M8CKQP !SU.<9 !Z-2$UP&I^ 9+9=\3>9@$D;=K?@,G/Z>V35WP3K\ERYMI6W
M?+E2QYR#R/4Y!SUX ]* .R!I:R_$6J-I<)F09;( R"5&3U."..WU(KDO^%A7
M']V/\F_^*H ]!HKS[_A85Q_=C_)O_BJ/^%A7']V/\F_^*H ]!)KC[OP9)J$[
MSS. C-D;>6P#@#H /E[\\]C74V4C31H[C#,JEA@C!(Y&#SUJ;;0!@OX'M678
M%(.!\P8[N._.5Y^GTQ7#7MN^ASE%;YXR,,/<9''T/(Y'4<BO5LUYSXSN?MMU
ML09*!4&WG)Z]N^3C'J* /0K6X%RBRKT=0PSUP1FN?\2Z'/J\J1J=L*J"23QN
MR0>!R3CIGCKR,FM[3[<VT21-U1%4XZ9  J>@#GK/P);PCY\N2!R20,]\!<=?
M<FN<\5>%5TE5EC8E2=I#8SG!(.0 ,8'_ .O/'<?VW;_\]8_^^U_QKB_%OB$:
ML5MX,LH.>GWF/ P,9XR1[D]. : .D\%WYO+<!NL9*9]0 ".W8''X9JK\0O\
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M<UG> M2,,WV<D[9 <#MN SGVX!''7C/3CN=0O!91O,?X%)P3C)[#/N>*\_\
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M17E=W?M87<DZ?>6:3&1D?>((_$4 >I8I17"V_A^X\1_Z3.^Q6R5!!/7'1<@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MELGG@]_7OP:A\/\ A]]=<W=P24)Y)X+D=AZ =./H/;OTC$8"J, #  X  [4
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MM(S^9 KTS% "BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RJZMQ<WC1-T>X*G'7!
M?%>J$5YA_P O_P#V]?\ M2O4* .7^(0_T=?^NH_]!:F?#N<&%X\_,),D>S*
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M@]ZX?P_9_P#"0W+W<N-JD$J><YR$'&!@ <^N.0<FNC\8:?+?PB*$9.\$C('
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!YGY#?VAMP<_:<XP<XW[L_3'.?3FO3,TE% &+XS_X])/^
M ?\ H:UD?#F A99,?*2H!]U!)_F*[&EH **** "BBB@#%\6SRP0,\'7/S$=0
MN#DC].>PR>,9'G>E:HVF2"9 "P!'S#(Y_4?@1Z=,BO7C310!Y_\ \+#N/[L?
MY-_\52IX_N9"%5$))P %8DD]OO5Z#10 4W%.H- ""O//#[_:=0,J<J7E;.#T
M(;!]NHZ^M>AT4 (:<!28S3J $Q7G=^_VG4@4YQ-&. ?X-H;\L'\L]*]$-)0
MA%**!2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7F?D-_
M:&W!S]ISC!SC?NS],<Y].:],IM #LUB^,O\ CTD_X!_Z&M;'6G"@#C?AS 0L
MLF/E)4 ^Z@D_S%=CBEHH ****  T444 !K.\02B&WE9N 8V'XL-H_4UHTA-
M'%_#J,XE;'!* 'MD;LC]1^==B\0<%2,@C!!Y!![4\"EH \]N_#]SH4OFVVYE
MZ J-QP>S+SG&.N,=#P> D?Q N% !"' ZE3D^_# ?D*]#HH \WE%YXF8'!V'&
M.JQ#!P3SU/)SU/7' Q7<:#I TJ(0CKU8YSEB!G'3CC XZ>]:%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HQ110 8HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "DQ2T4 &**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HQ110 4444 %%%% !1110 4444 %&*
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>favors.jpg
<TEXT>
begin 644 favors.jpg
M_]C_X  02D9)1@ ! @$ > !X  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
MQ@#+ -  U0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%%
M 4P!4@%9 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!
M\@'Z @,"# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+!
M LL"U0+@ NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#
MQP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-
M^ X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE
M3FY.MT\ 3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1 9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$> J($*@6N!S8(P@I*"
M](-7@[J$'82 A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @/" \;$10;(QP<%QH@)"8F'" D("4T+R D*"<K*SDK)R@I
M,#(U,C I-SL[.SLW.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]5HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M .^Q_C1_;EE_SVC_ .^Q_C1</9R[,O451_MRR_Y[1_\ ?8_QH_MRR_Y[1_\
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M+_C1_;MC_P ]XO\ OXO^- %ZBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\
MC0!>HJC_ &[8_P#/>+_OXO\ C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C
M1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_P ]XO\ OXO^- %ZBJ/]
MNV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\ C0!>HJC_ &[8_P#/>+_OXO\ C1_;
MMC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_SWB_[^+_C0!>HJC_;MC_SW
MB_[^+_C1_;MC_P ]XO\ OXO^- %ZBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_O
MXO\ C0!>HJC_ &[8_P#/>+_OXO\ C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[
M^+_C1_;MC_SWB_[^+_C0!>HJC_;MC_SWB_[^+_C1_;MC_P ]XO\ OXO^- %Z
MBJ/]NV/_ #WB_P"_B_XT?V[8_P#/>+_OXO\ C0!>HJC_ &[8_P#/>+_OXO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5);_ZP?6HZDM_]8/K36Y%3X6>IZ?_ *A/]VO./&W_ !_?
MA7H^G_ZA/]VO./&W_']^%=R/BZGQ,P****8@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHH&>O:1K,.KQ[D//<5H5XWINIS:7()$/3\J]*T#Q-#K"#G##KFD!MTF:.E%
M!2TE+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIKDCQ2LZL!E=A R.AZJ?44 8-%:?B/1_[$NC",E< J3UP?R[Y%5]*L&U2Y2
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M#F**O7]E']L:"VW.-^U<X))Z=@!U_2NFM? 4-M%YEY-L_P!T@ ?\";/\OSH
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M>IH0PYKS_4](ETV0JPX]>U<U2G8^CP.81K*SW*0HHZT5BD>DF%%%%, HHHH
M**** "BBB@ HHHH **** "N@TOQ;_9MJ+?RMV-W._'4D]-I]?6N?HIQDX[&5
M>A3KQY9JZW"BBBD:FCI&O3Z.3LY4]5/3_P"L:W#X_./]1SZ[_P#[&N2HJE4D
ME9,Y:N P]67-*.OS_0Z>U\=S1[C(@?)XPVT >G0US=Q+Y\C/C&YB<?4YIE%$
MIREN71PE&BVXJURQI]ZVG3K,O53^?J/Q%:NN^*6UF(1!-@!R?FW9].PK"HI*
M32L.>&I3J*HU[RV"K>FZM/I+[XCC/4'D&JE%)-K4TG",X\K5T=:GC\X^:$$^
MH?'_ +*:S-6\5W&J*8P B'J!R3]3_P#JK%HJW5FU:YS0R[#0DI*.OS"MW7O$
M_P#;<2Q^7LVMNSNW=B/[H]:PJ*E2:5C:I0A4E&36L=@K>TKQ?<:<@C8"15'&
M3@C\<'^58-%$9..P5L/3K1Y9JZ.IF\>.5(CB"$]RV[],"N9FF>X<NYR6.2:9
M13E.4MR:&$HT+\BM<*T-#U;^QI_-V[_E(QG'7'L?2L^BI3:=S2I3C4BXRV9U
M_P#PL'_IA_Y$_P#L*9+X_=E^2( ^I?/Z8'\ZY.BK]M/N<G]E87^7\7_F6+Z_
MEU*0R2')/Y#V%.T_4YM+D\R(X/?N#^%5:*F[O<Z_90Y.2WN]CK(_'S!0'A!/
MJ'Q^FT_SJAJGB^YU!2B@1J>N.3^?'Z"L*BJ=6;ZG-#+<-"7,HZ_,*U]#\22Z
M+E0-R$YP3CGV/-9%%2I.+NCHJT858\LE='0ZQXN_M6W:'RMN['.[/0@_W1Z5
MD:=J<VER>9$<'OW!_"JM%-SDW<BGA:5.#II>Z^F_YG61^/F"@/""?4/C]-I_
MG5#5/%]SJ"E% C4]<<G\^/T%85%-U9OJ90RW#0ES*.OS+VC:C'I<WG-'YA'3
MYMH'OT-3Z]X@DUMAD;57HN<\^N<"LJBIYG:QL\-3=3VC7O?U\B]H^K2:/-YB
M\CH1G (_6K&O:W'K9#>5L8<9W9R/3[HK)HHYG:W0'AJ;J*I;WNX4444C8***
M* "BBB@ HHHH **** "BBB@!*EM_]8/K4=26_P#K!]::W(J?"SU+3_\ 4+_N
MUYSXV_X_OPKT;3_]0O\ NUYSXV_X_OPKN1\74^)F!1113$%%%% !1110 444
M4 %%%% !6Y?>+[J_M#:LJ!2%&0&S\I!'\1';TK#HH **** -/2/$5WHO$3?*
M?X6Y7_ZWX5IR_$+4)%P!&ON%.?U8C]*YFB@#H(?&U[% 83M?=NRSABWS9_V@
M._'%<_110!=TC5IM%G$T6,X(PW((/TP?>I=;U^?7G5I=HV# "@@<]3R2>:S:
M* "KVEZU=:.VZ%R,]0>5/X'^?6J-% CJ/^%B7^,;8_\ OEO_ (JL34]8N=7?
M=,Y;'0= /P'']?6J5% R>PO&T^99E )0Y&>GZ8J[KGB&?7RAE"C9G&P$?>QZ
MD^E9=% !6_8^.-0L4"95P.GF D_F""?QK HH WM1\:W^HQF,E4!Z^6""?;))
M-8-%% !6QI/BN]T==B,&7LKC('TZ']<5CT4 =+/X_P!0F7:-B>ZJ<_\ CQ(K
MG996G8NQ)).22<FF44 36MW+92"2-BK#H1701?$+4(UP1&WN5.?T8"N9HH V
M=4\67VK+L=@JGJJ# /UZG]<5C444 ;6D^+KW2$\M"&4= X)Q],$'\,U8NO'>
MH7./NJ P.$!&<'.#DDX]<$5SM% &OK?B:XUY5654 0DC8".OU8UD444 ;NE>
M,KS2(! @0JN<;@21GGLP[UB2.96+,<DG))]33:* "M[3_&M_IZ!-P<#IY@S^
MH(/YFL&B@#I+CQ_J$Z[1L3/=5.?_ !XM7.RRM.Q=B22<DDY--HH LZ?J4^ER
M>9"Q4^W0^Q'0UOCXB7X&-L?UVM_\57+T4 =!;^.;^"1I"5<N ,,#@8ST (]:
MQK^\;4)FF8 %SDXZ?KFH** -'2-?NM$),3<'JK<J?\^U:D_Q U"92H")GNJG
M/ZL1^E<U10!MWGBZ[OK3[(X4KM4%L-N.T@YR6/)QSQ6)110 4444 %%%% !1
M110 4444""BBB@ ZTH!8X'4TZ&%[A@JC)]J[WPSX.6U FFY;M0,H>&/!IF(F
MGZ=A7=H@C& , >E.4!1@44@#I2T@XI: "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@!*J:AI\>H)L85;I,TK7'&3B[H\WUK0)
M-,<D<K61G->M7-JETNUAD5PVO^&GLB9(QE?Y5A4I6U1[V S-3M">YS])2_6B
ML#V$TPHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5);_ZP?6HZDMO]
M8*<;$5/A9ZEI_P#J%_W:\Y\;?\?WX5Z/I_\ J%_W:\X\;?\ ']^%=T3XR?Q,
MP****9 4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****!![U/8V$N
MH.$C&?7%6-(T:;6)-J#CN:],T708='C 49;N>] REX=\+QZ4H=AE_P"5=!11
M2 *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0!@T5O?\
M"%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0!@T5
MO?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%7WM0
M!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U'_"%
M7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (5?>U
M'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]_P (
M5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &#16]
M_P (5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?>U &
M#16]_P (5?>U'_"%7WM0!@T5O?\ "%7WM1_PA5][4 8-%;W_  A5][4?\(5?
M>U &#16]_P (5?>U'_"%7Q]* ,&MKP]X:EUA@Q&$SUK4T;P+*\@:?[H]*[R"
MW2V4*HP!2 @T[38M-0(@Z=^]7*2B@ HI:* "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $HI:* $HI:* $HQFE
MHH ;M%&VG44 )M%&!2T4 -VTN*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:*
M$Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B
M@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BE
MHH 3%&*6B@!,48I:* $Q1BEHH 3%&*6B@!,48I:* $Q1BEHH 3%&VEHH ;BE
MP*6B@!*,4M% ""C%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )B
MC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "
M8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10
M F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T4 )BC%+10 F*,4M% "8HQ2T
M4 )BC%+10 E%+10 4E+10 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%<UK'C)=*N6@
M*YV8_4 _UJE_PL-/[GZT =E17&_\+#3^Y^M'_"PT_N?K0!V5%<;_ ,+#3^Y^
MM'_"PT_N?K0!V5%<;_PL-/[GZT?\+#3^Y^M '945QO\ PL-/[GZT?\+#3^Y^
MM '945QO_"PT_N?K1_PL-/[GZT =E17&_P#"PT_N?K1_PL-/[GZT =E17&_\
M+#3^Y^M'_"PT_N?K0!V5%<;_ ,+#3^Y^M'_"PT_N?K0!V5%<;_PL-/[GZT?\
M+#3^Y^M '945QO\ PL-/[GZT?\+#3^Y^M '945QO_"PT_N?K1_PL-/[GZT =
ME17&_P#"PT_N?K1_PL-/[GZT =E17&_\+#3^Y^M'_"PT_N?K0!V5%<;_ ,+#
M3^Y^M'_"PT_N?K0!V5%<;_PL-/[GZT?\+#3^Y^M '94E<=_PL-/[GZT?\+"3
M^Y^M '8T"N9TKQHFIW A"XW>]=-0 M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 >5^-1_Q-)O^ ?\ H"UB8K<\:_\ (4F_X!_Z+6L.F 8HQ110(,48
MHHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH ,48HHH
M,48HHH ,48HHH ,48HHH ,48HHH ,48HHH&&*3%+10!L>$1_Q,8Z]6%>4^$?
M^0C'7JU# 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'EGC7_D*R_\
M _\ 0%K#K<\:_P#(4F_X!_Z+6L.F 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ;'A'_D
M(QUZM7E/A'_D(QUZM0P%HHHI %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MY9XU_P"0I-_P#_T6M8=;GC7_ )"DW_ /_1:UATP"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#8\(_P#(1CKU:O*?"/\ R$8Z]6H8"T444@"BBB@ HHHH **** "BBB@
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M10 4444 ;'A'_D(QUZM7E/A'_D(QUZM0P%HHHI %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !7%^%?\ D.ZA]5_F:[2N+\*_\AW4/JO\S0!VE8NH^,=+TF3RII@&'4 ,
MY'UV@X_&K>NW$EI8SRQ_?2)ROU"DY_"L+X?Z7:C3$F"J[S;B[, 23N(QD^E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/+/&O_(4F_X!_P"BUK#K<\:_\A2;_@'_ *+6L.F 5U>@WL,.C7,;.H9BV%+
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M8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQK_R%)O^ ?\
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MVMX([?B8%EP"O49R.?E[4 4[JUDLI#%(-K*<$&HJT+BTO+^]:)QNG9L$$KU
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M@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+/&O_(4F_P" ?^BUK#K<\:_\A2;_ (!_Z+6L.F 4444 %%%% !1110 4444
M%=/#=:+J=ND<RF!XQC<@R#^C$^O(S[US%% '76VKZ7X:1FM"TTK# 9P0!^87
MCOP.?6N3=S(Q8G))R?QIM% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110!L>$?^0C'7JU>4^$?^0C'7JU# 6BBBD 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE "UAW_ /Q]
M+_O5MUB:A_Q]K]: -NBBB@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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M* "BBB@ HHHH **** "BBB@ HHHH **** /+/&O_ "%)O^ ?^BUK#K<\:_\
M(4F_X!_Z+6L.F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 ;'A'_ )",=>K5Y3X1_P"0
MC'7JU# 6BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %)2T4 )TJA<:>9IA)Z&M"B@!**6B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH 2BEHH
M 2BEHH 2C%+10!#<6ZW"E6&0:X/Q#X=:P;S$'RFO0:CGA6=2K#(-3*"DCIPN
M+E0E=;'DG6CK70^(?#9LR9(QQW%<Z#7).#BSZC#XF%:%TQ:*,4=:DW"BBGP0
M/=-M49H2N3*:BKL2*%IVVJ,Y]*[GP[X;6S422#+5)X>\.K8*'898UT XKII4
M[:GSV89BZKY8[" 8HI:6MCRF)12T4 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2T4 8\2M
M]MSCC%;%)BEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RSQK
M_P A2;_@'_HM:PZW/&O_ "%)O^ ?^BUK#I@%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M&QX1_P"0C'7JU>4^$?\ D(QUZM0P%HHHI %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 E%+24 %%%&* (YH5F7:>E<3XC\-&W)EB''H*[JF21B48-3*
M"DCHPN*G0E=;'D5*>.*ZCQ'X9,),L0_ 5SMG927\FQ!WYKEE3:9]+1QM.K#G
MOZB6MH]XX1!7?:!X?33EW$98T_0]!334!/+5LUO3IVU/%S#,'5?+'8!112UJ
M>8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >6>-?^0I-_P#_T6M8=;GC7_D*3?\ _]%K6
M'3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH ****!&QX1_P"0C'7JU>4^$?\ D(QUZM0QBT44
M4@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2BEHH 2BBB@ HHHH 9)
M&)!@]ZJVFE0VC%E R?:KM%!2G)*P4444$A2TE+0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTT 96C_ZU_K6Q6/I'^M?ZUL4 )2T4E "T4E% &-#_P ?GYUM5BP_\?GYULT
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MUCZ;_P ?3?2MANAK'TW_ (^G^E &S2TE% "T4E% "TR3[II],E^Z: ,?3/\
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M]*/^$2N_3]* ,:BMG_A$KOT_2C_A$KOT_2@#&HK9_P"$2N_3]*/^$2N_3]*
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MN%("?^WY_04G]OS^@I/[$F]:/[#F]:8"_P!OS^@I?[?G]!3?[#F]:/[#F]:
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M8^C_ .L?_>-:] "T444 )1110!CQ<WOX5LUCQ?\ ']^%:] "T4F:6@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>secondary.jpg
<TEXT>
begin 644 secondary.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1$ 17AI9@  34T *@    @ ! $[  (
M   2   (2H=I  0    !   (7)R=  $    D   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=I;&)E<G0@
M2&5R;F%N9&5Z   %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,R
M,   DI(  @    ,R,   ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<_P#
MN7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K7/\
MP+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"AZUS_
M ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\ H>M<
M_P# N7_XNCR?%/\ T/6N?^!<O_Q='UNCW#^PLP_D_%?YGU)17RWY/BG_ *'K
M7/\ P+E_^+H\GQ3_ -#UKG_@7+_\71];H]P_L+,/Y/Q7^9]245\M^3XI_P"A
MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M3LF95<GQM&'/.%EIU75V[]SZWHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\
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M1Y/BG_H>M<_\"Y?_ (NCZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\
M%T>3XI_Z'K7/_ N7_P"+H^MT>X?V%F'\GXK_ #/J2BODC2-0\5:G->H?&>MQ
M?9IC'D7LIW=>?O\ M6GY/BG_ *'K7/\ P+E_^+JI8FE%V;,J63XVM!3A"Z?F
MO\SZDHKY;\GQ3_T/6N?^!<O_ ,71Y/BG_H>M<_\  N7_ .+J?K='N:_V%F'\
MGXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N']A9A
M_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[A_86
M8?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT>X?V
M%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K='N'
M]A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NCZW1[
MA_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+H^MT
M>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\ BZ/K
M='N']A9A_)^*_P SZDHKY;\GQ3_T/6N?^!<O_P 71Y/BG_H>M<_\"Y?_ (NC
MZW1[A_868?R?BO\ ,^I**^6_)\4_]#UKG_@7+_\ %T>3XI_Z'K7/_ N7_P"+
MH^MT>X?V%F'\GXK_ #/J2BOEOR?%/_0]:Y_X%R__ !='D^*?^AZUS_P+E_\
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MZUS_ ,"Y?_BZ/)\4_P#0]:Y_X%R__%T?6Z/</["S#^3\5_F?4E%?+?D^*?\
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M% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S_,UTE;U_XC_KH>;E?^Z1^?\
MZ4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO W_($G_Z^F_]!6NE
MKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1])_\ MITM%%%8'I!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$_P#(NC_KJW]*WIO^/>3_ '3_
M "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\ #+_VTZ&BBBL#T@HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7'WJA-0N%4!5$K  #@#-:.#4%+N<E/$J>(G02UC;\2"BBBLSK"BBB@ HHHH
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M]>2>*X^L*[BY:=M?4];*Z=2G1:FFE=\J>ZCT04445SGJ!1110 4444 %%%%
M!1110 5S7@;_ ) D_P#U]-_Z"M=+7->!O^0)/_U]-_Z"M;P_A2^7ZGFU_P#?
M:/I/_P!M.EHHHK ](**** "BBB@ HHHH **** "O0?A-Y7]I:CNQYWE)L]=N
M3N_7;7GU7]%UBYT+58KZS(WIPRGHZGJIK6C-0J*3.',,/+$X6=&&[7_!(+_S
M_P"TKG[9_P ?'G/YN?[^3G]:Z#X=?:/^$UMOL^[;L?SL=-FT]?QV_I6MJ%_X
M*\3L+V_FN=*O6'[W9&6W'WP"#]>#ZTJ>)?#OA73Y8O"J27E[,N#=3*1CZY _
M(#ZUM&$8SYW)67WGG5L35KX9T(T9*<E;5:+I>^UNQI:'Y7_"X-7\C&WR6SC^
M]\F[]<U&/'5P?'(TF.U@&GM=_92FSYB2VTMG_>Y^E<WX&URTTOQ-/?:Q<F-9
M8'!D*LQ9RRGL">QK/CO[9?'2Z@9/]%&I"<R;3]SS=V<=>G;K5^V:BG%VNSF>
M7*5><:D>91II)^:73S.DU'PI:3?%"/38DV6<RBXDC0X"C!) ]B1VZ9J;Q#XX
MNM#UJ32]%M;6&TM"(RAB^^<<].@K.\1>*K?_ (3RUUK1I!<I!&HY5DW?>#+R
M,]#U]ZMZK-X*\0WPU.YU&ZL9I #- (6.X@>H4@'WS3<DN94VD[_@3&E.7LI8
MN$I1Y+6LW:7FM]NI?\=7L6H_#G2[N"(0I-<(PC4<(=CY'YU<N-;&@_#72+I;
M>.><I&D'F+E48J?F_+/YUA^,?$.A:CX1LM.T68Y@G0B%HV!1 C#J1@]1WJXN
MO^%K[P38:/JUU)O6-%;RXFW0L ?FR1CVXSUK3G7/*TE>QRK#2^KTE*E+E4VV
MK.]OZ^\E\-:ZOCE;K1_$-M#(XB,D4R)@KR ?H1D8(]ZH^#]!M+"/6-7U6);K
M^RG>-(\9&Y!DG![],4:?K/A?PA:7$^B7,VIZA,NQ6>(H%'X@<9P3US@5E>$_
M%J:5<7EOK$;7-EJ!/GX&2&.03CN"#R*CGC>/.[O77\CI>'K.G6^K1<8/ELMF
M_P":R>UU]YJZ3\0;K4]:BL=6L[66QNY!#Y0C^YN.!UZCGFEE,_@SX@+I^D,J
M6FHR0DHR[BJ%B, GWW?I45B? VC:B-2AU&ZO&A.^&V,+?*W;DJ 2.W-<]J?B
M2;4O%:ZS)'CRY4>.'=T52"%S^'ZU,JCC%<TKN_X&U/"QJ59*C3<:;C9IJR<N
MFCZKN=A\1?$NHV&HOI5LZ"UN+0>8"@).XL#S]!7FM=YXKU#POXC4ZDNISQ7J
M6VQ+;R6PS#) )Q@<G!YK@ZRQ#<IWO=';E%.-/#*/(XR6]U:[_7U"BBBN8]@*
M*** "BBB@ HHHH **** &3?\>\G^Z?Y5@^"?^1='_75OZ5O3?\>\G^Z?Y5@^
M"?\ D71_UU;^E;Q_A2]5^IYM7_?J7^&7_MIT-%%%8'I!1110 4444 %%%% !
M1110 4444 >E^"+9+SX;ZM;RSQVR2SR*TTAPJ QIR:9H<6@>"5N=1EUNWU*Z
M:,QQQ6S \=<<$\D@<G&*R=!U[3;+X>ZKIES<[+RX>0Q1^6QW HH'(&!R#U-<
M;7:ZL81BTKM+[CYR&!J5ZM>,Y.,'+:VZLNO^1Z9\,[HW,_B&[N ,RM'*X XY
M,A-8Z:W<^//$%AI-Y'#!9>>9%CB4@A54DC.?0$4WP%KVFZ+:ZLFIW/D-<(@B
M'ELVX@/GH#CJ.M<SI.I2Z1JUO?VX!>!]P!_B'<?B,BE[2U.";TZ_>-8)RQ6(
MJ*-I67(^E^6VGS.Y\1^-+CP]K#Z3H5K:P6UJ K*T6=YQD]^G/UJWXKU"'5?A
M=;7MO"L*32J3&HP%;<P8#\0:S-5N?!?B6[74KO4+K3[EU'G1+"6W8&.H4C/3
MG/X5)XH\1^'[OP3%I>BS,&B= D+1L"%7/))&/?KWK9S=IWDK6T.&&'CS8?DH
MR4U)<SL_G=]=>IJIK2Z#\+=-N_(CGF("0+(N5#G=S^ !JKX8\0_\)I+<:/XB
MM8)MT1DCD1,%<''X'G@CTJ*T\0>&+CP+::-J]U)OV!7$<3;HFR2&SC''MGK5
M?3-6\*>$8;BZTBZGU2_D38F^(H%'7N!@<#/7I3Y]8^\N6VIG]7_=U5[*7M7)
M\KL^^COLD)X0\.V=G=ZUJ.K(MS%I#O&JD9!9,EFQ] ,?6C3?B)>:AK45IJ5G
M:R:?<R"(P"/.P$X'7KUY_I65X4\7?V1J5X=40W%KJ!)N !R&)/S8Z=SD?X5I
M68\"Z7J0U*+4;JY\IO,BM3"W#=1R5&<=LFLH2]V/([=SMQ%%^UJ/$TW-M+E:
M3:6FMK;._4EOC-X+\>K:Z,5CMM1,3-&R[MJER"!GW!_.KOQ&\2ZCINH?V7:N
M@M;JR_> H"3N+J>?H*XW6O$DNK^)UU8Q[1$Z&*(G[JJ<@$_7)_&NC\4ZEX6\
M31#43J,\%]':E$MO);YF&2JDXQU.,YI^T3C.,';707U24*U"IB*?,^6TFE?7
M2U[?F<#1117 ?4!1110 4444 %%%% !1110 4444 8?C'_D6+C_>3_T(5]->
M&O\ D4](_P"O&'_T 5\R^,?^18N/]Y/_ $(5]->&O^13TC_KQA_] %>Q@OX;
M]3\^XD_WQ?X5^;-.BBBNT^:*FJ_\@>]_Z]W_ /037RSX*_Y%M/\ KHW\Z^IM
M5_Y ][_U[O\ ^@FOEGP5_P BVG_71OYUQ8W^%\SZ/AS_ 'U_X7^AT%%%%>.?
MH84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5S?B7_ )#^@?\ 7P?YI725
MS?B7_D/Z!_U\'^:5O0_B??\ D>;FG^ZOUC_Z4CI****P/2"BBB@ HHHH ]#^
M$O\ Q^ZG_P!<X_YFO/*[OX8:A9:?=Z@;^[@M@Z(%,TJINY/3)KA*Z*C7LH?,
M\G"Q:Q^(;6CY/R9W?BW3[*V\ Z#<6]I!%/*D1DECB56?,63D@9//-;>NMH?A
MWPS87C:%8W-S-&J(K0J 25!+-QS_ /7K$\6ZA97/@'0;>WNX)9XDB$D4<JLR
M8BP<@'(YXIWCS4;*\\-Z-%:7EO/)&HWI%*K%/D'4 \5TRDH\S79'C4Z=2K["
M$[V<YWWVZ&S=Q>&X/#,/BA]#M][Q*%M5 "%V.,$8QQSSCI67J=CIOB#X>MK=
MGIL&GW=LWS+;J%5L, 1P.>#GUS46JZC92?">QM([RW>Y5DW0+*I<<GJN<T:5
MJ-E'\)[ZTDO+=+EF?; TJASR.BYS3<HM\KM;EO\ ,5.E4IP51.7,JEEJ_AOM
MZ%GPCX4@7PS_ &U-IHU6\FR;>UD950#..=W'/7)SQC K6M?#@UNWGM=<\+6N
MDG;F*YM'CX/T4Y]^<@USOA_5]*U;P>_AK6[H63H2T%P_W>NX<GI@DC!QQ4</
MAWPQI-I<SZSKD&HG81##8R L#Z\$\_7@=\T1<>5<JTMKJOQTN%:-9U:GM)-2
MYO=M&3=NG+:2CZW7J<?=VS6=[/;2$%X9&C8CN0<?TJ&E.,G' [9I*\X^O5[:
MA1112&%%%% '-^$_^/S6/^OL_P S725S?A/_ (_-8_Z^S_,UTE;U_P"(_P"N
MAYN5_P"Z1^?_ *4PHHHK ](**** "BBB@ HHHH **** "BBB@ HHHH ****
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M2"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M _Z^#_-*WH?Q/O\ R/-S3_=7ZQ_]*1TE%%%8'I!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '-^$_^/S6/^OL_S-=)7-^$_P#C\UC_ *^S
M_,UTE;U_XC_KH>;E?^Z1^?\ Z4PHHHK ](**** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KFO W_($G_Z^F_]!6NEKFO W_($G_Z^F_\ 05K>'\*7R_4\VO\ [[1]
M)_\ MITM%%%8'I!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ,F_X]Y/]T_RK!\$
M_P#(NC_KJW]*WIO^/>3_ '3_ "K!\$_\BZ/^NK?TK>/\*7JOU/-J_P"_4O\
M#+_VTZ&BBBL#T@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,/QC_P BQ<?[R?\
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M^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T"=2_[\?_ %Z/J]7^4/[7P/\
MS]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE_P!^/_KT?5ZO\H?VO@?^?J-^
MBL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\ UZ/J]7^4/[7P/_/U&_16!_PE
M:?\ 0)U+_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$
MZE_WX_\ KT?\)6G_ $"=2_[\?_7H^KU?Y0_M? _\_4;]%8'_  E:?] G4O\
MOQ_]>C_A*T_Z!.I?]^/_ *]'U>K_ "A_:^!_Y^HWZ*P/^$K3_H$ZE_WX_P#K
MT?\ "5I_T"=2_P"_'_UZ/J]7^4/[7P/_ #]1OT5@?\)6G_0)U+_OQ_\ 7H_X
M2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\ ?C_Z]'_"5I_T
M"=2_[\?_ %Z/J]7^4/[7P/\ S]1OT5@?\)6G_0)U+_OQ_P#7H_X2M/\ H$ZE
M_P!^/_KT?5ZO\H?VO@?^?J-^BL#_ (2M/^@3J7_?C_Z]'_"5I_T"=2_[\?\
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MO^_'_P!>CZO5_E#^U\#_ ,_4;]%8'_"5I_T"=2_[\?\ UZ/^$K3_ *!.I?\
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MU+_OQ_\ 7H_X2M/^@3J7_?C_ .O1]7J_RA_:^!_Y^HWZ*P/^$K3_ *!.I?\
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M_OQ_]>C_ (2M/^@3J7_?C_Z]'U>K_*']KX'_ )^HWZ*P/^$K3_H$ZE_WX_\
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M +\?_7H_X2M/^@3J7_?C_P"O1]7J_P H?VO@?^?J-^BL#_A*T_Z!.I?]^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y/\6?\ DI?PU_[";_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y/\%?^0YXZ_P"PR_\
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M* "BBB@ HHHH **** "BBB@#SOX[?\DAU/\ ZZP?^C5KL?#7_(IZ1_UXP_\
MH KCOCM_R2'4_P#KK!_Z-6NQ\-?\BGI'_7C#_P"@"@#3HHHH J:K_P @>]_Z
M]W_]!->>_L__ /)*8/\ K[F_F*]"U7_D#WO_ %[O_P"@FO/?V?\ _DE,'_7W
M-_,4 >FT444 %%9?B+Q#9^&-).I:DEPUJCJLC01&0Q@_Q$#G:.YJ71]=TOQ!
M9"[T2_@OH#U>%PVT^A'4'V- %^BL/Q7<^)+;2U_X0ZPL[N_9P#]MD*QQKW)
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >=_';_DD.I_\ 76#_ -&K78^&O^13TC_KQA_] %<=\=O^20ZG
M_P!=8/\ T:M=CX:_Y%/2/^O&'_T 4 :=%%% %35?^0/>_P#7N_\ Z":\]_9_
M_P"24P?]?<W\Q7H6J_\ ('O?^O=__037GO[/_P#R2F#_ *^YOYB@#TVBBB@
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M &?/^26)_P!?LW]*](O_ /D&W/\ UQ?^1KS?]GS_ ))8G_7[-_2@#U"BBB@
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M44 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"PF_\ Z'!0!ZQ1110
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MV\BAF*;-OS A5(;(^]TXK/\ @7K6DVG@8Z'<30V6K6%S,MW;S,$D)WDAL'J
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MV@Z7;^)=<\,:?%X?E=-\$<S&ZA1C\I8D[?3MU(SBI?VAP#X$TH$9!UF'(/\
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M!B>(O!OA[Q8B+XATJ"],8VI(V5=1Z!U(8#VS2^'O!_A_PI&Z>']+@LO,&'=
M6=AZ%F))_.MJB@!DL2SPO$^[;(I5MK%3@C'!'(/N*SO#WAK2/"NF?V?H%FMI
M;;S(4#LY9CU)9B2?Q-:E% ',^(?AUX3\57RWNO:-%<W*@#S@[QLP'3<4(W?C
MFMS3=,LM'T^*QTNUCM;6$82*)<*M6J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "O)_V=O^2?ZC_P!A>7_T7%7K%>3_ +.W_)/]1_["\O\ Z+BH ]8HHHH
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MHNG3W8.1<26B-(#Z[B,U8MM)TZRO9[RST^UM[JYQY\\4*J\N.FY@,M^-6Z*
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MKYH7^[OQG'/3-6Z*  C(P>165#X7T"VOC>V^AZ;%=DY,\=I&LF?7<!FM6B@
MJI8Z5I^E^=_9EA:V?GN9)?L\*Q^8W]YL 9/N:MT4 5+?2M.M+^>^M;"UAN[G
M'GW$<*K)+CIN8#+?C1<Z5IUY>V]Y>6%K<75J2;>>6%6>$_[+$97\*MT4 5=0
MTRPU:T-KJME;WUN2&,-S$LB$CH<,"*LHBQHJ(H55& H& !Z4M% !1110 5Y/
M\6?^2E_#7_L)O_Z'!7K%>3_%G_DI?PU_[";_ /H<% 'K%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'D_P5_Y#GCK_L,O_P"A/7K%
M>3_!7_D.>.O^PR__ *$]>L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z *X[X[?\
M)(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_ /037GO[
M/_\ R2F#_K[F_F*] UF01:%?R/\ =2VD8_0*:\#^%GQ@\.>#/ \>D:O#?O<K
M/)(3!"K+ACQR6% 'T317E'_#1?@S_GWU;_P'3_XNC_AHOP9_S[ZM_P" Z?\
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M7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KUY/\6?^2E_#7_L)O\
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MH_X:+\&?\^^K?^ Z?_%T?\-%^#/^??5O_ =/_BZ /5Z*\H_X:+\&?\^^K?\
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M^??5O_ =/_BZ /5Z*\H_X:+\&?\ /OJW_@.G_P 71_PT7X,_Y]]6_P# =/\
MXN@#U>BO*/\ AHOP9_S[ZM_X#I_\71_PT7X,_P"??5O_  '3_P"+H ]7HKRC
M_AHOP9_S[ZM_X#I_\71_PT7X,_Y]]6_\!T_^+H ]7HKRC_AHOP9_S[ZM_P"
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MOJW_ (#I_P#%T >KT5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#I_\
M%T >KT5Y1_PT7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KT5Y1_P
MT7X,_P"??5O_  '3_P"+H_X:+\&?\^^K?^ Z?_%T >KT5Y1_PT7X,_Y]]6_\
M!T_^+H_X:+\&?\^^K?\ @.G_ ,70!ZO17E'_  T7X,_Y]]6_\!T_^+H_X:+\
M&?\ /OJW_@.G_P 70!ZO17E'_#1?@S_GWU;_ ,!T_P#BZ/\ AHOP9_S[ZM_X
M#I_\70!ZO17E'_#1?@S_ )]]6_\  =/_ (NC_AHOP9_S[ZM_X#I_\70!ZO17
ME'_#1?@S_GWU;_P'3_XNC_AHOP9_S[ZM_P" Z?\ Q= 'J]%>4?\ #1?@S_GW
MU;_P'3_XNC_AHOP9_P ^^K?^ Z?_ != 'J]%>4?\-%^#/^??5O\ P'3_ .+H
M_P"&B_!G_/OJW_@.G_Q= 'J]%>4?\-%^#/\ GWU;_P !T_\ BZ/^&B_!G_/O
MJW_@.G_Q= 'J]%>4?\-%^#/^??5O_ =/_BZ/^&B_!G_/OJW_ (#I_P#%T >K
MT5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#I_\ %T >KT5Y1_PT7X,_
MY]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >GW_ /R#;G_KB_\ (UYO^SY_
MR2Q/^OV;^E4[K]H;P=-9S1);ZKN>-E&;=.I'^_7(?"KXO>'?!?@E=)U>*_>X
M%Q)+F"%67#8QR6'I0!]%T5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#
MI_\ %T >KT5Y1_PT7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KT5
MY1_PT7X,_P"??5O_  '3_P"+H_X:+\&?\^^K?^ Z?_%T >KT5Y1_PT7X,_Y]
M]6_\!T_^+H_X:+\&?\^^K?\ @.G_ ,70!ZO17E'_  T7X,_Y]]6_\!T_^+H_
MX:+\&?\ /OJW_@.G_P 70!ZO17E'_#1?@S_GWU;_ ,!T_P#BZ/\ AHOP9_S[
MZM_X#I_\70!ZO17E'_#1?@S_ )]]6_\  =/_ (NC_AHOP9_S[ZM_X#I_\70!
MZO17E'_#1?@S_GWU;_P'3_XNC_AHOP9_S[ZM_P" Z?\ Q= 'J]%>4?\ #1?@
MS_GWU;_P'3_XNC_AHOP9_P ^^K?^ Z?_ != 'J]%>4?\-%^#/^??5O\ P'3_
M .+H_P"&B_!G_/OJW_@.G_Q= 'J]%>4?\-%^#/\ GWU;_P !T_\ BZ/^&B_!
MG_/OJW_@.G_Q= 'J]%>4?\-%^#/^??5O_ =/_BZ/^&B_!G_/OJW_ (#I_P#%
MT >KT5Y1_P -%^#/^??5O_ =/_BZ/^&B_!G_ #[ZM_X#I_\ %T >KT5Y1_PT
M7X,_Y]]6_P# =/\ XNC_ (:+\&?\^^K?^ Z?_%T >KT5Y1_PT7X,_P"??5O_
M  '3_P"+H_X:+\&?\^^K?^ Z?_%T >KT5Y1_PT7X,_Y]]6_\!T_^+H_X:+\&
M?\^^K?\ @.G_ ,70!ZO17E'_  T7X,_Y]]6_\!T_^+H_X:+\&?\ /OJW_@.G
M_P 70!ZO17E'_#1?@S_GWU;_ ,!T_P#BZ/\ AHOP9_S[ZM_X#I_\70!I_';_
M ))#J?\ UU@_]&K78^&O^13TC_KQA_\ 0!7A_P 3?C+X:\7^ KS1M*AU!;F=
MXF4SPJJ_*X8Y(8]AZ5[;X5D$W@W19$SM>P@89]#&M &M1110!4U7_D#WO_7N
M_P#Z":\]_9_'_%J8/^ON;^8KT+5?^0/>_P#7N_\ Z":\]_9__P"24P?]?<W\
MQ0!Z;@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'
MI1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I11
M0 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48
M'I110 8'I1@>E%% !@>E&!Z444 &!Z5Y/\61_P 7+^&O_83?_P!#@KUBO)_B
MS_R4OX:_]A-__0X* /6,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB
M@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP
M/2BB@#R?X*C_ (GGCK_L,O\ ^A/7K&!Z5Y/\%?\ D.>.O^PR_P#Z$]>L4 &!
MZ48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z44
M4 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&
M!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !
M@>E&!Z444 &!Z5Y/^SN/^+?ZC_V%Y?\ T7%7K%>3_L[?\D_U'_L+R_\ HN*@
M#UC ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C
M ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2BB@
MP/2C ]*** # ]*,#THHH ,#THP/2BB@ P/2C ]*** # ]*,#THHH ,#THP/2
MBB@ P/2C ]*** *]^!_9MSQ_RQ?^1KS?]GP?\6L3_K]F_I7I%_\ \@VY_P"N
M+_R->;_L^?\ )+$_Z_9OZ4 >H8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I
M1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'
MI110 8'I1@>E%% !@>E&!Z444 &!Z48'I110!YU\=@/^%0ZGQ_RU@_\ 1JUV
M7AK_ )%/2/\ KQA_] %<=\=O^20ZG_UU@_\ 1JUV/AK_ )%/2/\ KQA_] %
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MIKM)I-H[L69H$)8G))VCF@"S17G?Q=\4ZMH-CH^FZ#<+976M7HM?MS@$6ZY
M)YX!^8<^@-43\.O'.D207N@_$*^O+L2+YT&J%I('7/S84DX[\ 9]"* /4J*:
MF\1KYA4O@;BHP"?:G4 %>3_%G_DI?PU_[";_ /H<%>L5Y/\ %G_DI?PU_P"P
MF_\ Z'!0!ZQ1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!Y/\ !7_D.>.O^PR__H3UZQ7D_P %?^0YXZ_[#+_^A/7K% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#\A4] !7D_Q9_P"2E_#7_L)O_P"AP5ZQ7D_Q9_Y*7\-?^PF__H<% 'K%%%%
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M-'QY";0QC]B3SC_=[$UH^*/#?@+X:Z7<>*8?#]J+^,@6D;.[!YS]T*A8@>O
MX )KB]1T?5_#?AO1HM1OY+'5O&FJ+_;&I X>",D8B#?P_>R?H1TH ]ZT^PMM
M+TZWL;")8;:WC$<4:CA5 P*L5XGXF\-VGPFUCP[J?@V\NXI+[4$M+JPEG,BW
MB-]YB#W' SV++C%>V4 %%%% !1110 4444 %%%% !1110 4444 %>3_L[?\
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M5Z1?_P#(-N?^N+_R->;_ +/G_)+$_P"OV;^E 'J%%%% !1110 4444 %%%%
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MOC /S#C/<>M1^+-%\0>%_B4/'7A;3&U>&[MA:ZG81-B5@, .OK]U.@)^7T/
M!SOQ(T#QAX%\%SWVC^-=8O[(NBW(NIF,T.6&UTE!W 9PI'3YN_;JO%VF^);K
MP5HWB'PIJEZFJZ=:Q3R6HG<QWJ;06#IG#-U//)Y'7%<K\2-?\8>.?!<]CH_@
MK6+&RWHUR;J!O.FPPPB1 9(SAB?]FNE\6:AXF/AC1?"GA33;Z/4+^UBBN=0,
M#K%91[ &R^,!^O?(^I% &';^,]8^+VNZ;IGAF6^T32K5$N-7NH93')OQ_JE=
M2#CJ!TSU(XK9\7:EJ%A\:?!6F6FH7D5E-$XF@%P^R; ."XS\QXZG-8[^"=5^
M$6J:?K?@J"]UFPEC2VUC3XE,DDI'_+5%'N3QV^C'&MXJL+_4_C+X(U:RTZ^>
MQCA=I9C:N%AR#@/D?(>>C8- &/XHG\4ZK\?&\/:#X@O--M9K%&FV2%DB3&69
M4)VASP >O-4]:_X3;P5XXLO"NB>*;O4HM?A"PSZFWG26K;L,X)]%!QVYZ9&:
MZF+2M1'[24VIFPNAIYTD1B[\EO*+<?+OQC/MFCQEI6HW7QN\&7]M874UG;)(
M)[B.%FCBSNQN8# _&@#&U=/$'PO\7^'+AO%.I:YIVK78M+RWU"0OM)(&Y/[O
MWB0!C[H'(-;/C+5M1M?C=X,L+:_NH;.Y20SV\<S+'+C=C<H.#^-'QBTK4=3N
MO"1TVPNKP6^K)),;>%I/+7*_,V!P/<T?%'0=;7Q)X=\8>'+!M3FT:1A/9(?G
MDC/=1W_B'&3R#@\T +\==5U'2/!NF3Z3?W5C*^KQ1O);3-&S*8Y"5)4C(R!Q
M["J'QIU7Q!8^)?!=KX7U&XL[F]N9HPL<A$<C;H0N]1PP&X\$$<FN<^)FI>+O
M'VEZ:+'P9K%EIUK>([I/;L9I)"K 'RP,A%&[YNF6%=E\3=*U&_\ B'\/KFQL
M+JY@M-0D>YEAA9UA7?#RY PHX/)]#0!S/C>'Q;\*[?3?$%GXNU#6C<7(MKJT
MOV+Q.[*S#8N?E'RMTY''-2^+=&\:>"_"(\8OXUU&ZU.U>)[NSE;_ $4AW"E5
MCZ<%@.G3.,5T/QUTK4=7\&Z9!I-A=7TJ:O%(\=M"TC*HCD!8A0<#)'/N*UOC
M#87FI_"?6+/3;2>\N9/(V06\9D=L3QDX4<G !/X4 =7I-^-5T6RU!%V+=V\<
MX7/W0RAL?K7E?Q]>>-/";V40FN%U0&*(G =QC SVR>*])\*0RVW@W18+B-XI
M8]/@1XW4JR,(U!!!Z$'M7$?&+2M1U.Z\)'3;"ZO!;ZLDDQMX6D\M<K\S8' ]
MS0!?T+Q!\2+O7+6#7?!EI8:>[$3W*7\;F,8/(4.2><=JY3QM=>*K_P".MKX>
M\-Z[=:=%=:<I?$C&.)?G+.$SC=@8!Z\_C7M->97&E:BW[25IJ:V%T=/723&;
ML0MY0;YOEWXQGGIF@"#Q1J6M?#OPOI?AW2-6N=9U[6[XP6MYJ+;WC!V@GDG.
M"R@9X&?;!==_#OQEI^F/J6E?$#5[K6HD\SR)VW6TS 9V",Y"YQ@<&M?XH^$-
M2\16.F:IX;:,:WH=T+JT60X63D$ID\<E5//!Q@]<UD7?Q$\9:AIDFG:7\/\
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M#+')<ZO+8(VY=.DOB;=3G/ QG]:]#M+2"QLXK6SA2"WA0)''&,*BC@ "I:*
M.=UWP3IWB/Q%I>K:K/=2C2V\R"SWKY!?^^R[<D]._;ZYN^(_#>E^*]%DTO7+
M87%LY# 9PR,.C*>Q&36K10!P_A_X2Z!H&LPZHUQJ6J75L,6S:E<"46X[; %&
M,=O2NXHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G_9V_P"2?ZC_ -A>
M7_T7%7K%>3_L[?\ )/\ 4?\ L+R_^BXJ /6**** "BBB@ HHHH **** "BBB
M@ I" RD, 01@@]Z6B@#SZ]^"WA>>^FN=.FU/1OM!S-#IMWY4<GL5(/'L,"NF
M\+^$=&\':8;'0;7R(W;=([,6>5O5F/6MNB@ KGO"W@O3O"-QJLNFS74K:I<F
MYF%PZD*Q).%PHP.>^:Z&B@#DO#?PVT'PKXGU'7=*%R+N_#!UEEW)&&8,P48S
M@D \D]*ZVBB@#GM \%Z=X<\0:WK%C-=27&M2B6X69U*(06/R *"!\YZD]J@\
M5_#O0/&,\-UJ<,T%] ,17MI*8ID'IGH?Q!QVKJ** .0\,_#+P_X7U1M4@^UW
M^IL-OVW4)_.E Q@X. !QWQFNN8$J0"5)'4=J6B@#GO"G@K3?"+7\ME-=7=UJ
M,YGNKN\=7ED;T)"@8Y)QCN:S?$WPMT+Q+K)U=I]0TO4639+<Z9<>2\J^C9!!
M[?D/2NSHH Q?"WA+2/!VD_V?H=N8XV8O)([;I)6_O,W<UM444 %%%% !1110
M 4444 %%%% !1110!7O_ /D&W/\ UQ?^1KS?]GS_ ))8G_7[-_2O2+__ )!M
MS_UQ?^1KS?\ 9\_Y)8G_ %^S?TH ]0HHHH **** "BBB@ HHHH **** "BBB
M@##\4^#M$\9:<MGK]F+A8R3%("5>(GJ58<CH..AQS7-V/P8\,V^H07=_/JFL
M&W;,,6I7?FQQ^@"@#@>AS7H%% '.>*_!&G>,GTX:O/=BVT^<3K:PNJQ3,,8W
M@J21C(X(X)KHP,# X%%% ')7/PVT&[^(,?C&47/]I1A3L$O[HLJ[0Q&,Y  '
M7''2K5OX(TZ'QY<>+I9[NYU&6'R$69U,=NG Q& H(Z'J3U/K71T4 %8?BWPK
M:^,=$.DZA>7EM:/(KRK:.J&4 Y"L2I^7.#QCH*W** *:Z38+HPTG[+$; 0_9
M_LY7*&/&-N/3%<)#\#O"L5U&7GU6:QCE\U-,EN]ULK9S]W&?U[UZ/10 B(L<
M:I&H1% "JHP /04M%% !1110 4444 %%%% !1110 4444 %%%% 'G?QV_P"2
M0ZG_ -=8/_1JUV/AK_D4](_Z\8?_ $ 5QWQV_P"20ZG_ -=8/_1JUV/AK_D4
M](_Z\8?_ $ 4 :=%%% %35?^0/>_]>[_ /H)KSW]G_\ Y)3!_P!?<W\Q7H6J
M_P#('O?^O=__ $$UY[^S_P#\DI@_Z^YOYB@#TVBBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KR?XL_P#)2_AK_P!A-_\ T."O6*\G^+/_ "4OX:_]
MA-__ $."@#UBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#R?X*_\ (<\=?]AE_P#T)Z]8KR?X*_\ (<\=?]AE_P#T)Z]8H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *\G_9V_P"2?ZC_ -A>7_T7%7K%>3_L
M[?\ )/\ 4?\ L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !5'_"D[W_HH'B#_ +^M_P#%4 >L45Y/_P *3O?^B@>(/^_K?_%4?\*3O?\
MHH'B#_OZW_Q5 'K%%>3_ /"D[W_HH'B#_OZW_P 51_PI.]_Z*!X@_P"_K?\
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M_HH'B#_OZW_Q5'_"D[W_ **!X@_[^M_\50!ZQ17D_P#PI.]_Z*!X@_[^M_\
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M)WO_ $4#Q!_W];_XJ@#UBBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\
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M!X@_[^M_\50!ZQ17D_\ PI.]_P"B@>(/^_K?_%4?\*3O?^B@>(/^_K?_ !5
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M#_OZW_Q5'_"D[W_HH'B#_OZW_P 50!ZQ17D__"D[W_HH'B#_ +^M_P#%4?\
M"D[W_HH'B#_OZW_Q5 'J%_\ \@VY_P"N+_R->;_L^?\ )+$_Z_9OZ52NO@M>
MQ6<TA\?:^VV-FVF4X.!T^]7(_"KX;7/BGP2NHP^*]6TI3<21_9[20A.,<]1R
M: /HNBO)_P#A2=[_ -% \0?]_6_^*H_X4G>_]% \0?\ ?UO_ (J@#UBBO)_^
M%)WO_10/$'_?UO\ XJC_ (4G>_\ 10/$'_?UO_BJ /6**\G_ .%)WO\ T4#Q
M!_W];_XJC_A2=[_T4#Q!_P!_6_\ BJ /6**\G_X4G>_]% \0?]_6_P#BJ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\G^+/\ R4OX:_\
M83?_ -#@KUBO)_BS_P E+^&O_83?_P!#@H ]8HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH \G^"O_ "'/'7_89?\ ]">O6*\G^"O_
M "'/'7_89?\ ]">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V
M=O\ DG^H_P#87E_]%Q5ZQ7D_[.W_ "3_ %'_ +"\O_HN*@#UBBBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** *]__ ,@VY_ZXO_(UYO\ L^?\DL3_ *_9OZ5Z
M1?\ _(-N?^N+_P C7F_[/G_)+$_Z_9OZ4 >H4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110!YW\=O^20ZG_UU@_]&K78^&O^13TC_KQA_P#0!7'?';_DD.I_
M]=8/_1JUV/AK_D4](_Z\8?\ T 4 :=%%% %35?\ D#WO_7N__H)KSW]G_P#Y
M)3!_U]S?S%>A:K_R![W_ *]W_P#037GO[/\ _P DI@_Z^YOYB@#TVBBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KR?XL_\E+^&O\ V$W_ /0X*]8K
MR?XL_P#)2_AK_P!A-_\ T."@#UBBBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#R?X*_P#(<\=?]AE__0GKUBO)_@K_ ,ASQU_V&7_]
M">O6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O)_V=O^2?ZC_V%Y?_
M $7%7K%>3_L[?\D_U'_L+R_^BXJ /6**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH KW_P#R#;G_ *XO_(UYO^SY_P DL3_K]F_I7I%__P @VY_ZXO\ R->;
M_L^?\DL3_K]F_I0!ZA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'G?QV_Y
M)#J?_76#_P!&K78^&O\ D4](_P"O&'_T 5QWQV_Y)#J?_76#_P!&K78^&O\
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MU#3M1D\WS%Q\P6)B"GID9]<T =%\4_%VK^'8-%TWPX88M2UJ]%K%<3+N6$9
MSCURR]<\9XKH_"MAX@T[2Y(?%6LQ:Q=&4LEQ';K#A,#Y2JC'!!Y]Z\@^+?A2
M:#QQX9E;Q#J\HU;5]J(]P2MCEX^8?[A&[CZ"NF\4WNJ_#+PE;Z5I&LW^M:UK
M=^(+.?5)?.>$L%4X)[ XP.F6S0!ZI17F*_#SQCIUE_:-AX_U2ZUI%W^1=-NM
M)6ZE/+)PH/3/XUD?#;QK>Z3\$=8\1>(+JZU&>QNY0OVN=G<G;&$3<V2!N;'M
MDT >RT5Y+H7@_P 7^,=#@U[7_'&K:9<7R">"TTU_*BA1AE00#\W';\R:U]/\
M+>,]8\.2Z/XN\0W%G):78>UU32+@Q3W,8##$@ P!R#ZG STR0#HO!?C/3O'6
MAOJND0W4,"3M 5ND56W  DX5B,?,.]5] M_&4?C#69/$%W9RZ&Y_XEL4*@/&
M-W&3@'[O7)//3 KRWX$>$Y]2\/1:U'XBU>SCM=2.[3[>X*V\VT(?G3OG.#["
MNM\#:Q?W/Q>\<VM]J-S+9VC)Y,,T[-'",G.U2<+^% 'IU%>.Z WB7XNW%]K
M\1WWA_P_%.T%E;Z:_ERR[?XV?KW'X\#'>]HVK^(? WQ(L?"7B35I-:TO5XV-
MA>W _?1NO\#'JW3'/=E/'(H ]4HKP['BSQ-\;_$F@:;XFO\ 3=,B"/,8Y2QB
M0*F%B!.$)8]1CO\ 0ZFEW6O^ ?BUIOAG4->O-=TC6H6:)[]R\T#@-_$>>J@>
MF&Z<4 >NT444 %>3_%G_ )*7\-?^PF__ *'!7K%>3_%G_DI?PU_[";_^AP4
M>L4444 %%%% !17E?Q U[Q:/BGH?A?PIK::6NHV;2,TEM'*NY?,.3N4GHF.*
MBU&X^+7@NV?5+J\T[Q580C?<0I (940=2NU1V[_-]* /6:*QO"?BG3_&/ARW
MUC2F;R9LAHW^]$XZJWN/U&#WK9H **** "BBJ&N:O!H.@WVK7@)ALX'F<+U8
M*,X'N>E %^BO)-%NOBGXUT9?$.GZQIFAVUQE[.P:V$GF)G WN02,^H^N!72?
M#CQW-XJ\/7TFN01V>HZ3.UO?!/\ 5Y7G<.N.AR.>AH [>BO)=&U[Q_\ $@7.
MJ^&-0LO#NB1S-%:M+;":6YVGDG<" .W&,=.<9K:\#^,]9N/%6H^#O&L-LFM6
M,8GBN+7(CNHN/F /?Y@>/?@;30!Z!1110 4444 >3_!7_D.>.O\ L,O_ .A/
M7K%>3_!7_D.>.O\ L,O_ .A/7K% !1110 4444 %%%% !1110 4444 %%%%
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M30[2'6[XW^H+&/M%QY:H&?O@*  !T%:% !1110 4444 %%%% !1110 4444
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M!@[F!Z/GBH]1M_BSXSM6TN[L].\*V$PV7,R7 EE=#U"E6/;Z?6@#G?AMK_\
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M;:8;&,87&W?L^4_Q#CL1W%)'?_&"TTW^RSH>E7=TB>6NK_:U"GMO,9();OT
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M HHHH **** "BBB@ HHHH \[^.W_ "2'4_\ KK!_Z-6NQ\-?\BGI'_7C#_Z
M*X[X[?\ )(=3_P"NL'_HU:['PU_R*>D?]>,/_H H TZ*** *FJ_\@>]_Z]W_
M /037GO[/_\ R2F#_K[F_F*]"U7_ ) ][_U[O_Z":\]_9_\ ^24P?]?<W\Q0
M!Z;1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y/\6?\ DI?PU_["
M;_\ H<%>L5Y/\6?^2E_#7_L)O_Z'!0!ZQ1110 4444 %%%% !1110 5R&H^
MSJ_Q*L/%.HZEYMOIL6VTT_R,!'_OE]W)R<_=[+Z5U]% !1110 4444 %%%%
M!1110 4444 >3_!7_D.>.O\ L,O_ .A/7K%>3_!7_D.>.O\ L,O_ .A/7K%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7D_[.W_ "3_ %'_ +"\O_HN
M*O6*\G_9V_Y)_J/_ &%Y?_1<5 'K%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 5[__ )!MS_UQ?^1KS?\ 9\_Y)8G_ %^S?TKTB_\ ^0;<_P#7%_Y&O-_V
M?/\ DEB?]?LW]* /4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MA]_T'6_\ I__ (B@#T"BO/\ _A>/P^_Z#K?^ 4__ ,11_P +Q^'W_0=;_P
MI_\ XB@#T"BO/_\ A>/P^_Z#K?\ @%/_ /$4?\+Q^'W_ $'6_P# *?\ ^(H
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MO^@ZW_@%/_\ $4?\+Q^'W_0=;_P"G_\ B* /0**\_P#^%X_#[_H.M_X!3_\
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M%>?_ /"\?A]_T'6_\ I__B*/^%X_#[_H.M_X!3__ !% '<7_ /R#;G_KB_\
M(UYO^SY_R2Q/^OV;^E6KOXW> );*>--<8L\;*H^QS\DC_<KBO@]\3?"?A3P"
MNFZ]JAMKL7,DAC%M*_RG&#E5([4 >]T5Y_\ \+Q^'W_0=;_P"G_^(H_X7C\/
MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
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MO^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\ B*/^%X_#[_H.M_X!3_\
MQ% 'H%%>?_\ "\?A]_T'6_\  *?_ .(H_P"%X_#[_H.M_P" 4_\ \10!Z!17
MG_\ PO'X??\ 0=;_ , I_P#XBC_A>/P^_P"@ZW_@%/\ _$4 >@45Y_\ \+Q^
M'W_0=;_P"G_^(H_X7C\/O^@ZW_@%/_\ $4 >@45Y_P#\+Q^'W_0=;_P"G_\
MB*/^%X_#[_H.M_X!3_\ Q% $?QV_Y)#J?_76#_T:M=CX:_Y%/2/^O&'_ - %
M>/\ Q8^*7A#Q/\.;[2]$U4W-Y*\12,VTJ9"R*3RR@= :]>\+.LO@_1G0Y5K"
M @^H,:T :M%%% ",H92K $$8((ZUCIX.\,1KMC\.:2J^BV,0_P#9:V:* ,?_
M (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'PW_T+
M^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P" 4?\
M\31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]
M*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P# */\
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MPB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\
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M'_\ $T?\(CX;_P"A?TK_ , H_P#XFMBB@#'_ .$1\-_]"_I7_@%'_P#$T?\
M"(^&_P#H7]*_\ H__B:V** ,?_A$?#?_ $+^E?\ @%'_ /$T?\(CX;_Z%_2O
M_ */_P")K8HH Q_^$1\-_P#0OZ5_X!1__$T?\(CX;_Z%_2O_  "C_P#B:V**
M ,?_ (1'PW_T+^E?^ 4?_P 31_PB/AO_ *%_2O\ P"C_ /B:V** ,?\ X1'P
MW_T+^E?^ 4?_ ,31_P (CX;_ .A?TK_P"C_^)K8HH Q_^$1\-_\ 0OZ5_P"
M4?\ \31_PB/AO_H7]*_\ H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO
M_H7]*_\  */_ .)K8HH Q_\ A$?#?_0OZ5_X!1__ !-'_"(^&_\ H7]*_P#
M*/\ ^)K8HH Q_P#A$?#?_0OZ5_X!1_\ Q-'_  B/AO\ Z%_2O_ */_XFMBB@
M#'_X1'PW_P!"_I7_ (!1_P#Q-'_"(^&_^A?TK_P"C_\ B:V** ,?_A$?#?\
MT+^E?^ 4?_Q-'_"(^&_^A?TK_P  H_\ XFMBB@#'_P"$1\-_]"_I7_@%'_\
M$TU/!OAB-<1^'-)09SA;&(?^RUM44 8__"(^&_\ H7]*_P# */\ ^)H_X1'P
MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
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MW_T+^E?^ 4?_ ,36Q10!C_\ "(^&_P#H7]*_\ H__B:/^$1\-_\ 0OZ5_P"
M4?\ \36Q10!C_P#"(^&_^A?TK_P"C_\ B:/^$1\-_P#0OZ5_X!1__$UL44 8
M_P#PB/AO_H7]*_\  */_ .)H_P"$1\-_]"_I7_@%'_\ $UL44 8__"(^&_\
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M H__ (FMBB@#'_X1'PW_ -"_I7_@%'_\31_PB/AO_H7]*_\  */_ .)K8HH
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1(,!0.  .PIU% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6794298512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 11, 2018 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stock split, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, offering price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriters fees | $</a></td>
<td class="nump">$ 56,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 56,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 67,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,315<span></span>
</td>
<td class="nump">$ 67,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,034<span></span>
</td>
<td class="nump">46,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,383<span></span>
</td>
<td class="nump">25,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,892<span></span>
</td>
<td class="nump">93,162<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 213,059<span></span>
</td>
<td class="nump">$ 123,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember', window );">Majority Shareholder | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.80%<span></span>
</td>
<td class="nump">56.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember', window );">Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="nump">47,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Underwriters Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,999,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,999,550<span></span>
</td>
<td class="nump">5,047,514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Follow-on Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares sold upon completion of follow-on public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">288,124<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Convertible Preferred Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares of convertible preferred stock converted (in shares)</a></td>
<td class="nump">2,065,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6591717872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Oxford Term Loans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total principal payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unamortized debt discounts and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,492</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long term debt, net of discounts and issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73,508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6631747216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 1,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2021</a></td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2022</a></td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2023</a></td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2024</a></td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total operating lease payments</a></td>
<td class="nump">6,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1,366)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 5,093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779922512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,257,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,321,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(273,734)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled/forfeited (in shares)</a></td>
<td class="num">(328,117)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,977,401<span></span>
</td>
<td class="nump">3,257,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">800,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 11.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">9.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled/forfeited (in dollars per share)</a></td>
<td class="nump">15.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">14.07<span></span>
</td>
<td class="nump">$ 11.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 12.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding</a></td>
<td class="text">8 years 6 months 4 days<span></span>
</td>
<td class="text">9 years 3 months 4 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">8 years 3 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 7,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">7,198<span></span>
</td>
<td class="nump">$ 7,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 1,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract', window );"><strong>Vested and expected to vest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">3,977,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 14.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Average remaining contractual term (Years)</a></td>
<td class="text">8 years 6 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 7,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6786096800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Deficit) - 12 months ended Dec. 31, 2019 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>IPO</div></th>
<th class="th"><div>Follow-on Offering</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A Preferred Stock</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>IPO</div>
</th>
<th class="th">
<div>Common Stock </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Additional Paid In Capital</div></th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>IPO</div>
</th>
<th class="th">
<div>Additional Paid In Capital </div>
<div>Follow-on Offering</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Gain</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 84,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 207,408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (123,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,999,550<span></span>
</td>
<td class="nump">288,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,022<span></span>
</td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,022<span></span>
</td>
<td class="nump">$ 2,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(90,034)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(90,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive gain</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">33,562,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 79,457<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (213,059)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6789483104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 21, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EVOLUS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001570562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,728,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Smaller Reporting Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782143024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements and Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any short-term investments for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> investments had been in a continuous unrealized loss position for more than 12 months, and the Company did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t record any other-than-temporary impairments on these securities. </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not transfer any assets or liabilities measured at fair value on a recurring basis between levels during the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company determines the fair value of the contingent royalty obligation payable based on Level 3 inputs using a discounted cash flow method. The significant unobservable input assumptions that can significantly change the fair value include (i) timing of regulatory approvals of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, (ii) projected and timing of net revenues during the payment period, which terminates in the quarter following the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States, (iii) the discount rate and (iv) the timing of payments. During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company utilized discount rates between </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">16.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, reflecting changes in the Company&#8217;s risk profile. Net revenue projections were also updated to reflect changes in the timing of regulatory approval and expected sales. &#160;Significant increases (decreases) in discount rate would result in a significantly lower (higher) fair value measurement, which could impact materially the fair value reported on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Assumption of the royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Financial Assets and Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s financial instruments consist primarily of cash and cash equivalents, short-term available-for-sale debt securities, accounts receivable, accounts payable, accrued expenses, lease liabilities, and long-term debt. The carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company estimates the fair value of contingent promissory note payable to the Evolus Founders, long-term debt and operating lease liabilities using the discounted cash flow analysis based on the interest rates for similar rated debt securities (Level 2). As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note and long-term debt was estimated to be </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,696</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$76,203</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. The fair value of operating lease liabilities&#160;at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> approximated their carrying value. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the fair value of contingent promissory note was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$17,181</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6781132144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Effective Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax at statutory rate</a></td>
<td class="num">$ (22,063)<span></span>
</td>
<td class="num">$ (9,828)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of Federal benefit</a></td>
<td class="num">(3,905)<span></span>
</td>
<td class="num">(3,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount', window );">California NOL write-off</a></td>
<td class="nump">5,174<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation', window );">Revaluation of contingent royalty obligation</a></td>
<td class="nump">1,040<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment', window );">Meals and entertainment</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in state tax rate</a></td>
<td class="num">(1,371)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">521<span></span>
</td>
<td class="nump">474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(294)<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount', window );">Promissory note - debt discount</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther', window );">Other, net</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">4,691<span></span>
</td>
<td class="nump">9,801<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit) provision for income taxes</a></td>
<td class="num">$ (15,027)<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Net Operating Loss Write-off, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationNetOperatingLossWriteoffAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Promissory Note, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationPromissoryNoteDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Revaluation Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32059-109318<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible meals and entertainment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in other income tax contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>28
<FILENAME>0001570562-20-000061-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001570562-20-000061-xbrl.zip
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MMCHP5E_9!F(!W^Y+$J4@VF(,E, .<4Z5PB4_,.+-JXV$AL8O;8.1KL_NPA#
M#$@;PI5!%DL<)2D90@3"[:O?,'K]GYO?3:\N/[=0M@Y^S7NC-^-!]OT_L]L=
MOBNB0=K!$^XTL4X21.GRNS:2P#;-A,8O;8%Q5]:ST"#3B_DL*;G!<+RY,\&>
M(FCA_>!7/PVR_O :]AS\_GM<@U&)2#@RB'AFF4/"8\>7,"K8O# TR8'BA:5
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M$XS8R!T-4H+%8X.G,@IA+3%15F/D1+)UW'8&JQF5S6A VC]^."T.R?=S0:D
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MK\%R.,QMJL@P#TX&P$BXX%98R\LB?(HC*:I!>X:WVK(< ^9:#=I&ZHB=!)L
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M34#/$ 2N&D)"R)0@1LOK2YCZBI4)-HV^/_#+>W#U,???)T5KKVQ0M""=?IJ
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MH_:LX0[*3%,P1A"U *AA6"^K>,%"<UFY&TY G6_N^O*[N\'2)H&D#&#R<26
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MVUF83>$:GFMJ8!@20V<^N'FPMBW!WN'7'P/@5GHR/<UP;=]CS+1T2W-90"6
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M")NWS:,X1Q-%O7=G'].C$+K1:&%<=P+?IU0#WG8%-S2A$6)X+MAC6JOK6%6
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MEL?I4,_6A4^-@ &(3A!H?C&25WA8K-'3#$+K=AH]!7QO0\QZEBE\G_I:8)/
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MUWOOU/&Y.7!\HI)U"@RI7+RBZ+TJH1I*FMR*\NS,";2E)583]HMDB<W7@!=
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M%JT?HW!]1N+"IV7KU0:= &KPIQY5U0\U5WG3C#$U19WPO$%Y=SJHKP!_@$#
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MXOA)G'J^) [I5- 6>4#@4)W O1O;@^&P;%V?,4%UY8R5\<G[>D7Y)^T9-%^
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M]LH/W6]__<__^//6%S5W]!\"*^YC\%DBPUTA,-QO&D+7!P3H^IP#95#WIYV
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M*X^IB#N1\1:I\Y=$-(UM<WG7M<<M U]@^L1,G]B+!:C=*\WHG9< F?3&'J/
MX/[S, H\Q_KUXR_68X3E*N%\7H40-@]HH&^WRYM0V7B(@1,2O=.U=,T3,H/F
M8= \7L$^GUE6F0;1FANJV9=1N';\9*W-P#2NIW9]VV[U2L-N;(I@U4^&3M=4
MG:QD=.QQM[28K"F28:*MYQGG'PSKZ;&2EBH"L#X?B_N-'[BG/6J5-PZLZ1[@
M"4G>Z5JP!@I9]1"F39$P$V-E6435R1/3.9GL^C!>8Z[=V.X.2P...J]4?OW$
MZG2-ULD*D,%,-,'7*]CG2Q*ZW^ ]EBL6Q)6E^YKG$O8[U:,=-D4.3TCD3M>
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M?\,H**.@GJ+.X'ASM!KH69DA6"]>J;O_^),IN_>" %Y.M&#.Z,<E'B_C5](
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MBL1"G!BV-;[4"0:JBQ&I+?9]!4^F"W=3 />- Z''(!G>')1CD,"^HO-!:PI
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M%URO0.62\$?J@'@DSE;^GQ>T&)38-T2)[5YV^MWQ8"3_+0\E=E *2NR@^[9
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MKO^6?SP]K.H:8H'U>CGZKQ-FH/[@LE7E^V>;\,1A\CZ'A?"AZ-GUUY?6%\;
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M'4&X-I 5GA3M<ONNSLV ^>'O*#WXF0<>5+36DFD:8)R-7UPR)Q S=CEN>08
MJ@[-<J!N]*5/\DL3^27U%1P$L]*RO;RB)*O!(/R:F4H"K\3VZWY)E-]^)]O^
M2^NC-KVZW2,Q&MK:W*/M-^.T$U,&<AAYXK-]ED3>D*V/6[*+RF.P3I@Z9YZI
MZ\IEFP5%!$!6H=TMHE+FO3VWD.8'K;_M30LYE6N;GJ+IC4<*[[SWEG,<7VYL
M=XZ4?4Y7%V!ML79?+)_XEK<V(=?>W4RR(:@81IA9CL^15(WHA#@\X2PUWYRX
M*50@JB&JY9"(S%Q_CVU@-N V<?Z!31#AVO'Q6(OODM#.?OAHH6Z!N&OFW7O4
M@.%B<\8]I;6P88(W6\$O9M]VG;RCK01R'T^Z.\<;+;-QHB(QW'@WH)=#4^^T
MQ>#: CV(^&.\8A.N(=9TIJ%HJ*0@3G4:R2,[CK\NW.>CD+5=)45YS9\3!#A<
MFKHQA3GG!Y79V%O5]6KD;<]<:6[X[:5UJ-G>S#3S77$\;<2.0U69#UY,":MM
M[I8UP)O"0KW2PN'<#%&/E=7I]^UAKTIP%>T$#YL0(H_G18^SNN[8'AY)$VX$
M$!PCZ)X:H85MU?*ELD8)..-(R>&!W3K2-N\FQ ;_O\?0IBBA3J#.QVRZX]B<
M6I%4E4T[QZO9V;7$.]1>_R3M]0_F8)-I!@;TA5 POF+Q^8<,!>-H?NTFL#7Z
M 6FR&ZXUJY2B,OEP?IG=[T-VVF5+'%EU[KY?<]DN#N6YOW ^)^!4*CM"J 1$
M7, \_0R1$B(:)<U_Y "U\!;.-Y[,QZX9_N[JP/ABVZ@4&9.B,#[WSG:!A:)H
MP-ZU&AOCA(:8FR:G-P]..PBG@B+ $):+A2C ZT'*P6^/=3C>K[3>)%N%5N<I
M$0.TPBR1GH>[4PHBEW@P_O1^_K3>ZSO6SS"<#?XZWLGLL0)=E*$GR@7Y*<T_
MV RW-'=&\S?F4'KOLVPZI>OP/^LF:SW5[)8>)'NY\Z<]&E=%T),#EM)@.. ]
MM"YL 56^BM@"X9<@X$;\BV-A,A>@KU;=Q=%XZZ"?WV ;)!4+$3P[C3=F*V==
M%(JB*..9)N^@H".2*!%#U-=4O\@U*>%.>7P"!_V_!,0#[L,8!\+K%36]6HC!
M1XG)&9L[6.F:'1UL/1M=G30@"<O*(:<,,?_C7"W8+.7OH<(G[CV)27(B8P*K
M@"==6I."EPA=, SZ,09O/!17;L;G*5]+EHM1.2>Z<?P3I>R%D06'RZ>"8L)3
MI-?2O3;XW/G&1/&6.%-3R5;R7>FE1&)6W!,OB0F?,\;^,Y)T*9Q3%K YA^ET
MX68>!U?D>49Q.66- FI&0TP^)_@6I:O$7<LQ; 25 +=[YSUHCP22>#20?!HQ
MQUV(RM7GG V\SU?G.P0-,[8,J.H_.\M3,Z"PHI&&/X'B>GPO3A&Q^9L>A=]
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M"Q;PD[$#]]1'[?*&US3= CRADW>Z&JR!AZQZP+VFG##C8V51Q$<'7"K+"ZA
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MM#IE8P75'-)NKS/OMK>5W'HQ4(8DT@'&F,G][6>KE9[[:SZ;TMT.F?"\E;)
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M3([:+I;WJP+:58:P7QU!<0T"<,AD1F(.6/E+% ;PXXR1TS$)W.M')WA@\:=
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MEEQJIU\:L1*_:L<#R(ZE1L7\UN"3P;P!JW8^QZZ]4"Z8/7EA&OOH;V+X1-A
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MU_[IO];DZ&O*?TY;#-,?-V"=[[<,=>8;8GVXH2&?2455$\5K:G* ?U/9%-,
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M];BE;"ECE6ULFV,A7C 0IVL$_ "GE3[TL;<PVF1%N$XPGL1_R/H_BAZZ*?-
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MTA_M,R<@C\>__Y</&Z^5A,M#T/PW>&[M[?/3(OKXGN4SD#*<+C_NW/=])AK
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MK)3K2@:4 VEY%CAR[=;0X,B]^0UQQ^>A[X?/I%8);(PCR\%5,3>5BMA)F%C
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M$V/\Q"T__XN4J$/1@M2O2-XPJQTN. [.3X6\%\-<'4;)91I7XM ^"U1%]J?
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MNL+Z6?AP/+FV%=YM7XR6%E4%U_823R@VJY33[J=1[O&955(NWNZ/4\X_>4E
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MH/Q)G1'VI7RAY EEIZ?Z)7]!SZ@]$803>2I>JC,IG[*WXL,DCN;+PWGEII2
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M>#*;83_2O>0GK>FWIHZF7/C+$&T0K&QH>S3ZI+4*C.,ZL>0C\4_/;AZ69OW
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M_5RP,*3S>B#5K0::@UOB/]A7]<*/?WCQT&Z =VEY!\I;-UM<_S'#%[I0JCC
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MM>MC:-[RD?/EB!U!L\H7#Q+-KM:YPS5KZ ODWQ>Y/;O&P1A]G(SPE26$_N;
M=9&%TS$VXO#O?WUQZ0(*Y),XO;S)9G8R#T:P\\D+-R[W*[S_E-)B^%%JU=B*
M(J!5>XYE$+=2>;5<EA\>)^+?_NW_ 5!+ P04    " #X@%E0@$5L/MI;  "
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MP]L7C:1?LMEJ\9=Q=O\F_OF-&H_S53IQWQ[2^2)=A&^OF[C+TYN__IQFLT5
M"$J(-OC\CP/%EX\/Z5]_7DSO'V8!E#>-=,6FR]%T=FZ/7M5JHV.?1I]G9R/U
MLE(CW=*C653\Q[LT79[LSM["S7?C_2@/H_TN74['H]E9?=I;LY$.FNS^?KJ,
ML]!"S2<FFR_#?!7FK>EI)9:HVG87PY\>LGG\R_7-51HFG2VC0KGK %?^?U:C
M4'H9YL4OZ=OY39;?KZ?(DJ.G]0^W#8]?+5=Y^MMT/KU?W;\?/:X+_3Z?I/F[
M;&XBO69QY%T_I/DHUEI+4G9N:?N[;8/SVRAT<KI\O+YYV8^KZ>CS=#9=3IM
MXOR/M"WVNU&>KVE97[A#3;4M0KDUIG0#C72WL.7"IUP<^8_/1OVIGI:IVT@G
M7:B=/::I3N?IS73Y/JPPI_IVI$I;72I)S-,U&^F@'TWSOX]FJ_2W,&[#K%80
MZN-=EB\_I?G]V_F7=+'AV:DN5VFK<R'48I&N__ALCMI6FUS//Z3C59Z'D:1'
MBVG9";*CSW<.U;ES:1-M=RYD@#P+L^9LNIZ/KF_VU;V^V<VORP_9XV@65KS/
ML^GMNDHP .)\VP)&+76M<XCWCH,OH4NQ<S[+/XY:@:_"9SN'IMQ:7[W%1@3Z
M-<LF7Z>S6?CBV_ER-+^=AD]L)K)3/2]1M>TNNL5R>A_]3QNS7=T'S*;_7H^/
M[:[F^N:I3MDYO[4/M@W'N9-ZA:;:%B%ZOR:KL,&ZL<$TFD^7Z;K09/N/J]"C
M[^K4E[:!K[8-3+G9I'0#C73W[3S\F'X:?3O=L3U%F^["<\>&":;69EL2%)J&
MGR>AR':$EJ1+_9:;%O#9!_>9FN?+=5Z#38MS[FQ5HFK377QMI;F;FW0<OQO^
M>GZOSVBM:4'*S1X'*S3=G=_G><#B=C[]]YI\VWUP!0:7:ZB1[E_GMZ/Y=JT_
MU<-]91OO1$FTCE1IIDO?;K)\$BW5JVPT/]V=_<7;Z,K6@QEFLKBN?UZ6!>RL
M5MKH^+DS8\GJ;72UW,1RM%(CW?J0SJ)9_GZ4+Q\_Y>$;HW$D_,F>G:K7:N=*
MJK=D]4:Z^G$9/G6_-75&BSL_R[Z>[.#12HUW:WL<$0!8.\?O'_+T+EA?@>]7
MV>*LOI9KJ7$!/BZS\3_OLMDDS1?N7ZOI\C'N.L;3Y3E]/]E(0]VNW-5>N_>_
MT\?H5%DK-YBVJ_N'<P9<S6;;%>W<Q>'LAMKM_M-6^T.Z6.;3<9C9UH5_#SMM
M%<WA==EZHE7Y2%=BKXM<KXG3O+BG&V]9S/@'/5JDZ^DTS*7/76.UQ3RC\7;%
M+&?UE*S>3%=7]_>C_#$P8!IV0^$KHWD@^CA;K0\0WF>S:9FXF/-:Z;#C;^\?
M@M%S?:,FV<-F\ZP68T'0]?QYL%%9@K7WR0XA.7L=J-5JAX(U2]8>25MREJC0
MUD$A1OFXD&/[XW-1=@&LT_GRS61Z_V9;YLUH]BJH[T"(;!'U&L-KZ;KWSVHV
MW:GP<S3&L_DOD_1FM)HM*W;Q8#LM=CB['TWG]?O[HIG&N[MN_9?[]/YSFE?M
MZ[XVFN[H76@O'Z\^I[_LH*G8W2,M'>ST]A H%+T*_]R6COVJ$G^]^4KZ;9G.
M)^FD^>_LG;7;^]R^6:G!KQT);F[K*T?"E1O\9.GXXVZ^V61(<#<];C!,MYL.
M5XVF[:9WQZV^71]B#XH^S++QOCEX/?_>C!:?UY/P:O'+[6CT\"8:/&_2V7)1
M_&9M OT"X/9^SO_8_CJ)?K<7/0L"IF^7Z?VN2T&OZ>RO/X?/)Z<K)4Y@J8ES
M@AD.D.$4:T.\XQYZK)F%+P6=Q7M(6;[%NF-)UW/I.5*N*R3<(Z@U0M0H'<1B
M2BFTE1!I:5T9"9_XI/+Q3UD>AM%??]YALUV&S[(BXQVPYI64M8!(Z'SXQ=I.
M^(_Q+%NDD[_^O QKW-,OPQ?""'"SM><UF CI;?RA!$D6!5B+=/R7V^S+FTDZ
MW1 D_/":%^%7R55Z.YIMXJC5M^D^RN\IE5#"I,& 6Z^!@L93JF0AKY/4=,B
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M/,I*O-/.%E(;"TN9C]UZ*II0X0E6U,:I+W;8Z6*=J^[#:)F>S8[O*R<8$@N
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M8*"W2#KM"AF1X@,,N&M1]4W!5#E3C\]BV-;U_/HF[&NF\]N#BCU2.B%A<N-
M$T$U0%Q0X2C:]C4F)*D>3MU:,%P+*FT.H.ZBY]?)+]^/\N7C,_D7^O'Y7T[L
M)\HWDE@C-.3"Q^!T:01DVHD"!<QJ'%:?'^EV>1N,UG#N@VTG#<;O"R>(&L>
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MW%KA[58N:0.@U=EP&8[+%L%JEP2?[H(=.[I9'C[S/+.9Q,<GX9EG%B+/%96
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M1@-$I@#8"]:E<5[:ZU)5M?LYTB)<W1T'+Y;7-[]FV>3Y_/@QFQUSU!ZNE !
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M1P)F2 BG/+5VM]'G6-:X.-U:,I:FMT!= M@W[7Z?A][/IO].)W_+9C$BY->
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M<9J&B")#S!4S).]>A]AWQ?9JN4"9L4 @PY1F #A*D#"HD,4#6R-.Z>+/(.H
MU9722R4-C(^Q!-TL-P[)>'KV*=OX(X_0I&;+"<%:"BN,AC0>^0-M3;'YPAR8
M&L2Z^..';J%]HF)+*:_.2W.U[4H;7_S?Z>/?B]>K5#!E[A_6F;YMO*XX6QSH
M3T<Q1?KU6J/R?#2_70=?Z<>G(N]'C_%7*A+LJDR:KMJ-)\9QI<.T9A%CWG%B
MXT/"#@J)&6#8^S(CM27DQG?I9+6.:3PEYN*0G"<S@C7UC<0RC3U3RC%.)5#<
M0DXW.-+X/&Z-??#9$][Q9&(=4N:UZZ4GL$=#SENVD2KT\\35I!?E$FI06',P
M"RM0#'CQ#G%8  "%KG[\VG9>LNXI\'I_4 /'3N-0*V'S)-U\$O?F,1#\]/65
M%CZ78$PQA1AI$>PB)JVTRNZ0-<@.^X9419;LBX =!K!_4K<YA/NA[(F[6A?,
MV'Z8ZNX?9MECFJXW%-?KS<+)&UX'ZR0L""(1UD@Q:9B3%#I3V$1(#O%)\7Y5
M_3JK8$/ #F::.X2='TWSM1_QV18U/C8T7J:3OV>ST,PL^AE&RZ.[EO:_GB#N
MJ,(>6!+^*Y&2,8__%G<H;?6H]?X(W>+.9G *N<B!\&&Z^*?/T[1X;*W+8;#O
MVXGV<<8QF!!ED7$:[)91!CA%U3?U[5T"_4$&00/JZ'0(?'>:]+W<G\\9_)_2
M_!Z>XGXK'TV4HTXKX3@2# OK-9'%1 .5I-5-F?;>H>B9]$/0PT5.^(7 Q86?
M/NR>Y]].$'%$&*DED!@Y1DD\V-EBSF2-M^U:.P_MF_L#4D=?9UWO1GE\5O9+
MVO=9T_.<7V6.C_:63YS@RL;WNA!@%"@DB3:<2V:$=@26>SRO]1.AV&7]N!;@
MC#.>U[42( 2E F,AX^/DR"AEU596RL-&<RBG-C4U=?@@IB8B@SY::>=)&$NQ
M$@Q::*GA849R6NP 4AYWF0JPZM%+=:6?]3[,>4AUYO=KY$60L ?W3$/'F16*
M(ND9+(8>0YZ!81]O-*2W4D^#5$/JQV+#($\,AD2"?I1?[\$08@'@##-B# -&
M>XL)*F0R"E:_8=_QRS"E=7/RP9#S$.GNRE63.> Q9=I1:IU3WA#/&0&RD)&K
M&E>.V\X!W^;R7Q.ESL9[S7S@U@FO'=1.(F,A#,+%V.^-5(KJH6=]K:^MTXG!
MJT'THQ!@V.M\GWKO:X%O*R&\M9II3#B07@#ME/$<%/(ZJ@=X/%I':6<FA#\/
MG,[L@$83PEO&##3,ZC!4-("",>6V,G+/6/4@H;83PK=A!S2$4F=,:#G9-\<<
M$(>(8DA30!#EN!A7'$L]\-C'!K1Y?M;O:I#]40@S3+MBB#SIAQ_G98=WTGGJ
MH:.8:H&HE(KL9- 05W]IM,_L\*45<S [_'FP5%3M(E\^4VOXUVN5AE\E'^(!
MY@'+X,7?$R$ E8PSQ6&\Z:X8Y'3;9Z$1JFX&GG]>W)L54 >1UK5X<%B^*I%(
M1#T2C!K(K93024@*+YC@6 STL;>*V+_67"T,+D>'@UI&NU5==RK[+<!WO[H_
MJK0791*DH8 >2!R/%L)D8XV&1=\)&M)>NC+J63.RMZJWT;?3>GM>)D%.!JE!
M7+:1@\1)X79]9P)5/P!I/#JV$;W5D+V<WA:%A(MT_)?;[,N;23K=Z"W\\%IE
MX5?)57H[FKGY<KI\/&"M["F54$TLU-IAXCBA#% 3$YALNHX4J'YW]/S4#+W9
M+/5Q:4FEF_X<W%.^+I((+CT"'"L'!(58*\N*=4,:+? PS99:\&>-0G$A>AR4
MZ=*+^LY5VZ'4=N9OREV_N[HRQY\%>UTN(0IBBK'FQ#D?Y-,DIH3<],^K&F^]
M-&ZE5(<V:PZ R@I25^_7'SZNGI>EUKF"J0;*6>2Y-EYS7<S_4KH:PZ=Q4Z09
MY=02ORNOF%XMIC'9O1IO$JM%9(\?MQRHD2  O.>0$:D,Q893I(O $HD *I6D
MIJ'7!GH_;&D&HSXY$'_,T].7^T_6333@0&J+J;8!1F^IQJR0F3DU4*=-8YHL
MP8PF\/IC<&50%M9P*=+0*N_6EVO>SL?'E_E7Q1(?%SGGL=.622()I:HX(U!*
MU+B;V-K128.(9XT!T]FYV#JSX=,[HU$?IZV ([42; %&DAKHB 6$"@<-*>1$
MQ%9_;O/\%U]ZMP2:PZEG/IR<W8_62YQ1PA!*-+4*0^T,PD6XD<) \V%; 8UH
ML1PS:N'U8W-DD*O_\*C1#R5^3>=I/IJI^41-[H,*%LO-?=MX9WB^.'P^>%;]
MA%/M0 #1< >PI I1( K9K85=YE0LG[*X"5UF[:/5%5/^GBZ6T_GM"0/C6:F$
M(0*)L/$1>ZH %Y33(@9:&RFJ3PSGO][5NT%1'9>.]7MR,7A1+@',8@>9P)P9
MJ('&&!7&<2"Q)\,V$"II9;]F:^%QV3H>Y +?O6K[4>F!3"'K/(+Y:!ZFLNOY
MZ67\C%82$%<C*XDW$@&OA1.P6)XT]C7>IVUM,:^HQW(Y61K :#A<^?0U:X K
MNU82R[ Q\8TWR9U&0B**BE@.'>RGZB9 :UG>NN)*58RZXLKS1Y2?A20O]./S
MOYRP!LLWDD@79V<?S^HXTQ9)CPNWJT:DQKM+YS_*V;NQV!IL?9#GI+'Q?>'$
M>X;"( #42NFUQ%RS8G]E+!-BV%9E&^H[PI!:F/THC!BD#3I,(O1#@-]&_Y7E
MT^4F;=TFU=M)2^-@G411CS1&GC(-#&)A.E6ZD%%KV2D=RMD5=125M0-+FR'/
MYFZ:WKAOZ7@5_5O7-S?3\1&%GZB1..0T-L@80C@"U$$)Z0XIH:OO0%LS(QM0
M=[.@=#7.JSVZ X#T'%(=1-$,0X'B2Z=;61!Z_2#].>/Y_%>U>S?_ZD#3\U;R
MHAXC$2+LN;2C( Q*!+!T;N<6,EJP@?LN*[*DBU=)J@'[)W6;0WB0YO %,[8?
MIC;[CHZ0ED@"E#+2:B0$]JA8CBR'N'JD[V6]HU-:U:7?T3D/V.YVW(ME/HUY
MO]<]_CVH;?'AX^\G"72T7N($MMHY8C5PU@E.G2\<HM9Q7MWYW]^S'5V2J$EP
M*P>('NC$XGV:WV3Y_6@^3DTVWSSOOC@>1%JAJ41 CX%UB!N'P^2/"59F-UP<
M'V"@:4-:RSH%KG%Z_#;*_YDNZS)C?RL)8MYB"0 7UGDOD:*VB-2UT+OJP:<M
M[O [(T4CF'6U[KQ,6[>>61=JM;S+\NF_XS/E!Q>>XQ43I835F@H/)>94.LEV
M]J*C2G2:"/K\M(!7M5\6:!2>/LGP=K%8G4V$3:7$$B(X<]A;C\*\)5U,H;V5
M4@,X0$=@^R2H!$V?!+A>+1?+49C,YK=GLN!9S2"O,RHL@Q8S#9AQ-EZ*7LL;
MMH]*5S\P;NTMK?:I4!V?KOAP,+_I<R[__I#--P6?.U_/225[N+4$$6H44A8J
M*@R%7%*'"UPHLM4?&6GM':IF>=,^9OW,+>]'^76^#MB>K!_ "I;T6J+24\RA
M!A+DPZH*.-40:2XB[EH4T@<XJF]8SL_J,H"9IB&8NIMP=D\IG&&+'JF5: W#
M?HLYJ7T0U"%BC"WD-,I6SU1^_HWYGB:0IK#I@0,59HD2M1/"))520^6UUP S
M:!@LY YK;75.G']WLF].-(11;_/#R>W)@1H)P8X9;B$31F+&I'=L-_\!:ZJ?
M89]_W:5O#M3 I3>]E]N5'*N6>!MVVLP Z8&33GB"T,Y, H)4SV-T?@SK,!A0
M'9R>PYS5?;::+Q<OLC&?'^>\KY7$(JZ%I)19R@7 UM,G,RG8V36299P?ZM(+
M2]H#J\--[#(//5R-9M>?9]/;T0EZ["V?:&0YD<PZ%V"CS"@GU6Y 0(NJ$^%"
M/)I-P-*5RJ^R^6U\._Q=MDP7[T>/)Q[&W5<\X=Y0CPSDFEH49D!/O"XD@\C4
M.("_$.]E ZATMRX\;$Z"@_0O8CG3S\NC"\'A:F$%] (21+5"P@5>$ZWH;C+S
M=5Y$OA"798/H5#[=-*.'Z7(T6\\]T\^KB*0/ $V_I#&54/:B7SK+\^QK,%[V
M!;+6:"W!G!*""06:0!^/9X3?R<I=#1<"'+@3LCO0!A-->"BZY-TJ AX0+>^5
M:OQ;"2%&ARVYE!)[*R!SB#Y;;.MD7KT0WV;?D Z>IN_3?!Q^'MVFUS?/MG.;
M-^DV>=O;8&R)SR9<,6^#Y0"%X(1SZZS930@$D1J)G2_$$SL@=*NOQT\^ S79
MQ+>$I6&S0FS&UH=TD>9?TLE-EOO5<I6GT:\4 Z0.+LK5FTP0] )80J%TA#%M
MF0*[4],PG*N?#L*!>W([1JX'-]]>.7P)4E5N*X&0>*\@E A9+>*RH-G.Y>U@
M#39=GD^X%<@&OWRN_V>;4R+,NM-L MM8+O=\)FRHF/2: FN-(1)@Z>GNO$5*
M5,/1>"'NZ![1'#POW;]6T^7CV_EBF:\V._+E79I_NAO--U<;%K^&)I:+M_.-
M_&UP]LPN)!PX!!V&U%/"PR1!#26%!ER=.T_H0ASG T6Z4ZY_/BW^Y^_$__8P
MS=>%RY&YB6\DT#(#L),@&- (02R!W)G/.NP1J[/U0KS[?4%9>2=RLL.?#W38
MCZ;Y.M1!!2/F?C.B_I%.;^^6Z41]2?.PS8H)/F-<?_1^']JV=/7]A&-H--,,
M":*@%H!+NS.QH.,UJ#GP<X@APSQXBV&?^(6\=OIE.DGGDP^CY;$-5.O?3@PD
MG"&.%-/(A#T$=1SMI@I=(X<]NI CEJ%!/'A:7Q>BIOEXNDAW1M"G+&Q6W\83
MBOEB.EXCTP:SS_A\(CQ60@F-L0\6F@?>\-V$PK"MGO0(#?S4:, H=Y969[;6
M9SK9C\$V@?@1AI9K()$*2\*QYI) )+6@$CUY\12L,8%>R(%0*SAUGC BS;],
MQ^E^$=[%>QV+:+3$H;%8CX'G?S?98ODN6_Z_=/DA'6>W\WBJ]2SIP;&D3IU\
M/P826Z\ELEYZC"7"X,D5$Z^C5.?HA9S[#!'FBZ?X9D7P6;[]52QWS%?;;4<2
M3;&+]_R-6[])0@FVNPE'0%4CD_+ #Z8N N_!F[DG78!_7\/VPC#:;0EZ\?X>
MZU!"&;)8(*)(X)'GRAOLGH(&0?5D .A"#M8N O>+7Q.>6MI4>HU5+Z;0B3XE
M!&(9<\E39H%#%(9-R^X.GM*@>DP7NI!SOTN!OK*GNMP>97O@?B"FL%I#"?0^
M" 6X14A[XQPV0.XF $]E97+A@1_"=8+7X(_27JP1+T,@VSA5._*YQ$C/F5'2
MQ2LB%EBF\2[.4EE7/?H/_^@';,VA.GBS=^_Y]J]YMCA)UV:_ED .N66 2RQQ
MF B 9'IWI.Z-J#%O#OS,;3B@/I'U/]^\PC.(]\_U'_;\?MO&"VB_?OWZEW3]
M3/1?QMG]FS6J:YPVV?@7&R/;AG;&T^53BO ]^=W4>#G]LBZ['$UGBY<]3K\M
MT_DD+-\#'F$[9K0QH)YH!Y%%6BC&O73A1VR)$MA[@J6UCJ-2-V9:0NXI _PI
M,0]F&OUTXCIA8]](H%1" 8X(\HY@'^#C>HNCL:C3EUA'L]GAR:=+RKR>J7H"
M>ST_1;0FR_\8S[+0XE]_#IOT].F7V7P9I@0W6W_[KS\OTMOXPX"?=1!0<P>#
M2:&@D6NIO2M4 #2N$8)Z-MNJONK0%06.O@%Q'HZ#L<HN()&^1-@'A3"EJ',\
MV@_(%LA2 _ EO0%1FB5=9-2O!NR?U&T.X7XH>]8;$!?%V'Z8VDX:?P##_EY#
MPJ4"3G*'&5*%K$3KZMO1RWH+HK3*STKC?QZX@YGR*I\8[5SI'[+9S&=YK-3+
MD>&^CB10&:XX8%8(P8#Q5F"^U8;C7ETBU5O<^PQ9-S_02-EX7?L=))L^)(P8
M9JU5&BCG@RJH%<5LY5R8%W^@\=$R2;L?2Y54>/G#:'AW$PGB1H-X<N(=@)X@
M*FBA 0!-C3/W/P?1$#5X^6/H99C/ "*\$D$%XU0CR"'17FD,&=AJP!ML:QSH
M_CF&AJC!RQ]#03$WZ;3O8?1=+Q(DF.8$6A;F,>XT%C'S\E8/'+CJ-^5;NR?T
MAQ])=95X^8-IIZA7=VK7Z[0=+=-=%.I@W SG]#01RCC"D)6,.ZREUE 4)T'>
MFAK9RH9G(EZ$'Z)%Y?V1!N/ 1V B( 60$< QT@Q8C+Q#A>94,%'^D.Z-=K@_
MP#%\IOHO?^"^W-4.<_2>V<=$<:*LM4!H[P4CAF*YW58X8 2L<=_SSR'<UQ!N
MEP.7/XY?[JR'.8[/[&."I(:40 \I]40A0B%'A0XM=M6=I)?LX+GP<=PN!RY_
M'&_W]:L\?9TK:B"#^)P.)MX'K4$6<UDA0RC#E.-">Y+SZI?0+]FQ=.$CN$4"
M]'_CXEE"BW(W+;;=;:57\0^'[@SV??^CU)W9[?7'\%.\R_(R?T*\+[NX*G$9
MI.$O)1P0Y#D-%)0$&^\\Q1L7DX" $%'J5:6V;X8T(W/Y6R(-?B_ATBAG-,5>
M,FR<LI1M#D8%,,1T&L-_],9(;[PZ>'VD/RT,^BK)VWF8*]/U"['QFU=;\4]<
M+#E2*[%.*@F 0QI*;;'6%N$"' E-C9?TNKIFT@M5LK80[LIL/]#CD^'X1^LE
M,;D5!<Q:XT#8G7"HN-_*:H'6?MA70AK18CEFU,+KQ^;((.]>#(\:_5#BUW0>
M]C<S-9^HR7U00=@:A4Y_2;>F^,FK%:7J)X! !+UFA&'.--).:53('OY1XXV_
MMO;*#>DR:Q^M#B_?I.%;=Z'S-OV2SK*'"$Q9GI2HG0@.-+-4>$JT#]MJBN#6
MR@0^K-[539?6SC;:84GS6/UHF7DMXT8J+N)EXB ^Q9KA8C\"):M^"M;:?#*4
M'5DK /?EVUK;^"UZKU;W]Z/\\?KFXS1H(GQQ-%^J\3@^S1X?0\IFH0^]?_[M
M_<-HO+R^49/L8<,<M1@+@J[G>C2+KXA]O$O39=\NM7?IUV==S[-Y^'&\N:IX
MG9N[Z+A].W]>8CH?3Q]F:1DG6NVV$V8-@X8 BC'2TANAD".4&8#<^MVU_MQF
M564[Y1ZKU6YB)%,^3#(&< B!M(1YN<5+,RFJ'WTT[ ;KD!E9?_@.VL&E)O^U
M6BS7@OLL/P++J5PJY[23:&B41T!+;+1G.MY@)EL #41@L+E6.J+-:YN@16R[
MLCSCG?:G1?#D=F1?\81K02&TGGA@"*3Q\0*TDXP#,6QG5TM:S%H#[D>BQB!]
M7 -F1$_;TYW\'^,KWS%M\>\/D[ ;"N490">I4:I^HJ4(VS%!//0& VH)-<4T
M;"S479[ E-R<UE/AZ]6D!9"Z(LAU6*M'L>M7:=@9?X@1(-<WOR_B.V#I\@@Q
MCM9+8%B*(?"&8>V $\!)#0HC$C/3Z>11CA#]&<Y-(MD/:ZZFH\_3V73Y:%9Y
MOC:S2]+F=<7$R_^_O6OK;5LYPN_],>W>+R\%]@H4R$D*M\5Y7"@2[;!'$0-1
M<H[_?7<M4<ZQ+9*B>%-.@<")%0ZU\\W'Y>S,["R5\;ECQ$E* 6!$0U5I2P6>
MX2ZIN?#F2B@G)L['8K/LRIT7V: DTPYK(:P"6EGAG1:5SBF0-[\2X]G1IS.:
M8S'(9O=9'-_J+@[1Q+_S72ORU(D%R:U#B@IJC-?4,XQ(A:$SW'<_]FZPPM;I
M>-,CD$,'T5M%DS\NMH>,Y-0!XVC%^$CNGE*3NIW:/)?N/J?!VD2$FX4#MTQP
M%[U;PJV@"E,#%'-02,(X0[)5A&CH2LFS:K0O?JR_17#2208P!@XJ"ZT1!K(#
M"M2ZB,M< KE]&O1LB6*O6,TZ*&OB'!6_ZW"P_%U>_J:?6K2SKI$*! GNGS/0
M<9GH,8Z+1ER!8^RH!1X=JP[[LGXQ%&ACN11O1IS&VU@B5B,5/(315Y+.*FBY
MC*M[A7VEI\5JYGVE>[%@$RNN1NOG9<<L0ZMS(\54Q8/%PW;Q[4N^?#/V%H6#
M#;)!0VD]4\XQS[@E3@!!3U,NX3-L5MN+!=^4#/:+TV03A7[2V6;Y)2Y"?KO<
MT?B#:# &,0D,)H9SCYUAVE8:.Z;UF!TF9^]M7(/<=%RI!GWYF^65:. (8L,=
MM,YYZ;@BF*%*8XN9O#GGHZ-!&YG2"VY_!L;<BD,R$Z),5:W^F&WVF8] 10WB
M\)>[7_/=%[,O=\77;-NB7KV%? #"LY0V)S(%A*U P,)*=TE0]U#I>"Y*9W.^
M*5KO'[".9"FWNQ^($G][39+X40HIK?;+W:?ML2+[C$]R[M+@//?2<D>IYTP+
M;](!H0=-?-J^,6)V91X^2$](C6#S,BI['&!Y]G51>WUPVF&GC60"0TLQD,D%
M/^I$O)]IJ=CU)GIKZ][ ^3D,/ROG8";VGL8#. ZR\4W_A^L"AA)@#91"" ";
MMEBI8_"&$>95]Z5E[V_TGFSR.AUR!1JCE?%M=ODJ7^]3GO)?V7*_C5AGI?M]
MN=ZOLM7! _GZ;;\[[J1RB^TFWSR4_\RVATU/3^_?H*D"?;AO#5(;)!WTVDD(
M.>#$25GA+ #NGCZY/.4^#V=B?J!/2^Y6)RLVB0:K"8#"6JJMX<)J(-6+QM;/
M/!$S"RZTXN?5D/\9R#8K3^FGYM@TW#KM>'YI.]?HBYV5"89$%X0H! 6(;Y#H
MN&)2Z4B-=S-L7=Z?V8IA0!JQ<<0 I[82@J@4-GJH!"(#A'2*5KK&14SW/:B#
M%4</1H@^@1IR%7[JD_&2TURL:^)N9Z\/6A$L"0"*&DZB#M837>E$V!4;D.F-
M^LM]PC4H!0Y5;C^.L#80<_;ZH !V GH/B#12((J $)5.@E T3U^V)SL5PR'T
M<UA_5L[EG(S>Q=AEI7Z9+?_Z4#S^[;EJ?/N4#,ZK7Y*]^0_V/GX<C'K'N"__
M&604,R!Z*EI*BKV E)#C@!EF8D:[)7L"OK@2@K'<-I\@S3Y$9V7UC\UNL7G(
MXXOI>1M>J9]^6?RWV)KUHFR*FEUPEV  LE R+@Q&W'"-D3SA(!#J'EMG-_I6
M'Q[$&9#I9?RMX@X7WBD8+H%B&GN)L%5 0,M!A4=TC<D\_81!+=^>73TB^G^F
MS<HGN66"34,LF[IUYI_WA\*9AR]Q\$T1C',B05M C%!*4.FTA0QA;4]O?$C'
MW'?5,G@QF U?;ZCL![+1DLS%_>[[8IO]T*>S.>%\3B9XY B/SB(V#BD(G4:T
M>L X5[[[##)83&LL6O2%V5B\^+A/@TM=/+\5V[3!]CDH5T.*]P6"EE0Q2"W2
M&%#N*2.L6AQR;.P,&R</N%6S%XQ&VQM3%*OO^7J=^G/FVT-WX+*. >\+!,.D
MH%03K>+J,M5, E^M*SG5MGN=X6!SPH ,Z 6CZ3W1_Y39_7[](;^OV\3=1CS8
MJ#FCCAJI4(00>V[YB?O:S[#'QX#L& "QL;CR0NA/]Z]?I(?L<YSN*O;7D.:B
M^P3EHNMDN'(06HN%,UK3$]#>=V^C/5BGCP'9,R1T,]GU<%(C:17_K/Z]^+TV
M 7OQW0(FU&-MC/3"$"F0]*<<IN!(=-\1<7EF;GI*#0]@,[&R8ET^TP6B(UG2
M)^&7?)W%46RRX_F(YYN5U5T>D"<0 R&PE)JJY'US5XW64:5'#-E.9^X>$1J[
M..<N6Z?# *J&5WE6-G>M:Y0- %--)5>()3_,:J.]J72FQG</;_ ;8L50<'5^
MY*..CWD*"J9NL'?9YSB:J*DI]M^*3?R_A^WBW:9*K64#I )SXRQ,><SX;X1.
MF<Q(?]K=G1 W9/:AX.IL]L/7EZ?O+P]]RM('QZGJK-5;B 8C)#(,"@P<BJMP
MY$35[8()'Q'J;'1Y:T;O'ZW1RH#7Z^)[.BLDLM46^\^[N%@Z]H8K[[)EEC\V
M-!QK=X-@@(<B'5<#I!8,,HN<K[2WEEYQ;@2X(;(,"MI8E#G-<.\,OH8H=6+!
MQ6=#L>=,.&2>4J!)M::2Q)@KZ'&+T<X>H9IB'OE0+#81D$,_U2(M<'[=YKOL
MT_U][2:K=G<(3  #H<?68(ZDX]8#5NDOWIR]?@E5;C$L.@QJH[%F]1AQB53?
M/+0X(.[-Q4$:0QEQS/N4H/9127AZ%AB55YP_>HM!T*L!NI%=G.IKF@GKF-+'
M_8.)\RQ%S$ 3?SA&#-&HPL[Y:W8QW6*,= I,7_@X85_DF1SVUWC@X1&B].-S
M? '\_2__ U!+ P04    " #X@%E0Y@)X%&/O   0U0P %0   &5O;',M,C Q
M.3$R,S%?;&%B+GAM;.R]:W/<.)HE_'U_!=_>B#>J(^0N$KS/SLP&KCV.=94<
MMJM[)RHV,E*9E,VI5%)-9MK6_/HE>,N4E)D"0("$//NAJV5=$N<Y#W .[OCG
M__G];N-\S<HJ+[;_\B?O+^Z?G&R[*M;Y]O.__.FWCV_@1_SV[9_^Y[_^MW_^
M_]Z\^=_HPSN'%*O]7;;=.;C,EKML[7S+=U^<OZ^SZ@_GMBSNG+\7Y1_YU^6;
M-^T?.<T7FWS[QS_Q_]PLJ\SY7N7_5*V^9'?+=\5JN6O*_K+;W?_3SS]_^_;M
M+]]ORLU?BO+SS\!U_9^'OSK[&_Q?;_I?>\._]<8#;WSO+]^K]9^<.L)MU90M
M4$C_Z]^?_?XWO_EM+TW3GYN?#K]:Y:=^L?Y8[^?__<N[CTV<;_)MM5MN5]F?
M_O6_.4Y+1UELL@_9K</__[</;\^B2W_FO_'S-OO,^7Z?E7FQ_KA;EKMWRYML
M4\-H/NU+F=V>_HA-63[Z!,Y0RAGR(L[0?W_A@W</]]F__*G*[^XW-3T_C\"O
M 'CW'*PI= T)OZJ O,3JTP_4C/=3W70SO8B??Z1FS&U%H]NUB?K[]&,U8]<+
MV6C-*';+C>::\>PCSV+>\-]Z5W_5_2+_] ORVQ3>B>K1!V??=]EVG:T;T7ST
MT4Z^_I<_U5\M]M6;S\OE_>)M[5IWV:?E=Y)7JTU1[<L,WE2[<KG:+7Q*_30!
M-$PH\]S HP"2,,61&T0^ GZP:#YRD6W?_/:Q!]!\2U\1?Y+AX3G#9585^W+5
MVE.-C;MS"_=?6U1.#<LYX')^[Y']GW_^^1#/(QJ+U:EZT>"Y758W#:@N]!J<
ME_Z<;795_YTW_#MO7*]SV?\NP-%39HN55F9;HC:\/U&475U\5&5@N7**<IV5
M=3^G_Z-EN7HA(]UO_+PJ:O.^W[UYE!S>WS$02:&_WK7LU,&<8D:D,7VJVR*J
M(_UCP5@$2,0(\2+?\XF;0N#V1<8A=!>[P4!4FI1X03)M:G?&U(0:5E:=;40&
MZ%,6(S/,:5$C#LUIL,VO1P--<H(DSZZUBJ00RLN2I,J/J";]M2C6W_+-!F[7
M;[?U4.IS?K/)8%5EN^J$+H84IR#P"*S%T4-A0@A /B8^0) %"4@%6YG>0LTU
MNQZGL]RNG0-2IX5J0\= BLD++=-,1NQHJH9B*Z:HTW*-F4^*K/>;[/KV*80:
M50_PT[+^[D%6B%_+"O$#ZI.($!8#C&F/),2 R/0[3)1ON#O20W:*VQ,MG+?[
M'K=<9\5(*L34=>XLR&FL> +J_@X'[<S6ZU$@]H+DFDR3'<)K-,)BNDJO)L+%
M+<NW^2Y[EW_-GED"V^^X'=P5Y2[_SV:JGGZ_S[95]@0B)EZ2(M=S ?;\$'O8
M0YU/(!<CZ*FH\R3 )I1M6NWRNV;-I 7O'*-W.O@GY45-TJ=)K)S66Y=3=1-H
M WG31/(\95<7DVR+0^A(AX!U3)IUNSQEVM#/F,T,_(NZ$%OFY=^6FWUV&'Q4
MP^B#1A'%413&21( +PU\&,3M5 )&<9Q20?$9588Y,>&PG ;7T0B]FFV(?HFE
M"VU<"[EVM%D]H10&*I]BFVH;^"_9DI>ZOMY^R%;[LLRWG]&RRJO?ML5-E95?
M>3-_N[W?[^H?UT3EF[Q1@:;Y+U),0!)'E*:4!G[DQE&2# C=U)?IV$V)RW"_
M[M!VK_HA8!^.4_O\$)#31'3E',?D-$$YCZ/JN@3GV_S\F9846\N2K*K-4^77
MK*:/3X:(!4R8<LL<8\K(SQG,Y.P+^U&^7=8E+3=OM[7O-=L'X?>\6H0H)9 F
M81 P!( ;T2@!?6E1[8Q2WJ)8AFF?Z&$Y!UQU#Z]&)JOTJAP*JO8$]$DJL )S
M9C3T-#67]' DF99HV]@HGNJ4%E9$->=3N=Q6MW6#A=OUQUKV\E4MA->W)T!4
MG^H/KD[_B!1WRWR["*/0\UW@!X'K^R!A 0MP!Q%'& 0R0C4IL!G4K1[ MN D
M!6[:A(FIHK6Y&B^E FDRHJ8Z*;T@P;-DS@[=GB?TPH*6(^806;&I%KC8[FI$
M=2$?BH?E9O=P?;/)/S<]X5^RNYNL7*"(I1A"XJ$H""(_I,SS^D)I0!(1S==4
ME&$5/P!T.H3. :*8B.OB]+(LST"GG-!>9-+YO<4GZ(NZ*%UW![::/[*)VD?
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MZ^;8D>PRJ!$CTO+K$(]:??VOIRW^$0<G6KL:1_.V=$7,Q9A:(=G"._U(0<A
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MXY#/M&\E5N9OW&JPBY&U0:Q9MX_!XW^#]/K7=^]P?[P$>G[H^R@.*&6U<J
M^'T9#$*A.[74/MGT3!S^-[%&K<C+Y99MGA+)B3?\;V\XEBNG1O-RYUT'0>MB
MM>>3>\W%-S,2]0B'*<*>R"*/JE$^#W2Z=S+.$^(WCH]Y%7 D]D)'C9#00OCN
M?5-(5P(*_#!$+J0$L!AAAF+4G_M/4RK6RU'Y7,,ZV*.1:.NRQ A(H4%.Y(2P
M!Z*B@;*\2"B@07[4]$^<)S'I>QS@.>%3I,$"V5-%7HRO!')[I]"^RK=95<'5
M/_9YE3>WTO$Q9!TQ8[$7!2G$H8_C$*#^G'$*7,!D=E*IEF%8"GM8SA$NI6WG
MRAQ>5LHIZ9-3317FC&S-.D/-"3W11:8=V[9&1U'HK6+C-8=_6699-]1%;NRF
MB/@A(DG*& F1'_7E1A1*/9T\OK09=.C*Z3$J;D#7P+&Z.IFC=[Q.R3 [F68]
M(DQ2O=3(ME?'%.,14+0Q3 D-(>G78K.OWFY779>-\>X:93Y%)$J#- A#V.^(
MA3 )D? 84O:#3<^6-W"NG!K07R0&3-+T"(PD33(C.65^($5E-"E-CL1PTB1)
M:N-)*;+$AI1/@CPWIE3EPH)!I3+T0D-=D#R2LUT5=]EPG<P[3EO?J?2)ZX,T
MQ!X-B!N$"?5PT)<( B+U!OB8<@R+9 O-&; Y/3BE,>8H0L5Z<E-Q*2>KRC2:
M.0MTGJ,+W38=S-K18=,2R=,31-K8&:E._8V<&"8X" ,4$NA[B&+@]Y<[0-]%
ML09]$BQI/H52&G..I'642AE@5)M.S3+,O,B3O%9)\FNU6LG&(J972@R)*M9?
MLVU6+C=PNX;KNWR;5[NR+O1KQI^#V5;]28TX1-2M!1+'U/73$(+03?JR"?&$
M=F/J+=&P@G4@FV>GEH]@RBF7)GK%%&QZ9N64[)C4QPB=#N),![&%B+L@;7J)
MMT/B-,=4F*RJ<I+'W[?B[UKQ;F $ B](B.?2.(1NG(1QV-\^BG":2'7)9#[7
ML'QU4)0&A%+TB F3*6;DY$>0%",*<\3 !1U1X<D.M5!"7HRO)4HMO^M0N1'Q
MJ1<E?AQA#[G(]T$_057+#I.ZTT7NDZ=J_4J#+4F2I!3  #^*&C#+T.D1"R_K
M@"1;5BF!+/;36J#$P,@'IOGCF/R"J=67['K;]T1<WO$@:<!P"ER&$IIX?4\$
M^0Q+#8!TEFM82<X_Y-N^TMOA=6K 6IYU5N->3(+FHEU.H$X^B7QXS?41Y3.-
MEB2(O*!Q)M)AAP(:B4SLV5\-[.E3ST_?BOY6X\C'F+@H2F.*0)*"$/3'A5$0
M!E*C+)WE6J*>-6#=ZBG!O2[U-$.[(?6LP5JKG@.1H]13/AVO13T5(I-63U7V
M1-7S0[99[OB#[.7NX>@VTPH]'/^D&0JGE ^"&3^=&4>(@)3Y_599!() :LNJ
MQF(-:V>'QVD *<UCZ:183"-G8E=.(J6(-:* XC1=$$ #7-NA?R8"*XS74W7U
MZX;XC$6@%E8W)&G*4.K'*.I7-S&)DD15Y00_?EHU4YJ74R%-7K<,\#5*GV:9
MIWM.B* 22;)GG^+(!G!!692X$%607Y;_493Y[J'IR7TI-C5%77\-A@P@'[ P
M0BX&$0ICB/KR$$JEA$2]%,-ZT@-SCI#)J<D( L5$91KNY+3E%&TS#0//TG-!
M:<93:H?@:(BCT%W9Q*^AQ%_R[)9^SU9[OF'A^O8V7PVE44"1CP'&01 #-Z1>
MZH6#V"5(:$EQ;!F&I:>!Y@S8G Z<^)65H_B[K#U34B>G/&=8F_!ZRPN\G) <
M74S.?_6EEB@*O?5+KJ_3SDO5?]*,R%PW9;$7HKH(%/E> IC;C\@P *G4DUER
MGVQ86!HP#D>C--TCR9)8)\8<07+R(<Z-D<[*(QHN=%#4Z+*C4Z*(O=!18;2L
MO!V6.2KT</B=;AFD 79 MUV_KRL8?TVKOP,P05&*:.C60S7@^BFEPX8KC))(
M:C/4+  G5">UA_MFR=JHQ3U[$J:NEO.\#&B 3_G%P&G29X=ZSTN!V/+BE/D0
M]1)Z=[\I'K*L>5SQ^I[C[/JR24J"-' AQ"E!($E\!OI;P4CL^4SN=7OU<F1D
M0NE=^Q9-):?F(W@3D^1I"-.\NZ+%.=.,VEG&+BCG>);MD#\-<12ZZY_LDF"U
M*_/5+ELW)?ZVS7?5AX^_]0/KQ">(TH @EQ*:Q"%E_09@0N.8RHG1N+*,"U(-
M15*-1I(GNDHX%6NR"X8]KNXUZ :9\Q.G\<\S:=%%KBZN)>K@V Y-TA3+LQ5&
M?0P)7;UUIL#J?5;>%N7=LN8"%]MU<Q%8U4NDQWR74!!CZM=C?S_P(1XDDL;B
MUW.9*-ST5H<:GG.$SSD E+BTR@CKEW7."L(U2M_5F2RHW"%F)!T2]XS-G1:U
MN\B4TC/RLC(%ID[XD7'2+;CTS&AXQ4255X.1_;(L_\AVSQ" B!$_==TX(92Q
M%,"0]+=8$H]1H<O43)0[A7VUT/0ZERK-(TQK H:U^M4SVG5:E2K_&EQJ@CP8
M,2CQ9C#.FT[S(VM+(UFVV)'&1B9B1EK8$YWLP9ME55W?-@C>Y=OL[2Z[J^K!
M6PQ)0+P8N%'H0I &J/<\&GB>U"E!M1),;YWBH)SBMFMLOW-@3H-,<BU1D3^Q
M>1[SU,F9A@IK1B9U3A)S83)G')%V3.*,C*'06;7D-.9]G?FL+#N=:Y8N*KC?
M?2G*_#^S]0+"A" 4)LQ+_3A,:1H-6S-H"!-71FQ&%F58=09T3L7A73E5 ]!9
M#@B=G_)M]]T_RPG16)+%%&E"?N6DZ4#MQY;:%IMS #>M0ETFZH)4:6+8#LW2
M%4QAI!:.5[&W5;6O"R1!D,01]1EAH.YIIY2$@VPBUY/:L36BF)G4*V_0Z54N
M46+55<L IWH4JP4VOUJU."252I)5>U5*-A !A5+B9HPZ7>]WU6Y9#R.WG^M2
M*89!$!,_0FZ$*>'/Q3>E8@ @DKJZ8&Q9,^E4<8"H5ZRD>%97+%,4ZY&M(W3S
M:]<1&$D!4R'97A53BD9 RM19$IZ7*K9?LW*7WVRR\UKZVWVQ;7^QXC/"( @Q
M!)!X,$QPZ,5I2/T>20@(EIJU,E"^8=W[=<_G"?GT3"]XM\[J$(9S_U@7^Y^-
MZ;H9R9+@W-C,"9*<.3O*P^6.G[.O,3L'T!-/K,FS>FG:S6".[!!=HQ$^G;(S
MSJ9:9_/]LKPNFZ<RUG];;O;9^ZQL$"T JX?@;APB#Z XX7.+*.D+K]$([;W2
M7.347<_[9>E\Y0@;C5T7F\VRK)S[6J8;O1W5^53G7:4/.@GE([NB-<:ZR;?O
M\ZR=!B;?VM,*[)R]TG/D"7=.1[-OAUSJ#NIB5U439^(]UKN[8GMZ1A(A#Y%Z
MT)\B5A=)08 QZ4O$D$1R/5/U<DROJC;0#"QNC.)6M#\Y#:VR_<:&43O6-"Y0
M=+$3.)Y8.]1+2R3/.G6ZV%'0J;,*&41IF*;(@PPQY/J1AR.O+[D>TJOJE7)Y
MD^J6WCZ;%KJE)6P2IL=(F45=-0':Q.1M-.G6R=SXB,[+G2:VE+MGW7),X-,(
MQ\2+$ISZ490R&@V=09=@J4M\5,N8H5MV-7K95IE0Q?Z8 2[']\6N9EFN/<.-
M3"=,DDWKE$DMBI<Z7TJL*"O0\2H*(R%,(NRFS*4I35@ P#!1YR:!-TJ&9 J:
M18NT+,V.XU=1E4Q1JT.:9EN2O<22C$BID&NI4BF%\I)<J?,S\G$,>%?LM[OJ
M^O;H>PL"8I2D81B1,$Y<G[#P,*T&@E#'ZQA*Y1I6M/Z6]/OFEO3= 9BS;- Z
MM9[5@\>\.-]),$^]F+K-Q;J<V#V^EOX(TY73(>4KWT??M^)-C5,D7M!"$ZFP
M0QJ-1";VK(8&]B3VK]12L-KMEYOKFTW^N3VSB ")@S0BE.(X#B,,:0H'D?8(
MD-RAHE""\>[=EC\6RJ^C*HN'Y:9NH,4 KI;(AR7? ;$K'/JUV.PKA]4)J>N;
MY"4[BN0*;RPQS*OTUI$>CW, -/FVD.><7-[X,8)#.W1J9 S/-V^,9D14>]X5
MV\^?LO+NUV*75>_;-K>(&0X9P%Z,0@+J_B$+&.J+\@!F,M*C5,!TRG-?YS*O
MJJ)\<+8U0FVRH\:KF.H8IU1.=!H83H?CROFU;C+[LJS)G59W3K%R079&D6B'
MZHP+H=!8J60'BO?M-91U[^K1TT/9S:X>F[+$"T"(($AH+7(!@N'0Q6)8:CEQ
M5$&FMW]UR)RZKU,^&A;>%&59?*OU2?HZP3&TBH[Z)F)4=IAW/]!YZSP>]'%H
M4X_JSI-T<1BG@5L[E$E/*,\&:MKX$;IY"2_O\]URT_3&\IL][X2QFI#\:[;-
MZA[#(PQH:+,+/PZ#P ]"%P4>XV=($S8@B:G8_BV3Y9ON6[6H^8F! ;;#:PAO
MCLUUP[>'('AK'2=^1C-U61-M29+D$+'+SS'B*X<]SLEC!44VY43B8B<+<J-V
MP9.9'(G=]J1&V@E;FR(%%MS^9#K"8KH*K?D]FW.O);1GSZYOG^UA# *,4N2E
M:>HSDG@1!>'1# >46M>>'IUA7_UE^3V_V]\YVZ<G]X[V3#<3%<[N2^;<UW^K
MOCH^0VK%AA]V9U7.B(^?93B.YOAM!N>F>_3TZ?,-/*8KYW"*<^;=WMKS<F&8
M-%\=L&-L-6/\L@_F&,Z$<:=ZG]5-M^Z\?<ZN;X_V3S2[*CH]7L0P8@1@STN2
M.(AC0@D>S#4 @3^):>D :MB_X';+5Z7R[:K,:OA\FT,'F>O77>=NIZ[?R/[!
M_W!73&5B6K)NV,^F3OCDUO;^4?4X"K&[3[(+\I78G$"Z3#B>SEKRRLU/*Q6Z
M?%!_?L0F-@][ ^&ZO3BX'E2V8\O6DC]D559^S=:W1<GVNWV9\<W._,;[!?!8
MXI(@]%(:1!$B$72'&UQJRQ:Z-\4X"--6-N#M_:KLH/*YS>:P1/,ZA/3XRWQV
M1&8T+4F,[,Z7XUW-1QGJY]*Z$=*'XTRUZ)T>OBU)DIGBM"19BO.<)I,F.-VI
M3N#9.<\)<F+#Q.<48183UW7E4SHG<;!G.#PO8 QZ7@H 00D?ZZ)H.*](/<EK
MQW27;M@W/VHU2X-)$!N\S<O_&'LT(*_:#P.)47IQ7ZFI]-@Q%#(8W_FS1$:8
M-#Z/U_SG;UG%-WV^;X[7> M&HI2AT"4$XR!U_92%P\GQ- 52)Y F!69Z<,,A
M.5];3$J'D:9-D^&)-M,9FGQBK<UO%Y'S_G)^[9I%.Y$+$[-F8U)NAS7,$[JN
M6;'Q_!LW%/J/?;Y[>+NM=N6^W9&X^Y*5G[XLM^V;Z]5?ZX_856^W+?Y%[%+@
M4=\+61C$M36&N/[_#CY-HD#N(71K8,L(G=J;ZH>7[MI[B/?-2W>?.<PQ]Y%8
MPZ!I^YHSXY-;6QNL<Q2MTX3K[.IXG2[@*Z<-F1^U?E7N)YE*$\YHJC:]<M<T
M1HLN1S6;-RFWO7D9_LTS^-_O\[+YY0Z?1R+L^C1U/2\!P/-3-QW6Q% 08 4[
MG027<;\\/O];C_WN^-IY<2_Q%O(,N9)P0.N2-+W%#=',9UXZLO"2.TV::8OL
M9]JX3_G+#,P+;5IX$=S-&7!LF9?-I9&PJO9WK1C^/<L_?ZE'$+!6V>7GK,:?
M\4$&/_^ZB'T/HPA%( F@AQ(W3LDP=^G16-!<[,)LW'AZ<,ZR1>=D'3PU&[*+
M/9%=$]: M=J^>+#=!;Y'X5XY0_7I(G;ZD!T>\ZNL,Q*;.*P!;7['AWUU2&R;
MR%0I.K>GQ+HJ8L$&%/LX*6QNU!--C9^"W^,E^==\G6W7'Y:[;(&]((Y #&"$
M /92$-(8#'U$1.!$<^+:\!KO8PUZMNY@.0]YMED[=<\[&S?0GS?/AJ? 9TFP
M-3VKH=+TH3H\UE<RY2V:.A-SW=JKC46S#';PH6MVVU"FC#OE=0\U*U=YE0W3
M[Y^*W7+SEA_QWU;YJHELD3 ?)C!!OL]BES*7X7@P^<@GR41FJ1.R<;]L0#EY
MCZI[I^=@E$[6A;%6O7;9"AY-^^=<.9_<0J\/GMF%>E@COG*&2%N7?24.*I$\
M$R9JHNZ\<A\U0HDN*S67+U$WA9LFL]GZ= S<U[=5MDBAGP:QC^(T\$"*DC %
MA_,<T),</&HJU+BC-5NP._%:'8M<UB*4<R]=5(OYSPP<JSO(X R')M,.I2Z1
M;$3YQ6B[H-V:>;=#?74'51BMJW(*2._N-\5#EGW,RJ_Y*CL-X5?^;'O%9P2Y
M;%>-/A__'!?5[M=B]^_9[D.V*CYO^>TJC7IT"L\?SB,,I8"PE/E^"GSWL*&6
MO_8N<_S!#L2&ST7\MBT'7-UFU'8<42MQM9.<=;.#,4'EM@/LC,(_Q/9XI'#E
M\*#JG^Z<AVSG'.+JWY:9UBDF2=,%H[&KFMCA4Y9Q4MC<L"UQR7; PXJR^Q;_
M/6^!0I\FB,28$C<(DS#PR6#UB0=C*^Q2#;IAWWRV,ZB=:&O.&N^//;6Q4?[N
MQDWF'+YMB:\JUHJ9#=9\A3#MM&<=]OVA%AT%]X,X[LF\S6&]XRK0#^[!(\F9
MRHQUY'#^ Y5_:\)^-!\YK/LMP@@0/P$!#+P8L!@R[-/#,S6N.\E9?K,A&';I
M=JWLEF\B&);)EDT=<]H*9\OYRG'UP/!2F3U58/+%,\&SERT!Q^MJAXTKKV1)
M;5229SF5J:76V6'FMI,TV8E-C3F=?<A]^*3VCY[&N@@\/XW2F(81<2D(O<@G
M9+A."+E2#T/8&\64$]CM8+LX*+32YE%[N9Q[Y#UI93 ]"*??5YM]<_?V?[&)
M[Q>2.,MDN*Z*98>?OP*>)ILTUYM9H4.U8@O=W:5_S0L='F-UN6Y, $ ,4^IC
M-QVZ%BQ,A>__UE^T8?\\@M)>.C1Z(XZI%%SV/@O8ES.L 6LW_D3/QZD=7N<(
M\+PID#C].6\JU(YQ:DZ)V!E,::+.':8TQ[@%IR(-!E=,4FLGNE3HT3CZ\8-4
M"YRR.,(PI?5_*'%)A/SA&2I(J/R;3E,#-&R%OSY]@[ ;+XR[CV_R+$K,!MN<
MP,GG>I_,YCY_A_"57$IT(4$OS=/.51_L&+7-2X&N6XOTY6.JHX*/K^G[:UE4
MU<*+O9A$;ISZJ5_[JIM&:+BKC^%$:$ V)S[#5M4AD[HRUJ[UIO/<&CRQ-2:3
M%FG47 QH/H\U/AO""E4/!!M$U[=X67UAF^);!6^JYE+)!6%)0A(_XJ>]@I!
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M7EI',ILN.P38=)!/UX*FX%1H$F)87'J7+:OL []MM;C]K>*O866[1_.OE,(
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MUB?O$C2JR[L9_O3)>XU/H[Q+4#I>WLU0JU_>A2@>)>\#$Y+R+L^@O?*N$(N
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M-%>F=#F6OHPI&9H$?8)69R(A]IF@D2@OV*,Y5A6,D]])!#_7 #XO=UGGUF&
M?"^( B]*798RZ +47T.4!! +/4NEJ2C3-MC#&3L>4J)1VLM,,SC2LCB\6@8'
M3D<.BI0X578?T]QJ,AE)CE6,Y 038GXQAD+K;&%4,.?5?SQ'HT9')\9F/D(@
M]4./)(F+,/8#E/1W)"0X(N*[<#66.=WH9ZES4FP4S2-&-H89UC>2T3IG-HIM
M#:,4PZSK'Y48GU*[0(WLB&,$N=99B9ZH1$84HUE36[7OMDQ=W[XO\^TJOV^
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MKH_/Q+RP\[R$ZARH=_DV>[O+[JH%IC%$$$6D'C(P&@<DCE ++'(CGTDMQDT
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MHSQ<!D#&A5 8?*=4/]GAXXN\V*]W7];Y]N,>K^_S>KWKR@2>C\27H7X*HH2
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M4#V-2=4B.1Q8=4>-"+V4V>8ZGWLQP 5MVY:!!GWY+\Y'&N6#(B#$%4%87+'
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MC%J_#-*9#NK%"IT%S^1GYJN,_^SWYK.AAVQ7W(OMS7V9U(]P&C.<,LHBFM#
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MV]^S_/8[?SQ\R,KU;?;Y(.[%N+QI%%P>ZJKF[QM7]5P,8%$:@8#_Q_-\@+T
MNN@T"YXJ?9MB28)E&/:J/ZQ;V2WG*J<X*78.XF!TGGV(:6BN^158[E\@M>%G
M^RQ%:-JJ2CF6+J 6U1#;"W8ZQ4XK6:20W]JJ/),].WWU[!V LN7Z6@:K;0=9
M3-H&%,?9A[(\;L=_L63_VJZCTRW.*:8AX6I2+P1Q$@9^$@1A1  E 6)J1SQ:
ME&&9\)UR<43U0UYQ98IKAS8K0'(0OPSO%<?XG>U#NX<NWM@'.M?*H;[10S,!
M]FMO&92>(M#G\PA3>:M(:Y9MQ:F7+W=881KP3H$&89"$,:#,\]VP+Q721.D
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M2/2LOQ@;GQH]"QHUZ_K/3D9=6R8#XZAZFY^+_]% _2@_"1-Q;;7OQ5Z &$3
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M?NCYGR87#G_,?;:I\X=LITA'K0J4PZ+MFE/CX8LJ:P1=.!\;]R<_9O:Y,P/
M&^/C,D@W*H*7Q\:.=$-EB%CLSXMQ41H)6OII$GM)Z'NL/XV6)!'"JN-"I8=/
M,!@L]L,X&^09 !=AY%]$4=A RH\O_#BX2%-O$9A3KTOYP:BU:E0?@9YJ<$:Z
M/??DG4&GEGW+X)J^_%>&ER-\D/[J9KO-Q<ZG]>[+.M]^W./U?5ZO=RO(HLA+
M4(SB, 0N1BFC85\:B9C2$;>Z95CFVTF6(TX=_Y#OG4VK3/';&UT+Y7@RA7MJ
M6#DS3DARN''X'>/L?'7SNC,#<!GKY3(8,SJ*Y]_;&'%%X3N_P]VAV5[9' _%
M07=?9M^S?<4[\7:M3]Q@]3FK+V^NUC]7H0\AX$HH"2D%A$'D'T>IJ8^4SC@P
M7;9M0IWD]C>-G MV;M>YXMW=QLV79-B,OBNR[<SR]A2Z)UK[W0>_";E_:0_#
M+6[$9H3)/SA4,70(B9:J9B&HM!7=RT\6+;HHB]:O6<V)D&WINMSS@51UIHID
M-_DFKU>(^1%Q$:,QH&[J4\2'QEW!-%*DJ8'B)@3HMI4T;3M]WZ*!IFG0WV6T
M1I,!%=;>Q;&+<BL$41!$#(1ADE ,H,>.Q_U3@FFLLFU(X_&3[!ZJU)?B)EHO
M4EHGDC9S&0UH3 #OK@LI>F'J/,>51T'H0CZ>2$"2DM@G$4B.[3()J.8N.[W"
MIMYZU\QK:C0F2U;+I?.3NJR6O[]^:N.RCFJ4V^,WSMEE\,I<.(I',BKZ)-W9
M;[YGV\,NN[P1"7ZQ%YM_+F^.&Y2[BPM1MN<I1WTEME1<93]KQ"WYQXHF,4]
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M-JWU.PW7EP$VLR%)K]1I^R4+O1-9Q;7A3U<)V^\">6K78W@%:00\'$/J>82
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M43_<WA\SW17C*<I8BG@8\H"G/O30D-,2'B10.<VT9,^QKDDX<F^R.722!_D
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M>_S0P13O3(<3[ 504 U(@8 *\AZKQH*!PY H+.\L(QIZ(_R &9R!O@''\/3
M@40.;I^%!RTJ/!H+.<L(T[05'(?A4IL 3B;OTN30?306,'&<P<EJUB?<ULFC
MV_NSW>/;>U[632L+!1;UNLRWO^9B#DP91#&'012'C%(8QSXG R2>!DKSTEF
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MXIAP#VO=C+5DTK%T=2CE*_=9_-!PD$%S5\X2MXH;<?/3JKGW-C!Z@G@##O#
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M*;"['&U3(G-$Z.P&8QFJ9]FG2VUH+#*F73M\]^K"P?"MWCZ)&4HH%VD@#>*
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M&W>LK0->4!Y.2K;Y'R#O@/\OW<O@MEE7$]:K$JXGK$>N!=9C=4AYD*ZZ!T?
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M=5)]HHDYM@INP*[0[I<SC;"I9WBL<V7CN,X"5OFUU_3UF%SH0HVF$^\>K)G
MR61E>7W0<15C1'&2($Q8ZJ=9ZOO' XZQ ,16N^*;[./WU4!M)IA5>IVRP^OT
M"J'RJW4Z+9P/R RE: K#$W7)%:OV1.J-P]A7EJS7G.GHEP'C"Q4S$X_>4S9C
MMDPNJJP(B7",(DI\\;\D"V%(AJ,?B<CCM(HL3#*@E3Q-K;=P/&?QZMJ)^:V3
M]RF<*%RVV;.@5)=OCUS_RHB.0NE0NU!)TG)!X7J')A\31.=L;?)X;R2#+,[$
M+V<0$S\1LT-&P\%HP (\<?8VQ93C6=Q;-]_.-J&F7W^;1*NV)+EFU$"<SJ#=
M@+_6\EK& JZRO4&8FD*9,+TXK3)RYK)JF7-DIE]_K:K-[^5VV[7.:L636=YM
MBX.4OOQ\15/DA0D*,@$(81CY+(MZ7#CV>6(V<W0$:IYYY0D6R!^JNBW_;79@
MRU6$3-1R]JA8%M2S&*'QC'E&1=4@55MT701LR;KLQ%\EZ7;'M)FZRYWT<O?M
MK+EFL\HR81NA" :RUP\. R^2F^F1#Q,2(8]:4_$IQN=1ZY='J&I9<.-#=?]A
M+SXQG$V;LF^BT,X8MZS$/<[SIJ^+$.,W^-,679,8+%E<C?Q2$E%SYLS$\G,M
MRP^T3[)S;"N4G/UK7SY*&"N4)C1,(@Y3)O#P-$LC(E%D*80D]@RW3*Q F$<X
M#YTK.H4$F^*Q+M:EM3S7@'X3S71,N67E'-"*CR3>[C+!$?$2)/0BG=I":AZ8
M)<NI!>^41-46B[K2>FPP>7Z.TX\#FK"(TY!2Y",>,C04CL 8^:<%!/V=FDGV
MIHBFS8T;[:/[=EC6DTMWS+I8,+V.!K[%D8+@&5&[+'4S<^6"E%G@QRPE7,4H
M(+[GAZD/$>1A$J;9L!1+",FX@6)I6II'JSYUB=TKI3*HQ*7%IDDB9X=!RYKT
M:>2HXXQ9F7;RI4SFLE1HJA-*J90F)QK*4^YD*9-=6Y=W>SF=DLF:+&?RI5A7
MWW;EOXO-"J88THBG**$Q]](H0-(^#R+.LR#,=(L"6K#H?I=9@@3K,Y0-:"L0
M>?Y/__P+>!0_K2U*-HA6UJB9.=:6K([><X#=G/(:O4N4R!K7,(MD+T;2;/KT
M6N&L,Z;<94W6G/M>;06!C9R.MH=[%V6SWE;-OBY._68QQG'B10@&41AS@C,4
M)UV_V0B1D,%4J_F:-:N.A>\<Z/\$!ZC@)QFP==EJMD.Q2+6:[%V'93WI>Y-@
M"1.<<()_7*U1MC*%(X)H/PS+$$4'?KWL#N>(N9,XGC]-'\5'__4?PU?$'[(P
MXW_]Q_\'4$L#!!0    ( /B 65#M0*DIG9@  '66!P 5    96]L<RTR,#$Y
M,3(S,5]P<F4N>&UL[+UK=QN[L2;\?7[%?C.?=S;NE[,F,PO7',_QMC2V=S+G
M$Q8MM21.*+8.+[:57_\"))O6A9<FT=ULT<E*8EMJH%%//5VH @J%__&_OM^/
M?OE:3*;#<OR7/\$_@S_]4HRORNOA^/8O?_KCTZ_JDWGW[D__ZW_^M__Q__WZ
MZ__5']__8LNK^7TQGOUB)L5@5ES_\FTXN_OE[]?%]!^_W$S*^U_^7D[^,?PZ
M^/779:-?%G\9#<?_^+?T?U\&T^*7[]/AOTVO[HK[P?OR:C!;O/MN-GOXM]]^
M^_;MVY^_?YF,_EQ.;G]# .#?UJVV/I'^]6OUV*_I1[]"]"N&?_X^O?[3+U'"
M\73Q[AHOJ1[__NKY;WCQ-)12_K;X[?K1Z7#3@[%;^-O__?W]IX6<OP['T]E@
M?%7\Z7_^MU]^6<(Q*4?%Q^+FE_3G'Q_?/>ND^%J.YM,_7Y7WOZ5?_Z:NKB;S
MXMI]?RC&TV(:W[WHXFY2W/SE3T4YFD:QH81H*?1_W_+X[/&A^,N?IL/[AU&4
M]+=&AF*+V6 X.G1$+UJU,;#/@R^C@Y%ZWJB18>G!*"G^TUU1S/8.9^/#S0_C
M<C")G_!=,1M>#48'C6ECRT8&:,K[^^$LF9:I&E^;<CR+1B@:H^%^)=9HVO80
MXZ\>RG'ZS<7-^R):DA6CXG,7$:[)_YD/XM.S:.R^%N_&-^7D?F'W:GX]K;^X
M;7C\?#:?%+\/Q\/[^?WEX''QT!_CZV+RH1R;1*]1^O(N'HK)(+5:2%+7MK3]
MWK;!^7T0!SF</5[</!_'^^'@RW TG V;0.+PE[0M]H?!9+*@9;YPV[IJ6X1Z
M<TSM#AH9;N6@Q5>Y].4_/OGJ]XVT3MM&!NEBZ_*Q*'0Q+FZ&L\LXP^P;VXXF
M;0VI)C'WMVQD@'XPG/QM,)H7O\?O-EJUBE"?[LK)[',QN7\W_EI,ESS;-^1C
M^NI<"#6=%HM?/K%1JV;7%^./Q=5\,HE?DAY,AW4-9$>O[QRJ0VUI$WUW+F2$
MO(Q6<S1<V*.+FTUM+V[6]G7VL7P<C.*,]V4TO%TTB0Y LK<M8-32T#J'>.-W
M\#4.*0W.EY-/@U;@.^*UG4-3;ZX_OL=&!/IK65Y_&XY&\8WOQK/!^'887[$T
M9/M&7J-IVT-TT]GP/BTJ+=UV=1\Q&_YS\7VLHIJ+FQ]MZMK\UE[8-AR'&O4C
MNFI;A+3Z=3V/ =:-C:[1>#@K%@]=K_[Q/H[H59M\:1MX:]O U+,FM3MH9+CO
MQO&OQ>?!]_T#V_!HTT-XNK!AHJNU#$NB0HOX]^OXR.H+K4F7_)Z;%O#)"S>Y
MFH?+=5B'38MSJ+6JT;3I(;[TTMS-37&5WAM_>_BH#^BM:4'J68^M#9H>SA_C
M2<3B=CS\YX)\JSCX" ;7ZZB1X5],;@?CU5R_;X2;GFU\$#71VM&DF2%]ORDG
MU\E3?5\.QON'L_GQ-H:R6L&,EBS-ZU]F=0$[J)<V!GZH9:S9O(VAUC,L.QLU
M,JR/Q2BYY9>#R>SQ\R2^8W"5"+]W9/O:M3JXFNJMV;R1H7Z:Q5?=KUR=P?3.
MC\IO>P>XLU'CPUIM1T0 %HOC]P^3XBYZ7Y'O[\OI06.MUU/C GR:E5?_N"M'
MU\5DZOYK/IP]IJCC:C@[9.Q[.VEHV$</]:3#^X_B,2VJ+)0;7=OY_<,A'UQF
MM^V*=NCD<'!'[0[_1ZC]L9C.)L.K:-D6#_\1(VV5W.'%LWFB'?.2KL1>/'*Q
M($[SXN[OO&4QTR_T8%HLS&FTI4^7QK+%/*#S=L6LY_74;-[,4.?W]X/)8V3
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MM.PFR=X#S73@WOVU+*^_#4>C^ 6_B\W'M\,HPO*C/ID?MV-,/Q1<P[$[J)]
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M0(DSVXUNCR;[^-B8"DY&Q?3!KGZVFF'3=G;\<PG=^'HUX4X_W45=+*X&>_J
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M O >IKUOHZ5U3!##636'$,6S+O/J;S6;#BF9#7FK\=#AU=[R>@W,(D\ITYH
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M'!*#M>0* 9NJ_U>>I0(NJUASCVQ)AMXV:?XH[(XOU[C(%7TWOMH=2[UX+-6
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M;+WO&S^0JZ32VT(_7BZ0W9575;^7X*E&1&A+D3?1#X7<\RK:,1KKG(6S(RY
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MMWLF]B^$K&+9G%&)%;JXV^OI-R")JJLD2B I2M4K9K7M*H($,C\D,A-YX0X
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MZ-*TZX#>IZ>8+JKQ?SZ_S,!9'\/JYZB<)/ OJCC%0L^*T?C'+JWJZ!<%:S6
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M$,.5"V-#/6--CBD]P+39/DWI;CEQ>B+VML_98TSME^K7:++XM;=:<_/!03G
M%(32<D,]8L1ZO3T;F++D/9G(G:&@ZI@M)P/LMW(2970U+9Z861\B)Z??RV^3
M8N<-2>.QP7.$O8GG!X2.*:"]I8\D@BPGT__BS.->X-4!5\YAV7R8SY>I#=K-
M75W;^D#CS<.#@T8&0R99ZIT="2@\Y766F802Y40E#/#X/!,(.^-'WVZ<F[LT
MR7KJJYS%!EZ<-T8%XSR*4IP*28Q1B!@F:G=5E.0T1VUK;A>_$QG8/C_ZPMW3
MKK8-9=ZN(8$ IUQ4'Z"BR!H+.+&U]J"4\CF(&VZ)B#,CKB5FG/.P_3"-Y!E-
M/B^C'CJ^N8M,CB0Z\LQ]\QTAM2TU#AEO*//6(<M@G::5(M-R;DD&&!!X;MG7
M$5O.JP>F=DK5=-4]X&@U\,G8H#R(RR366D$L1<)*72=;*2]83E[' .M!#!"*
M.>SH7PE<S?)X+?#UL$"BIH&8YTQHJ*62"&Q3"[1166K@<.,$SXV_]AAR#NGW
MM%_!$?;ORV$!$Z%D6B.DB&"JHQI2:[P:P*RKCP%V>3@WYMKCQ#ELCR,PMV]8
MX-A("""'DAOL@.":U(54-,<ON]8?YUAN7MW@G<F[%CER^J7%$_P_=4*^=?Q_
M2/5%IL6J"\N_RL6/%"^V^/5AFMKNE#^+%$:V\WJCW<\$[C&A4A,I&4;&*F0?
MJ2.QS&J%,\!BVV>] CDKZX9WJ]S*S7$TYKAU%#OAI!=Q_4;Y.OQ<8ZNS&I4?
M'VE]K@"'OB1M9XSI"YYI]NG_TX;Z.9H4J]H0D2CE.!X:Z1=J>OO\!T^>7+?K
M>YFAX_X:3Y:IZU7\RZHFU)=X +F[NV)O<$2_$PG:VGA@:4T44T( QYRH*V(:
M ++ZY1T?I=;Y+NDDB&+0'+N(_=/5=@A>>B4MU=QJQ3$ 0LOZ*#1$\9R".D<'
MN3VL.!T1.%N\,XP?R8;W#5D&C"+0<LH,@=P@[V5] AO#1:]%I->0==/;]P;8
MXYC0%V!_7SX\3%:4&DUJ2GV8WE6S^S6G&W2);/:&0"05Q%GO*1>1^))%2[E>
MO[/)X7!-MP*= + ;4O=7+6#=V??SJ+R-NOT>2+UX,B H8;JKH$!8!(5!:$LO
MXP#*ZC,_0.BTS>576?\YU.T++<\+L-0^C#V@>7M $(1YCR7"SFO'<*0,KXL7
M1!J1G)29(29'=XR=5HC<IS*6"/"IFH[C7Q^S)::W;S@14JW\235?SHH&AU[N
MJP--%82TA-:FJJ20 6ZV%,,JZXY\@)&27<.R9W:<[+B/\TM3?7IOL+?2Z^%!
MP4$K+"#06*>8@ QRXK<S%UGFZ #/QOX8777$@3:QHZO9K/HS+GEG!L'>08$;
M1WFJA&RDQP8"Y%&=CN8,H=>9.C 8")W,B%P(?:H6Q>'DIC<?#MP[;85PPEFL
MM<(6\EI".R)!/WTEWQ5DLAAP,E1.R(;;EVPEO)9.>&J-L00AB92MPR!=2O[O
M]4K@2O'2'OU;0,WG2)1R/J]FOQ)^#T/F^?/!(\613"<K8012Z(FK \>< KZ?
M#HSO!B]9Q#\=+.LJAFD:L_+;<M,*YV<Q6Z0\NC23?\W**/ON[G;"I_$;@H><
M1A6-Q?]@9CEA0-5*6EP;4=<5'G\F0'7%CC8AYB-)RY]%ZL%4W1VG3)_VMD"\
M0C:E@BH@,":$L&TM)><HR8E*'J#C>S#0:Y\UN7IW7=BW3@[9%>M^<$RP%D/M
MJ!&"JKA?D"*H3GCR%)B<NY3A!KJ?50MO@P\GX^=%"X7DN/_VZ_.*:+O@LV=(
M4(( )PBV#'G.J'4 U\+7$^UR"E(TCU5_'^AICPV]!:JG5L<WVU;'-]\6HW*:
MXN[JL*$H5]\NCO]K7QS[Z6\-4AM.R,H=C!T@UA-6MS+T MAK:^+7.U#[YU'N
M0?IQ-+V=1!:F[?2UB#19?+A_F%4_BQUU;1N/#1!I8.,^A(98812 W&W7 1 3
M.5C[VYW>'2=R$;5>;>J(]6$:%YC^OKG</ "GW0.#Y,0HR:#2Q&F+A#%NXW-!
MP N3DY%]0K3X=6.I-3;T=S>],EA6G=ANRT6DP_S#=+Q,_-3+1;25_T^Q"M#8
M>P?=[!7!$F B19WB&''GI-< UQ2P#&>E+0SPLOEL!VA'#,F5;9N>6%':_C%-
M70"/,3_WC@U8 ($\8\X +:.D%@Z)>AU4V9RD5WAJW9WK@E97O'C$U/_Z[U=L
M^!A_L/K5F[_9O.<578N?U60Y_Z]Q=;_FQS8"<GYS]R0K:'IKJGC,%S^*Z;S\
MN>I)_7QJQ5^+N'V*V_^WE_Y%U7VQG6BSWN-OC0@6.P2-(0H*;Z4RTB!'B(,@
M[F[&5".'3$<!OO5<OQYHEOG\P< QL)0CRHFV*A4QMA#7*R+4925K#N_,R.;K
MRTC='&*>J(/,9XLGL(C_>@F)^*.4&'J['"]N9K\7LY]EU)C^*M\Z W8]&J04
MD#+IX\FEG2-2*4[KE3A"KRS<Z%0V5JU2L0<\)+F\F>#<5O?1\-\/BM?/!T2,
M)H)0L"JH"K224M=KX@;EW+ -"!GY+'V-C6QB]E@X)<WWM^+^6S';<Y0\>RY0
MRS16!E*K0*H $XDAZK5H#G/NOX8)C!Q^OJYT<C(E>TLA6B_U("J>/1>23NHC
M>;7E(MI#SE$(UFOQDCG>3^SAA:(BAY*]H:(^.J/-4'R(?]V7N_'ZX> PY!";
M^(>&@AJJ!&?UJJ*M=*U-[4Y3-%JC8W_ED'X6TV6CAH@O'PW"* P5HYQI)CP6
MQD?BT'01ZQ$"6>T.!W2>M,'25Z6+LBC9,S92Z9I5/$><:2I+8Y;S1;319MLZ
M!NF6*O[O]NOHK\/P.>9MP7N!/:2.$2SC>4LCB4Q-8"_8E1DYI\/B;7QU2.K>
MO//5?'%S]X^JNGUZ:O]>3?;ZXW<."@ 0 90Q44O3R$8#@:1@H_4JM8(Y5]A#
M/LSR159K-.T+.?^85?-YU/CNRGUGVI.G@A;2&$RI0Y@:3(#U:KL.%O\O QL#
M["O=(C9.)V+O.<RK*Z%Y(W5GYYA@7+034M%>2AE70,>5JGJ-U,J<V(0!YE"T
M")2V2-J?03V)[_S^CV(:YSV)<D_=WI?3,LTY%>3;K&*OI=WD!<%H)@%D<;-@
M)"  T1+UV]5#GW5]-SQ M8""5V9X!V3N3\N>%_%;J6:-C7K;I%HUD3Z,K;WC
M@D/,2.Z-],XS)QP!>+M6P5Q.WLX %9WV(=4F=4^.&XAZ_&BR7-&_VM=";1/4
MNBN$X,C7! F5COJ<,U@1R:F#%O%Z=1*:'.P,,$JE/>ST0.R^A)(M(IO&Y6JF
M\>^38L7'*%COJ]FB_)]=Z:?'# \(>,^=@SR2%:785$WP=N5&YD2_'ZU&_2QF
MWZJ+ 5J'9#Z;1GZ,)KZ*<HZGM_$,:<6-T S:K?RU+N>*<X#]C=L'3BY%>T?)
M.BSD:8S2/IP\/AVL83P:*#9*6:SCJCA%6[>6<^+*D-*%K78R,7L#R>)',?L4
MC]OG,]Y NXFEW^@%04MO$-$2:P0EB+M"85VO'B&;XXP>8.9RFU#J@KY]H6L=
M6IH(L9[UH8*)KYX.(OG ,(<..66( -JK[;6PIS['KSA$Z[YE9K^JF9A+X&&(
MI9/%45#$.D)QU-Q %,9&>Z]0O5JE0<Z)-D3+OELXM4KK_D12?2+7-WPO6S[H
MXJZ:%>OGOH[^*N;NKTBGR.5R.IK]6DGS%#F?[@:KE>NL+D5Z,.*ZDZ\&2 %8
M%3^5"EFFC;=X>[(@!W,\#L=79K@D+6TX3.D7_'$EFSVJBVFQ_XYOQXA@.634
M>PT]AP*G'F5B*S,P]OW4;KA$?:X=@O8%F*@A-+(>GST7'-'6<(\=]Y!JJXD1
M6]IPR7+ <7P;P4N22#ED[%4U>Y;]]#CE./^;NXCMMWNW-+4FLUX>A-,:.A)I
MAH1PRE-KM\X8CN6U%5IHV]3LD_CGANP?TSC[2?D_Q>W_KB8IINL?HW*:5GLS
M_;T8+V>K_$<U*^?Q5W:9LA37RZ^)<0*0<S^9E'6%9;36,"(@=22S:NM&(CHK
M"&NH!G%/D&RX&WKF8'_!@J]6V@#F>T8%9#3APJ102 NY%PS;K?W'",J*/ST>
MJI>D!K1'U;[0XT:S::I%%Z'^^X](+CV:E^-T_5].EHMB7[SI@9'!6.ZMXU'A
M,<3X2$_'M[<TTO"L./D!NFQ:1%&[E.T+2?\J4@&GXE;]C$;X]^+3,F4'W=RM
M5G"S7,P7HVD2NLT!=MH+ _:I"A2)?T"(L(%$ ?VH?,LLZ37 0(X6<=<+P7LN
M_;!J,?PCGO>1$>O.PC9:[>-'UTGO51^>M.9Z/;DF#<^:C ^.NB@CI+ (09B:
M$P*TJ5^%# 2L4<^]CM=_9$4(S)AF!%"C$?)2,^507;7&.(:O),&[(R[OKP]Q
M'&E[3^%<+SKI5M4T[>H=12,:C4OM4BB/ I$+H&UJ=D'TIH$!LIJ"*TNN.I71
MN_#2 DE[TVR?3W5G68F]SP?(D34:*VN!DU(QA[2MUX:QR*K(.&"XY/'YI3[;
M F7[JS&QX<A*ZC8H-?'Z\:"CNB6=-5$<$R6H<-BZ>F4,JBO#3"9W7U6<R"9H
MCXZ7^VK:#">OG@W28.:TPAXZ1[ BG FV69.CVN?$ 0_0.FX7)+G4[ LAZO:V
M3+P935+=Q0_3387&@VC9.RY@B+1.56@E9L)BPOBV?*.#S.>(EP':M^TBITW*
M]H:B\7AYOUPUD-CEVCZ,J*;O") (""R!'$*G333H': U#:0@.=<4 TSS;!E=
M'5&YOZ2\=<WUV@%Y$%9O#P@&86*@4,0HJHU #$E?K\ZPK-C/ ;;/:A=#K9"T
M=Q/=3$;SVMO6U#Q_.29PIXBTD.E(MQ1O+T1=G18Y@K*R%@:H$K5MFF>2LS>M
M^<DT#]KDKQ\./"4*>D0QIEYQ8#'P=KNJN-#K,JY:X.Y+W3F7I/V95]O>;4<:
MY0=&!D2\20O6A!AM&+%(RLUZ4SYS5D'ZX4$HA^&O[*XV"=O;(;7\-B]OR]'L
MU^^C2='PD-HU)DC&H21*.B,DMX8S3FHGF+<4]ELOYV(.J9;(V1MD'F?Y:70?
M__IU-IK.1^-5RO&A0^OPX* , Q(K!"'A3 ,#%:\=6AYS<&7)42UP_R6>VB9Q
M;W'\GV\.'E_;9X*70")/E0.(81,%*.>UTN^=PU?F2&Z3J2]C]T\DZ<DU3'PU
MF51_WDSK)AD[F;[GZ8"]9E8)K2!PW&% XPY9SQ4#9NFUV4/ML[\]XO9N4'\\
MK6RQ%@Y[@ETD$W32,&J]K%>%\;4UNF_;A#Z5CCUF@3T+E?XP?1T;\B7"W5>S
M/T>S?;%U1[XI,(FELIY:P:F@<:MQ3&MZ..>OO^AQ8T"\SAKKD-"]B:44 CC_
M,)\O]T9L/GTL& 61AX)!#+E/C:? HX!U(LN;=S1D'E:!_)&MLT6GP.F,VR\E
MUNF$[N\D>[GPO2?9RX<#8HH2A#&1.G[!<J4]K%<ED>JUE-_5P2>7W"?KQ;:(
M<O5V59Z[_+9,?$D9W.N.U/7J;^Z^%*L[M/CCN-YB7)0_]Q7ZRWEG0) 3!:1T
M%"LBI-38;EJH8^@!R>F2.D!W3M< ZYL??0DS6_XL;XOI[3YM?/M,< P)CCB/
M1HDRTD7- =6Z M3,Y&11G]J6LOL&]WW)KE/)W%_,S[^7ZU(]\Z_5CG"3%S?&
M-W=/'.NV^+8O^K^-UP>DC3?,8J64<,!!02RN*0>5:Y0<<#GW\WTA\PRL.?D<
MWDSG;2$="?&]_%E,BW1O]%1.ZVHVJ_Y,40F[SN+<]P87R2VP<XY80B%Q3#UN
M:@)-3E^N 9:;Z^4\[IDGO1H8:Q/H:;;VVC1:;ZMY7.JS+?:8YWW(&#GYQ0%;
M"#B,G#+8*DTT]H\[6!"1<[=S?%6GBT?P69AR9@C_<S19%AT@N-E[@R:8,JX5
M\DX0+D \BM2&5DA*:3, /, *46<&<"<\&80(_E3\N?K5R:)V^X(@&"-**.<)
MI-+S%"WKZ]4C1G)$ZO%EJ:X=D7G$'X+HS$#>\_&!&X"I 4I("*FR0+/Z1@DC
MP_6UE:0:@BP\E?@GFT)[MT'Z^6@Z+I)<WN8<16NNFDZ+U<UTZC 8R1:)FUKN
MK"CT>3)Z*SRHNX\%[JP15AH-"*5<"(2%J2D%259-QQ,*]EP\3 ?#J;8QO=I@
M/4$ZZUL!8R QL9XAA1QP'J ZT@,C;5B6X!U@[,LY$=TGHX;DA%WMY&^1V+?)
M'5=,YRN@?"GBVN;EHM@T^US3Z$LQKKY/5V]9D2O309OSZ1#5?PR\,88";S61
M@MGZNA<11:ZMOM&0O+<]\JVOG7):G6!F+!#(,*49 (X2) RJU^*!S0I,'607
MJ[Y0F$/FOB#3J+1G:L45^;I8NYS3U>[7:NUQW@.RS#<'@K445A@-:8J& =J:
MVE3%')@L6+[CBZU^V3+DF#:F >801&U'$ ,I @:">B50BBQ#Z^CKJ754DIO>
M7@7(,NA\*2%MUBKA,?2228ZUHIS 6E?&EN:EKAY]-71EZ,FE]B.&.BQ+.;12
ME(UK3KXH.PB$D%&-12Y=2PCM#*:22L, 489AW>B&J*\M^JE:%+:<CR?5?#DK
MOD;JZOCI_QRU<W>\(VBM:5JT0)$.WFBI**OI@)VXLI+NIX+@X%9MA[SGW,'_
M?_'KGW7_8Q6/L/N'51<BFVIY3.87M[\9IH9)RW4D-U8><*P0<U#(R 8AFJ6G
M=K2_QS^*V^4J46Q3&?NY+:YFL]'T^[KXK_[U^,SGT:_T,Y4.F8-U9]OZ1K!,
M8\^4<HQ3"12WD-.:CE*K+'5Q\/*A,8A>RH<SD;\WW^1J@O&3!TH0/'LN4(.B
M/H19U(Y2(+1WB,-Z+3!*W^N"TADP\-(=F$']7BW8DVCSN+KI;7+CIX3;PW4-
M.OA<P#BJXA C+:*F'\6%M,IN*6M03K#1 '%](JK>,I7/RXB^(.[N'R;5KZ)8
M:5XW*ZWJ8/V$G6,"BPN1"&ND6%0CG:30F?4:&4#2ZS[!UH?7^KQ >5D%NB6V
M#$:Z[J+=QR:I^]DO#\9QI95F%C'F'2>6,UU3C6'O,\ \P!OR\VL$O;-L\$#W
MHW*VNMM\8O*FYJCC17'[SVH27S-)[KW18J^UU?W7 ^*.*NR!)?%/B91,?;@V
M=(?2YB1Y#E#)Z!.H;>V1SIAYD9OH2SG_CY\51=V4NL\M]-:W@_;I6#:8$&61
M<1IL-54&.$4YCHPAGC57LH%:8&6OV^=59,WK=7\[1G!\+6;W\-"^Z>2C03GJ
MM!*.(\&PL%X360LIJ"3-L30&&*-U[@TS!!Y>Y$%3+[A.JC^'KO;TVP$11X21
M6@*)D6.4I#O@#<V9S.H!/L3Z95=RT+3 RG/>WGT:Q66GN.9+O:^#SB!KN2,(
M:HB1]!(!SB4S0E.!FD7+=WY?EZBO?ZVJ41]Q _=R5+IVIE1@+.(J/45&*:OJ
MM7)GKJQT[JF,WGVGEDG0W@MAMMK\T5*L!(,66FIXE$A.B^U:E<=75OF]%:X?
MU0GR./KV=HG02B=(%U? -'2<6:%HW'L,FLW:&/+LRB[S6^)SHTZ0QU&V+]3D
MM?<C%@#.,"/&,&"TMYB@>DU&P9P22P-$2R9?#[;W.XZ:O9]1K70_PI1I1ZEU
M3GE#/&<$R'J-7&75C1FBCZW+LRF3MKU)F,Q62-8)KQW43B)C(8R+2REEZU4I
MJJ],%6Z!NX=;(1U'TOZ.HJY:(5FKF<:$ ^D%T$X9SVN#@CFJ>[T9ZR,B(H?E
M1S9#.HZTO9U9K39#LHP9:)C5<:-I  5CRFW6R#UC.=%;0W1S=W%FM43;WO#3
M<6<DCCD@#A'%D*: (,IQO1LYELU22R[H3,OG_O&=D8XC<5_ .JXSDI/.4P\=
MQ50+1*549+L&#7%.]_0APJ1%IN[LC'0<24^$Q7RV> *)^*^7<(@_"E_2'<2.
M,^G9[X,0@$K&F>(P%1M1#'*ZF;/0".6H+T.\+FKQ_,FA8^>\WRD(7CP1)*(>
M"48-Y%9*Z"0DM8=!<"RNI!GLB;QZR>F3:-8EKW\KI^7]\GXOMY\]$Y"& GH@
M<?(S1H1;HV$]=X+Z-5=ZX/>Q'*O:H5NG/!_]=9CG3Y\)R,FX:I!.)^0@<5*X
M[=R90#F>U 'YQ5KA>0;=FO%\7C-]7HS_ZWOU\[]OBW+-\_B7E^R./PH?B^^C
MB9LNTB7FVP?Z&T\%JHF%6CM,'">4 6I2J:3UU)$".<EN RSCTN:QGD_-CH"P
MGL]."_'E(T%PZ5'*&75 4(BULJP^Y:31XDHD?1:[JE9(=WJ-2?._E;OY]/&C
MV=_<].5S@2B(*<::$^=\7)\FJ:[K>GY>977V&AAK3V-+U1[Q3F:N^OAY]>']
MK'W^U*I(.=5 .8L\U\9'N[$65E*ZK#T[H).Z'<9FD:XOGXQ>SLO4&42-UQ4.
M$T_VNXIWC B1OMYSR(A4AF+#*=+U!:Y$ .4DJPVPK4L7CN)V*'M.Y*2_SHK#
M>>8'QP8-.)#:8JIM)*.W5&-6KYDY=25F?VN<;X"D'/J>?,BX58#NA^EX_RGS
MXK'@DYQT'CMMF2224*IJ1Z52(BNWXD*X?R*WJM:(VMNEP*K.Y&,[YL3+PX?0
MGE$!6X"1C&:U(Q80&FUB0^IU(F)SNA(/L#M3%P=1>]0],XH.'D1[QP5GE#"$
M$DVMPE [@W!]OZ\PR.L-,CPDM<+U9D@ZB;Y]8>D?Q;28C29J>JMN[\MIF0+S
M5R7Q_TI)-+MO+HX:'SC5#D0B&NX EE0A"D2]=FOAE55[:@D'5?>4[@ME_RSF
MBW+Z_< Y]^2IP!"!1%@('*<*<$$YK6/@M)%9I2@'V+2MBW/M=&KVC(J#Y]:S
MYP)@%CO(!.;,0 TTQJC6["+T_96%2IS$Q;>1<!+]SIP&O"IS,QM-X_ZXF1X^
MC8YX2P!),%I)O(G6I=?""5A+2HU]5F?>X>+H6 PTR[)M@;[#P=G7/ZL6<+9]
M2[ ,&Y.ZO4GN-!(2453?6^JH!N2<9 /R(O>-LU/IVQ?.GK:>?A+=-M>_GO[F
M@$+4_"5!NG0J^.2TYTQ;)#VNG6<:D:PN2@-L*=J%OM09L<\!N8,ZU>N'@_<,
MQ:T#J)72:XFY9K5A8BP36=UFA@>A+MB]!U$GT;@OY/PV^G<U*Q?K"AGKBA('
MC\"=8X*B'FF,/&4:&,3BKE.Z7J/6\HIQ="R3JVY(VF6\F_E1%G?NKV*\3+Z'
MF[N[<KP'+ =&!(><Q@890PA'@#HH(=U22N@<6VZ NE$+4&F7H'W)E]-*Q ,@
M/8=4QZ5HAJ% J1GG9BT(O>P1?YP<&6"SZBYTFAR"GMDBNZBJ[T)$\T,["N)6
M1@!+Y[:>&:,%NS*?U(FHZJ/J^W&,Z*U@2ZM5WX6T1!*@E)$V&KP">U0+ \LA
MSHD]&F2.\WF!TKCJ^W%LZ<\HG"]F92IFMYKQ']-R,?_R^Q\'X;=W7' "6^T<
ML1HXZP2GSM=^'>LXS_&='JVWO3L(MLF:DV.==DQB_KF8W56S^]1[W533==?I
M^?YXJ!->%03T&%B'N'$X'CR88&6VF\WQ*XN9:HGC5:]$;QU:OXUF_RD6N:AZ
M^RT!,6^Q!( +Z[R72%%;!YU9Z%U.'-4@+='> -4*O7LK3/.DG,K'!FU/WGP^
MTH\K2RR,%CBC0"%)=+U/'($P*Y)J@-*I"\.U#<+V!9KGU7+6?9_5<O&CFI7_
ML[<5]_Z!02EAM:;"0XDYE4ZRK6'EJ,IKSCT\%&5RO.J0M.<$TL%^[KL'!4N(
MX,QA;SV*AZQTJ;KE9I4:P"OSKG8/H)/(>D[PW"P7\\4HGKS3[T<BZ,G(N%YG
M5-3W+&8:,.-LRM]<K=<@I'3.U?( BV)U#Z/3:=N;&K2K%-S3??#'0S5=/SB/
M3-VG)!W_MH (-0HI"Q45AD(NJ<,U72BR.86M!U@(IUW,=4_O\\BTSZ/9S6P5
M57V[:M@03=75BAJ+METO",A'30!PJB'27"2Z:U&O/I(CQYLPP/H,74JXEDC<
MGZ#;5F8^0F_?,RIH#;6-VH'4/B[4(6*,K==IE,VI83O Q."V!5=;=#T#?DZ0
M3@U&!\(DE5)#Y;77 #-H&*S7'?6#'#P-,+^O,SRU1-^SR:6#9N".$8%@QPRW
MD DC,6/2.[:5N\":G""* >;1="R/3J+IV3#3S/K;-RQX2Y5@!D@/G'3"$X2V
M:B$0)*>TS0"CBCM&S^F$/7/0NKJOEM/%_%F9UN.CUM]Z2["(:R$I999R ;#U
M]%$MC#9)5N6+ <9XM8NP[@C=HZ-AU0AL.9K<?)N4WT<'H/7F\T$CRXEDUKE(
M-LJ,<E)M-Q.TZ,KN6UKW%F23M"^X?*RFWU,OTT_5HIA_'OTZT';OK<<#]X9Z
M9"#7U*(H>3WQNEX91"8K>NKJO>(M4+2_L^QA'8835_\L\+KXMJ\3Y;YA\=3V
M A)$M4+"Q3U!M*);(>KS>C5>O2N\1<J>'%IB1@_E8C19R;SRVS+QP$?BE#^+
M5)*H>C8O7<UFU9]167LK "#C;0%S2@@F%&@"?;IN%'Z[5NZR7$3P:IW;_1%\
M,''ONT(*/RU3!$VD:'./9>O?"H08+3644F)O!60.T2<*0E[1TZOWF9^;'8.'
M^.=B-D[(^%[<W#TQF]?MJ-95P;M >X//!JZ8MU';@4)PPKEUUFR%"4$DJY#S
MU7OX!\29TW6(1[^.NET'-<8C:7TRK??EE\C=V<_B]JZ:^>5B.2N2WS!%U.Y4
M)$Y_94#0"V )A=(1QK1E"FPC"*(HR&H!?;4W!#U3_0PNX#?7X1L \N1W!0B)
M]PI"B9#5(AU'FFVO4AS,0N)[NFOHA-R#/_)7_]E4CXG2OJQN81='_!N?B<8G
MDUY38*TQ1 (L/=W> 4J)LIS05W_-<49.#![3ZS;B'Z;SQ6RY]GPL?A2SKS]&
MTW7FX/P?\16+^8?I>OU=X/W(*00.'((.0^HIX5' 4$-)S0&7E\F,CKZ0Z;N#
M[AEW0[=\ZG6G?#N\_&^OEO_70SE;/=QL*[3QC0 M,P [":+)@!#$$LBMP:"C
M19V#]4%F4G> ]3,PXF3+[>"$O^V8L!^5LU78D(K*U_UZ/_ZK*+__6!2W*C(N
MFJ6I"F]*?DNW([O,O+Z^'SB&1C/-D" *:@&XM%O5$#J>!>Q!YF>W:!4.E$F#
MUW7>6GZ]7EO^+&^+Z>V7T6*?R=GYMX.!A#/$D6(:F6@Y4<?15M#HK&X)Z.@+
MO,O9&$-ET. WQ4V]U&(V+N?%5GW[6D4#_T.ZQ9K.R_&*,EWLBR,^'X3'2BBA
M,?91M_3 &[X51PS;G*I]Z.A;R7>T-;KC46_5W28K-!2W;]-@TY]@#[Z;O2!(
MA27A6'-)()):4(D>?:X*9@GOHZ\<+P^AG5"Y]PI:Q>QG.2[>7L*GE,\V3^I6
MVECSU0YZ^GM3S1>?JL7_*19?BG'U?9IN3I_4<=I7Z*&7[Z=D!.NU1-9+C[%$
M&#RZOU(:7@["K_YN<8@LNOCML3Z+?#7;_"@]M\\OW^]$@J;8I>)#QJT:-5&"
M[598":BR:NM?[>7G1?!J\*K]08?M/U=D>Z;.;<V@LWCZ]TTH4(8L%H@H$G'D
MN?(&N\<@7I!3; 9=_>7M1?#LXL^BQS>M![VDU5G4MP-S"@1BF3J34&:!0Q1&
M,VV;MZPTR(F31%=_MWPI;#OY1J*93;8)"-D1XWO:BP+T/BX*<(N0]L8Y;(#<
M"@]/908P\=5FWO5"Z\%?UCX[FYZ')'=Q;[OG<\%(SYE1TJ44-0LLTW@;]ZRL
MRXG&Q5>?^C< C@Q>S7\S^N(?LVI^$.KM?BU #KEE@$LL<10B0#*]#?CP1F3)
MZZO/6SP_0QZ!_K_^^Q4OX@+_L_K5F[_9O.<5>8M5R_O_&E?W:Z:L:+5N&S1?
M&Q:VN"O'Y>*Q0.L;17K5>%'^7#V[&)63^?-9%W\MBNEM5#MZ,!M6,U;?YJML
MY'VZ_+,'0S1[N!<$(,RA]4XB PGVGF!I#4>R4?!F1S+GL2[NR>7COQY(<6[M
M&P%*)13@B"#O(@$C^;BNZ6C1M;7H/A5$+^7*F<C?V]7>28V;!-3<P:@'*&CD
M:@'>;=9B@<99\=3#@](9,+"WR]-QU!^, G8!79XDPCXRA"E%G>/IN$>VIBPU
M("OU;WBX/A%5?71Y.HX1_56<Z*+5#H#1D-*0<*F D]QAAE2]5J)UCMX_R!CE
M\P+FJ%8[Q[%F,))V%_VV9E87ENVC#0>115HHQKUT\:_8$B5JJCF.<LI?#-".
M/;]VT#O+!@_T@[=NVRN%+]5DXJM9&G26*]NW)A*@,EQQP*P0@@'CK<!\PPW'
MO>KU1.AA _4(W]ZN=5O@ZQ7MLK4'^;P;;#V'P(AAUEJE@7(^LH):41_ISD7E
MH<^]];!R-OZ^&,T6P]QA'<.\_]UX$@@N?R,.+PN9(&XT2/=(W@'H":*"UAP
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MQ\/M:%'$YQE !S'5:'R(AXGS5! /O<& 6D)-O4F-A?K*0B;SV/]23G5 X+[
M=:ID_]@@MB/[W8%9PZ A@&*,M/1&*%3K.:FW[95UF#S/*=LWE_I"]LU#D0+Z
MIM\_%J-Y\27ER]W<_3$OU'Q>[+/7]HX+,!(6 F\8U@XX 9R,]O5FK9B9*SN+
M>\1&U1T7SH.XC^7H6SDI%[_,<I9HW1AR+P<&+ZF,IQ$C3E(* ",:JGJU5."<
MF_M!]F0;"NHR&7%FV'VJIN-3D?<X-BC)M,-:")MJ^UCAG1;UFE.X4Y^7EN]'
MX.5SHB_TV0T#O\0IFOAGN6@$O'W#@N36(44%-<9KZAE&I*:A,]SG5 L:X.WA
M^3#7(A,&<Y/P:31;YW%<VV4! !)Z;I5SFF,)160M9 Z*J.1;+<D@TI0C>J,8
M6_SZ/$F\F=ZFB_%5TD/SS./]KPA..LD QL!!9:$UPD!64\%9<65^US;@L#/(
MH%5*]W7<F"B@BNDJ5:N:?BGG_]&_DB_G@&]_SZA D.!^E72#O/(8$P]PO4YC
MKRV7KGWV5UV1^FR02O,]F/R[9]2J3+<@TED%+9<6:H5]O4Z+U96%6K?"\4,H
M.IFZ_27^5M]GHX<?Y?C5W!LD_1X8&S1,S;BCL&>><4N< ()N=R/A.8[02T#4
M*=Q_E>[;+HW/>.#I8CK^$57A_QQ_ZCT;&HQ!3 *#B>'<8V>8MO6*'=-9A:<&
MZ%X_Q]&70^_S(:R>]/&'X(NA@2.(#7?0.N>EXXI@ANH56\RN76Z=#("#R,JB
M<W]E"GX6TV7A(Z'JPH3_*A<_S'*^J.Z+68-"!0W&!R \2U$ 1":?F!4(V-H2
M<I*@*ZLMW1X47E4K:)_8)P)M/EL\ 5G\UTN Q1^%*,1OE^/%S6P3)+_C,-SU
M:'">>VFYH]1SIH4W%MC-2GRJ^7%=CNW.#K^6Z-L#4N9QL9L)SG>>;'N?#TX[
M[+21+.5U4 QDTA@W:R+>7\GM;SY+7V,CFYB]Y6&M)WGP;'KV7,!0 JR!4BC2
MV::*+FICYS+"O,K1I(<)C!Q^OO1(9E"RMQB\Z:*\+2?+=+'P>S%>SLI%6<S=
M7^/)\K:X79^9]P_+Q28=RXUFJ1KS_',Q6^=N_7K[!8="DKO[:I#:(.F@UTY"
MR $G3LJ:S@(TJWIZ.7=LG=M^PV'5>;?$I]']8=_IH:'!:@*@L)9J:[BP&DCU
MN&+KK\R!.@CL-,+SR2SJO7#98W6#@R?YSC'!D'@($86@ %$:1+4'DWJ-U'C7
M*PS["+QJC^F[*H-EDKC'^HJO2@I\^?V/)I45=X\+A" JA8T:#H'( "&=HO5:
MHP*=D[XVR#B^SN#4)IF[-#RW!24?+Q]&DSU^BIW/!ZT(E@0 10TG<0W6$UVO
MB;"LS$<ZO .Q4V=%6T3N%#C%]Y<SW.NQV/E\4  [ ;T'1!HI$$V=>.LU"4*O
M)*VG);Y6[5.T&4KF-4SFQ?B_OE<__WL5]C/[E9#"ZW\DH/ G0-G\.!CU!BH>
M?QED'&9 /%BUE!1[ 2DAFPDSS,0U02"?:54F^?K24'P9#[WB8SQ9;S]$ODR_
MEU$>KI(CYOK7;Z-_5S,S&<T/.1B.>$LP %DH&1<&(VZXQDANZ2 0RO%]LN'
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MI<EV3GXTD#.;7Z3_?(N&Y?_W__Q?4$L! A0#%     @ ^(!94)J-Y'-]H0$
MH8D3 !$              ( !     &5O;',M,C Q.3$R,S$N>&UL4$L! A0#
M%     @ ^(!94" $T$H<$@  %,   !$              ( !K*$! &5O;',M
M,C Q.3$R,S$N>'-D4$L! A0#%     @ ^(!94-&)/W-W*   MK ! !4
M         ( !][,! &5O;',M,C Q.3$R,S%?8V%L+GAM;%!+ 0(4 Q0    (
M /B 65" 16P^VEL  (!K!  5              "  :'< 0!E;VQS+3(P,3DQ
M,C,Q7V1E9BYX;6Q02P$"% ,4    " #X@%E0Y@)X%&/O   0U0P %0
M        @ &N. ( 96]L<RTR,#$Y,3(S,5]L86(N>&UL4$L! A0#%     @
M^(!94.U J2F=F   =98' !4              ( !1"@# &5O;',M,C Q.3$R
@,S%?<')E+GAM;%!+!08     !@ & (H!   4P0,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6774263296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Employee Benefit Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company maintains a defined contribution&#160;401(k) plan covering substantially all employees.  On July 1, 2019, the Company began providing matching contributions, which totaled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$479</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI http://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI http://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782140960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Accrued Expenses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782691216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Schedule of Impact of Adoption of ASC 842 on the Balance Sheet</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779181952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>year</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Investments in a continuous loss position for more than 12 months</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary Impairments recorded on investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">44,683,000<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable</a></td>
<td class="nump">16,696,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Oxford Term Loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Contingent promissory note payable</a></td>
<td class="nump">$ 76,203,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term | Contingent Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input | year</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Minimum | Contingent Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Measurement Input, Discount Rate | Maximum | Contingent Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AlternativeInvestmentMeasurementInput', window );">Measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AlternativeInvestmentMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure alternative investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AlternativeInvestmentMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_OxfordTermLoansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793220304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAdditions', window );">Capitalized computer software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,415,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,853,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,208,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets', window );">Assets acquired, indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,076,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration upon successful completion of certain technical and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Acquired Finite-lived Intangible Asset, Period Of Extension Of Terms Based On Certain Performance Requirements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AcquiredFinitelivedIntangibleAssetPeriodOfExtensionOfTermsBasedOnCertainPerformanceRequirements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With License And Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions made to capitalized computer software costs during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6774273312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Summary of Significant Accounting Policies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Reclassification&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (&#8220;Daewoong&#8221;) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method with prioritization of the items with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for any periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of goodwill for any of the periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau&#174;&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;upon being placed in service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of long-lived assets for any periods presented.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon, the Company recognized a contingent royalty obligation payable to the Evolus Founders. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined at each reporting period end and recorded in operating expenses in the statements of operations and comprehensive loss and as a liability in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon (See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information), the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the statement of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term debt represents the debt balance with Oxford Finance (&#8220;Oxford&#8221;), net of debt issuance costs. See Note 6, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Oxford Term Loans</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates product revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States and service revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> through a distribution partner in Canada.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada as it does not control the product before control is transferred to a customer. &#160;The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. For the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of revenue related to Canada sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and purchase volumes. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and future expectations. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,709</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for rebate and coupon programs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12,325</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,616</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the&#160;year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.  The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, allowance for doubtful accounts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provision for bad debts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and there were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> write-offs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is within one year.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Advertising Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Advertising costs are expensed as incurred and primarily include costs related to social media ads. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company incurred advertising costs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,407</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Prior to the IPO, the Company calculated its income tax amounts using a separate return methodology and presented these amounts as if it were a separate taxpayer from Alphaeon in each jurisdiction. Subsequent to the IPO, the Company has prepared its stand-alone tax return. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. For the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, excluded from the dilutive net loss per share computation were stock options of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,977,401</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,257,801</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, and non-vested RSUs of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">179,758</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">221,292</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, because their inclusion would have been anti-dilutive. Although these securities were anti-dilutive for these periods, they could be dilutive in future periods.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recently Adopted Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740,&#160;Compensation - Stock Compensation - Income Taxes. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarified that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that superseded the lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard required lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allowed companies to continue to use the legacy guidance in ASC 840, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allowed for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying balance sheet, but did not have an impact on the statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recent Pronouncements&#160;Not&#160;Yet Adopted&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">(Topic 326)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">: Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 for public business entities, excluding entities eligible to be smaller reporting companies, and early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of determining the effects adoption will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2019, the FASB issued&#160;ASU No. 2019-12,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2019-12&#160;eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This ASU also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6795085568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 42,756<span></span>
</td>
<td class="nump">$ 27,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">1,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther', window );">Other deferred assets</a></td>
<td class="nump">2,470<span></span>
</td>
<td class="nump">2,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation', window );">Accrued compensation</a></td>
<td class="nump">1,962<span></span>
</td>
<td class="nump">608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeferredTaxAssets.OperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount', window );">Contingent obligation - imputed interest</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other, net</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(36,972)<span></span>
</td>
<td class="num">(32,280)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets</a></td>
<td class="nump">14,131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible amortization</a></td>
<td class="num">(12,970)<span></span>
</td>
<td class="num">(15,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(1,017)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed asset depreciation</a></td>
<td class="num">(144)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(14,131)<span></span>
</td>
<td class="num">(15,055)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (15,055)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssets.OperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets. Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssets.OperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeferredTaxAssetsPromissoryNoteDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Promissory Note, Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeferredTaxAssetsPromissoryNoteDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6789309456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 34,925<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Product cost of sales (excludes amortization of intangible assets)</a></td>
<td class="nump">8,014<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">26,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">113,593<span></span>
</td>
<td class="nump">29,146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">3,973<span></span>
</td>
<td class="nump">6,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayable', window );">Revaluation of contingent royalty obligation to Evolus Founders</a></td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,132<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">125,858<span></span>
</td>
<td class="nump">46,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(98,947)<span></span>
</td>
<td class="num">(46,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income</a></td>
<td class="nump">1,839<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest expense</a></td>
<td class="num">(7,953)<span></span>
</td>
<td class="num">(863)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(105,061)<span></span>
</td>
<td class="num">(46,802)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="num">(15,027)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(90,034)<span></span>
</td>
<td class="num">(46,867)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive gain:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on available-for-sale securities, net of tax</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (90,028)<span></span>
</td>
<td class="num">$ (46,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (3.19)<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares outstanding used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">28,237,816<span></span>
</td>
<td class="nump">24,402,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 34,237<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total net revenues</a></td>
<td class="nump">$ 688<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RevaluationofContingentRoyaltyObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Contingent Royalty Obligation Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RevaluationofContingentRoyaltyObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>159</ContextCount>
  <ElementCount>470</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>60</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfStockholdersEquityDeficit</Role>
      <ShortName>Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StatementsOfCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Fair Value Measurements and Short-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssets</Role>
      <ShortName>Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Oxford Term Loans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoans</Role>
      <ShortName>Oxford Term Loans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Fair Value Measurements and Short-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Goodwill and Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsTables</Role>
      <ShortName>Goodwill and Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/GoodwillAndIntangibleAssets</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpenses</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Oxford Term Loans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansTables</Role>
      <ShortName>Oxford Term Loans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/OxfordTermLoans</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Stockholders' Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders' Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.evolus.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/Organization</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Impact of Adoption of ASC 842 on Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/SummaryOfSignificantAccountingPoliciesImpactOfAdoptionOfAsc842OnBalanceSheetDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Impact of Adoption of ASC 842 on Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsShortTermInvestmentsAvailableForSaleDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Fair Value Measurements and Short-Term Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/FairValueMeasurementsAndShortTermInvestmentsReconciliationOfFairValueMeasurementOfContingentRoyaltyObligationPayableDetails</Role>
      <ShortName>Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsScheduleOfDefiniteAndIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsEstimatedFutureAmortizationExpenseOfIntangiblesDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Goodwill and Intangible Assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/GoodwillAndIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/AccruedExpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Oxford Term Loans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansNarrativeDetails</Role>
      <ShortName>Oxford Term Loans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Oxford Term Loans - Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/OxfordTermLoansMaturitiesOfDebtDetails</Role>
      <ShortName>Oxford Term Loans - Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Commitments and Contingencies - Components of Lease Expense and Other Quantitative Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesComponentsOfLeaseExpenseAndOtherQuantitativeInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Components of Lease Expense and Other Quantitative Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesMaturityOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Maturity of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Commitments and Contingencies - Future Minimum Payments Under Non-cancelable Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/CommitmentsAndContingenciesFutureMinimumPaymentsUnderNonCancelableOperatingLeasesDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Payments Under Non-cancelable Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Stockholders' Equity (Deficit) - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Stockholders' Equity (Deficit) - Key Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitKeyValuationAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Key Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitScheduleOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2408406 - Disclosure - Stockholders' Equity (Deficit) - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/StockholdersEquityDeficitStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity (Deficit) - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2409401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Income Taxes - Components of Current and Deferred Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesComponentsOfCurrentAndDeferredTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Components of Current and Deferred Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Income Taxes - Reconciliation of Effective Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesReconciliationOfEffectiveTaxDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Effective Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2411401 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.evolus.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.evolus.com/role/RelatedPartyTransactions</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="eols-20191231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - eols-20191231.xml</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - eols-20191231.xml</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>eols-20191231.xml</File>
    <File>eols-20191231.xsd</File>
    <File>eols-20191231_cal.xml</File>
    <File>eols-20191231_def.xml</File>
    <File>eols-20191231_lab.xml</File>
    <File>eols-20191231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6794374592">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;">eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
<td class="num">$ (239,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable', window );">Deemed Contribution From Parent, Increase Of Related-Party Receivable</a></td>
<td class="th" style="border-bottom: 0px;">eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable</td>
<td class="nump">1,051,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings', window );">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</a></td>
<td class="th" style="border-bottom: 0px;">eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings</td>
<td class="nump">13,188,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
<td class="nump">66,998,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">6,971,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Stock Issued During Period, Value, Conversion of Convertible Securities</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">53,446,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember', window );">Follow-On Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">67,379,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;">eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
<td class="num">(239,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable', window );">Deemed Contribution From Parent, Increase Of Related-Party Receivable</a></td>
<td class="th" style="border-bottom: 0px;">eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable</td>
<td class="nump">1,051,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings', window );">Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</a></td>
<td class="th" style="border-bottom: 0px;">eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings</td>
<td class="nump">13,188,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt', window );">Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
<td class="nump">66,998,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_Dividends</td>
<td class="nump">1,385,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
<td class="nump">6,971,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member] | IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">53,445,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital [Member] | Follow-On Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">67,379,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_NetIncomeLoss</td>
<td class="num">(46,867,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_Dividends</td>
<td class="nump">$ 615,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
<td class="nump">2,065,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan', window );">Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</a></td>
<td class="th" style="border-bottom: 0px;">eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
<td class="nump">34,602<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member] | Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
<td class="num">(1,250,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution From Parent, Forgiveness Of Related-Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionFromParentForgivenessOfRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed Contribution From Parent, Increase Of Related-Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DeemedContributionFromParentIncreaseOfRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodSharesIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Issuance Of Common Stock In Connection With Incentive Equity Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockIssuedDuringPeriodValueIssuanceOfCommonStockInConnectionWithIncentiveEquityPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=51819886&amp;loc=SL6014347-161799<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=eols_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793136944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Reclassification&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. These reclassifications had no effect on the previously reported net loss.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Management is required to make certain estimates and assumptions in order to prepare financial statements in conformity with GAAP. Such estimates and assumptions affect the reported financial statements. The Company&#8217;s most significant estimates relate to net revenues, allowance for doubtful accounts, fair value measurements, goodwill and long-lived asset valuations and impairment assessments, inventory valuations, income tax valuations, stock-based compensation and royalty obligations, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company&#8217;s actual results could differ materially from those estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties and Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Risks and Uncertainties</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2013, Evolus and Daewoong Pharmaceuticals Co. Ltd. (&#8220;Daewoong&#8221;) entered into the Daewoong Agreement, pursuant to which, the Company has the exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Great Britain, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company&#8217;s commercialization of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Daewoong Agreement, and Daewoong&#8217;s rights relating to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, are subject to litigation. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 7</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for additional information regarding such litigation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the United States in May 2019 and in Canada through its distribution partner in October 2019 and, as such, has a limited history of sales. If any previously granted approval is retracted or the Company is denied approval or approval is delayed by any other regulators, it may have a material adverse impact on the Company&#8217;s business and its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is subject to risks common to early stage companies in the pharmaceutical industry including, but not limited to, dependency on the clinical and commercial success of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates, ability to obtain and maintain regulatory approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and any future product candidates in the jurisdictions where approval is sought, the need for additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and patients, significant competition and untested manufacturing capabilities.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents, short-term investments and accounts receivable. Substantially all of the Company&#8217;s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company&#8217;s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for doubtful accounts based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers&#8217; ability to pay.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Segment Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has determined that it operates in a single </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">operating and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">reportable segment. The Company&#8217;s chief operating decision maker is its Chief Executive Officer who manages operations and reviews the financial information as a single operating segment for purposes of allocating resources and evaluating its financial performance.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Cash and cash equivalents consist of cash and highly liquid investments with remaining maturities at purchase of three months or less that can be liquidated without prior notice or penalty. Cash and cash equivalents may include deposits, money market funds and debt securities. Amounts receivable from credit card issuers are typically converted to cash within two to four days of the original sales transaction and are considered to be cash equivalents.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Short-Term Investments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Short-Term Investments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Short-term investments consist of available-for-sale U.S. Treasury securities with original maturities greater than three months and remaining maturities of less than twelve months. These investments are recorded at fair value based on quoted prices in active markets, with unrealized gains and losses reported in other comprehensive gain (loss) in the Company&#8217;s statements of operations and comprehensive loss. Purchase premiums and discounts are recognized in interest expense using the effective interest method over the terms of the securities. Realized gains and losses and declines in fair value that are deemed to be other than temporary are reflected in the statements of operations and comprehensive loss using the specific-identification method. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company periodically reviews all available-for-sale securities for other than temporary declines in fair value below the cost basis whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company also evaluates whether it has plans or is required to sell short-term investments before recovery of their amortized cost bases. To date, the Company has not identified any other than temporary declines in fair value of its short-term investments.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Inventories</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Inventories consist of finished goods held for sale and distribution. Cost is determined using the first&#8209;in, first&#8209;out method with prioritization of the items with the earliest expiration dates.&#160;Inventory valuation reserves are established based on a number of factors including, but not limited to, finished goods not meeting product specifications, product excess and obsolescence, or application of the lower of cost or net realizable value concepts. The determination of events requiring the establishment of inventory valuation reserves, together with the calculation of the amount of such reserves may require judgment. No material inventory valuation reserves have been recorded for any periods presented. Adverse changes in assumptions utilized in the Company&#8217;s inventory reserve calculations could result in an increase to its inventory valuation reserves.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in an orderly transaction between market participants in a principal market on the measurement date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value hierarchy defines a three-tiered valuation hierarchy for disclosure of fair value measurement is classified and disclosed by the Company in one of the three categories as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 1&#8212;Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 2&#8212;Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities in active markets; quoted prices in markets that are not active; or other inputs that are observable, either directly or indirectly, or can be corroborated by observable market data for substantially the full term of the asset or liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:13px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Level 3&#8212;Prices or valuation techniques that require inputs that are unobservable that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Goodwill</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-style:normal;font-weight:normal;">Goodwill represents the excess of the purchase price over the fair value of the net tangible and intangible assets acquired in a business combination. The Company reviews goodwill for impairment annually and whenever events or changes in circumstances indicate the carrying amount of goodwill may not be recoverable. The Company performs an annual qualitative assessment of its goodwill in the fourth quarter each calendar year to determine if any events or circumstances exist, such as an adverse change in business climate or a decline in the overall industry demand, that would indicate that it would more likely than not reduce the fair value of a reporting unit below its carrying amount, including goodwill. If events or circumstances do not indicate that the fair value of a reporting unit is below its carrying amount, then goodwill is not considered to be impaired and no further testing is required. If further testing is required, the Company performs a two-step process. The first step involves comparing the fair value of the Company&#8217;s reporting unit to its carrying value, including goodwill. If the carrying value of the reporting unit exceeds its fair value, the second step of the test is performed by comparing the carrying value of the goodwill in the reporting unit to its implied fair value. An impairment charge is recognized for the excess of the carrying value of goodwill over its implied fair value. For the purpose of impairment testing, the Company has determined that it has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reporting unit. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of goodwill for any of the periods presented.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Intangible Assets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, the in process research and development (&#8220;IPR&amp;D&#8221;) related to Jeuveau&#174;&#160;was evaluated as completed and reclassified to a definite-lived distribution right intangible asset, which is amortized over the period the asset is expected to contribute to the future cash flows of the Company. The Company determined the pattern of this intangible asset&#8217;s future cash flows could not be readily determined with a high level of precision. As a result, the distribution right intangible asset is being amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company capitalizes certain internal-use software costs associated with the development of its mobile and web-based customer platforms. These costs include personnel expenses and external costs that are directly associated with the software projects. These costs are included as intangible assets in the accompanying balance sheets. The capitalized internal-use software costs are amortized on a straight-line basis over the estimated useful life of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;upon being placed in service.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company reviews long-term and identifiable definite-lived intangible assets or asset groups for impairment when events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset or an asset group, further impairment analysis is performed. An impairment loss is measured as the amount by which the carrying amount of the asset or asset groups exceeds the fair value for assets to be held and used or fair value less cost to sell for assets to be disposed of. The Company also reviews the useful lives of its assets periodically to determine whether events and circumstances warrant a revision to the remaining useful life. Changes in the useful life are adjusted prospectively by revising the remaining period over which the asset is amortized. There was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> impairment of long-lived assets for any periods presented</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02 as adopted on January 1, 2019, at the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, upon lease commencement, the Company records a lease liability which represents the Company&#8217;s obligation to make lease payments arising from the lease, and a corresponding right-of-use (&#8220;ROU&#8221;) asset which represents the Company&#8217;s right to use an underlying asset during the lease term. Operating lease assets and liabilities are included in ROU assets, current portion of operating lease liabilities and noncurrent operating lease liabilities in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease ROU assets and lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company&#8217;s incremental borrowing rate applicable to the underlying asset unless the implicit rate is readily determinable. Operating lease ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received, if any. The Company determines the lease term as the noncancellable period of the lease and may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. The Company&#8217;s leases do not contain any residual value guarantees. Leases with a term of 12 months or less are not recognized on the balance sheets. For operating leases, the Company recognized rent expense on a straight-line basis over the lease term. There were no significant finance leases as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Research and development costs are expensed as incurred. Research and development expenses include personnel-related costs, costs associated with pre-clinical and clinical development activities, costs associated with and costs for prototype products that are manufactured prior to market approval for that prototype product, internal and external costs associated with the Company&#8217;s regulatory compliance and quality assurance functions, including the costs of outside consultants and contractors that assist in the process of submitting and maintaining regulatory filings, and overhead costs, including allocated facility related expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Payment Obligation Payable and Contingent Promissory Note Payable to the Evolus Founders, a Related Party</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Payment Obligation Payable to the Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon, the Company recognized a contingent royalty obligation payable to the Evolus Founders. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. The Company determines the fair value of the contingent royalty obligation payable at each reporting period end based on Level 3 inputs using a discounted cash flows method. Changes in the fair value of this contingent royalty obligation are determined at each reporting period end and recorded in operating expenses in the statements of operations and comprehensive loss and as a liability in the balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Contingent Promissory Note Payable to Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, related to the acquisition of Evolus in 2013 by SCH and Alphaeon (See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information), the Company recognized a contingent promissory note payable at present value using a discount rate for similar rated debt securities based on an estimated date that the Company believed the contingent promissory note will mature. Discount amortization related to the contingent promissory note is recorded in interest expense in the statement of operations and comprehensive loss with a corresponding increase to the non-current liabilities in the balance sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Long-term Debt</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Long-term Debt</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Long-term debt represents the debt balance with Oxford Finance (&#8220;Oxford&#8221;), net of debt issuance costs. See Note 6, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Oxford Term Loans</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. Debt issuance costs represent legal, lender and consulting costs or fees associated with debt financing. Debt&#160;discounts and issuance costs are allocated pro rata between the funded and unfunded portions of the debt and are amortized into interest expense over the term of the debt.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company applies Accounting Standards Codification 606, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;ASC 606&#8221;), to account for revenue generated since the commercial launch of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in May 2019. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes revenue when control of the promised goods or services is transferred to its customers, in an amount that reflects the consideration to which the Company expects to be entitled in exchange for the goods or services. In order to achieve that core principle, a five-step approach is applied: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue allocated to each performance obligation when the Company satisfies the performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account for revenue recognition.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">General</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company currently generates product revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States and service revenue from the sale of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> through a distribution partner in Canada.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For product revenue, the Company recognizes revenue when control of the promised goods under a contract is transferred to a customer, in an amount that reflects the consideration the Company expects to receive in exchange for those goods as specified in the customer contract. The transfer of control occurs upon receipt of the goods by the customer since that is when the customer has obtained control of the goods&#8217; economic benefits. The Company does not provide any service-type warranties and does not accept product returns except under limited circumstances such as damages in transit or ineffective product. The Company also excludes any amounts related to taxes assessed by governmental authorities from revenue measurement. Shipping and handling costs associated with outbound product freight are accounted for as fulfillment costs and are included in selling, general and marketing expenses in the accompanying statements of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For service revenue, the Company evaluated the arrangement with the distribution partner in Canada and determined that it acts as an agent in the distribution of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174; </sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in Canada as it does not control the product before control is transferred to a customer. &#160;The indicators of which party exercises control include primary responsibility over performance obligations, inventory risk before the good or service is transferred and discretion in establishing the price. Accordingly, the Company records the sale as service revenue on a net basis. Revenue from services is recognized in the period the service is performed for the amount of consideration expected to be received. For the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recognized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of revenue related to Canada sales. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disaggregation of Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s disaggregation of revenue is consistent with its operating segment as disclosed above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Gross-to-Net Revenue Adjustments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company provides customers with trade and volume discounts and prompt pay discounts that are reflected in the invoice price. Revenues are recorded net of sales-related adjustments, wherever applicable, for rebates and coupon programs. Accrued rebate and coupon balances are recorded in accrued expenses on the accompanying balance sheets.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Volume-based Rebates - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Volume-based rebates are contractually offered to certain customers. The rebates payable to each customer are determined based on the contract and purchase volumes. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Coupons - </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company issued customers coupons redeemable into gift cards funded by the Company for the benefit of patients. The coupons are accounted for as variable consideration. The Company estimates the coupon redemption rates based on historical data and future expectations. The coupons are accrued based on estimated redemption rates and the volume of products purchased and are recorded as a reduction to revenues on product delivery. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the accrued volume-based rebate and coupon liability was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,709</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provisions for rebate and coupon programs were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12,325</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which were offset by related payments of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,616</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Contract balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A contract with a customer states the terms of the sale, including the description, quantity and price of each product purchased. Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration becomes unconditional. As payment terms are short-term, the Company does not have any significant financing components in customer contracts given the expected time between transfer of the promised products and the payment of the associated consideration is less than one year. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all amounts included in accounts receivable, net on the accompanying balance sheets are related to contracts with customers.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any contract assets nor unbilled receivables as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Sales commissions are included in selling, general and administrative expenses when incurred.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Contract liabilities reflect estimated amounts that the Company is obligated to pay to customers or patients under the rebate and coupon programs. The Company&#8217;s contract liabilities are included in accounts payable and accrued expenses in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the&#160;year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company did not recognize any revenue related to changes in transaction prices regarding its contracts with customers and did not recognize any material changes in revenue related to amounts included in contract liabilities at the beginning of the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Collectability</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accounts receivable are recorded at the invoiced amount and do not bear interest. At the time of contract inception or new customer account set-up, the Company performs a collectability assessment of the customer&#8217;s creditworthiness. The Company assesses the probability that the Company will collect the entitled consideration in exchange for the goods sold, by considering the customer&#8217;s ability and intention to pay when consideration is due. On a recurring basis, the Company estimates the amount of receivables considered uncollectable to reflect an allowance for doubtful accounts.  The Company writes off accounts receivable balances when it is determined that there is no possibility of collection. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, allowance for doubtful accounts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.  For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, provision for bad debts was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$387</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and there were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> write-offs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Practical Expedients</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company expenses sales commissions when incurred as the amortization period is one year or less. These costs are recorded within selling, general and administrative expenses in the accompanying statements of operations and comprehensive loss. The Company does not adjust the amount of promised consideration for the effects of the time value of money for contracts in which the anticipated period between when the Company transfers the goods or services to the customer and when the customer pays is within one year.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company recognizes stock-based compensation expense for employees, consultants and members of the Board of Directors based on the fair value at the date of grant.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company uses the Black-Scholes option pricing model to value stock option grants. The Black-Scholes option pricing model requires the input of subjective assumptions, including the expected volatility of the Company&#8217;s common stock, expected risk-free interest rate, and the option&#8217;s expected life. The fair value of the Company&#8217;s restricted stock units (&#8220;RSUs&#8221;) is based on the fair value of the grant date of the Company&#8217;s common stock. The Company also evaluates the impact of modifications made to the original terms of equity awards when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The fair value of equity awards that are expected to vest is amortized on a straight-line basis over the requisite service period. Stock-based compensation expense is recognized net of actual forfeitures when they occur, as an increase to additional paid-in capital in the balance sheets and in the selling, general and administrative or research and development expenses in the statements of operations and comprehensive loss.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Advertising Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Advertising costs are expensed as incurred and primarily include costs related to social media ads.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company accounts for income taxes under the asset and liability method. Under this method, deferred tax assets and liabilities are determined on the basis of differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Prior to the IPO, the Company calculated its income tax amounts using a separate return methodology and presented these amounts as if it were a separate taxpayer from Alphaeon in each jurisdiction. Subsequent to the IPO, the Company has prepared its stand-alone tax return. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A valuation allowance is recorded against deferred tax assets, to reduce the net carrying value, when it is more likely than not that some portion or all of a deferred tax asset will not be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, and ongoing prudent and feasible tax planning strategies in assessing the amount of the valuation allowance. When the Company establishes or reduces the valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is made.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Additionally, the Company recognizes the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefit recognized in the financial statements for a particular tax position is based on the largest benefit that is more likely than not to be realized upon settlement. Accordingly, the Company establishes reserves for uncertain tax positions. The Company has not recognized interest or penalties in its statement of operations and comprehensive loss.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company is required to file federal and state income tax returns in the United States and various other state jurisdictions. The preparation of these income tax returns requires the Company to interpret the applicable tax laws and regulations in effect in such jurisdictions, which could affect the amount of tax paid by the Company. An amount is accrued for the estimate of additional tax liability, including interest and penalties, for any uncertain tax positions taken or expected to be taken in an income tax return. The Company reviews and updates the accrual for uncertain tax positions as more definitive information becomes available. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s income tax returns are based on calculations and assumptions that are subject to examination by the Internal Revenue Service and other tax authorities. In addition, the calculation of the Company&#8217;s tax liabilities involves dealing with uncertainties in the application of complex tax regulations. The Company recognizes liabilities for uncertain tax positions based on a two-step process. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than&#160;50%&#160;likely of being realized upon settlement. While the Company believes it has appropriate support for the positions taken on its tax returns, the Company regularly assesses the potential outcomes of examinations by tax authorities in determining the adequacy of its provision for income taxes. The Company continually assesses the likelihood and amount of potential revisions and adjusts the income tax provision, income taxes payable and deferred taxes in the period in which the facts that give rise to a revision become known</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period including contingently issuable shares. Diluted earnings per share is based on the treasury stock method and includes the effect from potential issuance of ordinary shares, such as shares issuable pursuant to the exercise of stock options and the vesting of restricted stock units. Because the impact of the options and non-vested RSUs are anti-dilutive during periods of net loss, there was no difference between the weighted-average number of shares used to calculate basic and diluted net loss per common share for the periods presented. For the years ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recently Adopted Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the SEC adopted the final rule under SEC Release No. 33-10532, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Disclosure Update and Simplification</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements on the analysis of stockholders&#8217; equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders&#8217; equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of comprehensive income is required to be filed. This final rule was effective on November 5, 2018 and it did not have a material impact on the Company&#8217;s financial statements upon adoption on January 1, 2019.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Financial Accounting Standards Board (the &#8220;FASB&#8221;) issued&#160;ASU No. 2018-09,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which clarifies certain amendments to guidance that may have been incorrectly or inconsistently applied by certain entities and includes Amendments to Subtopic 718-740,&#160;Compensation - Stock Compensation - Income Taxes. The guidance in paragraph 718-740-35-2, as amended by the amendments in&#160;ASU 2016-09,&#160;Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, is unclear on whether an entity should recognize excess tax benefits (or tax deficiencies) for compensation expense that is taken on the entity&#8217;s tax return. The amendment to paragraph 718-740-35-2 in this update clarified that an entity should recognize excess tax benefits in the period in which the amount of deduction is determined. The Company adopted the guidance on January 1, 2019, and such adoption did not have a material impact on its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In February 2016, the FASB issued ASU No. 2016-02 and its related amendments which introduced </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 842, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8220;ASC 842&#8221;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, a new comprehensive lease accounting model that superseded the lease guidance under&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases (Topic 840)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The new accounting standard required lessees to recognize ROU assets and corresponding lease liabilities for all leases with lease terms of greater than 12 months. It also changed the definition of a lease and expanded the disclosure requirements of lease arrangements. In July 2018, the FASB added a transition option for implementation that allowed companies to continue to use the legacy guidance in ASC 840, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Leases</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, including its disclosure requirements, in the comparative periods presented in the year of adoption. The Company adopted the guidance effective January 1, 2019. The Company elected the transition package of three practical expedients and elected the optional transition method that allowed for a cumulative-effect adjustment in the period of adoption without a restatement of prior periods. Further, the Company elected a short-term lease exception policy, permitting the Company to not apply the recognition requirements of this standard to short-term leases (i.e. leases with terms of 12 months or less) and an accounting policy to account for lease and non-lease components as a single component for certain classes of assets. As a result of the adoption, the Company adjusted its beginning balance of 2019 by recording operating lease ROU assets and liabilities through a cumulative-effect adjustment. The adoption impacted the accompanying balance sheet, but did not have an impact on the statements of operations and comprehensive loss. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The impact of the adoption of ASC 842 on the accompanying balance sheet as of January 1, 2019 was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:44%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Adjustments Due to the Adoption of ASC 842</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">January 1, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Operating lease right-of-use assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,029</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current portion of operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">916</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred rent</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Recent Pronouncements&#160;Not&#160;Yet Adopted&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No. 2016-13,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">(Topic 326)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">: Measurement of Credit Losses on Financial Instruments, which modifies the measurement and recognition of credit losses for most financial assets and certain other instruments. The new standard requires the use of forward-looking expected credit loss models based on historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount, which may result in earlier recognition of credit losses under the new standard. The new guidance also modifies the impairment models for available-for-sale debt securities and for purchased financial assets with credit deterioration since their origination. Subsequent to the issuance of ASU 2016-13, the FASB issued ASU 2018-19,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Codification Improvements to Topic 326, Financial Instruments - Credit Losses</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. This ASU does not change the core principle of the guidance in ASU 2016-13, instead these amendments are intended to clarify and improve operability of certain topics included within the credit losses standard.&#160;The FASB also subsequently issued ASU No. 2019-04, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Codification Improvements to Topic 326, Financial Instruments&#8212;Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> which did not change the core principle of the guidance in ASU 2016-13 but clarified that expected recoveries of amounts previously written off and expected to be written off should be included in the valuation account and should not exceed amounts previously written off and expected to be written off. The guidance is effective for interim and annual reporting periods beginning after December 15, 2019 for public business entities, excluding entities eligible to be smaller reporting companies, and early adoption is permitted. As a smaller reporting company, the guidance will be effective for the Company during the first quarter of 2023. The Company is in the process of determining the effects adoption will have on its financial statements. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No. 2017-04,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">&#160;Intangibles&#8212;Goodwill and Other (Topic 350):&#160;Simplifying the Test for Goodwill Impairment</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The update simplifies the accounting for goodwill impairment by removing step two of the goodwill impairment test, which requires a hypothetical purchase price allocation. A goodwill impairment will be the amount by which a reporting unit&#8217;s carrying amount, including goodwill, exceeds its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. The update is effective for the Company beginning January&#160;1, 2023. The standard requires prospective application. Early adoption is permitted. The Company is evaluating the effect of this standard on its financial statements and related disclosures as well as whether to early adopt the new guidance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU 2018-13, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The update&#160;is part of the disclosure framework project and eliminates certain disclosure requirements for fair value measurements, requires entities to disclose new information, and modifies existing disclosure requirements. Under the new guidance,&#160;entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies will be required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In August 2018, the FASB issued&#160;ASU No. 2018-15,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2018-15&#160;requires implementation costs incurred by customers in cloud computing arrangements (i.e., hosting arrangements) to be capitalized under the same premises of authoritative guidance for internal-use software, and deferred over the noncancellable term of the cloud computing arrangements plus any option renewal periods that are reasonably certain to be exercised by the customer or for which the exercise is controlled by the service provider. The guidance is effective for interim and annual reporting periods during the year ending December 31, 2020. Early adoption is permitted. The Company does not expect adoption of this guidance will have a material impact to its financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In December 2019, the FASB issued&#160;ASU No. 2019-12,&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.&#160;ASU 2019-12&#160;eliminates certain exceptions for recognizing deferred taxes for investments, performing intraperiod allocation and calculating income taxes in interim periods. This ASU also includes guidance to reduce complexity in certain areas, including recognizing deferred taxes for tax goodwill and allocating taxes to members of a consolidated group. ASU 2019-12 is effective for annual and interim periods in fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating the impact this change will have on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6774298608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Stockholders&#8217; Equity (Deficit)</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Convertible Series A Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to IPO, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,500,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized, of which </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,250,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were issued and outstanding to Alphaeon. The number of shares of common stock to which a preferred stockholder was entitled was the product obtained by multiplying the Series A preferred stock conversion rate by the number of shares of preferred stock being converted, subject to adjustments as provided in the amended and restated certificate of incorporation. In connection with the IPO, all shares of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Series A preferred stock</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock. In addition, the Company also amended and restated its certificate of incorporation. As a result, shares of Series A convertible preferred stock were canceled, with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized, issued or outstanding as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Preferred Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">none</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> were issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">33,562,665</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares were issued and outstanding.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Equity Related Transactions</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of February 12, 2018, the Company assumed from Alphaeon the revised payment obligations under the Amended Purchase Agreement of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (comprised of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent royalty obligation and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related to the contingent promissory note at that date). See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for more information. Pursuant to the Amended Purchase Agreement, Alphaeon agreed to offset and reduce the amount of related party borrowings by the estimated value of the revised payment obligations on a dollar-for-dollar basis and pursuant to the services agreement (see Note 11, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). Additionally, the Company paid </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to Alphaeon in satisfaction of a portion of the outstanding related party borrowings (see </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">). The remaining balance of related party borrowings of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,188</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recharacterized as a capital contribution from Alphaeon pursuant to the services agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">2017 Omnibus Incentive Plan and Stock-based Compensation Allocation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 21, 2017, t</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">he board of directors and the then-sole stockholder of the Company approved the Company&#8217;s 2017 Omnibus Incentive Plan (the &#8220;Plan&#8221;). The Plan provides for the grant of incentive options to employees of the Company, and for the grant of nonstatutory options, restricted stock awards, restricted stock unit awards, stock appreciation rights, performance stock awards and other forms of stock compensation to the Company&#8217;s employees, including officers, directors, consultants and employees of the Company. The maximum number of shares of common stock that may be issued under the Plan is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4,361,291</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares, plus an annual increase on each anniversary of November 21, 2017 equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">4%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the total issued and outstanding shares of the Company&#8217;s common stock as of such anniversary (or such lesser number of shares as may be determined by the Company&#8217;s board of directors). On November 21, 2018 and 2019, an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,091,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1,337,821</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares, respectively, were reserved under the evergreen provision of the Plan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has available an aggregate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,249,380</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock for future issuance under the Plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Stock-Based Award Activity and Balances</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Options are granted at exercise prices based on the Company&#8217;s grant date common share price. The restricted stock units (&#8220;RSUs&#8221;) and options generally vest over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">four</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period. There have been </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> awards granted with performance conditions or market conditions for the period presented. The options generally have a contractual term of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">ten years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Black&#8209;Scholes option pricing model has various inputs, including the grant date common share price, exercise price, risk&#8209;free interest rate, volatility, expected life and dividend yield. The change of any of these inputs could significantly impact the determination of the fair value of the Company&#8217;s options as well as significantly impact its results of operations. The fair value of RSU grants is determined at the grant date based on the common share price. The Company records stock-based compensation expense net of actual forfeitures when they occur.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The significant assumptions used in the Black-Scholes option-pricing are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Determining Fair Value of the Underlying Common Stock.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;For options awards granted after the completion of the Company&#8217;s IPO, the fair value for its underlying common stock was determined using the fair value of the grant date price as reported on the Nasdaq Global Select Market. Since the Company&#8217;s common stock was not traded in a public stock market exchange prior to the Company&#8217;s IPO, prior to such date the Board of Directors considered numerous factors including new business and economic developments affecting the Company and independent appraisals, when appropriate, to determine the fair value of the Company&#8217;s common stock. Independent appraisal reports were prepared using conventional valuation techniques, such as discounted cash flow analyses, from which a discount factor for lack of marketability was applied. This determination of the fair value of the common stock was performed on a contemporaneous basis. Prior to the Company&#8217;s initial public offering, the Board of Directors determined the Company&#8217;s common stock fair market value on as needed basis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Volatility.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company has limited data regarding company&#8209;specific historical or implied volatility of its share price. Consequently, the Company estimates its volatility based on the average historical volatility of the stock price from a set of peer companies, since our shares do not have sufficient trading history. Management considers factors such as stage of life cycle, competitors, size, market capitalization and financial leverage in the selection of similar entities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Expected Term.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The expected term represents the period of time in which the options granted are expected to be outstanding. The Company estimates the expected term of options with consideration of vesting date, contractual term, and historical experience. The expected term of &#8220;plain vanilla&#8221; options is estimated based on the midpoint between the vesting date and the end of the contractual term under the simplified method permitted by the SEC implementation guidance. The weighted&#8209;average expected term of the Company&#8217;s options is approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Risk&#8209;Free Rate.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The risk&#8209;free interest rate is selected based upon the implied yields in effect at the time of the option grant on U.S. Treasury zero&#8209;coupon issues with a term approximately equal to the expected life of the option being valued.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Dividends.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;The Company does not anticipate paying cash dividends in the foreseeable future. Consequently, the Company uses an expected dividend yield rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">zero</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.32%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,321,451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(273,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(328,117</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">800,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">12.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested and expected to vest, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The aggregate intrinsic value of outstanding and exercisable options represents the excess of the fair market value of our common stock over the exercise price of underlying options as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The total intrinsic value of options exercised in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,311</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded expenses related to stock options of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$8,302</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,099</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,529</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of total unrecognized compensation cost, net of actual forfeitures, related to stock option-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.6 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSUs activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(25,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">229,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15.89</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">During the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company recorded expenses related to restricted stock units of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,216</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,304</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Total fair value of RSUs vested during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$357</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$771</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. As of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, there was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,377</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of total unrecognized compensation cost, net of actual forfeitures, related to RSU-based compensation arrangements granted under the Plan. The cost is expected to be recognized over a weighted-average period of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0.7 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, during the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">106</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, of stock-based compensation expense in capitalized software. Capitalized software is a component of intangible assets and is presented in the accompanying condensed balance sheets. See </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 4</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for capitalized  software information. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Separation of Service with the Former President and Chief Executive Officer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In May 2018, the Company entered into a separation agreement (the &#8220;Separation Agreement&#8221;) with its then President and Chief Executive Officer. Pursuant to the Separation Agreement, the Company modified previously </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">granted stock options resulting in an incremental vesting of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,424</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> stock options and related stock-based compensation expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$451</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As part of the Separation Agreement, the Company issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">34,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock net of tax withholding for vested restricted stock units. An additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50,112</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock were immediately vested and will be issued in February 2020. Stock-based compensation expense relating to the issuance of common stock and accelerated vesting was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$980</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and reflected in selling, general and administrative on the statements of operations and comprehensive loss for the year ended December 31, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959392896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Goodwill and Intangible Assets</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">63,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">84,699</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80,846</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">    ________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">     *   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying balance sheets.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">41,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the acquisition of the Company by SCH in 2013, the Company recorded goodwill of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$21,208</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and IPR&amp;D of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,076</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The IPR&amp;D recognized represents the license and associated distribution right to develop Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the initial term of which expires in September 2023 and is automatically extended for unlimited additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year terms provided that the Company meets certain performance requirements. Additionally, pursuant to the Daewoong Agreement, up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in additional cash consideration was due to Daewoong based upon the Company&#8217;s successful completion of certain technical and sales milestones. Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;on February 1, 2019, the Company paid Daewoong a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment which increased the cost basis of the IPR&amp;D, and the IPR&amp;D project was completed and reclassified as a definite-lived distribution right intangible asset, which is amortized on a straight-line basis over the estimated useful life of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20 years</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In connection with EU approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company paid a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> milestone payment to Daewoong in the fourth quarter of fiscal year 2019, which also increased the cost basis of the distribution right. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company capitalized </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,415</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively, related to costs of computer software developed for internal use. The software is amortized over a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year period using the straight-line method. For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, total intangible assets amortization expense of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$3,853</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was recorded within depreciation and amortization on the accompanying statements of operations and comprehensive loss, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6789302096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Reconciliation of Fair Value Measurement of Contingent Royalty Obligation Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayable', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">$ 4,160<span></span>
</td>
<td class="nump">$ 10,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember', window );">Contingent Royalty Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">50,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(9,677)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Assumption of the royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RevaluationofContingentRoyaltyObligationPayable', window );">Change in fair value recorded in operating expenses</a></td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 44,683<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RevaluationofContingentRoyaltyObligationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revaluation of Contingent Royalty Obligation Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RevaluationofContingentRoyaltyObligationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=eols_ContingentRoyaltyObligationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6660874768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">$ 5,794<span></span>
</td>
<td class="nump">$ 931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and related benefits</a></td>
<td class="nump">5,229<span></span>
</td>
<td class="nump">2,577<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">Accrued volume-based rebate and coupon liability</a></td>
<td class="nump">1,709<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,228<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 13,960<span></span>
</td>
<td class="nump">$ 3,718<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782041760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Current and Deferred Income Tax Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The current and deferred expense is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current provision</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred (benefit) provision </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total (benefit) provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">42,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other deferred assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent obligation - imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(36,972</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(32,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12,970</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fixed asset depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,905</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">California NOL write-off</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in state tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6697452784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Accrued expenses consisted of the following:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued professional services</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,794</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">931</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued payroll and related benefits</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,229</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,577</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued volume-based rebate and coupon liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,709</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">13,960</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,718</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6658942112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Payments Under Non-cancelable Operating Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Operating leases, future minimum payments due</a></td>
<td class="nump">$ 1,029<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6789548432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Schedule of Restricted Stock Unit Activity (Details) - RSUs<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Restricted Stock Unit Activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">271,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(25,125)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(19,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">229,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">18.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">24.81<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">13.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.89<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6774461408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,435<span></span>
</td>
<td class="nump">$ 2,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases to current year tax positions</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,761<span></span>
</td>
<td class="nump">$ 2,435<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959355664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Current and Deferred Tax Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred (benefit) provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(10,299)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(4,756)<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred (benefit) provision</a></td>
<td class="num">(15,055)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total (benefit) provision for income taxes</a></td>
<td class="num">$ (15,027)<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793807472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (90,034)<span></span>
</td>
<td class="num">$ (46,867)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">4,132<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,518<span></span>
</td>
<td class="nump">6,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProvisionsForRebateAndCouponPrograms', window );">Provisions for rebate and coupon programs</a></td>
<td class="nump">12,325<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="nump">387<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on short-term investments</a></td>
<td class="num">(1,038)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_OperatingLeaseRightofUseAssetAmortization', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and issuance costs</a></td>
<td class="nump">2,156<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(15,055)<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Revaluation of contingent royalty obligation to Evolus Founders</a></td>
<td class="nump">4,160<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(4,482)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(11,048)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,874)<span></span>
</td>
<td class="num">(992)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(2,742)<span></span>
</td>
<td class="nump">2,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(654)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredLiabilities', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(190)<span></span>
</td>
<td class="num">(211)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(93,383)<span></span>
</td>
<td class="num">(25,667)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(345)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForSoftware', window );">Additions to capitalized software</a></td>
<td class="num">(4,222)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(113,867)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">95,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(23,434)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_PaymentsOfContingentRoyaltyObligation', window );">Payment of contingent royalty obligation to Evolus Founders</a></td>
<td class="num">(9,677)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentsForIntangibleAssets', window );">Milestone payment for intangible assets</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt, net of discounts</a></td>
<td class="nump">73,906<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="num">(2,205)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment for debt obligation</a></td>
<td class="num">(1,044)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from initial public offering, net of underwriting fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">56,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from follow-on offering, net of underwriting fees</a></td>
<td class="nump">73,315<span></span>
</td>
<td class="nump">67,680<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments for offering costs</a></td>
<td class="num">(203)<span></span>
</td>
<td class="num">(1,060)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan', window );">Issuance of common stock in connection with incentive equity plan</a></td>
<td class="nump">2,455<span></span>
</td>
<td class="num">(239)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">133,547<span></span>
</td>
<td class="nump">118,838<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Change in cash and cash equivalents</a></td>
<td class="nump">16,730<span></span>
</td>
<td class="nump">93,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">93,162<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">109,892<span></span>
</td>
<td class="nump">93,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">5,166<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Related party receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(68,767)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashNoteObligation', window );">Note obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(140,688)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentPromissoryNote', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionConvertibleNoteWriteOff', window );">Capital contribution from Parent, convertible note write-off</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66,998<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,188<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashDeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,885)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AccountsPayablePaidbyParent', window );">Accounts payable, paid by Parent</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">5,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashLandlordPaidTenantImprovement', window );">Landlord paid tenant improvements</a></td>
<td class="nump">781<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashFinanceAndInsurancePayment', window );">Financed D &amp; O insurance payment</a></td>
<td class="nump">1,561<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capitalized software recorded in accounts payable and accrued expenses</a></td>
<td class="nump">87<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashAccruedandUnpaidOfferingCosts', window );">Accrued offering costs, unpaid</a></td>
<td class="num">$ (90)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AccountsPayablePaidbyParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Paid by Parent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AccountsPayablePaidbyParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionConvertibleNoteWriteOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Convertible Note Write-Off</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionConvertibleNoteWriteOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Forgiveness of Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionForgivenessofRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentPromissoryNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Promissory Note</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentPromissoryNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentsForIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payments For Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentsForIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashAccruedandUnpaidOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Accrued and Unpaid Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashAccruedandUnpaidOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Deferred Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashFinanceAndInsurancePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Finance And Insurance Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashFinanceAndInsurancePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashLandlordPaidTenantImprovement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Landlord Paid Tenant Improvement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashLandlordPaidTenantImprovement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashNoteObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Note Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashNoteObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_OperatingLeaseRightofUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_OperatingLeaseRightofUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_PaymentsOfContingentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments Of Contingent Royalty Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_PaymentsOfContingentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From (Payments For) Issuance Of Common Stock In Connection With Equity Incentive Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProvisionsForRebateAndCouponPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Rebate And Coupon Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProvisionsForRebateAndCouponPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6789171408">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 109,892<span></span>
</td>
<td class="nump">$ 93,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">19,911<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">10,661<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">6,407<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,326<span></span>
</td>
<td class="nump">1,177<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">152,197<span></span>
</td>
<td class="nump">94,339<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">902<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,068<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">59,638<span></span>
</td>
<td class="nump">56,076<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,429<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">240,442<span></span>
</td>
<td class="nump">171,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">5,796<span></span>
</td>
<td class="nump">1,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">13,960<span></span>
</td>
<td class="nump">3,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">3,483<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">24,439<span></span>
</td>
<td class="nump">5,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,893<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">41,200<span></span>
</td>
<td class="nump">50,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">17,945<span></span>
</td>
<td class="nump">16,904<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of discounts and issuance costs</a></td>
<td class="nump">73,508<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">160,985<span></span>
</td>
<td class="nump">87,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.00001 par value; 10,000,000 shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.00001 par value; 100,000,000 shares authorized; 33,562,665 and 27,274,991 shares issued and outstanding at December 31, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">292,509<span></span>
</td>
<td class="nump">207,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive gain</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(213,059)<span></span>
</td>
<td class="num">(123,025)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">79,457<span></span>
</td>
<td class="nump">84,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 240,442<span></span>
</td>
<td class="nump">$ 171,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Royalty Obligation Payable to Related Party, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ContingentRoyaltyObligationPayabletoRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6636592704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Oxford Term Loans - Maturities of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2022</a></td>
<td class="nump">$ 26,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2023</a></td>
<td class="nump">39,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2024</a></td>
<td class="nump">9,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal payments</a></td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Unamortized debt discounts and issuance costs</a></td>
<td class="num">(1,492)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long term debt, net of discounts and issuance costs</a></td>
<td class="nump">$ 73,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779984896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 19,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">19,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S treasury securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">44,683<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Contingent royalty obligation payable to Evolus Founders | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 44,683<span></span>
</td>
<td class="nump">$ 50,200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6774255808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Estimated Future Amortization Expense of Intangibles (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 5,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">3,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">2,955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">41,621<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="nump">$ 59,638<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779427488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Income Taxes</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s loss before income taxes was entirely generated from its U.S. operations. The current and deferred expense is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Current provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total current provision</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred (benefit) provision:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Federal </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(10,299</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(4,756</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred (benefit) provision </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total (benefit) provision for income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal net operating loss (&#8220;NOL&#8221;) carryforwards of $</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">179,589</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2034. The federal NOLs generated in 2018 and in the subsequent years do not expire. </font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">,</font><font style="font-family:Times New Roman;font-size:11pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">the Company has state NOL carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$94,118</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2038. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has federal research and development (&#8220;R&amp;D&#8221;) credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,377</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which will begin to expire in 2034. The Company also has California R&amp;D credit carryforwards of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which has an indefinite carryforward period. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The NOL and the R&amp;D credit carryforwards generated by the Company in tax years ended February 11, 2018 and prior have been included in the consolidated and unitary income tax returns of Alphaeon. After the Company left the Alphaeon consolidated and unitary income tax group on February 11, 2018, the Company files its own standalone income tax returns. Deferred tax assets in the accompanying financial statements reflect the Company's standalone tax attributes that are reportable on its own income tax returns.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In general, if a company experiences a greater than 50 percentage point aggregate change in ownership of certain significant stockholders over a three-year period, utilization of its pre-change NOL carryforwards and R&amp;D credit carryforwards is subject to an annual limitation under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and similar state laws. The annual limitation generally is determined by multiplying the value of the Company&#8217;s stock at the time of such ownership change, subject to certain adjustments, by the applicable long-term tax-exempt rate. The annual limitations may result in the expiration of NOL and R&amp;D credit carryforwards before utilization and may be material. The Company has started but has not completed an analysis to determine whether its NOL and R&amp;D credits generated through  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> are likely to be limited by Section&#160;382 and 383. The Company anticipates that an ownership change as defined under Section&#160;382 may have occurred and that the resulting limitation would significantly reduce the Company&#8217;s ability to utilize its NOL and R&amp;D credit carryforwards before they expire. Additionally, future ownership changes under Section&#160;382 and 383 may also limit the Company's ability to fully utilize any remaining tax benefits. The Company&#8217;s net deferred income tax assets have been offset by a valuation allowance. Therefore, any resulting reduction to the Company&#8217;s NOL and R&amp;D credit carryforwards once the analysis is complete will be offset by a corresponding reduction of the valuation allowance and there would be no impact on the Company&#8217;s balance sheet, statement of operations, or cash flows.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The components of deferred tax assets and liabilities were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net operating losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">42,756</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">27,929</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,430</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other deferred assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,470</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,176</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Accrued compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,962</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">608</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent obligation - imputed interest</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">199</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">101</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">12</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(36,972</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(32,280</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">14,131</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(12,970</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Operating lease right-of-use assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,017</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fixed asset depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(144</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(14,131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Net deferred income taxes</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,055</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in February 2019, the Company&#8217;s IPR&amp;D intangible asset was reclassified to a definite-lived distribution right intangible asset. As a result, management determined that it was more likely than not that certain deferred tax assets became realizable due to the future reversals of the deferred tax liability associated with such intangible asset. Accordingly, the Company released </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15,055</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of its valuation allowance for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The total valuation allowance balance did not significantly change in 2019 due to the increase related to the current year operating loss as offset by the release as discussed above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the difference between the provision (benefit) for income taxes and income taxes at the statutory U.S. federal income tax rate is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(22,063</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,828</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">State income taxes, net of Federal benefit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,905</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,148</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">California NOL write-off</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,174</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Revaluation of contingent royalty obligation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,040</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,938</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Meals and entertainment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,002</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in state tax rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,371</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Stock compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">521</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">474</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Research and development tax credit</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(294</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Promissory note - debt discount</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">128</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">105</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Other, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,691</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9,801</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Income tax provision (benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(15,027</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">65</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.01587301587301%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,109</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Increases to current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">326</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,761</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,435</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has considered the amounts and probabilities of the outcomes that can be realized upon ultimate settlement with the tax authorities and determined unrecognized tax benefits primarily related to credits should be established as noted in the summary rollforward above.  The Company&#8217;s effective income tax rate would not be impacted if the unrecognized tax benefits are recognized. Additional amounts in the summary rollforward could impact the Company&#8217;s effective tax rate if it did not maintain a full valuation allowance on its net deferred tax assets. The Company does not expect its unrecognized tax benefits to change significantly over the next 12&#160;months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s policy is to recognize interest expense and penalties related to income tax matters as a component of income tax expense. There were </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> accrued interest and penalties associated with uncertain tax positions as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company&#8217;s tax returns for all years since inception are open for audit.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6642603616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Oxford Term Loans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Oxford Term Loans</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Oxford Term Loans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On March 15, 2019, the Company entered into a credit facility of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$100,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> with Oxford. Pursuant to the terms of the credit facility, the lender extended term loans (the &#8220;Term Loans&#8221;), available in </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">two</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> advances, to the Company. The first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was funded on the closing date. The second tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> may be drawn, at the request of the Company, no later than September 30, 2020, upon achieving specified minimum net sales milestones based on a trailing </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month basis and no event of default. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had not yet met the net sales milestone to draw the second tranche. The credit facility bears an annual interest rate equal to the greater of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, or the 30-day U.S. Dollar LIBOR rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">7.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The Company agreed to pay interest-only on each tranche funded for the first </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> until May 2022, which is followed by a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">23</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period. Notwithstanding the foregoing, if the Company maintains compliance with the specified minimum net sales covenant and meets other conditions during the initial interest-only period, upon the Company&#8217;s request, the interest-only period may be extended by an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to a total of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">48 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> followed by an </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month amortization period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Upon the earliest to occur of the maturity date, the acceleration of the term loans, or the prepayment of the term loans, the Company is required to pay to Oxford a final payment of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.5%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the full principal amount of the term loans funded (&#8220;Final Payment&#8221;). The Company may elect to prepay all amounts owed prior to the maturity date, provided that a prepayment fee is also paid, which shall be equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs on or prior to March 15, 2020, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs after March 15, 2020 and on or prior to March 15, 2021, or </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of the amount prepaid if the prepayment occurs thereafter (&#8220;Prepayment Fee&#8221;).  If the Term Loans are accelerated following the occurrence of an event of default, the Company is required to immediately pay to Oxford an amount equal to the sum of all outstanding principal of the term loans plus accrued and unpaid interest thereon through the prepayment date, the Final Payment, the Prepayment Fee and all other obligations that are due and payable, including payment of Oxford&#8217;s expenses and interest at the default rate with respect to any past due amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility is secured by substantially all of the Company&#8217;s assets. The credit facility includes affirmative and negative covenants applicable to the Company and any subsidiaries it may create in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal corporate existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain requirements regarding deposit accounts. The negative covenants include, among others, restrictions on us transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets and suffering a change in control, in each case subject to certain exceptions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The credit facility also includes events of default, the occurrence and continuation of which could cause interest to be charged at a default interest rate equal to the applicable rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and Oxford, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including foreclosure against the property securing the credit facility, including the Company&#8217;s cash. These events of default include, among other things, any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness and one or more judgments against the Company, the institution of certain temporary or permanent relief in connection with pending litigation, or the breach, termination or other adverse events under the Daewoong Agreement. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company was in compliance with its debt covenants.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">At the closing date, the Company incurred </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,094</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,205</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in debt discounts and issuance costs related to the Term Loans, respectively. Debt&#160;discounts and issuance costs related to the entire Term Loans have been allocated pro rata between the funded and unfunded portions. Debt&#160;discounts and issuance costs allocated to the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> have been presented as a deduction to the debt balance and are amortized into interest expense using the effective interest method. The Final Payment on the first tranche of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,125</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and amortized into interest expense over the life of the term loan. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the borrowings outstanding under the Term Loans were classified as long-term debt in the accompanying balance sheets. Debt discounts and issuance costs associated with the unfunded tranche are deferred as assets until the tranche is drawn and are amortized into interest expense using the straight-line method over the term of the debt. The overall effective interest rate was approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">11.6%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the principal amounts of long-term debt maturities during each of the next five fiscal years are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:70%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:28%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">26,087</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,130</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total principal payments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">75,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Unamortized debt discounts and issuance costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(1,492</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Long term debt, net of discounts and issuance costs</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">73,508</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6604850368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Composition of Lease Expense and Other Quantitative Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.0</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity of Operating Lease Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.27777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,366</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Payments Under Non-cancelable Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.48412698412699%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779271104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Short-term Investments Available-for-sale</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company did not have any short-term investments for the year ended </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, all of the Company&#8217;s investments had remaining maturities of less than 12 months. The following is a summary of the Company&#8217;s short-term investments, considered available-for-sale, as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Amortized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gross Unrealized</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Estimated</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,905</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company measures and reports certain financial instruments as assets and liabilities at fair value on a recurring basis. The fair value of these instruments was as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Available-for-sale debt securities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">U.S treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">19,911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.60317460317461%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December&#160;31, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Liabilities</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Contingent royalty obligation payable to Evolus Founders</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Reconciliation of Fair Value Measurement for Contingent Royalty Obligation Payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table shows a reconciliation of the beginning and ending fair value measurements of the contingent royalty obligation payable:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, beginning of period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Payments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(9,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Assumption of the royalty obligation payable to Evolus Founders</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">39,700</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Change in fair value recorded in operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,160</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">10,500</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Fair value, end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">44,683</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">50,200</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6793308704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>unit </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,925,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentCurrent', window );">Accrued volume-based rebate and coupon liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,709,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued volume-based rebate and coupon liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,229,000<span></span>
</td>
<td class="nump">2,577,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_ProvisionsForRebateAndCouponPrograms', window );">Provisions for rebate and coupon programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,325,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RebatesAndCouponsCreditsAndPayments', window );">Payments for accrued rebates and coupon liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,616,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for bad debts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">387,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs', window );">Write-offs of allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,407,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember', window );">Software development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful lives of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,977,401<span></span>
</td>
<td class="nump">3,257,801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Securities excluded from the computation of diluted net loss per share (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179,758<span></span>
</td>
<td class="nump">221,292<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk | Revenue From Contract with Customer Benchmark | Service revenue | CANADA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_ProvisionsForRebateAndCouponPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provisions For Rebate And Coupon Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_ProvisionsForRebateAndCouponPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RebatesAndCouponsCreditsAndPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rebates And Coupons, Credits And Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RebatesAndCouponsCreditsAndPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loans and leases that have been written off from both loan receivables and allowance reserve for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=SL6953423-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.7(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForLoanAndLeaseLossesWriteOffs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=119407570&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959349648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contributions to 401(k) plan</a></td>
<td class="nump">$ 479<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6655122784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Components of Lease Expense and Other Quantitative Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Fixed operating lease expense</a></td>
<td class="nump">$ 1,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable operating lease expense</a></td>
<td class="nump">110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term operating lease expense</a></td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease expense</a></td>
<td class="nump">$ 1,275<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6717046896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Key Valuation Assumptions (Details) - Options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">59.32%<span></span>
</td>
<td class="nump">57.76%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">2.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">6 years 2 months 1 day<span></span>
</td>
<td class="text">6 years 2 months 27 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6794955760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Impact of Adoption of ASC 842 on Balance Sheet (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 4,068<span></span>
</td>
<td class="nump">$ 1,029<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">3,893<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Adjustments Due to the Adoption of ASC 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6642603616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumptions Used to Determine Fair Value of Options Granted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The weighted-averages for key assumptions used in determining the fair value of stock options granted were as follows:    </font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Volatility</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59.32%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">57.76%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.42%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2.65%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Expected life (years)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6.24</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Dividend yield rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">&#8212;%</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Options Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of stock option activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Weighted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Remaining</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Aggregate</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Exercise</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Contractual</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Intrinsic</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Per Share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Terms (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,257,801</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">11.99</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.26</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,119</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,321,451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.63</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(273,734</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9.98</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Cancelled/forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(328,117</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">15.15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Exercisable, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">800,595</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">12.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.28</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,880</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested and expected to vest, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,977,401</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">14.07</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8.51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">7,198</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of RSUs Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">A summary of RSUs activity under the Plan for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, is presented below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Restricted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Average</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Grant Date</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Units</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">271,404</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">16.53</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Granted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">18.33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Vested</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(25,125</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">24.81</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Forfeited</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">(19,409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">13.71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Outstanding, December 31, 2019</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">229,870</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">15.89</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table summarizes stock-based compensation expense arising from the above Plan:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Selling, general and administrative</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">8,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,570</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">656</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,401</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">9,518</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">6,971</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6957354736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The table below shows the weighted-average life, original cost, accumulated amortization and net book value by major intangible asset classification:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:18%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Definite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Distribution right</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(2,679</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,397</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Capitalized software</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">4,415</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,174</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,241</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Intangible assets, net</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">63,491</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">59,638</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible asset</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2019</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">84,699</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(3,853</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">80,846</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:30%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Weighted-Average Life (Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Original Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Accumulated Amortization</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Net Book Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;">Indefinite-lived intangible assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">IPR&amp;D**</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">56,076</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Goodwill</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">21,208</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total as of December 31, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">77,284</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">    ________________________</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:0px;text-indent:48px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">     *   Intangible assets with indefinite lives have an indeterminable average life.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:60px;font-size:8pt;"><font style="font-family:Times New Roman;font-size:8pt;color:#000000;">** IPR&amp;D is presented as &#8220;intangible assets, net&#8221; in the accompanying balance sheets.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense of Intangible Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table outlines the estimated future amortization expense related to intangible assets held as of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> that are subject to amortization:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:57.14285714285714%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:57%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:41%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,423</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">3,729</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2,955</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2024</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">2,955</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">41,621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">59,638</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>68
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O*FR=-GOSCXTO@ET+O^ZB^P)02P,$%     @ ^(!94)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M!!-2P?U/H+L9.-(0$_(-?@,0Z&]&?!$$0W$5BM\!%/J;>7]Z&PP3^-NC^!U
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MVE=5&[HVU:<NO4/(=[>+(NS;_C3MSNOKCM_UHJW.XVYF<MM27?T'4$L#!!0
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MUTE_=?8-AMOA6>",;Y/\/U!+ P04    " #X@%E0_+\9J= #  "]$   &
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MO%@E'YR X+>\H%XDWO."C!.#1N7;,2H0B?#,,G@(!-2.PG: L:,P1QB59\$
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MSG&JQ8;F277+MK00_ZQ8F2=<#,NU4VU+FBP;49XYR'5#)T_2PAX-FFMOY6C
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M*O,*,5J=9P"#M#K/(>949T<TN^LX@CN.F@B!$D'O0LO@ABD:1O/Q:!(H0E%
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MKKO8.\P^],WT%*O[X\,F/G3#U]!_;PYW. X/7;V?[J<LCY=D;O\'4$L#!!0
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M+AP_^[,9QVPT'';3#V+S-RY> 5!+ P04    " #X@%E0C@^EF;0!  #2 P
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M9SN-V61XT\\_B"W?N/P%4$L#!!0    ( /B 65 9"GDPM0$  -(#   9
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M=V]R:W-H965T<R]S:&5E=#$S+GAM;'U3VV[;, S]%4$?4"5*NJ:!;:#I,&S
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MG7_9V/\:T8%/);GQ(]3Z#[88"FH7CI_\V4QC-AD.^_D'L>4;%W\ 4$L#!!0
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M#)N? 6=G?J5!4*#4&/8_ ^;.1M>#0*%JPRV  7]GHVI#H%"UX2[ @,4SO]=
M4*#9,-P(&'!Y-JH# ,I#=8![ 0-&ST=U@$"!.B#<#0@8?613" K4 >%N0,#I
MN5\'$!2H \+M@(#3TZFO T!YH.T0;@<$K)[[;0>" FV'<#\@8/5)ZNL@D#_S
M)'<C5B74R0V7.MK+2^TFV[O=88#=D!O1_L&[Z?<[5Z>BUM&K-';0<^/844HC
M[%G2!]LSSG;@'A:E.)KV=6;?53=U=@LCFWZB3H:Q?OT74$L#!!0    ( /B
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M#[8:"AH?CG=XMO.8S88WP_*#V/J-RS]02P,$%     @ ^(!94,\4C)[3 0
MG 0  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL;51A;]L@$/TKB!]0
M$I(X:61;:CI-F[1)4:>MGXE]ME'!>(#C]M\7L.NY&5\,=[Q[[P[?D0Y*OY@&
MP*)7*5J3X<;:[DB(*1J0S-RI#EIW4BDMF76FKHGI-+ R!$E!Z&J5$,EXB_,T
M^,XZ3U5O!6_AK)'II63Z[01"#1E>XP_'$Z\;ZQTD3SM6PR^PO[NS=A:964HN
MH35<M4A#E>&']?&4>'P _.$PF,4>^4HN2KUXXWN9X95/" 04UC,PMUSA$83P
M1"Z-OQ,GGB5]X'+_P?XUU.YJN3 #CTH\\](V&3Y@5$+%>F&?U/ -IGIV&$W%
M_X K" ?WF3B-0@D3OJCHC55R8G&I2/8ZKKP-ZS">[),I+!Y IP Z!QR"#AF%
M0N9?F&5YJM6 ]'CW'?._>'VD[FX*[PQ7$<Y<\L9YKSG=;U)R]403YC1BZ *S
MGA'$L<\2-"9QHO^%TWCX)IKA)H1OENKWASC!-DJP#03;3R5N;TJ,879QD5U4
M9!<A2&Y$8IA]7"2)BB01@L.-2 QS?R-"%MTA0==A+@PJ5-^&F5QXY]%[H*&[
M_L''N?W)=,U;@R[*NAX-G50I9<&ELKIS!3?NJ9@- 97UV[W;ZW%@1L.J;GH+
MR/P@Y>]02P,$%     @ ^(!94+VSN93> 0   04  !D   !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL=53KCIP@%'X5P@,LRLSH9*(F.]LT;=(FDVW:_F;T
M>,F"6,!Q^_8%=*V=LG^$<_@NYR"035*]Z!; H%?!>YWCUICA1(@N6Q!,/\@!
M>KM22R68L:%JB!X4L,J3!"<TBA(B6-?C(O.YBRHR.1K>]7!12(]",/7[#%Q.
M.8[Q6^*Y:UKC$J3(!M; -S#?AXNR$5E5JDY KSO9(P5UCA_CTSEU> _XT<&D
M-W/D.KE*^>*"SU6.(U<0<"B-4V!VN,$3<.Z$;!F_%DV\6CKB=OZF_M'W;GNY
M,@U/DO_L*M/F^(A1!34;N7F6TR=8^CE@M#3_!6[ +=Q58CU*R;7_HG+41HI%
MQ98BV.L\=KT?IWDE319:F$ 7 ET)1^]#9B-?^0=F6)$I.2$U[_W W"^.3]3N
M3>F2?BO\FBU>V^RMH,<H(S<GM&#.,X9N,/&*(%9]M: ABS/]CT[#]%VPPIVG
M[[;TZ!W_?5!@[P7V_[08W[48PKQ3Y2%H<@@([.Y,0IA]V"0)FB0!@<.=20B3
MA$W2H$D:$$CO3$*8XYT)V1Q! :KQET^C4HZ]O_B;['J_'ZD_PG_A\^/PE:FF
MZS6Z2F,O@C^NM90&;"G1@]W5UKY':\"A-FZ:VKF:;^4<&#DL#PY97[WB#U!+
M P04    " #X@%E00ZSAWM\!   !!0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R-BYX;6QU5.N.G" 4?A7" RP.,Z.S$S79V:9IDS:9;-/V-Z/'2Q;$ H[;
MMR^@:XVE?X1S^"[G()".4KWJ!L"@-\$[G>'&F/Y,B"X:$$P_R!XZNU)))9BQ
MH:J)[A6PTI,$)S2*8B)8V^$\];FKRE,Y&-YV<%5(#T(P]?L"7(X9WN'WQ$M;
M-\8E2)[VK(9O8+[W5V4CLJB4K8!.M[)#"JH,/^W.E\3A/>!'"Z->S9'KY";E
MJPL^EQF.7$' H3!.@=GA#L_ N1.R9?R:-?%BZ8CK^;OZ1]^[[>7&-#Q+_K,M
M39/A$T8E5&S@YD6.GV#NYXC1W/P7N .W<%>)]2@DU_Z+BD$;*6856XI@;]/8
M=GX<IY4XGFEA IT)="&<O ^9C'SE'YAA>:KDB-2T]SUSOWAWIG9O"I?T6^'7
M;/':9N\Y/3VFY.Z$9LQEPM 59K<@B%5?+&C(XD+_H=,P?1^L<._I^S4]2L("
MAZ# P0L<U@*/T:;%$.8_31Z#)L>  -V8A##[L$D<-(D# H>-20AS#)LD09,D
M(!!O3$*8[3\AJR,H0-7^\FE4R*'S%W^57>[W$_5'^"]\>AR^,E6WG48W:>Q%
M\,>UDM* +25ZL+O:V/=H"3A4QDT3.U?3K9P"(_OYP2'+JY?_ 5!+ P04
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MBZ;[ZZV/C9+ED$53*;/7_IA7W?$TY'\+PP-@"( Q@(87 ]@0P,8 1B\&A$-
M. 9 ?#& #P'\?T _WK[W;ICWF<H6LUJ>O+I_'PY9^]K16ZX?U[J]V3V=[C<]
MST;??5DP1F?!2YMHP-SU&)A@8(I98A@VQ=QCF'"*66$8/F("W<O8$* -09>
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M5)&[#OCJ'\6D7&SYC2\/Y;.WS ^C%-R$D,)L>XPWPGA31*XC_' UQ>P,F'B
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MV'Y1\+UN;E-S+]LQKEUH47<C:M#/R<M_4$L#!!0    ( /B 65!']YD96P(
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MQT94ROX/-B>E1>VRF%)J]MY=R\9>+]V3C+@P.("X -('&.Y[ ;$+B*\!Z=T
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MI#1@"<,'VVYM7X4IX% 9-WVT<S7<C2$PLANO/9[>GOP?4$L#!!0    ( /B
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M\BU4CW(J4TXYY<C8;E(V.UI;1\[%?#B0/'F3IDJFU*0P,<TDG)2._3@9RTI
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MQHJY_$?&)*@BO2=U6I7Z'HP; D>IEZE:\WXH]AO)VF'@H_&K4_P#4$L#!!0
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M C.,@9T4F0R#(I-AS&;80Y1D2>JN"E., 4!93R@4F4_H*+K<'"=THW4PPQC
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M8*)=TP^/@$>XWF0EKO%SOJV;#H>:&$.>_P)GVA9T5Y@PIL:]S\ORF;'^4I?
MG[)&]GE 73_54QLJ!^PG?=UEW9 \_RL?_$I&^"O,[O#GJGZ$8\FSMJ[@"#^T
M;3]YAA^J+D>^4#SD2$>9SB%^_$U69M4JQ_7G71LSPR_W==_"H0^F9=G=^10]
M9VT+8P[^FK7WQ(M7^$/^][YXR$IX?/#@]3ULUB$L8P-3><C;;C/V%! U2HTV
M:?)5#D/=E'F:5/E@H1]@B*JKFV*XQY^:?)L5ZR3_!M*E!5K'V=7=/9#9:N=2
MOM0=W-?=SWQJ0&8U<"(X**YVB\L8G>+'+5Y.)(\2SCA/FN+NOCNL;P][^,?X
MZ'#,6757P*+E@=&!_UC7ZT>0:X,/TAIWK6WB"&7%/Q3935'"[1KNJ3N6;?:$
M9S+R=[CD?L^?VXMR^E-7();A09Q04S]E)>QU#9SHCB6D?#_IZN3= US@%B1#
M#SQZ>'W#T]SO@]NFWA1M"\PVJ>HN?\'7?JBK.R;N=7[#])#4M\D:9 !O'-(+
M#-W3]5S5[? 8WN:W.4QVG739-S?? ?-R3XU=?U[SSK5N-@7?/+ZTNO85/)P<
M_(2+/GL=O87*VW?M-EOE__$;T,[:O'G(?_.'9'#!4<#<UR5NS__\?\^7B[/O
MZ88,UP W5!8A0NG5?#9'@0H;WB3 /_K\^V0Q3^%7^-^D99F5]1WPD.(?^?I[
M.![]+6XJC$27W NU).L2X&KYY@:NA"IR]%#\V_,4MK+=YL1<R\%<0^DY/M&=
M,STZ2D%)2$]/3^CSR[-T>7:<7EPL_IL6<+E>D\ $PD"V> AR8)5M"R"4D4O<
M;_J2% KAER! F_P>KC0*GCO0PW>]L\YOBU4Q093MWM0Q(&):]?[O1S+PX%.&
M5^4^[PI0QUZ#3'R5_$[V?E2S7RS'Y2 *^9Q44[C8[XL*/E*@@EJ+0C*MO'MZ
M;YF,'/4D!W <Z[HLLP9X*^PXS2N^@,,!!G1& _%O]WY;".\7O&GI=,?K<G=^
MX:+#MU^TXK%7TSW6._[>GJMU]-$B@8C$ ].3R/<JN$D_U.W^RMGG'%2=/O]N
M_)Z@H&GXB3%E9=VO.A(W.*<6-#.X$/FW5=FO<3,WJ+_^@R4K_+V(U8_!&D'1
MAYF#F+P=WG,OXU4+&$SY&O1>>"!-0.+D:%[AUF3K35&1N88,;+CZ%@RH%>N8
M:UAH69/*-;)+0%MN*:N=6L3S\OQM#L<%]YL>IUF:O1H_B7JP_J&2 )MW"SJ&
M/COBF& EKJB ]>9X5#32Z\%.DD$ 2K0\.?EG&6!T)C?Y;=WD^BW0.H8S_N#^
MEAS<P)G!L;^>&O,GH,02QAU?T5"4#-;TM6KRK*2[C7]/<.<?LJ)$%>P0IGJ(
M])NT.>AT)!><E@73&[G)YG-CT]+I>@Z4)C=9"R8O45I1]ITPB^=9U5]SU.WS
M]6'V .=ZEX_Q2=#ZUTAXN!$P],BWJL&,=O-FOMQR^4<MA6M0U0H0A?+,;HYE
M];=_2]Z1;$T.WK)01[FY6"8;]IGEZ#-+ B?9WNR,+LN SCY]',ABV/7Z\1"(
MX.,M"*$11T6D1L)B45FX3*+?[]+H=OUM9$[VS\_/SVA>G] @_5 E5Q.:U^23
M(Y.8?GB/*1EUC>]E>%'^^(R*]W9<Q7N3WQ55A51^(\J7(5S19*<=#,.WGWL#
MV%)#=B20)__T&FENE(+_UV?8%>#SS6/6K >JV0<UR4AF>.F_Z^9-O3-J$!W"
M/<_7=.MACT?%QQ2#'/J"UGMN\<"K&KWZW.,A8R 7SWN@K/UU%GKEEEZQ\@[-
M&C13QGT,Z[_UXA5"/@GBMP8-&SB^XXOP6_R9/$W$3E%(C(P\D"S *Q^*EI0Q
MD",P] VL3PS@?HMNA::^:[+-F ;%+])[-]F:S/OAU"-%2LU^%&'M?GZO:(3Z
MY<ZCP21@IGXF+_ _[%((KNY!0T3;H9)9T,#&6!OL_4_[G-AS],,[M_N=3SVH
MB1DZ_&#QVU$_W10K)=(2JYCTC[:^[8!?#"1F\(W]3O;'K!-]9?]W!GNVS_KC
M/;ME$W7WGF5/:M'^LQKSCW!5@0U6Y#6C0?'*#$R*D1NVRO.UGK-AK>4S+K6)
MM? 5)^+?3>^?S#3I<;_<9R99P5ZB.X4C)+7(6C=#VI]'/'/8^]M\U"XSP]TZ
MJ?T+1K)KUM?'E_LY9Q$.9C@<[4W=-/4C/#P])$RHV?.=22F*SJ:ZJM W!;][
M++I[Y"XP/,HX=M\D6Y!)DQ=@BPP8E<V;I[T(FOD3?7??P,1D! /L :>9($L9
M#3CM>#M'C][4>]?]=EN2C 5*0IH&"=<WO(-ZD6$9+C8\^EV*<\@U(WMO]U.1
M4!F)>%6']''#;F -?M_-? 9\/J0O'[X9?@1$[_15$U66V%%3W/1$.'1/V(^7
MXE_ RNJ(IY"7'B](#K+Q]N5CP7+N@!2KO"7NO"^].U&Y^\K%49.4CP)(F;__
M"R)&L',=J(8L%?)O*R;WD</=%07X 4ZUK)LU3Z?+*PR4%QN\:_FH/&)O)^K_
MR?_,-MOODX_P>2!7NO/"[B<V/Q"GI-0U:YY]%NT.NUF>"21IH"G<^!0X):YE
ML*'-759-.&WLWU(P@ZJV+HNU=_A\PD@'W$Y5I[S'UVC'TSY?.WP2_(-]^.VJ
M*;8Z]IN^+8@&6<:F8-.M9FER@([NY?Q[_BW]8_%] F<-!D,B?Y,8M_P1S"#0
MR)#ET$7%X[G)LQZ(><7/ :FL2*F #Z_S$FB?=G'+S@32ZW#P-B]O#^%<D@SX
M +G.DTW6_)QW,]#Y<PVLRRU'OP;\,MLB :$C[#8I4"053=OIR,F?\_X!9@+3
M7IP=?Y\<;)OLIN[ZLJCZ35=_*ZK+PV\/MV#*T/W$\;[.KF>@;=0<&GG;]'?)
MI7$5P@(.S#Z\?WOI]Z!*WN<W38^Q?31O>-(ZD\<,MJAL:YDPRY8_Y:#QW(.I
M4V7K# >X[._ &B'KD[Z/GWK7HU:95912 <H%S4'/Z,I^_CK?=ARD&7Z?3PA&
M:HJ<T@\NYO/DY[?P.] 3;PN<CVY,0CN3=$_;/+G$6TYV.'ZV (-N1;SJ5N@!
MOK>M&QS/W&0]3UAJGC4JHC?UFO)&4*MK<R !L#?+["9'-Q?PC0I=:[1#G*(
M^R6+A+.!?_,32HYXD]=]V;4A:: :D#=X7\JGI,SZ:G4/DXVH0&;W%10J\M;
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MF<2(_0+)T7);(O%T]W#D9G7$6>#ZB@*+81^2B/F:#]X^BCR5:9!%B[M$I^S
MFR4?#4_6"&MPO4A"E3D.4- 21XTL1QX?/GUT#%=]&_#J23H_/DM/%L>3^_]X
M7ZS("L$8&%-'_@TY%>A,( CPW\[L C-7CKUHY,APQ[;B!4CD4YGWR$Y]-4,/
MC%\%\/Y5KAS +3%YM5C.0!BX Y^0MF@=;M6&A->(OWPK0#''LWUU<IH>'<V3
M[!;F#T(>A0X%(*PQ&2:FK)P\0[.%PH-D])!C,E2UB$?&-AVN @YDG%WN8 B3
M3(!N(ES:&HV-%<D081[$PF'CENG\]"0]/SN9V/+)>0J9:<@3=F!RYB]GQ7@/
M;ON&$['&WD;J89.6KI?-'1GE42%_PC5D(<_S&2F>2\ '%\^,.]CPO89F =F7
M(]+17-_,N#3BZVNNZE%Z&F;-R''L?UV!#=[VP*!>>FU1#/LK.YS%\.I.7MCE
M_%>XL*=GZ>GYW&N^W@_TJ]]AM:OH)']"+5'UIG_R-$_2BXN+].3D__9IGITO
MHUF\X#071[_":9X=I4>+D__FT[RDF8PGC)$-DR:7/WSZT^6[CS_!@CS#4G%Z
M66[OL[RNO'8E1]6"X?<W8!_=TR'H_FPL7:,!=M]N\Z?DBBR"/X&>BWX23 3O
MMVGRPP]7Y%L!"P!VQ%D1UU=_.L09R -.T[OZD_\L?V1Y,CO_+4W^Y'0V_^V4
M&KN/OF5SXV8@<?*$/%"+Q2Q1E]4G<O=0;GFVXG@ 31\,)<J/<$XONC6TK[I?
M"7M@6&>IL@U1%>WRFZ*&1^!%MN9=NB69+7BORE*7I?E8'=@JY5JU.Z4['%"_
MMJ"MBRTM=-SWN43-@#24LIL<9[2>F(^SZJ*SIYE&7QQY6N>B;_U0_+TOUH6$
M7+RWY*JN^'+2I%^BLFXQD;MAA3(3DZ2[SR@UN]_D\@^[59@5[?:#E?>[FE47
M,'V;B@V"=4U*OG"A!%_,;.P11]UD3ZKW^XO<=Q08HU.#N?0X)GKCNB<\$?@-
MSQ%9 ONVY--HFI=DV_*IK(#O@AH\0=0FKD;$ 937WC)=3KT2)TNN3)JO4%.%
M-(R;TS<M+>%&?4Z\)?#FSDVQ=@+PS!IX$YIQMWV'7FO6_9U5)4N4%&:>4@GK
M8KU)%N)\@;1@9]N@T;$QC'#PGETLGQ6Z28%D@#&O8$%H8;3W=5^N ]JX09&B
MV=P[: 1X!(8H*$ZQ9>>@'09$#OZIEQQL_ %?IH"-]\#"]J 3)1!W@[^3R+D
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M./ 1$..(08KA%)<BB M'9Y0%.&<$9. ON<<J&2R%\.=<5Z:.D!.K]6%6HG9
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MQ%E,/D*@;C&8TXID55-XXT0_)"DG9D7#,.PH:Z;8BZ"P]9CE&TP_UOI*!.]
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M^-0)ETNS .JB;"F#W;^SL^:HYX)4.]^$<8!'143YY[Y\,A?/0^6/UEQRQ/(
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MCRY.Q@1 3I:]8&]G L7A6U7 6:DHG,^)?QDD]%GR*1*E 3A4-!9_5W#*G1Y
MVD1),[5I(7X!'E_;9V0CEWS$ZMN'C&N^Y/.NX.&+<[%CJ&9US[?R[(17D#EX
M-45W@WVE_%$X\2"+VKZ]Y+<Q=P13VIKLL7(=V5#=H/*70/&CB"S27<,!5:\@
M'<U3TDVE'QE#7-,M=]BWVCX*C;I8^ >)\<#A*%N_+;XEAQ2P%>;/68/<M8\J
M2O/;K"^[YSPROLR'@UU/F'(E=2PCDR&]$3:#^6VP;>+!BTCJAKBN[T0>^);0
MG9>5>IZ@CV4B_RYF)QA.$,Y]-#]<PSE\G5W/DK=PQX%]_/#AS<?//,86'61G
M&'^(BN!1OW.(2OK=0ZH]JR5#34]<"$03))B8CDZU;Q)FN92"S[Y<&MV#N1IG
MXF0)J,%R)".X'S/L!(#7R>4O,UML<JI-3+4FP6F[TH>FM5UR?)/5'92#W3FK
M3,H<66GF.A('A1:$O533#W=(@V"3&JU< K46AN_JW7&7'_<H4*U]8RKB1BQW
MX?2/S_7WP?Y6V-ACUP9_U;D"S6$G &)45,VO5]6Y;]>$_B!B-R_SH/;+L"E'
M@U0A%H"OV8?LP459?@+G):PZDS0_,]8)TKI*R1XDF #>9V54<6J8I]"K0DN\
MIS$E3*(L-+P->!AY*28T+R8 ?:-=WMIZ[FBO0KLLLQMRF[.JALHIJK]Z0=K[
MC,M@W#4_PFNJX'6\.!H'5.;B=K#/C.[-)<QN:E:\(4M=_H(AV=0/1Y)"X>EO
M+8@6%K_@<YUW+^B)??(/O<]S?V323M=(=('/9!HE'F6CSO0%3K.OJ7EOS/]W
MTF:Q(:B&#HM](CIU-80!BY8VOY0'9BHQ/,4.2978LZI+W">$=TL% >T.7=Q&
M<]#M'OJ;&E Y_RK<1E:M<6[$[FPS!=^ZNN?'7+S*UXR8.^F;O#@X&-<4VU=$
M"LH.;[3$AY%!BRY.7(TL0BSW[QULP;B@Q%QEC*@PLVO[&]Q=:4BY(^^.;9.)
M(359-;L%B;;)AM7X*BK:D?Z13HY6G/&%4RJ 6IJ"B[N0HZQ(9#L[MN<60S@7
M^TG_%9D1)M2C_4OG1%E[^@!3IU*WJ;!5<4AU6=0%![N#8-X9JA'?*(%7BB9#
M2'K-$TD5_'4D04Q2QU+SE4I;T'&OZ[M<_#+8+L/G!@<Y]QYU$.P]3+*+H-=&
M=GUB/[2*ARM'*C!Q/40Y5S>5I&AB*R &2:&8J9>LZ#N^ 6Z!^'H8B;[+[KB8
M%^O=[P14TO@P$4@A(\.3ZK5 7M,3 @'!U\FZ%6BK?N8A;?8ED@/%U8H<GQ'0
M&YMQU_98%\3912L7;A?(]]24#K2!T]<E8W\3O,()DK=M25O7%#WBAH9ILL''
MU7NJ =CD#(X#>UY%44>8-VPB)7ME[OKO4&S-W?(:ZXGFSC"OH=Q4?ZX,V9]Z
MA<]Y;5TY&)+=FD*6 AH17UKV#KD1.5ZK"(>QM6;0.&ITT+'I:8?&,LX<D?KW
M'6B,7:$W5='N!J<S>AT2]*!PX\4GC*.6.*\(*%O4+".&//8E<5X/[3.8;Y;<
M-$1RQAGK+^B.%\>6!YN%1=75B@9VY1B$7]3F0O #(B3)_>1V@;^I<^%-L!=:
M-!6J?Z'\W;_UZSO);AV2@BKH;5=T_=#KK*F[!.6 [G3*\,$:WENYF($G="O9
M0KXRV6G(O(VI2Y@3[!F>O^Z G+G?UJ$[?E^+]3%CO.7(.F+HE)O.'Z)#/[6&
M_P32%+IM+X[9E[=,E_,3+A-^KE-:U#[/JV]Q,L+S3=>BH;">H0D40E/%]\M[
ML^W5_LUVE?)F\8B/Q4\IB$,B<S2 [*PLF39["N+^7$\X[^'U15'N(9N-&FB(
M#EIO:M:@<;TZ3A?+$^N2G9R$;ULL(8- SWV.:%VW[C90G/T], =,28]AB"1*
MA=D+@/GY\QUIUNL(1?>+_?7:&\4ES[-'A+9 'D2 6/22_8)3'?/;[VH$B$=-
M6AFVU!Y2!"OB"CW :3N@1"\6L]/?[D )WWV L5'.Q2SAL9A*%_&OJ&!A;]JW
MCOK7V>B.V'>F7" *:"^35\GR-)V?GW&<]>@B71S-.7A]D9Z='TFR@I^?:P @
M9/ZU\B?Q/"<[6*3'%\OD-;7+3-S:?)_+72^_2LXPA#IP>5\A3F[G2YU<$C]6
M>+WHX?W\XKN'\%WMI5^Z]9-(F_$:S)=5KM*^<.B #D\H2B'+5'I-HJ^KK8)]
MHR721S"SRF,+S'EY)'B,-RQ(KS)@-753%1DW9/-:K@*2@((L\]7^;M0BE5K>
M<[)&-$V&I[HMON4.C()(E)QJX@N7,<49BDY._2Q'_]>V.'0IKNT91QZ>]HL[
M[#%+X@L9H97;DWCRK,KEDF%)6=U(%>TS0U,.?K7B183!<G$!:8J#622S@N7)
MC G&WS"'M&:[]HJCF[K4YGB7614"AMYKT:+XA6CKGZ1FTD]FX+A+(Y4PZ/OF
M%:Y<0BX$_<82XNC4.4R'50GACCAG"RK7[.QC*PT!LL&XQN@ 'H1WVCHW&2-9
MF ^(@X7?M_H@>@J=:80A#!F*(1YHR\@X"I5?WSG=;LP] [1*P3)91NAH'L@,
M0_F!]_ETKE\W#OT(Z0QA'^&J*A[,YX]?@^JQ.'N4)\B_GJ)3+F^T(+PZ40=Y
MZ*Z@5KA*8\"POX^!NPP[)08HP,(?<*.BBX0Y/* >9\F;K+F!<4*&LQ]#$=EH
M6LZXS!$JW\D23O"!MU8,O+COW= (S9][4 D6 77979YB4C0 \J,C>[>[?PGY
M2&4\S'/(^/0H>=S)_3:LG2(A]T6S/N2^>,RR:49PX[D-?"W?L\D+M&[YHUUX
MQ-4%BN!14/U,]8K$3^@WJIC)6Q-);)BDZ"H^Q2M""O;Y7/5]<EL<UK>'>+Z<
M>AH9..9Z9.T$#ELL8[7)!=(]5?_3K-IBC<3%Z<)WP$MA47DNCBRQQ)UGS;KA
M! -0J7A,+P:*S1_A?<[9PR#73=@YA2(FOFXFI!Z?2X G9;A(H3??0_S8KPEQ
M1KT7% >RK3$SU#DC!Y!4@LI*!.UJH^SP$J?S0'.NJRDB1"' O&(4L1WEBDXV
M#@^.X8<19I1QH_P]PGXB=6=^D25*@6-0;,,E#U>H[:5EMU[6L7#ENS2-E "H
M4>+W0GI990/L0*Y),QK[SGR6]Z1K37WN%5SA.=R6OVBOMJD'%XNY( $P;YIX
M[/R$AER>G4R:,W^-,_-]I;X('?S P1-G:Y_,YL,WPI*XB]GQ;XU.'4Q(C-GX
MHCP+ANX3K'ZE;A;Q_(9\28O(F3E)]VC%8M)_[JP<H5[E$9;-B].K@W1>6VTT
MYF[<.9U)<U92M35QP/$][XR8MFZ8(T9*@;12FS9BYTR5\P5G92_(L4;&+?QX
M<LZ6[2(] MV2#%OX\?3"9F4O%L=BY\93<[,_38]/+D!!;^'SA>#/.9?  8YX
M"E;M)\$!VJL6"!/-YA=4NNZBIN)YQE9)LC<>^:85Y)N4 E2K)X/.I.0A,?3;
MNC$09:)&*_C.3);:< 3+=@MYAM>=2Z.;H^-)?P8F.(H6]B^B TWC"7K//>/F
MX)*2BSD3R^+H@@G%H&&D\^4%)J!Q*TYKX.^;W]2&5NC*#('Q QW:I1DR\+PT
MX%/]3SK16AS>T,OTZC@]G2^QXZ+(++>]^@'[X4@7<L\,DXS9#X>]%F\HL1%V
M$<Q1D^Y_W6^W")NF1S3(UAM+?!]1B GUCCAGD$>LE04P6#0S0L=S@]-&P96[
MS\%:5 Q513S&ST7%[>]Z#"O!=^'W&$S@5L%I<MFC)"C1%/G<MRW^_Q4!_3WF
M6=F14PUK@C >@8O5X6@GZAX>N+S%1J445GO,RY+#:X<3JR-Q($1ML[/_G&TS
M4:P^20-+ D:O>M20-%AOWZ"::\:20A6L:WH&I[=6%\WO/VNX)R,&V[VH6]XP
MJ?([,+V1Z-B5'<X2#6G*&V"XAN&)*5*S=N D*\N]OBXL%I;[EZ1HD_+L<0L$
MZYV-TBB)'V/F?]/&9#=UUX.$![+OX&I4R8&&\N"QB'Q>\ZYU&-JFDGT*N'M.
M.Q8@"MP 5#]D#;GZAI7%>W*(--DV[Y$6Y8R'!*Q)!;Q?:S<5PC_D5JN9U"E1
MNT$$I,--=6TE3#+=,)4?>-&9&'&OEE1?XKO44@:!MFU%8\^'"<BHM#4VB+GF
MONA4X# V/+%ROS4Q4R&-9X/^'=L&R=LCW,/5486I71BMD]B'S>!>!OTN-]G/
M^;!.H@T*)0@#S 5GJUM,4:"D1=LB1W0_Q=@P";2Q11=MPR[?O[_;(#]@UH7K
MNT==TXWV;*IZ1U9C4ZN)"IB*A[L5I3"L(C$BLELE18A$'Z5WT<ZB%ZTA@6Z2
M:-CH9%9H]$NY B,.R/OZ$;MSI)1/BL^V^5"RV80K3-AT><YN$5GS,Z:I,M)N
M)=TY^;J;6Z<) AY(=^>GM#VX;+[+6 TC[-JG^H%352P*-YSDED3Y>.90[#KR
M, RB0$6KTAA!U&?@!TI:^H0XWOF:(H$?>)X5FI:8SM0W+/IO,#26MW&GR(I#
M!E702Y<L)Z^6,<B.ND5H*CF?KZL4-);28]:@DZ3PV@ZJIW3;U#+#Q(--Y1N&
MC3MH0$?EF(S3'4-MD> !"4S:0M2B-"00>I0EQ49F+VG#U)AL++4E2#9+8;,$
M^$ZSURD.S;U+ N%**8CH-O7>&$(V0!<'*&^TN::[#O<>+<4K:;J<8PXU=PP3
MD'>>:25M5()'$.XH=-:X"C3,!W>Q1/8I:)+D!#-R)4JSY,=\_022%11 !Q!O
MUFJXEO=GH'!_( ]9*[ OG;=;,<)+8+62BHTM*WK8AQM*R:3^XO+)%%$K9RZ/
M57[K,#W5FT==PCCEQ!O#USW9/ W,LV^<BXQ4-_R'<8<6WJ%Z-DO^BCQ;,MY7
MDF8792FF;DO@V_F=JBD' IQD==R'HF:1:[X'RB<Z>)(O#9[E-0( H66QZLA)
M"\I\\8!->M=8L;(X/?L^.3I>GCI2UMWV29DTAS7!IY?Y^LXY]C9%Z_'PXUP<
M^G8KWX8_Z(J &-6@C5,S&>.'P(@F7 2D7^#%O2^VH>8H*%GQ]H#<*B6!)-;B
M;K"16,.XL0V%9_PD-7L73I::P7+9%J<VH9)QV[<<]9$67_N,;Z&O0CON+KMC
MLNHK(-7;OL2 !8%L4&NG)NO7/8+$.%::.&:YY1ZO[%AB6I")&GIXTP.CHT)6
M9-BWX=DOSI;SN94@P&\Q-F$1EI[;.2K-*-J8*3L[$,2;4KISQL/6KO*]OZ X
MZL98&1:N!A!B([I(0<">L"\*>1_NF+G] NI%*K8M[1IR*I_LKG]K\_SG=CSI
M#R\P-VMD;$_NTU:(RW#;2V^7=;8!BFB%I#//<!T@%./F^EX42EODNRZU]X^K
M.1_?BX>ZT'RJ'#W"J]PA#-&;YL;FVHP:"Z:*]JYN[EQ@(*,B#\FF?&S@,UCW
M\20C8P.($N,9VCE$,G6-3>39M25#O0OP\AV_2OAJ'6W+ ]I9?^LK#GU(@A_\
M_;ZX*;HXWYI,>I^?HY;DKJR]A/'YU?Z$/XT3&\P#9"W<LOS) 8'?YKEZ;ML8
M1BEN)T+]NFI6L&@;;%H^IBUCA]$"MAL>(#L6=VI J*QO#)I/]94FP+MXBVR
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MY'BC#C!B" "3Q$<^5 \S:79Q=OCE\G"Q.#X9?.)R%4ID'=]]FF4SB^'X0]K
M#)ZW("O7XA&"[RJ/^X)P_;?X-?S-X@+I723U?9Z1\\SYCW XKND,DM%57MN6
M.FC*,:*,^#)J]77 @=X4:Y**, 2G/ V\?D)\ [15%%&@E6>M]E4B5$4>V$K,
MP,B"JT12T];:1!2%!3&(K$B@%_[7J3@0*"!J/;@IINQPK0P9JH1@3IH@CL*!
ML2'1IB[I_I':.MFZH6@+!)UB;!-H#VYJ2?'$S%&#DTNI%KEO7Y4_NG+A@P?1
MUT7-'Y&1X77T!FK@U[,!]["B1&TKL5.>MR%8[4#:\51"#'OTA&.EP&L5HDJ
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M8<^<  TX9<:PI,E-LM-,GIOGEWN;?&7ZLTX.C^2\.$H7Y^<*T@JWEMU%_U#
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M)<@'FMJ%5;<PE<'69*T#=_6U=2&ND/?!#.[;Z]G8_3S7'*V+-*H615B9A;5
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MQ7&!B @$ !"\5@WJ,WC1X(JON751K#9*02TI]D3=#"H3EY5BO83=;4Y7QM@
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ME,8\\_6J]UJ &%J'+ FAV<*#$Y31T:OBX?<7[K4E1O)72]@E"">FT9H9>>8
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MQY7:&,%GQAAP;D#>.08ED?O,9A-C6,M@!^]^OH^^@YZ]S \5 S$S0X"F'16
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M"WK $>@E(^]$?W>ZPN7C'81LJ(835G_]^J4"]8@IXSC1XY)!-O"!CS7A&0#
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M81-)!L7KKAL971!.] AO0VK#=EP%5LK(P>8='VB=?(7.)97I++&V[$+U)>$
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MQL8X0255=V:+=3* G?W5"/<6[:I52Q' SK[%,2E9/=$[W9MA^ M02P,$%
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M?$\+><JE9==<=8)]%]QU]O\6#KWC<AEWCP\(Y =:R*_&S-92J9YJ"NK1BP#
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M9C^@" ?I#5?-N67A9[-K6=7AUO-.J0FDG6D(R/O/<\(]GKY[^O0?4$L#!!0
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MX^MM0&_CZVU ;^/K[4!OY^OM0&_GZ^U ;^?K[4!OO\)9-SKLYNOM0&_GZ^U
M;^?K[4!OY^OM0&_GZ^U ;^?K'8'>D:]W!'I'OMX1Z!WY>D>@=^3K'8'>\0K/
M*M'#2K[>$>@=^7K'B=ZYJ8>T?2G#H=WG2Y=\&OYMS03N7-Z/Z?(9YZG?[I\H
M7<8M*9P_+Z[.>>I'1/CT]L?C7U!+ P04    " #X@%E05=WD$-D!  "^(0
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MGU!+ 0(4 Q0    ( /B 65 ?(\\#P    !,"   +              "  0
M  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( /B 65 GZ(<.@@   +$    0
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M965T,RYX;6Q02P$"% ,4    " #X@%E0_+\9J= #  "]$   &
M    @ $,$P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M^(!94(F6>Q Z P  $@T  !@              ( !$A<  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( /B 65"+H$H-3@8  # C   8
M          "  8(:  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    " #X@%E0@XW0,[$!  #2 P  &               @ $&(0  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ ^(!94,$ W"*S 0  T@,
M !@              ( ![2(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( /B 65#A'''6M0$  -(#   8              "  =8D  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " #X@%E0[_&#(+8!
M  #2 P  &0              @ '!)@  >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( /B 65".#Z69M $  -(#   9              "
M :XH  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ ^(!9
M4!D*>3"U 0  T@,  !D              ( !F2H  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    " #X@%E0,+XQ];4!  #2 P  &0
M        @ &%+   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( /B 65 Z\F>7LP$  -(#   9              "  7$N  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ ^(!94'I@M6"T 0  T@,
M !D              ( !6S   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    " #X@%E0-B-+-;4!  #2 P  &0              @ %&,@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( /B 65!A6_$C
MM0$  -(#   9              "  3(T  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ ^(!94*8V+ZG  @  X@L  !D
M ( !'C8  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #X
M@%E0_>+=M+<!  #2 P  &0              @ $5.0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /B 65"HDM?2T $  )P$   9
M          "  0,[  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#
M%     @ ^(!94!)[Y.3& 0  -P0  !D              ( !"CT  'AL+W=O
M<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #X@%E0*^*0A;@!  #2
M P  &0              @ $'/P  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM
M;%!+ 0(4 Q0    ( /B 65!!RGHSM@$  -(#   9              "  ?9
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ ^(!94,\4
MC)[3 0  G 0  !D              ( !XT(  'AL+W=O<FMS:&5E=',O<VAE
M970R-"YX;6Q02P$"% ,4    " #X@%E0O;.YE-X!   !!0  &0
M    @ 'M1   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M /B 65!#K.'>WP$   $%   9              "  0)'  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ ^(!94!57#^>#!   N1<  !D
M             ( !&$D  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    " #X@%E0%[4TNWP#  !O$   &0              @ '230  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( /B 65#EQ'L'90(
M &0(   9              "  851  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ ^(!94(6W_P;4 0  R@0  !D              ( !
M(50  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #X@%E0
M)O8T-)("  #T"@  &0              @ $L5@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /B 65#0*X7HVP(  #,+   9
M      "  ?58  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ ^(!94$?WF1E; @  I <  !D              ( !!UP  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #X@%E0QM-?$N\"  #^"P
M&0              @ &97@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( /B 65"1CG6Y^P$  ,$%   9              "  ;]A  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ ^(!94/8__SK(
M @  5 L  !D              ( !\6,  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    " #X@%E0@J;!\1 "  #Y!0  &0
M@ 'P9@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( /B
M65!"8^ :' ,  *\.   9              "  3=I  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ ^(!94-_/\$?Y 0  7@4  !D
M         ( !BFP  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    " #X@%E0.S$E5,\"  #+"@  &0              @ &Z;@  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( /B 65 , 6_(" (  ,X%
M   9              "  <!Q  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ ^(!94$Z.-U(? @  D@8  !D              ( !_W,
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    " #X@%E0'ZDY
M+-$!  "'!   &0              @ %5=@  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( /B 65 U?PI?V08  "HJ   9
M  "  5UX  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M^(!94/S' SX- @  _04  !D              ( !;7\  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    " #X@%E0%<\#@60#   E#@  &0
M            @ &Q@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( /B 65 VHN96:0(  ,P'   9              "  4R%  !X;"]W
M;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ ^(!94&%R</(N @
M@08  !D              ( ![(<  'AL+W=O<FMS:&5E=',O<VAE970T."YX
M;6Q02P$"% ,4    " #X@%E0C.!C^+X!  #4 P  &0              @ %1
MB@  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( /B 65!8
MRVD_7P(  -\'   9              "  4:,  !X;"]W;W)K<VAE971S+W-H
M965T-3 N>&UL4$L! A0#%     @ ^(!94"(1<\5P @  <P@  !D
M     ( !W(X  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /B 65 MNL31D@,  +P1   9              "
M 8J>  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ ^(!9
M4/8@U],0MP  K, " !0              ( !4Z(  'AL+W-H87)E9%-T<FEN
M9W,N>&UL4$L! A0#%     @ ^(!94#/+@%=R @  )@X   T
M ( !E5D! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #X@%E0.RFM3I,$  ![
M)0  #P              @ $R7 $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ^(!94&4-O+_] 0  #2(  !H              ( !\F ! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^(!94%7=Y!#9 0  OB$
M !,              ( !)V,! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ $$ 00"Y$0  ,64!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6786123872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationPeriod', window );">Operating lease, termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate', window );">Operating lease, period to provide written notice to terminate contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent', window );">Operating lease, equivalent rent termination period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_OperatingLeasePercentageOfAnnualRentEscalation', window );">Operating lease, rent escalation percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Impairment recorded to right-of-use assets related to original lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseObligation', window );">Purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Total rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 334,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">68,767,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyBorrowings', window );">Related party borrowings</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_DaewoongMember', window );">Daewoong</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement', window );">Contingent milestone payment (up to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Period Of Written Notice Prior To Lease Terminate Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeasePeriodOfWrittenNoticePriorToLeaseTerminateDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Fee, Period Of Rent Equivalent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationFeePeriodOfRentEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LesseeOperatingLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LesseeOperatingLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment In Connection With License And Supply Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_MilestonePaymentInConnectionWithLicenseAndSupplyAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_OperatingLeasePercentageOfAnnualRentEscalation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Percentage Of Annual Rent Escalation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_OperatingLeasePercentageOfAnnualRentEscalation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888369&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_DaewoongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_DaewoongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6799145504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 12, 2018</div></th>
<th class="th"><div>Feb. 11, 2018</div></th>
<th class="th"><div>Dec. 14, 2017</div></th>
<th class="th"><div>Nov. 21, 2017</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 21, 2019</div></th>
<th class="th"><div>Nov. 21, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,562,665<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,562,665<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200,000<span></span>
</td>
<td class="nump">$ 50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">16,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,945,000<span></span>
</td>
<td class="nump">16,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings', window );">Capital contribution from Parent, forgiveness of related party borrowings</a></td>
<td class="nump">13,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Maximum number of shares authorized under the plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,361,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase percentage of maximum shares outstanding (equal to)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Additional shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,337,821<span></span>
</td>
<td class="nump">1,091,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,249,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,311,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,518,000<span></span>
</td>
<td class="nump">6,971,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_AllocatedShareBasedCompensationExpenseCapitalized', window );">Capitalized share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm', window );">Weighted average expected term of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield rate of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,302,000<span></span>
</td>
<td class="nump">$ 4,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized stock option costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,529,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,216,000<span></span>
</td>
<td class="nump">1,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for unrecognized costs to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of awards vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357,000<span></span>
</td>
<td class="nump">$ 771,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized costs other than options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember', window );">RSUs Performance Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember', window );">RSUs Market Conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Share-based Compensation Award, Tranche One | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,602<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-based Compensation Award, Tranche Two | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,862,000<span></span>
</td>
<td class="nump">$ 5,570,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Compensation Award, Tranche One | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative | Share-based Compensation Award, Tranche Two | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember', window );">SCH | Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">55,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">$ 140,688,000<span></span>
</td>
<td class="nump">$ 56,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,562,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Series A Convertible Preferred Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares of convertible preferred stock converted (in shares)</a></td>
<td class="nump">2,065,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_AllocatedShareBasedCompensationExpenseCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Allocated Share-Based Compensation Expense Capitalized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_AllocatedShareBasedCompensationExpenseCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CapitalContributionForgivenessofRelatedPartyBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Contribution, Forgiveness of Related Party Borrowings</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CapitalContributionForgivenessofRelatedPartyBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_SharebasedCompensationArrangementbySharebasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsPerformanceConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=eols_RestrictedStockUnitsRSUsMarketConditionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6717364000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,518<span></span>
</td>
<td class="nump">$ 6,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">8,862<span></span>
</td>
<td class="nump">5,570<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 656<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6782132624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Organization</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Evolus, Inc., (&#8220;Evolus&#8221; or the &#8220;Company&#8221;) is a performance beauty company focused on delivering products in the self-pay aesthetic market. The Company received the approval of its first product Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (prabotulinumtoxinA-xvfs) from the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) in February 2019. The product was also approved by Health Canada in August 2018 and the European Commission (&#8220;EC&#8221;) in September 2019. The product is a proprietary 900 kDa purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as &#8220;frown lines,&#8221; in adults. The Company commercially launched Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in the United States in May 2019 and in Canada through a distributor in October 2019. The Company is headquartered in Newport Beach, California.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company&#8217;s board of directors and its then-sole stockholder approved an amendment to the Company&#8217;s amended and restated certificate of incorporation to effect a split of shares of the Company&#8217;s common stock on a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.6527</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-for-1 basis (the &#8220;Stock Split&#8221;). The Company&#8217;s then-outstanding shares of convertible Series A preferred stock (&#8220;Series A preferred stock&#8221;), the par value of the common stock, and the authorized shares of the common stock were not adjusted as a result of the Stock Split. All issued and outstanding shares of common stock, stock options, restricted stock units and related per share amounts in the accompanying financial statements have been retroactively adjusted to reflect this Stock Split for all periods presented. The Stock Split was effected on January 26, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On February 12, 2018, the Company completed its initial public offering (&#8220;IPO&#8221;) and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,047,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;shares of common stock, which included the exercise by the underwriters of their option to purchase </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">47,514</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> additional shares of common stock, at an offering price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$12.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,330</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> after deducting underwriting discounts and commissions, excluding other offering costs. In connection with the IPO, the Company&#8217;s then-outstanding shares of Series A preferred stock were automatically converted into </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2,065,875</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock. In connection with the completion of its IPO, the Company&#8217;s amended and restated certificate of incorporation was further amended and restated to provide for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">100,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;authorized shares of common stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10,000,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> authorized shares of preferred stock with a par value of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.00001</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share.   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In July 2018, the Company completed a follow-on public offering and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">3,600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">600,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$67,680</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In November 2019, the Company completed a follow-on public offering and issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">5,999,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of its common stock, which included the exercise in full by the underwriters of their option to purchase an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">782,550</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> shares of common stock, at a price to the public of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$13.00</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> per share. The Company received net proceeds of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,315</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from the offering, after deducting underwriting discounts and commissions, excluding other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, ALPHAEON Corporation (&#8220;Alphaeon&#8221;), which is majority-owned by Strathspey Crown Holdings Group, LLC, formerly known as SCH-AEON, LLC, (&#8220;SCH&#8221;), owned&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">25.8%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">56.0%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the Company&#8217;s outstanding shares of common stock, respectively. See Note 11.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;"> Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, for more information.</font><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In 2019 Alphaeon changed its name to AEON Biopharma, Inc. and contributed all of the shares it held in the Company to Alphaeon 1, LLC. The Company continues to refer to the renamed AEON Biopharma, Inc. as &#8220;Alphaeon&#8221; and Alphaeon 1, LLC as &#8220;Alphaeon 1, LLC.&#8221;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Liquidity and Financial Condition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The accompanying financial statements&#160;have been prepared&#160;on a basis that&#160;assumes that&#160;the Company will continue as a going concern, and do not include any adjustments that may result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company&#8217;s assets and the satisfaction of the Company&#8217;s liabilities and commitments in the normal course of business and does not include any adjustments to reflect the possible future effects of the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. Since inception, the Company has incurred recurring net operating losses, which include operating losses of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$90,034</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$46,867</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Additionally, the Company used </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$93,383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25,667</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in cash for operations in the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">years ended December 31,</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, respectively. Management expects operating losses and negative cash flows to continue for at least the next 12 months. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$109,892</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in cash and cash equivalents plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$19,911</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in short-term investments and an accumulated deficit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$213,059</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s ability to execute on its business strategy, meet its future liquidity requirements, and achieve profitable operations, is dependent on a number of factors, including its ability to gain and expand market acceptance of its product and achieve a level of revenues adequate to support its cost structure and operate its business and sell products without infringing third party intellectual property rights.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes that its current capital resources, which consist of cash, ca</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sh equivalents and short-term investments, are sufficient to fund operations through at least the next twelve months from the date the accompanying financial statements are issued based on the expected cash burn rate. The Company may be required to raise additional capital to fund future operations through the incurrence of additional debt allowed under existing debt arrangements, the entry into licensing or collaboration agreements with partners, sale of its equity securities, grants or other sources of financing. Sufficient funds may not be available to the Company at all or on attractive terms when needed from equity or debt financings. If the Company is unable to obtain additional funding from these or other sources when needed, or to the extent needed, it may be necessary to significantly reduce its controllable and variable expenditures and current rate of spending through reductions in staff and delaying, scaling back, or suspending certain research and development, sales and marketing programs and other operational goals.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6777228816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Feb. 12, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares, issued (in shares)</a></td>
<td class="nump">33,562,665<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">33,562,665<span></span>
</td>
<td class="nump">27,274,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6797131280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 12, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 11, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 14, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,059,000<span></span>
</td>
<td class="nump">123,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Increase in related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">73,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contingent royalty obligation payable to Evolus Founders</a></td>
<td class="nump">$ 39,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,200,000<span></span>
</td>
<td class="nump">50,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Contingent promissory note payable to Evolus Founders</a></td>
<td class="nump">16,042,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,945,000<span></span>
</td>
<td class="nump">16,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach', window );">Period available to cure breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessAcquisitionUnwindingFee', window );">Unwinding fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON | Majority Shareholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">$ 140,688,000<span></span>
</td>
<td class="nump">$ 56,275,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionTermOfAgreement', window );">Term of service agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionRenewalPeriodOption', window );">Period of successive renewal of services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodToNotifyTermination', window );">Period to notify termination to the other party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payments on related party borrowings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier', window );">Related party transaction, debt balance multiplier</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 615,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_NonCashRelatedPartyReceivable', window );">Increase in related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,051,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Related party receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73,690,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Deemed distribution to parent</a></td>
<td class="nump">$ 66,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=eols_ALPHAEONMember', window );">ALPHAEON | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired (at least)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember', window );">Evolus, Inc. | SCH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="nump">$ 55,742,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval', window );">Up-front payment upon obtaining FDA approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale', window );">Period of termination of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses | ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | ALPHAEON</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Related party transaction amount in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessAcquisitionUnwindingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Unwinding Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessAcquisitionUnwindingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Up-front Payment Upon Obtaining FDA Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_BusinessCombinationUpfrontPaymentUponObtainingFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_NonCashRelatedPartyReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non Cash Related Party Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_NonCashRelatedPartyReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Amounts of Transaction, Debt Balance Multiplier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionAmountsofTransactionDebtBalanceMultiplier</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period Of Termination Of First Commercial Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodOfTerminationOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionPeriodToNotifyTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Period To Notify Termination</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionPeriodToNotifyTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionRenewalPeriodOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Renewal Period Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionRenewalPeriodOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_RelatedPartyTransactionTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_RelatedPartyTransactionTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_StockPurchaseAgreementPeriodAvailabletoCureBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Purchase Agreement, Period Available to Cure Breach</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_StockPurchaseAgreementPeriodAvailabletoCureBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_ALPHAEONMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_ALPHAEONMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_MajorityShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=eols_EvolusIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=eols_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=eols_SCHAEONLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=eols_SCHAEONLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6780172016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Released valuation allowance for deferred tax assets</a></td>
<td class="nump">$ 15,055,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Accrued interest and penalties related to income tax matters</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">179,589,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">1,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOL carryforwards</a></td>
<td class="nump">94,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State | R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">$ 1,383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6660932240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements and Short-Term Investments - Short-term Investments Available for Sale (Details) - U.S treasury securities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 19,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract', window );"><strong>Gross Unrealized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gains</a></td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 19,911<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6779694816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets - Schedule of Definite and Indefinite-Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,853)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,208<span></span>
</td>
<td class="nump">$ 21,208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_IntangibleAssetsGrossIncludingGoodwill', window );">Intangible assets, gross (including goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Total net book value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,846<span></span>
</td>
<td class="nump">77,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived intangible assets (IPR&amp;D)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Definite-lived intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Weighted-Average Life (Years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Original Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Book Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_IntangibleAssetsGrossIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Gross (Including Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_IntangibleAssetsGrossIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6786145776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Oxford Term Loans - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 15, 2019 </div>
<div>USD ($) </div>
<div>advance</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment', window );">Percentage of final payment of full principal amount</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths', window );">Prepayment fee percentage, next twelve months</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo', window );">Prepayment fee percentage, year two</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter', window );">Prepayment fee percentage, thereafter</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt discount</a></td>
<td class="nump">$ 1,094,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs</a></td>
<td class="nump">$ 2,205,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember', window );">Term Loan Facility | Applicable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentDefaultInterestRate', window );">Default interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LineofCreditFacilityNumberofAdvances', window );">Number of advances | advance</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments', window );">Period of interest only payments</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">23 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment', window );">Additional period of agreement of interest payment</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentTermAggregatePeriod', window );">Aggregate period</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_DebtInstrumentAdditionalAmortizationPeriod', window );">Additional amortization period</a></td>
<td class="text">11 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | LIBOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | First tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember', window );">Secured Debt | Second tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn', window );">Period to achieve net sales milestone before second drawn</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Final payment amortized into interest expense over the life of the term loan</a></td>
<td class="nump">$ 4,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Additional Period Of Agreement Of Interest Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAdditionalPeriodOfAgreementOfInterestPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Default Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Percentage Of Principal Amount, Balloon Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPercentageOfPrincipalAmountBalloonPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPeriodOfInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Period Of Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPeriodOfInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Thereafter</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentPrepaymentFeePercentageYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Prepayment Fee Percentage, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentPrepaymentFeePercentageYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_DebtInstrumentTermAggregatePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Aggregate Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_DebtInstrumentTermAggregatePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LineofCreditFacilityNumberofAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Advances</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LineofCreditFacilityNumberofAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Period to Achieve Minimum Net Sales Milestone Before Second Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">eols_LineofCreditFacilityPeriodtoAchieveMinimumNetSalesMilestoneBeforeSecondDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>eols_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=eols_ApplicableRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=eols_ApplicableRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=eols_TermLoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6644291728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">&#160;&#160;&#160;&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Related Party Transactions</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Services with Alphaeon</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Prior to the Company&#8217;s IPO in February 2018, the Company had funded its operations primarily through contributions and related party borrowings from Alphaeon. For 2018, selling, general and administrative expenses included </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$383</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> of expenses allocated by Alphaeon. After completion of the Company&#8217;s IPO, Alphaeon did </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">t incur any administrative or research and development expenses on the Company&#8217;s behalf. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018, the Company entered into a services agreement with Alphaeon, or the services agreement, which became effective upon the Company&#8217;s IPO. The services agreement sets forth certain agreements between Alphaeon and the Company that governs the respective responsibilities and obligations between Alphaeon and the Company </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">as it relates to the services to be performed between them</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The services agreement has a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year term and thereafter will renew for successive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">one</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> year terms unless sooner terminated by either party. The Company or Alphaeon may terminate the services agreement upon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sixty days</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#8217; notice to the other party. In accordance with the services agreement, the Company paid Alphaeon </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$5,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> during the first quarter of 2018, subsequent to the IPO. There were no significant services provided under the services agreement after the IPO. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Evolus had </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">no</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> related party accounts receivable or payable with Alphaeon. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Note Obligation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to certain debt transactions entered into by Alphaeon in 2016 and 2017 and guaranty provided by the Company, as a co-obligor to these debt obligations, the Company applied the accounting guidance provided in ASC 405-40, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Obligations Resulting from Joint and Several Liability Arrangements </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">and recorded a note obligation. During the first quarter of 2018, Alphaeon issued </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$800</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;additional convertible promissory notes, including&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$24</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;convertible promissory notes to the Company&#8217;s former President and Chief Executive Officer and former member of the board of directors. As a result of this additional issuance, the total note obligations under all the notes increased to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140,688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.5</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> times the total outstanding principal amount of  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$56,275</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) immediately prior to the IPO. Approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$615</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in excess of the then balance of additional paid-in capital was recorded in accumulated deficit. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In January 2018 immediately prior to its IPO, the Company recorded&#160;an increase of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,051</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the receivable from Alphaeon with a corresponding increase in additional paid-in capital. The related party receivable balance increased to&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,690</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;immediately prior to the IPO. As of February 12, 2018, the Company was released of the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$140,688</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;note obligation for all guaranty and security obligations under the guaranty agreements, and its related party receivable from Alphaeon of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$73,690</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;was settled, resulting in a capital contribution of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$66,998</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Alphaeon&#8217;s security interest in Evolus&#8217; assets was also terminated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evolus Founders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Certain of the Evolus Founders from whom SCH purchased its equity interests included individuals who were previously employed by the Company in operational roles, including the Company&#8217;s former Chief Operating Officer and consultant to the Company through December 31, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Payment Obligations Related to the Acquisition by Alphaeon</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company was acquired by SCH in 2013 and subsequently by its subsidiary, Alphaeon Corporation, by means of a stock purchase agreement (&#8220;Stock Purchase Agreement&#8221;) pursuant to which Alphaeon assumed certain payment obligations related to the acquisition. On December 14, 2017, the Stock Purchase Agreement was amended (&#8220;Amended Stock Purchase Agreement&#8221;), and, as a result, effective upon the closing of the Company&#8217;s IPO, the Company assumed all of Alphaeon&#8217;s payment obligations under the Amended Stock Purchase Agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, the payment obligations consisted of (i) a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,200</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;up-front payment upon obtaining FDA approval for Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for the treatment of glabellar lines which was paid in full in 2019, (ii) quarterly royalty payments of a low single digit percentage of net sales of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iii) a&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20,000</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;promissory note that matures in November 2021. The payment obligations set forth in (ii) above terminates in the quarter following the&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">10</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-year anniversary of the first commercial sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in the United States. Under the Amended Stock Purchase Agreement, the Company recorded the fair value of all revised payment obligations and the promissory note owed to the Evolus Founders of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;(comprised of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$39,700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;related to the contingent royalty obligation payable and&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$16,042</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;related to the contingent promissory note) as of February 12, 2018. See&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:normal;">Note 3</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;">Fair Value Measurements and Short-Term Investments</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;for more information about the Company&#8217;s accounting thereof.&#160;In addition, the outstanding related party borrowings from Alphaeon as of February 12, 2018 were offset and reduced, on a dollar-for-dollar basis, taking into account the then-fair value of all payment obligations the Company assumed from Alphaeon, the fair value of which, as of February 12, 2018, was&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$55,742</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Under the Amended Stock Purchase Agreement, Evolus paid one-time bonuses of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$1,575</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to certain current and former employees upon FDA approval of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;in February 2019, including a one-time bonus of&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$700</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;paid to the Company&#8217;s Chief Medical Officer and Head of Research &amp; Development.&#160;The payment is included in research and development expenses in the accompanying statements of operations and comprehensive loss for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company has the right to prepay the promissory note, in whole or in part, at any time and from time to time without penalty. Upon an event of default under the promissory note, all unpaid principal becomes immediately due and payable at the option of the holder. An event of default occurs under the terms of the promissory note upon any of the following events: (i) Evolus fails to meet the obligations to make the required payments thereunder, (ii) Evolus makes an assignment for the benefit of creditors, (iii) Evolus commences any bankruptcy proceeding, or (iv) Evolus materially breaches the Amended Stock Purchase Agreement or Tax Indemnity Agreement (which is defined below) and such breach is not cured within&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">30 days</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In addition, upon a change-of-control of Evolus, all unpaid principal becomes immediately due and payable. Under the terms of the promissory note, a change-of-control is defined as (i) the sale of all or substantially all of Evolus&#8217; assets, (ii) the exclusive license of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;or the business related to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;to a third-party (other than a sublicense under the Daewoong Agreement), or (iii) any merger, consolidation, or acquisition of Evolus, except a merger, consolidation, or acquisition of Evolus in which the holders of capital stock of Evolus immediately prior to such merger, consolidation, or acquisition hold at least&#160;</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">50%</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">&#160;of the voting power of the capital stock of Evolus or the surviving entity. Notwithstanding the foregoing, the promissory note expressly provides that neither the IPO or any merger with or acquisition by Alphaeon or any of its subsidiaries or affiliates constitutes a change-of-control.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Amended Stock Purchase Agreement, the Company entered into a tax indemnity agreement with the Evolus Founders (&#8220;Tax Indemnity Agreement&#8221;). Pursuant to the Tax Indemnity Agreement, the Company is obligated to indemnify the Evolus Founders for any tax liability resulting from the Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement from Alphaeon. Such assumption of the revised payment obligations occurred upon the completion of the IPO. Under the Amended Stock Purchase Agreement, the payment obligations are contingent and thus eligible for installment sale reporting under Section 453 of the Internal Revenue Code of 1986, as amended. Under the Tax Indemnity Agreement, the Company was obligated to indemnify the Evolus Founders for any taxes or penalties required to be paid by the Evolus Founders in the event the U.S. Internal Revenue Service or other taxing authority were to determine that Company&#8217;s assumption of the revised payment obligations under the Amended Stock Purchase Agreement rendered continued installment sale reporting unavailable to the Evolus Founders. Any taxes or penalties paid by us on behalf of the Evolus Founders under the Tax Indemnity Agreement will be offset dollar-for-dollar against the promissory note and future royalties that will be payable to the Evolus Founders under the Amended Stock Purchase Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Exclusive Distribution and Supply Agreement with Clarion Medical Technologies Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On November 30, 2017, the Company entered into an exclusive distribution and supply agreement (&#8220;Distribution Agreement&#8221;), with Clarion Medical Technologies Inc. (&#8220;Clarion&#8221;). The Distribution Agreement provides terms pursuant to which the Company will exclusively supply </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to Clarion in Canada.&#160; Clarion was previously a wholly-owned subsidiary of Alphaeon. However, pursuant to previous agreements among Alphaeon, Clarion, and previous equity holders of Clarion, the previous equity holders of Clarion had the option, and have exercised such option, to unwind Alphaeon&#8217;s acquisition of Clarion. As a result, Alphaeon owes the equity holders of Clarion an unwinding fee of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$9,600</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (&#8220;Unwinding Fee&#8221;). The Distribution Agreement sets forth that a portion of the proceeds received by the Company from each unit of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> purchased by Clarion shall be paid directly to the previous equity holders of Clarion, and will reduce, on a dollar-for-dollar basis, the amount of the Unwinding Fee Alphaeon owes. In addition, Alphaeon and SCH have agreed with Clarion to pay the unpaid amount of the Unwinding Fee on December 31, 2022, if demanded by the previous equity holders of Clarion. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The service revenue related to the sale of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> through Clarion in 2019 was recorded based on terms that were not in the scope of the Distribution Agreement.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6959451376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-weight:bold;"> </font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company leases office facilities under various operating lease agreements. The Company&#8217;s corporate headquarters is located in Newport Beach, California, in a facility that it subleases under a non-cancelable operating lease for a fixed amount each month. The sublease for this facility expired on January 20, 2020. On May 15, 2019, the Company entered into a non-cancelable operating lease for the same office facility with the original lessor. This non-cancelable operating lease commenced on February 1, 2020 and expires on January 31, 2025. Lease payments increase based on an annual rent escalation clause that occurs each year on February 1. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company may, under certain circumstances, terminate the lease on the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">36</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">-month anniversary of the lease commencement date by providing a written notice </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> prior to such anniversary and paying a termination fee&#160;equal to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">six months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> basic rent plus certain other expenses. The Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, which is not recognized as part of its ROU assets and lease liabilities. The lease with the original lessor is a modification of the existing sublease that is not accounted for as a separate contract.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company also leases an office facility in Santa Barbara, California, under a non-cancelable operating lease, the payments of which include a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">three</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> percent</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> annual rent escalation clause that occurs on each June 1 anniversary</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. The lease for this facility expires on May 31, 2020 and the Company has an option to extend the term of the lease for an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">60 months</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. In June 2019, the Company subleased the Santa Barbara, California facility to a third-party for a term starting on June 1, 2019 and expiring on May 31, 2020. The </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">sublease</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> income was not significant. Upon signing the sublease, the Company recorded an impairment charge of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$80</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> to the right-of-use asset related to the original lease.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company&#8217;s lease agreements do not contain any residual value guarantees or material restrictive covenants. The payments associated with the renewal will only be included in the measurement of the lease liability and ROU assets if the exercise of the renewal option is determined to be reasonably certain. The Company considers the timing of the renewal period and other economic factors such as the financial implications of a decision to extend or not to extend a lease&#160;in&#160;determining&#160;if the renewal option is reasonably certain to be exercised.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">For the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the components of operating lease expense and other quantitative information were as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.25396825396825%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:17%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Year Ended December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Fixed operating lease expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Variable operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">110</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Short-term operating lease expense</font></div></td><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">85</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">$</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">1,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">As of December 31, 2019</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average remaining lease term (years)</font></div></td><td colspan="5" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5.0</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#333333;">Weighted-average discount rate</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">9.4%</font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:8pt;color:#000000;"> </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Operating lease&#160;expenses were included in the selling, general and administration expenses in the accompanying statements of operations and comprehensive loss. Operating lease right-of-use assets and related current and noncurrent operating lease liabilities are presented in the accompanying balance sheets. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The following table presents the maturity of the Company&#8217;s operating lease liabilities as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, future minimum payments under the operating lease agreements with non-cancelable terms as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:65.27777777777779%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:78%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:20%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2020</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,201</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,205</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2023</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,312</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">2024</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">114</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Total operating lease payments</font></div></td><td colspan="2" style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">6,459</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Less: imputed interest</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">(1,366</font></div></td><td style="vertical-align:top;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">Present value of operating lease liabilities</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;">5,093</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As required by the new lease accounting standard, legacy disclosures are provided for periods prior to adoption.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Total rental expense for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">year ended December 31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$334</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, annual future minimum payments under the operating lease agreements with non-cancelable terms greater than one year are as follows:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:64.48412698412699%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:21%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;font-weight:bold;">Fiscal year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2019</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">890</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2020</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">2021</font></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">$</font></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#231f20;">1,029</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:Times New Roman;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Purchase Commitments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, the Company has entered into commitments to purchase services and products for an aggregate amount of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$4,602</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. Certain minimum purchase commitments related to the purchase of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> are described below.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">License and Supply Agreement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Pursuant to the Daewoong Agreement, the Company has an exclusive distribution license to Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> from Daewoong for aesthetic indications in the United States, European Union, Canada, Australia, Russia, Commonwealth of Independent States, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. The Product is manufactured by Daewoong in a recently constructed facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">) in a territory covered by the Daewoong Agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company held an option to obtain the therapeutic rights to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> in its licensed territories which was held in trust for Alphaeon during the fourth quarter of 2017 for a </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$2,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> reduction in related party borrowings. In September&#160;2018, Alphaeon exercised the right to obtain the therapeutic option to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and remitted the option exercise price directly to Daewoong.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In connection with the Daewoong Agreement, the Company was obligated to make milestone payments to Daewoong for certain confidential development and commercial milestones associated with </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, Daewoong is eligible to receive remaining contingent milestone payments of up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$10,500</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Daewoong Agreement also includes certain minimum annual purchases the Company is required to make in order to maintain the exclusivity of the license.</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> The Company may, however, meet these minimum purchase obligations by achieving certain market share in its covered territories. These potential minimum purchase obligations are contingent upon the occurrence of future events, including receipt of governmental approvals and the Company&#8217;s future market share in various jurisdictions.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company&#8217;s exposure under these agreements is unknown because they involve claims that may be made against the Company in the future, but have not yet been made. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">No</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> amounts were accrued as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">December&#160;31, 2019</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2018</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">Medytox Litigation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, Daewoong and other individuals and entities are defendants to a lawsuit brought by Medytox, Inc. (&#8220;Medytox&#8221;) originally instituted </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">in the Superior Court of the State of California in June 2017. With specific regard to the Company, Medytox alleges that (i) the Company has violated California Uniform Trade Secrets Act, Cal. Civ. Code &#167; 3426 because Daewoong&#8217;s alleged knowledge of the misappropriation of certain trade secrets of Medytox is imputed to the Company as a result of the Company&#8217;s relationship with Daewoong, (ii) the Company has stolen the botulinum toxin bacterial strain of Medytox through our possession of and refusal to return the botulinum toxin bacterial strain, (iii) the Company has engaged in unlawful, unfair and fraudulent business acts and practices in violation of California Bus. &amp; Prof. Code &#167; 17200, including conversion of the botulinum toxin bacterial strain and misrepresentations to the public regarding the source of the botulinum toxin bacterial strain used to manufacture Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (iv) the Daewoong Agreement is invalid and in violation of Medytox&#8217;s rights</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;Medytox Litigation&#8221;). </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">Medytox seeks, among other things, (i) actual, consequential and punitive damages, (ii) a reasonable royalty, as appropriate, (iii) a declaration that the Daewoong Agreement is void and unenforceable and that Medytox is entitled to disgorgement of all property wrongfully and unjustly retained or acquired by the defendants, including unlawfully gained profits, (iv) injunctive relief prohibiting the Company from using the license under the Daewoong Agreement and distributing Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">, and (v) attorneys&#8217; fees and costs.  </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company believes it has meritorious defenses and intends to vigorously defend Medytox&#8217;s claims. The Company is unable to determine the likelihood of success of Medytox&#8217;s claims against the Company, and an estimate of the possible loss or range of loss cannot be made. While the Company is entitled to indemnity under the Daewoong Agreement, the indemnity may not be sufficient. </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">An adverse ruling by the Superior Court against either us or Daewoong could materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm.</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;font-style:italic;font-weight:normal;">ITC Case</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">On January 30, 2019, Allergan, plc and Allergan, Inc. (collectively, &#8220;Allergan&#8221;) and Medytox filed a complaint against us and Daewoong in the U.S. International Trade Commission (the &#8220;ITC&#8221;), containing substantially similar allegations to the Medytox Litigation, specifically that Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is manufactured based on misappropriated trade secrets of Medytox and therefore the importation of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> is an unfair act. The ITC matter is entitled </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">In the Matter of Certain Botulinum Toxin Products</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> (the &#8220;ITC Complaint&#8221;).  The ITC instituted an investigation as ITC Inv. No. 337-TA-1145 (the &#8220;ITC Action&#8221;). The ITC Complaint seeks (i) an investigation by the ITC pursuant to Section 337 of the Tariff Act of 1930, (ii) a hearing with the ITC on permanent relief, (iii) issuance of a limited exclusion order forbidding entry of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States, (iv) a cease and desist order prohibiting Daewoong and us from engaging in the importations, sale for importation, marketing, distribution, offering for sale, the sale after the importation of, or otherwise transferring Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within the United States, (v) a bond issued during the presidential review period, (vi) the return of Medytox&#8217;s trade secrets and other confidential information including the alleged stolen botulinum toxin bacterial strain, and (vii) exclusion and cease and desist orders. The Company intends to defend itself vigorously in the proceedings. In January 2020, the three sets of parties to the ITC Action, (i) the Complainants - Allergan and Medytox, (ii) the Respondents - the Company and Daewoong and (iii) the OUII, each submitted pre-hearing briefs to the Administrative Law Judge assigned to the ITC Action setting forth each party&#8217;s positions on the substantive issues prior to the evidentiary hearing.  From February 4-7, 2020, the Administrative Law Judge held an evidentiary hearing on the ITC Action.  An initial determination by the Administrative Law Judge is due by June 5, 2020 and the target date for the final determination by the ITC is October 6, 2020. An adverse ruling by the ITC against either the Company or Daewoong could result in the imposition of an exclusion order which would bar imports of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> into the United States and a cease and desist order which would bar sales and marketing of Jeuveau</font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;"> within the United Sates either of which would materially adversely affect the Company&#8217;s ability to carry out its business and which would have a material adverse effect on the Company&#8217;s business, financial position, results of operations, or cash flows and could also result in reputational harm. Even if the Company is successful, the ITC Action may result in reputation damage or other collateral consequences.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;font-style:italic;">Other Legal Matters</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">The Company, from time to time, is involved in various litigation matters or regulatory encounters arising in the ordinary course of business that could result in unasserted or asserted claims or litigation. These other matters may raise difficult and complex legal issues and are subject to many uncertainties, including, but not limited to, the facts and circumstances of each particular case or claim, the jurisdiction in which each suit or regulatory encounter is brought, and differences in applicable laws and regulations. Except as set forth above, the Company does not believe that these other matters would have a material adverse effect on its accompanying financial position, results of operations or cash flows. However, the resolution of one or more of the other matters in any reporting period could have a material adverse impact on the Company&#8217;s financial results for that period.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
